

Acta Haematologica

International Journal of Haematology Journal International
d'Hématologie Internationale Zeitschrift für Hämatologie

Organe Officiel de la Société Européenne d'Hématologie

CONTRIBUTING EDITORS*

A. ALDER, Assez
H. ALVARADO, Santiago
G. BECKEL, Genève
B. M. VON BOMSDORFF
Helsinki
W. O. CRUZ, Rio de Janeiro
C. R. DAS GUPTA, Calcutta
C. JORDANI DIAZ, Madrid
H. DUBOS-FERRELL, Genève
P. FARRERAS, Barcelona
A. FISCHER, Genova
L. GROSS, Bronx, N. Y.

J. GUASCH, Barcelona
G. HENDRICKS, Lawrence
A. HITTMAIR, Innsbruck
P. INTROZZI, Paris
F. KOLLER, Basel
C. D. DE LAROSSE, Utrecht
J. H. LAWRENCE,
Berkeley Calif.
P. LAYNE, Raritan, N. J.
W. LÖWEN, Zürich
J. MALLARDI, Paris
L. M. MEYER, Brooklyn, N. Y.

J. MOLLER, Leiden
W. P. MURPHY, Boston, Mass.
E. NEUMARK, London
N. G. NORDENSKIOLD, Stockholm
A. PAVLOVSKY, Buenos Aires
E. POUSSER, Borch-sur-Yvette
F. REIMANN, Istanbul
I. SCAFFER, Brooklyn, N. Y.
E. STOKER, Modena
E. UHLMANN, Basel
M. VASKELA, Buenos Aires
A. VONSTRASS, København

EDITORS

L. Hellmeyer
Freiburg/Bz

E. Moulengracht
København
J. Waldenström
Lund

S. Moeschlin
Solothurn

EDITORS-IN-CHIEF

H. Löffler
Basel

G. Rosenow
New York



1966

Vol. 35

BASEL (Schweiz)

S. KARGER

NEW YORK

KETTERER, H.: <i>vide</i> BEIGEMANN, H.	
KUMAR, S.; DUBE, B. and MENNOTRA, P. N. (New Delhi) The Macrocytosis in Cirrhosis of the Liver: A Clinical and Experimental Study	30
LALA, P. K.; PATT, H. M. and MALONEY, M. A. (San Francisco) An Evaluation of Erythropoiesis in Canine Marrow	311
LAMVIE, J. O. (Bergen) Separation of Lymphocytes from Human Blood	294
LE COULTER, L.: <i>vide</i> BORG, L.	
LEIDEN, S.: <i>vide</i> VOMADOUR, P.	
LEONARD, G.: <i>vide</i> STORRI, E.	
LEVIGNE, M.: <i>vide</i> GROSDEAU, L.	
LEWIS, S. M. (London); BLEISBERG, I. and DANOV, D. (Rishovoth) Red-Cell Osmotic Fragility as an Indication of Marrow Depression after Irradiation and Effectiveness of Marrow Graft	333
MAGGIORIO, G.; IOPPOLO, C. and ORLANDI, G. (Rome) Contribution to the Knowledge of the Immunological Properties of Adult and Fetal Haemoglobin and of Their Polypeptide Chains	321
MAGLITULO, E.: <i>vide</i> RONCIANELLI, E. G.	
MALONEY, M. A.: <i>vide</i> LALA, P. K.	
MARIANELLI, L.: <i>vide</i> BARTOLOZZI, G.	
MATTEI, S.: <i>vide</i> TARDIGA, O.	
MATTEI, C.: <i>vide</i> TORRELLI, U.	
MCCREARY, D. J.: <i>vide</i> INGRAM, G. I. C.	
MENNOTRA, P. N.: <i>vide</i> KUMAR, S.	
MELONI, T.: <i>vide</i> VECCHIO, F.	
MORAY, G.: <i>vide</i> VOMADOUR, P.	
MORSE, G. E.: <i>vide</i> ULINSON, K.	
MORIYA, H.: <i>vide</i> KAGAMI, M.	
PAGGIACCIULLI, I.: <i>vide</i> TRIARIELLO, A.	
PATT, H. M.: <i>vide</i> LALA, P. K.	
QUAGLINO, D.: <i>vide</i> TORRELLI, U.	
RAFFETTER, J.: <i>vide</i> BEIGEMANN, H.	
REIZENSTEIN, P.: <i>vide</i> SCHIFFER, L. M.	
RONCIANELLI, E. G.; TRENTA, A.; MAGLITULO, E.; VALLINO, V. et GERRA, G. (Pavia) Morphogénèse des microcytes supplémentaires (pseudocorps de Jolly) dans les cellules érythropoïétiques irradiées. Recherches cinématographiques en contraste de phase	232
RUBINO, G.: <i>vide</i> VECCHIO, F.	
RYDER, R. J. W. (Dublin) Promyelocytic Leukaemia and Hypofibrinogenaemia	181
SALVINO, E.: <i>vide</i> TRIARIELLO, A.	
SCHETTINI, F.: <i>vide</i> VECCHIO, F.	
SCHIFFER, L. M.; BRAND, L.; GROVETTS, E. P. and REIZENSTEIN, P. (Stockholm) Iron Absorption and Excretion in Regenerative Anemia. A Collaborative Swedish-American Whole Body Counter Study	4
SEVER, J.: <i>vide</i> VOMADOUR, P.	
SERINER, M.: <i>vide</i> WULF, H. R.	
SPENCER, H.: <i>vide</i> INGRAM, G. I. C.	
SPINGLER, D.: <i>vide</i> BROOKER, H. J.	
STANLEY ELIZABETH M.: <i>vide</i> FIELD, E. O.	

Contents - Sommaire - Inhaltsverzeichnis

Vol. 33

AMORARA, T. vide TARDORA, O.	
AVERY, G. vide VONACOR, P.	
BARTOLOZZI, G. and MARIANELLI, L. (Florence): Estimation of Fœtal Haemoglobin in Leukaemia	214
BECKER, H.J. and SPENGLER, D. (Frankfurt a. M.) Die Verdauungsphysiologie. Tierexperimentelle Untersuchungen über den Einfluß des Blutvolumens auf die Erythrozytenregulation	1
BECKMANN, A. vide BRUNSWIG, J.	
BECKMANN, H., RASTETTER, J., WAGNER, R. and KETTERER, H. (Münster) Der Wert der Vitamin B ₁₂ -Bestimmung im Blutserum für die klinische und hämATOLOGISCHE Diagnostik	144
BENNETT, J. vide GROSSA, I.	
BUNNEN, L. vide LEWIS, S. M.	
BOLIVIN, O. G. de (Freiburg im Br.) On Standardization in Haematology	193
BRAND, L. vide SCHÖFFER, L. M.	
BRUNSWIG, J. and BECKMANN, A. (Königsberg) Leukozytenanhangs bei Knapen Leuk und ihre Beeinflussung durch den Stoffwechsel	246
BONI, L., JEAN, G. and LA COURTE, L. (Milan) Ultrastructural Aspects of Platelets and Megakaryocytes in a Case of Primary Thrombocythæmia	113
GEORGE, E. P. vide SCHÖFFER, L. M.	
DANON, D. vide LEWIS, S. M.	
DINE, B. vide KIRAN, S.	
FIELD, E. C. and STANLEY ELIZABETH, (London) The Migration Cells to the Thymus	21
FRICK, F. vide VONACOR, P.	
FORBES, G. vide STONE, E.	
FRANCISCO, L. de vide GROSSA, I.	
GROSSA, G. vide MAGGIORI, G.	
GRUBB, G. vide ROMANINI, E. G.	
GRUBB, L. (Brooklyn, N. Y.) The Rouscher Virus. A Mixture of the Friend Virus and of the Mouse Leukemia Virus (Gross)	200
GROSSA, I., BENNETT, J. et LEVITZKY, M. (Rabat) Hémoglobines anormales chez des malades marocains cancéreux	53
HARRIS, T. vide WETTER, O.	
HALSTED, S. Oslo The Central Nervous System in Regulation of Erythropoiesis	63
INGRAM, G. I. C., McFEE, D. J. and SPENCER, H. (London) Fatal Pulmonary Embolus in Congenital Fibrinopenia: Report of two Cases	56
LORENZO, C. vide MAGGIORI, G.	
JEAN, G. vide BONI, L.	
KAGAMI, M. and MORITA, H. (Tokyo) Parahaemophila. The Report of One Family from Japan	102

Aus der I. Medizinischen Universitätsklinik Frankfurt a. M. (Direktor: Prof. Dr. F. Hory)

Die Verdünnungsanämie

Tierexperimentelle Untersuchungen über den Einfluß des Blutvolumens auf die
Erythrozytenkonzentration

HJ. BECKER UND D. SPENGLER

Untersuchungen des Blutvolumens bei Patienten mit chronischen Anämien unter Transfusionsbehandlung (5) und bei Polycythämiekranken nach Aderlässen und Behandlung mit Radio-phosphor (4) hatten uns zu folgenden Vorstellungen über die Blutregulation geführt: Zellkonzentration und Blutvolumen (BV) werden weitgehend unabhängig voneinander reguliert, stehen aber in enger Wechselbeziehung zueinander. Die Größe des BV ist eng verknüpft mit der anatomisch und funktionell bestimmten Kapazität des Gefäßsystems und paßt sich ihr durch Änderungen des Plasmavolumens (PV) an. Eine Größenänderung des PV wirkt sich aber – im Sinne der Bluteindickung oder der Verdünnung – auf die Zellkonzentration aus. Die Regelung des Gesamtvolumens, das aus Kreislaufgründen möglichst konstant gehalten wird, ist dabei der Regelung der Erythrozytenkonzentration übergeordnet. Für die Sauerstoffversorgung des Gewebes sind aber in erster Linie die Erythrozyten- bzw. Hämoglobinkonzentration im Blut von entscheidender Bedeutung; nicht die Größe des BV bzw. die Gesamtmenge zirkulierender Erythrozyten (Erythrozytenvolumen = EV). Die Sauerstoffkonzentration im Gewebe bestimmt aber das Ausmaß der Erythropoese im Knochenmark unter Einschaltung noch unbekannter Rezeptoren, erythropoetinbildender Gewebe und humoraler Faktoren.

Somit ist zu erwarten, daß eine Abnahme der Zellkonzentration im Blut (Ery. mm³) auch dann zu einer Aktivierung der Ery-

Durchgeführt mit Unterstützung der Deutschen Forschungsgemeinschaft, Bad Godesberg

thropoese führt, wenn das EV konstant bleibt. Solche Bedingungen lassen sich experimentell durch Infusionen großer Mengen eines Plasmaexpanders erzeugen. Es resultiert dann eine Verdünnungsanämie mit unverändertem EV.

ERLEY (18) fand nun aber bei derartigen Versuchen bei Kaninchen weder einen Anstieg der Reticulozyten noch eine Aktivierung der Erythropoese im Knochenmark. Er vermutete, daß die Abnahme der Zellkonzentration durch eine erhöhte Zirkulationsgeschwindigkeit soweit ausgeglichen werden könne, daß im Gewebe keine Hypoxie entstehe. Dieser an 4 Kaninchen erhobene Befund gilt seitdem als grundlegend für die Theorie der Erythrozytenregulation (12-29). Da es uns unwahrscheinlich erschien, daß eine erhebliche Senkung der Hämoglobin- und Erythrozytenkonzentration durch Änderungen der Kreislaufgrößen völlig kompensiert werden könne, haben wir die Versuche von ERLEY nachgearbeitet. Dabei ergab sich, daß die Verdünnung des Blutes allein zu einer starken Aktivierung der Erythropoese mit vorübergehender reaktiver Polyglobulie führt.

Methoden

Versuchstiere: 10 ausgewachsene männliche Kaninchen, 4,5 bis 5 kg schwer, Trockenkot (Kornbrotver Rabbitt Ration, Hope Farms). Wasser ad lib. - 5 Tiere starben im Stadium der maximalen Hypervolämie. Die Untersuchungen bei 12 Tieren wurden unterteilt: Vorbehandlung A 1, 2, 4; bis Versuchsbeginn 6 × 1 u. B 12, 30 γ und 50 mg Fe (Ferro-Sorbitol-Zitrat Komplex, Jersifer®) i. m. - A 3, 3, 6 je 60 γ 1 u. B 12 und 100 mg Fe. A 8, 15 je 30 γ 1 u. B 12 und 50 mg Fe vor Versuchsbeginn und 0 × innerhalb der ersten 4 Versuchswochen. - Die Versuche wurden erst begonnen, nachdem konstant NI Wert in der Vorbeobachtungsperiode festgestellt waren.

Nahrung: Mafrodex® 6%, mit physiologisch ungewogener Elektrolytlösung¹⁾.
 Kränken in die marginale Ovariole 2 Nadeln, jeweils je 18 ml/kg. Diese Dosis wurde von den meisten Tieren gut toleriert; größere Infusionsmengen (25 ml/kg) führten nach einigen Tagen zum Tod der Tiere.

Blutuntersuchungen: Hämoglobin (Hb) Cyanhämoglobinmethode (Doppelbest.). Erythrozyten Zählung in Thoma-Zählkammer (Doppelbest.). Reticulozyten (Retic.) Färbung mit 1% Brillantkresylblau in 0,9 NaCl-Lösung. Mischung in der Pipette. Färbung in Leuckert-Kammer 20 min, Ausstriche. Auszählung von je 2000 Erythrozyten. Angabe der Reife in % der Erythrozyten. - Hämatokrit (Hk): nach einem Vorschlag von SCHMIDT (48) wurden Hk-Rohwerte verwendet, die über der Hk-Bestimmung auch die Aktivitätsmessung chromatischer Erythrozyten in Vollblut und Erythrozytenmediment gestatten, da sie ein konstantes Volumen (0,5 ml) besitzen²⁾. Höhe 65 mm. Teil nuplänge 50 mm. Zentrifugieren 60 min, 3000 UpM. Radius der Zentrifuge 18 cm. Korrekturfaktor (packed plasma nach den für diese Rohrechen ermittelten Werten (48)). Alle Hk Werte sind nach dieser Korrektur angegeben. - Plasmaeweiß

¹⁾ Wir danken der Firma Knoll AG Ludwigshafen für die Überlassung der Versuchsmengen.

²⁾ Hersteller: Rhema-Ges., Hofheim/Taunus.

Barret-Methode nach WEISSHALDBAUM. Im Gegensatz zu den Untersuchungen anderer Autoren mit einem amerikanischen Destranpräparat (28) wird diese Reaktion nicht durch eine Präzipitation von Macrodex beeinträchtigt (56) – Serumweis Raithophenanthromethode (Ferropack®) – Knochenmarkuntersuchung: Punktion der oberen medialen Tibiafläche (62) Ausstriche, Färbung nach Pappenheim. Auszählung von je 1000 Zellen der myeloischen Reihe und der darauf entfallenden Zellen der Erythropoese (M/E-Index).

Abtastzählbestimmung. Entnahme von 7 ml Blut mit geringem Heparinzusatz. Bei wiederholten Bestimmungen Messung der Restaktivität. Zentrifugieren 5 min mit geringer Tourenzahl (wegen der vermehrten Agglutinationsneigung der Retic. (34). Erythrozytensediment mit 7μ C $\text{Na}_2\text{Cr}^{24}\text{O}$ in 0,9% NaCl-Lösung 30 min bei 37° inkubiert unter gelegentlichem Umrühren. Zugabe von 25 mg Ascorbinsäure (43) und eingekehlter 0,9%-NaCl-Lösung. Einmaliges Waschen mit geringer Tourenzahl. Auffüllen bis zum Ausgangsvolumen. Nach Abtastung des Meßstandes (Doppelbest.) Injektion einer exakt definierten Menge der Erythrozytenaufschwemmung. Blutenahme nach 1 Std. (Doppelbest.)

Alle Aktivitätsmessungen wurden in den beschriebenen Hk-Röhrchen durchgeführt (Bohrloch-Schwellenstähler Fricke & Hoepfer 488 aus 10 cm starker Bleiabschirmung!)¹⁾ die Erythrozytenzelle bleibt dabei immer im optimalen Meßbereich des Bohrlochkristalls. Aktivitätsmessung des 1-Std. Wertes und des Meßstandes (nach exakter Entfernung des Überstandes) und von 0,2 ml des Standard-Überstandes (zur Korrektur für die Aktivität des trapped plasma). Berechnung des EV nach GRAY und SMOLARNO (nach Korrektur für trapped plasma) wobei auch der durch die laufenden Hk-Bestimmungen entstandene Blutverlust (je 0,5 ml) berücksichtigt wurde (Einzelschritten bei 56) Berechnung des BV aus EV und (korrig.) Hk. Wie in-vitro-Versuche zeigten, wird der Hk auch durch hohe Macrodenkonzentrationen nicht beeinträchtigt (56).

Bestimmung der Lebenszeit chrommarker Erythrozyten. Der 1-Std. Wert der BV-Bestimmung wurde als 100% Wert für die Lebenszeitbestimmung eingezeichnet. Hk-Bestimmungen in regelmäßigen Intervallen, Messung der Aktivität im Erythrozytensediment der Hk Röhrchen, Umrechnung auf 1 ml gepackte Zellen. Messungen im Vollblut waren wegen der im Versuchsverlauf auftretenden Plasmanormenänderungen nicht möglich.

Leberrückung jugendlicher Erythrozyten. Die Untersuchungen wurden 5 Tage nach Beginn der Reticulocytoze, 7 Tage nach einer umfangreichen Chrommarkerüberzug durchgeführt. Der relative Anteil jugendlicher Erythrozyten war infolge der seit mehreren Tagen erhöhten Reticulocytenzahl bereits stark vermehrt, erkennbar an dem deutlichen Abfall der Aktivität der zuvor markierten Erythrozyten (gl. Abb. 8). Wegen ihrer geringeren Dichte können Reticulocyten und jüngere Erythrozyten durch Zentrifugieren in der oberen Schicht weiter angereichert werden (42) allerdings bei Kaninchen nicht so gut wie in menschlichem Blut (63). Aus der Differenz der Aktivität des Gesamtblutes und der oberen Schicht nach Zentrifugieren (jeweils umgerechnet auf 1 ml gepackte Zellen) ergibt sich der Anteil älterer Zellen (die 7 Tage zuvor markiert wurden). Die Aktivität der oberen Schicht lag um 30% niedriger als die des Gesamtblutes. Auf eine heftige Abtastung und damit eine noch größere Ausbreitung junger Zellen durch längeres und schäufertes Zentrifugieren wurde wegen der bekannten Agglutinationsneigung der Retic. (34) verzichtet. Das Blut der oberen Schicht, das so mit jüngeren Erythrozyten angereichert war, wurde nun zur Bestimmung der Lebenszeit mit Cr^{24} markiert und nach oberer Kreuzprobe auf andere Kaninchen übertragen.

¹⁾ Wir danken Herrn Prof. Dr. W. LÖNNER, daß er uns die Untersuchungen in der Un. an der Klinik für Strahlentherapie und Nuclearmedizin Frankfurt i. M. ermöglichte sowie Herrn Dr. S. GRUBB für seine freundliche Hilfe bei den Messungen.

Ergebnisse

1 Erzeugung der Verdünnungsanämie mit Macrodex

Macrodex eignet sich wegen seiner relativ langen Verweildauer in der Blutbahn (2) gut zur Erzeugung einer Verdünnungsanämie. Wir infundierten meist $2 \times$ täglich 18 ml/kg über 7 Tage (insgesamt 250 ml/kg). Der größte Teil des Plasmaexpanders wird bei derartig gehäuftten Gaben wieder ausgeschieden oder aber im extravasalen




Abb. 1 Änderungen des Plasmavolumens bei 3 Kanariichen nach häufiger Macrodex Infusion.





Abb. 2 Hämoglobinspiegel bei Messung jeweils vor und 30 min nach Macrodex Infusion.



143 Die Änderungen von Erythrozytenkonzentration und -gesamtenzahl, Reticulozytenzahl und Plasmaprotein im Verlauf der Verdünnungsanämie bei 3 Karpfen.

Tabelle I

Ausmaß der Verdünnungsanämie, maximale Reticulocytose und reakt. Polyglobulie bei 12 Kaninchen.

Tier Nr.	Ausgangswerte				«Maximale Anämie»			
	Hb g%	Ery Mill.	Hk	Gen.-Erv %	Hb g%	Ery Mill.	Hk %	Gen.-Erv %
1	10,3	4,6	32	5,63	6,8	3,2	24	3,85
2	10,6	4,8	32	6,45	6,9	3,3	22	3,85
3	11,2	5,5	35	6,0	5,5	2,9	19	3,25
4	11,0	4,8	31	6,05	6,4	2,8	20	3,9
5	11,8	5,7	36	5,75	6,5	3,3	22	4,0
6	10,6	4,9	33	6,4	6,4	3,1	19	4,1
8	11,7	5,3	36	—	7,2	3,4	24	—
9	12,5	5,5	36	—	7,5	3,0	25	—
10	11,9	5,6	36	—	6,2	3,0	22	—
11	10,5	5,4	32	6,6	7,5	3,6	24	3,1
12	9,9	5,1	30	5,55	6,9	3,2	21	3,2
13	11,1	5,3	32	6,05	6,5	3,0	20	3,2

Raum abgelagert und strömt erst in der Folgezeit allmählich wieder in die Gefäße zurück. Bei 2 Tieren, die unter der Infusionsbehandlung starben, fanden wir erhebliche Pleuraergüsse und Ascites. Aus Abb 1 geht hervor, daß nach Infusion von insgesamt 900 ml das PV nur um 65 ml im Mittel anstieg.

Die Blutkontrollen wurden täglich jeweils vor den Infusionen durchgeführt. Um den täglich auftretenden Tiefpunkt der Anämie zu erfassen, haben wir bei 2 Tieren die Hb-Werte jeweils vor und 30 min nach Ende der Infusionen bestimmt (Abb 2). Jede Infusion des Plasmaexpanders führt zu einem Hb-Abfall von 1–2 g/. Die Hb-Konzentration steigt dann in den folgenden Stunden wieder an ohne den vorherigen Wert wieder zu erreichen.

Die Infusionsbehandlung wurde beendet, wenn die Anämie den gewünschten Schweregrad erreicht hatte und bei weiterer Volumenerhöhung eine deletäre Kreislaufüberlastung zu erwarten gewesen wäre.

2 Blutveränderungen bei Verdünnungsanämie

In Abb 3 ist der Verlauf von Hb, Erythrozytenzahl und Hk während der Verdünnungsanämie bei 3 Tieren dargestellt. Die übrigen 9 Tiere verhielten sich völlig gleichsinnig (Tabelle I). Etwa am 6. bis 9. Tag nach Beginn der Infusionsbehandlung war der gewünschte Tiefpunkt der Anämie erreicht; der Mittelwert des Hb auf 6,6 g/ abgefallen.

Tabelle I (Fortsetzung)

nr	m	Reticulocyten				Maximale Polyglobulie		
		Ausgang Tag	max. Retic.-Anstieg Tag	max. Retic.-Anstieg ‰	d. Vorw.	Tag	Hb. g	Ery. Mill.
63		4	(9)	298	458		am 9. Tag gestorben	
64		5.	13.	215	336		nicht untersucht	
84		5.	17	322	583		nicht untersucht	
70		6.	11	222	317		nicht untersucht	
63		5	11	285	419		nicht untersucht	
70		5.	11	198	280	33	11,2	6,2
72		7	13.	300	417	35.	13,0	6,2
50		5.	11	269	528	40.	13,9	6,3
74		7	12.	356	481	38.	13,0	6,2
59		5.	16.	321	545	40.	12,5	6,4
73		5.	13.	311	427	40.	12,0	6,1
72		5.	14.	376	522	33.	11,9	6,0

Die Blutverdünnung löst gesetzmäßig eine Aktivierung der Erythropoese aus, erkennbar an einer erheblichen Reticulozytose. Diese begann meist am 5 (4 bis 7) Tag nach Infusionsbeginn und erreichte am 11 bis 17 Tag ihr Maximum, durchschnittlich 11 (4 bis 10) Tage nach Beendigung der Infusionen. Setzt man den Ausgangswert der Retic. (‰) gleich 100 / dann betrug der maximale Retic. Anstieg 280 bis 545 ‰, im Mittel 425 ‰ dieses Ausgangswertes (Tabelle I). Diese enorme Ausschüttung von Retic. geht mit einer sehr deutlichen Linksverschiebung einher, also einer Vermehrung der Knäuel- und Netzformen (Abb. 4). Die Retic. Zahl erreicht den Ausgangswert nach unterschiedlicher Zeit (16 bis 32 Tage nach Beendigung der Infusionen, im Mittel nach 21 Tagen). Auf Einzelheiten der Retic. Kurve wird weiter unten eingegangen.

Nach Beendigung der Infusionen bleiben Hb-, Ery- und Hk-Werte in den folgenden Tagen niedrig. Der Zeitpunkt, zu dem die Blutwerte zum Vorwert zurückgekehrt sind, hängt von der Geschwindigkeit ab, mit der das im extravasalen Raum eingelagerte MacroDEX in die Blutbahn zurückströmt. Im Anschluß an die Verdünnungsanämie kommt es infolge der Aktivierung der Erythropoese zu einer vorübergehenden Polyglobulie (Tabelle I, letzte Spalte). Das Maximum dieser Polyglobulie war zwischen dem 27 und 33 Tag nach Infusionsende erreicht (Anstieg des Hb von 11 lg auf 12,5 g, der Erythrozyten von 5,3 auf 6,2 Mill./mm³).




Abb. 4 Vermehrung der unreifen Reticulozyten auf dem Höhepunkt der Reticulocytose

Gesetzmäßig sinkt die Retic. Zahl in dieser 2. Phase erheblich unter den Ausgangswert ab. Der Tiefpunkt dieser negativen Retic. Bewegung ist nach 34 bis 49 (im Mittel nach 40) Tagen erreicht, die Retic. Werte betragen zu diesem Zeitpunkt 39 % des Ausgangswertes (vgl. Tabelle III, Zeitpunkt V).

Bei 4 Tieren wurden die Blutkontrollen fortgesetzt, bis alle Blutwerte zur Norm zurückgekehrt waren. Dies war für Hb und Erythrozytenzahl zwischen dem 50. und 65. für die Retic. Zahl zwischen dem 60. und 90. Tag nach Ende der Infusionsbehandlung der Fall. Es dauert also 2 bis 3 Monate, bis die Störung des steady state völlig ausgeglichen ist, die durch eine 7tägige Infusionsbehandlung mit dem Plasmaexpander hervorgerufen wurde.

Parallel zur Abnahme der Erythrozyten kommt es unter der Behandlung mit dem Plasmaexpander auch zu einer Verdünnung der Plasmaproteinkörper (Abb. 3, Tabelle I). Der Ausgangswert ist 8-24 Tage nach Beendigung der Macrodexinfusionen wieder erreicht; es kommt dann zu einem weiteren Anstieg des Plasmaproteins, der längere Zeit anhält (64), analog der reaktiven Polyglobulie.

In einer gesonderten Mitteilung werden wir auf diese Elektrolytverschiebungen eingehen, insbesondere auch im Hinblick auf das zirkulierende Totaleisweiß.

Tabelle II

Relative Erythrozytenzahl (pro cmm) absolute Menge (EV) und Total-Erythrozytenzahl in der 2. Phase der Verdünnungsanämie.

Datum	Hb g%	Ery./cmm	Hk %	EV ml	PV ml	BV ml	Ery Total 10 ⁹	% des Ausgangswertes		
								Ery/cmm	EV	Total- Ery
12.6.64	10,5	5,4	29,5	63	157	220	1188			
14.7.64	10,8	3,95	32,4	94	186	280	1660	110	149	140
12.6.64	9,9	5,1	27,6	51	139	190	969			
14.7.64	11,2	5,83	32,4	84	166	250	1457	115	165	150
12.6.64	11,1	5,3	29,5	61	153	214	1134			
14.7.64	11,6	5,6	32,4	83	183	276	1546	106	155	156

3 Erythrozytenvolumen (EV) und Total Reticulocytenzahl

In Abb. 3 sind die Werte des EV im Verlauf der Verdünnungsanämie den Konzentrationswerten (Hb Ery Hk) gegenüber gestellt. Anhand der absoluten EV Werte ist ersichtlich, daß es sich in der Tat um eine reine Blutverdünnung handelt. Denn während die Konzentrationswerte stark abfallen, bleibt das EV unverändert und steigt infolge des inzwischen eingetretenen Retic. Anstiegs an. Der maximale Wert des EV wird dann erreicht, wenn die Reticulocyten gerade abgeklungen ist und die Konzentrationswerte gering über den Ausgangswert angestiegen sind. Da aber das PV zu diesem Zeitpunkt immer noch deutlich vergrößert ist (20 Tage nach Beendigung der Macrodex Infusionen!) ist – bezogen auf den Ausgangswert – die Erhöhung des EV größer als es der Erhöhung der Ery Zahl/mm entspricht (Tabelle II). Zu diesem Zeitpunkt besteht also eine Polyämie, bei der die EV Erhöhung infolge der gleichzeitig bestehenden PV Erhöhung nicht zu erkennen ist und nur durch eine BV Bestimmung erfaßt werden kann.

Infolge der nun einsetzenden PV Abnahme (Ausscheidung des Macrodex) steigen Hb und Erythrozytenzahl noch weiter an bis zu den Werten, die in Tabelle I (letzte Spalte) angegeben sind.

Aus Tabelle II geht außerdem hervor, daß die Zunahme des EV – bezogen auf den Ausgangswert – etwas größer ist als die der Total-Erythrozytenzahl. Dies dürfte darauf beruhen, daß das mittlere Volumen des einzelnen Erythrocyten (MCV) infolge der vorangegangenen Reticulocytose größer als normalerweise ist. Auf die Änderungen des Erythrocyten-Einzelvolumens im Verlauf der Verdünnungsanämie werden wir in einer späteren Mitteilung eingehen.

Die absolute Vermehrung der Erythrozyten (EV) hält außerordentlich lange an, so daß selbst bei der Messung 106 Tage nach




Abb. 4 Vermehrung der unreifen Reticulocyten auf dem Tiefpunkt der Reticulocyten

Gesetzmäßig sinkt die Retic. Zahl in dieser 2. Phase erheblich unter den Ausgangswert ab. Der Tiefpunkt dieser negativen Retic. Bewegung ist nach 34 bis 49 (im Mittel nach 40) Tagen erreicht, die Retic. Werte betragen zu diesem Zeitpunkt 39 % des Ausgangswertes (vgl. Tabelle III Zeitpunkt V).

Bei 4 Tieren wurden die Blutkontrollen fortgesetzt, bis alle Blutwerte zur Norm zurückgekehrt waren. Dies war für Hb und Erythrozytenzahl zwischen dem 50 und 65., für die Retic. Zahl zwischen dem 60 und 90 Tag nach Ende der Infusionsbehandlung der Fall. Es dauert also 2 bis 3 Monate, bis die Störung des steady state völlig ausgeglichen ist, die durch eine 7tägige Infusionsbehandlung mit dem Plasmaexpander hervorgerufen wurde.

Parallel zur Abnahme der Erythrocyten kommt es unter der Behandlung mit dem Plasmaexpander auch zu einer Verdünnung des Plasmasweißkörpers (Abb. 3 Tabelle I). Der Ausgangswert ist 8-24 Tage nach Beendigung der Macrocrunfusionsen wieder erreicht, es kommt dann zu einem weiteren Anstieg des Plasmasweißes, der längere Zeit anhält. A analog der reaktiven Polyglobulie.

1. einer gründlichen Mitteilung werden wir auf diese Erwiderungen eingehen, insbesondere auch im Hinblick auf das zirkulierende Totaleiweiß.

Tabelle III
 Reticulocytenbewegung im Verlauf der Verdünnungsanämie.

Datum	Zeitpunkt	Retic. ‰	/ des % normales	Retic./ mm ³	des % normales	Total-Retic. 10 ⁹	d. Vor- versuch
28.3.	I	72	100	385000	100	735	100
7.4.	II	77	107	263000	68	—	—
17.4.	III	310	431	1120000	291	—	—
29.4.	IV	70	97	356000	93	—	—
22.5.	V	32	44	195000	51	390	53
8.4.	I	50	100	274000	100	565	100
13.4.	II	53	106	249000	91	—	—
20.4.	III	269	538	892000	326	—	—
5.5.	IV	54	108	278000	102	718	127
2.6.	V	18	38	113000	41	269	47
28.3.	I	74	100	412000	100	702	100
8.4.	II	88	118	262000	64	—	—
13.4.	III	336	481	1350000	328	—	—
23.4.	IV	73	101	387000	94	—	—
22.5.	V	32	43	189000	46	335	51
12.6.	I	59	100	318000	100	726	100
23.6.	II	72	122	274000	86	795	110
30.6.	III	233	428	1088000	342	3190	440
9.7.	(III)	321	545	1457000	457	—	—
14.7.	IV	58	98	345000	109	966	133
5.8.	V	19	32	103000	33	—	—
18.8.	VI	44	75	231000	73	520	72
1.10.	VII	68	112	350000	110	750	103
12.6.	I	73	100	376000	100	697	100
23.6.	II	108	147	364000	97	898	129
30.6.	III	311	427	1290000	327	2850	410
14.7.	IV	81	111	472000	126	1180	169
28.7.	V	46	63	275000	74	632	90
5.8.	(V)	34	47	181000	48	—	—
18.8.	VI	68	93	352000	94	733	105
1.10.	VII	75	103	384000	102	753	108
12.6.	I	72	100	381000	100	805	100
23.6.	II	118	164	400000	105	1160	144
30.6.	III	310	431	1200000	315	3260	405
1.7.	(III)	376	522	—	—	—	—
14.7.	IV	74	103	415000	109	1145	143
28.7.	V	20	28	115000	30	275	34
18.8.	VI	59	82	307000	81	670	85
1.10.	VII	68	95	350000	92	740	92

Zeitpunktes I = vor Versuchsbeginn, II = vor oder zu Beginn der Reticulocytose, III = erster Reticulocytenanstieg, IV = Rückgang der Reticulocytenzahl (%/m) zum Ausgangswert, Zeitpunkt der Reticulocytenbewegung, VI = Wiederaufstieg der Reticulocyten zum Ausgangswert, I = Spätstadium bei Versuchsende. Bei K 8-10 wurde die Total-Reticulocytenzahl mit $2 \times$ t, bei K 11-13 bei Zeitpunkt I-VII.




Abb. 6. M/E-Index und relative Verteilung der Reifestadien der Erythropoese. 19.6. = vor dem Versuch 27.6. = Höhepunkt der Reticulozytose 7.6. = Hemmung der Erythropoese.

erhöht, ebenso die $\%$ Retic., während Retic./mm³ noch normal bzw. erniedrigt sind. Auch auf dem Höhepunkt der Reticulozytose (= Zeitpunkt III) ist die Zahl der Retic./mm³ wesentlich niedriger als es den tatsächlichen Verhältnissen entspricht, die $\%$ Retic. Zahl stimmt jedoch gut mit der Total Retic. Zahl überein. Zum Zeitpunkt IV des Versuchs sind die Werte in $\%$ und pro mm³ etwa zum Ausgangswert zurückgekehrt. EV und BV haben inzwischen ihr Maximum erreicht, so daß die Total-Retic. Zahl noch deutlich erhöht ist.

Abb. 5 und Tabelle III zeigen überdies eindrucksvoll, wie stark in der 2. Phase im Stadium der reaktiven Polyglobulie, die Retic.-Einschwemmung aus dem Knochenmark eingeschränkt ist.

Zusammenfassend ergibt sich, daß die Retic. Zahl nur bei Berücksichtigung der Blutmenge einen wirklichen Rückschluß auf die Erythrozytenproduktion erlaubt. Die Angabe in $\%$ der Erythrozyten kommt den Total Retic. Werten näher als die Angabe pro mm³.

4 Knochenmarksbefunde

Bei 3 Tieren wurde das Knochenmark vor Versuchsbeginn, unmittelbar vor dem Höhepunkt der Reticulozytose und zum Zeitpunkt der Retic. Depression untersucht und die Relation von Granulo- zu Erythropoese (M/E-Index) ermittelt. Innerhalb der Erythropoese wurde differenziert in Proerythroblasten (Kernklasse K 2) Makroblasten (K 1) basophile, polychromatische und oxyphile Normoblasten (K 1/2, K 1/4 K 1/8) zusammengefaßt Mitosen. Im oberen Teil von Abb 6 ist die Aktivierung der Erythropoese als Folge der Blutverdünnung und ihre Hemmung als Folge der reaktiven Polyglobulie an dem veränderten M/E-Index zu erkennen. Der untere Teil der Abb gibt den relativen Anteil der einzelnen Reifestadien der Erythropoese wieder. Bemerkenswert ist, daß die Relation der Proerythroblasten zu den übrigen Erythroblasten etwa konstant bleibt, wie dies von SCHWARZ (50) und WEICKER (66) unter normalen und auch unter pathologischen Bedingungen gefunden wurde.

5 Bestimmung der Lebenszeit der Erythrozyten

Um mit Sicherheit annehmen zu können, daß es sich bei der Aktivierung der Erythropoese allein um die Auswirkung der Blutverdünnung handelt, war auszuschließen, daß es zu einer Hämolyse infolge der hohen Macrodexkonzentrationen im Blut kommt, zumal von NORLANDER et al. (40) bei Dextrangaben beim Menschen eine vermehrte Zeldestruktion dokumentiert wird.

Die Werte des EV das zunächst konstant bleibt und im weiteren Verlauf deutlich zunimmt (s. o.) lassen eine stärkere Zellzerstörung bereits weitgehend ausschließen. Der sichere Beweis dafür daß es unter den Macrodex Infusionen zu keiner Hämolyse kommt, ist durch die unveränderte Lebenszeit (Lz.) der Erythrozyten gegeben. Lz. Bestimmungen chrommarkierter Erythrozyten wurden bei 5 Tieren durchgeführt. Bei 3 Tieren begannen wir mit den Infusionen 6 Tage nach der Chromierung, bei 2 Tieren bereits am folgenden Tag (Abb. 7) Die tägliche Abbaurate der Erythrozyten bleibt unverändert während der Blutverdünnung die an dem Absinken des Hk zu erkennen ist. Damit ist eine vermehrte Hämolyse als Ursache der Aktivierung der Erythropoese ausgeschlossen.

Diese Messungen können nur im Erythrozytensediment durchgeführt werden, da bei einer Messung in Vollblut infolge der gleichzeitigen Blutverdünnung (und damit




Abb. 7 Erythrozyten-Lebenszeit während der Infusionen von Macroder.

Abnahme der Ery/Ramteinheit) eine stärkere Abnahme der Aktivität und damit eine scheinbare Lz.-Verkürzung resultieren würde. Die Lz.-Kurven sind auch nur solange verwertbar wie die Retic. noch nicht angestiegen sind. Mit Beginn der Reticulocytoze wird der relative Anteil markierter Zellen durch die vermehrte Einschwemmung unmarkierter d. h. nach der Chromotierung gebildeter Zellen vermindert. Auch dadurch wird die Lz. der markierten Erythrozyten scheinbar verkürzt. Die Beziehung zwischen Retic.-Zahl und Cr⁵¹-Lz. der Erythrozyten wird aus Abb. 8 deutlich: die erste Lz. Bestimmung (gezogene Kurve) wurde vor Versuchsbeginn, die zweite (gestrichelt) bei Anstieg der Retic. vorgenommen. Die zweite Kurve zeigt einen Knick nach unten, d. h. eine scheinbare Verkürzung der Lz., sobald die Retic. stärker ansteigen. Von STROMAN (37) wurde empfohlen, bei ansteigender Erythrozytenzahl (also z. B. während einer Retic. Krise) die Lz.-Bestimmung im Vollblut durchzuführen. Das ist zweifellos besser als die Bestimmung im Erythrozytenpräparat, kann aber nur dann zu richtigen Ergebnissen führen, wenn das BV konstant bleibt, d. h. wenn das PV in dem gleichen Ausmaß abnimmt, wie das EV zunimmt. Bei der experimentellen Verdünnungsanämie ist dies nicht der Fall, bei der Regeneration chronischer Anämien nicht immer (25).

Weiterhin war die Bestimmung der Lz. jener Erythrozyten von Interesse, die in der Phase der starken Aktivierung der Erythropoese gebildet worden waren. Da in dieser Phase kein Fließgleichgewicht besteht (Schwankungen der Erythrozytenneubildung und des PV) kann eine solche Lz. Bestimmung nicht beim Versuchstier selbst erfolgen, sondern nur nach Übertragung auf ein Empfängertier. Etwa auf dem Höhepunkt der Reticulocytoze wurde bei 3 Tieren Blut entnommen, nach weiterer Anreicherung jugendlicher Erythrozyten (s. Methoden) mit Cr⁵¹ markiert und auf unbehandelte Empfängertiere übertragen. Bei einem dieser Tiere




Abb. 8. Die Beziehung zwischen der Reticulocytenzahl und dem Aktivitätsabfall nach Markierung mit Cr⁵¹ (Messung im Erythrocytensediment)

kam es am 8. Tag infolge Bildung von Isoantikörpern zu einem rapiden Abfall der Aktivität auf Null. Die Lebenszeitkurven der beiden anderen Tiere sind in Abb. 9 dargestellt, im Vergleich zu den Lx. Kurven, die bei den Versuchstieren selbst vor Versuchsbeginn gewonnen worden waren.

Die Lx. Kurve der übertragenen Zellen verläuft flacher entsprechend dem größeren Anteil jüngerer Zellen in dieser Population. Ihre Cr Halbwertszeit betrug 19 bzw. 22 Tage, im Vergleich zu 16 bzw. 17 Tage vorher. Bei dieser nur relativ geringfügigen Verlängerung der mittleren Lx. ist aber zu berücksichtigen, daß es sich bei diesen Erythrozyten zum Zeitpunkt der Reticulocytoze nicht um eine reine «Kohorte» (14) handelt, d. h. um junge, zur gleichen Zeit im Knochenmark gebildete Zellen, sondern lediglich




Tabelle IV

Lebenszeit radiochrommarkierter Erythrozyten in verschiedenen Phasen der Verdünnungsanämie ($t/2$).

Zeitpunkt	K 11	K 12	K 13
12. 6. Vor Versuchsbeginn	~ 16 T	~ 16 T	~ 17 T
30. 6. Reticulozytose, Übertragung auf Empfänger	19 T	—	~ 22 T
28. 7. Hemmung der Erythropoese, Reticulozyten vermindert	~ 17 T	~ 17 T	~ 22 T

Die Messungen konnten aus methodischen Gründen meist nicht ganz bis zur $t/2$ durchgeführt werden. Die Cr^{51} -Halbwertszeit wurde dann durch Verlängern der Lebenszeitkurve bis zur 50%-Achse ermittelt.

um eine Anreicherung jüngerer Erythrozyten neben älteren Zellen, die sich schon vor der Reticulozytose im Blut befanden.

Orientierende $t/2$ -Bestimmungen — mit weniger Meßpunkten — wurden von den gleichen Tieren auch im weiteren Verlauf durchgeführt. Die Ergebnisse sind in Tabelle IV zusammengestellt.

Die scheinbare Verlängerung von $t/2$ zur Zeit der Hemmung der Erythropoese hat den gleichen Grund wie — im umgekehrten Falle — die scheinbare Verkürzung während des Retic.-Anstiegs (Abb. 8) da der Zeitschub geringer ist als die (normal weitergehende) Destruktion, verschiebt sich die Relation von markierten zu unmarkierten Erythrozyten weniger als wenn Produktion und Destruktion im Gleichgewicht stehen.

Diskussion

I Die Regulation der Erythropoese bei der Verdünnungsanämie

Die experimentelle Verdünnungsanämie hat unter den hämatologischen Krankheitsbildern kein typisches Analogon. Bei vielen Anämien spielt zwar eine Verdünnungskomponente eine gravierende Rolle, hierbei handelt es sich dann aber um eine primäre Abnahme des EV, die durch eine PV-Zunahme voluminmäßig kompensiert bzw. häufig überkompensiert wird (5-33). Eine primäre PV-Vermehrung, die über eine Blutverdünnung eine verstärkte Erythropoese auslöst, dürfte in einzelnen Fällen von Lebercirrhose (37) sicher aber bei der dekompensierten Herzinsuffizienz von Bedeutung sein (31-35). In solchen Fällen fand HEDLUND neben einer erheblichen PV-Vermehrung eine hyperplastische Erythropoese, Retic. und EV-Vermehrung. Es handelt sich hierbei aber auch nicht ausschließlich um die stimulierende Wirkung der PV-Vermehrung auf das Knochenmark, da außerdem die kardial bedingte Gewebshypoxie erythropoetisch wirksam ist.

Die experimentelle Erzeugung einer länger anhaltenden reinen Scheinanämie setzt die Anwendung einer Substanz mit möglichst langer Verweildauer in der Blutbahn und einer guten Verträglichkeit auch in hoher Konzentration voraus. Diese Bedingungen sind bei Macrodex erfüllt (Übernacht bei 51) von dem sich nach einmaliger Infusion beim Menschen nach 8 Std. noch 50% und mehr (2-28) nach 24 Std. noch etwa 30% in der Zirkulation befinden (28, 49-64). Bei Infusion so großer Mengen, wie sie zur Erzeugung einer Verdünnungsanämie erforderlich sind, verschwindet Macrodex allerdings schneller aus der Blutbahn (Ausscheidung über Niere und Magen-Darm, Abwanderung in den extravasalen Raum, Abbau) wie aus dem Mißverhältnis von zugeführter Macrodexmenge und Anstieg des PV hervorgeht (Abb. 1). Eine die Erythrozyten direkt schädigende Einwirkung von Macrodex, auch in Konzentrationen, die den Hk erheblich senken, ist nicht nachweisbar. Dies geht aus dem unveränderten Aktivitätsabfall nach Markierung der Erythrozyten mit Cr^{51} (Abb. 7) und der Zunahme des EV im Verlauf der Verdünnungsanämie hervor.

Über die Wirkung protrahierter Gaben von Plasmaexpandern auf die Erythropoese liegen nur wenige Angaben vor. Die klinische Indikation dieser Stoffe ist die Auffüllung des Kreislaufs nach Blutverlusten. Eine fortlaufende Anwendung, die zu einer länger anhal-

tenden Blutverdünnung führen könnte, verbietet sich deshalb. Zudem wird die Erythropoese in solchen Fällen ohnehin durch den vorausgegangenen Blutverlust aktiviert.

Lediglich von GAZANOV (zit. 20) und GOLDMAN (26) wurde über eine Stimulierung der Erythropoese nach Infusionen mit Polyglucin, einem russischen Dextran-Präparat mit etwa dem gleichen mittleren Molekulargewicht wie Macrodex, berichtet. EASLEV (18) dagegen konnte nach 4tägiger Infusion von Dextran bei Kaninchen keine Erythropoeseerhöhung (gemessen an Retic. Zahl und M/E-Index im Knochenmark) feststellen. Dieser Befund, der bisher bei allen Überlegungen zur Regulation der Erythropoese eine wichtige Rolle gespielt hat, dürfte darauf zurückzuführen sein, daß EASLEV seine Blutkontrollen nicht lange genug ausdehnte. Im Gegensatz zu den von ihm durchgeführten Aderlaßversuchen, bei denen die Erythrozytenverminderung plötzlich eintritt und einen Retic. Anstieg bereits nach 48 Std. auslöst, tritt die Dilutionsanämie allmählich ein und erreicht den gleichen Schweregrad erst am 4. Infusionstag. EASLEV führte aber seine Knochenmarkskontrolle bereits am 5. Tag durch und verfolgte den Retic. Verlauf nur bis zum 8. Tag.

Der Verdünnungsanämie kommt beim Problem der Erythrozytenregulation insofern grundsätzliche Bedeutung zu als nach unseren Vorstellungen die Sauerstoffspannung im Gewebe an den noch unbekannten hypoxieempfindlichen Rezeptoren das erste Glied innerhalb der humoralen Steuerung der Erythropoese ist. Die Menge des im Gewebe verfügbaren Sauerstoffs hängt nun in erster Linie von der Erythrozyten(Hämoglobin)-Konzentration ab. Sinkt sie, dann kann dies – neben einer vermehrten Sauerstoffausnutzung (54) – nur in geringem Ausmaß durch Erhöhung des Herzminutenvolumens und der Umlaufgeschwindigkeit des Blutes ausgeglichen werden. Zur völligen Kompensation der anämiebedingten Hypoxie reichen diese Kreislaufveränderungen aber nicht aus (32, 35) im Gegensatz zu der Annahme von EASLEV mit der er seine Befunde zu erklären versuchte.

Bei der Verdünnungsanämie liegt zudem sicher die Situation einer Herzinsuffizienz als Folge der rasch erzeugten Hypervolämie vor, die mit einer Abnahme des Minutenvolumens und Verlangsamung der Strömungsgeschwindigkeit einhergeht (32). Bei 3 Kaninchen haben auf dem Höhepunkt der Verdünnungsanämie die Kreislaufzeit gemessen (Injektion von Coomassieblau in ein Ohr

Ohrheit am andern Ohr) Sie war gegenüber der Voruntersuchung unverändert. Bei der Verdünnungsanämie gleichen sich also die Beschleunigung der Zirkulation infolge Anämie und die Verlangsamung infolge Herzinsuffizienz und Hypervolämie aus.

Da die kreislaufdynamische Anpassung nur eine untergeordnete Rolle spielt, stellt die Erythrozyten bzw Hämoglobinkonzentration den entscheidenden Parameter für die Sauerstoffspannung im Gewebe und damit für die Regulation der Erythropoese dar.

Unsere Versuche zeigen, daß die absolute Größe des EV ohne Bedeutung für diese Regulation ist. Sie sprechen damit gegen die von BRECHER und STOHLMAN (12) aufgestellte Hemmfaktorentheorie. Dieser Theorie zufolge enthält der alternde Erythrozyt einen Hemmfaktor für das Knochenmark. Eine Verminderung der Hemmfaktoren (Blutverlust, Hämolyse) führt zur Erythrozytenproduktion, eine Zufuhr von Hemmfaktoren (Transfusion) zu einer Knochenmarkshemmung. So bestehend diese Theorie zur Erklärung z. B. des völlig kompensierten hämolytischen Syndroms (bei dem eine Hypoxie keine Rolle spielt) sein mag, bei der Verdünnungsanämie tritt die Stimulierung der Erythropoese auf, ohne daß ein «Hemmfaktorenverlust» vorausgegangen wäre. Denn das EV bleibt unverändert.

Die erhebliche Mehrproduktion von Erythrozyten ohne gleichzeitigen Zellverlust muß zwangsläufig zu einer vorübergehenden Polyglobie führen. Diese kommt in der Zunahme des absoluten EV deutlicher zum Ausdruck als im Anstieg der Konzentrationswerte, weil die noch immer bestehende PV Vermehrung sich im Sinne einer Verdünnung auswirkt.

Für die Rückkehr von diesen überhöhten Werten zur Norm sind 2 Möglichkeiten denkbar: entweder tritt eine vorübergehende Hemmung der Zellneubildung auf, oder aber die überschüssig gebildeten Erythrozyten werden vorzeitig abgebaut.

Für diese zweite Möglichkeit, die Verkürzung der Lebensdauer der neugebildeten Zellen, sind klinische und experimentelle Beispiele bekannt.

Eine Reihe von Autoren konnte zeigen, daß bei starker Aktivierung der Erythropoese nach Hämolyse, Blutverlust und Erythropoetiningaben sowie nach Behandlung von Eisenmangelanämien besonders große Erythrozyten (bzw. Retic.) mit verkürzter Lebensdauer im Blut gegangen (7, 10, 11, 13, 14, 30, 38, 39, 58, 59, 61, 63). Die Autoren meinen an, daß diese Retic. nach beschleunigter Reifung unter Überspringung von Reifestadien und vorzeitiger Entkernung ausgeschieden werden. Der Grad der Makrozytose und der Lebenszeitverkürzung ist dabei von der Intensität der vorausgegangenen Beschleunigung abhängig (39). Es ist jedoch nicht ihre Größe, die diese Zellen vorzeitig der Hämolyse anheimfallen läßt, da auch bei splenektomierten Tieren die

gleiche Lebenszeitverkürzung beobachtet (60). Man muß vielmehr einen Defekt dieser überstürzt gebildeten Zellen annehmen. Im Knochenmark wird eine Vermehrung der unreifen Vorstufen der Erythropoese gefunden (53).

Dieser „Panikmechanismus“ (59) der Erythropoese wirkt sich scheinbar wie eine planvolle Steuerung aus, da zunächst viele Zellen produziert werden und der Ausgangswert ohne stärkere Gegenreaktionen wieder erreicht wird. Um eine echte Regulation handelt es sich dabei aber nicht.

Es ist außerdem darauf hinzuweisen, daß dieser Befund einer verkürzten Lebensdauer überstürzt gebildeter Erythrozyten von anderen Autoren (1-19) nicht bestätigt werden konnte.

Bei der Verdünnungsanämie liegen die Verhältnisse nun aber grundsätzlich anders, d. h. es handelt sich um eine echte Regulation, die auf die scheinbare Anämie mit einer Aktivierung der Erythropoese und Ausschwemmung von Erythrozyten mit normaler Lebenszeit, auf die reaktive Polyglobulie dagegen mit einer Markhemmung antwortet. Unsere Befunde unterscheiden sich deshalb in wichtigen Punkten von denen, die bei dem oben skizzierten „Panik Mechanismus“ erhoben wurden.

Die Relation der einzelnen Reifestadien der Erythropoese, insbesondere die der Proerythroblasten zu den übrigen Erythroblasten bleibt unter der Stimulierung unverändert (Abb. 6). Der Retic.-Anstieg setzt zumeist erst am 5. (4 bis 7) Tag ein (Tabelle I) nicht schon nach 48 Stunden wie in den Experimenten von STOLMAN *et al* (39). Die Lebensdauer der neu gebildeten Zellen ist nicht verkürzt (Abb. 7). Die Folge dieser Mehrbildung vollwertiger Erythrozyten ist eine starke Vermehrung des EV (Tabelle II) und eine Polyglobulie. Diese löst eine Hemmung der Erythropoese aus, erkennbar an dem verminderten Anteil der Erythroblasten im Mark (Abb. 6) und dem Absinken der Retic. unter den Ausgangswert (Tabelle III Abb. 5).

Die gleiche Regulation, die somit allein über eine Änderung der Knochenmarkaktivität wirksam wird, findet sich auch bei der Höhenanpassung sowohl in der Phase der Mehrproduktion von Erythrozyten (35) als auch nach Rückführung Höhenangepaßter in normale Sauerstoffverhältnisse (45). Ändert sich jeweils die Zellproduktion, nicht aber die Destruktionsrate. Ebenso wird auch nach einer Transfusions-Polyglobulie die normale Zellkonzentration nicht durch eine vermehrte Hämolyse, sondern durch eine vorübergehende Knochenmarkshemmung erreicht (9) wahrscheinlich über einen humoralen Inhibitor (36, 46). Eine sichere Erklärung der unterschiedlichen Reaktion der Erythropoese auf die Stimulierung durch Aderlaß, Hämolyse und Erythropoetinalgaben einerseits und

der Verdünnungsanämie andererseits kann vorerst nicht gegeben werden. Es ist zu vermuten, daß die unterschiedliche Geschwindigkeit, mit der die Anämie eintritt, eine wichtige Rolle spielt. Bei plötzlich einsetzender Anämie würde dann der «Panik Mechanismus» der Ausschwemmung kurzlebiger Makrozyten, bei allmählich einsetzender Anämie die geregelte Bildung normallebiger Erythrozyten einsetzen.

II Die Verdünnungsanämie als Modell

Die experimentelle Verdünnungsanämie als Modell ist geeignet, die engen Beziehungen aufzuzeigen, die zwischen Gesamtblutmenge und Zellkonzentration bestehen. Hb-Wert, Erythrozytenzahl und Retic. Zahl geben uns nur dann einen verlässlichen Hinweis auf die Knochenmarkleistung, wenn das Blutvolumen keine größeren Abweichungen von der Norm zeigt. Steigt das PV – z. B. im Rahmen einer Anämie – an, dann ist die Gesamtmenge zirkulierender Erythrozyten größer als es nach der Erythrozytenzahl scheint. Diese Konstellation ist geläufig z. B. bei der Schwangerschaftshydramie.

Weniger in Betracht gezogen wird zumeist, daß bei der Bewertung der Retic. Zahl, einem der wichtigsten Parameter zur quantitativen Erfassung der Erythrozytenproduktion, die Gesamtblutmenge ebenfalls eine Rolle spielen kann. Nicht nur die relative Retic. Zahl (angegeben in ‰ oder ‰) sondern auch die sog. «absolute» Zahl (Retic./mm³) oder die für den Hk Wert korrigierte Retic. Zahl (24) erhält unter diesem Gesichtspunkt u. U. einen nur relativen Wert.

Im Extremfall der Verdünnungsanämie mit ihren großen Änderungen des Blutvolumens wird dies evident: hier kommt es zu einer erheblichen Diskrepanz zwischen der absoluten Total Retic. Zahl und diesen sog. «absoluten» Werten, die eben im Hinblick auf die Schwankungen des BV auch nur relativ sind. In unseren Versuchen war die Übereinstimmung der Total Retic. Zahl mit der relativen (‰) Retic. Zahl sogar besser als mit der Retic. /Raumeinheit (Tabelle III, Abb 5). Im Falle einer Hydrämie kann die Zahl der Retic. pro Raumeinheit niedrig sein, während tatsächlich eine vermehrte Retic. Ausschwemmung vorliegt (s. Zeitpunkt II in Tabelle III und Abb 5).

Bei hämatologischen Erkrankungen mit einer erheblichen Diskrepanz zwischen Erythrozytenzahl/mm³ und absolutem EV

Abschließend sollen die hämatologischen Kriterien, die üblicherweise zur Beurteilung der Erythropoese herangezogen werden, auf ihren Aussagewert bei der Verdünnungsanämie und im allgemeinen geprüft werden (Abb 10)

1 Die Werte der Zellkonzentration (Ery/mm³ Hk) sind auch von der Größe des PV abhängig. Sie geben immer dann ein ungenaues Bild der Situation, wenn eine Abweichung des BV von der Norm besteht. Damit muß aber zunächst einmal bei allen schweren chronischen Anämien (ebenso bei Polyglobulie und Polycythämie) gerechnet werden, weil keiner Anämieform ein bestimmter «Volumentyp» zugeordnet werden kann (5). Bei der Verdünnungsanämie wird diese Diskrepanz zwischen absoluter und relativer Zellzahl ganz besonders deutlich.

2. Die Bewertung der Retic. Zahl führt bei jeder stärkeren Regeneration, die mit einer vorzeitigen Ausschwemmung unreifer Retic. einhergeht, zu einer Überschätzung der effektiven Erythropoese, weil die Ausreifungszeit im Blut verlängert ist und die an mehreren Tagen ausgeschwemmten Zellen sich in der Retic. Zahl summieren.

Umgekehrt kann die effektive Erythropoese auch auf Grund der Retic.-Zahl zu gering eingeschätzt werden, wenn die Ausreifung ganz überwiegend im Knochenmark erfolgt, wie z. B. bei der perniziösen Anämie (24).

Diese Diskrepanz zwischen der Retic. Zahl und dem Ausmaß der Zellproduktion betrifft sowohl die relative wie auch die sog. «absolute» und die Total-Retic. Zahl. Auf Grund unserer Untersuchungen möchten wir der relativen Retic. Zahl (%) den Vorzug geben gegenüber der Retic. Zahl/mm³, weil sie von den Schwankungen des PV unabhängig ist und jeweils den Anteil der Erythrozyten angibt, die sich noch im Retic.-Stadium befinden.

Wenn somit auch die Retic. Zahl zur quantitativen Erfassung der effektiven Erythropoese ungeeignet ist, so bleibt davon ihre große Bedeutung für die praktische Beurteilung hämatologischer Krankheitsbilder unberührt.

3 Das Verhältnis von myeloiden zu erythropoetischen Zellen im Knochenmark (M/E-Index) ist eine relative Größe, die nur bei unveränderter Aktivität der Granulopoese brauchbar ist. Täuschungsmöglichkeiten durch Untermischung von peripherem Blut sind gegeben. Der M/E Index ist ein Maß der *totalen* Erythropoese, die sich bei stärkerer ineffektiver Erythropoese erheblich

von der im peripheren Blut gemessenen *effektiven* Erythropoese (Retic.) unterscheiden kann (22-23)

Für klinische Zwecke ist aber der M/E-Index zusammen mit der Retic. Zahl das brauchbarste Kriterium zur Beurteilung der Aktivität der Erythropoese (17)

4 Das Erythrozytenvolumen, als Resultante von effektiver Produktion und Destruktionsrate, ist ein Maß zur quantitativen Bestimmung der Erythropoese wenn die Lebensdauer der Ery bekannt ist und ein Gleichgewicht zwischen Zellbildung und -abbau besteht.

Im speziellen Fall der Verdünnungsanämie ist auch die Messung der Zellmehrproduktion nach Aktivierung der Erythropoese möglich (6). Das so berechnete mittlere tägliche Produktionsmaß ist in Abb. 10 den oben unter 1 bis 3 aufgeführten Größen gegenüber gestellt.

5 Zur Problematik der Bewertung des Plasmaeisen turnover und der Inkorporationsrate von Fe^{59} für eine quantitative Erythrokinetik wurde von anderen Autoren Stellung genommen (14-22, 57). Wir selbst haben derartige Versuche am Modell der Verdünnungsanämie nicht durchgeführt.

Die meisten der hier mitgeteilten Ergebnisse sind in der Dissertation von D. SPANO-LEN (Frankfurt a. M. 1963 in Vorbereitung) enthalten. Dort wird auch auf methodische Einzelheiten näher eingegangen.

Wir danken Frä. M. ARNDT für ihre Hilfe bei den Blutuntersuchungen und Frau U. GATNOW für die Plasmacellfärbungen.

Zusammenfassung

Durch Infusion großer Mengen eines Plasmaexpanders über mehrere Tage kann bei Kaninchen eine Verdünnungsanämie erzeugt werden, die durch eine Abnahme der Erythrozytenkonzentration (Ery/mm^3) bei unverändertem Erythrozytenvolumen charakterisiert ist. Diese Scheinanämie stimuliert wie eine echte Anämie die Erythropoese, es kommt zu einem starken Reticulocytenanstieg und anschließend zu einer Polyglobulie mit Zunahme des Erythrozytenvolumens. Als Folge dieser Polyglobulie tritt eine Hemmung der Erythropoese ein, erkennbar an einer Abnahme der Erythroblasten in Knochenmark und der Reticulocyten im Blut. Die Ausgangswerte von Erythrozytenzahl und Blutvolumen werden erst nach vielen Wochen wieder erreicht. Die Lebenszeit der Erythrozyten bleibt während des Versuchs unverändert. Die Bedeutung dieser Befunde im Hinblick auf die Regulation der Erythropoese und die Beziehung von Zellkonzentration und -gesamtheit wird diskutiert.

Summary

The infusion of large quantity of plasma expander over several days in rabbits produces dilution anaemia characterised by decreased erythrocyte concentration (Ery/mm^3) and unchanged erythrocyte volume. This pseudo-anaemia, like true anaemia,

stimulates erythropoiesis resulting in a sharp increase in reticulocytes and finally a polyglobulia and increase of erythrocyte volume. The polyglobulia in turn inhibits erythropoiesis which can be recognized by the reduction of erythroblasts in the bone marrow and of reticulocytes in the blood. The original values for erythrocyte count and blood volume are regained only after several weeks. The life span of erythrocytes remains unchanged during the experiment. The implications of these findings for regulation of erythropoiesis and the relationship between concentration and total number of cells are discussed.

Résumé

Par l'infusion pendant plusieurs jours de grandes quantités d'un expanser plasmatique une anémie par dilution peut être obtenue chez le lapin, anémie caractérisée par une diminution de la concentration des érythrocytes (Erytasm⁹) le volume érythrocytaire restant inchangé. Cette soit disant anémie stimule l'érythropoïèse comme une anémie véritable: le nombre des réticulocytes augmente fortement puis apparaît une polyglobulie avec augmentation du volume érythrocytaire. Cette polyglobulie est suivie d'une inhibition de l'érythropoïèse qui est reconnaissable à la diminution des érythroblastes dans la moelle osseuse et des réticulocytes dans le sang. Le nombre des érythrocytes et le volume sanguin ne retournent à leur valeur initiale qu'après plusieurs semaines. Le temps de vie des érythrocytes ne change pas durant toute l'expérience. La signification de ces constatations par rapport à la régulation de l'érythropoïèse et à la relation existant entre la concentration et le volume érythrocytaire sont discutées.

Literatur

1. ALPHE, E. L. AND CHAMBERLAIN, D. Observations on the Regulation of Erythropoiesis and on Cellular Dynamics by Fe⁵⁹ Autoradiography. I. STROMMAN. The Kinetics of Cellular Proliferation, p. 790 (New York 1959)
2. ARTERSON, G. AND WALLGÖTE, G. The intravascular persistence of Dextran of different molecular sizes in normal humans. Scand. J. clin. Lab. in test. 16, 76 (1964).
3. BALDOL, M. AND PARRACCIALLI, I. The maturation of reticulocytes. Blood 15, 614 (1960)
4. BECKER, HJ. Das Blutvolumen bei der Polycythaemia vera und seine Änderung unter der Behandlung. Ein klinischer Beitrag zur Frage der Blutelementregulation. Folia haemat., N. F. 7, 236 (1963)
5. BECKER, HJ. UND ARGENTON, H. Untersuchungen über die Blutmenge bei Anämien und ihre Regulation nach Transfusionen. Verh. 8. Kongr. Europ. Ges. Hämatol., Wien 1961
6. BECKER, HJ. SPENGLER, D. UND HARTJE, U. Verh. 10. Kongr. Europ. Ges. Hämatol., Strassburg 1963.
7. BERLIN, N. I. AND LOTZ, C. Life span of the red blood cell of the rat following acute hemorrhage. Proc. Soc. exp. Biol., N.Y. 78, 788 (1951)
8. BERLIN, N. I. WALDMANN, T. A. AND WEISSMAN, S. M. Life span of red blood cell. Physiol. Rev. 39: 577 Suppl. 3 (1959)
9. BIRKBEIL, F. R. MALONY, M. A. AND LEVENSON, S. M. Effect of transfusion poly-cythemia upon bone marrow activity and erythrocyte survival in man. Blood 6, 1021 (1951)
10. BORDOON, H. A picture of erythropoiesis at the combined morphologic and molecular levels. Blood 24, 702 (1964)

11. BOSSOOK, H.; LIPKOWITZ, J. R. SOARO, J. L. AND MILETTE, R. L. Synthesis of haemoglobin in relation to the maturation of erythroid cells. *Nature* 196. 347 (1962)
12. BRECHER, G. UND STORILMAN, F. Humorale Faktoren in der Erythropoese. In *Fortschritte der Hamatologie* Bd. II p. 108 (Thieme, Stuttgart 1961)
13. BRECHER, G. UND STORILMAN, F. Reticulocyte size and erythropoietic stimulation. *Proc. Soc. exp. Biol. N.Y.* 107 687 (1961)
14. CLINE, M. J. AND BERLIN, N. I. Red blood cell life span using DFT³² as cohort label. *Blood* 19 715 (1962)
15. CLINE, M. J. AND BERLIN, N. I. The reticulocyte count as an indicator of the rate of erythropoiesis. *Amer. J. clin. Path.* 39 121 (1963)
16. CROWY, W. H. The metabolism of hemoglobin and heme pigment in hemolytic disease. *Amer. J. Med.* 18 112 (1955)
17. CROWY, W. H. FISCH, C. A.; HAURANG, F. L. STORILMAN, F. AND WASSERMAN, L. Modern methods of quantitation of red cell production and destruction. *Erythrokinetics. Blood* 18 225 (1961)
18. EASLEY, A. J. Erythropoietic function in dilution anemia. *Blood* 10 616 (1955)
19. EASLEY, A. J. The effect of anemic anoxia on the cellular development of nucleated red cells. *Blood* 14 386 (1959)
20. FEDOROV, N. A. Experimental study of polyglobin. A Soviet analog to Dextran. *Proc. 7 Congr. Internat. Soc. Blood Transfusion, Rome 1956*, p. 462 (Karger, Basel/New York 1959)
21. FISCH, H. v. MALLINGBOERT, A.; FRANK, M. UND WIEGNER, H. Die Beeinflussung der Erythrozyten- und der Reticulocytenzahl durch die Veränderungen des Plasmavolumens während der Reticulocytenkrise. *Schweiz. med. Wochschr.* 89 1069 (1959)
22. FISCH, C. A. Some quantitative aspects of erythropoiesis. *Ann. N. Y. Acad. Sci.* 77 410 (1959)
23. FISCH, C. A.; GIBBLETT, E. R.; DOMENGE, D. M.; HURTADO, A. V.; MOTULSKY, A. G. AND REIFF, R. H. Quantitative aspects of erythropoiesis in man. *Transact. Am. Soc. Physicists* 69 149 (1956)
24. GIBBLETT, E. R.; COLEMAN, D. H.; FISCH, C. A.; DOMENGE, D. M.; MOTULSKY, A. G. AND FISCH, C. A. Erythrokinetics. Quantitative measurements of red cell production and destruction in normal subjects and patients with anemia. *Blood* 11 291 (1956)
25. GIBSON, J. G., HARRIS, A. W. AND SWIGART, V. W. Clinical studies of the blood volume. VIII. Macrocytic and hypochromic anemias due to chronic blood loss, hemolysis and miscellaneous causes, and polycythemia vera. *J. clin. invest.* 18 621 (1939).
26. GOLDMAN, I. L. The effect of polyglobin on hematopoiesis. *Pat. Biol. i. clasper ter (Moskva)* 4 54 (1960)
27. GRAY, S. J. AND STERLING, K. The tagging of red cells and plasma proteins with radioactive chromium. *J. clin. invest.* 29 1604 (1950)
28. HAMMARSTEN, J. F.; HELLER, B. I. AND EMMET, R. V. The effect of Dextran in normovolemic and oligemic subjects. *J. clin. invest.* 32 340 (1953)
29. HARRIS, J. W. The red cell. Production, Metabolism, Destruction. Normal and abnormal, p. 129 (Harvard Univ. Press, Cambridge, Mass. 1963)
30. HARRIS, E. B. AND BELCHER, E. H. Radiolotope techniques in the study of red cell life span in experimental animals. 9. Internat. Kongr. Radiologie, München 1959. Bd. 2, p. 905 (Thieme, Stuttgart)
31. HEDLUND, S. Studies on erythropoiesis and total red cell volume in congestive heart failure. *Acta med. Scand. Suppl.* 284 (1933)
32. HEDGLEY, R.; RUTENFRANZ, W.; KAUFMANN, G.; LUTNY, E. UND SCHWY, H. Krenkungsdiagnostik mit der Farbstoffverdünnungsmethode. Stuttgart 1962.

- 33 HUBER, H. LEWIS, S. M. UND SEITZ, L.: Erythrocytenmenge und Anämie bei Myelokleiose. V. Congr. Internat. Soc. Haematology Stockholm 1964 Abstr. B 20.
- 34 JANDA, J. H. Sequestration of reticulocytes and of abnormal red cells by filtration at low pressure. *J. clin. Invest.* 37: 905 (1958)
- 35 KROGER, P. L.: Circulatory adaptations in hypoxia. *Physiol. Rev.* 39: 687 (1959).
- 36 KREYENOWSKI, T. ET KREYENOWSKA, H. Demonstration eines Inhibitors der Erythropoese im Plasma von Tieren mit experimenteller Polycythämie. *Acta physiol. polon.* 11: 1 (1960); zit. *Blood* 16: 1512 (1960)
- 37 MCFARLEAN, A. S. J. TODD, D. UND TRUMP, K. C.: Observations on the anemia of cryptogenetic splenomegaly. *Blood* 13: 524 (1958)
- 38 MOORE, R. R. STOLLMAN, F. UND BARCER, G. Humoral regulation of erythropoiesis. VI The pattern of response to specific therapy in iron deficiency anemia. *Blood* 27: 286 (1963)
- 39 NEUBERGER, A. UND NIVEN, J. S. F.: Hemoglobin formation in rabbits. *J. Physiol.* 112: 292 (1931)
- 40 NORLANDER, O., THORELL, L. UND ÅBERG, B. Changes in total hemoglobin and blood volume in surgical cases treated with blood transfusions and with dextran solutions. *Acta chir. scand. Suppl.* 196. (1954)
- 41 PLUM, C. M. On the reticulocytes, their occurrence and development. *Acta haemat.* 2: 317 (1949)
- 42 FRANKED T. A. J. The aging of red cells. *J. Physiol.* 113: 325 (1958)
- 43 READ, R. C. Studies of red cell volume and turnover using radiochromium. Description of a new closed method of red cell volume measurement. *New Engl. J. Med.* 250: 1021 (1954)
- 44 REEF, R. H. NUTTER, J. V. DEBOWIE, D. M. AND FRICH, C. A. The relative number of marrow reticulocytes. *Amey J. clin. Path.* 30: 199 (1958).
- 45 REYNARSKI, C.; LOZANO, R. UND VALDIVIAO, J. The polycythemia of high altitudes. Iron metabolism and related aspects. *Blood* 11: 433 (1959)
- 46 REYNARSKI, C. RAMOS, J.; PATRA, J. AND VILLAVICENCIO, D. Humoral control of erythropoietic activity in man during and after altitude exposure. *Proc. Soc. exp. Biol., N.Y.* 116: 649 (1964)
- 47 ROWNTREE, L. G.; BROWN, G. E. AND ROTH, G. M. The use of blood and plasma in health and disease. Philadelphia 1929
- 48 SCHMIDT, H. A. E. period. Mitteilung.
- 49 SCHWARTZOFF, W. Zur Wirkung von Dextran als Plasmaexpander. *Z. klin. Med.* 157: 156 (1962)
- 50 SCHWARTZ, E. Maturation and proliferation in normo- and megakaryoblastic erythropoiesis. *Acta med. Scand.* 139: 443 (1951)
- 51 SEGAL, A. The clinical use of dextran solutions. New York 1964
- 52 SEITZ, M. Reticulocytes studies. *Acta med. Scand. Suppl.* 282 (1933)
- 53 SENO, S. MIYAHARA, M.; ASAKURA, H.; OCHI, O. MATSUOKA, A. UND TOYAMA, T. Macrocytosis resulting from early de-nucleation of erythroid precursors. *Blood* 24: 582 (1964)
- 54 SHARPEY-SCHAEFER, E. P. Cardiac output in severe anemia. *Clin. Sci.* 5: 125 (194)
- 55 SPÖRTRAND, T. Relationen zwischen Bau und Funktion des Kreislaufsystems und ihre Veränderungen unter pathologischen Bedingungen. *Forum cardiol. (Mannheim)* 3. (1961)
- 56 SPÖRTRAND, T. Die experimentelle Verdünnungsanämie. *Dis. Frankfurt a. M.* 1966 (in Vorbereitung).
- 57 STOLLMAN, F. The use of Fe^{59} und Cr^{51} for estimation of red cell production and destruction: an interpretive review. *Blood* 18: 236 (1961)
- 58 STOLLMAN, F. Humoral regulation of erythropoiesis. VI Mechanism of action of erythropoietin in the irradiated animal. *Proc. Soc. exp. Biol., N.Y.* 187: 751 (1961)

59. STOKELMAN, F. Humoral regulation of erythropoiesis. VII Shortened survival of erythrocytes produced by erythropoietine or severe anemia. *Proc. Soc. exp. Biol., N.Y.* 107 864 (1961).
60. STOKELMAN, F. BRECHER, G. UND MOORE, R. R. Humoral regulation of erythropoiesis. VIII. The kinetics of red cell production and the effect of erythropoietin. I. JACOBSON¹ and DOYLE. *Erythropoiesis*, p. 162 (Grune and Stratton, New York 1962).
61. STOKELMAN, F. HOWARD, D. AND BELAND, A. Humoral regulation of erythropoiesis. XII Effect of erythropoietin and iron on cell size in iron deficiency anemia. *Proc. Soc. exp. Biol. Med.* 113 906 (1963).
62. SCHOMBERG, D. AND HODGSON, R. E. Aspiration of bone marrow in laboratory animals. *Blood* 4 337 (1949).
63. SUTHERLAND, D. A. EISENTRAUT, A. M. UND MCCALL, M. S. The direct Coombs Test and reticulocytes. *Brit. J. Haemat.* 9 68 (1963).
64. THORNTON, G. : Dextran as plasma substitute. *Lancet* 1 132 (1949).
65. VAN DYKE, H. C. AND BERLIN, N. L. Production of normal-lived erythrocytes with erythropoietin. *Proc. Soc. exp. Biol., N.Y.* 104 373 (1960).
66. WIECKE, H. Das Maß- Mengen- und Zeitgefüge der Erythropoese unter physiologischen und pathologischen Bedingungen. *Schr. eiz. med. Wacht* 87 1210 (1957).

Adress der Autoren: Dr. H. Becker und Dr. Spangler I. Med. Univ.-Klinik, Frankfurt a.M. (Deutschland).

33. HUBER, H., LEWIS, B. M. and SEITZ, L.: Erythrocytopenie und Anämie bei Myelodysplasie. V. Congr. Internat. Soc. Haematology Stockholm 1964 Abstr. B 20.
34. JANDL, J. H.: Sequestration of reticulocytes and of abnormal red cells by filtration at low pressure. *J. clin. Invest.* **37** 903 (1958).
35. KOURIL, P. I.: Circulatory adaptations in hypoxia. *Physiol. Rev.* **39** 687 (1959).
36. KRZYWOWSKI, T. and KRZYWOWSKA, H.: Demonstration eines Inhibitors der Erythropoese im Plasma von Tieren mit experimenteller Polycythämie. *Acta physiol. polon.* **11** 1 (1960) *int. Blood* **16** 1512 (1960).
37. McFAZEEKAN, A. S. J., TODD, D. and TRANA, K. C.: Observations on the anemia of cryptogenic splenomegaly. *Blood* **13** 524 (1958).
38. MOORE, R. R., STOFFMAN, F. and BRICHER, G.: Humoral regulation of erythropoiesis. VI The pattern of response to specific therapy in iron deficiency anemia. *Blood* **22** 286 (1963).
39. NECKERS, A. and NIVEN, J. S. F.: Haemoglobin formation in rabbits. *J. Physiol.* **112** 292 (1951).
40. NORLANDER, O., TROELL, L. and ÅBERG, B.: Changes in total hemoglobin and blood volume in surgical cases treated with blood transfusions and with dextran solutions. *Acta chir. scand. Suppl.* **195** (1954).
41. PLEW, C. M.: On the reticulocytes, their occurrence and development. *Acta haemat.* **2** 317 (1949).
42. PRANDEN, T. A. J.: The aging of red cells. *J. Physiol.* **111** 325 (1958).
43. READ, R. C.: Studies of red cell volume and turnover using radiochromium. Description of a new closed method of red cell volume measurement. *New Engl. J. Med.* **230** 1021 (1954).
44. REED, R. H., TUTTLE, J. S., DONOVAN, H. M. and FRICK, C. A.: The relative number of marrow reticulocytes. *Amer. J. clin. Path.* **30** 199 (1958).
45. REYNAFARJE, G., LOZANO, R. and VALDIVIA, J.: The polycythemia of high altitudes. Iron metabolism and related aspects. *Blood* **14** 433 (1959).
46. REYNAFARJE, G., RAMOS, J., FALBA, J. and VILLALBA, D.: Humoral control of erythropoietic activity in man during and after altitude exposure. *Proc. Soc. exp. Biol.* **115** 649 (1964).
47. ROWNTREE, L. G., BROWN, G. E. and ROTH, G. M.: The volume of blood and plasma in health and disease. Philadelphia 1929.
48. SCHMIDT, H. A. E.: persönl. Mitteilung.
49. SCHWARTZLOFF, W.: Zur Wirkung von Dextran als Plasmaexpander. *Z. klin. Med.* **157** 156 (1962).
50. SCHWARTZ, E.: Maturation and proliferation in normo- and megaloblastic erythropoiesis. *Acta med. Scand.* **159** 445 (1951).
51. SEIGAL, A.: The clinical use of dextran solutions. New York 1964.
52. SEITZ, M.: Reticulocytes studies. *Acta med. Scand. Suppl.* **282** (1953).
53. SENO, S., MIYAMURA, M., ASAKURA, H., OCHI, O., MATSUOKA, K. and TOYAMA, T.: Macrocytosis resulting from early dedifferentiation of erythroid precursors. *Blood* **24** 382 (1964).
54. SHARPEY-SCHAEFER, E. P.: Cardiac output in severe anemia. *Clin. Sci.* **5** 125 (1945).
55. SJÖSTRAND, T.: Relationen zwischen Bau und Funktion des Kreislaufsystems und ihre Veränderungen unter pathologischen Bedingungen. *Forum cardiol. (Münster)* **5** (1961).
56. SPENGLER, D.: Die experimentelle Verdünnungsanämie. Diss. Frankfurt a. M. 1966 (in Vorbereitung).
57. STOFFMAN, F.: The use of ^{59}Fe and Cr^{51} for estimation of red cell production and destruction: an interpretative review. *Blood* **18** 236 (1961).
58. STOFFMAN, F.: Humoral regulation of erythropoiesis. VI Mechanism of action of erythropoietin in the irradiated animal. *Proc. Soc. exp. Biol.* **117** 751 (1961).

Bone marrow: Sternal bone marrow smears were examined in all patients and their differential marrow composition was established by counting at least 750 cells in each instance. The bone marrow reaction has been classified into (1) normoblastic, (2) macro-normoblastic (3) megaloblastoid and (4) megaloblastic. The normoblastic reaction represented the normal line of erythrocytic maturation while the macro-normoblastic reaction showed that at comparable stages of cell development, both the size of the cell as well as of the nucleus was larger than normal. Further the nuclear chromatin was less compact than in normal cells. The megaloblastoid reaction referred to here has also been called 'typical megaloblastic' (12) and 'intermediate megaloblastic erythropoiesis' (7). Compared to the megaloblastic reaction described below the nucleus in megaloblastoid cells was central and the nuclear chromatin coarser. The stippled character of the nucleus was maintained so that it presented sieve-like appearance. Pyknosis of the nucleus was seen only in late megaloblastoid cells. In megaloblastic reaction the developing cells were more irregular with eccentric nuclei. The nuclear cytoplasmic ratio was more and the nuclear chromatin very fine and lacy without any evidence of clumping. The different lines of cell development described above are shown in Fig. 1



Fig 1 Nucleated red cells at comparable stage of development (a) intermediate megaloblast, (b) intermediate megaloblastoid cells, (c) intermediate macro-normoblast, (d) intermediate normoblast. $\times 1500$.

Biochemical investigations included estimation of serum bilirubin, cephalin cholesterol flocculation test and determination of serum protein and serum albumin employing standard techniques (9-15).

The *anemia* was classified into 3 categories on the basis of clinical features, mainly of decompensation, biochemical disturbances as shown by decrease in albumin-globulin ratio and positivity of non-specific flocculation tests, and the histological changes seen in the liver biopsy.

Animals

Adult albino rats of both sexes of known strain, ranging from 100-150 g in weight were employed to produce cirrhosis. The animals were maintained on standard synthetic diet and allowed water *ad libitum*. For the production of cirrhosis, the animals were injected carbon tetrachloride subcutaneously twice a week, in dosage of 0.1 ml/100 g body weight, diluted with an equal amount of liquid paraffin.

Hematologic estimations were made at weekly intervals or more often where necessary. To study the development of macrocytosis in parallel with cirrhosis, the animals were killed in batches at intervals of 8, 11 and 18 weeks, presumably signifying the period of slight, moderate and marked degree of cirrhosis respectively. The animals were sacrificed by exsanguination, the blood subsequently being used for biochemical tests.




Fig. 2. Gross and microscopic (H - E) appearance of liver in grade I cirrhosis. $\times 50$.

All animals were autopsied. Grading of cirrhosis was based on the gross appearances of the liver and its macroscopic picture in conformity with the following criteria (17).

Grade I Grossly the liver showed fine granularity of surface, the granules being less than 1 mm in diameter. Microscopically the cirrhosis was insular or inter-insular. The reticular fibres were seen as thin strands and the collagen fibres were sparse. There was no incipient pseudolobule formation (Fig. 2).

Grade II The granules were slightly coarser, varying from 1-2 mm in diameter. Cirrhosis in these livers was early annular in type. Fibrous septa tended to be thicker and pseudolobule formation had taken place (Fig. 3).

Grade III The granules are markedly coarse and usually more than 2 mm in diameter. The cirrhosis was annular with marked pseudolobule formation. Reticular fibres were thick and condensed and collagenisation of fibrous tissue had taken place (Fig. 4).

Besides the changes described above, the liver showed evidence of fatty or hydropic degeneration particularly in animals who died in the early stage. There was variable degree of necrosis and regenerative activity was evident in all instances in the form of hypertrophied liver cells containing one or more macro-nuclei. The vascular changes comprised great reduction in the number of central veins as compared to portal radicals. The portal branches frequently showed dilatation. Bile duct proliferation was often





Fig. 3. Gross and microscopic appearance of liver (Wilder's reticulum stain) in grade II cirrhosis. $\times 50$

seen and the fibrous septa showed infiltration with chronic inflammatory cells, mostly lymphocytes.

It may be mentioned that there was fair degree of correlation between the gross and microscopic appearances, but not so in all instances. In grading cirrhosis, therefore, although gross appearance of the liver was taken into account, the classification was mainly held on the basis of microscopic picture.

Results

Clinical cirrhosis Measurement of the mean corpuscular diameter in 45 patients of hepatic cirrhosis showed that macrocytosis was present in 25. In these patients the MCD ranged from 8.6 to 11.5 microns with a mean of 9.7μ (Table I). The MCD of 8 normal subjects averaged 7.6μ . Of the 45 patients studied, 12 presented with slight (grade I) cirrhosis, it was moderate (grade II) in 10 while 23 patients suffered from severe degree of cirrhosis (grade III). The distribution of MCD in the 3 groups is represented in Fig. 5



b

Fig. 2. Gross and microscopic (H + E) appearance of liver in grade I cirrhosis. $\times 50$.

All animals were autopsied. Grading of cirrhosis was based on the gross appearances of the liver and its macroscopic picture in conformity with the following criteria (17).

Grade I Grossly the liver showed fine granularity of surface, the granules being less than 1 mm in diameter. Microscopically the cirrhosis was insular or inter-insular. The reticulin fibres were seen as thin strands and the collagen fibres were sparse. There was no attempt at pseudolobule formation (Fig. 2).

Grade II The granules were slightly coarser, varying from 1-2 mm in diameter. Cirrhosis in these livers was early nodular in type. Fibrous septa tended to be thicker and pseudolobule formation had taken place (Fig. 3).

Grade III The granules were markedly coarse and usually more than 2 mm in diameter. The cirrhosis was nodular with marked pseudolobule formation. Reticulin fibres were thick and condensed and collagenisation of fibrous tissue had taken place (Fig. 4).

Besides the changes described above, the liver showed evidence of fatty or hydropic degeneration particularly in animals who died in the early stage. There was variable degree of necrosis and regenerative activity was evident in all animals in the form of hypertrophied liver cells containing one or more macro-nuclei. The vascular changes comprised great reduction in the number of central veins as compared to portal radicles. The portal branches frequently showed dilatation. Bile duct proliferation was often

Table II
Serum bilirubin and reticulocyte levels in anemic cirrhotic patients

Anemia	No. of patients	Average serum bilirubin mg %	Average reticulocyte %
Normocytic	12	1.8 (0.5-3.0)	1.5 (0.5-5.5)
Macrocytic	25	1.0 (0.5-2.5)	2.5 (0.5-6.0)




Fig. 5. Variation in red cell diameter (MCD) in relation to severity of cirrhosis.

*These figures represent patients in each group.




Fig. 6. Comparison of anisocytosis in nutritional megaloblastic anemia and hepatic cirrhosis. Points in the two graphs represent patients of comparable hemoglobin levels.

The occurrence of macrocytosis did not bear any relationship either to the severity of anemia, the erythropoietic response as judged by reticulocytosis, or to the level of circulating bilirubin (Table II)

The peripheral blood smears of macrocytic patients showed that the red cells were uniformly enlarged, presenting a picture of what may be called *iso-macrocytosis* in contrast to the extreme variation in the red cell size met with in other types of macrocytic anemia. As a quantitative measure, the anisocytosis in the patients was expressed in terms of standard deviation of the mean red cell diameter as employed by other workers (3)

Fig II represents the degree of anisocytosis in cirrhosis of the liver. A group of patients suffering from nutritional megalomegalic anemia was included for comparison. Each point in the graph represents a single patient. It is apparent that the variation in the red cell diameter was far more limited in cirrhotic patients in comparison to those of nutritional anemia.

A significant feature was the presence of flattened red cells in 12 of the 25 macrocytic patients, so that a false impression of hypochromia was evident on blood smears. Subsequent determination of the red cell indices showed that in 10 of these 12 patients, although there was an increase in the MCD the mean corpuscular volume (MCV) had remained within the normal limits, thus leading to a decrease in the mean cell thickness (MCT)

The red cell indices of 25 patients showing macrocytosis are summarized in Table I. The MCV varied between 80 and 154 μ^3 . It was only in 15 patients that the increase in the MCV was accompanied by an increase also of the MCD. The mean corpuscular thickness fluctuated widely. It was greater than the normal mean in 11 and less in 10 of the patients. In the remaining 7 patients its value was within the normal limits.

Bone marrow: Bone marrow smears were examined in all the 25 patients showing macrocytosis. The marrow cellularity was normal or increased in all instances. Two patients showed megaloblastic reaction. 15 macro-normoblastic. In 3 the bone marrow contained megaloblastoid cells, while in the remaining 5 the picture was normoblastic. In all the patients showing macrocytosis with decreased MCT the bone marrow reaction was macro-normoblastic. Differential cellular composition of the bone marrow in these patients is detailed in Table III. The significant changes in the bone

Table III
Myelogram in patients with cirrhosis of the liver

Cell type	Normal (8)	Cirrhosis (25)
Blasts	3.0	1.5
Proerythrocyte	6.0	3.5
Myelocyte	15.0	16.0
Metamyelocyte	16.0	13.2
Neutrophil	30.0	20.0
Eosinophil	2.0	5.0
Lymphocyte	12.0	5.3
Monocyte	1.0	0.25
Plasma cell	0	1.5
Proerythroblast	1.0	2.5
Normoblasts		
- Basophilic	5.0	13.5
- Polychromic	6.0	12.0
Orthochromic	3.0	6.0
M. E. Ratio	48 : 1	17 : 1

marrow were erythroid hyperplasia, plasmocytosis and lymphopenia.

Experimental cirrhosis The overall incidence of anemia in 46 rats who developed cirrhosis of the liver was 54.0 %. At the height of anemia the red cell diameters were measured in all the 25 anemic animals. Nine showed macrocytosis. In these animals the mean red cell diameter progressively increased with the severity of hepatic fibrosis. Table IV shows that the normal MCD of 7.40 μ increased to 7.57, 7.87 and finally to 8.06 as the liver disease progressed from normal to first, second and third grades of cirrhosis. It further shows that the increase in MCD was not accompanied by a corresponding rise in reticulocytes. Nor was it related to the severity of anemia.

In another group of 10 animals, the mean corpuscular diameters were measured at different periods of carbon tetrachloride

Table IV
Macrocytosis in relation to the severity of anemia in 25 anemic rats

Group	No. of animals	Average MCD	Hemoglobin %	Retic. %
Normal	80	7.40*	15.3	4.1
Cirrhosis				
Grade I	4	7.57	11.5	4.85
Grade II	8	7.87	9.5	4.73
Grade III	15	8.06	6.8	6.10

* Average of 10 animals only

injection. The results summarized in Table V clearly reveal a progressive increase in the MCD parallel with hepatic damage. The initial MCD of 7.50 microns increased through 7.66 and 7.96 to 8.04 as the injections were continued for 46, 89 and 120 days respectively.




Fig. 7. Price Jones curves on animals suffering from cirrhosis of grade I, II and III. Each graph is derived from the average of animals in the group.

Table I
MCD at different periods of CCl₄ injections in rats

Days after CCl ₄ injection	MCD
0	7.40
46	7.76
89	7.96
120	8.04

Price Jones curves constructed on both the groups of animals conformed to a similar general pattern. The increased MCD was reflected by a shift of the curve to the right (Fig. 7). Since variation in the red cell size was minimal, the base of the curve was not




Fig 8 Red cell frequency distribution curves in 9 cirrhotic rats suffering from macrocytic anaemia.




Fig 9 Flattening of red cells in cirrhotic rat. A number of target cells can be seen

significantly different from the normal. An analysis was made of the red cell frequency distribution curves in all the 9 animals. LARSEN (14) who analysed frequency distribution curves of patients with hepatitis started with the assumption that the curves could be divided into two cell populations, each having a normal distribution around its mean. On this basis he constructed theoretical curves, each curve representing a different proportion between the two cell populations. By finding which of these theoretical

injection. The results summarized in Table V clearly reveal a progressive increase in the MCD parallel with hepatic damage. The initial MCD of 7.50 microns increased through 7.6 and 7.96 to 8.04 as the injections were continued for 46, 89 and 120 days respectively.




Fig. 7. Price Jones curves on animals suffering from cirrhosis of grade I, II and III. Each graph is derived from the average of animals in the group.

Table I
MCD—different periods of CCl₄ injections in rats

Days after CCl ₄ injections	MCD
0	7.40
46	7.76
89	7.96
120	8.04

Price Jones curves constructed on both the groups of animals conformed to a similar general pattern. The increased MCD was reflected by a shift of the curve to the right (Fig. 7). Since variation in the red cell size was minimal, the base of the curve was not

total of 24 injections were given to both the groups. The increase in the mean corpuscular diameter of red cells in the two groups was more or less the same (Table VII)

Discussion

The incidence of macrocytic anemia in cirrhosis of the liver as observed herein was 55.5 / in human subjects and 36.0 / in experimental animals. These figures are in conformity with those reported by other workers. Thus, the frequency of macrocytic anemia in three different series was reported to be 52.8, 64 and 61 / (1, 2, 3). In experimental cirrhosis, likewise, macrocytosis was observed in 36 / of the animals, in one study (2) and one third of the animals in another (22).

That the macrocytosis was due to changes in the liver is shown by the increase in red cell diameter in parallel with the extent of liver damage. Further the incidence of macrocytosis was highest in the most severe form of the disease, lesser in grade II and was least in grade I cirrhosis both in clinical as well as experimental material.

The macrocytosis does not appear to be due to the presence in circulation of immature red cells as shown by lack of correlation between the increase in the MCD and the reticulocyte response. Reticulocytes are, on an average, one micron larger than the fully mature erythrocytes (19). It is unlikely that an average increase of 2.1μ in the MCD of patients with cirrhosis could be produced by reticulocytosis of 2.5 / only.

Some workers have considered the osmotic changes in plasma brought by alteration in its concentration of electrolytes, bile acids and proteins due to cirrhosis, as responsible for macrocytosis (18, 21). We did not observe any increase in serum bilirubin or clinical jaundice either in the patients or in animals. Osmotic disturbance as the cause of macrocytosis in liver cirrhosis seems untenable for another reason. It has been shown that the osmotic concentration must be lowered by at least 0.1 / before measurable increase in the red cell diameter occurred (14). The osmotic concentration of 0.1 / sodium chloride solution at 37 C is about 330 mm of Hg. Since total concentration of plasma colloids is only 30-40 mm Hg, it is difficult to visualize, how change in this fraction could be the cause of macrocytosis. Further if red cells increased in size

curves best fitted the curve being analyzed he determined the diameter of each component. In our study only rough determinations of the mean diameter of the various components were made. Seven of the 9 curves could be broken down into 2 normally distributed cell populations. The other two showed three components. The curves were skewed in their shape depending on the relative sizes of the components, and whether the smaller component was on the right or the left of the larger (Fig 8). Six curves showed that the bigger component was on the right and that the smaller of the two cell components had a normal MCD.

Blood smears revealed little anisocytosis. There was flattening of red cells giving a false appearance of poor hemoglobinization as was observed in human subjects (Fig 9).

The effect of splenectomy on the development of macrocytosis. In a group of 13 animals previous splenectomy was performed before the injections of carbon tetrachloride were started. Six unsplenectomized animals were included as control. Both the groups received equal number of injections. The effect of splenectomy was studied in another group of 4 animals. It was observed that the increase in the mean red cell diameter of the splenectomized and unsplenectomized cirrhotic rats was not significantly different. Splenectomy *per se* did not result in any increase in the MCD (Table VI).

Table II
Effect of splenectomy on macrocytosis of experimental cirrhotic

Animals	Numbers	Hemoglobin %	MCD
CCl ₄ injected	6	9.7	7.73 ± .33
CCl ₄ injected and splenectomized	13	12.7	7.68 ± .40
Splenectomized	4	15.2	7.48 ± .28

Table III
Effect of vitamin B₁₂ administration on macrocytosis of experimental cirrhotic

Animals	Numbers	Hemoglobin g	MCD (mm. run)
Injected with CCl ₄	6	11.7	7.8 ± 0.25
Injected with CCl ₄ and vitamin B ₁₂	9	11.8	7.76 ± 0.30

The effect of vitamin B₁₂ administration on macrocytosis. A group of 6 rats were given injections of carbon tetrachloride while another 9 received vitamin B₁₂ in doses of 25 µg intramuscularly twice a week, in addition to carbon tetrachloride in identical doses. A

tients who suffered from macrocytic anemia, in as many as 20 the bone marrow reaction was abnormal in as much as the nucleated red cells, at the comparable stages of development, were larger than those seen in the normal bone marrow. Two patients showed megaloblastosis, 15 macronormoblasts and in 3 megaloblastoid forms were present in the bone marrow. It is significant that in all the 10 patients who showed thin macrocytosis, the bone marrow reaction was macronormoblastic.

That the macrocytes may be derived from their abnormal precursors in the bone marrow is further suggested by the fact that when the liver damage is prolonged, granulopoiesis is also affected, as reflected by a shift of the myeloid elements to the left, loss of indentation and lobulation of the younger myelocytes and appearance of over segmented neutrophils in peripheral blood (24).

If there is any link between liver damage and the type of bone marrow change, its precise nature is not known. It has been postulated (1) that macrocytosis may be due to macro-normoblastic maturation of cells consequent upon chronic hemolysis of secondary hypersplenism accompanying hepatic disease. Our observation that splenectomized rats subjected to experimental cirrhosis also show similar macrocytosis as the non-splenectomized animals does not support this view. Moreover not all patient of hepatic disease have accompanying hemolytic process. HALL (8) was able to confirm shortened red cell survival with the use of chromium⁵¹ tagged erythrocytes, only in half of the 14 patients with liver disease. He further failed to observe any correlation between the rate of erythropoiesis and the mean red cell diameter. Thus, chronic hemolysis *per se* cannot account for macrocytosis.

It is difficult to visualize that defect in the shortage of vitamin B₁₂ contributed to the development of macrocytes. Administration of vitamin B₁₂ to cirrhotic rats in adequate doses failed to prevent the formation of macrocytes. There was hardly any difference between the average values of MCD of vitamin B₁₂ administered rats and those that did not receive this vitamin. The metabolic functions of liver are so diverse that there is always a possibility of the deficiency of an unidentified factor(s) that may be responsible for the faulty maturation of red cells. The role of protein in this relation has been suggested (3). Further studies on the role of protein deficiency in affecting the red cell size are required.

Summary

A clinical and experimental study was made of macrocytosis in histologically proven cirrhosis of the liver. Its incidence was found to be 55.5% in human subjects and 36.0% in animals. In both, the increase in red cell diameter paralleled liver damage and the frequency of macrocytic anemia was highest in severe cirrhosis. The macrocytosis did not bear any relation either to the severity of anemia, or the reticulocyte response, or the level of bilirubin in blood. Blood smears showed minimal anisocytosis but there was considerable variation in the thickness of macrocytes. The red cells were thicker than normal in 8 and thinner in 10 of the 25 patients who suffered from macrocytic anemia. In the rest the MCT was within normal limits. Bone marrow changes in patients with cirrhosis indicate that the macrocytes are due to abnormal maturation of their precursors. Neither splenectomy nor the administration of vitamin B₁₂ prevented the development of macrocytosis following experimental cirrhosis.

Résumé

Une étude clinique et expérimentale de la macrocytose dans des cas de cirrhose du foie est présentée. Son incidence était de 55,5% chez l'homme et de 36,0% chez l'animal. Chez les deux, l'augmentation du diamètre des érythrocytes était en relation avec le degré de gravité de l'atteinte hépatique. La macrocytose n'avait aucun rapport avec la gravité de l'anémie, la réaction réticulocytaire et le taux de bilirubine du sang. Dans les frottis sanguins, l'anisocytose était minime et les variations de l'épaisseur des macrocytes considérables. Les érythrocytes étaient plus épais que normalement chez 8, et plus minces chez 10 des 25 malades atteints d'anémie macrocytaire. Chez les autres malades, l'épaisseur des cellules était normale. Les examens de la moelle osseuse chez les malades, atteints de cirrhose démontraient que les macrocytes sont dus à une maturation anormale de leurs précurseurs. Dans la cirrhose expérimentale, ni la splénectomie, ni l'administration de vitamin B₁₂ ne peuvent empêcher l'apparition d'une macrocytose.

Zusammenfassung

Bei histologisch nachgewiesener Leberzirrhose wurde die Makrozytose klinisch und experimentell untersucht. Ihre Häufigkeit betrug beim Menschen 55,5% und bei Tieren 36,0%. Bei beiden stand die Zunahme des Erythrozytendurchmessers in Beziehung zum Ausmass der Leberschädigung, und bei schwerer Zirrhose war die makrozytäre Anämie am häufigsten. Die Makrozytose zeigte keine Beziehung zur Schwere der Anämie zur Reticulocytenreaktion und zum Bilirubingehalt des Blutes. Im Blutausstrich fand sich eine maximale Anisocytose neben einer beträchtlichen Dickenvariation der Makrozyten. Die Erythrozyten waren dicker als normal bei 8 und dünner bei 10 von 25 Patienten mit makrozytärer Anämie. Bei den übrigen Patienten lag die Zelldicke im Bereich der Norm. Knochenmarksuntersuchungen bei Patienten mit Zirrhose zeigten, daß die Makrozyten durch eine anormale Reifung ihrer Vorstufen bedingt sind. Bei experimenteller Zirrhose vermochten weder die Splenektomie noch die Zufuhr von Vitamin B₁₂ die Entwicklung der Makrozytose zu verhindern.

References

1. BERMAN, L. AXELFORD, A.R. HOKAN, T. V. JACOBSON, S.D. SHARP, E.A. and VON DER HAIDE, E.C. The blood and bone marrow in patients with cirrhosis of the liver. *Blood* 4: 511 (1949).

2. BRANCO, A. AND JOLLIFFE, N. Anemia of alcohol addicts, observations as to role of liver disease, achlorhydria, nutritional factors and alcohol on its production. *Amer J med. Sci.* 196: 414 (1938).
3. BOKROS, J. The macrocytosis of hepatic disease. II. Thick macrocytosis. *Blood* 15: 244 (1960).
4. CHENAY, G. The morphology of the erythrocytes in cirrhosis and other disorders of the liver. *Can. Med.* 32: 90 (1933).
5. DAVENON, L. S. P. AND FULLERTON, H. W. Some rare types of macrocytic anemia. *Quart. J. Med.* 7: 43 (1936).
6. DEKE, B. AND KIMAR, S. Anemia in experimental cirrhosis of the rat. *Acta haemat., Basel* 28: 341 (1962).
7. FEDERBERG, H. AND ESTREIN, S. Koenigsdorfer megaloblastic anemia. The intermediate megaloblast in the differential diagnosis of pernicious and related anemias. *Amer J Med.* 21: 190 (1956).
8. HALL, C. A. Erythrocyte dynamics in liver disease. *Clin. Res.* 5: 210 (1957).
9. HANFORD, F. M. Serological differentiation of obstructive from hepatogenous jaundice by flocculation of cephalin and cholesterol emulsions. *J. clin. Invest.* 18: 261 (1939).
10. HAYMAN, C. A. AND SOUTHWORTH, H. Hemolytic anemia associated with liver disease. *Amer J med. Sci.* 221: 448 (1951).
11. JAKES, J. H. The anemia of liver disease. Observations on its mechanism. *J. clin. Invest.* 34: 390 (1955).
12. JONES, O. P. Atypical megaloblasts in bone marrow from patients with partial deficiencies in liver principle. *Anat. Rec.* 94: 473 (1946).
13. KOTZ, E. J. AND WOOTEN, L. D. P. Microanalysis in medical chemistry pp 57 and 41 (Churchill, London 1956).
14. LAMBER, G. The distribution of red blood cell diameters in liver diseases. *Acta med. scand. Suppl.* 220 (1948).
15. LUNDQVIST, G. Red blood cell diameter in acute hepatitis. *Acta med. scand.* 151: 221 (1949).
16. LÖNN, H. Hämatologie und Biopsy bei Leberkrankheiten. *Helv. med. Acta* 17: 340 (1950).
17. MARGALIS, V. S. MISKOTRA, R. M. L. AND NAIR, N. C. The pathogenesis of necrosis in carbon tetrachloride cirrhosis. *J. Path. Bact.* 73: 239 (1957).
18. MITSURETACHY, E. AND GOMBERG, H. Blood and bone marrow in infective subacute and chronic atrophy of the liver. *Blood* 3: 1416 (1946).
19. PERCOTT, E. L. Studies on red blood cell diameter; the relative diameter of immature (Reticulocytes) and adult red blood cells in health and anemia especially in pernicious anemia. *J. clin. Invest.* 7: 615 (1929).
20. PIERCE JONES, C. Red blood cell diameters (Oxford Medical Publishers, London, 1933).
21. ROSENBERG, D. H. Macrocytic anemia in liver disease, particularly cirrhosis. *Amer J med. Sci.* 132: 86 (1936).
22. STANLEY, J. AND HEDGECOCK, M. L. Blood forming organs in experimental cirrhosis of liver. *Folia haemat. Pr.* 35: 93 (1936).
23. SUMAKER, H. B. (J.) AND WINTROBE, M. M. Morphologic changes in blood associated with experimentally produced hepatic damage. *Bull. John. Hopk. Hosp.* 59: 343 (1936).
24. TETTERMAN, G. *Acta med. scand.* 130: 371 (1948).
25. WINTROBE, M. M. Relation of disease of the liver to anaemia. *Arch. intern. med.* 57: 289 (1936).

Department of Pediatrics of the University Bari (Director: Prof. F. VECCHIO) and Naples (Director: Prof. G. MURANO)

Electrophoretic Studies of Erythrocyte Glucose-6-Phosphate Dehydrogenase in Normal and Enzyme-Deficient Sardinian Subjects*

F. VECCHIO, F. SCHETTINI, L. DI FRANCESCO, T. MELONI AND G. RUSSINO

The deficiency of glucose-6-phosphate dehydrogenase (G-6-PDH) of the erythrocytes is characteristic for a group of blood disorders (favism, primaquine haemolytic anaemia, some types of congenital nonspherocytic haemolytic anaemia) (1). The lack of G-6-PDH may be quantitative and also qualitative (2, 3). Favism is a blood disorder of the Caucasian subjects while the primaquine sensitive haemolytic anaemia occurs in Negroes.

The G-6-PDH show electrophoretic differences in these racial groups with a sex linked inheritance. Some phenotypes of G-6-PDH have been identified by electrophoresis of the enzyme from human erythrocytes (4). Three electrophoretic patterns of G-6-PDH were found in erythrocytes of Negroes. A slow G-6-PDH identical in migration to that encountered in Caucasian, a slightly faster G-6-PDH and a broad band representing a mixture of both the slow and fast enzyme (5, 6, 7, 8, 9). These were designated respectively II, A and BA according to the nomenclature of Boyer *et al.* (6). Negro females have an electrophoretic fast, slow or both G-6-PDH; the males have one of the other (9). A fourth electrophoretic variant formerly designated C has also been observed. This variant with very slow electrophoretic mobility has been called 'Baltimore' (6, 10).

In this paper we describe our studies on the electrophoretic mobility of the erythrocytic G-6-PDH in Sardinian subjects carried

*Research supported by grant from C.N.R., Italy and carried out in the Department of Pediatrics of the University Sassari Italy (Head: Prof. F. VECCHIO).

out with the method of KIRKMAN *et al.* (9) that is of considerable value in population survey (10)

Material and Methods

Ten apparently unrelated mothers and one son from each mother were selected. The children were from 7 days to 18 months old. Furthermore 11 normal subjects, 22 G-6-PDH deficient subjects, 20 G-6-PDH females and 5 premature infants were examined.

The Sardinian origin of the subjects was accurately ascertained.

The experimental procedure was carried out according to the method of KIRKMAN AND HEDERSTRÖM (9).

Collection of samples: The blood samples of each subject were collected by venipuncture. The heparinized blood was promptly centrifuged at 1000 G for 15 minutes, supernatant plasma and buffy-coat were removed and cold saline solution (0.15 M NaCl) was added and stirred and the centrifugation was repeated. The supernatant fluid was removed and the packed erythrocytes were added in distilled cold water (1:20). After 10 minutes of standing at 4°C each haemolysate was transferred into centrifuge tubes and centrifuged at 16000 G for 20 minutes (SERWALL superspeed 85T). The hematocrit with capillary tubes (Cellotrite centrifuge Ljungberg) was determined on packed red cells.

Each stroma-free supernatant was distributed in tubes (0.50 ml in each tube) and stored at -40°C until the assay.

The haemoglobin concentration of stroma-free supernatant was assayed by DRABIN's method.

Assay of glucose-6-phosphate dehydrogenase was performed by the spectrophotometric method of KIRKMAN AND RILEY (11) and the results expressed in units per ml of haemolysate and per 100 ml of red blood cells. A unit of G-6-PDH was defined as the amount of enzyme necessary for the reduction of 1 μ M of TPN per minute at 25°C.

Preparation of haemolysates for electrophoresis: Each supernatant haemolysate was adjusted to 0.05 M Tris-HCl, pH 8.0; 2.7 mM EDTA, pH 7.0; 7 mM β -mercaptoethanol and 0.015 units of G-6-PDH per ml. Haemolysates from G-6-PDH deficient persons were diluted to final concentration of 0.40 g of haemoglobin per 100 ml regardless of activity.

If faint turbidity was present in the haemolysate, it was removed by centrifugation at 16000 G per 20 minutes.

Electrophoresis in starch gels: The starch gel was prepared from a mixture of 50 ml of 0.5 M Tris-HCl, pH 8.5; 5.0 ml of 0.27 M sodium EDTA, pH 7.0; 67 g of hydrolysed starch and 450 ml of deionized water as described by BERANKE, into 8-Chamch vertical electrophoresis tray. 5 ml of 1 mM TPN were mixed thoroughly into the molten gel just before it was poured. After few minutes the gel was covered with plastic coperture and placed at room temperature for 2 hours and after at 2°C for 2 hours.

The slot mould was removed and a strip of filter paper was carefully placed in the slots for 20-30 seconds and then removed. Each slot received 50 μ l of sample. The slots were covered with molten (50°C) petroleum jelly. The reservoir solution consisted of 0.05 M Tris-HCl, pH 8.0; 0.05 M sodium chloride and 2.7 mM EDTA-Na, pH 7.0. The cathodic reservoir compartment nearest in the gel contained 10 μ l of TPN. Electrophoresis was performed at 2°C for 14-16 hours at gradient of 4 volts per cm.

Stain for G-6-PDH: The gel was sliced. A mixture of 5.0 ml of 0.5 M Tris-HCl, pH 8.0; 0.5 ml of 0.5 M MgCl₂; 3.5 g of starch and 30.0 ml of deionized water were heated until molten and cooled at 45°C then 1.0 ml of 20 mM G-6-P or 1.0 ml of 20 mM 2-de-

Department of Pediatrics of the University Bari (Director: Prof. F. VACCARO) and Naples (Director: Prof. G. MURANO)

Electrophoretic Studies of Erythrocyte Glucose 6 Phosphate Dehydrogenase in Normal and Enzyme-Deficient Sardinian Subjects*

F. VECCHIO, F. SCHETTINI, L. DI FRANCESCO, T. MELOTTI AND G. RUBINO

The deficiency of glucose-6-phosphate dehydrogenase (G-6-PDH) of the erythrocytes is characteristic for a group of blood disorders (favism, primaquine haemolytic anaemia, some types of congenital nonspherocytic haemolytic anaemia) (1). The lack of G-6-PDH may be quantitative and also qualitative (2, 3). Favism is a blood disorder of the Caucasian subjects while the primaquine sensitive haemolytic anaemia occurs in Negroes.

The G-6-PDH show electrophoretic differences in these racial groups with a sex linked inheritance. Some phenotypes of G-6-PDH have been identified by electrophoresis of the enzyme from human erythrocytes (4). Three electrophoretic patterns of G-6-PDH were found in erythrocytes of Negroes. A slow G-6-PDH identical in migration to that encountered in Caucasian, a slightly faster G-6-PDH and a broad band representing a mixture of both the slow and fast enzyme (5, 6, 7, 8, 9). These were designated respectively II, A and BA according to the nomenclature of Boyer *et al.* (6). Negro females have an electrophoretic fast, slow or both G-6-PDH; the males have one of the other (9). A fourth electrophoretic variant formerly designated G has also been observed. This variant with very slow electrophoretic mobility has been called Baltimore (6, 10).

In this paper we describe our studies on the electrophoretic mobility of the erythrocytic G-6-PDH in Sardinian subjects carried

*Research supported by grant from C.N.R., Italy and carried out in the Department of Pediatrics of the University Sassari Italy (Head: Prof. F. VACCARO).

Table II

Electrophoretic phenotype of G-6-PDH red cells from sardinian normal and enzyme deficient or intermediate subjects.

No	Normal		Enzyme deficient				Enzyme intermediate			
	G-6-PDH activity (100 cells)	Electrophoretic phenotype	No	Sex	G-6-PDH activity (100 cells)	Electrophoretic phenotype	No	Sex	G-6-PDH activity (100 cells)	Electrophoretic phenotype
M	301	B	1	M	10	B-	1	F	75	B
M	224	B	2	M	0	B-	2	F	36	B
F	194	B	3	M	37	B-	3	F	28	B
M	235	B	4	M	0	B-	4	F	107	B
M	90	B	5	F	0	B-	5	F	104	B
F	147	B	6	F	0	B-	6	F	162	B
M	335	B	7	M	0	B-	7	F	64	B
M	139	B	8	F	0	B-	8	F	118	B
F	291	B	9	M	0	B-	9	F	86	B
M	128	B	10	F	0	B-	10	F	59	B
M	143	B	11	M	12	B-	11	F	101	B
M	198	B	12	M	10	B-	12	F	83	B
M	132	B	13	F	3	B-	13	F	76	B
M	183	B	14	M	0	B-	14	F	85	B
M	212	B	15	F	20	B-	15	F	68	B
M	186	B	16	M	0	B-	16	F	95	B
M	161	B	17	F	0	B-	17	F	53	B
M	258	B	18	M	0	B-	18	F	123	B
M	186	B	19	M	0	B-	19	F	78	B
M	227	B	20	F	19	B-	20	F	150	B
M	220	B	21	F	0	B-				
			22	M	0	B-				

The electrophoretic phenotype with 2d-G-6-P is of the slow type B.

2 females, have the same migration of type B observed in the mothers (Fig 1)

Phenotype of erythrocyte G-6-PDH from normal and enzyme deficient subjects (Table II) The electrophoretic migration in 21 unrelated normal subjects (18 males and 3 females) has been of the slow type B. The enzyme in 22 G-6-PDH deficient subjects shows a very little band with slow migration of type B- in 20 intermediate females the enzyme shows a normal slow migration of the type B (Fig 2)

In 7 subjects with G-6-PDH deficiency we have also investigated the pattern of migration of 2-desoxy-G-6-P. It has been the same for all tested subjects and has been defined of the slow type B for comparison with a control type B.

Phenotype of erythrocyte G-6-PDH from premature newborns (Table III) Five premature infants aged from 4 to 15 days, and of foetal




Fig. 1. Patterns of G-6-PD after migration on vertical starch gel electrophoresis. Channels contain the following samples: 1 and 5, 2 mother, 3, 5 son, 6, 7 mother, 6, intermediate, 5 son, 7, 6 mother, 7, 7 son, 8, 8 mother. All G-6-PD types are B.

Fig. 2. Patterns of G-6-PD after migration on vertical starch gel electrophoresis. Channels contain the following samples: 1 female enzyme intermediate n. 7 and 3 negro type A, 4 negro female type B, 5 normal n. 6, 6 and 7 negro type A, 8 female enzyme intermediate n. 10. The types of channels 1, 5 and 8 are B.

Table III

Electrophoretic phenotype of G-6-PDII (red cells in premarie infant) of fetal age of seven months.

♀	♂	♀	G-6-PDII mobility RFL	G-6-PDII phenotype
1	M	15	192	D-
2	M	7	240	B
3	F	5	585	B
4	F	4	341	B
5	F	4	298	B

age of seven months, have been investigated. One was a male with enzyme deficiency, one was an intermediate female and three were normal. The electrophoretic migration of the G-6-PDII in these infants is not different from the migration of the children and adult subjects. The picture has been of the slow type B.

The phenotype observed by vertical starch-gel electrophoresis in Sardinian normal subjects (European caucasian) has only been the phenotype B that corresponds to the slow migration of the enzyme.

A little band of enzyme activity with the same mobility as in normal subjects has been observed in subjects with erythrocyte enzyme deficiency; this band is identified as phenotype B.

The studies of the inheritance of the gene for G-6-PDH and of the electrophoretic phenotype of the enzyme have demonstrated the existence of two genetic polymorphisms of G-6-PDH. One is characterized by enzyme deficiency, the other by an electrophoretic variant. Both are determined by X-linked loci (6, 9, 10).

In subjects of Caucasian origin the first studies (5-9) have only shown the phenotype B. These researches carried out on unselected subjects of Sardinia confirm the presence of the phenotype B with genetical transmission also in this population.

We have not observed electrophoretic variants as those referred by PORTER *et al.* (10) on the samples of blood from Sardinian subjects of the north-eastern area of the isle. These variants have been defined as Sardinia, Sardinia 2 and Sardinia/Baltimore. Moreover a faster electrophoretic migration of the enzyme than in normal subjects had been observed (3) in U.S.A. in several males, with a low level of erythrocyte G-6-PDH, in a family of Italian origin.

The presence of almost two polypeptide chains in the G-6-PDH has been suggested (12) and it has been also indicated that the electrophoretic variants of the enzyme are due probably to the mutation of the aminoacid sequence of the polypeptide chains (10). We have observed the electrophoretic migration of the G-6-PDH in premature infants. But also in these subjects the pattern of the enzyme has always been of the type B. Therefore a foetal type of the enzyme detectable by starch gel electrophoresis, as it exists for the haemoglobin, has not been demonstrated.

The sardinian population is a homogeneous group where the enzyme deficient subjects exhibit several abnormal biochemical characteristics of the G-6-PDH. This enzyme variant has been defined as Mediterranean variant and has an electrophoretic migration of the type B (13). Our findings raises the possibility that the Mediterranean variant of the G-6-PDH with the phenotype II may be a prevalent one among these enzyme deficient subjects.

Acknowledgment. We are grateful to Dr. HELEN N. KERRMAN, Oklahoma City for the samples of blood of Negroes with G-6-PDH type A and AB.

Summary

Studies of erythrocyte G-6-PDH by means of critical starch-gel electrophoresis were carried out in sardinian subjects. A slow migration of the enzyme of type B was found in subjects with normal G-6-PDH and in intermediate females. The electrophoretic pattern in G-6-PDH deficient subjects has been of the type B-. The phenotype B- is also present in erythrocyte G-6-PDH of premature infants.

Résumé

Des études de la G-6-PDH érythrocytaire à l'aide de l'électrophorèse sur gel d'amidon ont été faites chez des personnes sardes. Une migration lente des enzymes du type B se trouve chez des personnes ayant une G-6-PDH normale et chez des femmes hétérozygotes. L'image électrophorétique est chez les personnes ayant un manque en G-6-PDH du type B. Le phénotype B se trouve aussi dans la G-6-PDH érythrocytaire d'enfants prématurés.

Zusammenfassung

Bei Einwohnern von Sardinien wurde die G-6-PDH der Erythrozyten mit Hilfe der kristallinen Stärkegel-Elektrophorese untersucht. Eine langsame Wanderung des Enzymes vom Typ B fand sich bei Personen mit normaler G-6-PDH und bei heterozygoten Frauen. Bei Mangel G-6-PDH zeigte das elektrophoretische Bild den Typus B. Der Phänotyp B kommt auch in der G-6-PDH der Erythrozyten von Frühgeburten vor.

References

1. TARDIF, A. R., BREWER, G. J., CARSON, P. E. and ALSTON, A. R. Primaquine sensitivity: Glucose-6-phosphate dehydrogenase deficiency: a inborn error of metabolism of medical and biological significance. *Arch. Intern. Med.* 90: 900 (1962).
2. HU, W. H., RILEY, H. O. and CROWELL, B. B. Different enzymic expressions of variants of human glucose-6-phosphate dehydrogenase. *Proc. Nat. Acad. Sci.* 6: 938 (1960).
3. MARAS, P. A. B. and GOSWAMI, R. T. Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency. *Nature* 194: 454 (1962).
4. PORTER, I. H., BOYER, S. H., SCHWARTZ, J. and MICHIGAN, V. A. Proc. 2nd Intern. Conf. Human Genet., Rome 1961.
5. BOYER, S. H., PORTER, I. H. Electrophoretic heterogeneity of glucose-6-phosphate dehydrogenase and its relationship to enzyme deficiency. *J. Clin. Invest.* 41: 1347 (1962).
6. BOYER, S. H., PORTER, I. H. and WALLACH, R. G. Electrophoretic heterogeneity of glucose-6-phosphate dehydrogenase and its relationship to enzyme deficiency in man. *Proc. Nat. Acad. Sci.* 48: 1868 (1962).
7. KIRK, K. H. Starch gel electrophoresis of human glucose-6-phosphate dehydrogenase. *Scandin. Med. J.* 55: 1431 (1961).
8. HU, W. H. Electrophoretic differences of human erythrocytic glucose-6-phosphate dehydrogenase. *Am. J. Dis. Child.* 104: 466 (1962).
9. HU, W. H. and BOYER, S. H. Sex-linked electrophoretic difference in glucose-6-phosphate dehydrogenase. *Am. J. Hum. Genet.* 15: 211 (1963).
10. PORTER, I. H., BOYER, S. H., WATSON-WATSON, E. J., ABRAHAM, A. and ALSTON, A. R. Variations of glucose-6-phosphate dehydrogenase in different populations. *Lancet* 1963: 1914.
11. KIRK, K. H. and RILEY, H. O. Congenital nonspherocytic hemolysis and anemia. Studies on family with qualitative defect in glucose-6-phosphate dehydrogenase. *Am. J. Dis. Child.* 107: 313 (1961).
12. CHEN, A. E. and LAMSON, R. L. Human erythrocytic glucose-6-phosphate dehydrogenase: Isolation and properties of the enzyme. *J. Biol. Chem.* 237: 2309 (1962).
13. KIRK, K. H. and SCHWARTZ, J. P. A. Mediterranean Asian glucose-6-phosphate dehydrogenase. *J. Lab. Clin. Med.* 63: 77 (1964).

Authors' addresses: Prof. F. V. Chi and Prof. S. Schimone, Inst. Pathol. dell'Università, Via Sallustiana 17, Rome; Prof. E. C. Emerson, Clin. Pathol., Università de la Bahia, Bahia, Bahia, Bahia and G. Ruggieri, Inst. Pathol., Univ. San Paulo, Sao Paulo, Bahia.

Centre National de Transfusion Sanguine Rabat

Hémoglobines anormales chez des malades marocains cancéreux

I GROZDEA, J BENEZGOMOS ET M LEVÊQUE

Une étude de l'hémoglobine a été pratiquée chez des malades marocains cancéreux, à la suite de la constatation d'une Hb A-C dans un néoplasme de la langue. L'intérêt de la recherche d'une éventuelle association entre cancer et hémoglobinopathie est renforcée du fait que des hémoglobines anormales C, S, K₁, ainsi que F et A₂ (dans la thalassémie) ont été identifiées chez les marocains. D'après les statistiques des laboratoires de Casablanca et Rabat (années 1956-1964) la thalassémie est la plus fréquente parmi les anomalies de l'hémoglobine rencontrées dans la population autochtone qui habite la côte (1,2%). Un nombre restreint de cas a été dépisté pour les autres hémoglobines.

Matériel et méthodes

Notre série comporte 50 malades adultes, hommes et femmes marocains, qui ont pas subi des traitements au préalable. Aucune sélection a été faite concernant le stade ou la localisation de la maladie: tube digestif, vessie, prostate, utérus et sein.

L'hémoglobine a été préparée sur du sang frais dans un délai de 24 h et stockée par la suite à 25 °C jusqu'au moment de son utilisation.

Pour l'identification des hémoglobines A, A₂, F et C, nous avons pratiqué l'électrophorèse sur papier (tampons citrate pH 4,9 et éronal pH 8,6 et 9,2) en gel AGAR (tampon citrate pH 3,2 et éronal pH 8,6) et en gel d'amidon (tampon borate pH 8,6).

Le pourcentage Hb F (R.D.A.) a été déterminé d'après la méthode de Szvaza *et al.* (1).

Pour l'Hb A₂ nous avons adopté une méthode visuelle de comparaison des fractions provenant des malades avec un témoin dosé à 3,5%.

Les taux supérieurs à 3,5% d'Hb A₂ et 2% d'Hb F ont été considérés comme pathologiques.

Résultats

Sur la série étudiée, 14 malades (28 %) ont présenté des hémoglobines anormales, avec la répartition suivante: Hb F (R.D.A.)

dans 7 cas, à des taux variant entre 3 20 et 23 / Hb A₂ dans 8 cas, à un taux supérieur à 3 5 /, Hb C dans 2 cas. Trois des malades portaient à la fois des hémoglobines A₂ et F

Discussion

La thalassémie, maladie connue dans le bassin méditerranéen a été trouvée au Maroc, associée à l'Hb S par MEGHALI *et al* (2) D autres auteurs ont publié la présence d'Hb F et A₂ dans des cas de maladies hématologiques comme la leucémie aigüe et chronique (3-4) la maladie de Di Guglielmo (4) le myélome multiple (5) et l'anémie aplasique (3)

Chez les malades marocains l'Hb F s'est avérée fréquente (7 fois) et en quantité importante (19-23 /) dans les cancers de l'estomac. La fraction d'hémoglobine A₂ dépistée 8 fois à un taux supérieur à 3 5 / a été trouvée chez des sujets avec une Hb F (RDA) normale ou une Hb F (la RDA inférieure à 2 /) augmentée. Trois cas ont eu à la fois Hb F et A₂. Une troisième association a été constatée entre cancer et hémoglobine C chez 2 autres malades.

Ces résultats montrent que les modifications ont portées sur les chaînes α et β (6-7). Le pourcentage élevé des sujets marocains ayant à la fois un cancer et une hémoglobine anormale permet de soulever l'hypothèse d'une relation génétique ou pathologique entre les deux maladies. Nous n'avons pas eu la possibilité d'étudier l'hémoglobine chez les mêmes malades au cours des divers stades d'évolution du cancer ni chez les membres de la famille. Dans l'avenir un tel travail nous aidera à mieux comprendre l'association entre cancers et hémoglobines anormales.

Remerciement Nous remercions le Docteur R. CABANES (Centre de Transfusion Sanguine et d'Hématologie Toulouse directeur Professeur J. R. VITZ pour l'aide technique et les indications qu'il nous a données.

Résumé

Une étude a été faite sur l'hémoglobine de 30 malades marocains cancéreux. 14 cas ont présenté une hémoglobine anormale. L'hypothèse d'une relation génétique ou pathologique entre les deux maladies mérite d'être retenue.

Summary

Fourteen out of fifty Moroccans with cancer presented an abnormal haemoglobin. The authors propose the hypothesis of genetic or pathological connection between cancer and the haemoglobin anomaly.

Zusammenfassung

Von 50 marokkanischen Krebspatienten zeigten 14 ein anomales Hämoglobin. Es wird die Hypothese einer genetischen oder pathologischen Beziehung zwischen Krebs und Hämoglobinanomalie aufgestellt.

Bibliographie

1. SEIDIZ, K., GERSHOFF, A. I. AND BRIGER, L. Studies on haemoglobins. I. Their demonstration in sickle cell anemia and other haematologic disorders by means of alkali denaturation. *Blood* 6, 413 (1951).
2. MICHAEL, D.; PLUMET, M. ET DE LA VASTÈRE, C. Premier cas d'anémie drépanocytaire au Maroc. *Bull. Inst. Hygiène-Maroc* 1-2, 157 (1955).
3. BEA AN, G. H.; ELLIS, M. J. AND WHITE, J. C. Studies on human foetal haemoglobin. II. Foetal haemoglobin levels in healthy children and adults and in certain haematologic disorders. *Brit. J. Haemat.* 6, 201 (1960).
4. GERSHOFF, A. I. The human hemoglobins in health and disease. *New Engl. J. Med.* 253: 329, 363, 416 (1955).
5. SEIDIZ, K. Clinical Significance of Abnormal Hemoglobins. In 'WARTMAN' The Year Book of Pathology and Clinical Pathology (1953-1954 book series) p. 302-394 (Year Book Publ., Chicago 1954).
6. ZIEGLER, W. W. AND ROBINSON, A. R. Haemoglobin: its significance in the genetics and evolution of haemoglobin. *Nature* 190-257 (1961).
7. HEDMAN T. H. J. AND PERL, H. K. Chromatographic estimation of four different human hemoglobins. *J. Lab. clin. Med.* 46, 255 (1955).

Adress des auteurs: Drs. J. Gersho, J. Bragman et M. Leclapart, Centre National de Transfusions Sanguines, Rabat (Maroc).

Fatal Pulmonary Embolus in Congenital Fibrinopenia

Report of Two Cases

G. I. C. INGRAM, D. J. MCBRIEN AND H. SPENCER

Fatal pulmonary embolus with pulmonary infarction occurring in a patient suffering from congenital fibrinopenia has previously been reported only once (10). We describe two similar cases of this apparently paradoxical situation.

Case Reports

Case 1 (E.E.) Female

Clinical history. The earlier history and investigations have been described in detail elsewhere (2, 4-9). Intensive studies failed to reveal any haemostatic abnormality other than absence of clottable fibrinogen in the plasma.

In summary the patient was born in 1932, of parents who were first cousins, and died in 1963. She suffered repeatedly from prolonged post-traumatic bleeding, following cuts, contusions or dental extractions, but bleeding could always be controlled by infusion of fibrinogen. Occasional haemarthroses appear always to have been traumatic, and until her last illness there was no evidence of spontaneous bleeding other than superficial bruises.

In 1954 the spleen was removed following traumatic rupture. This event probably was of great significance in playing part in her final illness.

Menstruation started at 15 years, and despite fears of uncontrollable loss proved entirely normal up to the time of her marriage at the age of 26 years. Thereafter there were episodes of menorrhagia which led to recurrent iron deficiency anaemia, and an endometrial curettage was performed in May 1962, under fibrinogen cover.

In November she was readmitted with haemoglobin of 37 (5.4 g%) on account of further menorrhagia and total hysterectomy was performed on November 15th 1962, covered by fibrinogen infusions, and without undue bleeding until 20th November (see below). Further haemorrhage from the vaginal vault occurred on December 4th and 18th requiring packing, but for the next two months she remained well.

In early March 1963 admission became necessary for severe left sciatic pain present for five weeks. There appeared to be no precipitating factor and the pain was constant. Four days after admission she had sudden severe pain in the right buttock which was found to be due to a large haematoma. This occurred spontaneously while the patient was lying in bed. The bleeding was considerable, the haemoglobin dropping from 67% (9.8 g%) to 46% (6.7 g%). As a result of numerous intravenous infusions over the years, the superficial veins had become so disorganised that intravenous in-

fusions were now only possible via a polyethylene catheter introduced into femoral vein, through which blood and fibrinogen were given over the next eight days. Unfortunately the catheter was allowed to remain in the same vein throughout this time. Two days after the start of the infusion, the patient complained of right-sided pleural pain, cough and blood-stained sputum. A blood-stained pleural effusion developed. Culture of the sputum and pleural fluid were sterile. An E.C.G. showed S₁-Q₃-T pattern. A pulmonary embolus was diagnosed; the episode settled and she was discharged home on April 7th 1963.

Apparently she became ill within a few days, with vomiting, fever and coughing up blood. She spent most of the time in bed but did not at first seek advice, although when she attended Outpatients on April 18th it was clear that she was very ill. Her weight had fallen by one stone (ca. 6 kg) she was febrile, her temperature was 38.5 °C and the right pleural effusion had re-accumulated. The right femoral vein was palpable as a hard cord. A new feature was extensive bruising on the trunk and limbs, the bruises having pale centres. A blood sample was obtained by arterial puncture, which gave rise to an enormous haematoma. Blood cultures remained sterile but the white cell count was 24,000/mm³ and within a few days the platelet count began to rise, reaching 1,027,000/mm³ by May 1st. Despite antibiotics the deterioration continued, spontaneous bruising increased, the dyspnoea became worse and the patient eventually died in heart failure on May 7th 1963.

Post-mortem findings: Postmortem examination showed a rather thin, young, edentulous woman with abdominal splenectomy and hysterectomy scars and an old scar situated below the left patella. The main internal findings included total collapse of the right lung by persistent pleural effusion amounting to about one litre. The lower lobe of the right lung was largely replaced by necrotic infarcted tissue and the main artery supplying this lobe was filled with pale thrombotic emboli. The right common iliac vein contained pale crumbling antemortem thrombus from which the emboli probably arose. The left lung was oedematous and the left pleural sac was partly obliterated by old adhesions. There were small petechial haemorrhages in the mucosa of the stomach and haematomas were present on the right side of the urinary bladder and in the perarticular tissues of the left shoulder joint. The liver was pale and fatty. The major arteries showed no atheroma.

Microscopically the principal changes included necrotic pulmonary infarct with overlying acute pleurisy in the lower lobe of the right lung caused by eosinophilic platelet thrombi obstructing the adjacent branches of the pulmonary artery. Organising platelet thrombi were present in the right common iliac vein but none of these thrombi contained stainable fibrin, although the stains used included Weigert's fibrin stain, phosphotungstic acid stain and the Martini-Scarlet-Blau method (M.S.B.). Masson 44/41 and the Fuchsin-Miller fibrin stain (7). Several lymph glands were sectioned and in one the sinus-lining cells contained unidentifiable eosinophilic droplets surrounding the nuclei. No microorganisms were found in any of the tissues examined.

Death was attributed to cardiac failure secondary to multiple pulmonary emboli causing multiple lung infarcts.

Fate of infused fibrinogen. Previous observations (5) of the fate of infused fibrinogen in this patient prepared from time-expired blood had yielded rates of disappearance of 14 and 15%/day after equilibration had been reached. A further estimate of 16%/day was obtained in 1962 at the time of the dental clearance. On those occasions sufficient superficial veins had still been available to obtain serial blood samples by venopuncture, and the rates of disappearance could be determined from daily observations of plasma fibrinogen concentration. Later, however, it was necessary to obtain almost all blood samples by arterial puncture, and their number was therefore severely limited. Following hysterectomy in November 1962 the monitoring of plasma fibrinogen concentration

was for this reason much less thorough than would have been desirable. In the immediate post-operative period, for instance, no determinations were made between the 15th and the 22nd November during which time the concentration was found to have fallen from 0.31 g/100 ml to about 0.03 g/100 ml, and by interpolation it appeared that the level would have been about 0.07 g/100 ml on 20th November 1962 when post-operative bleeding began. Four further infusions of fibrinogen were given over the next two weeks, and the plasma level probably did not fall below 0.10 g/100 ml during this period. Rates of disappearance, based in each case on only two or three determinations of plasma concentration following each infusion, lay between 18 and 22%/day; whereas the initial post-operative value was 26%/day. One further estimate of 20%/day was obtained in March, 1963, during the treatment of the haematoma in the right buttock. These values are higher than those previously obtained from this patient, but it must be remembered that the later estimates were based on very few points and therefore represent mean rates over the whole periods of the observations including any initial rapid fall. On this basis, values of up to about 20% probably do not greatly differ from earlier results. In any event there is no evidence of a progressive increase in the rate of removal of infused fibrinogen over the last few months of the patient's life.

Case 2 (N.N.), Male

Clinical history. A Greek aged 28 who, in 1937 at the age of 24 had been investigated for abnormal bleeding following tooth extractions at University College Hospital and was found to be grossly fibrinopenic.

His final illness began suddenly in mid-February 1961 with fever, right-sided pleural pain, cough and haemoptysis. He was treated with Tetracycline but failed to improve and when a pleural effusion developed he was admitted to hospital on 6th March, 1961.

Examination showed an ill man. He was sweating, with pallor due to peripheral constriction, and there was a large right pleural effusion. Pulse 120/min, B. P. 140/100. The history of abnormal bleeding was obtained at this stage and fibrinopenia was confirmed.

In view of the risk of precipitating bleeding, a fibrinogen infusion was given before aspirating the pleural cavity. Two litres of heavily blood-stained fluid were removed. It was necessary to give repeated infusions of blood, fibrinogen and plasma in an effort to stop bleeding into the pleura, but in the course of the next fourteen days about eleven litres of heavily bloodstained fluid were aspirated from the right pleural cavity. Each aspiration was necessary to relieve severe shortness of breath and falling blood pressure.

An E.C.G. taken on admission showed changes suggestive of posterior infarct. After the original fibrinogen infusion it was noticed that both calves were tender and later one cephalic vein became thrombosed. On the 27th March there was a fairly obvious deep vein thrombosis in the right calf. A bronchoscopy revealed no specific abnormality. A thoracotomy disclosed a mass in the right lower lobe which on biopsy was found to be only young fibrous tissue.

Following this operation a tension pneumothorax developed and further operation was undertaken in which the pleura was stripped and the leak from the lung was oversewn. Within a matter of hours, he developed increasingly severe failure and died.

Post-mortem findings: Postmortem examination disclosed the body of a slightly emaciated, obese young man with an unhealed incision over the sixth right intercostal space and a stab drainage wound in the intercostal space below.

The principal changes were present in the cardiovascular and respiratory systems. There was a recent infarct, the centre of which was liquefied, involving the outer part of the lower half of the posterior wall and apex of the left ventricle. Despite careful search no obstruction was found in either coronary artery and there was an absence of atheroma

in the major arteries. Both common femoral veins and the deep calf veins in both legs contained pale antemortem thrombus. The lungs showed multiple infarcts in both lower lobes and in the right middle lobe. Some of these infarcts were necrotic, others were in process of organisation, while the remainder of both lungs were extremely oedematous. An infarct in the right middle lobe had ruptured through the pleural surface causing bronchopleural fistula. The left pleural sac contained 300 ml of straw-coloured effusion but the right sac had remained empty since the operation. The liver was pale and fatty and no biliary obstruction was found.

Microscopical examination showed recent and pale infarcts in the lungs one of which was infected with an *Aspergillus* sp. Adjacent branches of the pulmonary arteries contained platelet thrombi in varying stages of organisation but these lacked fibrin (The same stains were used as in Case 1). There was ischaemic fibrosis in the wall of the left ventricle. Death had resulted from myocardial infarction of uncertain aetiology and multiple emboli causing infarcts in the lungs some of which were infected with *Aspergillus* sp.

Plasma fibrinogen concentration: This patient does not appear to have been intensively investigated when in normal health, and detailed information on his haemostatic mechanism is not available, but congenital fibrinopenia seems to be the most likely explanation of the results obtained. The findings in 1957 (for which we are indebted to Dr J. G. HAWORTH) were, whole blood unclotted after 3 h, prothrombin time 31.7 (control 12.2) clot formed by adding thrombin solution (Fibrinex) indicated 'very low' plasma fibrinogen concentration, electrophoretic fibrinogen band 'just detectable with normal bleeding time (2.5 min), and platelet count (380,000/mm³). On admission to St. Thomas' Hospital in 1961, the plasma fibrinogen concentration was less than 100 mg/100 ml by clot-weight method and the prothrombin time was over 2 min. The thromboplastin generation screening test (3) gave normal result and the platelet count was 175,000/mm³. The rate of disappearance of infused fibrinogen was not measured, but the plasma concentrations which were recorded following the infusions did not suggest an abnormal rate of disappearance.

Discussion

Postmortem findings: Fibrinopenia is a rare disease and the two cases presented above both provided an opportunity to study the structure of thrombi in the absence of fibrin formation. In both cases the patients died from the effects of thrombotic embolism despite their inability to form fibrin. Normally the majority of pulmonary emboli are mixed thrombi originating in distal leg veins which are the seat of phlebothrombosis. In both of the present cases no fibrin was demonstrable either in the primary thrombi or resultant emboli all of which consisted only of fused platelet masses with some entrapped circulating blood cells.

The changes found in both of our cases closely resembled those described by DE VRIES *et al.* (10). In all three cases the extensive pulmonary infarcts were characterised by liquefaction and by an absence of any fibrin but otherwise resembled normal infarcts in their microscopical features. The liquefactive changes

present in the pulmonary infarcts in both of our cases are unusual in the absence of chronic heart failure and remain unexplained. The possibility that absence of fibrin may have contributed to this change cannot be excluded. The staining properties of fibrin vary according to its age, fresh fibrin being stained by acid dyes of low molecular weight and small size while older fibrin approximates more closely to collagen in its staining properties. For this reason a variety of staining methods should be employed to detect fibrin at all ages. In our cases the failure of five different methods to detect fibrin in either the primary venous thrombi or resultant emboli and also in the lung tissue at the edge of the infarcted areas shows that it was absent both in older lesions and in those formed shortly before death.

With the electron microscope, JOHNSON *et al.* (6, 8) have shown in rat and guinea pig mesentery that haemostatic platelet aggregates formed *in vivo* come to contain fibrin strands among the platelets within a few minutes of the arrest of bleeding. They also demonstrated a fibrin network entrapping red cells. Our results suggest that fibrin formation (at least to the extent identifiable with the light microscope) is not essential to the continuing solidarity of a platelet thrombus.

The fate of infused fibrinogen. In the cases of BRÜNNMANN (1) and of DE VRIES *et al.* (10) an anti-fibrinogen was demonstrated in the patient's blood before death, destroying infused fibrinogen and rendering both patients refractory to treatment. In our patients, infused fibrinogen appeared (and in case 1 remained) in the circulation as would have been expected, providing good evidence against the development of an anti-fibrinogen in either

Thrombocytosis in case 1 In case 1 the platelet count rose to over $10^6/\text{mm}^3$ and many spontaneous bruises appeared, during the terminal illness. We think that this was an example of an exaggerated haemopoietic response such as may be seen in previously splenectomized subjects, and was presumably related to the pulmonary infarct. Work on other patients has shown (McCLURE, INGRAM, STACEY GLASS AND MATCHETT in preparation) that when a temporary rise in platelet count occurs even a long time after splenectomy the circulating platelets share some of the abnormalities shown by thrombocythaemic platelets. We therefore suppose that, terminally the platelets in case 1 became haemo-

statically ineffective as the platelet count rose and that this caused the extensive spontaneous bruising which had not hitherto been a feature of her haemorrhagic history

Acknowledgment: We are grateful to Dr B. CREAMER and to Dr H. K. GOADBY for their permission to publish these cases.

Summary

The terminal illnesses of two cases of congenital fibrinopenia are described. Both patients died of pulmonary embolism, and postmortem, the lungs of both showed liquefaction in the infarcted areas. A variety of staining techniques failed to demonstrate fibrin either in the original thrombus or embolus or around the infarct. The behaviour of infused fibrinogen showed that neither patient destroyed this material unusually rapidly indicating that neither had developed an antifibrinogen antibody. In one patient the white cell and platelet counts rose to high levels, and extensive bruising appeared; this myeloproliferative reaction was thought to be related to her previous splenectomy.

Résumé

Rapport sur le tableau clinique terminal de deux cas de fibrinopénie congénitale. Les deux malades moururent d'embolies pulmonaires. A l'autopsie, les poumons présentèrent une liquéfaction des parties infarctées. Il ne fut pas possible de mettre en évidence de la fibrine à l'aide de différentes méthodes de coloration, ni dans le thrombus primitif, ni dans l'embolus, ni dans la zone de l'infarctus. Une infusion de fibrinogène démontra que chez ces malades, celle-ci n'est pas dégradée plus rapidement que d'habitude. Il en ressort qu'il ne se trouvait aucun anticorps contre le fibrinogène. Chez l'un des malades, le nombre des leucocytes et des thrombocytes monta très haut, et il se forma des suffusions très étendues. Cette réaction myéloproliférative fut mise en relation avec la splénectomie effectuée antérieurement.

Zusammenfassung

Es wird über das terminale Krankheitsbild zweier Fälle von kongenitaler Fibrinogenopenie berichtet. Beide Patienten starben an Lungenembolie, und bei der Autopsie zeigten die Lungen eine Verflüssigung der infarctierten Bezirke. Weder im ursprünglichen Thrombus, noch im Embolus, noch im Bereich des Infarktes liess sich mit verschiedenen Färbemethoden Fibrin nachweisen. Bei keinem der Patienten wurde infundiertes Fibrinogen ungewöhnlich rasch zerstört, woraus hervorgeht, dass keine Antikörper gegen Fibrinogen gebildet wurden. Bei einem Patienten stiegen die Leukocyten und Thrombocyten auf hohe Werte an, und es bildeten sich ausgedehnte Blutungen. Diese myeloproliferative Reaktion wurde zu der früher vorgenommenen Splenektomie in Beziehung gebracht.

References

1. RAJESMAN, R. Congenital Afibrinogenemia. Mitteilung eines Falles mit multiplen Knochencysten und Bildung eines spezifischen Antikörpers (Antifibrinogen) nach Bluttransfusionen. *Acta haemat.*, Basel 11: 40 (1954)
2. HARDISTY, R. M. AND PROSSER, J. L. Congenital Afibrinogenemia; further observations on the blood coagulation mechanism. *Br. J. Haemat.* 2: 129 (1956).

present in the pulmonary infarcts in both of our cases are unusual in the absence of chronic heart failure and remain unexplained. The possibility that absence of fibrin may have contributed to this change cannot be excluded. The staining properties of fibrin vary according to its age, fresh fibrin being stained by acid dyes of low molecular weight and small size while older fibrin approximates more closely to collagen in its staining properties. For this reason a variety of staining methods should be employed to detect fibrin at all ages. In our cases the failure of five different methods to detect fibrin in either the primary venous thrombi or resultant emboli and also in the lung tissue at the edge of the infarcted areas shows that it was absent both in older lesions and in those formed shortly before death.

With the electron microscope, JOHNSON *et al.* (6-8) have shown in rat and guinea pig mesentery that haemostatic platelet aggregates formed *in vivo* come to contain fibrin strands among the platelets within a few minutes of the arrest of bleeding. They also demonstrated a fibrin network entrapping red cells. Our results suggest that fibrin formation (at least to the extent identifiable with the light microscope) is not essential to the continuing solidarity of a platelet thrombus.

The fate of infused fibrinogen. In the cases of BRÖNNIMANN (1) and of DE VRIES *et al.* (10) an anti-fibrinogen was demonstrated in the patient's blood before death, destroying infused fibrinogen and rendering both patients refractory to treatment. In our patients, infused fibrinogen appeared (and in case 1 remained) in the circulation as would have been expected, providing good evidence against the development of an anti-fibrinogen in either

Thrombocytosis in case 1 In case 1 the platelet count rose to over $10^6/\text{mm}^3$ and many spontaneous bruises appeared, during the terminal illness. We think that this was an example of an exaggerated haemopoietic response such as may be seen in previously splenectomised subjects, and was presumably related to the pulmonary infarct. Work on other patients has shown (McCLURE, INGRAM, STACEY, GLASS AND MATCHETT in preparation) that when a temporary rise in platelet count occurs even a long time after splenectomy the circulating platelets share some of the abnormalities shown by thrombocythaemic platelets. We therefore suppose that, terminally the platelets in case 1 became haemo-

World Federation of Haemophilia

The Third Congress of the World Federation of Haemophilia was held in Paris, September 7th to 9th 1963, sponsored by The International Society of Blood Transfusion. The Federation was founded in Copenhagen in 1963 following suggestion by Dr E. NEUMARK (London) and Dr J P SOULIER (Paris) echoed by Sir WILLOW DALRYMPLE-CHAMBERS in presidential address to the Haemophilia Society and stimulated by Mr F SCHWABEL (Montreal) president of the Canadian Haemophilia Society. The second congress was held in Amsterdam in 1964 under the presidency of Prof. S. VAN CREEVELD.

In the session on the detection of carriers of haemophilia with Prof. K. M. BRIDGES (USA) in the chair lively discussion developed, but everyone agreed that possible carrier could not be identified with certainty by laboratory tests at present and nobody was prepared to say whether woman was or was not carrier in haemophilic family. C. KERR (Australia) thought that haemophilia is transmitted under polygenic control. M. VERSTRAETE (Belgium) used capillary blood but his results were equally indefinite.

In session on the treatment of pain in haemophilia the continued widespread use of aspirin and salicylates was deplored by several speakers. P. WOLF (London) P. LEARN (France) and B. NOEL (France) stressed the usually prompt alleviation of pain in joint and muscle haemorrhage following an infusion of plasma, and pleaded for restraint in the use of analgesics, early haemobilisation when a limb was involved, but also early restoration of movement in joint.

Other papers were given by teams from Sweden, Switzerland, Russia, Israel on surgery in haemophilia, the necessity of vaccinating haemophilic patients, treatment of haematuria, which is a frequent complication in haemophilia treated by salicylates.

Representatives of the national haemophilia associations reported progress. (Argentina) described the laboratory control and production of factor VIII concentrates. It was agreed that haemophilia patients should not remain longer than absolute necessary in hospital, but should return as soon as possible to their own surroundings.

Representatives of the haemophilia society in New South Wales and of another society in Victoria were reported on different lines, but had friendly relations.

A. J. B. was a medical and scientific society on haemophilia in which looked after the patients' interests. C. HARRIS was a society of medical and social matters caused an uneven

patients were looked after satisfactorily. J. P. was a society of blood products of the more than 1000

organisations and their relationships with the World Federation of Haemophilia.

Representatives of the special identity of haemophilia and of its consequences for the patients and their families were discussed.

Representatives of the families of patients caused by haemophilia. E. J. B. appreciated that familial cases of haemophilia were rare.

Representatives of the families of patients could be sporadic or familial. R. BELLAKI (Greece) R. DELLA

R. BAKALJA (Yugoslavia) and R. DELLA NICOLA (Italy) and O. J. B. were the care of haemophilic patients.

The *haemophilic at school* presents special problems. D. ALAGILLE (France) described the medical and academic supervision in the two boarding schools and the recently gained permission of haemophilic boys to attend girls' schools. K. DORMANOV (London) told of the reply to her questionnaire sent to 150 families with haemophilic children in South-Eastern England and of the plan to set up a boarding school for them near Oxford. The *psychological disturbances* in the haemophilic school boy whether at home, at school or board were stressed in several papers.

The *working life of the haemophilic* was the subject of a session under the chairmanship of H. CHAZOMBAU (President of the French Haemophilia Society who was perfect host throughout the meeting). P. LEARN (France) suggested that working as clerk or accountant for those who were sufficiently well educated, and as an electronic mechanic was the best solution and that work with sharp tools was contra-indicated. E. NEUMARK (London) said that rehabilitation must start as soon as an acute episode was overcome. Prolonged stay in hospital can lead to gaps in education which are difficult to close later on. Illness may lead to the loss of a job and sometimes to the loss of the discipline of life and of work. Much effort is needed to avoid a man becoming unemployable.

Delegates did not think that an international identity card for haemophilic people was necessary. The World Federation of Haemophilia has become an Associated Member of the International Society for Rehabilitation of the Disabled. Its next meeting will be in Montreal in 1967.

E. NEUMARK, London

Varia

Standardisierung in der Hämatologie

Vom 14. bis 18. Juni 1965 wurde ein erstes internationales Standardisierungssymposium für die Hämatologie in Südamerika abgehalten. Die Tagung wurde in Ica (Peru) unter dem Vorsitz von Dr. E. REWALD (Argentinien) abgehalten; 2. Vorsitzender war R. EILERS (USA). Die Kurzfassungen der Vorträge sind von der Peruanischen Hämatologischen Gesellschaft in einem Heft herausgegeben worden. An der Sitzung wurde die Notwendigkeit der Standardisierung hämatologischer Methoden betont und die Gründung nationaler Standardisierungskomitees in den einzelnen amerikanischen Ländern angeregt. Am 11. Dezember 1965 fand in Mar del Plata eine zweite Sitzung statt.

Pediatric Research Institute, Rikshospitalet and Neurophysiological Laboratory at the
Anatomical Institute, University of Oslo, Oslo

The Central Nervous System in Regulation of Erythropoiesis

S HALVORSEN

The concept of central nervous system (CNS) participation in the regulation of erythropoiesis was originally based on clinical and experimental investigations showing a correlation between CNS disorders and polyglobulia, and polyglobulia following stimulatory or ablative procedures on the diencephalon. Most of this work is now considered inconclusive because only peripheral blood values were investigated. A recent clinical study has, however provided well documented evidence in favor of an influence on erythropoiesis from the CNS (11). The CNS participation in erythropoiesis regulation has on the other hand by many workers been considered as non-existent or non-specific. The case reports of STOHLMAN *et al.* (38) and SCHMID AND GILBERTSEN (34) have been considered to exclude the organs above the diaphragm as of primary importance for the regulation of erythropoiesis. Thus there is at present considerable controversy regarding the role of the CNS in the control of erythropoiesis. The purpose of the present paper is to summarize and analyze our own studies and to review other recent studies in an attempt to evaluate the data regarding this problem, and to draw some conclusions for future studies. BEER (4) SEIF (35) KOMYIA (23) HOLLAN (20) REMOZZE (33) and BACIU (2) have reviewed the extensive literature on this problem and these reviews should be consulted for a more detailed description of the previous studies.

The working hypothesis for our studies on the CNS control of erythropoiesis has been that the variations in oxygen tension are recorded in the hypothalamic area, and that the erythropoietin(s) are produced in one or several target organs stimulated via hypo-

thalamus by humoral or nervous routes. Our studies have therefore concentrated on the influence of hypothalamus on erythropoiesis. They have been divided into three types of experiments

(1) Stimulation experiments. Electrical stimulation of the hypothalamus using reticulocyte counts, red cell mass and plasma erythropoietin levels as parameters (36-19)

(2) ablation experiments. Hypothalamic lesioning procedures followed by short term hypoxia using reticulocyte counts as parameter. The hypoxic tests were performed with and without pretreatment with pituitary hormones (16)

(3) hormone experiments. Comparison of the effect of pituitary and target organ hormone administration with the effect of electrical stimulation of the hypothalamus (14-17-18)

The studies have been published in detail elsewhere and only the data used in the comparison between the effect of hypothalamic stimulation and pituitary hormone administration are included in this report. The data from the ablation experiments are not reported but are referred to in the discussion.

Material and Methods

The experiments were performed in adult male rabbits, except in the stimulation studies where both male and female rabbits were used. The reticulocyte counts and the red cell mass per kg body weight (RCM/kg) differed slightly in the various groups, but since relative more than absolute values are compared, this has not been considered significant. The experimental period has been 14 days, in some of the hormone experiments an additional 14 days. The red cell mass (RCM) was determined with the ^{51}Cr method as previously described (14-36). The reticulocytes were stained with the brilliant cresyl blue method (35) and 5000 or 2000 erythrocytes were counted. The plasma erythropoietin was tested in starved mice and intact mice (15) and in polycythemic mice (13, 47).

Results

Following electrical stimulation of the hypothalamus 8 of 28 rabbits showed a marked rise in reticulocytes and red cell mass (36). These 8 rabbits are referred to as the positive response group, and data from this group only are included here. Ten rabbits showed no reticulocytosis and no increase in RCM while 10 rabbits showed inconsistent variations in these parameters. These groups are referred to as the negative and the doubtful response groups, respectively. As the positive response group was a selected group, it has not been found justified to perform statistical evaluation of the differences between the groups.




Fig 1 Upper figure: Mean reticulocyte response to hypothalamic stimulation (positive response group) and to ACTH injections in intact rabbits compared with the reticulocyte values in control rabbits.

Lower figure: Mean reticulocyte response to porcine growth hormone (GH), GH-ACTH, and GH-ACTH-thyroxine-tesosterone (GH-ACTH-TH-T). The brackets indicate 2 standard errors of the mean. The figures below the group name indicate the number of rabbits in each group.

Fig 1 shows the mean *reticulocyte* response in the various types of experiments. The intact control rabbits had very stable reticulocyte counts indicating that this method is also useful in rabbits as a measure of erythropoiesis. The rabbits in the positive response group showed a marked rise in reticulocytes from the second or third day following stimulation, and the response differed markedly from the controls. ACTH increased the reticulocytes slowly but the increase was significantly different from the controls and also different from the positive response group. Both growth hormone (GH) alone and GH in combination with ACTH (AC) increased the reticulocyte counts and the responses could not be differentiated from the response to hypothalamic stimulation. GH-




Fig. 2. Upper figure: Mean of the differences between red cell mass (RCM) determinations after a 2 week experimental period and the values before this period in intact, control rabbits, in the positive response group of hypothalamic stimulation and in rabbits injected with ACTH, GH, ACTH-GH (AG) and with GH-ACTH-thyroxin-testosterone (GATT).

Lower figure: Mean of the differences in RCM/kg body weight in the same groups. The number of rabbits in each group is given below.

ACTH thyroxin-testosterone (GATT) also increased the reticulocytes, but less than GH alone and GH ACTH in combination.

Fig. 2 and Table I show the mean changes in *total RCM* and *RCM/kg body weight* in the various experiments. The results are expressed as the mean of the differences between the values after a 14 days experimental period and the values before this period. The controls showed a slight, insignificant rise in *total RCM* and a slight decrease in *RCM/kg body weight*. ACTH increased *total*

RCM and with a slight increase in RCM/kg body weight. In the GH treated group the total RCM increased less than in the controls, while the RCM/kg body weight increased relatively more due to weight loss of the animals. GH combined with ACTH increased the total RCM less than ACTH alone, while the RCM/kg body weight increased slightly. GH ACTH thyroxin-testosterone increased the total RCM markedly and more than in any of the other groups including the positive response group of hypothalamic stimulation. The RCM/kg body weight also increased markedly but this rise may give a false impression of the magnitude of the response because of weight loss of the animals. Electrical stimulation of the hypothalamus increased the total RCM and RCM/kg body weight more than did ACTH, GH and GH ACTH administration, but less than GH ACTH thyroxin testosterone.

Table I also lists the mean changes in the other parameters studied. *Hemoglobin, hematocrit and number of erythrocytes* did not change in the control group or in the ACTH injected group. In the positive response group the hematocrit increased moderately. In the GH and GH ACTH injected groups, the peripheral blood values dropped initially but at the end of the two week period the levels were only slightly below the initial values. In the group of rabbits injected with GH ACTH-thyroxin testosterone, the hemoglobin, hematocrit and number of erythrocytes increased to levels significantly above the other groups. The mean corpuscular volume (MCV) increased in the positive response group less in the GH, ACTH and GH ACTH injected groups while there was no change in the other groups.

Table II summarizes the results of the *plasma erythropoietin* determinations. Plasma from rabbits subjected to electrical stimulation of the hypothalamus for 2 weeks increased the reticulocytes and the Fe^{59} erythrocyte uptake more than plasma from control rabbits when tested in starved mice. Plasma from one of these rabbits also increased the reticulocytes and the Fe^{59} erythrocyte uptake in polycythemic mice. Plasma from the hormone injected rabbits withdrawn after 2 weeks of administration did not increase the Fe^{59} erythrocyte uptake significantly neither in starved nor in polycythemic mice. Plasma withdrawn from the rabbits injected with GH ACTH-thyroxin testosterone after the development of polycythemia seemed to inhibit erythropoiesis in starved mice.

erythropoietin may take place in this organ, neither of these functions can be located in the kidneys exclusively because erythropoiesis continues in the anephric man (38) and animal (28). The site of action of erythropoietin is still unclear and the reticulocyte release mechanism almost unknown. The effect of the hormones is no longer considered to be so definitely non-specific since recent work on thyroxin (27) testosterone (10) GH (9, 33) and prolactin (9, 21) provide evidence that these hormones may act directly in the bone marrow or stimulate erythropoietin production. These studies, as well as the studies of Evans *et al.* (7) on the interaction of erythropoietin and hormones, have renewed the interest in the effect of the hormones on erythropoiesis. The role of the CNS in this chain of reactions is not clarified, and it is of considerable interest to evaluate the relative importance of the various influences from the CNS on erythropoiesis.

Investigations on the participation of the CNS in the regulation of erythropoiesis are complicated by the fact that all procedures be they stimulatory or ablative, introduce a series of reactions in the experimental animals. These reactions may condition the animal and secondarily influence the erythropoiesis or the parameters measured without any real change in erythropoiesis. The latter is particularly true regarding all previous work which has been performed using changes in hemoglobin, number of erythrocytes or hematocrit as the only parameters because it is well-known that great changes in plasma volume may occur with procedures influencing the hypothalamo-pituitary system.

In our hands electrical stimulation of the hypothalamus increased the reticulocytes and RCM in 8 of 28 stimulated rabbits (36). Increased plasma erythropoietin levels were demonstrated in 6 of 16 rabbits studied (13) indicating that the effect of hypothalamic stimulation on erythropoiesis was mediated through erythropoietin. MIRANO *et al.* (29) have recently confirmed the latter finding in monkeys. Following electrical stimulation of the hypothalamus they found increased plasma erythropoietin levels using polycythemic mice as recipients. KELL *et al.* (22) observed polycythemia following electrical stimulation of cortical loci of the prefrontal and pyriform areas in dogs and cats. In some of these animals, however there was medial hypertrophy and intimal proliferation in pulmonary arteries suggesting that some degree of hypoxemia with secondary polycythemia may have occurred. In none of the above

Table I

the differences between the values after and before an experimental period of 2 weeks (\pm s.e.) in rabbits receiving electrical stimulation of the hypothalamus and rabbits injected with ACTH, GH and GH-ACTH-thyroxine-testosterone

	Control	Hypothalamic stimulation Pos. response	ACTH	GH	GH-ACTH
ml	1.8 ± 2.2	9.1 ± 1.5	5.5 ± 1.5	1.6 ± 1.5	2.7 ± 1.7
min, g	-0.4 ± 0.3	3.1 ± 0.3	1.1 ± 0.5	0.5 ± 1.0	0.9 ± 0.6
res, mmHg	0.0 ± 0.3	-0.3 ± 0.3	-0.2 ± 0.3	-0.5 ± 0.4	-0.6 ± 0.4
ts, %	0.2 ± 0.3	-0.1 ± 0.3	-0.2 ± 0.2	-0.4 ± 0.2	-0.4 ± 0.1
	-0.9 ± 1.1	3.0 ± 0.6	0.9 ± 0.5	-0.3 ± 0.9	-1.2 ± 0.9
	-4.6 ± 4.5	7.9 ± 3.6	5.6 ± 1.8	4.0 ± 2.9	5.6 ± 2.6

Table II

erythropoietin levels in rabbits following 2 weeks of hypothalamic stimulation (positive response) daily injections of ACTH, GH, GH-ACTH and GH-ACTH-thyroxine-testosterone for 2 weeks (see 13, 14, 17-18)

Effects	Intact units		Sieved units	
	Reticulocytes	Reticulocytes	Fe ⁵⁹ uptake	Reticulocytes
response group	increased	increased	increased	increased
	insignificant increase		insignificant increase	

H

H-Thyroxine-testosterone

inhibition (?)

Discussion

The concept of a humoral regulation of erythropoiesis through erythropoietin is generally accepted but the details in the mechanism are unknown for several steps. Hypoxia is considered to be the fundamental stimulus for erythropoietin production but there are few data regarding the site of recording of the variations in oxygen tension. Although perfusion studies of the kidneys (8, 24) and experiments with clamping of the renal artery (19) suggest that both the registration of oxygen tension and the production of

pothalamus but did not consider the possible effect of pituitary hypofunction. Their results are in contrast with ours regarding the localization of the lesions within the hypothalamus, but they otherwise support the concept that hypothalamic lesions may reduce the erythropoietic response to hypoxia.

The ablation studies referred to above, except the studies of PILIZERO *et al.*, indicate that hypothalamic lesions interfere with the normal erythropoietic response to hypoxia. Thus both stimulation and ablation of the hypothalamus induce marked changes in erythropoiesis. These studies provide a substantial amount of evidence that the hypothalamic area is of fundamental importance in the regulation of erythropoiesis.

The mechanism by which hypothalamus exerts its influence is, however unknown. The working hypothesis for our studies has been that a specific group of cells located in this area record the variations in oxygen tension and by nervous or humoral routes stimulate the target organ(s) to erythropoietin production. Although erythropoietin is produced following perfusion of isolated kidneys, this does not prove that the kidney is the only organ recording variations in oxygen tension in physiological conditions, and experiences with the anephric man (30) and animal (28) clearly indicate that this is not the case. Only few direct data are, however available on this point. BACRU *et al.* (1) have studied the effect of clamping the carotid artery in dogs with the contra lateral artery ligated or sutured to a transplanted kidney. They also investigated the erythropoietin levels in plasma of nephrectomized rats exposed to hypoxia. From these studies they concluded that erythropoietin was produced following cerebral hypoxia and not following renal hypoxia.

Studies on the unit activity in the hypothalamus following hypoxia have been performed by CROSS AND SILVER (3). They observed that a high proportion of tested neurons in the posterior and lateral areas of the hypothalamus was excited by hypoxia and that hypoxia induced a sympathetic discharge similar to that resulting from hypothalamic stimulation. These experiments give some evidence in favor of the presented hypothesis but they may also be interpreted as a stress reaction. Although supplying indirect evidence the theory of specific oxygen receptive cells controlling erythropoietin production has only vague, direct experimental support. Studies combining methods in neurophysiology

kidney physiology and hematology will be necessary to explore this field further.

There seems at present to be *three main routes by which the hypothalamic area may control erythropoiesis*, through the pituitary gland, through the autonomic nervous system or through specific nervous or humoral stimuli.

The generally accepted route is the control exerted *via the pituitary gland*. In the studies reported in this paper work has been done to compare the effect of hypothalamic stimulation with the effect of pituitary and target organ hormones. These comparative studies have revealed that GH may produce a similar reticulocytosis as hypothalamic stimulation but no increase in RCM. The combination of GH ACTH thyroxin testosterone produced polycythemia but the plasma erythropoietin levels were not elevated at the end of the experimental period as following hypothalamic stimulation, and there were signs rather of inhibition when the plasma was tested in starved mice. It may be concluded that hypothalamic stimulation and combined hormone therapy may have a similar end effect on erythropoiesis, *i. e.* polycythemia. This does not prove that the operating mechanism has been the same, and, in fact, the differences in the plasma erythropoietin levels found in the two groups indicate that it is not. It must, however be concluded that it is difficult to provide conclusive evidence in favor of an extrapituitary influence on erythropoiesis following hypothalamic stimulation unless the experiments are carried out in hypophysectomized animals.

It has repeatedly been stated that the effect of the hormones on erythropoiesis is secondary to their control of oxygen consumption (6). Although this remains an important part of the control, recent studies have changed this view considerably and have indicated that the hormones have a more specific role in the regulation of erythropoiesis. Thyroxin (27) testosterone (10) GH (9, 17, 33) and prolactin (21) have been found to stimulate erythropoiesis and erythropoietin production or interact with erythropoietin in an additive manner (7). The studies by JEPSON AND LOWENSTEIN (21) and in this laboratory* on the effect of ovine prolactin on Fe^{59} erythrocyte uptake in polycythemic mice may further indicate a direct effect of pituitary hormones on erythropoiesis, at least in

* Unpublished data

some species. These findings point to possible routes by which hypothalamus may exert its control of erythropoiesis unrelated to variations in oxygen consumption.

Another possible route of hypothalamic control of erythropoiesis is through *the autonomic nervous system*. Stimulation or ablation of hypothalamic structures interfere with the integrity of this system. This may influence the cardio-pulmonary function and possibly induce hypoxemia by this mechanism, a possibility which is relevant in the interpretation of the data reported by KELL *et al.* (22). In the stimulation experiments reported in this paper respiration and blood pressure were recorded in four of the animals showing a positive erythropoietic response, and there was no significant difference before and after stimulation. Of more direct concern in several experiments is the question of changes in vascular tonus or blood flow following stimulation or ablation of the hypothalamus, section of the spinal cord or resection of sympathetic or parasympathetic nerves. In view of recent evidence for erythropoietin production by the kidneys (8, 24-31) it is possible that the reduced response to hypoxia following such procedures or the effect of hypothalamic stimulation, may be due to changes in renal circulation.

Although most information concerning the control of renal circulation support the view of autoregulation (41) other data indicate that renal circulation is extremely sensitive to the catecholamines (41). Electrical stimulation of the splanchnic nerves causes severe, but transient renal vasoconstriction (40). GÖRÖR *et al.* (12) report data indicating both a cerebral and local regulatory mechanism for the control of renal circulation. If their findings are confirmed, both renal and cerebral hypoxia may lead to changes in renal circulation which possibly may be the basis for variations in erythropoietin production. This view opens the possibility for a uniform hypothesis regarding erythropoiesis regulation and is a working hypothesis which may stimulate to further experiments.

The studies of TAKAKU *et al.* (39) on the effect on erythropoietin production of bilateral splanchnic nerve resection lend some support to such a hypothesis while the studies of BACRU *et al.* (1) on transplanted kidneys in the dog and other studies on transplanted kidneys in the human do not support the theory.

Common to many studies on the influence of the CNS on erythropoiesis has been that the reticulocyte counts have shown the most marked deviations from the normal. This raises the question whether the reticulocyte response to such procedures could be the result of interference with the reticulocyte release mechanism. The intermediate links in this control are unknown, but the finding of reticulocyte increase following cholinergic stimulation (35) may indicate that the autonomic nervous system participates in the control. It is not likely however that reticulocyte release only was the cause of the reticulocytosis in our stimulation experiments because the increase was slow and reached a maximum after more than three days, and because a concomitant rise in RCM and plasma erythropoietin was found.

The concept of specific groups of cells in the hypothalamus recording variations in oxygen tension and regulating erythropoiesis through specific nervous or humoral stimuli has been the basis for the present work. The data presented in this paper fit well with and are readily explained by such a hypothesis. The finding of elevated plasma erythropoietin following hypothalamic stimulation (13-29) indicate that the erythropoietin production is subject to cerebral control. The reduced erythropoietic response to hypoxia following hypothalamic ablation (16-26) cord section (37) and splanchnic nerve resection (39) may point to the nervous system as mediator for the stimulus to the target organ. The data provide, however only indirect evidence, and it must be concluded that there is no entirely *conclusive* evidence in favor of this hypothesis. Progress in research in this field, particularly regarding the hormones, has made the terms specific non specific effects of less value and significance, and they should probably be abandoned in this connection.

Although the mechanism by which CNS controls erythropoiesis is not clarified, the data presented in this paper and referred to strongly support the concept that the CNS is of fundamental importance in the regulation of erythropoiesis. Future studies using perfusion techniques in hypophysectomized and/or nephrectomized animals with simultaneous recording of arterial oxygen saturation, oxygen tension and blood flow in the organs, may give more clear cut answers to the question of how the CNS exerts its influence on erythropoiesis.

Summary

Previous and recent data indicate that the central nervous system participates in the regulation of erythropoiesis. The present paper reports studies on the hematological changes following hypothalamic stimulation and on comparative hormone experiments. These studies strongly support that the hypothalamus is of fundamental importance in the regulation of erythropoiesis. The mechanism by which the central nervous system exerts its influence is unknown but there are at present three main possibilities; an effect through the pituitary gland, through the autonomic nervous system or directly on erythropoietin production.

Résumé

Les résultats d'études antérieures et récentes indiquent que le système nerveux central participe à la régulation de l'érythropoïèse. Le travail présent rapporte les études des altérations hématologiques causées par la stimulation de l'hypothalamus et des expériences comparées faites avec des hormones. Ces études confirment que l'hypothalamus a une importance fondamentale dans la régulation de l'érythropoïèse. Le mécanisme par lequel l'hypothalamus exerce cette influence est inconnu. Les trois possibilités principales sont les suivantes: une influence par l'intermédiaire de l'hypophyse ou du système nerveux autonome ou encore une influence directe sur la production d'érythropoïétine.

Zusammenfassung

Frühere und neuere Ergebnisse sprechen dafür daß das Zentralnervensystem bei der Regulation der Erythropoese eine Rolle spielt. In der vorliegenden Mitteilung wird über hämatologische Veränderungen nach Reizung des Hypothalamus und über vergleichende Versuche mit Hormonen berichtet. Die Untersuchungen bestätigen, daß dem Hypothalamus eine grundlegende Bedeutung bei der Regulation der Erythropoese zukommt. Der Mechanismus dieser zentralnervösen Steuerung ist unbekannt. Zur Zeit ergeben sich dafür drei Möglichkeiten: eine Wirkung über die Hypophyse, über das autonome Nervensystem oder direkt auf die Produktion von Erythropoietin.

References

1. BACU, I., OVIDIU, G.; DOMOFREU, M., ROMBERG, E., RUSU, M. AND CIOCESEVICU, C. Le rôle et la production de l'érythropoïétine. *J. Physiol. Paris* 55: 551-567 (1963).
2. BACU, I. Système nerveux et substances humores dans la régulation de l'érythropoïèse. *Rev. Roum. J.* 149-160 (1964).
3. BACU, I., SOLTUZ, V.; STORCA, N. AND RADCAN, N. Localisation dans l'hypothalamus des centres régulateurs de l'érythropoïèse. *Proc. Xth Congr. Int. Soc. Haemat.*, Stockholm 1964: M. 28.
4. BARR, A. G. Über die nervöse-humoral Regulation des Blutes. *Folia haemat.*, Lpz. 65: 222-298 (1942).
5. CROM, B. A. AND SILVER, I. A. Unit activity in the hypothalamus and the sympathetic response to hypoxia and hypercapnia. *Exp. Neurol.* 7: 375-393 (1963).
6. EVANS, E. S.; ROMBERG, L. L. AND SORSON, M. E. Erythropoietic response to calorigenic hormones. *Endocrinology* Springfield 68: 517-532 (1961).
7. EVANS, E. S.; DYER, D. C. VAN AND ROMBERG, L. L. Interaction of the ESH with calorigenic hormones. *Endocrinology* Springfield 75: 758-764 (1964).

11. FRIED, J. W. AND BOWDRELL, B. J.: The production of an erythropoietic factor by the *in situ* perfused kidney. *Acta haemat.*, Basel 26: 224-232 (1961).
12. FRIED, J. W.; ROW, B. L.; COOPER, C. AND NISWENDER, W. O.: Influence of cobalt, sheep erythropoietin and several hormones on erythropoiesis in bone marrow of isolated perfused hind limbs of dogs. *Blood* 23: 87-96 (1964).
13. FRIED, W.; GOWAN, R. DE FORD, R. AND GURNEY, C. W.: The erythropoietic effect of androgens. *J. lab. clin. Med.* 64: 858-859 (1964).
14. GILBERT, H. S. AND SILVERSTEIN, A.: Neurogenic polycythemia. Report of a patient with transient erythrocytosis associated with occlusion of a middle cerebral artery and review of the literature. *Amer. J. Med.* 38: 807-815 (1965).
15. GÓDOL, P., KOVÁČ, A. G., TAKÁČ, L., FÜRDŐ, M., SZABO, Gy., NAGY, Z. AND WILTMER, W.: The control of renal circulation in hypoxia. *Acta med. hung.* 16: 43-50 (1960).
16. HALVORSEN, S.: Plasma erythropoietin levels following hypothalamic stimulation in the rabbit. *Scand. J. clin. Lab. Invest.* 13: 564-575 (1961).
17. HALVORSEN, S.: Effects of ACTH on erythropoiesis in the rabbit. *Acta physiol. scand.* 58: 30-39 (1963).
18. HALVORSEN, S.: Plasma erythropoietin levels in cord blood and in blood during the first weeks of life. *Acta paediat.*, Uppsala 52: 425-435 (1963).
19. HALVORSEN, S.: Effects of hypothalamic lesions on the erythropoietic response to hypoxia in rabbits. *Acta physiol. scand.* 61: 1-19 (1964).
20. HALVORSEN, S.: Effects of growth hormone on erythropoiesis in the intact rabbit and the polycythemic mouse. *Acta physiol. scand.* (in press).
21. HALVORSEN, S. AND LÖNNMARK, R.: Effects of combined hormone therapy on erythropoiesis in the intact rabbit. *Acta physiol. scand.* (in press).
22. HANSEN, P.: Polycythemia produced by constriction of the renal artery in a rabbit. *Acta path. microbiol. scand.* 69: 465-472 (1964).
23. HOLLAN, S. R.: Über die neurale Regulation der Blutbildung. *Folia haemat.*, Lpz. 66: 138-152 (1963).
24. JEFFCO, J. H. AND LOWENSTEIN, L.: Effect of prolactin on erythropoiesis in the mouse. *Blood* 24: 726-738 (1964).
25. KELL, J. F.; HOFF, E. C. AND HERZOGAR, G. R.: Erythrocytosis or symptomatic polycythemia following chronic cerebral stimulation through indwelling electrodes. *J. Neurosurg.* 17: 1028-1038 (1960).
26. KOPPEL, E.: Die zentralnervöse Regulation des Blutbildes. (Georg Thieme, Stuttgart 1956).
27. KURATOWSKI, Z., LEWARTOWSKI, B. AND MICHALAK, E.: Studies on the production of erythropoietin by isolated perfused organs. *Blood* 18: 527-534 (1961).
28. LÖNN, P. O.: Zur zentralen Regelung der Retikulozytosezahl. *Pflügers Arch. ges. Physiol.* 268 (1958).
29. LÖNN, P. O.: Zentralnervöse Regulierung der Retikulozytosezahl im peripheren Blut. *Folia haemat.*, Lpz. 76: 282-290 (1959).
30. MERRILL, H. A. AND GRANT, R. C.: Evidence for a non-calorigenic effect of thyroxine on erythropoiesis as judged by radioactive utilization. *Proc. Soc. exp. Biol.*, N.Y. 117: 520-524 (1964).
31. MÉRLE, E. A. AND PRESTON, T. C.: Presence of plasma erythropoietin in hypoxic rats with or without kidney(s) and/or spleen. *Proc. Soc. exp. Biol.*, N.Y. 96: 49-51 (1957).
32. MÉRLE, E. A., GRACE, J. T.; JORDISON, G. B. AND MURPHY, G. P.: Effects of hypothalamic stimulation on the erythropoietic response in the Rhesus monkey. *Nature* 204: 1163-1165 (1964).
33. NATHAN, D. G.; SCHIFFMAN, E.; STUBELMAN, F. JR. AND MERRILL, F.: Erythropoietin in anephric man. *J. clin. Invest.* 43: 2158-2164 (1964).

- III OURA, S. Experimental study on an erythropoietic principle produced in the kidney. *Brit. med. J.* 2: 630-636 (1959).
52. FILIPPO, S. J. MEDICA, P. T. AND OURA, A. Influence of hypoxic stimuli upon erythropoiesis in hypothalamic lesioned animals. *Acta haemat., Basel* 28: 101-112 (1962).
53. REMBOUR, W. Die humorale Steuerung der Erythropoiese. (Springer Berlin 1963).
54. SCHMID, R. AND GILBERTSEN, A. S. Fundamental observation on production of compensatory polycythemia in case of patent ductus arteriosus with reversed blood flow. *Blood* 10: 247-251 (1955).
55. SEIF, M. Reticulocyte studies. (Grundt Trauum, Oslo 1953).
56. SEIF, M.; HALVORSEN, S.; AMUNDSEN, P. AND KAADA, B. R. Effects of hypothalamic stimulation on erythropoiesis in rabbits. *Scand. J. clin. Lab. Invest.* 15: 553-563 (1961).
57. SOMMER, J. C. Experimentelle Beiträge über die Rolle des sympathischen Nervensystems bei der Erythrocytose. *Z. Biol.* 96: 464-472 (1936).
58. STORLMAN, F. JR.; RATH, C. E. AND ROSE, J. C. Evidence for humoral regulation of erythropoiesis: studies on patient with polycythemia secondary to regional hypoxia. *Blood* 9: 721-733 (1954).
59. TAKAKU, F. HIRASHIMA, K. AND OKUDAIRA, S. Studies on the mechanism of erythropoietin production. II. Effect of bilateral section of the splanchnic nerves. *J. lab. clin. Med.* 59: 821-825 (1962).
60. TRUSTA, J. Studies of the renal circulation. (Charles C. Thomas, Springfield, Ill. 1947).
61. ULLRICH, K. J. AND MAREN, H. J. Kidney water and electrolyte metabolism. *Annu. Rev. Physiol.* 25: 91-142 (1963).
62. WENTRICH, A. H.; GORDON, A. B. AND CAMERON, J. F. Use of the hypoxia-induced polycythemic mouse in the assay and standardization of erythropoietin. *J. lab. clin. Med.* 62: 734-752 (1963).

Author's address: Dr. S. Halvorsen, Pediatric Research Institute, Rikshospitalet, University of Oslo, Oslo (Norway).

Department of Internal Medicine, Karolinska Hospital, King Gustav V Research Institute, Stockholm and Medical Research Center Brookhaven National Laboratory Upton, N Y

Iron Absorption and Excretion in Aregenerative Anaemia

A Collaborative Swedish-American Whole Body Counter Study*

L. M. SCHIFFER, I. BRANN E. P. CRONKITE AND P. REIZENSTEIN

It is known that the intestinal absorption of iron is influenced not only by the body iron stores (2, 6, 16, 19) but also by the level of erythropoietic activity (2, 3, 14, 28). Thus, hypertransfusion (3, 28) may reduce and increased erythropoiesis (2, 3) increase the absorption. Whether information about the level of the stores and/or of the bone marrow activity is transmitted to the intestinal cell via the intracellular iron concentration and apoferitin saturation (5, 8, 9) the plasma transferrin concentration (18, 27) the plasma iron turnover rate (29) the blood haemoglobin concentration (15, 24) or specific humoral factors (1, 7, 12) is not known. The purpose of the present study is to examine the relation between intestinal iron absorption and these other parameters in humans with reduced erythropoietic activity (aregenerative anaemia).

The rate of iron excretion has been studied less. Both in conditions with increased (10, 11, 21) and in conditions with decreased iron stores (19, 21, 22) the rate of excretion appeared to be reduced.

Because of the relative scarcity of patients with aregenerative anaemia in areas where whole body counters are available, the present study was carried out as a joint venture between the Swedish and American laboratories.

*Supported by Polhem, the Swedish Medical and Technical Research Councils, Swedish Nutrition Foundation, O. and E. Eriksson Foundation and US Atomic Energy Commission. Prof. T. Sjöström, kindly performed the total body haemoglobin in Stockholm.

Table I
General description of patients with regenerative anaemia.

Patient	Sex/Age	Diagnosis	Duration of disease (years)	Total transfusions	Remarks
AF	M/67	AA Pancytopenia	1.5	82	Late leukemoid blood picture, autopsy only AA
AJ	M/40	AA, Pancytopenia	1.5	37	Splenomegaly
EH	M/62	Myelodysplasia Pancytopenia	6	55	Previous polycythemia, splenectomy
MB	F/74	Myelofibrosis	8	1	Splenomegaly benign course
AL	F/60	Myelofibrosis Myelodysplasia	?	6	Pulmonary TBC splenomegaly
GM	M/78	AA	7	33	Benign course
SC	F/68	AA, Carcinoma of colon	5	III	Tumor resection 4 years before anemia hepatic metastases at autopsy
AR	M/70	AA	2	16	Insecticide exposure
VE	M/41	AA, Pancytopenia	6	30	Unusual reticulo endotheliosis. Myeloproliferative at end of course
EL	M/24	AA, Pancytopenia	2	40	Many infections
TR	M/53	AA	2	15	Prorhythroblastic maturation arrest
MA	M/60	AA Pancytopenia	1.5	40	Benign course
ST	F/5	AA, Fanconi' anemia, pancytopenia	5	2	Absence of thumbs, microcephaly renal anomalies
ZI	F/47	Myeloid metaplasia, myelofibrosis	5	200	Splenectomy
FR	M/67	AA	2.5	150	Leukemoid peripheral blood picture
FE	F/64	AA, Pancytopenia	3.5	300	Benign course
McC	F/12	AA, Pancytopenia	III	90	Congenital hypoplastic anaemia

AA = Regenerative anaemia

Approximate number

Material

It is recognised that a number of diseases of varying etiology pathologic and clinical picture can be characterized by an regenerative anaemia. Regenerative anaemia is here defined as an anaemia, not mainly due to bleeding or haemolysis or to deficiency of iron, vitamin B₁₂ or folic acid, with subnormal reticulocyte response, subnormal Fe⁵⁹ incorporation into erythrocytes, and refractory to treatment other than transfusions. Only patients without known primary diseases (renal, leucemia etc.) were included. Red cell Fe⁵⁹ incorporation is normally 70-90% of the tracer dose (4). In all our patients so studied, the results were subnormal-ranging from 0-55%.

The 17 patients are described in Tables I and II. Cases A. F. to G. M. were studied at Karolinska and S. C. to McC. at Brookhaven.

Normal Fe⁵⁹ absorption was studied in Stockholm in 20 male volunteers. At Brookhaven 9 male and 7 normal postmenopausal females were studied. Normal Fe⁵⁹ excretion was studied in Stockholm in 10 volunteer men or menopausal females, at Brookhaven in 9 persons.

Table II
Selected erythrocytic data of patients with regenerative anemia.

Bone marrow

Patient	Hemoglobin gm %	Total Reticulocytes per cent	Cellularity marrow	Fibrosis, sections	Iron stain, percentage
AF	4.0	0-21,000	a. NC b. HRC	—	moderate
AJ	7.3	0-117,000	NC	+	increased
SH	8.1	94,000-193,000	a. HRC b. HOC	+	
MB	7.1	48,000-180,000		+	
AL	8.6	22,000-62,000	HRC	+	small
GM	8.1	25,000	HOC	—	moderate
SC	6.7	16,640	NC	—	increased
AR	8.6	3,800	HOC	—	
VE	8.2	0	HRC	—	increased
BL	7.4	3460	HOC	+	increased
TR	7.8	0			increased
MA	5.7	30,880			increased
ST	4.1	39,390			small
ZT	11.4	19,150	HOC	+	increased
FR	6.0	0			increased
F	5.8	0			increased
McC	5.0	0			increased

Methods

Iron administration. 250 μ g Fe^{59} in the form of ferrous sulfate or ferrous citrate were administered orally to fasting patients. Stockholm patients received 1.5 μ g Fe^{59} . Brookhaven patients 1.5 μ g.

Because iron absorption was frequently low neither turnover nor red cell Fe^{59} incorporation could always be studied adequately on the basis of the absorbed iron. All Karolinska patients and 5 of the Brookhaven patients therefore received 1.10 μ g Fe^{59} in the form of plasma bound ferrous citrate intravenously when the absorption study was completed.

Absorption measurements: The principle of studying absorption with the help of whole body counting has been described (19-21). The total body radioactivity was measured initially after oral administration and also 10 to 21 days later when all unabsorbed iron had been excreted with the feces.

Two different whole body counters were used. Both the one in Stockholm (13, 13a) and the one at Brookhaven (19, 20, 21) have been described in detail. In principle,

Table II (Continued)

NCG = Normal cellularity HCG = Hypocellular HRC = Hypercellular

Serum iron mg/ 100 ml	UTBC mg/100 ml	Iron absorption per cent	Iron excretion % per day	Months followed	Erythrocyte Fe ⁵⁹ concn. per cent	Erythrocyte life span, days	Plasma Fe ⁵⁹ T % minutes
207	100	0.20	0	4.5	0	36	
207	42	0.01	0		29-33	33	
210	125-205	10.20	0.083	6.5	23-26	32	
				7			
19	200	1.05	0.078	4.5	6-30	69	
56-125	110	3.95	0.156	3.5	40-55	45	
159-208	251 160	1.5	0.199	5	33-45	40	
138	115	9.00			12.8		
		8.20	0.173	5	0.5		
225	0	6.40	0.109	7	3.5		
960	28	2.90					
169	23	29.00	0.177	6.5	0.4		190
238	135	10.20			22.0		307
247	144	29.80					
160	0	2.30	0.150	4	2.1		68
176	50	5.00			0		
242	30	3.10			0		270
214	30	2.00			23.0		275

each consisted of chair for the patient, steel shield to reduce background activity large stationary NaI (TI) crystal detector and multichannel analyzer.

Excretion measurements: The loss of absorbed (patients AR and VE) or injected Fe⁵⁹ was followed with the Brookhaven whole body counter for 4 to 7 months (average 170 days) and in Stockholm for 3½ to 7 months (average 150 days). The daily percentage loss (regression of the log Fe⁵⁹-content on time $\times 1/\log e$) was calculated on an IBM 1401 computer (Stockholm) or Marlin Digital computer (Brookhaven).

Measurement of Fe⁵⁹-uptake by red cell mass. Radioactivity of whole blood samples was measured in well-type NaI (TI) crystal detectors 1, 2 and 3 weeks after the oral or parenteral administration of iron. Cell counts and haemoglobin concentrations were determined in the customary manner.

At Brookhaven, circulating red cell mass was determined by labeling red cells with Cr⁵¹ (patients MA, ZI, SC and MC). In Stockholm, total body haemoglobin was determined in all patients with the alveolar carbon monoxide method of Sjöstrand (26).

Bone marrow punctures and smears were obtained by customary methods. I was not considered possible to judge bone marrow cellularity from smears alone. In 4 of the Stockholm patients (AF, AJ, AL and GL) sections of bone marrow particles collected

Table III
Iron absorption and excretion.

Group	Normal controls		Aregenerative anaemia	
	Iron absorption ^a	Iron excretion ^a	Iron absorption	Iron
Stockholm	18.1 ± 2.00 (20)	0.232 ± 0.078 (7)	2.82 ± 1.58 (6)	0.006 ±
Brookhaven	18.4 ± 1.41 (16)	0.150 ± 0.012 (9)	9.80 ± 3.03 (11)	0.150 ±
	17.5 ± 1.26 (36)	0.186 ± 0.035 (16)	7.36 ± 2.18 (17)	0.112 ±

^a % of oral dose (0.25 mg Fe⁵⁵) Mean ± S. E.

% of total body-radio iron per day Mean ± S. E.

Figures in brackets indicate No. of subjects.

on watch glass were studied for fibrosis or sclerosis, the amount of stainable non-haem iron, and the relative amounts of fat cells and bone marrow cells. At Brookhaven bone marrow sections were obtained at biopsy or autopsy in 5 of the patients.

Unsaturated iron binding capacity (UIBC) was measured by the colorimetric method (25). Serum iron and UIBC-determinations for Brookhaven patients were first performed in collaboration with the Haematology Department of Mt. Sinai Hospital, and then by a modified Schade's technique at Brookhaven.

The red cell life span was estimated in Stockholm by measuring the endogenous carbon monoxide production according to Sjörstrand (26). Statistical calculations were performed on an IBM 1401 computer.

Results

Iron absorption. The values are given in Table III. The mean absorption in the patients with aregenerative anaemia is less than half of that in the controls. The difference is statistically significant.

In patients with one iron absorption-regulator (erythropoiesis) out of function, one could have hoped to find a good correlation between the other regulator (body iron stores) and absorption itself. Such a relationship is suggested by Fig. 1 indicating that the patients having received the most transfusions absorb the least iron. (Correlation coefficient $r = -0.358$ regression coefficient $b = -2.584$ standard deviation of b $SDb = 1.74$) Similarly the patients with increased iron concentration in the bone marrow absorbed on an average 6.6% of the oral radioliron, as compared in the 9.3% absorbed by those with small or moderate amounts of bone marrow iron. Statistically however these findings are not significant.

A relation between the unsaturated transferrin level in the plasma and iron absorption has been suggested by HALLBERG and his group (27) but could not be confirmed initially (18, 21). Nor was there any significant correlation in the present material, either between the UIBC ($r = 0.089$ $b = 0.66$ $SDb = 1.99$) or between




Fig 1 Relationship of transfusions to iron absorption. Statistically the suggested decrease in absorption with an increasing number of transfusions is not significant.

the serum iron ($r = 0.093$ $b = 0.720$ $SDb = 2.069$) and the absorption.

A relation between the haemoglobin concentration and the iron absorption is suggested by Table IV but the coefficient of regression for the iron absorption upon the haemoglobin concentration does not differ from zero in a statistically significant manner. Later studies, however, where these and other patients were transfused and the iron absorption studied again when the haemoglobin values were normalized, confirm this relation (24).

The iron excretion is a multiple exponential function which was approximated as a single exponential in Tables II and III. The percentage excretion figures thus obtained are only relative, and do not indicate the loss of unlabeled iron.

A seemingly significant decrease in iron excretion was found in the patients with aregenerative anaemia, but the unexplained difference between Stockholm and Brookhaven groups in this respect makes this result subject to cautious interpretation.

Other results Thirteen out of 17 patients studied had hyperferritinemia, (mean 0.196 mg Fe/100 ml $SD 0.071$) and 14 out of 17 had low UIBC values (mean 0.085 mg/100 ml, $SD 0.068$). In all 6 patients, where the carbon monoxide haemoglobin concentration

Table IV

Relationship of iron absorption and hemoglobin at time of iron absorption

	Hemoglobin 4-5.9 gm %	Hemoglobin 6-7.9 gm %	Hemoglobin over 8 gm %
Iron absorptions	0.7	0.01	10.7
	10.2	1.05	3.95
	29.8	9.0	1.52
	3.1	2.9	8.2
	2.0	29.0	6.4
		5.0	2.3
Average	9.1	7.8	3.4

Statistically the suggested relationship is not significant.

was determined, a somewhat elevated level of COHb was found. Serum haptoglobin concentrations were normal in the 5 patients where they were studied.

A positive ($r = 0.689$ $b = 0.065$ $SDB = 0.018$) and statistically significant ($0.005 > p > 0.001$) relation was found between the UIBC and the total reticulocyte count, and also between the UIBC and the erythrocyte radio-iron uptake ($r = 0.56$, $b = 2.19$ $SDB = 0.91$ $0.05 > p > 0.025$). These results suggest simply that the more efficient erythropoiesis is, the higher are reticulocyte counts and erythrocyte iron uptake, and the more rapidly is iron removed from the plasma with an increasing UIBC as a result. In agreement with this reasoning, a *negative* correlation was found between the serum iron concentration on the one hand and the total reticulocyte count ($r = -0.45$) and the erythrocyte iron uptake ($r = -0.27$) on the other. These latter correlations however were not significant statistically.

Some expected and unexciting correlations were also found, such as between the reticulocytes and the erythrocyte iron uptake ($r = 0.51$) and the serum iron and the UIBC ($r = -0.36$).

Discussion

Method. The redistribution within the body of orally administered Fe^{59} will cause changes in the geometry even if the relative positions of crystal and patient are constant. An error is thus introduced into the absorption measurements (23). This error was not more pronounced for the Stockholm counter than for the more heavily shielded Brookhaven counter. A detailed analysis of the

magnitude of these errors in the Stockholm counter including regressions of body counter values on those obtained with the fecal recovery method or the red blood cell uptake method has been published separately (13)

It is known that the normal human intestinal passage time averages 5 days. However even 10 days after the oral administration of Fe^{59} radioactivity excretion is much more rapid than later on (22). This has been attributed to the desquamation of intestinal mucosa cells which have taken up Fe^{59} . Whether this iron should be regarded as absorbed or not is a matter of semantics. In the present study iron retained after 10-21 days was regarded as absorbed.

Absorption. If a wide range of intracellular iron, UIBC α , serum iron, plasma iron turnover rates, and haemoglobin values had been found in our patients, then the relative importance of these possible intermediate factors in the regulation mechanism could have been better studied. Under the present conditions, it is only possible to state that patients with aregenerative anaemia, most of whom had high intracellular iron, low UIBC α , high serum iron and slow plasma iron turnover rates, have a significantly decreased iron absorption. Only a systematic comparison with other clinical groups, where different values are found, will make it possible to single out the most important of the regulating factors.

The possible importance of the haemoglobin concentration for the iron absorption will be discussed elsewhere (24)

Excretion. It is difficult to interpret the excretion values except in connection with a complete kinetic analysis of human iron metabolism. Less of the radio-iron is found in the erythrocytes and more in other tissues in aregenerative anaemia than in normal controls. Intracellular iron in other tissues is increased. Both factors would be expected to increase the rate of excretion, yet no such increase was found. This suggests that the turnover of non-haemoglobin iron is slow even compared to the very slow turnover of erythrocyte iron during the first 4 months following injection.

Serum iron. The significant correlation between parameters related to the intensity of erythropoiesis (reticulocytes and erythrocyte iron uptake) and the serum iron and UIBC emphasize the importance of bone marrow iron uptake in regulating the serum iron metabolism.

Summary

Of 17 patients with aregenerative anaemia, 13 had hyperidremia and 14 low unsaturated iron binding capacity. The more depressed erythropoiesis was, the higher was the serum iron and the lower the UIBC. The average iron absorption was significantly lower in patients with aregenerative anaemia than in normal individuals. The most anemic patients seemed to absorb more than those with less anaemia and the more transfusions the patients had received, the less iron they seemed to absorb. These relations were not statistically significant. Although large amounts of iron had been given to these patients in the form of transfusions, and although they had hyperidremia and, often, increased iron amounts in the bone marrow, the rate of iron excretion was not increased.

Résumé

Parmi 17 malades atteints d'anémie arégénératrice, 13 avaient une hyperidémie et 14 une diminution de la capacité latente de saturation en fer. Plus l'érythropoïèse était réduite, plus le taux de fer sérique était haut et plus la capacité latente de saturation en fer était faible. La résorption moyenne de fer était chez les malades atteints d'anémie arégénératrice de façon significative moindre que chez des personnes saines. Les malades avec une anémie avancée semblaient résorber plus de fer que ceux avec une anémie faible, et plus ils avaient reçu de transfusions, moins ils semblaient résorber de fer. Ces relations n'étaient pourtant pas statistiquement significatives. Quoique ces malades aient reçu de grandes quantités de fer sous forme de transfusions ou quoiqu'ils présentaient une hyperidémie et des quantités augmentées de fer dans la moelle osseuse, leur excrétion de fer n'était pas accélérée.

Zusammenfassung

Von 17 Patienten mit aregenerativer Anämie hatten 13 eine Hyperidermie und 14 eine Verminderung der ungesättigten Eisenbindungskapazität. Je stärker die Erythropoese herabgemindert war, umso höher war das Serum-eisen und umso niedriger die ungesättigte Eisenbindungs-kapazität. Die mittlere Eisenaufnahme war bei Patienten mit aregenerativer Anämie signifikant geringer als bei Gesunden. Patienten mit fortgeschrittener Anämie schienen mehr Eisen zu resorbieren als solche mit geringerer Anämie, und je mehr Transfusionen sie erhalten hatten, umso weniger Eisen schienen sie zu resorbieren. Diese Beziehungen waren jedoch statistisch nicht signifikant. Trotzdem diese Patienten grosse Mengen von Eisen in Form von Transfusionen erhalten hatten und obgleich sie eine Hyperidermie und erhöhte Eisensmengen im Knochenmark aufwiesen, war ihre Eisenausscheidung nicht vermehrt.

References

1. BENTLEY, E. AND BUTTENWISER, E. The regulation of iron absorption. I. A search for humoral factors. *J. lab. clin. Med.* 55: 774 (1960).
2. BOYSEWELL, T. H., VAN DOORN-WEITKAMP, J. L., VAN W. DU PRETZ, M. L. AND ALPER, T. The absorption of iron. Radioiron studies in idiopathic hemochromatosis, malnutritional cyrodystrophia, and transfusional hemochromatosis. *J. lab. clin. Med.* 47: 836-848 (1953).
3. BOYSEWELL, T. H., FRANK-ENGLER, G. AND FISCH, C. A. Iron absorption. I. Factors influencing absorption. *J. lab. clin. Med.* 51: 24-36 (1958).

4. BOTSWELL, T. H. AND FIDON, C. A. *Iron Metabolism*. (J and A. Churchill Ltd., London 1962 Little Brown and Co., Boston)
5. CHERRY W. H. The control of iron balance by the intestinal mucosa. *Blood* 22: 441 (1963).
6. DUNAG, R.; CALLENDER, H. T. E. AND MOORE, C. V. Studies in iron transportation and metabolism. VI. Absorption of radioactive iron in patients with fever and with anemia of varied etiology. *Blood* 9: 525-540 (1948).
7. FISHER, D. S. AND PRICE, D. C. A possible humoral regulator of iron absorption. *Proc. Soc. exp. Biol., N. Y.* 112: 228 (1963)
8. GRAVEK, S. Protein apoferritin and ferritin in iron feeding and absorption. *Science* 83: 107-107 (1946)
9. GRAVEK, S. Metabolism and function of iron. Iron transport mechanism in the intestinal tract. Report of 19th Ross Pediatric Res. Conf. 15-19 (1956).
10. HEILMEYER, L. UND WÜHLER, F. Moderne Hämochromatose-Probleme mit besonderer Berücksichtigung der Desferrioxaminbehandlung. *Dtsch. med. Wochs.* 87: 2661-2667 (1962).
11. KARLSSON B.; BRAND, I. STRANDBERG, O. LAGERCRANTZ, R. AND REIDENSTEIN, P. Desferrioxaminbehandling av järnintoxikation och hemochromatosis. *Nord. Med.* 69: 965 (1963)
12. KRANTZ, S.; GOLDWASSER, E. AND JACOBSON, L. O. Studies on erythropoiesis. XIV. The relationship of humoral stimulation to iron absorption. *Blood* 14: 634-661 (1959)
13. LEDELL, B. STRANDBERG, O. AND REIDENSTEIN, P. Iron-59 Absorption measurements by whole-body counting and faecal recovery techniques. *Phys. Med. Biol.* 9: 189 (1964).
- 13a. LEDELL, B. An open booth body counter in 'Whole body counting' Internat. Atom. En. Ag. Vienna 1962, pp. 235-251
14. MINDEL, G. A. Studies on iron absorption. I. The relationships between the rate of erythropoiesis, hypoxia and iron absorption. *Blood* 18: 727 (1961)
15. MINDEL, G. A. Studies on iron absorption. II. The absorption of iron in experimental anemias of diverse etiology. *Blood* 22: 430 (1963)
16. MOORE, C. V. Iron metabolism and nutrition. *Harvey Lectures Series* 53: 67 (1961).
17. PERLO-BESOLL, G.; BOTSWELL, T. H. AND FISHER, C. A. Iron absorption. II. The absorption of radioiron administered with standard meal in man. *J. lab. clin. Med.* 57: 57-68 (1956)
18. POLLACK, S. BALCHERAK, S. P. AND CHERRY W. H. Transferrin and the absorption of iron. *Blood* 21: 53-58 (1963).
19. PRICE, D. C.; CORN, S. H.; WASSERMAN, L. R.; REIDENSTEIN, P. G. AND CHERRY, E. P. The determination of iron absorption and loss by whole body counting. *Blood* 20: 517-531 (1962).
20. REIDENSTEIN, P. G. CHERRY, E. P. AND CORN, S. H. Measurement of absorption of vitamin B₁₂ by whole body gamma spectrometry. *Blood* 18: 95-101 (1961)
21. REIDENSTEIN, P. G. PRICE, D. C. CORN, S. H.; CHERRY, E. P. AND WASSERMAN, L. R. Whole-body-counter studies of the absorption and turnover of iron and vitamin B₁₂. *Trans. europ. Soc. Haemat.* 8: 237 (1961).
22. REIDENSTEIN, P. AND BRAND, I. Normal and pathological radioiron excretion in man, in 'Radioactivity in man' (G. Minorsky Ed.) 2nd symposium Chicago 1962, pp. 391-401 (Charles C. Thomas, Springfield, Ill.).

23. SCHIFFER, L. M., PRUE, D. C.; CUTNER, J., COHEN, S. H. AND CROWTHER, E. P. A note concerning the '100% value' in iron absorption studies by whole body counting. *Blood* 23, 757 (1964)
24. SCHIFFER, L. M., PRUE, D. C. AND CROWTHER, E. P.: Iron absorption and anemia. To be published.
25. SCHADE, A. L. *Standard Methods of Clinical Chemistry* 2, 75-76 (D. Schögen, Ed., Ad. Press, N. Y. 1956).
26. SjöSTRAND, T. A method for determination of the total haemoglobin content of the body. *Acta physiol. scand.* 16, 211-231 (1948)
27. SÖLVELL, L. AND HALLBERG, L. Studies on the absorption rate of iron in man. *Acta med. scand.* 168, Suppl. 358, 71-104 (1960)
28. TURKILL, A., CLYTON F.; WELLS, M. AND FOSCH, C. A.: The mechanism and regulation of absorption of dietary iron. 8th Congr. europ. Soc. Haemat. 1962.
29. WEINTRAUB, L. R.; OGDEN, M. E. AND CHERRY W. H. The significance of iron turnover in the control of iron absorption. *Blood* 24, 19 (1964)

Author's address: Dr P. Reinhardt, Karolinska Hospital, Stockholm (Sweden).

University of Louvain, Laboratory of Physiopathology (Dir. Prof. Dr. J. VANMEERBROUCK)
Section of Bloodcoagulation and Proteolysis (Dir. Prof. Dr. M. VERSTRAETE)

The Activation of Fibrinolysis with 3-Pyridil Acetic Acid

J. VERMYLEN, F. FIERING, R.A. DE VREEKE
AND M. VERSTRAETE

The activation of fibrinolysis by nicotinic acid is well known (17-11). The molecular structure of 3-pyridil-acetic acid (3-PAA) is closely related to that of nicotinic acid (Fig. 1).

Activation of fibrinolysis by 3-PAA was first described by ANTONINI *et al.* (4) and DETTORI *et al.* (6) who observed shortened clot lysis times in approximately one third of the patients who were given 3-PAA per os. INTROZZI *et al.* (9) observed a significant increase of plasmin and plasminogen after one administration of 500 mg 3-PAA intravenously. LOMBARDI *et al.* (10) confirmed that increase of fibrinolytic activity may occur after administration of 3-PAA per os. GIBELLI *et al.* (8) found that one intramuscular administration of 150 mg 3-PAA resulted in a significant increase of the plasminogen level and of plasmin activity between 20 and 60 minutes after administration. Repeated intramuscular injection of 150 mg 3-PAA daily during 16 consecutive days provoked a significant rise of plasmin activity the first day only but a gradual increase of the plasminogen level over the sixteen day experimental period.

In this study we examined the effect of a single and of repeated intravenous injections of 3-PAA on fibrinolysis, the plasminogen level, the level of some clotting factors and on the venous leucocyte population.

Methods and Materials

3-Pyridil acetic acid was supplied in liberal amounts as "Lisovox"® by Lepetit S. p. a., Milano; vials for intravenous administration, containing either 150 mg or 500 mg 3-PAA, were delivered.

Fibrinolytic evaluations, comprising the determination of the lysis time of dilutions of whole blood, the fibrin plate technique, and the preparation of plasma and globulin fraction were performed as described by AUBRY *et al.* (1).

Thrombotest times (12) were determined on whole citrated blood.

One-stage prothrombin times were performed using D&B rabbit brain Thromboplastin.

P- and P-assay was performed as described by OWSEN AND AAS (13). Factor V was determined according to STROMBERG (14).

Scypren times were obtained by substituting Russell viper venom for brain Thromboplastin in the P and P-assay.


Thrombin times were measured as described by V. MYLÉN AND V. ESTRÅTTE (16).

Fibrinogen was determined on whole citrated blood with the FBT-test, as described by V. MYLÉN *et al.* (15).


Leucocyte counts were obtained using Turk's dilution fluid and Bürker's slide.

Plasminogen was assayed, using either a standard bovine clot test system or a caseinolytic method, according to DE VRIES (7). Statistical methods were adopted from HALEY (5).

Experimental procedure: At 5 p. m. blood sample A was drawn. At the same moment, 3-PAA was injected intravenously. Fifteen minutes later blood sample B was taken, and a slow intravenous infusion of glucose 5% was installed. At 9.00 p. m. 1 a. m. and 5 a. m., 3-PAA was injected into the intravenous lead. At 11 a. m. blood sample C was drawn and 3-PAA injected. At 8.15 a. m. blood sample D was taken. In the first series of 27 experiments, 150 mg 3-PAA were injected repeatedly. In the second series of 8 experiments, repeated injections of 300 mg 3-PAA were made.



Nicotinic acid



3-pyridyl-acetic acid

Fig. 1. Molecular structure of 3-pyridyl-acetic acid and nicotinic acid.

Results

A. Alteration of whole blood, plasma and erythrocyte fibrinolytic activity by repeated intravenous injections of 3-PAA

1 The alteration of the fibrinolytic activity of whole blood following repeated intravenous injections of 3-PAA was studied by determining the lysis times of clots made from serial dilutions of whole blood. With blood diluted 1 : 4 the test was found to be most sensitive for detecting increased fibrinolytic activity. Table 1 gives the distribution of the lysis times of blood, diluted 1 : 4 taken before and after a first and fifth injection of 150 mg 3-PAA.

As shown, no evidence of increased whole blood fibrinolytic activity was observed in the fifteen persons before the first injection of 150 mg 3-PAA. After the first injection, an important increase

Table I

Distribution of the lysis times of the blood samples diluted 1 : 4 (15 experiments).

Blood sample	Number of experiments with lysis time							
	0-9 h	10-19 h	20-29 h	30-39 h	40-49 h	50-59 h	60-69 h	70-79 h
A	—	—	—	—	1	—	—	14
B	7	1	2	1	—	—	—	4
C	—	—	—	—	—	—	—	13
D	—	—	—	—	—	—	—	15

Table II

Distribution of the surfaces lysed on unheated fibrin film by the different plasma samples (24 experiments with repeated injection of 150 mg 3-PAA)

Plasma sample	Number of experiments giving lysed surface of					
	0 mm ²	1-30 mm ²	31-100 mm ²	101-200 mm ²	201-400 mm ²	401-600 mm ²
A	24	—	—	—	—	—
B	16	2	2	2	—	2
C	24	—	—	—	—	—
D	24	—	—	—	—	—

Table III

Distribution of the surfaces lysed on heated fibrin film by the different plasma samples (24 experiments with repeated injection of 150 mg 3-PAA).

Plasma sample	Number of experiments giving lysed surface of					
	0 mm ²	1-30 mm ²	31-100 mm ²	101-200 mm ²	201-400 mm ²	401-600 mm ²
A	24	—	—	—	—	—
B	12	8	3	1	—	—
C	24	—	—	—	—	—
D	24	—	—	—	—	—

of whole blood fibrinolytic activity (lysis time 0-9 h) is observed in 7 : a moderate increase (lysis time 10-39 h) in 4 persons. No increased whole blood fibrinolytic activity is noted either before or after the fifth injection of 3-PAA.

2. The alteration of plasma fibrinolytic activity after repeated intravenous injections of 3-PAA was measured on unheated and heated fibrin film. The distribution of the surfaces of fibrin lysed by plasma obtained before and after a first and fifth intravenous injection of 150 or 500 mg 3-PAA is summarized in Tables II-V.

It is observed that plasma fibrinolytic activity is increased in 8/24 persons on unheated and in 12/24 persons on heated fibrin film after a first intravenous injection of 150 mg 3-PAA. A first

Thrombotest times (12) were determined on whole citrated blood.

One-stage prothrombin times were performed using Diko rabbit brain Thromboplastin.

P and P-essay was performed as described by OWSEN AND AAS (13). Factor V was determined according to STROMBERG (14).

Stypven times were obtained by substituting Russell viper venom for brain Thromboplastin in the P and P-essay.

Thrombin times were measured as described by VERMYLEN AND VERSTRAETE (16).

Fibrinogen was determined on whole citrated blood with the FPT-test, as described by VERMYLEN *et al.* (15).

Leucocyte counts were obtained using Turk's dilution fluid and Bürker's slide.

Fibrinogen was assayed, using either standard bovine clot test system or a caseinolytic method, according to DE VRIES (7). Statistical methods were adopted from BAILEY (5).

Experimental procedure: At 5 p. m. blood sample A was drawn. At the same moment, 3-PAA was injected intravenously. Fifteen minutes later blood sample B was taken, and slow intravenous infusion of glucose 5% was installed. At 9.00 p. m. 1 a. m. and 5 a. m., 3-PAA was injected into the intravenous lead. At 8 a. m. blood sample C was drawn and 3-PAA injected. At 8.15 a. m. blood sample D was taken. In the first series of 27 experiments, 150 mg 3-PAA were injected repeatedly. In the second series of 8 experiments, repeated injections of 500 mg 3-PAA were made.




Fig. 1 Molecular structure of 3-pyridil-acetic acid and nicotinic acid.

Results

A. Alteration of whole blood, plasma and erythrocyte fibrinolytic activity by repeated intravenous injections of 3-PAA

1 The alteration of the fibrinolytic activity of whole blood following repeated intravenous injections of 3-PAA was studied by determining the lysis times of clots made from serial dilutions of whole blood. With blood diluted 1 : 4 the test was found to be most sensitive for detecting increased fibrinolytic activity. Table I gives the distribution of the lysis times of blood, diluted 1 : 4 taken before and after a first and fifth injection of 150 mg 3-PAA.

As shown, no evidence of increased whole blood fibrinolytic activity was observed in the fifteen persons before the first injection of 150 mg 3-PAA. After the first injection, an important increase

3 The alteration of euglobulin fibrinolytic activity after repeated intravenous injections of 3-PAA was measured on unheated and heated fibrin film. The mean values of the surfaces of fibrin lysed before and after a first and fifth intravenous injection of 150 or 500 mg 3-PAA are given in Table VI.

From statistical calculations on individual paired samples it appeared that with 150 mg 3-PAA the increase of euglobulin fibrinolytic activity after a first injection was significant ($P < 0.001$ on unheated fibrin, $0.01 > P > 0.002$ on heated fibrin) after a fifth injection no variation of euglobulin activity was found ($P > 0.1$ on both substrates). The euglobulin fibrinolytic activity before a fifth injection did not differ significantly from the activity observed before the first injection of 150 mg 3-PAA.

With 500 mg 3-PAA the increase of euglobulin fibrinolytic activity after a first injection was significant ($0.02 > P > 0.01$ on unheated fibrin film, $0.05 > P > 0.02$ on heated fibrin film) after a fifth injection no variation of euglobulin fibrinolytic activity was found ($P > 0.10$ on unheated and heated fibrin film).

From Table VI it seemed apparent that the increase of euglobulin activity was more pronounced after a first injection of 500 mg than after administration of 150 mg 3-PAA. Statistical comparison of the mean euglobulin activity on unheated fibrin film after a first injection of 150 mg and after 500 mg 3-PAA showed the probability that both means would be equal to be 0.01–0.02. On heated fibrin film however this value is larger than 0.10.

Table VI suggests that after repeated injection of 500 mg 3-PAA the fibrinolytic activity of the euglobulins falls below the initial value. Statistical comparison of the mean euglobulin activity on unheated fibrin in sample A and in samples C and D shows a probability of equality of 0.01–0.002.

B Alteration of blood clotting factors by repeated intravenous injections of 3-PAA

Table VII summarizes the variations of the Thrombotest values, prothrombin times, the P and P assays, factor V assays, Stypven times and thrombin times after repeated intravenous injections of 150 mg 3-PAA.

As Table VII shows, the results of these coagulation tests were not modified by repeated injection of 150 mg 3-PAA intravenously.

Table VI

Mean euglobulin fibrinolytic activity on unheated and heated fibrin in the different samples.

Amount 3-PAA administered	Number of exp.	Sample A		Surface lysed (in mm ²) by euglobulin of				Sample D	
		on UFF	on HFF	Sample B on UFF	Sample B on HFF	Sample C on UFF	Sample C on HFF	on UFF	on HFF
a. 150 mg	20	155	55	332	77	171	48	171	32
b. 500 mg	6	155	47	382	78	119	37	112	41

Table VII

Mean results of several coagulation tests performed on the different samples (in sec.).

Coagulation test	Number of exp.	Normal value	Values obtained in samples			
			A	B	C	D
Thrombotest	18	46	45	46	48	47
Prothrombin time	18	12	12	12	12	12
P-and P-scan	18	21	21	21	22	22
Factor V assay	18	22	21	21	21	22
Stypven time	18	25	24	25	26	27
Thrombin time	18	18	19	18	18	18

Table VIII

Mean fibrinogen level in the different samples.

Amount of 3-PAA repeatedly injected	N° of exp.	Sample A	Fibrinogen level in mg % Sample B	Sample C	Sample D
150 mg	18	199.3	189.4	193.9	192.0
500 mg	6	186.7	200.8	219.8	238.8

The alteration of the fibrinogen level by repeated intravenous injections of both 150 mg and 500 mg 3-PAA was studied. The mean fibrinogen values in the different samples are given in Table VIII.

The significance of the observed alterations was evaluated statistically. It was found that the slight decrease of the fibrinogen level after the first injection of 150 mg 3-PAA was significant at the 5% level ($0.05 > P > 0.02$). The fifth injection of 150 mg 3-PAA caused no significant variation of the fibrinogen level. After five intravenous injections of 150 mg 3-PAA the fibrinogen level did not differ significantly from the pre-injection value.

No significant variation of the fibrinogen level was observed after the first intravenous injection of 500 mg 3-PAA. The slight increase caused by the fifth injection is borderline significant ($0.10 > P > 0.05$). The fibrinogen level in samples C and D is significantly elevated ($0.01 > P > 0.002$) compared to the pre-injection value.

Table IX

Mean plasminogen level (units per ml) in the different samples tested.

Amount of administered	PAA	Number of experiments	A	Plasma sample B	C	D
150 mg		17	8.512	8.594	8.974	9.359
500 mg		7	287	272	270	268

Table X

Mean leucocyte content (number per mm³) of the different blood samples.

Amount of administered	PAA	Number of experiments	A	Blood sample B	C	D
150 mg		16	7.718	5.618	7.544	6.881
500 mg		6	6.780	4.870	5.350	5.670

C The variation of the plasminogen level following repeated intravenous injections of 3-PAA

Using the standard bovine clot test system, the modification of the plasminogen level after repeated intravenous injections of 150 mg 3-PAA was measured. The same was done after repeated intravenous injections of 500 mg 3-PAA, using the caseinolytic assay technique. The mean values in the different plasma samples are summarized in Table IX.

Statistical calculations on individual paired samples showed no significant difference of the plasminogen content (samples 1 and 2, 1 and 3, 1 and 4 or 3 and 4 when compared had a probability of equality greater than 0.10) after repeated intravenous injection of either 150 or 500 mg 3-PAA.

D Variation of the leucocyte population following repeated intravenous administration of 3-PAA

1 Variation of the total leucocyte count Table X summarizes the mean variation of the total leucocyte count following repeated intravenous administration of either 150 mg or 500 mg 3-PAA.

Using the method of paired comparisons, the decrease of the total leucocyte count after a first intravenous injection of 150 mg or 500 mg 3-PAA was found to be highly significant ($P < 0.001$ after 150 mg, $0.01 > P > 0.002$ after 500 mg). No significant variation of the leucocyte level was observed after a fifth intravenous administration of 150 or 500 mg 3-PAA. The leucocyte level before the fifth injection of 150 or 500 mg 3-PAA did not differ

Table VI

Mean number of neutrophile granulocytes, of lymphocytes and of monocytes per mm³ following repeated intravenous administration of 500 mg 3-PAA.

Leucocytes determined	Number of exp.	A	Blood sample B	C	D
Neutrophile granulocyte	5	4.966	2.410	3.168	3.933
Lymphocytes	5	2.031	2.328	1.770	1.540
Monocytes	5	336	298	307	319

significantly from the value observed before the first 3-PAA injection.

² *Qualitative changes of the leucocyte population* The alteration of the number of neutrophile granulocytes, of lymphocytes and of monocytes was studied in five persons, repeatedly administered 500 mg 3-PAA intravenously. The mean variations are given in Table VI.

Statistical calculations on individual paired samples showed a significant drop of the neutrophile granulocyte level after a first intravenous injection of 500 mg 3-PAA ($0.01 > P > 0.002$) no change after a fifth injection ($P > 0.10$) and no difference between the pre injection level and the level before the fifth 3-PAA injection ($0.10 > P > 0.05$). No significant change of the lymphocyte or monocyte population was observed.

Discussion

The increase of whole blood, plasma and euglobulin fibrinolytic activity after a first intravenous injection of 3 PAA, previously described has been confirmed: this increase was no longer observed after a fifth injection of 3-PAA.

The enhancement of plasma and euglobulin fibrinolytic activity was much more pronounced after a first injection of 500 mg 3-PAA than after a first intravenous administration of 150 mg 3 PAA. Euglobulin fibrinolytic activity on unheated fibrin, measured before and after the fifth injection of 500 mg 3-PAA, was significantly lower than the pre injection value. A similar decrease of spontaneous activity has been observed previously in our laboratory (2) after repeated intravenous injection of a nicotinic acid compound (3-[methyl-oxyethylamino] 2-oxypropyltheophylline nicotinate) using the same experimental procedure. The following hypothesis was proposed to explain (a) the nonactivation and (b)

the decrease of euglobulin fibrinolytic activity after repeated injection the spontaneous blood fibrinolytic activity as measured in the euglobulin fraction would have at least two origins. One component, of limited amount would be of the same origin as the activity arising after nicotinate administration. At the stage of non-activation this origin would have become nonavailable for production of the spontaneous blood fibrinolytic activity which was actually observed to be reduced. This hypothesis can also be applied to explain the observations after repeated intravenous injections of 500 mg 3-PAA indeed it is remarkable that the euglobulin fibrinolytic activity decreases to approximately the same level, whether nicotinate or 3-PAA is repeatedly injected, suggesting that both drugs make the same origin non available. After repeated injection of 150 mg 3-PAA, the first administration of which produces only moderate increase of euglobulin fibrinolytic activity this origin would still be available for production of spontaneous activity only.

No modification of the Thrombotest values, the prothrombin times, the P and P-assays, factor V assays, Stypven times and thrombin times was observed after the first intravenous injection of 150 mg 3-PAA. A slight decrease of the fibrinogen level was observed after the first intravenous injection of 150 mg 3-PAA, but not after injection of 500 mg 3-PAA in the same way. The fibrinogen level before and after the fifth injection of 500 mg 3-PAA was significantly increased when compared to the pre injection value. That this finding could be related to the simultaneously observed decrease of spontaneous euglobulin fibrinolytic activity is purely conjectural. No significant variation of the plasminogen level was observed after a first or after repeated intravenous injections of either 150 mg 3-PAA or 500 mg 3-PAA. INTROZZI *et al* (9) and GIBELLI *et al* (8) found a significant increase of plasminogen after one administration of 3-PAA it is however possible that the observed increase of euglobulin fibrinolytic activity interfered in their test system. GIBELLI *et al* (8) also observed that repeated intramuscular injection of 3-PAA daily during 16 consecutive days provoked a gradual increase of plasminogen level over the sixteen day experimental period this is not necessarily in contradiction with our findings, as our experiments only lasted 16 h.

A significant fall of the total leucocyte count was observed after the first injection of either 150 mg or 500 mg 3-PAA intravenously this decrease was due to a fall of the number of neutrophile

granulocytes, whereas the number of lymphocytes and monocytes remained unchanged

A fifth injection of 150 or 500 mg 3-PAA did not modify the total leucocyte count or the leucocyte population. It is tempting to speculate that the activation of fibrinolysis by 3-PAA is in some way linked to the effect of this drug on the peripheral leucocyte count. A similar variation of the white blood cell population was also observed after intravenous injection of 3-(methyl-oxyethyl-amino) 2-oxypropyltheophylline nicotinate (3)

Summary

The modification of whole blood, plasma and euglobulin fibrinolytic activity of various clotting factors, of the plasma plasminogen level and of the leucocyte population are studied following repeated intravenous administration of either 150 mg or 500 mg 3-pyridil-acetic acid.

Résumé

Les modifications de l'activité fibrinolytique de sang coagulé, de plasma et d'euglobuline, ainsi que de différents facteurs de la coagulation, du taux de plasminogène plasmatique et des leucocytes ont été étudiées après l'administration intraveineuse répétée soit de 150 mg soit de 500 mg d'acide 3-pyridil-acétique.

Zusammenfassung

Nach wiederholter intravenöser Zufuhr von 150 bzw. 500 mg 3-Pyridyl-Essigsäure wurden die Veränderungen der fibrinolytischen Aktivität von Vollblut, Plasma und Euglobulin, sowie der verschiedenen Gerinnungsfaktoren, des Plasminogengehaltes im Plasma und des weissen Blutbildes untersucht.

References

1. AMERY A. VERMYLEN J. MAER, H. AND VERSTRAETE, M. Enhancing the fibrinolytic activity in human blood by occlusion of blood vessels. I The preparation of the phenomenon. *Thromb. Diath. haemorrh.* 7: 70 (1962)
2. AMERY A. VERMYLEN, J. VERKIER, R. A. DE VERMYLEN, C. AND VERSTRAETE, M. Enhancing blood fibrinolytic activity by nicotin compound. II. Activation and reactivation. *Amery J. med. Sci.* 299: 66 (1965).
3. AMERY A. VERMYLEN, J. AND VERSTRAETE, M. Enhancing blood fibrinolytic activity by nicotin compound. III Study of the activation mechanism. *Scand. J. Haematol.* (1966 in press)
4. ANTONINI, F. M. MASER, R. Modificazioni indotte dall'acido 3-piridilacetico sulle frazioni lipidiche e sull'acido urico del siero. *Riv. med.* 74: 262 (1960).
5. BAILEY N. T. J. *Statistical methods in biology* London: English Universities Press (1959).
6. DETTORI, A. G. FORARI, O. SALVI, G. Azione dell'acido 3-piridilacetico sulla fibrinolisi nell'uomo. *Riv. med.* 74: 1372 (1960)

7. VERHEIJ, R. A. DE. A technique for routine evaluation of plasminogen in humans during streptokinase therapy. *Acta haemat., Basel* 34: 305-320 (1965).
8. GIROLI, A., SACCHETTI, G.; MANDRIZ, L., BOARIN, F. Attivazione della fibrinolisi da acido 3-piridilacetico da acido nicotinico nell'uomo. *Acta vitamin.* 16: 107 (1963).
9. INTROZZI, P.; NICOLA, P. DE TURPIN, R., BOARIN, F. Le basi fisiopatologiche i risultati clinici della terapia trombolitica. Presented at the XVII. Congress of the Italian Society of Haematology, Genoa, november 1960.
10. LONGHINI, V., SCARDONE, G., GUZZI, G. Effetti di un omologo superiore dell'acido nicotinico (acido 3-piridil-acetico) sulla coagulazione e sull'attività fibrinolitica del sangue. *Settim. med.* 49: 170 (1961).
11. MURROGHY, P., PROCTOR, F. Attivazione fibrinolitica del sangue da acido da alcool nicotinico. *Arch. Mar.* 14: 69 (1958).
12. OWREN, P. Thrombostat - new method for controlling anticoagulant therapy. *Lancet* ii: 754 (1958).
13. OWREN, P. A. AND AAS, K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. *Scand. J. clin. Lab. Invest.* 5: 201 (1951).
14. STORVICKER, H. The preparation of proaccelerin deficient (Parahemophilia) plasma for the assay of proaccelerin. *Scand. J. clin. Lab. Invest.* 9: 273 (1957).
15. VERMYLEN, C.; VERHEIJ, R. DE AND VERSTRAETE, M. A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerization time (FPT). *Clin. chim. Acta* 8: 418 (1963).
16. VERMYLEN, C. AND VERSTRAETE, M. Antithrombin V: critical evaluation of its assessment and properties. *Thromb. Diath. haemorrh.* 5: 267 (1960).
17. WEISS, M., REDMON, W. AND STEELE, J. M. Occurrence of fibrinolytic activity following administration of nicotinic acid. *Proc. Soc. exp. Biol., N. Y.* 98: 735 (1958).

Authors' address: Dr. J. Vermeylen, Dr. F. Flamen, Dr. R. A. De Vreder and Dr. M. Verstraete, Laboratory of Physiochemistry, University of Louvain, Louvain (Belgium).

SECRET

1/10/66

From the Department of Internal Medicine (Director Prof. H. MORIT)
 School of Medicine Toho University Tokyo

Parahaemophilia: The Report of One Family from Japan

M. KAGAMI AND H. MORITA

In 1943 QUICK (19) observed that one-stage prothrombin time of ovalated plasma was stored in the refrigerator became progressively prolonged which was able to be corrected by adding small amounts of fresh plasma, in which the prothrombin itself was greatly depressed.

A few years later the clinical significance of this new factor became apparent from an exhaustive investigation by OWREN (17) who described a female patient with bleeding tendency due to a deficiency of this factor which he originally termed factor V^W and later renamed proaccelerin. This deficiency condition was designated as parahaemophilia by him.

Since then about thirty additional families (3, 4, 7, 10, 21) have been reported from various parts of the world.

This communication presents the results of investigations on a Japanese male with a coagulation defect indistinguishable from that of Owren's parahaemophilia.

Case History

B. O. 30-year-old Japanese male was referred to us on May 9, 1958, for the investigation of bleeding tendency—time when he was during the asymptomatic stage.

Haemorrhagic diathesis was first recognized by his mother who noticed subcutaneous ecchymoses appearing in the child about six months of age. Thereafter the patient experienced many bleeding episodes: easy bruising, epistaxis, severe and persistent bleeding following cuts and dental extractions. At the age of 13, persistent bleeding following tonsillectomy continued for over 10 days, and he was once in moribund condition due to large blood loss. He developed haemarthrosis of the right knee following traffic accident when he was 23 years old. Since then, haemarthrosis of the same joint occurred twice resulting from slight trauma. Four days prior to his

admission, massive haematemesis with epigastralgia occurred, from which moderate pallor of the face developed.

Family history His parents are first cousins. According to the patient's statement, no incidence of excessive bleeding had been noted for three generations, except one of his sisters, who has repeated bleeding episodes very similar to his (fig 1). The patient and his wife are also first cousins. There are two children (one male and one female) with haemorrhagic episodes.




Fig 1 Family pedigree of the patient. Arrow indicates probandus. Hatched Clinically affected, not tested.

Physical Examinations

Physical examination was not remarkable except for moderate anemia. There was no ecchymosis nor external bleeding. The heart and lungs were normal. Abdomen was almost negative. The liver edge was palpable under right costal margin. The spleen was not palpable or enlarged to percussion. There was no adenopathy. No residual deformities or functional disturbances of the right knee were evident on both physical and X ray examinations.

Examinations of the blood revealed a red-cell count of 3080000, haemoglobin 66%, and a white-cell count of 10800 with 65.5% neutrophils, 2.0% eosinophils, 0.5% basophils, 7.5% monocytes and 24.5% lymphocytes. The reticulocytes numbered 66% and the blood platelets 422000 per mm³ (14).

Methods

The bleeding time was performed according to Duke. In our laboratory, bleeding time over 5 minutes is considered pathological.

Tourniquet test (Rumpel-Leede) was performed with the cuff of sphygmomanometer and during 5 minutes positive pressure was maintained at 10 mm under the systolic blood pressure.

Whole blood coagulation time was determined according to LEE AND WHITE (11). Normal values: 7-12 minutes (glass tube), 20-30 minutes (silicone coated glass tube).

Platelets were counted by the indirect method of MORITZ AND YONGSTRA (14). Normal values: $525,000 \pm 119,000$ per mm³.

Recalcified plasma clotting time was estimated by Howell method.

One-stage prothrombin time was measured with Quick's method and the method of ROSENFIELD AND TUFT (20).

Residual prothrombin concentration in serum was measured one hour after coagulation at 37 °C according to ROSENFIELD AND TUFT one-stage procedure.

Thromboplastin generation test was performed with a modification of the original method as described by BLOOM AND DOUGLAS (18).

All tests were carried out in ovalist system. Sera for reagent were separated after 24 hours incubation at 37 °C. Sera were diluted at least half an hour prior the tests.

Quantitative estimations of prothrombin, labile factor VII antihemophilic factor were performed according to WARE-SILVERMAN two-stage method (23) Wolf method (24) HOLLER's method (9) and PITNEY's method (18) respectively.

The plasma thromboplastin component (PTC) activity of plasma was tested by determining its capacity to correct the abnormally long clotting time of plasma known to be deficient in PTC.

The investigation of circulating anticoagulant was performed by the determination of recalcified clotting time after addition of increasing amounts of the patient plasma to normal plasma.

Clot-retraction was measured according to MACFARLANE (15).

Plasma fibrinogen concentration was estimated by Micro-bjeldahl method.

Platelet procoagulant-like activity was measured by method of HJORT *et al.* (6) and modified WARE-SILVERMAN's method (25).

Results

1 Nature of the coagulation defect in the patient

The results of the laboratory tests on B.O. are summarized in Table I. The bleeding time, tourniquet test, clot retraction, clot lysis and fibrinogen assayed normally.

The clotting time of whole blood, however, was moderately prolonged in both glass and silicone coated tubes, as was recalcified clotting time. This abnormality was associated with prolongation of the one-stage prothrombin time. By the modified procedure (ROSENFIELD AND TUFT) in which the test plasma is diluted with normal barium sulfate adsorbed plasma, the defect measured by the customary procedure was completely corrected. Residual prothrombin in serum one hour after coagulation, measured by modified one-stage procedure was abnormally high.

Thromboplastin generation test was abnormal when the reaction mixture consisted of normal platelets, normal serum.

Table I
Haematologic studies in the patient.

	1958 May 11	1958 May 16	1958 Oct. 18	1958
1. Routine Examinations				
Bleeding time, min (Duke)	31		4	
Rumpel-Leede Test	negativ		negative	
Platelet Count, $\times 10^4$ (Morita)	40.2		41.7	
Whole blood clotting time				
in glass tube, min	17	22 $\frac{1}{2}$	19 $\frac{1}{2}$	
in silicon coated tube, min			ca. 180	
Recalcified plasma clotting time, second	262 (148)		337 (156)	34
2. Plasma-screen Examinations				
One-stage prothrombin time, sec				
method of Quick	22.4 (11.0)	22.6 (11.6)	19.2 (10.5)	21.
method of Rosendorf and Tuft	12.2 (12.4)		12.0 (11.8)	13.
Two-stage prothrombin concent., %		105	103	
Labile factor activity * (Woll)	5 >	ca. 5	5 >	
Factor VII activity (Koller)		100		
A. H. F. activity % (Pitney)		116	102	
P. T. C. activity		normal	normal	
Residual prothrombin in serum,	55		45	
Thrombin time, second		34 (38)	31 (29)	2
Circulating anticoagulant	negative		negative	+
Plasma clot retraction, %	85		80	
Plasma fibrinogen, mg/dl			347	
Plasma clot lysis, 24 hr, 37 °C	negativ		negative	+
Platelet factor 1	reduced	ca. 5%	reduced	
Platelet factor 3	normal		normal	

1) Modified Ware-Seegers two-stage method.

2) Parenthesized passages indicate the control values.

barium sulfate adsorbed plasma of the patient and calcium solution (Table II)

When a mixture of equal amounts of patient's and haemophilic's barium sulfate adsorbed plasma was used as reagent in this test yielded a complete correction of the (Fig. 2)

It could be concluded from different mixing experiments the prolonged one-stage prothrombin time of the patient's could be corrected respectively by normal plasma, barium adsorbed normal plasma and haemophilic plasma (Table I)

To exclude the possible existence of circulating anticomponents of plasma from a normal person with a recalcified clotting time of 148 sec were mixed with the patient's plasma his plasma recalcified clotting time was 392 seconds. As shown in Table IV only 20% of normal plasma was added to the

Table II
Thromboplastin generation test.

Thromboplastin generating mixture			Time in minutes that thromboplastin generating mixture was incubated before added to substrate-plasma					
Source of platelets	Source of substrate plasma	Source of serum	1	2	3	4	5	6
			Clotting time in seconds of plasma to which thromboplastin generating mixture and CaCl_2 were added					
Normal	Normal	Normal	42.2	16.8	11.4	9.8	10.0	10.2
Normal	Normal	B. O.	39.0	17.6	10.4	9.6	9.6	9.8
Normal	B. O.	Normal	49.4	28.2	22.4	19.8	20.2	20.0
B. O.	Normal	Normal	40.6	17.2	10.6	10.2	9.6	9.6
B. O.	B. O.	Normal	54	30.8	22.4	22.8	24.4	26.2

Table III
Correction of prothrombin time by the addition of various plasma samples.

		Mixing ratio					
Normal plasma	10		2.5				
Hemophilic plasma				2.5			
Stored norm. plasma					2.5		
BaSO adsorbed plasma	10						2.5
Patient plasma		10	7.5	7.5	7.5	7.5	7.5
Prothrombin time in seconds	11.0	360	22.4	11.4	11.6	28.6	11.2

Table IV
Correction of recalcified clotting time by the addition of normal plasma.

		Mixing ratio				
Normal plasma	10	8	5	2	0	
Patient's plasma	0	2	5	8	10	
Recalcified clotting time in seconds	148	115	144	188	322	

plasma, the recalcified clotting time was in the normal range and thus the presence of a circulating anticoagulant was excluded.

Finally, quantitative estimation of the labile factor activity in the patient's plasma showed a marked reduction (5% or less of normal value). In contrast, the antihemophilic factor (factor VIII) activity was completely normal, as were the P.T.C. (factor IX) and factor VII activities. Hartert's thrombelastogram of the whole blood revealed the increased r and l value with almost normal maximum amplitude (ma value) (Fig. 3).

2. Platelet factor I (proaccelerin-like activity) of the patient's platelets

As described before, the thromboplastin generation test resulted abnormal when adsorbed plasma obtained from the patient




Fig. 2. The correction of the clotting defect by mixing the patient's plasma and known hemophilic plasma on the thromboplastin generation test.



Fig. 3. Thromboplastinogram using patient's whole blood. The α -value 35, k -value 17 m -value 50 and mE value 100. Normal range α 15-25, k 7-15 m 50-60, mE 100-150.

was used in reaction mixture. It was observed, as shown in Table II that the abnormality was exaggerated when the patient's platelets were used instead of normal platelets together with patient's adsorbed plasma in the reaction mixture. This observation suggests that the patient's platelets are deficient in the proaccelerin-like activity since the thromboplastic factor (platelet factor 3) activity seemed to be normal if determined by the thromboplastin generation test using normal serum and normal adsorbed plasma.

The platelet factor 1 activity (as proaccelerin-like activity) was thus determined. The activity was markedly reduced (Table I). Furthermore, the fact that the defect in platelet factor 1 was correctable by exposing the abnormal platelets to normal plasma was reconfirmed (Table V).

Table I
Studies on platelet factor I

Reaction mixture	Clotting time
by the addition of	(seconds)
0.2 ml normal platelet suspension (N. P. S.)	41
0.2 ml factor V free plasma	0.2 ml heated—53 °C, 10 min—N. P. S.
0.2 ml thromboplastin	0.2 ml trypsin treated N. P. S.
0.2 ml 1/40 CaCl ₂ solution	0.2 ml trypsin treated, resuspended in normal plasma, N. P. S.
	0.2 ml patient platelet suspension in saline
	0.2 ml saline as control
	48.
	56.

Table II
Coagulation studies of the family members (March 3, 1962).

	Wife	Son	Daughter	Control
Recalcified plasma clotting time sec	142	318	362	154
One-stage Prothrombin time (Quick) sec	12.4	13.2	15.6	12.4
Residual Prothrombin in serum, 1 h, %	10	35	32	(<15)
Factor V activity (Wolf) %	98	23	17	(80—120)
Factor V III activity (Pitney) %	110	116	95	(60—180)
Circulating anticoagulant	neg	neg	neg	
Plasma clot retraction (Budtz-Olsen) %	92	88	90	(>77)

Values in parentheses indicate the averaged normal value.

3 Hemostatic studies on the family members

As shown in Figure 1 the proband patient has two children, a son and a daughter. Both of them have had several hemorrhagic episodes characterized by nasal bleeding and subcutaneous ecchymoses.

The results of routine coagulation tests performed on the patient's wife, son and daughter were summarized in Table II.

Prolonged one-stage prothrombin time and decreased factor V activity were recognized on both children but not on wife.

Discussion

The hemorrhagic tendency of the patient described at first appeared with subcutaneous ecchymoses when he was about

6 months old. Subsequently he had repeated haemorrhagic episodes including persistent bleeding following cuts, dental extractions and tonsillectomy.

The laboratory tests showed a defective coagulation mechanism in the patient's blood. One-stage prothrombin time of the patient's undiluted plasma was moderately prolonged, but it became normal after the addition of normal barium sulfate adsorbed plasma. Thromboplastin generation test was abnormal when the reaction mixture consisted of normal platelets, normal serum, barium sulfate adsorbed plasma obtained from the patient and calcium chloride. Furthermore, when a mixture of equal parts of patient's and known haemophilic adsorbed plasma was used instead of patient's adsorbed plasma alone, resulted in a complete correction of defective thromboplastin formation. These observations suggest that the substance deficient in the patient's plasma must be different from factor V III (antihemophilic factor). This was confirmed by the estimation of the labile factor activity in the patient's plasma, which revealed 5 % of normal or less than that. These results have led the authors to conclude that this patient had parahaemophilia, the very first case ever reported in Japan.

Parahaemophilia occurs in both sexes, but the exact mode of its inheritance (2, 5, 16) is not clear. In the present case, the parents of the patient are first cousins, and one of his sisters has a haemorrhagic tendency very similar to that of the patient. Furthermore, his two children have haemorrhagic episodes and their factor V level in the blood was proved to be very low.

Seven cases of simultaneous occurrence of the deficiencies of antihemophilic factor (factor VIII) and labile factor (factor V) have been reported in the literature (7, 15, 21, 26).

In our cases, this possibility was excluded, since i) the known haemophilic's plasma was capable of correcting the defective coagulation mechanism of the patient's blood and ii) the antihemophilic factor (factor VIII) activity of the patient's blood was completely normal.

Ware and his collaborators (22) have demonstrated the presence of proaccelerin-like activity in normal platelets, and LEWIS AND FERGUSON (12) as well as HJORT *et al* (6) have reported that the parahaemophilic platelets are deficient in proaccelerin like (platelet factor 1) activity. The defect as determined by the thromboplastin

generation test was exaggerated in this case by the use of patient's platelets and barium sulfate adsorbed plasma in the reaction mixture. This observation suggests that the parahaemophilic platelets were deficient in factor I activity and that the platelet factor I in normal platelets can substitute the plasma factor V in the thromboplastin generation test at least in part (8).

Furthermore, after a series of tests the authors believe that the platelet factor I and factor V in the plasma are closely related and platelet factor I in blood platelets is perhaps resulted from the adsorption of plasma factor V from plasma.

Summary

A family of parahaemophilia is described. Propositus is 30 year-old (in 1958) Japanese male with moderately severe haemorrhagic tendency since the age of about 6 months. The defect in the patient's clotting mechanism was attributed to deficiency of factor V (proaccelerin) in his plasma. Two children, one son and one daughter of the patient also have had bleeding manifestations very similar to his. The results of the haemostatic examinations indicated the moderate deficiency of factor V in their blood. That the parahaemophilic platelets are deficient in the platelet factor I activity was confirmed.

This is the first case report of parahaemophilia in Japan.

Résumé

Une famille atteinte de parahémophilie est décrite. Le propositus est un japonais âgé de 30 ans (en 1958) ayant une tendance modérée aux hémorragies depuis l'âge d'à peu près 6 mois. La défectuosité dans le mécanisme de coagulation sanguine du malade fut attribuée à un manque en facteur V (proaccélérine) dans le plasma. Deux enfants, un fils et une fille du malade, avaient également des manifestations hémorragiques très semblables aux siennes. Les résultats de l'examen de l'hémostase révélèrent un manque modéré en facteur V dans le sang. Le manque en facteur I des thrombocytes parahémophiles fut confirmé. Il s'agit du premier rapport de parahémophilie au Japon.

Zusammenfassung

Es wird eine Familie mit Parahämophilie beschrieben. Der Propositus ist ein 30 Jahre alter Japaner (1958) mit einer mittelschweren hämorrhagischen Diathese seit dem Alter von ca. 6 Monaten. Die Gerinnungsstörung beruht auf einem Mangel an Faktor V (Proaccelerin) im Plasma. Ein Sohn und eine Tochter waren sehr ähnliche Blutungserscheinungen auf wie der Patient. In ihrem Blut fand sich ein mäßiger Mangel an Faktor V. In den parahämophilen Plättchen wurde ein Mangel an Plättchenfaktor I nachgewiesen. Es ist dies die erste Beschreibung einer Parahämophilie in Japan.

References

1. BOGGS, R. AND DOUGLAS, A. S. The thromboplastin generation test. *J. clin. Path.* 6: 23 (1953)
2. BRUCE, A. J. AND KINGLEY, C. S. A familial disorder of blood coagulation due to deficiency of the labile factor. *Quart. J. Med.* 65: 19 (1952)
3. BARNHART, K. M. Hemophilia and hemophiloid diseases (Univ. of North Carolina Press, Chapel Hill 1957)
4. COKURO, E., VERRASTRO, T., JANRA, M. Parahaemofilia, apresentacao de caso de deficiencia de Fator V (Fator Labil, proacelerina, globulina aceleradora do plasma, Ac-globulina). *Rev. Hosp. Clin.* 12: 216 (1957)
5. DE VRIES, A., MATOYS, Y. AND SWANER, Z. Familial congenital labile factor deficiency with syndactyly. *Acta haemat.* 5: 129 (1951)
6. HJORT, P., RAPAPORT, S. I. AND OWREN, P. A. Evidence that platelet accelerator (platelet factor 1) is adsorbed plasma proaccelerins. *Blood* 10: 1129 (1955)
7. IVERSEN, T. AND BASTRY-MANDEL, P. Congenital familial deficiency of factor V (parahaemophilia) combined with deficiency of antihemophilic globulin. *Brit. J. Haemat.* 2: 263 (1956)
8. KAGAMI, M. Studies on blood coagulation. I. Thromboplastin generation test. *J. Jap. Soc. Int. Med.* 46: 1562 (1958)
9. KOLLER, F., LOEWIGER, A. AND DICKERT, F. Experiments on a new clotting factor (Factor VII). *Acta haemat.* 6: 1 (1951)
10. LARSEN, M. J., CADE, P., GREGG, E., CAYLA, J. ET BERNARD, J. Hypoprothrombinémie congénitale (Parahémophilie d'Owren). *Sang* 27: 117 (1956)
11. LEE, R. I. AND WHITE, P. D. A clinical study of the coagulation time of blood. *Amer. J. Med. Sci.* 143: 493 (1915)
12. LEWIS, J. A., FERROUSOV, J. H. Hypoprothrombinemia. *Blood* 10: 351 (1955)
13. MACFARLANE, R. G. A simple method for measuring clot retraction. *Lancet* 199 (1939).
14. MORITA, H. Blood platelets in clinical Medicine. *J. Jap. Soc. Int. Med.* 46: 803 (1957)
15. OERI, J., MATTER, M., ISCHWED, H., HADNER, F. UND HOLLER, F. Angeborener Mangel an Faktor V (Parahaemophilie) verbunden mit echter Haemophilie A bei zwei Brüdern. *Mod. Probl. Ped.* 1: 575 (1954)
16. OWREN, C. A. JR. AND COOPER, T. Parahaemophilia. *Amer. Med. Ass. Arch. I & Med.* 85: 194 (1955)
17. OWREN, P. A. Parahaemophilia, haemorrhagic diathesis due to the absence of previously unknown clotting factor. *Lancet* 446 (1947)
18. PITNEY, W. R. The assay of antihemophilic globulin (AHG) in plasma. *Brit. J. Haemat.* 2: 250 (1956)
19. QUICK, A. J. On the constitution of prothrombin. *Amer. J. Physiol.* 140: 212 (1943)
20. ROSENFELD, R. R. AN. TUFF, H. S. Estimation of prothrombin from prothrombin time. *Amer. J. Clin. Path.* 17: 329 (1948)
21. SCHMIDT, R. H., MARSHALL, A. JR. AND RATNOFF, O. III. Observations on hemophilia, parahaemophilia and coexistent hemophilia and parahaemophilia. *J. Lab. clin. Med.* 52: 449 (1958)

22. WARE, A. G. FARLEY, J. L. AND SARGENT, W. H.: Platelet extracts, fibrin formation and interaction of purified prothrombin and thromboplastin. *Amer. J. Physiol.* 154: 140 (1948)
23. WARE, A. G. AND SARGENT, W. H.: Two-stage procedure for the quantitative determination of prothrombin concentration. *Amer. J. Clin. Path.* 19: 471 (1949)
24. WOLF, P.: A modification for routine laboratory use of Stefansson's method of estimating factor V activity in human oxalated plasma. *J. Clin. Path.* 6: 54 (1953)
25. YOSHIOKA, A.: Two-stage plasma factor V assay. *J. Nara Med. Ass.* 8: 45 (1957).
26. JONES, J. H., REEZA, C. R., HARDISTY, R. M., DORMANDY, A. M. AND MACPHERSON, J. C.: Combined deficiency of factor V and factor VIII. *Brit. J. Haematol.* 8: 120 (1962)

Authors' address: Drs. M. Kagami and H. Mita, First Med. Department, Teikyo Univ. Hosp., 11 Omori-2-chome, Ohta, Tokyo (Japan).

Institute of Medical Semiology University of Milan (Director Prof. E. L. POLLI) and
Medical Department 'Talamona' Maggiore Hospital, Milan (Head Physician Prof.
L. BUMI).

Ultrastructural Aspects of Platelets and Megakaryocytes in a Case of Primary Thrombocythaemia

L. BUMI G. JEAN AND L. LE COULTRE

The concept of thrombocythaemia implies a persistent, marked increase of the platelet-count (at least 800 000/mm³) with related changes in haemostasis and the onset of a thrombophilic or an haemorrhagic state, the latter being a nearly constant finding in the majority of the cases reported.

In the present terminology primary and secondary thrombocythaemia are usually referred to. The existing literature on this subject has already been surveyed by one of the authors (1). Cases which, from the clinical-haematological standpoint, can be classified as primary thrombocythaemia are definitely found (13). On the other hand the pathological features of such cases are not substantially different from those of other myeloproliferative disorders. The assumption has thus been made that primary thrombocythaemia should itself be regarded as one form, or possibly one phase, of a multi-faceted myeloproliferative disorder rather than as a distinct entity' (4).

From previous investigations of platelet ultrastructure in some thrombocythaemia cases (7-10) we concluded that certain ultrastructural differences between cases of primary thrombocythaemia and cases of splenogenous thrombocythaemia were evidenced by the electron microscope although the observed differences could not indicate whether or not the ultrastructural changes were merely the expression of the increased thrombopoietic activity.

Recently we have examined the ultrastructure of megakaryocytes and platelets from a patient affected by primary' thrombo-




Fig 1 Electron-microscopic findings in platelets. A) Platelet diameter in μ . B) Number of mitochondria per section. C) Number of dense granulations per section. D) Number of light elements per section.

Fig 2 Polymorphic appearance of the platelets. Platelets with plenty of cytoplasmic organelles are adjoined to others (platelets 2,4) which have almost none at all. Note overabundant mitochondrion and lipid droplet in platelets 1 and 4 respectively. Areas of lower electronic density can be noted in the hyalomere of platelet 3.



cythaemia. Since we have not found in the existing literature any similar investigation, this study has been undertaken in the attempt of defining eventual ultrastructural changes characteristic of megakaryocytes and platelets in primary thrombocythaemia.

Methods

Ultrastructural investigation of platelets and megakaryocytes was carried out at the Milan University Institute of Medical Semiology; the methods have been previously described (6-12).

Case Report

The patient, 28-year old housewife was found slightly anaemic on medical checkup at the beginning of pregnancy (December 1962). Since then she complained of moderate fever accompanied by painful heaviness in the left hypochondrium. In March 1963, the patient was hospitalized because of splenic infarctions. Her spleen was enlarged (4 cm below the left costal margin). The injection of 1 mg of adrenalin resulted in reduction of the splenic size. The clinical course was complicated by thrombophlebitis in the right leg on the third hospital day. Laboratory findings are reported in Table I.

The diagnosis of 'primary thrombocythaemia' was made. The patient was discharged and subjected to routine prenatal care. No changes were noted in haematological checkups performed during the following months.

In September 1963, spontaneous labour resulted in stillbirth. Several infarctions could be traced in the placenta. The patient was subsequently treated with F⁷⁰; the platelet-count was reduced within normal limits and clinical symptoms improved. Remission is still present.

Blood coagulation tests (clotting time determination on glass and silicone, activity of prothrombin complex, prothrombin consumption, thromboplastin generation tests) have been normal on several occasions.

Platelet enzyme determinations have shown higher levels than normal (Table II). This finding previously-observed in cases of primary and 'secondary' thrombocythaemia (1) is probably related to a younger platelet population.

Comment. In Table I our patient's and OZER's cases data are compared. The marked enlargement of the spleen was the only finding inconsistent with the diagnosis of primary thrombocythaemia. However it may be worth noting that quite a few cases which had been diagnosed as primary thrombocythaemia in the past were accompanied by a marked enlargement of the spleen (4). On the other hand no case appears to ever have been reported of

Fig. 3. A granulocyte containing only of light elements. 18900.

Fig. 4. Platelet 1: residues of platelet demarcating membranes. Platelet 2: bull's eye shaped dense granulation (arrow). Platelet 3: organelles of a Golgi origin (arrow). 17500.



Table I

Comparison between Ozeri's data and our patient findings.

Conditions for diagnosis of 'primary' thrombocythaemia according to Ozeri	Our patient
Thrombosis and/or haemorrhage	Thrombosis
Slight enlargement of the spleen	marked enlargement
Erythrocyte count under 5 millions	4,500,000
Haemoglobin below 18 g ^o	10.5 g ^o
Haematocrit value under 54	32
Leukocyte count under 40,000	10,000
Platelet count in excess of 800,000	1,100,000
Hyperplasia of all bone marrow series	present
Megakaryocytosis	present
No leukaemic infiltrates	?

Table II

Platelet enzyme values.

	Normal	Our Patient
Aldolase	40 U	70 U
Lactodehydrogenase	63 U	170 U
G. O. Transaminase	3.5 U	6 U
G. P. Transaminase	1 U	1.9 U
Acid phosphatase	620 U	1830 U
Alkaline phosphatase	15 U	73 U

a congestive enlargement of the spleen (which was our patient's condition, in view of the considerable reduction of her spleen induced by adrenalin) associated with secondary thrombocythaemia. Generally splenomegaly and secondary thrombocythaemia are found in Hodgkin's disease in sarcoidosis, in certain cases of spherocytic icterus or in primary fibrosis of the spleen. A congestive splenomegaly is usually associated with thrombocytopenia.

The most likely hypothesis in this case appears to be that of a primary thrombocythaemia with accompanying thrombosis of the splenic vein.

Electron Microscope Findings

Platelets

The results of our electron-microscope investigation of patient's platelets are reported in Table III and Figure 1

Fig. 5 Platelets with rod-shaped dense granulations. 14000.

Fig. 6 Giant dense granulation. 22750.



Table III

A comparison between platelet changes in primary thrombocythaemia and those observed in our patient.

Ultrastructural features	Primary thrombocythaemia	Our patient
Size	Microcytosis	Microcytosis
Hyalomere structure	Frequently irregular	Irregular in small percentage of sections
Glycogen	Reduced	Reduced
Steatosis	Never observed	Present
Mitochondria	Fewer	Fewer
Dense granulations	Normal or reduced number some of them non-typical	Fewer; some of them non-typical
Light elements	Normal or fewer	Fewer

Size The average platelet diameter is below normal (2000 instead of 2500 μ m)

Hyalomere Areas of lower electronic density (Fig 2) are shown in the hyalomere of a small percentage of platelets. Such areas are similar to those reported in some cases of primary thrombocythaemia (8-10)


Mitochondria The number of mitochondria appears to be slightly below normal (1.3 per section instead of a normal 2-3). Particularly large mitochondria (Fig 2) were noted in 2.6% of the sections examined.

Dense granulations The number of dense granulations, too, was found to be slightly below the norm (5 instead of 7-10 per section) the reduction resulting from the high percentage of sections (12%) containing no dense granulation (Figs 2 and 3). Morphologically abnormal dense granulations were found in 18% of the sections. They were rod-shaped (8%) (Fig 5) bull's eye shaped (8%) (Fig 4) or giant size (2%) (Fig 6).

Light elements Also the number of these elements was found to be slightly below normal. While unusually large elements of this kind were seldom noted (they are instead quite numerous in secondary thrombocythaemia [8-10]) saccules and vesicles originating from the Golgi apparatus (Fig 5) were frequently observed (26% of the sections).

Steatosis Lipid inclusions (Fig 2) were found in 2.6% of the sections.

Fig 7 Perinuclear area of megakaryocyte with large number of bull's eye shaped dense granulations (arrows). Golgi apparatus (G) is well represented. (3137)



Glycogen Clusters of argentaffine granules, identified as glycogen (7-9) were noted in just 26% of the sections instead of 40 to 50% as in normal platelets.

Megakaryocytes

Under the electron microscope (3) a normal megakaryocyte cytoplasm appears to consist of 3 concentric, structurally different areas: a *perinuclear* one with plenty of mitochondria and ribosomes and a very well developed Golgi apparatus; an *intermediate area* in which platelet demarcating membranes are prevalent; and a *peripheral area* with no cytoplasmic organelles. Besides a fusion of platelet demarcating membranes, a gradual maturing of granulomere organelles can be observed in the intermediate area. Particularly worth noting appears to be the gradual reduction in the size of mitochondria and the maturing of dense granulations originating from vesicles of the Golgi apparatus through several stages: compound vacuoles, bull's eye shaped granulations, and dense mature granulations (12).

Our patient's megakaryocytes were featured by a remarkable polymorphism: for besides a number of cells with plenty of cytoplasmic organelles (Figs. 7-8) we noted other megakaryocytes (Figs. 9-10) containing very few mitochondria, dense granulations and vacuoles, while the proportion of platelet demarcating membranes was quite normal.

Mature platelets were moreover frequently noted in the megakaryocyte center (Fig. 11). They were surrounded by a vacuole equipped with a double membrane similar to the platelet demarcating ones.

Several other ultrastructural changes were ascertained in both the perinuclear and intermediate areas. The appearance of the peripheral area of these megakaryocytes was instead normal.

In the *perinuclear area*, the ergastoplasmic membrane system was particularly well developed (Fig. 7) and free ribosomes, too, were quite plentiful. Besides the number of compound vacuoles and of bull's eye shaped granulations (Figs. 7-8) was definitely above the norm.

Fig. 8. Intermediate area of megakaryocyte. Note paucity of cytoplasmic organelles. One bull's eye shaped dense granulation can also be seen (arrow). 34500.

Fig. 9. Peripheral area of megakaryocyte. A dense granulation is to be seen. Note persistence of particularly large mitochondrion (MI) and cytoplasmic membrane (mn). 25873.



In the *intermediate area* such gradual reduction in the number and size of mitochondria which occurs in the normal megakaryocyte (3) could not be observed. As a matter of fact, particularly large mitochondria were noticed even in the cell most eccentric areas (Figs. 10-11). Maturation of dense granulations appeared to be inadequate, the number of bull's eye shaped dense granulations being elevated also in the intermediate area of these megakaryocytes.

Conclusions

The ultrastructural features of our patient's platelets and those found by one of us in other cases of primary thrombocythaemia are reported in Table II (10). Microcytosis, reduction of all granulomere organelles and of intrathrombocytic glycogen, and presence of nontypical forms in dense granulations are found in our case as well as in other cases of primary thrombocythaemia on which reports are available.

In our case, a small percentage of platelets contained lipid droplets; this finding so far has been reported only in a case of secondary thrombocythaemia and fibrosis of the spleen (10-11).

Finally, we should like to emphasize certain ultrastructural features (particularly large mitochondria, bull's eye shaped dense granulations, Golgi apparatus residues) which are observed in both primary and secondary thrombocythaemia (10-12). The submicroscopic changes herein described were regarded as the indication of an altered platelet maturation process (3, 10-12) an assumption which our findings in this particular case have confirmed. As a matter of fact, the presence of oversized mitochondria, of bull's eye shaped dense granulations and of residues of the Golgi apparatus in peripheral blood platelets is associated with marked changes in the maturation process of cytoplasmic organelles in megakaryocytes: mitochondria undergo no gradual reduction in size from the perinuclear to the peripheral area, bull's eye shaped dense granulations are plentiful in the intermediate area as well, Golgi apparatus membranes and vesicles are also found in cytoplasmic areas where a very lively platelet forming activity is in progress.



References

1. BURE, L. Le trombocitemie XVIII Congr. Soc. ital. Ematologia. 1961
2. DAMEWICK, W. Some speculation on the myeloproliferative syndromes. *Blood* 6. 372 (1951)
3. GAUTHIER, A. JEAN, G.; PROMET, M. ET FALCÃO, L. Ultrastructure des mégacaryocytes et problèmes de plaquetogénèse. *Arch. Ital. Anat. Istol. pat.* 37. 502 (1963)
4. GONZ, F. W. Haemorrhagic thrombocythæmia, critical review *Blood* 15. 706 (1960)
5. HAGGEMAN, P. HOLLMAIER, A. H. LEVY, J. P. ET BOSCH, M. Etude au microscope électronique des plaquettes sanguines dans les leucémies humaines. *J. Microsc.* 2. 529 (1963)
6. JEAN, G. Thrombocytes et thrombopathies. *Experientia* 17. 428 (1961)
7. JEAN, G. BOSCH, M. Aspetti ultrastrutturali delle piastrine nella trombocitemia. *Bosch* (1)
8. JEAN, G. ET GAUTHIER, A. Essais de cytochimie ultrastructurale. Sur la mise en évidence du glycogène dans les thrombocytes humains normaux et pathologiques. *C. R. Acad. Sci.* 253. 2274 (1961)
9. JEAN, G. AND RACINE, L. On the structure of normal human thrombocytes. *Proc. 5th Congr. E. M. Philadelphia* 1962. pp. 00-8.
10. JEAN, G. RACINE, L. GAUTHIER, A. ET MARX, R. Modifications ultrastructurelles des plaquettes lors de thrombocythémies. *C. R. 9^e Congr. Soc. europ. Hémat. Liège* 1963.
11. JEAN, G. RACINE, L.; MARX, R. ET GAUTHIER, A. Sur la présence de graisses neutres dans les thrombocytes humains normaux et pathologiques. *Thromb. Diath. hæmorrh.* 9. 1 (1963)
12. JEAN, G. RACINE, L.; GAUTHIER, A. ET MARX, R. Granulations denses anormales dans les thrombocytes humains. *Thromb. Diath. hæmorrh.* 10. 42 (1963)
13. OZER, F. L. TRUAX, W. E. MARSH, H. C. AND LEVIE, W. C. Primary hemorrhagic thrombocythemia. *Amer. J. Med.* 28. 807 (1960)

Authors' address: Dr. L. Burel, Medical Dept. "Talavera", Maggiore Hospital, Milan (Italy) G. Jean and L. Le Castra, Institute of Medical Hematology Via Po, Milan (Italy).

Institute of Medical Pathology University of Modena (Directors Prof. E. STURMI)

Regulatory Mechanisms for Protein Synthesis in Normal Blood Cells

U. TORELLI, D. QUAGLIO AND C. MAURI

Knowledge of the mechanisms regulating protein synthesis is highly relevant in understanding the general phenomena which control cell turnover and are responsible for the principle immunological reactions, both humoral and cellular.

It is well established that information for protein synthesis, i.e. the sequence with which aminoacids are inserted in the polypeptide chain is conveyed by the DNA molecule. Still undetermined are instead the processes which, at a certain stage of cell life, operate the transcription of the message into a coordinated sequence of aminoacids. It is known that the mediator between DNA and protein is RNA, but only quite recently as a result of the work of biochemists and microbiologists, some insight has been gained into the mechanisms, whereby information is transferred from DNA to the protein synthesizing structures. This result has been achieved by the identification of three different types of RNA, which are structurally, metabolically and functionally quite distinct: ribosomal RNA, transfer RNA and messenger RNA.

Ribosomal RNA is quantitatively the most important fraction (20). It is metabolically stable (6, 27) and its molecular size is conspicuous (18-28 S or multiple of these values) (26). Its role in the regulation of protein synthesis is still far from clear although its amount has been considered to act as limiting factor (24, 15).

Transfer RNA acts as adaptor and carries each aminoacid to its proper site. Although the exact number of transfer RNAs is still uncertain (5), there appears to be as many different molecular types as the number of standard aminoacids involved in protein synthesis. Their molecular size is uniform (4-8). Each aminoacid enters the polypeptide chain not because of its structure but on account of the arrangement of the bases of the transfer RNA to which it is attached. The mechanism by which transfer RNA may play part in the regulation of protein synthesis will be discussed later in connection with the findings obtained in lymphoid cells.

Messenger RNA is the fraction which appears to be most important in it of protein synthesis.

A considerable advance in our knowledge regarding the regulation of protein synthesis was made when JACOB AND MONOD in 1961 (11) on the basis of the experimental results obtained by different investigators, elaborated a new and comprehensive theory on the genetic mechanisms which control protein synthesis. They suggested that each gene or DNA cistron may act as a template for the synthesis of molecules of messenger RNA, on which the polynucleotide sequence is transcribed. These messenger RNA molecules would then attach themselves temporarily to the ribosomes and the complex messenger RNA ribosomes would represent the functional unit concerned with protein synthesis. According to the current concepts regarding messenger RNA, this fraction is endowed with three characteristics: a base composition complementary to that of DNA, a variable molecular size (6 to 16 S) and a high degree of metabolic instability. The existence of such an RNA fraction was demonstrated in bacteria (2) and also in animal cells (3, 25, 26, 7) thus indicating that the mechanism through which the genetic message is transmitted from DNA to ribosomes appears to be fundamentally similar.

The experimental proof of the existence of a messenger RNA fraction, besides its significance as a fundamental biochemical acquisition, was a preliminary but important confirmation of the validity of the model put forward by JACOB AND MONOD (11) for the regulation of DNA function. According to this model, a set of cistrons, residing in contiguous areas of the DNA molecule form an operon by virtue of the fact that their functional activity is coordinated by a common gene, the *operator*. Its function consists in activating or repressing the synthesis of messenger RNAs on the operon. The operator gene in its turn undergoes the control of a *regulator* gene, which gives rise to a specific substance, the *repressor*. This product directly engages the operator gene and represses it, thus preventing the synthesis of messengers on the operon. The synthesis of a particular protein would take place as a result of the interaction of the repressor with a substrate called the *inductor*. This reaction would inactivate the repressor and initiate the synthesis of specific messenger RNAs. Inhibition of protein synthesis would be due to the interaction of the repressor with a substrate, the *corepressor*. By this process the repressor would become activated and would block the synthesis of new messengers on the operon. Genetic regulation therefore appears to be principally a repressive mechanism.

and according to JACOB AND MONOD the main function of the repressor would consist in preventing the *formation* of messenger RNA rather than its function as a template for protein synthesis.

A great deal of the experimental work carried out in the last few years has confirmed the general applicability of the model proposed by JACOB and MONOD and particularly the suggestion that the action of the repressor consists in preventing the formation of messenger RNA rather than its function. These studies however have been mainly concerned the biochemist and the geneticist, investigating the metabolism of microorganisms. It seems needless to point out the importance which for the haematologist might have the demonstration that mechanisms similar to those previously mentioned may be involved in regulating protein synthesis in blood cells. Such a demonstration is at present beyond our possibilities, but considerable progress has been achieved by the application of autoradiographic methods.

The lack of uniformity in the haemopoietic tissue, which comprises cells with markedly different functional characteristics, requires that a certain metabolic feature and its relation to a particular functional activity should be studied only at the cellular level. This requirement is met by the use of high resolution autoradiography. The autoradiographic findings hitherto obtained concerning RNA and protein metabolism in different types of blood cells suggest the existence of two different mechanisms for the regulation of protein synthesis. However since the experimental data at present available are still limited, the interpretations which will be put forward must be considered purely hypothetical and presented only for the primary aim of stimulating new pathways of research which might confirm or modify the conclusions expressed.

Differentiating Blood Cells and the Operon Model. A Mechanism for the Repression of Messenger Formation

Some of the cell systems studied, such as the granuloblastic and erythroblastic series, are characterized by a process of differentiation which from the primitive blast cells and through intermediate stages leads to the formation of mature erythrocytes and granulocytes. A process of differentiation is allied with the synthesis of specific proteins and therefore the study of the regulation of protein synthesis and protein metabolism during differentiation may provide




Fig. 1. Schematic representation of the variations in RNA and protein synthesis during erythroblastic differentiation. P = proerythroblasts, B = basophilic erythroblasts, PI = polychromatic erythroblasts, O = orthochromatic erythroblasts, R = reticulocytes.



Fig. 2. Schematic representation of the variations in RNA and protein synthesis in the course of plasma cell differentiation. P = plasmoblasts, Pp = proplasmocytes, Pl = plasmocytes.

information on the mechanism by which these syntheses are regulated.

In both cell series RNA and protein synthesis is present in the precursor blast cells and decrease as maturation progresses (29-31). However the rate of decrease is different, with the result that in the more differentiated stages of both cell series protein formation takes place in the absence of any significant RNA synthesis (Fig. 1). Furthermore about 50% of the radioactivity incorporated in both types of myeloid cells during the one hour incubation with labelled nucleosides, is linked with a highly unstable RNA, the synthesis of which ceases before that of the stable RNA fraction. The labile RNA fraction, which appears to be confined to the more immature cells of both series, was tentatively identified with messenger RNA (29-31).

As far as RNA is concerned, a sequence of events similar to that described for the granuloblastic and erythroblastic systems, also takes place in the plasma cell series (17-33). In this series, RNA synthesis decreases at the proplasmocyte stage and is almost completely absent in mature plasma cells, whereas protein synthesis steadily increases and reaches its maximum intensity only in the fully mature plasmocyte (Fig. 2). Thus the increasing rate of protein synthesis distinguishes the plasma cell series from the other two differentiating cell systems and is obviously the expression of the intense globulin synthesizing and secretory activity of mature plasmocytes. In plasmoblasts and proplasmocytes from 40 to 50% of the label incorporated into RNA is unstable and once again, as for the two myeloid series, this short-lived RNA fraction was tentatively related to the presence of messenger RNA (33).

Another observation concerning a differentiating cell system, such as the erythron, has been the demonstration that haemoglobin synthesis takes place in reticulocytes in the presence of a stable RNA fraction and in conditions in which the synthesis of a DNA-dependent RNA could be excluded (14-18). Haemoglobin synthesis in reticulocytes is in fact unaffected by treatment with actinomycin D (23). It seems reasonable to assume that these stable templates are formed in the earlier maturation stages, when messenger RNA can be synthesized on the DNA primer—a possibility which no longer exists in reticulocytes.

It has been further shown that even in the more immature erythroblasts protein synthesis continues unmodified for some hours after DNA inhibition by actinomycin (29). Since haemoglobin synthesis only begins in intermediate erythroblasts (28) it appears likely that also non-haemoglobin proteins are synthesized in the erythroid series on relatively stable templates. Also for these non-haemoglobin proteins a certain length of time must presumably elapse between the stage when information is elaborated and that when it is utilized for the actual synthesis, on the basis of what has been observed in reticulocytes.

However the autoradiographic findings have also indicated that part of the RNA of immature cells is labile. Since metabolic instability appears to be a characteristic of messenger RNA, it seems that also in erythroid cells messenger fractions are synthesized in much the same way as in other animal cells (26, 1-25). Information is therefore elaborated in the early maturation stages.

It is possible to reconcile the apparently contradictory existence of short lived messenger fractions together with that of stable templates, on which protein synthesis takes place, if one considers that synthesis of messenger RNA occurs in the nucleus, that protein synthesis is mainly cytoplasmic and that transfer of RNA from nucleus to cytoplasm presumably requires in myeloid cells a certain interval of time. Possibly the metabolic instability of the information carrying structures is linked with the duration of their stay in the nucleus.

Elucidation of the mechanisms whereby RNA is transferred from the nucleus to the cytoplasm might certainly contribute to clarify the problem of the presence in erythroid cells of unstable messenger fractions and stable templates, but such a clarification does not appear to be immediately forthcoming (9)

The processes described, which give rise to highly specific proteins, such as haemoglobin and antibody γ -globulins, may represent a type of protein synthesis regulation, characteristic of differentiating cell systems. In a cellular system of this type it may therefore be possible to visualize the following sequence of events. When an operator gene has been switched on in a stem cell, production of short-lived messenger RNA is initiated. Soon after DNA synthesis takes place and when the latter reaches the tetraploid value the cell undergoes mitotic division. The existence of a mutual relationship between DNA and messenger RNA synthesis may be supported by some experimental results obtained in bacteria.

In microorganisms it was found that, although DNA is not essential either for the induction or for the synthesis of the induced protein (3) the rate of the latter is dependent on the number of copies of the particular gene (12). It was also observed that the protein synthesizing capacity doubles as the particular gene is duplicated (16-8). Notwithstanding such a relationship is still far from having been demonstrated in differentiating blood cells, the above reported findings may provide an explanation for the observation that unstable RNA synthesis appears more intense in the presence of active DNA synthesis (29-31).

It may be that in haemic cells at a certain stage a repressor engages and closes the operator and the number of short lived messenger RNAs well as the rate of DNA synthesis gradually decrease. Consequently also protein synthesis comes to a halt. Obviously the production of specific proteins, which follows that of structural and

enzymatic proteins, also ceases but the arrest occurs later in the differentiating sequence. For mature plasmocytes this arrest must occur fairly late in their life-span.

The interpretations we have put forward fit in quite well with the general outline of the operon model and especially with the concept that *the progressive decrease in the rate of protein synthesis during differentiation depends on a gradual inhibition of messenger RNA synthesis rather than on a reduced utilization of preformed templates*.

Evidence for a Mechanism Involving Inhibition of Messenger Function

We will now present the findings obtained in blood cells which metabolically do not display a pattern such as one might expect from cells belonging to a particular stage of a differentiating cell system.

In our laboratory a detailed autoradiographic study was undertaken in circulating mononuclear cells on the rate of incorporation of cytidine, uridine and leucine and on the rate of breakdown of the two nucleosides after blocking RNA synthesis with actinomycin D (30-32). Peripheral blood lymphocytes were subdivided in four different groups according to their morphological features: a fifth group consisted of monocytes.

The morphological and metabolic characteristics of the different cell groups are summarized in Fig. 3. RNA and protein synthesis takes place, although at a different rate, in the majority of circulating mononuclear cells. In contrast with the findings obtained in erythroblasts, granuloblasts and plasmacells, the labelling pattern with ^3H -uridine differs considerably from that observed with ^3H -cytidine. With the latter heavy labelling was found in immature lymphocytes, in which protein synthesis was minimal, whereas with ^3H -uridine the most intense radioactivity was seen in monocytes. In these cells a high ^3H -leucine incorporation was also observed.

The variations in the intensity of labelling may be due to the synthesis of RNAs with different functional significance. In support of this hypothesis are the differences in leucine incorporation and the different rate of release of the two nucleosides following incubation with actinomycin D. In cells with prolymphocytic features (B cells) which are labelled more rapidly with cytidine than with uridine, the former is incorporated both in stable and short lived

B

C


D

E

F



AVERAGE LABELLING OF RNA AND PROTEIN IN PERIPHERAL MONONUCLEAR CELLS INCUBATED FOR 1 HOUR WITH TRITIATED CYTIDINE URIDINE AND LEUCINE



AVERAGE RNA LABELLING IN PERIPHERAL MONONUCLEAR CELLS INCUBATED FOR 1 HOUR WITH TRITIATED CYTIDINE AND URIDINE AND SUBSEQUENTLY WITH ACTINOMYCIN D



H 1 1 1 1 1 with cell myel D

RNA, while uridine is only incorporated in a stable RNA. It seems likely therefore that in prolymphocytes two RNA fractions are synthesized one of these, on account of its marked instability of its presumable high uridine content* and because of the low protein synthesis with which it is associated, has been identified, in conformity with the observations of ALLFREY (1) with a messenger fraction the other RNA fraction, characterized by considerable metabolic stability may in our opinion, represent ribosomal RNA.

A third fraction, which appears metabolically unstable, but is associated with a high rate of uridine incorporation and intense protein synthesis, was observed, although in variable degree, in other types of lymphocytes and in monocytes. This fraction was considered, on a purely hypothetical basis, to represent transfer RNA. The results of experiments using phytohaemagglutinin in short-term tissue cultures of normal peripheral blood lymphocytes support the hypothesis of the existence of a transfer RNA synthesis in these types of lymphocytes. In the presence of phytohaemagglutinin (PHA) RNA and protein synthesis rapidly increases in the more common types of lymphocytes, i.e., in small and medium-sized cells (C and D) while striking morphological changes take place, leading to the emergence of large, nucleolated, pyromnophilic, primitive-looking cells (10-33). It is worth emphasizing the fact that protein synthesis already increases rapidly during the first hours of culture and that its rise proceeds in parallel with that of RNA (Fig. 4). More than 50% of the radioactivity incorporated in PHA-transformed lymphocytes, when incubated for one hour with ^3H uridine is linked with a metabolically unstable RNA (33).

What is the more likely interpretation of these findings? The lymphoid cells we have indicated as B cells (prolymphocytes) display metabolic features which may be compared with those of early myeloid cells, although the rate of RNA and protein synthesis is much greater in the latter. Prolymphocytes are in fact charac-

* It may be convenient to point out that the low incorporation of uridine, compared to that of cytidine, may be ascribed to the fact that the intracellular pool of nucleotides and therefore RNA is richer in uridine than in cytidine, the result being that labelled uridine is more diluted.

Fig. 3. The morphological features of five different types of peripheral blood mononuclear cells and the pattern of labelling following incubation with tritiated cytidine, uridine, leucine are shown in the upper half of the figure. In the lower half are illustrated the rates of RNA breakdown in the different types of cells after treatment with actinomycin D.




Fig. 1 Schematic representation of the variations in RNA and protein synthesis in the course of lymphocyte transformation induced by phytohemagglutinin *in vitro*. L = small and medium mature lymphocytes, F = intermediate nucleated lymphocytes with prolymphocytic features, B = primitive looking 'blast' cells.

terized by a high ratio between RNA and protein synthesis and by the coexistence of a short lived RNA together with a metabolically stable fraction. In contrast, medium and large lymphocytes as well as monocytes have metabolically little in common with the more mature myeloid cells, because in the latter protein synthesis takes place in the absence of any significant RNA synthesis, whereas in the former protein production is associated with intense RNA synthesis. In our view the latter type of RNA appears to be different from the fractions predominating in the myeloid series and in plasma cells, which have been thought to represent both messenger and ribosomal RNA.

The obvious question which now arises concerns the functional significance which may be attached to the synthesis of such an RNA fraction, especially in view of the fact that great amounts of protein

are synthesized in other cell types, such as mature plasma cells, without any concomitant RNA synthesis. The question may be somewhat clarified by the events which take place when lymphocytes are cultured *in vitro* in the presence of PHA. As previously mentioned, PHA stimulation is followed by a rapid increase in both RNA and protein synthesis. Indeed the latter increases within a few hours, long before DNA synthesis takes place and before any significant morphological changes may be observed.

It therefore seems difficult to escape the conclusion that the mechanism which regulates the synthesis of the newly-formed proteins is dissimilar from that operating in differentiating cell systems. In fact it appears unlikely that the rapid rise in protein synthesis, observed in the course of *in vitro* lymphocytic transformation, depends upon a fairly complex set up such as would be the synthesis of messenger RNAs and their transfer to the protein synthesizing sites. Such a mechanism implies that the increase in protein synthesis should follow RNA synthesis only after a certain lag period. The existence of an interval between template formation and utilization was indeed postulated for differentiating haemic cells. It seems instead much more reasonable to assume that under these circumstances a different regulatory mechanism is required for the rapid increase in protein synthesis. This mechanism should obviously operate not by influencing the elaboration of the information carrying structures but by regulating their utilization, in other words by acting on messenger RNA function rather than on messenger RNA formation.

Is it possible to conceive the existence of such a mechanism? Recently STENT (27) has argued in favour of such a possibility. According to his hypothesis, such a mechanism might operate through the regulation of transfer RNA synthesis. Indeed only if adequate numbers of aminoacyl transfer RNAs are available, polypeptide synthesis may proceed at a sufficiently rapid rate. Owing to the probable degeneracy of the genetic code (5) some of the twenty standard aminoacids are represented by more than one triplet and are therefore cognate to more than one transfer RNA. This means that if the intracellular availability of different species of transfer RNA, cognate to the same aminoacid, is widely different, extremely variable will also be the rate of entry of the particular aminoacid in the polypeptide chain. Hence also the rate of synthesis of the polypeptide chain itself will vary considerably

A similar kind of mechanism implies that control of protein synthesis should not depend upon the formation of messenger RNA, in its turn regulated by an operator gene, but should be related to factors influencing messenger function. Stent suggests that suppression of messenger function prevents its further synthesis, indicating the possible existence of a feed-back connection between the two processes. In this particular case, in contrast to the mechanism supposedly involved in the operon model, the primary function of the repressor might consist in *inhibiting messenger function*. On the basis of the experimental results previously illustrated, we have some reason to believe that a mechanism similar to that proposed by STENT may regulate protein synthesis in lymphocytes and monocytes.

Suppression of messenger function might indeed be a common occurrence in most lymphocytes and monocytes and this may be followed by inhibition of messenger formation. Template function may be resumed through an increased availability of transfer RNAs, the synthesis of which appears to predominate in some lymphocytes and in monocytes. PHA would possess the property of enhancing such a mechanism and, by inhibiting a repressor would stimulate both RNA and protein synthesis, which increase in parallel so that the template becomes fully activated. Following this and as a consequence of the above mentioned mechanisms, new messengers would be synthesized, their formation being no longer hampered by their defective utilization. As in the course of the differentiating process, messenger formation would be followed by DNA synthesis and cellular division. That this may be so is evidenced by the high degree of thymidine uptake and by the number of mitoses present from 48 hours onwards in PHA-cultures (21)

The scheme we have presented is purely hypothetical, but the recent findings of COOPER AND RUBIN (4) seem to provide some confirmation for the hypothesis put forward. These authors were able to observe in PHA-stimulated lymphocytes a sharp rise in radioactivity in the US region which would be in keeping with our interpretation that the main effect of PHA is exerted in stimulating transfer RNA synthesis.

We have given an account of the experimental observations obtained in different types of blood cells. The findings pertaining to differentiating cell systems appear to provide a further confirmation of the model proposed by JACOB AND MONOD while the results

derived from studies on cultures of lymphoid cells would correlate well with the scheme outlined by STRYER. The latter results were of course obtained from cells cultured in a highly artificial medium. What happens to the various types of lymphoid cells in their normal environment is still a problem open to future investigations, but several considerations (13-19, 32) would suggest that a differentiation process, involving a regulatory mechanism such as we have previously described may also take place in the lymphoid system. Whether at any particular stage these two different types of mechanism are mutually exclusive or whether they may coexist remains one of the many unsolved aspects of the fascinating and intriguing problem concerning the regulation of protein synthesis in human blood and bone marrow cells.

Summary

The experimental results hitherto obtained by different methods of approach, but especially by autoradiographic techniques, on the RNA and protein metabolism of normal differentiating blood cells and of peripheral blood mononuclear cells, are reviewed and discussed in the light of our present knowledge. The data would suggest two different mechanisms for the regulation of protein synthesis. The first, characteristic of differentiating cellular systems, would appear to follow the general principles of the operon model, involving the progressive repression of messenger formation. The second, pertaining to lymphoid cells and possibly monocytes, seems to conform to the scheme outlined by STRYER and would consist in regulation of messenger function brought about by variations in the intracellular availability of transfer RNAs.

Résumé

Les résultats expérimentaux obtenus jusqu'à présent par différentes méthodes d'investigation, spécialement par l'autoradiographie dans le domaine du métabolisme de l'ARN et des protéines de cellules sanguines se différenciant ainsi que de cellules mononucléaires du sang périphérique, sont discutés à la lumière de nos connaissances actuelles. Ils suggèrent la présence de deux mécanismes différents régulant la synthèse des protéines. Le premier qui est caractéristique pour les systèmes cellulaires se différenciant semble apparemment suivre les principes généraux du modèle operon comportant une inhibition progressive de la formation de l'ARN messager. Le second trait aux cellules lymphoïdes et peut-être aux monocytes. Il semble correspondre au modèle proposé par STRYER et consisterait en une régulation de la fonction messagère réalisée par des variations de la disponibilité intracellulaire de l'ARN de transfert.

Zusammenfassung

Die Ergebnisse verschiedener Untersuchungsmethoden, insbesondere der Autoradiographie, auf dem Gebiete des RNA- und Eiweißstoffwechsels von normalen differenzierenden Blutzellen und von mononukleären Zellen des peripheren Blutes werden im Lichte unserer derzeitigen Kenntnisse kritisiert. Sie sprechen für das Vorliegen

differentierende Zellsysteme und scheint den allgemeinen Prinzipien des Operon-Modells mit progressiver Unterdrückung der Bildung von «Messenger-RNAs» zu folgen. Der zweite betrifft die lymphoiden Zellen und wahrscheinlich auch die Monocyten; er dürfte dem Schema von STEIN entsprechen und beruht auf einer Störung der «Messengers»-Funktion durch Veränderungen der intrazellulären Wirkumwelt von Transfer RNAs.

References

1. ALLFREY V. G. Nuclear ribosomes, messenger RNA and protein synthesis. *Exp. Cell Res., Suppl.* 9: 183-212 (1963).
2. BAUDOUX, S., JACOB, F. AND MISELSON, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. *Nature* 190: 376-381 (1961).
3. COHEN, S. S. AND BARNER, H. D. Studies on unbalanced growth in *Escherichia Coli*. *Proc. U. S. nat. Acad. Sci.* 40: 883-893 (1954).
4. COOPER, H. L. AND RICH, A. D. RNA metabolism in lymphocytes stimulated by phytohemagglutinin. Initial responses to phytohemagglutinin. *Blood* 25: 1014-1027 (1965).
5. CRICK, F. H. C. The recent excitement in the coding problem; in DAVIDSON's AND COHEN' *Progr. in Nucleic Acid Research*, vol. 1 pp. 163-217 (Academic Press, 1963).
6. DAVEN, C. L. AND MISELSON, M. The molecular conservation of ribonucleic acid during bacterial growth. *J. mol. Biol.* 2: 153-162 (1960).
7. DI GIROLAMO, A., HENSHAW, E. C. AND HAYT, H. H. Messenger RNA in rat liver nuclei and cytoplasm. *J. mol. Biol.* 8: 479-488 (1964).
8. GORMAN, J.; TARDO, P., LABERGE, M. AND HALVORSON, H. Timing of enzyme synthesis during synchronous division in yeast. *Biochem. biophys. Res. Comm.* 15: 43-46 (1964).
9. HARRIS, H. Breakdown of nuclear ribonucleic acid in the presence of Actinomycin D. *Nature* 202: 1301-1303 (1964).
10. HAYMER, F. G. J. AND QUAGLIANO, D. Autoradiographic investigations of RNA and DNA metabolism of human leucocytes cultured with phytohemagglutinin: uridine-3-³H as specific precursor of RNA. *Nature* 205: 151-154 (1965).
11. JACOB, F. AND MONOD, J. Genetic regulatory mechanisms in the synthesis of proteins. *J. mol. Biol.* 3: 318-356 (1961).
12. JACOB, F.; SCHAEFFER, P. AND WOLLMAN, E. L. Epigenetic elements in bacteria. *Microbial Genetics, Xth Symp. Soc. Gen. Microbiol.* Vol. 10, pp. 67-91 (Cambridge University Press, 1960).
13. LEIBLOD, C. F. AND SAINT-MAUR, G. Models for lymphocyte and plasmocyte formation; in WOLFFENBUEHL AND O'CONNOR's CIBA Found. Symp. on Hormones, pp. 152-172 (Churchill, London 1960).
14. MARKS, P. A., BURKA, E. R. AND SCHLESINGER, D. Protein synthesis in erythroid cells. I. Reticulocyte ribosomes active in stimulating amino acid incorporation. *Proc. U. S. nat. Acad. Sci.* 48: 2163-2171 (1962).
15. MARKS, P. A., RUTENF, R. AND DANON, D. Polyribosomes and protein synthesis during reticulocyte maturation 'in vitro'. *Proc. U. S. nat. Acad. Sci.* 50: 336-342 (1963).
16. MASTERS, M., KUMPEL, P. L. AND FARMER, A. B. Enzyme synthesis in synchronous cultures of bacteria. *Biochem. biophys. Res. Comm.* 15: 38-42 (1964).
17. MITCHELL, J. AND NORDAL, G. J. V. Ribonucleic acid metabolism in the plasma cell sequence. *Nature* 197: 1121-1122 (1963).

18. NAYAK, D.; VON EISENSTEIN, G., MOURA, R. AND LIPMAN, F. Protein synthesis from antibiotic-soluble ribonucleic acid. *Fed. Proc.* 21: 127-133 (1962).
19. NORDAL, G. J. V. AND MURELL, C. Autoradiographic studies on the immune response. I. The kinetics of plasma cell proliferation. *J. exp. Med.* 115: 209-230 (1962).
20. PALADE, G. E. AND SCHERWITZ, P.: Liver nekrocytes. An integrated morphological and biochemical study. *J. biophys. biochem. Cytol.* 2: 171-200 (1956).
21. QUAGLINO, D.; COWLING, D. AND HAYMON, F. G. J. Cytochemical and autoradiographic studies on normal and leukaemic cells in short-term tissue cultures. *Brit. J. Haemat.* 10: 417-436 (1964).
22. RAKE, A. V. AND GRAMAK, A. F. Turnover of ribonucleic acids in mammalian cells. *Biochem. biophys. Acta* 53: 267-289 (1962).
23. RIVICK, E. Biochemistry of Actinomycetes. *Cancer Res.* 23: 1428-1441 (1963).
24. ROWLEY, P. T. Protein synthesis in reticulocytes maturing *in situ*. *Fed. Proc.* 24: 223 (1965).
25. SCHA, A. DE KLOET, S. R.; ALLFREY, V. G. AND MURPHY, A. E. Isolation of nuclear RNA fraction resembling DNA in its base composition. *Proc. U. S. Nat. Acad. Sci.* 48: 471-477 (1962).
26. STADLER, T. WATSTEIN, P. O., OGURA, H. AND KOLA, H. Determination of the coding ratio based on molecular weight of messenger ribonucleic acid and associated with cytosomes of different aggregate size. *Nature* 201: 264-270 (1964).
27. STENT, G. S. The Operon on its third anniversary. *Science* 144: 816-820 (1964).
28. THOMELL, B. Studies on the formation of cellular substances during cell production. *Acta Med. Scand. Suppl.* 280: 1 (1947).
29. THOMELL, U., ARTER, T., GROSS, G., EMILIA, G. AND MACIEL, C. An unstable RNA in normal human erythroblasts. *Nature* 207: 755-757 (1965).
30. THOMELL, U., GROSS, G., ARTER, T. AND EMILIA, G. RNA and protein synthesis in normal peripheral mononuclear leucocytes. *Acta haemat.* 30: 213-137 (1965).
31. THOMELL, U.; GROSS, G., ARTER, T., EMILIA, G., ATTIVA, I. R. AND MACIEL, C. RNA and protein metabolism in normal human erythroblasts and granuloblasts. *Acta haemat.* 32: 271-279 (1964).
32. THOMELL, U.; GROSS, G., ARTER, T., EMILIA, G., ATTIVA, I. R. AND MACIEL, C. RNA turnover rates in normal peripheral mononuclear leucocytes. *Exp. Cell Res.* 36: 502-509 (1964).
33. THOMELL, U., QUAGLINO, D., ARTER, T., EMILIA, G., FERRARI, G. AND MACIEL, C. An autoradiographic study of the RNA and protein metabolism of normal plasma cells and phytohemagglutinin-stimulated lymphocytes. *Exp. Cell Res.* (in press).

Authors' address: Drs. U. Torchi, D. Quaglino and G. Maciel, Inst. of Med. Pathology, Univ. of Modena, Modena (Italy).

differentierende Zellsysteme und scheint den allgemeinen Prinzipien des Operon-Modells mit progressiver Unterdrückung der Bildung von «Messenger-RNAs» zu folgen. Der zweite betrifft die lymphoiden Zellen und wahrscheinlich auch die Monozyten; er dürfte dem Schema von STOUT entsprechen und beruht auf einer Steuerung der «Messengers-Funktion» durch Veränderungen der intrazellulären Wirksamkeit von Transfer-RNAs.

References

1. ALLFREY V G. Nuclear ribosomes, messenger RNA and protein synthesis. *Exp. Cell Res.*, Suppl. 9: 183-212 (1963)
2. BRUNNER, S.; JACOB, F AND MISSELSON, M.: An unstable intermediate carrying information from genes to ribosomes for protein synthesis. *Nature* 190: 576-581 (1961)
3. COHEN S. S. AND BARBER, H. D. Studies on unbalanced growth in *Escherichia*. *Coll. Proc. U. S. Nat. Acad. Sci.* 40: 883-893 (1954)
4. COOPER, H. L. AND RICH, A. D. RNA metabolism in lymphocytes stimulated by phytohemagglutinin. Initial responses to phytohemagglutinin. *Blood* 25: 1014-1027 (1965)
5. CRICK, F. H. C. The recent excitement in the coding problem. in *DAVIDSON's AND COHEN's Progr. in Nucleic Acid Research*, vol. 1 pp. 163-217 (Academic Press, 1963).
6. DAVERN, C. I. AND MISSELSON, M. The molecular conservation of ribonucleic acid during bacterial growth. *J. mol. Biol.* 2: 153-162 (1960).
7. DE GIROLAMO, A., HENSHAW E. C. AND HIAIT H. H.: Messenger RNA in rat liver nuclei and cytoplasm. *J. mol. Biol.* 8: 479-488 (1964)
8. GORMAN, J., TARDO, P., LABERGE, M. AND HALVORSON, H.: Timing of enzyme synthesis during synchronous division in yeast. *Biochem. biophys. Res. Comm.* 15: 43-46 (1964)
9. HARRIS, H. Breakdown of nuclear ribonucleic acid in the presence of Actinomycin D. *Nature* 202: 1901-1903 (1964).
10. HAYMON, E. G. J. AND QUAGLIO, D.: Autoradiographic investigations of RNA and DNA metabolism of human leukocytes cultured with phytohemagglutinin. uridine-³H as specific precursor of RNA. *Nature* 205: 151-154 (1965).
11. JACOB, F. AND MONOD, J. Genetic regulatory mechanisms in the synthesis of proteins. *J. mol. Biol.* 3: 318-356 (1961)
12. JACOB, F., SCHAEFFER, P. AND WOLLMAN E. L. Epigenetic elements in bacteria. *Microbial Genetics, Xth Symp. Soc. Gen. Microbiol.* Vol. 10, pp. 67-91 (Cambridge University Press, 1960)
13. LEBLOED, C. F. AND SADVE MAREZ, G. Models for lymphocyte and plasmacyte formation in WOLSTENFOLME AND O'CONNOR. *CIBA Found. Symp. on Hemopoiesis*, pp. 152-177 (Churchill, London 1960)
14. MARKE, F. A.; BURR, E. R. AND SCHLEWEDER, D. Protein synthesis in erythroid cells. I. Reticulocyte ribosomes active in stimulating amino acid incorporation. *Proc. U. S. Nat. Acad. Sci.* 49: 2163-2171 (1962).
15. MARKE, F. A.; RUTKIN, R. AND DANON, D. Polyrribosomes and protein synthesis during reticulocyte maturation *In vitro*. *Proc. U. S. Nat. Acad. Sci.* 50: 336-342 (1963).
16. MATTERS, M.; KUMPEL, P. L. AND PARDUE, A. B. Enzyme synthesis in synchronous cultures of bacteria. *Biochem. biophys. Res. Comm.* 15: 36-42 (1964).
17. MITCHELL, J. AND NOMAL, G. J. V. Ribonucleic acid metabolism in the plasma cell sequence. *Nature* 197: 1121-1122 (1963)

Methoden und Material

Methode. Das Vitamin B_{12} -Bestimmung im Serum wurde mit der biologischen Methode nach USP 16 mit Hilfe von *Lactobacillus Leichmannii* (Stamm ATCC 7830) durchgeführt (26). Der Serumanschuß erfolgte nach ROSENTHAL und SARETT (24). An Stelle des 1%igen Acetatspuffers verwendeten wir den Standard-Acetatspuffer der Firma Merck (pH 4,62). Das Serumpuffergemisch wurde auf pH 5,3 eingestellt, da sich bei pH 5,1 die Proteine nicht vollständig absetzten. Die Eichkurve wurde mit Cyanocobalamin (Cytobion® der Firma Merck) aufgestellt.*

Die Konzentration des Vitamin B_{12} wird durch seine wachstumsfördernde Wirkung auf den *L. Leichmannii* bestimmt. Die durch das Bakterienwachstum entstandene Trübung wird optisch gemessen. Sie entspricht der Menge des vorhandenen Vitamin B_{12} .

Material. Wir untersuchten insgesamt 23 gesunde Personen und 300 Patienten mit verschiedenen Erkrankungen, darunter 119 mit hämatologischen. Bei nahezu allen Patienten standen uns die Werte des peripheren Bluthätes zur Verfügung, die zum Zeitpunkt der Vitamin B_{12} -Bestimmung angefertigt wurden. Bei 143 Patienten konnten wir zusätzlich Serumspunktionen durchführen. Die Vitamin B_{12} -Werte, vor allem die außerhalb der Norm liegenden, wurden durch Doppel- oder Mehrfach-Bestimmungen gesichert. Die bei 23 gesunden Patienten ermittelten Normwerte lagen zwischen 150 und 650 μg Vitamin B_{12} /ml Serum. Sie befanden sich damit in Übereinstimmung mit den in der Literatur angegebenen Werten, die mit den gleichen oder anderen Methoden ermittelt worden waren, weshalb wir auf eine größere Kontrollgruppe verzichteten (16, 21). Wegen des großen Streubereiches des Vitamin B_{12} im Serum haben wir bewußt auf die Angabe von Mittelwerten verzichtet. Patienten, bei denen nachweisbar eine Vitamin B_{12} -Therapie vorausgegangen war, wurden eliminiert, auch wenn diese Behandlung Monate zurücklag. Ebenso haben wir Patienten, die vorher unter einer antibiotischen Therapie standen, aus dem Untersuchungsgut herausgenommen, weil durch Antibiotica im Serum das Wachstum des *L. Leichmannii* gehemmt wird und folglich niedrige Vitamin B_{12} -Werte entstehen.

Ergebnisse

Die Aufschlüsselung des Krankengutes nach Krankheitsgruppen und die Höhe der einzelnen Vitamin B_{12} -Werte ist aus Tabelle I ersichtlich. In Tabelle II werden zusätzlich zu den Vitamin B_{12} -Werten 143 Knochenmarksbefunde angegeben. Die Werte der Vitamin B_{12} -Bestimmung bei Magenresezierten und die dazu gefundenen hämatologischen Befunde werden in Tabelle III besonders berücksichtigt.

Diskussion

Wenn man die Ergebnisse überschaut, dann fällt auf, daß sich in fast allen Krankheitsgruppen Patienten mit niedrigen Vitamin B_{12} Werten finden. Betrachtet man dabei die Gruppen, bei denen

* Wir danken der Firma Merck AG, Darmstadt, für die Überlassung der Bakterienstämme und Tindlungen.

I. Med. Abteilung des Städtischen Krankenhauses München-Schwabing
(Chefarzt: Prof. Dr. H. BECKMANN)

Der Wert der Vitamin B₁₂-Bestimmung im Blutserum für die klinische und hämatologische Diagnostik*

H. BECKMANN, J. RASTETTER, R. WAUBKE
UND H. KETTERER

Die Bestimmung des Vitamin B₁₂ im Serum hat sich bei der Aufklärung von Vitamin B₁₂ Mangelzuständen als wertvoll erwiesen. So konnte für die perniziöse Anämie eine «kritische» Grenze, die bei einem Vitamin B₁₂-Serum-Spiegel von 100 µg/ml lag, festgelegt werden. War der Serum Vitamin B₁₂-Gehalt unter diese Grenze abgefallen, sollten die bekannten hämatologischen und klinischen Störungen in Erscheinung treten. Wir stellten uns die Frage, ob bei einem größeren Krankengut neben der Perniciosa ein Vitamin B₁₂ Mangel festzustellen wäre und ob sich die Höhe des Vitamin B₁₂-Gehaltes im Serum mit klinischen Befunden und hämatologischen Daten korrelieren ließe. Dazu zogen wir als Kriterien den Hämoglobingehalt/100 ml Blut, den Hämoglobingehalt des Erythrozyten (Hb₂) und den Sternalmarkbefund heran. Von Interesse erschien auch, ob dabei passagere Vitamin B₁₂-Mangelzustände zu finden seien, die durch andere Untersuchungen nicht erfaßt würden. Im Gegensatz zu KAHN (16) bei dem von 57 Patienten mit hämatologischen Erkrankungen nur ein Fall einen pathologischen Vitamin B₁₂-Gehalt aufwies, fanden wir solche Fälle in unserem Krankengut wesentlich häufiger. Außerdem war es wertvoll festzustellen, ob bei bestimmten Krankheitsbildern, ähnlich der perniziösen Anämie, charakteristische unter bzw. über der Norm liegende Vitamin B₁₂-Werte vorhanden waren, die eventuell als differentialdiagnostisches Kriterium dienen könnten.

Herrn Prof. Dr. J. FAHR, Frankfurt/Main zum 60. Geburtstag.

Die Untersuchungen wurden mit Unterstützung der Deutschen Forschungsgemeinschaft durchgeführt.

Method and Material

Method. Die Vitamin B_{12} -Bestimmung im Serum wurde mit der biologischen Methode nach USP 16 mit Hilfe von *Lactobacillus Leichmanii* (Stamm ATCC 7830) durchgeführt (26). Der Serumauflauf erfolgte nach ROSENTHAL und SARETT (24). An Stelle des 1%igen Acetatpuffers verwendeten wir den Standard-Acetatpuffer der Firma Merck (pH 4,62). Das Serumpuffergemisch wurde auf pH 5,5 eingestellt, da sich bei pH 5,1 die Proteine nicht vollständig absetzen. Die Eichkurve wurde mit Cyanocobalamin (Cytobion® der Firma Merck) aufgestellt.

Die Konzentration des Vitamin B_{12} wird durch seine wachstumsfördernde Wirkung auf den *L. Leichmanii* bestimmt. Die durch das Bakterienwachstum entstandene Trübung wird optisch gemessen. Sie entspricht der Menge des vorhandenen Vitamin B_{12} .

Material. Wir untersuchten insgesamt 25 gesunde Personen und 300 Patienten mit verschiedenen Erkrankungen, darunter 119 mit hämatologischen. Bei nahezu allen Patienten standen uns die Werte des peripheren Blutbildes zur Verfügung, die zum Zeitpunkt der Vitamin B_{12} -Bestimmung angefertigt wurden. Bei 143 Patienten konnten wir zusätzlich Serumalkalpositionen durchführen. Die Vitamin B_{12} -Werte, vor allem die außerhalb der Norm liegenden, wurden durch Doppel- oder Mehrfach-Bestimmungen gesichert. Das bei 25 gesunden Patienten ermittelte Normwerte lagen zwischen 130 und 650 μg Vitamin B_{12} /ml Serum. Sie befinden sich damit in Übereinstimmung mit den in der Literatur angegebenen Werten, die mit den gleichen oder anderen Methoden ermittelt worden waren, weshalb wir auf eine größere Kontrollgruppe verzichteten (16, 21). Wegen des großen Streubereiches des Vitamin B_{12} im Serum haben wir bewußt auf die Angabe von Mittelwerten verzichtet. Patienten, bei denen nachweisbar eine Vitamin B_{12} -Therapie im Gange war, wurden eliminiert, auch wenn diese Behandlung Monats zurücklag. Ebenso haben wir Patienten, die vorher unter einer antibiotischen Therapie standen, aus dem Untersuchungsgut herausgenommen, weil durch Antibiotika im Serum das Wachstum des *L. Leichmanii* gehemmt wird und folglich niedrige Vitamin B_{12} -Werte entstehen.

Ergebnis

Die Aufschlüsselung des Krankengutes nach Krankheitsgruppen und die Höhe der einzelnen Vitamin B_{12} Werte ist aus Tabelle I ersichtlich. In Tabelle II werden zusätzlich zu den Vitamin B_{12} Werten 143 Knochenmarksbefunde angegeben. Die Werte der Vitamin B_{12} -Bestimmung bei Magenresezierten und die dazu gefundenen hämatologischen Befunde werden in Tabelle III besonders berücksichtigt.

Diskussion

Wenn man die Ergebnisse überschaut, dann fällt auf, daß sich in fast allen Krankheitsgruppen Patienten mit niedrigen Vitamin B_{12} -Werten finden. Betrachtet man dabei die Gruppen, bei denen

Wir danken der Firma Merck AG, Darmstadt, für die Überlassung der Bakterienkulturen und Testlösungen.

Abstand B₁₂-Gehalt im Serum bei verschiedenen Anämieformen

[illegible]

Tabelle II
Vitamin B₁₂-Gehalt im Serum, Knochenmarkbefunde.

Krankheit	Zahl der Fälle	B ₁₂ -Gehalt im Serum $\mu\text{g/l}$			Darm- Störn. Funkt.	Mögliche Veränderungen	
		<150	150-600	>600		vorhand.	fehlt
1. Perniköse Anämie	19	14 ¹			12	12	0
			5 ¹		5	5	0
2. Eisenmangel- Anämie	7	3			3	0	3
			4		2	0	2
3. Hämolytische Anämien	6		6		5	0	5
4. Leichte Anämien unklarer Genese	9	3			0		
			6		1	0	1
5. Pancytopenie	12	4			3	2	1
			7		7	1	6
				1	1	0	1
6. Osteomyelose	7	2			2	0	2
			3		2	0	2
7. Polycythaemia vera	3	3			3	2	1
Polycythaemia	2		2		2	0	2
8. Erythrämie	4	1			1	1	0
			3		3	3	0
9. Akute myel. Leukämie	8	1			1	0	1
			7		6	1	5
10. Chronische myel. Leukämie	17	2			2	1	1
			6		4	0	4
				19	12	0	12
11. Chronische Lymphadenose	13	5			4	0	4
			8		7	0	7
12. Lympho- und Retikulose	4		4		3	0	3
13. Lymphogranulo- matose	12	5			1	0	1
			7		3	0	3
14. M. Waldenström	4	3			3	3	0
			1		1	0	1
15. Plasmocytom	1		1		1	0	1
16. Magenkrebs mit Anacidität	34	10 ⁶			6	3	3
			22		5	0	5
				2	0	0	0
17. Magenkrebs ohne Anacidität (Ulcer, Gastritis, Neoplasma)	19	3 ¹			2	1	1
			15		1	0	1
				1	0		
18. Magenresektion	23	5 ¹			3	3	0
			19 ¹		8	1	7
				1	1	0	1
19. Hepatitis	7		7		1	0	1
20. Sonstige Lebererkr. vorwiegend Cirrhosen	9	1			0		
			8		3	0	3
21. Diabetes mellitus	7	2			1	0	1
			5		0		
22. Schilddrüsen- erkrankungen	8	5			0		
			3		0		

Tabelle II (Fortsetzung)

Krankheit	Zahl der Fälle	B ₁₂ -Gehalt im Serum µg			Davon Serum-Punkt	Megaloblast. Veränderungen	
		<130	130-450	>450		vorhand.	Abnorm
23. Sonstige Stoffwechs.	5	3			1	0	1
Erkr. (Hämophil., Porphyria congen.)			1	1	0		
24. Erkrank. d. Darms	3	3			3	0	3
25. Herzinsuffizienz	12	3			0		
			9*		1	1	0
26. Entzündl. Erkrank.	9	2			1	0	1
			7		3	0	3
27. Sonstige Erkrank.	24	5			1	0	1
			18		2	0	2
				1	0		
	300	88	186	26	143	40	103

je 1 dimorphe Anämie

2 dimorphe Anämien

1 dimorphe Anämie

Patienten mit pathologischem Vitamin B₁₂-Spiegel deutlich überwiegen, so heben sich einige Krankheitsbilder besonders ab.

Erwartungsgemäß war die Verschiebung in den pathologisch erniedrigten Bereich bei der *perniciösen Anämie* am hervorstechendsten. Doch fanden sich immerhin 5 Fälle mit normalem Serum-Vitamin B₁₂, so daß ein Vitamin B₁₂-Mangel als Ursache der megaloblastischen Veränderungen auszuschließen ist. Am nächstgelegenen wäre ein Folsäure-Mangel zu diskutieren.

Trotz der geringen Anzahl der untersuchten Patienten mit *Polycythaemia vera* und *Polyglobulie* zeichnete sich bei diesen Kranken eine Erniedrigung des Vitamin B₁₂-Spiegels ab. Zusammenhänge zwischen den in der Literatur mitgeteilten Fällen (4 9 11 27 31) über die wechselstetigen Beziehungen zwischen Polyzithämie und megaloblastischen Anämien könnten damit erklärbar werden. Es wird angenommen, daß durch starke Zellproliferation der Erythropoese ein ständiger Mehrverbrauch an Vitamin B₁₂ entsteht, aus dem schließlich ein Vitamin B₁₂-Mangel resultiert, der zur megaloblastischen Anämie führen kann. Der Beweis für einen Vitamin B₁₂-Mangel konnte bei den Fällen aus dem Schrifttum dadurch belegt werden, daß es nach genügender Vitamin B₁₂-Zufuhr wieder zur Polyzithämie kam.

Ebenfalls als Folge eines vermehrten Vitamin B₁₂-Verbrauchs durch gesteigerte Zellproliferation könnte der erniedrigte Vitamin B₁₂-Gehalt bei *Lymphadenosen* angesehen werden, der bei unseren Kranken im unteren Normbereich oder darunter lag. Gleiche Beobachtungen machte ERDMANN-OEHLECKER (10) bei 21 Lymphadenosen im Gegensatz zu MOLLIN UND ROSS (20) deren 9 Fälle ein normales Serum Vitamin B₁₂ aufwiesen.

VAN DOMMELEN *et al.* (8) erklären einen Fall von megaloblastischer Anämie bei *Morbus Waldenström* (M. W.) ebenfalls durch den erhöhten Verbrauch des Vitamin B₁₂ infolge der plasmazellulären Neoplasie. Bei den von uns untersuchten 4 Patienten mit M. W. waren die Vitamin B₁₂-Werte dreimal deutlich unter dem Normbereich. Diese Fälle waren auch durch megaloblastische Markveränderungen gekennzeichnet. KILLANDER (17) sah dagegen bei seinen drei Fällen mit M. W. normale Vitamin B₁₂ Werte, jedoch bei Plasmacytome erniedrigte. Unser *Plasmacytom* Fall hatte dagegen ein normales Serum Vitamin B₁₂.

Die Ursache der Vitamin B₁₂ Mangelzustände durch Mehrverbrauch bei den oben angeführten Krankheitsbildern ist denkbar. Berücksichtigt man aber die Befunde bei den akuten und besonders bei den chronischen myelösen Leukämien, also Erkrankungen, bei denen die Proliferation des hämopoetischen Systems wohl am stärksten ist und daher der Vitamin B₁₂-Verbrauch am größten sein sollte, so wird man diese Meinung nicht mehr vertreten können. In Übereinstimmung mit anderen Autoren fanden wir den Vitamin B₁₂-Gehalt im Serum bei den meisten *akuten myelösen Leukämien* im Normbereich, bei *chronischen myelösen Leukämien* meist weit oberhalb der Norm (2, 10, 15, 16, 20, 23). Eine ausreichende Erklärung dieses Phänomens steht bis heute noch aus. Die Vermutung, daß die Höhe des Vitamin B₁₂-Gehalts von der Zahl der Leukozyten (3, 20) dem Anteil der Basophilen (15) oder dem Anteil der unreifen Blutzellen in der Peripherie (3) abhängig sei, ließ sich durch unsere Untersuchungen nicht bestätigen. Man wird eher annehmen dürfen, daß für die Vitamin B₁₂-Erhöhung grundsätzlich andere Faktoren verantwortlich sind. (Aus diesem Grund wurden chronisch myelöse Leukämien in Tabellen IV und V nicht berücksichtigt, s. u.) Wir werden diese Befunde jedoch an anderer Stelle noch ausführlich diskutieren.

Hervorzuheben sind in diesem Zusammenhang die bei der *Distomyelaklerose* gefundenen niedrigen oder normalen Vitamin B₁₂-

Werte. Möglicherweise ergeben sich daraus wertvolle differentialdiagnostische Hinweise gegenüber der chronisch myelösen Leukämie, wie auch weitere pathogenetische Gesichtspunkte.

Beim größeren Teil unserer Patienten mit *Schilddrüsenerkrankungen* lag der Vitamin B₁₂-Spiegel im Normbereich und darunter. Diese Befunde sind wichtig, weil in den letzten Jahren Zusammenhänge zwischen der perniziösen Anämie und Schilddrüsenerkrankungen (Hypo- bzw. Hyperthyreosen) aufgedeckt wurden. Als Ursache werden immunologische Vorgänge angenommen, da bei beiden Krankheiten zu einem großen Prozentsatz Antikörper sowohl gegen Schilddrüsengewebe als auch gegen Parietalzellen der Magenschleimhaut nachweisbar sind (7, 14, 19).

Bei den Fällen mit *Hämochromatose* war der Vitamin B₁₂-Spiegel wie bei anderen Untersuchern (18) stark erniedrigt. Megaloblastische Anämien waren dabei im Gegensatz zu den in der Literatur niedergelegten Einzelberichten nicht oder noch nicht vorhanden. Auf Grund des Vitamin B₁₂-Mangels wäre es denkbar, daß bei unseren Patienten noch mit dem Auftreten einer megaloblastischen Anämie zu rechnen ist. Andererseits sind Fälle mit Hämochromatose beschrieben worden, bei denen die megaloblastischen Veränderungen eindeutig auf einen Folsäuremangel (29) oder Mangel an Vitamin B₉ (28) bezogen werden konnten. Als Ursache eines Vitamin B₁₂-Mangels könnte man Veränderungen der Magenschleimhaut (verminderte Intrinsic-factor-Bildung, gestörte Resorption) oder eine verminderte Speicherkapazität der erkrankten Leber diskutieren.

Neuere Untersuchungen haben gezeigt, daß Patienten mit *Anacidität* des Magensaftes ein deutlich höherer Prozentsatz mit Antikörpern gegen Parietalzellen gegenüber Normaciden gesehen wird. Damit ergeben sich Parallelen zur kryptogenetischen perniziösen Anämie (25). So fanden BALAZS *et al.* (1) im Serum von 78,5% ihrer Perniziösa-Kranken gegen Magenschleimhaut gerichtete Antikörper dergleichen bei 43% der Patienten mit Achlorhydrie, aber nur bei 8,2% der Kontrollen. Prüft man nun bei den anaciden Patienten lediglich den Vitamin B₁₂-Gehalt im Serum, so überrascht bei unseren Untersuchungen die relativ hohe Zahl (30%) mit einer B₁₂-Hypovitaminose (unter 150 µg/ml). Nimmt man dazu noch die Patienten, bei denen der Vitamin B₁₂-Spiegel im unteren Normbereich lag (unter 200 µg/ml), so erhöht sich die Zahl sogar auf 50%. Magenkranke ohne Säureverlust wie auch

Tabelle III

Vitamin B₁₂-Gehalt im Serum und hämatologische Befunde bei Magenresezierten.

Geschl.	Alter J.	Zeit nach der Op.	B ₁₂ i. S. µg	Op- Art	Hämatolog. Knochenmark	Serum- B ₁₂	Bemerkun- gen	
1.	M	61	39 Jahre	191	?	megalobl. Anämie	Hypochr Anämie	Dismorphe Anämie
2.	M	75	33 Jahre	913	?	o. B.	o. B.	
3.	M	68	23 Jahre	166	?	—	o. B.	
4.	M	52	16 Jahre	142	?	—	normochr Anämie	
5.	M	43	16 Jahre	< 100	Bilroth II	megalobl. Anämie	hypochr Anämie	Dismorphe Anämie
6.	W	48	14 Jahre	< 100	Bilroth II	megalobl. Anämie	hyperchr Anämie	
7.	M	60	13 Jahre	437	Bilroth II	o. B.	hypochr Anämie	
8.	W	62	12 Jahre	310	Bilroth II	Farbst. Anämie	hypochr Anämie	
9.	M	43	12 Jahre	246	Bilroth II	—	normochr Anämie	
10.	M	47	10 Jahre	252	?	—	o. B.	
11.	M	63	9 Jahre	301	Bilroth II	—	o. B.	
12.	W	60	9 Jahre	240	?	o. B.	o. B.	
13.	M	52	5 Jahre	355	?	Farbst. Anämie	o. B.	
14.	M	59	5 Jahre	324	Bilroth II	—	o. B.	
15.	W	49	4 Jahre	12	Bilroth II	—	o. B.	
16.	M	72	5 Jahre	< 100	subtotalph. Fundekt.	megalobl. Anämie	hyperchr Anämie	
17.	M	43	2 Jahre	576	Bilroth II	—	normochr Anämie	
18.	M	?	1 Jahr	214	?	—	—	
19.	W	76	0 Jahre	162	Bilroth II	—	normochr Anämie	
20.	M	42	0 Jahre	617	Bilroth II	—	normochr Anämie	
21.	W	48	0 Jahre	347	Bilroth II	Farbst. Anämie	normochr Anämie	
22.	W	53	0 Jahre	415	Bilroth III	—	normochr Anämie	
23.	M	53	0 Jahre	252	Totale Magenres.	—	normochr Anämie	
24.	W	68	0 Jahre	300	Bilroth II	Farbst. Anämie	hypochr Anämie	
25.	W	72	0 Jahre	646	Bilroth II	KM-veröf. Prozess	normochr Anämie	

Magenresezierte wiesen fast ausschließlich normale Serum-Vitamin B₁₂-Verhältnisse auf. Wie aus der Tabelle III hervorgeht, war beim größten Teil der Patienten eine Magenresektion nach Billroth II durchgeführt worden. Über die Häufigkeit des Auftretens

von megaloblastischen Anämien nach *Magenresektion* liegen keine bindenden Zahlen vor. Man weiß aber, daß sowohl die Ausdehnung der Resektion als auch die Zeitspanne nach der Operation für den Beginn einer megaloblastischen Anämie verantwortlich zu machen ist (22). Resorptionsversuche (SCHILLING-Test) ergaben nicht nur bei totaler Magenresektion, sondern auch bei partiell Resezierten – wenn auch in geringerer Anzahl – eine der perniziösen Anämie vergleichbar gestörte Vitamin B_{12} -Aufnahme (6, 13). Im allgemeinen gilt ein Zeitraum von 3 bis 4 Jahren post operationem als kritisch, da nach dieser Zeit das Vitamin B_{12} Depot der Leber erschöpft ist. Von unseren Patienten bekamen nach dieser Zeit nur vier eine megaloblastische Anämie, zwei davon eine dimorphe Anämie (s. u.). Insgesamt überwiegen in unserem Krankengut, wie auch bei anderen Untersuchern (30) Farbstoffanämien. Möglicherweise läßt sich auch die geringe Anzahl von Vitamin B_{12} -Mangelzuständen durch die weit verbreitete Anwendung von Vitamin B_{12} -Präparaten erklären. Drei Patienten mit *Darmerkrankungen* hatten unter der Norm liegende Vitamin B_{12} -Werte. Während die verminderte Vitamin B_{12} -Resorption bei einem Patienten mit Malabsorptionsyndrom durch die Mitbeteiligung der Vitamin B_{12} -resorbierenden Anteile des Dünndarms verständlich ist, ist bei den zwei Patienten mit Colitis ulcerosa eine Deutung nicht ohne weiteres möglich. Wahrscheinlich wird die Aufnahme des Vitamins durch die gleichzeitig bestehenden Resorptionsstörungen im gesamten Magen-Darmtrakt (beschleunigte Magen-Darm-Passage, entzündlichen Veränderungen im Bereich der Vitamin B_{12} -resorbierenden Darmanteile) gehemmt.

Bei Betrachtung der Vitamin B_{12} Werte der anderen Krankheitsgruppen (Nr 2–8, 12, 13, 15, 19–21, 23, 25–27 der Tabellen I und II) ist trotz Fehlens charakteristischer Veränderungen für einzelne Erkrankungen wiederum die nicht geringe Zahl der Patienten bemerkenswert, die einen pathologisch erniedrigten Vitamin B_{12} -Gehalt im Serum aufweisen. Die auffallend seltene Manifestation megaloblastischer Anämien läßt darauf schließen, daß es sich mit Wahrscheinlichkeit um passagere Zustände handelt. Diese Annahme wurde durch spätere Kontrollen bestätigt, bei denen ohne therapeutische Vitamin B_{12} -Zufuhr eine Normalisierung der Werte festzustellen war. Sicher spielen bei der Entstehung des B_{12} -Defizits mehrere Faktoren eine Rolle. So könnte z. B. im Verlauf von kardialen Dekompensationszuständen die durch die Stauungs-

Tabelle IV

Beziehungen von B₁₂-Gehalt im Serum, Hämoglobin (Hb g/100 ml) und Einzeleryth (Hbz) (mit Ausnahme von chron. myel. Leukämien und Erythroleukämien)

B ₁₂ -Gehalt im Serum pM	Hämoglobin g/100 ml mittl. Mittelw.	Strömung (g)	Hämoglobin d. Einzeleryth. (Hbz) mittl. Mittelw.	Strömung (g)
0-100	12,8	3,8	33,7	4,8
100-150	12,7	3,4	30,9	4,4
150-250	12,4	3,1	32,2	3,9
250-350	12,9	3,0	31,4	2,8
350-450	11,6	3,4	32,6	2,6
450-650	12,8	3,1	31,6	2,5
über 650	13,6	3,0	32,8	1,2

erscheinungen gestörte intestinale Resorption, bei degenerativen Lebererkrankungen eine Änderung der Depotfunktion von Bedeutung sein. Die therapeutischen Konsequenzen, die sich aus einem erniedrigten Vitamin B₁₂-Spiegel im Serum ergeben, sollen zunächst dahingestellt bleiben.

Bei der Besprechung der Krankheiten war bereits die oft erhebliche Differenz der Vitamin B₁₂-Werte innerhalb der Gruppen aufgefallen. Wir prüften nun, ob der Höhe des Vitamin B₁₂-Spiegels ein spezifisch hämatologisches Untersuchungsergebnis zugeordnet werden kann. Teilt man, wie das in Tabelle IV durchgeführt ist, den Gehalt an Serum-Vitamin B₁₂ in bestimmte Größen ein und stellt diesen die dazu ermittelnden Hb-Werte (Mittelwerte) gegenüber so ergeben sich keine festen Korrelationen. Auffallend erscheint besonders, daß in der Gruppe von 0 bis 100 µg/ml also bei erheblichen B₁₂-Hypovitaminosen, keine stärkere Anämie nachweisbar war. Dieser Befund könnte wieder auf latente bzw. passagere Vitamin B₁₂-Mangelzustände hinweisen. Allerdings würde sich das Bild etwas ändern und eine Anämie deutlicher werden, wenn unsere Patienten mit Polycythaemia vera, die bei hohem Hb einen deutlichen Vitamin B₁₂-Mangel im Serum aufwiesen, in dieser Gruppe unberücksichtigt blieben.

Setzt man nun den Hb-Gehalt des Einzelerythrozyten (Hbz) in Beziehung zu den angeführten Größenbereichen des Serum-Vitamin B₁₂, so lassen sich auch hier wiederum keine signifikanten Abweichungen unter den einzelnen Gruppen nachweisen. Dieser Befund ist deshalb erstaunlich, da beim Vitamin B₁₂-Mangel das Auftreten einer Hyperchromie zu erwarten wäre. Kommt es doch beim Vitamin B₁₂-Defizit im wesentlichen zu einer erheblichen

Störung in der Zellbildung während die Abweichungen in der Hämsynthese weniger in Erscheinung treten. Die Folge ist, daß die Erythrozyten stärker als normal mit Hb gefüllt werden, dementsprechend das HbF über 94% ansteigt. Aus dem Fehlen einer Hyperchromie bei einer heterogenen Gruppe von Patienten, die lediglich durch den Vitamin B₁₂-Mangel im Serum gekennzeichnet ist, läßt sich folgern, daß ein pathologisch erniedrigtes Vitamin B₁₂ nicht mit einer Hyperchromie einherzugehen braucht. Noch eindeutiger wird dieser Befund, wenn man die bei den einzelnen Patienten ermittelten Werte des HbG und des Serum Vitamin B₁₂ betrachtet. Fanden wir doch auch Hyperchromie bei normalem oder erhöhtem Vitamin B₁₂-Spiegel wie auch hypochrome Anämien beim Vitamin B₁₂-Mangel, selbst wenn man die eindeutig definierten dimorphen Anämien ausklammert.

In diesem Zusammenhang soll auch auf die verhältnismäßig große Zahl der Patienten mit *dimorphen Anämien* hingewiesen werden, wie sie auch unter anderem auch von Bel. (5) beobachtet wurden. Man versteht darunter hypochrome Anämien in Kombination mit megaloblastischem Knochenmark. In unserem Krankengut fanden sich immerhin 8 Fälle, bei denen dieser Befund zutrifft. Erfahrungsgemäß sprechen diese Patienten therapeutisch nur auf eine Kombination von Eisen und Vitamin B₁₂ an.

Als Kriterium eines Vitamin B₁₂-Mangels gilt u. a. das Auftreten von Megaloblasten im Knochenmark. Daher schien es uns wichtig zu prüfen, ob sich zwischen dem Vitamin B₁₂-Gehalt im Serum und dem Knochenmarkbefund Beziehungen herstellen ließen. Von 86 untersuchten Patienten ohne megaloblastische Veränderungen im Knochenmark wiesen 23 (=27%) einen niedrigen Vitamin B₁₂-Gehalt im Serum auf. Aber auch von 35 Patienten mit Megaloblasten hatten 10 Fälle einen normalen Vitamin B₁₂-Spiegel. Der erste Befund könnte damit erklärt werden, daß nicht nur der Vitamin B₁₂ Mangel als Ursache einer Megaloblastose angesprochen werden kann. Am naheliegendsten müßte ein Folsäuremangel berücksichtigt werden, womit sich die Notwendigkeit von Folsäurebestimmungen im Serum ergibt. Schwieriger zu interpretieren ist die fehlende Megaloblastose beim Vitamin B₁₂ Mangel.

Folgende Möglichkeiten müßten zur Diskussion gestellt werden

1. Der Vitamin B₁₂-Mangel muß eine gewisse Zeit bestanden haben, um morphologisch-manifesten Störungen im Nucleosäurestoffwechsel zu führen. Für diese Annahme könnten die Befunde bei Gastrektomierten sprechen, bei denen es durch die

Tabelle V

Beziehungen zwischen Knochenmark-Befunden und B₁₂-Gehalt im Serum (ausgenommenen Erythritiden und chron. myel. Leukämien)

Knochenmark	Anzahl der Fälle	B ₁₂ -Gehalt in Serum (µg) unter 150 150-650 (Normaler) über 650
Ohne megaloblast. Veränderungen	86	23 (27%) 61 (71%) 2 (-2%)
Mit megaloblast. Veränderungen	35	25 (72%) 10 (28%) 0 (0%)

Schlende Vitamin B₁₂-Resorption zu einer Erschöpfung der Vitamin B₁₂-Depots kommt und schließlich eine Megaloblastose auftritt (22, 30). Dagegen spricht aber das Verhalten von Vegetariern, bei denen trotz niedrigem Vitamin B₁₂-Spiegel niemals Megaloblasten beobachtet werden (12).

2. Zum Vitamin B₁₂-Mangel müssen noch andere zusätzliche Faktoren hinzukommen, um eine Megaloblastose zu erzeugen.

3. Bestimmte Stoffwechselfunktionen des Vitamin B₁₂ können durch Folsäure übernommen werden. Es wird vermutet, daß die in normaler Menge vorhandene Folsäure eine Mobilisierung des quantitativ reduzierten Vitamin B₁₂ aus anderen Stoffwechselfunktionen bewirkt, wodurch für die Hämatopoese noch ausreichende Mengen Vitamin B₁₂ zur Verfügung stehen. Beim Folsäuremangel kann diese Funktion durch das Vitamin B₁₂ übernommen werden (32). Diese Annahme wird gestützt durch die Beobachtung, daß schon geringe Mengen Vitamin B₁₂ (0,1 µg) beim Perniziösen Kranken eine Besserung des Blutbildes herbeiführen können (33).

Die Erythrämie, die in unserem Krankengut, ausgenommen ein Fall, normale Vitamin B₁₂-Spiegel aufwies, aber alle schwerste megaloblastische Knochenmarkveränderungen zeigten, und hier bei (Tabellen IV und V) nicht berücksichtigt. Die Ursache der megaloblastischen Entartung ist dabei nicht ein Vitamin B₁₂- oder Folsäure-Mangel, sondern eine andere tiefgreifende Störung im Zellstoffwechsel, was auch die Therapiereaktion gegenüber diesen Vitaminen eindeutig zeigt.

Wir danken Frau I. SCHUMACHER für ihre Mitarbeit.

Zusammenfassung

Es wird über Vitamin B₁₂-Bestimmungen im Serum bei 300 Patienten mit verschiedenen Erkrankungen berichtet. Charakteristisch niedrige Werte finden sich, abgesehen von der perniziösen Anämie, bei Polycythämie, Lymphadenosen, Morbus Waldenström, Schilddrüsenerkrankungen, Magenkrankungen mit Anacidität und Darmkrankungen. Bei Patienten mit Magenerkrankung zeigt der Vitamin B₁₂-Gehalt im Serum kein einheitliches Bild. Auffallend hohe Werte werden bei der chronischen myeloischen Leukämie gefunden. Dieser Befund läßt sich eventuell differential-diagnostisch gegenüber der Osteomyeloklerose verwerten, die normale oder niedrige Vitamin B₁₂-Werte aufweist. Erniedrigte Werte bei anderen Krankheitsgruppen ohne klinische oder hämatologische Manifestation eines Vitamin B₁₂-Mangels weisen auf die Häufigkeit passagerer Mangelzustände hin. Es wird betont, daß ein Vitamin B₁₂-Mangel nicht mit einer Hyperchromie einhergehen braucht, wie auch hypo- oder normochromes Blutbild einen Vitamin B₁₂-Mangel nicht ausschließt.

Summary

Serum concentration of vitamin B₁₂ in 300 patients with various diseases is reported. Apart from pernicious anaemia characteristically low values are found in polycythaemia, lymphadenosis, Waldenström's macroglobulinaemia, thyroid disease, gastric disturbances with anacidity and intestinal disorders. The vitamin B₁₂ content in the serum of patients after gastrectomy is not consistent. Markedly high values are found with chronic myeloid leukaemia. This finding might be useful in the differential diagnosis from osteomyelosclerosis in which vitamin B₁₂ levels are normal or low. Lowered values in other diseases without clinical or haematological evidence of vitamin B₁₂ deficiency indicate the frequency of temporary deficiency conditions. It is emphasized that vitamin B₁₂ deficiency is not necessarily associated with hyperchromia and that low or normal blood colour index does not rule out vitamin B₁₂ deficiency.

Résumé

Le taux en vitamine B₁₂ a été déterminé dans le sérum de 300 malades. Des valeurs basses caractéristiques se trouvent, l'anémie pernicieuse mise à part, dans la polycythémie, les lymphadénoses, la maladie de Waldenström, les maladies de la glande thyroïde, les maladies de l'estomac accompagnées d'anacidité et les maladies des intestins. Chez les malades ayant subi une résection de l'estomac, le taux sérique en vitamine B₁₂ varie. Dans les leucémies chroniques, les valeurs sont élevées de façon frappante. Cette constatation peut fournir éventuellement une indication dans le diagnostic différentiel de l'ostéomyélosclérose qui, elle, présente des taux de vitamine B₁₂ normaux. Des valeurs abaissées dans d'autres maladies sans manifestation hématologique révèlent la fréquence d'états de carence passagers. Il est insisté sur le fait qu'un manque en vitamine B₁₂ n'est pas nécessairement accompagné d'une hyperchromie, sous comme une hypochromie ou une normochromie n'exclut pas un manque en vitamine B₁₂.

Literatur

1. BALAZS, V., SZABO, J. und FRISCH, M. Autoantikörper bei perniziöser Anämie und bei anderen Säuremangelkrankheiten. Orvosi Hetilap 103, 1729 (1964).
2. BEARD, M., PITNEY W. SARNHAN, E., SAROL, M. and BLOOMBERG, H. Serum concentrations of vitamin B₁₂ in acute leukaemias. Ann. intern. Med. 41, 523 (1954).
3. BEARD, M. F.; PITNEY W. R. and SARNHAN, E. H. Serum concentrations of vitamin B₁₂ in patients suffering from leukaemia. Blood 9, 789 (1954).
4. BEGMANN, H. Die perniziöse Anämie. Hb. d. ges. Hämatologie 2. Aufl., Bd. 3 (Urban & Schwarzenberg, München/Berlin 1960).
5. BEL, A. Les anémies hypochromes de l'adulte (Baillière, Paris 1959).
6. CASTRERO, T., LOPEZ, P. and SCHWARTZ, M. The absorption of vitamin B₁₂ before and after partial gastrectomy. 10th Congr. Int. Soc. Hemat., Stockholm 1964.
7. COX, E. V. The clinical manifestations of vitamin B₁₂ deficiency in Addisonian anaemia. In HARRISON's Vitamin B₁₂ and Intrinsic Factor (Enke, Stuttgart 1962).
8. VAN DOMMELIN, C. H. V.; OLIZ, R. J. and SLAATSMA, G. B₁₂ lack ("pernicious anaemia") possibly caused by "parazitization" (consumption by acroplasma) in case of Waldenström's macroglobulinaemia. Acta med. scand. 176, 611 (1964).
9. ENGEL, A. G. und STICKNEY, J. M. Pernicious anaemia and polycythaemia vera. Arch. intern. Med. 109, 168 (1962).
10. EIDMANN-OETIKER, S. Der Vitamin B₁₂-Stoffwechsel bei Hämoblastosen in HARRISON's Vitamin B₁₂ und Intrinsic Factor (Enke, Stuttgart 1957).

11. HALMES, V. und VOLPE, R. Coincidental myxoedema and pernicious anaemia with subsequent development of polycythemia after vitamin B₁₂-therapy. *Ann. Intern. Med.* 55: 301 (1961).
12. HERBERT, V. *The Megaloblastic Anemias* (Grune and Stratton, New York 1959).
13. RIDER, J. D. and MOLLER, D. L. Megaloblastic anaemia following partial gastrectomy. 10th Congr. Int. Soc. Hemat., Stockholm 1964.
14. IRVINE, W. J.; DAVIES, S. H. DELAMORE, J. W. and WILLIAMS, A. W. Immunological relationship between pernicious anaemia and thyroid disease. *Brit. med. J.* 51: 454 (1962).
15. JAVORSKOWSKY, L. I. und MAY, L. A. Zum Vitamin B₁₂-Gehalt des Serums bei Leukosen; in HERBERT, V. *Vitamin B₁₂ und Intrinsic Factor* (Enke, Stuttgart 1962).
16. KAND, P. Zur klinischen Bedeutung der Vitamin B₁₂-Bestimmung im Serum. *Med. Klin.* 68: 51 (1963).
17. KILLANDER, A. and LARSSON, S. O. Serum B₁₂ concentration in multiple myeloma and other forms of hypergammaglobulinemia. *Proc. 8th Congr. europ. Soc. Hemat. (Karger Basel/New York 1961)*.
18. KOLLEWEI, B. J. The occurrence of megaloblastic erythropoiesis in patients with hemochromatosis. *Blood* 7: 1182 (1932).
19. MACKENZIE, J. C. and MOORE, J. M. Autoimmunity in pernicious anaemia and iron-deficiency anaemia. *Lancet* ii: 1240 (1962).
20. MOLLER, D. L. and ROM, G. I. M. Serum vitamin B₁₂ concentrations in leukemia and in some haematological conditions. *Brit. J. Haemat.* 7: 155 (1955).
21. MOLLER, D. L. and ROM, G. I. M. The pathophysiology of vitamin B₁₂ deficiency in the megaloblastic anaemias; in HERBERT, V. *Vitamin B₁₂ und Intrinsic Factor* (Enke, Stuttgart 1957).
22. MOLLER, D. L. and RIDER, J. D. Late post-gastrectomy syndromes. *Proc. roy. Soc. Med.* 57: 375 (1964).
23. PERRY, W. R. BEARD, M. F. and VAN LOON, E. J. Observations on the bound form of vitamin B₁₂ in human serum. *J. biol. Chem.* 207: 143 (1954).
24. ROSENTHAL, H. L. and SARETT, H. E. The determination of vitamin B₁₂ activity in human serum. *J. biol. Chem.* 109: 433 (1932).
25. TAYLOR, K. B., RORTY, J. M., DOWNIE, D., COUCHMAN, K. G. and SHAPLAND, A. Immune phenomena in pernicious anaemia: gastric antibodies. *Brit. med. J.* ii: 1547 (1962).
26. U. S. Pharmacopoeia 16. 1960.
27. VASOTTI, A. Polycythémie et anémie pseudo-pernicieuse. *Rev. med. Suisse rom.* 72: 664 (1952).
28. VETRA, R. et MAHER, P. A. Anémie hypochrome mégalo-blastique grave, avec hyperhidrotisme et hémochromatose, corrigée par la pyridoxine. *Schweiz. med. Wochs.* 51: 1215 (1961).
29. WAGNER, K. und HINDEL, G. Megaloblastose bei Hämochromatose. *Munch. med. Wochs.* 106: 1715 (1963).
30. WEITHALER, K. Agastrische Anämien; in Hb. d. Gen. Hämatol., Bd. 3 (Urban & Schwarzenberg, München/Berlin 1960).
31. ZARAFONETTI, CH. J. D., OVERMAN, R. L. and MOLTEN, L. M. Unique sequence of pernicious anaemia, polycythemia and acute leukemia. *Blood* 12: 1011 (1957).
32. BECK, W. B. The metabolic functions of vitamin B₁₂. *New Engl. J. Med.* 266: 814 (1962).
33. SMITHMAN, J. W. and HANSEN, N. Studies on the minimum daily requirement

Neonatal Thrombocytopenia in Association with Rubella

P VOXLAUGH, S LEIKIN G AVERY G MONIF AND J SEVER

Thrombocytopenic purpura has been found in association with many infections of the newborn period. In older children this hemorrhagic diathesis has frequently been associated with rubella. We have recently observed thrombocytopenia in seven newborns with the characteristics of the rubella syndrome and from whom German measles virus was cultured. The purpose of this report is to call attention to the relationship between thrombocytopenia and German measles infection in the newborn period.

Case Reports

Seven patients with purpura or other hemorrhage developing within 12 h of birth were seen by us in the newborn nursery from November 1964 to February 1965. The pertinent clinical and laboratory data on these infants and their mothers are shown in the Table. There was history of exposure to rubella or of rash, fever and lymphadenopathy suggestive of clinical rubella during the first trimester in six of the seven mothers. Two of these women received gamma globulin shortly after exposure. Neither thrombocytopenia nor platelet antibodies were present in the blood of any of the mothers. No evidence of blood group incompatibility was found. Most of the mothers received vitamins and iron medication during the antepartum period. Two were given diuretics during the last trimester of their pregnancies.

Five of the seven infants were of premature birth weight. In six cases the presenting symptom was purpura. The purpuric lesions were distributed over the body and face and were red, blue or violet in color. Two patients had minimal gastrointestinal bleeding. Mild to moderate hepatosplenomegaly was found in five infants. Jaundice was seen in four patients, being mild in three and severe in one. Eye findings included bilateral and unilateral cataracts, transient glaucoma and retinal pigmentation. Evidence of heart disease was present in all but one patient. The cardiac abnormalities consisted of patent ductus arteriosus, auricular septal defect, ventricular septal defect, coarctation of the aorta and pulmonic stenosis, as diagnosed by clinical examination and catheterization. One patient was found later to be deaf.

Marked thrombocytopenia ($<50,000/\text{mm}^3$) was present in all of these babies. All had normal hemoglobin levels, leukocyte counts and differentials. Three of the seven infants had increased normo-

We are indebted to Dr N. R. SWEETMAN for performing the platelet antibody studies.

blast counts for their age. Bone marrow examinations uniformly showed hypocellularity and absent or markedly diminished numbers of megakaryocytes. Abnormal liver function tests were obtained in one patient. Direct and indirect Coombs tests and studies for toxoplasmosis, cytomegalic inclusion body disease and syphilis were consistently negative. Sepsis was excluded by the absence of positive blood cultures.

Rubella virus was cultured by the interference technique (1) from throat swabs of all the infants. The virus was also cultured in some cases from rectal swabs and urine.

Several cases required specific therapy for heart failure. Steroids were administered for the thrombocytopenia in only one instance. The duration of thrombocytopenia ($<150,000$ platelets/mm³) ranged from 7 to 30 days. In those cases where bone marrow examinations were repeated after recovery from the thrombocytopenia numerous megakaryocytes were found.

Death occurred in two infants, both from cardiac causes. Autopsy performed on one of these revealed patent ductus arteriosus, myocardial hypertrophy hepatitis, extramedullary hematopoiesis of the liver and spleen, and focal interstitial pneumonitis. Measles virus was grown from the heart of this patient.

Discussion

Within the past few years many of the causes of previously unexplained neonatal thrombocytopenia have been found. Although the newer syndromes include drugs (2) and immune mechanisms (3, 4) intrauterine and neonatal infections probably account for many more cases. These include toxoplasmosis, cytomegalic inclusion disease, gram positive and negative septicemia (5) viral hepatitis (5) generalized herpes (6) and syphilis (7). With the exception of the mothers of two of our patients who received diuretics, none of the above causes was present.

Until recently only scattered cases (5, 8, 9) of congenital thrombocytopenia were recorded in infants whose mothers had a history of clinical rubella in the first trimester. Although viral studies were not performed in any of these previously reported cases, the infants showed the usual characteristics of the rubella syndrome. Recently RUDOLPH (10) has reported a number of newborns with rubella syndrome and thrombocytopenia from whom measles virus was cultured.

Table

Clinical and laboratory observations on seven infants with neonatal thrombocytopenia.

Maternal history

Case No.	Exposure to rubella	Clinical disease	Parental drugs	Sex	Birth weight	Feeding	Other
1	+	+	G.G.	M	5 lb 12 oz	+	None
2	+	None	G.G. /D.	M	5 lb 2 oz	+	None
3	+	+	D	F	6 lb 6 oz	+	None
4	+	+	None	F	5 lb 15 oz	None	Rectal
5	None	None	None	M	3 lb	+	G.L.
6	+	+	None	M	5 lb 1 oz	+	None
7	+	None	None	M	3 lb 4 oz	+	None

Gamma Globulin
Diuretics

In this report six of the seven mothers had a history of exposure to rubella and/or clinical manifestations during the first trimester. Various stigma of the rubella syndrome were noted in all of these infants. This report documents an additional seven cases of neonatal thrombocytopenia associated with the presence of rubella virus in newborns.

Decreased megakaryocytes were noted in the bone marrow specimens examined during the period of thrombocytopenia. Numerous megakaryocytes were found after the peripheral platelet counts returned to normal. From these observations it would appear that the cause of the thrombocytopenia is decreased megakaryocytopoiesis. The isolation of virus from the bone marrow of such patients which has recently been reported (11) is suggestive of direct effect on the megakaryocytes. In contrast, older children with thrombocytopenia following rubella have numerous megakaryocytes in their bone marrow. This would suggest a different mechanism for the platelet deficit in the latter situation.

Table (Continuation)

Thrombocytopenia megakaryocytes	Jaundice	Platelets (mm ³)	WBC (mm ³)	Haemoglobin (gm. per 100 ml)	Blood smear megakaryocytes	Throat culture for rubella virus	Duration of thrombocytopenia
None	+	1 000	18 000	22	Deer	+	4 weeks
+	None	22 000	11 000	16	Deer	+	10 day
+	None	34 000	20 000	18	Deer	+	2 weeks
+	+	35 000	8 100	17	Deer	+	4 weeks
+	+	48 000	8 700	17	Deer	+	7 days
+	None	14 000	13 000	20	Deer	+	4 weeks
None	+	20 000	12 700	22	—	+	2 weeks

Although significant thrombocytopenia was present in every instance, serious bleeding did not occur. Therefore vigorous therapy such as steroid administration and platelet transfusions was not necessary. Thrombocytopenia was self limited in all instances. The major problems of these patients centered around their cardiac defects.

It is interesting to note that hepatosplenomegaly was always present. Hepatitis, cardiac failure and extramedullary hematopoiesis may account for this enlargement.

Summary

Seven newborns with thrombocytopenic purpura and various characteristics of the rubella syndrome were observed. In all of these cases the rubella virus was isolated from pharyngeal cultures. The thrombocytopenia appeared to be due to decreased megakaryocytopoiesis and was of relatively short duration.

Résumé

7 nouveaux cas de purpura thrombocytopénique et de différents syndromes caractéristiques d'un syndrome de roséole ont été observés. Dans chacun des cas, le virus de la roséole a pu être isolé du pharynx à l'aide de cultures. La thrombocytopénie semble avoir été due à une diminution de la mégacaryocytopoïèse et été de durée relativement courte.

Zusammenfassung

Es wird über 7 Neugeborene mit thrombocytopenischer Purpura und verschiedenen Erscheinungen des Rubellen-Syndromes berichtet. Bei allen Fällen wurde aus den Kulturen der Rachensabstriche das Rubellenvirus isoliert. Die Thrombocytopenie schien durch eine Verminderung der Megakaryocytopoese bedingt zu sein und war von relativ kurzer Dauer.

References

1. SEVER, J. BRADY, J. SCHIFF, G. McALLISTER, R. AND CUTTINO, R. Rubella epidemic in St. Paul Island in the Philippines 1963. *J. Amer. med. Ass.* 191: 624 (1965).
2. RODRIGUEZ, S., LEBRY, S. AND HILLER, M. Neonatal thrombocytopenia associated with ante-partum administration of thiazide drugs. *New Engl. J. Med.* 276: 881 (1964).
3. HARRINGTON, W. AND ARDUZZA, G. Immune reactions of platelets. In Henry Ford Hosp. International Symposium Blood Platelets. JOHNSON, S., MOVTO, R., RESICK, J. AND HORN, R., p. 639 (Little Brown and Co., Boston 1961).
4. FRASCH, H.; SHULMAN, R.; MORRIS, V. AND CONG, T. Immune neonatal purpura: Clinical and therapeutic considerations. *Blood* 23: 154 (1964).
5. BALMER, J.; ZART, P.; BALMER, J.; NAVRATIL, F. AND DAVY, L. Thrombocytopenia in newborn. *Pediatrics* 19: 463 (1964).
6. NELSON, W. Editor. *Textbook of pediatrics*. 8th ed., p. 54 (Saunders, Philadelphia 1964).
7. WITTAKER, J., SARTAN, P. AND SHANLEY, M. Hematological aspects of congenital syphilis. *J. Pediatr.* 66: 629 (1963).
8. BRIGGS, T., BEUTHEAVE, F. AND NELSON, L. R. Congenital hypoplastic thrombocytopenia in rubella embryopathy. *Acta paed. exp.* 32: 349 (1963).
9. HUGH-JONES, A., MANTFIELD, P. AND BREWER, H. Congenital thrombocytopenic purpura. *Arch. Dis. Child.* 35: 146 (1960).
10. R. DOLPH, A.; YOW, M.; PHILLIPS, C.; DANKOW, M.; BLATTNER, R. AND MELNICK, J. Transplacental rubella in infants. *J. Amer. med. Ass.* 191: 843 (1963).
11. ZINERAM, W. H. AND MEDRASS, H. V. J. Blood and bone marrow picture in congenital rubella. *Proceedings of the Society for Pediatric Research*, Philadelphia 1965.

Author addresses: Dr. P. Vonnahme, Dr. V. Lehm and Dr. G. R. Avery, Children's Hospital of the District of Columbia, Washington, D. C. (USA); Dr. G. R. O. Monif and Dr. J. L. Sever, National Institute of Neurological Disorders and Blindness, National Institutes of Health, Bethesda, Md. (USA).

From the Department of Pathology Karolinska Sjukhuset, Stockholm

An Attempt to Separate Erythrocytes According to Age by a New Type of Centrifuge*

A. WILTON

With technical assistance of GARY RASTLE PERROV

Many facts speak in favour of the reticulocytes having larger cell volume but lower density than the erythrocytes. By simple sedimentation or conventional centrifugation the reticulocytes are concentrated in the top layer of the packed cells (1, 2, 3). The difference in the sedimentation rate has been ascribed to the difference in the density but it has also been said that the inability of the reticulocytes to form rouleaux is the main cause (3). The size of the particles is a dominating factor for sedimentation rate and erythrocyte aggregates have a more rapid one than single erythrocytes (4). Thus red cell separation is difficult, especially, as the sedimentation rate is determined by many other factors than the density and the size of the cells (5).

It has been known for a long time that the red cells with malarial parasites are concentrated in the top layer by centrifugation (6) and that the parasites first attack the young red cells (7). It is also known that in pernicious anaemia with nucleated red cells (megaloblasts) in the blood, it is possible to concentrate these cells in the top layer by centrifugation (8). These and other observations have led to the conclusion that the red cells can be separated by centrifugation according to their age. Recently performed investigations support this hypothesis. For instance it has been shown that cholesterinase activity which diminishes with the ageing of the red cells, is highest in the top layer of the packed red cells and lowest in the bottom layer (9). Investigations with the isotope Fe^{59} indicate the same thing. Thus after intravenous administration of the isotope of which the incorporation is limited

*Supported by grant from Stiftelsen Theres och Johan Anderssons Minne

to the *immature red cells* (10-11) the concentration is highest initially in the top layer, increases in the bottom layer between 15th and 90th day after the administration and then decreases in the bottom layer after the 90th day (12). From these data the authors have concluded that the top, middle, and bottom layers of centrifuged erythrocytes have young, intermediate, and old mean cell ages, respectively. The decrease of the isotope activity in the bottom layer after 90 days is considered to be caused by the disappearance of senescent cells. Other investigations with the isotope Fe^{59} performed in the same way although ultracentrifugation was used gave the same result in principle (13).

Methods

For separating the erythrocytes, a new type of centrifuge constructed by RASTOILS (14) was used. This centrifuge is able to separate the particles into great number of fractions according to their sedimentation rate.

RASTOILS described the principles of his centrifuges in the following way: A suspension is run continuously through a large number of intercommunicating shallow centrifuge tubes arranged either perpendicular to or (and) coaxial with the centre of rotation. A channel communicating with the centre of the centrifuge rotor is obtained by laying lengths of plastic tubing in spiral or circular groove or winding it around coaxial cylinder. The peripheral wall of the groove, or the inner wall of an outer casing (dependent upon the construction of the centrifuge) is provided with a number of ridges or thresholds. These ridges press the corresponding points on the peripheral wall of the tubing towards the centre and thus divide the tubing into a large number of chambers or compartments, corresponding to a large number of intercommunicating shallow centrifuge tubes. When suspension is continuously run through any one of the models, the heavier and larger particles sediment at the beginning of the tubing and the lighter and smaller ones are carried further away and deposited more distally or peripherally. The rotors contain a large number of chambers or compartments and are constructed so that no particles escape from the peripheral open end of the tubing and all of them are quantitatively caught and differentiated within a short time.

Using the RASTOILS centrifuge about 10 ml blood (with an anticoagulant added) are needed. In order to get rid of the white blood cells which through forming aggregates spoil satisfactory separation of the red blood cells the blood samples first are centrifuged in an ordinary centrifuge for 10 minutes. After that, the supernatant and the top layer of the packed cells containing among others the white blood cells is removed by suction. The remaining mass of red cells is resuspended into a solution of physiological saline and the suspension is dropped down into the centrifuge by tubing with drop counter.

The type of RASTOILS centrifuge used is shown in Fig. 1. The plastic tubing wound round the top and bottom bolts of the rotating interior cylinder so that divided into U-shaped compartments. For centrifugation the author has used a suspension of 2 ml red cells in 500 ml physiological saline dropped down into the RASTOILS centrifuge at a rate of one drop per second. The quantity and concentration of the red cell suspension and the speed of the centrifuge have been chosen so that the greatest number of the erythrocytes are caught in the first 5 compartments (fraction I-V). After finishing the centrifugation which takes about 1 hour with thus reexamine the packed cells are in the lower part of the U and the solution of physiological saline in the upper




Fig 1 The rotating interior cylinder of RASTULLEN centrifuge. The plastic tubing is wound round the top and bottom bolts, so that it is divided into U-shaped compartments.

parts. The winding plastic tubing is cut off the upper bolts and the first 5 U' are centrifuged in an ordinary centrifuge during 18 minutes. After that, the shafts of the U' are cut off the border between the packed cells and the supernatant.

If these erythrocyte samples the number of cells in millions per ml (N) has been established in the ordinary manner in BURKHA chamber through the dilution with Hayem's solution has been 1:400. The mean corpuscular volume has then been calculated according to WRETENSKY in μ^3 ($\frac{H}{N} \cdot 10 = \frac{100}{N} \cdot 10 \mu^3$). The haemo-

globin eight mg corresponding to 100 ml of the erythrocyte mass (Hb) has been determined with Specker photometer for 20 ml of the erythrocyte mass haemolysed in 5 ml DRABERY' solution. Then the mean corpuscular haemoglobin concentration

(MCHC) has been calculated as $\frac{Hb}{H} \cdot 100 = \frac{Hb}{100} \cdot 100 = Hb$. Consequently

with this technique the MCHC has the same numerical value as Hb. The mean corpuscular haemoglobin (MCH) has been calculated to 10^{-12} g.

The reticulocyte percentage has been established by counting 1000 red cells on smears stained with 0.5% solution of methylene blue.

For determination of HbF two different methods were used (15)

1. The present author employed the method of *JAENIS, CERN *et al.** (16). On smears treated according this method, the red cells with HbF have pink colour while the red cell with adult haemoglobin (HbA) because of the dissolving of HbA appear as colourless rings. In each fraction 1000 red cells were counted.

2. The same blood samples were examined by *S. BAIRD* according to the method of *BATES* (17) with slight modification of *BAIRD* (18). After haemolysis of the red cells the total amount of Hb and—after the dissolving of HbA—the amount of HbF was determined by Beckman quartz spectrophotometer.

Method 1 is below called the cell counting method and method 2 the densitometric method.

Material

The investigations have been made with human blood, both normal blood (cord blood and blood from adult blood donors) and blood from patients with iron deficiency anaemia and macrocytic anaemia. Furthermore an examination has been made of pig, horse and rabbit blood.

Results

Normal Human Cord Blood

Blood from the umbilical cord was withdrawn a few minutes after birth and before separation of the placenta. Twenty five infants were investigated. The data in Table I show that the percentage of reticulocytes increases successively from fraction I (0.2 ± 0.03) to fraction V (2.0 ± 0.4) and the difference is strongly significant ($P < 0.001$). In 4 instances the percentage of reticulocytes was also established in fraction VI; the mean value was 5.5 ± 0.6 . The results were as expected since fraction I corresponds to the bottom layer and fractions V and VI to the top layer obtained by ordinary centrifugation.

Table I
Normal human cord blood (25 cases)

Fraction (Reticulocyte)	R	MCV μ^3	MCHC	MCH 10^{-1}
I	0.2 ± 0.03	123 ± 2.3	31.9 ± 0.3	39.7 ± 0.7
II	0.2	120 ± 2.0	30.6 ± 0.2	36.3 ± 0.6
III	0.3	116 ± 1.8	29.8 ± 0.2	34.4 ± 0.5
IV	0.6	112 ± 1.8	29.2 ± 0.2	32.8 ± 0.5
V	2.0 ± 0.4	109 ± 1.9	28.5 ± 0.2	31.1 ± 0.6

R = mean percentage value of the reticulocytes. MCV = mean corpuscular volume. MCHC = mean corpuscular haemoglobin concentration. MCH = mean corpuscular haemoglobin.

The table shows how R increases whereas MCV, MCHC and MCH successively decrease from fraction I to fraction V.

Table I shows furthermore that the mean corpuscular volume (MCV) decreases successively from fraction I (125 ± 2.5) to fraction V (109 ± 1.9). The difference is strongly significant ($P < 0.001$) and cannot depend upon the reticulocytes, as these have a greater volume than the erythrocytes and the number of reticulocytes increases from fraction I to fraction V. Furthermore Table I makes clear that the mean corpuscular haemoglobin concentration (MCHC) also decreases successively from fraction I (31.9 ± 0.5) to fraction V (28.5 ± 0.2) and this difference is also strongly significant ($P < 0.001$). As the difference also exists for the 4 infants where no reticulocytes were to be found in the first 5 fractions and the mean percentage of the erythrocytes for these fractions is very high (99.8 — 98.0) the reticulocytes cannot be the reason for the difference.

A phenomenon resulting from the decrease of MCV as well as MCHC from fraction I to fraction V is that the mean cell haemoglobin (MCH) also decreases (fraction I = 39.7 ± 0.7 fraction V = 31.1 ± 0.6) and the difference is strongly significant ($P < 0.001$).

The above mentioned investigations consequently have shown that as MCV decreases so does the MCHC, and a strongly significant positive correlation between MCV and MCHC has been pointed out ($P < 0.001$) (Fig. 2).




Fig. 2 The diagram shows strongly significant positive correlation between MCV and MCHC in normal human cord blood and in normal human adult blood.

Table II
Normal human adult (10 cases)

Fraction (Reticulids)	R	MCV μ^3	MCHC	MCHI 10^{-12}
I	0.2 ± 0.01	105 ± 1.8	32.2 ± 0.3	33.8 ± 0.6
II	0.3	102 ± 1.4	31.6 ± 0.3	32.1 ± 0.5
III	0.4	90 ± 1.2	30.9 ± 0.2	30.1 ± 0.4
IV	0.4	95 ± 0.9	30.5 ± 0.3	28.7 ± 0.4
V	0.8 ± 0.06	91 ± 0.7	29.7 ± 0.3	27.1 ± 0.4

Indications: Table I

The table shows in principle the same results as for the cord blood (Table I).

Normal Human Adult Blood

The blood samples have been examined immediately after drawing from 10 donors. As shown in Table II the investigation gave the same result as for the cord blood. The reticulocyte percentage increases from fraction I (0.2 ± 0.01) to fraction V (0.8 ± 0.06). The value of MCV on the other hand successively decreases (fraction I = 105 ± 1.8 , fraction V = 91 ± 0.7) and so does the value of MCHC (fraction I = 32.2 ± 0.3 , fraction V = 29.7 ± 0.3). Figure 2 shows a strongly significant positive correlation between MCV and MCHC ($P < 0.001$).

Blood from Patients with anaemia

The investigations of blood samples from patients with iron deficiency anaemia (9 cases) and macrocytic anaemia (10 cases) will be presented here only as a correlation between MCV and MCHC. As seen from Fig. 3 the correlation between MCV and MCHC in the cases of iron deficiency anaemia is strongly significant positive ($P < 0.001$) and in the cases of macrocytic anaemia significant positive ($P = 0.01$).

Blood from Normal Animals

Also here only the correlation between the value of MCV and MCHC will be presented. Blood samples from 9 pigs (aged 6 months), 8 rabbits (aged 2 months) and 9 adult horses have been investigated. As seen from Fig. 4 the correlation between MCV and MCHC in pigs is strongly significant positive ($P = 0.001$) and in rabbits and horses significant positive ($P = 0.01$).




Fig 3. The diagram shows significant positive correlation between MCV and MCHC in blood from patients with iron deficiency anemia and pernicious anemia.




Fig 4. The diagram shows significant positive correlation between MCV and MCHC in normal blood from horse, pig, and rabbit.

Table III
Normal human cord blood (9 infants)

Fraction (Rastgeids)	Cell counting method red cells containing HbF	Denaturation method HbF of total Hb
I	87.0 ± 1.6	85.0 ± 1.4
II	84.9 ± 1.9	81.9 ± 1.6
III	77.1 ± 3.2	79.4 ± 1.5
IV	70.0 ± 3.6	74.0 ± 2.8
V	64.7 ± 4.3	63.6 ± 5.1

The percentage figures obtained by the cell counting method are in near agreement with the corresponding figures obtained by the denaturation method. The figures decrease successively from fraction I to fraction V.

The continued investigations were an attempt to make clear the age relation of the red cells in fractions I-V. As it has been maintained that young red cells are more resistant to haemolysis than older cells an analysis of the cell fragility in the different fractions was done. However no conclusion could be drawn. More distinct results were obtained from the investigations of foetal haemoglobin (HbF) in normal human cord blood, planned according the principle—the larger the amount of HbF in a fraction, the older the red cells in the fraction. These investigations were carried out in collaboration with S. BRODY (15).

The Amount of HbF in the Five Fractions

Cord blood from 9 normal infants was investigated by the two methods. Table III shows the results. The mean number of red cells with HbF is expressed as a percentage of the total number of red cells and the mean value of the amount of HbF as a percentage of the total amount of Hb. The percentage figures obtained by the cell counting method are in near agreement with the corresponding figures obtained by the denaturation method. They are largest in fraction I (with the cell counting method 87.0 ± 1.6 with the denaturation method 85.0 ± 1.4) and decrease successively from fraction I to fraction V. The corresponding figures in this fraction are 64.7 ± 4.3 and 63.6 ± 5.1 respectively.

By statistical analysis a strongly significantly positive correlation was obtained between the middle corpuscular volume and the amount of HbF determined by both the cell counting method ($P = 0.001$; Fig. 5) and the denaturation method ($P = 0.001$) (Fig. 6).




Fig 5. The diagram shows strongly significant positive correlation between MCV and the mean percentage value of the erythrocytes with foetal haemoglobin in normal human cord blood (see text).

As has been observed earlier some of the red cells in cord blood contain HbF as well as HbA (16). In our later investigation, therefore, the percentage figures in fraction I and fraction V for the red cells with 1. only HbF, 2. HbF as well as HbA, and 3. only HbA were determined. Table IV shows the results. The number of red cells with only HbF is largest in fraction I ($51.6 \pm 2.3\%$) and smallest in fraction V ($37.7 \pm 1.5\%$) while the contrary is the case for the red cells with only HbA (corresponding figures are $13.1 \pm 2.3\%$ and $31.1 \pm 3.4\%$) and the differences are strongly significant ($P < 0.001$). There is no significant difference for the intermediate group

DISCUSSION

The examinations have shown that the erythrocytes in fraction I i.e. the erythrocytes with the most rapid sedimentation rate, have the greatest values for MCV and MCHC and consequently also for MCH. The values successively decrease from fraction I to fraction V and by Student's *t* test a statistical significant positive correlation




Fig 6. The diagram shows a strongly significant positive correlation between MCV and the mean percentage foetal Hb of the amount of foetal haemoglobin in normal human cord blood (see text)

Table IV
Normal human cord blood (9 infants)

Fraction (Kamperdick)	only HbF	red cells containing HbF and HbA	only HbA
I	51.6 2.3	33.3 2.4	15.1 2.3
V	37.7 1.5	30.1 2.2	31.1 3.4

The percentage figures of red cells with only HbF are largest in fraction I and smallest in fraction V while the contrary is the case for the red cells with only HbA.

between MCV and MCHC as well as MCH has been obtained in all groups.

Investigations of normal human cord blood have also shown that the greater the value of MCV in a fraction the greater the amount of HbF found in the fraction. A strongly significant positive correlation between MCV and the amount of HbF has been obtained.

The fact that the amount of HbF is greatest in fraction I indicates that the erythrocyte with the greatest sedimentation rate are the oldest red cells. Thus the investigation of HbF has given the same result as the isotope investigations which spoke in favour of the erythrocytes with the greatest sedimentation rate—and therefore by ordinary centrifugation obtained in the bottom layer—being the oldest red cells.

Thus the remarkable fact seems to exist that the amount of haemoglobin of the erythrocytes is correlated to the age in such a manner that the oldest erythrocytes have not only the greatest size but also the greatest amount of haemoglobin. As the formation of haemoglobin takes place only in the young red cells (10-11) this fact is difficult to explain. A cause to the successively descending value for MCV from fraction I to fraction V may be a difference in the ability of old and young cells to form aggregates (3). However the investigations performed with the above mentioned technique do not support this hypothesis and an increase of the value for MCHC by formation of aggregates is not very likely. The present author is disposed to relate the problem to the correlation between the degree of maturation of the red cells and their survival in the blood (19-20-21). This problem will be discussed further when the author has finished some comparative experiments by RASTOELDI and ordinary centrifuge techniques.

Summary

In blood samples from human beings and animals (pig, horse and rabbit) red cells were separated in RASTOELDI centrifuge in such manner the 5 fractions of erythrocytes with different sedimentation rates were recovered. The more rapid the sedimentation rate for an erythrocyte fraction the greater were its MCV, MCHC and MCH values in all groups investigated. In the 5 fractions of normal human cord blood there is a relation between the amount of foetal haemoglobin and the sedimentation rate of the erythrocytes.

Résumé

Dans le sang d'êtres humains et d'animaux (cochon, cheval et lapin) les érythrocytes ont été séparés à l'aide d'une centrifuge en 5 fractions ayant une vitesse de sédimentation différente. Plus la vitesse de sédimentation d'une fraction est grande, plus le volume cellulaire moyen, la concentration moyenne d'hémoglobine et le contenu moyen d'hémoglobine sont grands dans tous les groupes étudiés. Dans les 5 fractions de sang humain normal provenant du cordon ombilical, il existe une relation entre la quantité d'hémoglobine foetale et la vitesse de sédimentation des érythrocytes.

Zusammenfassung

Im Blut vom Menschen und von Tieren (Schwein, Pferd, Kaninchen) wurden die Erythrocyten mit der RASTOELDE-Zentrifuge in 5 Fraktionen mit verschiedener Sedimentationsgeschwindigkeit aufgeteilt. Je schneller die Sedimentation in einer Fraktion war um so größer waren bei allen untersuchten Gruppen das mittlere Zellvolumen, die mittlere Hämoglobinkonzentration und der mittlere Hämoglobingehalt der roten Blutkörperchen. In den 5 Fraktionen von normalem menschlichem Nabelschnurblut fand sich eine Beziehung zwischen dem Gehalt an fötalem Hämoglobin und der Sedimentationsgeschwindigkeit der Erythrocyten.

References

1. KEY, J. A. Studies on erythrocytes with special reference to reticulum, polychromatophilia and mitochondria. *Arch. intern. Med.* 28, 511 (1921).
2. STEPHENS, J. G. Surface and fragility differences between mature and immature red cells. *J. Physiol.* 99-30 (1940).
3. CH. LUTY, D. Differences between young and mature rabbit erythrocytes. *J. Cell. comp. Physiol.* 47, 215 (1956).
4. FÄHRBAEL, R. The suspension stability of the blood. *Acta med. scand.* 55, 1 (1970).
5. MILL, H. C. MITCHELL, L. T. AND THORRELL, B. Continuous free-flow fractionation of cellular constituents in rat bone marrow. *Blood* 25, III (1965).
6. BARN, C. G. AND JONES, F. M. A method of concentrating malaria plasmodia for diagnostic and other purposes. *Amer. J. trop. Dis. prev. Med.* 3, 298 (1916).
7. FARBER, J. W. GIBSON, J. G. AND PEACOCK, W. C. Studies on malarial parasites. IV. Some observations regarding the age of the erythrocytes invaded by plasmodium vivax. *J. infect. Dis.* 72, 180 (1946).
8. ROO, A. S. Concentration of megaloblasts. *J. clin. Path.* 2, 232 (1949).
9. PUTCHARD, J. A. Erythrocyte age and holocoenzyme activity. *Amer. J. Physiol.* 153, 11 (1949).
10. WALSH, R. J. THOMAS, E. D. CROW, S. H., FLEMARTY, R. G. AND FRETZ, C. A. Iron metabolism. Heme synthesis in vitro by immature erythrocytes. *Science* 170-396 (1949).
11. LAFFI, A. L. G. AND SEITZ, H. D. Uptake of radioactive iron (^{59}Fe) by nucleated red cells. *Brit. J. Haemat.* 1, 55 (1955).
12. BORTON, E. R. FROESCH, W. G. AND PR. S. M. The distribution of Fe^{59} tagged human erythrocytes centrifuged specimens as function of cell age. *J. clin. Invest.* 36, 676 (1957).
13. RAHM, D. A. AND HOE, R. R. D. Ultracentrifugal fractionation of human erythrocytes on the basis of cell age. *J. Lab. clin. Med.* 58, 242 (1961).
14. RASTOELDE, S. The Threshold Centrifuge. *Acta physiol. scand.* 41 suppl. 152 (1951).
15. WILSON, A. AND BRODY, S. Über die Beziehung von fötalem Hämoglobin zu der Größe der Erythrocyten. *Proc. 8th Congr. europ. Soc. Haemat., Wien 1961* art. N. 299.
16. KLEIN, U. R. E. BRACH, H. AND RAY, H. Demonstration von fötalem Hämoglobin in den Erythrocyten eines Blutaustriebs. *klin. Wochs.* 35, 637 (1957).
17. BETKE, H. Der menschliche rote Blutfarbstoff (Springer Berlin/Göttingen/Heidelberg 1954).

18. BRÖDY, S. The intrauterine age of the foetus at birth. *Acta obstet. gynaec. 37* 374 (1956)
19. WILTON, Å. Gewebshistologische Studien über die Pathogenese der Addison-Bermer'schen Anämie. *Acta paedat. 28*, Suppl. 6: 101 (1941)
20. BORSOOK, H., LE-GALL, B. L., SCARD, J. L. AND MINETTE, R. L. Synthesis of hemoglobin in relation to the maturation of erythroid cells. *Nature 196* 347 (1962)
21. WASSERMAN, M. AND RICHY, H. True red blood survival. *Ann. N. Y. Acad. Sci. 119* 506 (1964)

Author address: Dr. A. Wilton, Dept. of Pathology Karolinska Spälskmet, Stockholm (Sweden).

Istituto di Patologia Medica (Director: Prof. Dr. A. FRASCATI) and Istituto di Ematologia,
Università di Genova (Director: Dr. E. SALVADIO)

A Simplified Procedure for Brewer's Methemoglobin Reduction Test*

A. TIZIANELLO, I. PANNACCIULLI AND E. SALVADIO *

In 1960 BREWER *et al* (2) introduced their methemoglobin reduction test as a simple screening method for the detection of G-6-PD deficiency in red blood cells. This method is based on the oxidation of hemoglobin to methemoglobin by sodium nitrite and the subsequent reduction to hemoglobin by methylene blue through TP\H linked MetHb-reductase. Applied to large scale screening of a great number of cases it has proved highly sensitive and satisfactory (3, 4, 7, 8).

We have performed more than 4000 Brewer's tests, finding this method simple, reliable and inexpensive. The modifications here described are intended to overcome some of its disadvantages, preserving at the same time its high sensibility.

Material and Methods

The original methemoglobin reduction test introduced by BREWER *et al.* (2) can be summarized as follows: in 1 ml of blood, freshly collected in ACD, 0.1 ml of 0.18 M sodium nitrite solution and 0.1 ml of 0.0001 M methylene blue solution are separately added. After 12 gentle inversions, the test tubes are incubated at 37°C. at exactly 1, 5, 10 and 15 minutes the blood is mixed by blowing one breath of air gently through 1 ml paper. At 180 minutes 0.1 ml of the red cells are hemolyzed in 10 ml of 0.05 M phosphate buffer, pH 6.6, and photometric readings of the remaining methemoglobin before and after the addition of drops of 0.4 M sodium cyanide are taken (540 nm). The total Hb on the same sample is determined by transferring 2 ml of the hemolyzate in 8 ml of 0.05 M phosphate buffer, pH 6.6, one drop of 0.6 M potassium ferricyanide and one drop of 1.4 M sodium cyanide are added to this second solution and the readings are taken (540 nm).

Supported by U. S. Public Health Service Grant HE-578.

Principal Investigator: P. H. C. van HEIJL.

The following modifications have been introduced

(1) Sodium nitrite in distilled water and methylene blue in sodium chloride solution were pipetted in dark vials of 5 ml capacity lyophilized, filled with nitrogen and sealed. At the end of the lyophilizing procedure each vial contained 0.574 mg of methylene blue, 53 mg of sodium nitrite and 20.25 mg of sodium chloride. The vials, kept in the dark, can be stored for several months without alterations in the activity of the reagents. Immediately before its use the content of each vial was dissolved into exactly 5 ml of distilled water. 0.1 ml of the solution was pipetted into the test tube containing 1 ml of blood.

(2) A rapid twelvefold inversion of several test tubes at the same time was made possible by the use of rigid pad, having the surface of 20 test tubes rack, and which was covered with washable rubber sheet.

(3) The amount of both buffer solutions necessary for the methemoglobin and hemoglobin readings was reduced respectively to 5 ml and 4 ml. 0.1 ml of blood was transferred from the test tube to the first buffer solution and 1.0 ml of the hemolytic was thereafter transferred to the second buffer solution.

In order to overcome the disadvantage of the long (3 h) incubation time, set of experiments was performed substituting Nile blue (0.1 ml of 14.5% solution) for methylene blue. Owing to the faster recovery rate of methemoglobin to oxyhemoglobin induced by the first dye (1) the incubation time was then reduced to two hours.

Blood of normal and G-6-PD deficient subjects was screened. G-6-PD deficient cases were controlled, performing G-6-PD assays according to KOWENIG AND HOSCHKE (6).

Results

(1) A comparison between the amount of methemoglobin remaining in the tested blood of 57 normal and 58 mutant subjects checked at the same time with the original Brewer's test and the vial method is summarized in Table I. The χ^2 test for paired observations was employed in the statistical analysis. The difference between the two groups was not statistically significant. In the second group there was no case which had abnormal methemoglobin values with the original Brewer's test and yielded normal values with the vial method.

(2) In 4059 normal cases screened by means of the original Brewer's test the mean percent of remaining methemoglobin was 3.88. In a group of 264 normal subjects tested by the modified vial method the mean percent of remaining methemoglobin was 3.77.

(3) In the experiments carried out with Nile blue the results obtained in normal cases were comparable with those of the original Brewer's test, whereas the determinations performed on intermediate G-6-PD mutants were unreliable, owing to false negative results (Table II).

A Simplified Procedure for Brewer's Methemoglobin Reduction Test*

A. TIZIANELLO, I. PANVACCHILLI AND E. SALVADIO**

In 1960 BREWER *et al* (2) introduced their methemoglobin reduction test as a simple screening method for the detection of G-6-PD deficiency in red blood cells. This method is based on the oxidation of hemoglobin to methemoglobin by sodium nitrite and the subsequent reduction to hemoglobin by methylene blue through TP\H linked MetHb-reductase. Applied to large scale screening of a great number of cases it has proved highly sensitive and satisfactory (3, 4, 7, 8).

We have performed more than 4000 Brewer's tests, finding this method simple, reliable and inexpensive. The modifications here described are intended to overcome some of its disadvantages preserving at the same time its high sensibility.

Material and Method

The original methemoglobin reduction test introduced by Brewer *et al* (2) can be summarized as follows: to 1 ml of blood, freshly collected in V.C.D. 0.1 ml of 0.18 M sulfuric nitrite solution and 0.1 ml of 0.0001 M methylene blue solution are separately added. After 12 gentle inversions, the test tubes are incubated at 37°C in water-bath. At 60 and 120 minutes the blood is mixed by blowing one breath of air gently through 0.1 ml pipette. At 180 minutes 0.1 ml of the red cells are hemolyzed in 10 ml of 0.02 M phosphate buffer pH 6.4 and photometric readings of the remaining methemoglobin before and after the addition of a drop of 0.4 M sodium cyanide are taken at 640 nm. The total Hb on the same sample is determined by transferring 2 ml of the hemolyzate to 8 ml of 0.05 M phosphate buffer pH 6.6, one drop of 0.6 M potassium ferricyanide and one drop of 0.4 M sodium cyanide are added to the second solution and the readings are taken at 440 nm.

The attempts made to replace methylene blue with Nile blue in order to shorten the incubation time of the mixture (point 6) have failed, owing to the false negative results which were frequently obtained on the blood of intermediate subjects, which had been checked also by G-6-PD assays.

In our opinion the above listed modifications of Brewer's test may increase its routinary exploitation in clinical laboratories and blood banks. As a matter of fact the detection of G-6-PD deficiency in blood donors should be currently pursued in view of the possibility of unexpected hemolytic reactions following the administration of certain drugs in recipients of G-6-PD deficient blood (9).

Summary

Several modifications of Brewer's methemoglobin reduction test are described. Among them, the lyophilisation of both sodium nitrite and methylene blue solutions into single vial improves the stability of these reagents. These modifications, extensively checked, do not impair the sensibility of the methemoglobin reduction test.

Résumé

Plusieurs modifications du test de la réduction de la méthémoglobine d'après BREWER sont décrites. Parmi celles-ci la lyophilisation du nitrite de sodium et du bleu de méthylène dans le même récipient améliore la stabilité des réactifs. Ces modifications ne diminuent pas, selon les épreuves étendues auxquelles elles ont été soumises, la sensibilité du test de réduction de la méthémoglobine.

Zusammenfassung

Es wurden verschiedene Modifikationen des Methämoglobin-Reduktionstestes nach BREWER beschrieben. Dabei lässt sich durch Lyophilisierung der Lösungen von Natriumnitrit und Methylenblau im gleichen Gefäß die Stabilität dieser Reagentien verbessern. Eine ausgedehnte Prüfung ergab, daß die Modifikationen die Empfindlichkeit des Methämoglobin-Reduktionstestes nicht beeinträchtigen.

References

1. BOWMAN, J. E.; CARSON, P. E.; FRECHER, H.; KAHN, MIRIAM AND ADAM, F. A. A capillary tube, Nile blue Methemoglobin reduction test for Glucose-6-Phosphate dehydrogenase deficiency. Personal communication.
2. BREWER, G. J.; TARLOV, A. R. AND ALVINO, A. S. Methemoglobin reduction test: new simple, reliable test for identifying primaquine sensitivity. *Bull. World Hlth Ass.* 22: 633 (1960).
3. BURNETT, P. Personal communication.
4. CONTI, L.; PITUR, F.; MARCOLOVIO, R.; LEONETTI, L. Primi risultati con un nuovo test per l'identificazione del difetto della G-6-PD negli eritrociti. *Atti XVII. Congr. Soc. Ital. Emat.* 556 (1960).

5. FAIRBANKS, V. F. AND BUTLER, E. A simple method for detection of erythrocyte glucose-6-phosphate dehydrogenase deficiency (G-6-PD spot test). *Blood* 20: 591 (1962).
6. KORNBERG, A. AND HORWITZ, B. L.: in "Methods in Enzymology" vol. 1 (Colowick and Kaplan, V.V. Acad. Press New York).
7. MOUTRIKY, A.G. in "The genetics of migrant and isolate populations" p. 68. Ed. Williams and Wilkins Comp., New York 1963.
8. SALVEDO, E., PARMACIPELLI, I. ET TIZIANGELLO, A. Evaluation expérimentale de quelques méthodes biochimiques permettant de détecter la susceptibilité à l'hémolyse due aux médicaments. *Nouv. Rev. franç. Hémat.* 3: 233 (1963).
9. TIZIANGELLO, A., PARMACIPELLI, I., SALVEDO, E. AND CLAY, A.: Erythrocytic G-6-PD deficiency as a problem in the selection of blood donors. *Vox Sang.* 8: 47 (1963).

Authors' address: Dr. Alberto Tiziangello, Dr. Ivo Parmacipelli, Istituto di Patologia Medica, and Dr. E. Salvedo, Istituto di Ematologia, Università di Genova, Genova (Italia).

Pathological Laboratories, St. Kevin's Hospital, Dublin

Promyelocytic Leukaemia and Hypofibrinogenaemia

R. J. W. RYDER

Bleeding during the course of leukaemia may be troublesome and the reason for it obscure. CROIZAT AND FAVRE-GILLY (7) considered that there was insufficient information to determine the cause of bleeding in patients with leukaemia, and investigated the coagulation mechanism routinely in their patients. They found that bleeding was usually associated with thrombocytopenia, and that the fibrinogen level was normal or even raised. However they described one instance of the unusual association of hypofibrinogenaemia with bleeding in a patient with myeloid leukaemia. Prior to this RYAN (26) had reported fibrinogenopenia in a patient with myeloblastic leukaemia. Other reports have been accumulating, and now there are records of about 60 patients with hypofibrinogenaemia and myeloid leukaemia. ROSENTHAL (27) believes that there is now sufficient evidence for regarding 'promyelocytic fibrinopathic leukaemia' as a distinct syndrome. Characteristic features of this syndrome are the presence of abnormal promyelocytoid cells in the bone marrow and an unexplained hypofibrinogenaemia. A rapid downhill course, little influenced by therapy with severe haemorrhagic manifestations, culminating in death from either gastrointestinal or cerebral haemorrhage, is commonly seen. Lymphadenopathy hepatomegaly and splenomegaly are unusual, and when present are slight. This report deals with another patient with this syndrome.

Methods

Routine haematological methods (8, 9) were employed. For platelet counts the method of MACFARLANE AND BLOOD (19) was used. The one-stage prothrombin time was measured using human brain thromboplastin. The prothrombin and proconvertin estimation was carried out by the method of OWREN AND AAS (24). The thromboplastin generation screening test (15) was performed using Inosithin (17) and Bell & Alton chloroform extract of acetone-dried human brain as platelet substitutes. Prokrombin,

factor V and factors VII and X were measured by the methods of ALAOKLE (1) and factor X by the technique of DIMORE (10). Fibrinogen was estimated by the method of L. RAM (17), and subsequently by electrophoresis of plasma and serum, by measurement of the turbidity after addition of calcium-thrombin solution (15) by measurement of the turbidity after addition of ammonium sulphite (18) by measurement of the coagulated protein after heating at 56 °C for 10 minutes, and by an immunological method (Fi-test, Hyland Laboratories). Fibrinolysis was sought by observation of the clot in whole blood for 48 hours, and observation for 72 hours of the clots in serial dilutions of citrated plasma in buffered saline, after the addition of human thrombin in one series and recalcification of the other the tubes being kept stoppered in a water-bath at 37 °C.

Case History

A 73 year old woman was admitted from a home for patients with senile dementia with a history of intermittent epistaxes during the preceding month. She had lost several ounces of blood on the previous day but her bleeding had ceased before admission. There was no history of previous bleeding or abnormal bruising. She had had respiratory infection, and prior to admission had received intramuscular penicillin and streptomycin, and had also been given digoxin and chlorpromazine.

On examination she was pale, without cyanosis or jaundice. Her temperature was 97° F. Occasional scattered petechiae were seen. There was extensive bruising of her buttocks and thighs, and ecchymoses were present on the backs of her hands. Her liver and spleen were not palpably enlarged. There was no superficial lymphadenopathy. Bone tenderness was absent. Examination of her respiratory system revealed signs of emphysema without evidence of infection. Her blood pressure was 160/80 mm Hg, and auscultation of her heart revealed slow atrial fibrillation and an apical systolic murmur. There were no other significant findings. The results of a blood count are shown in Table I. These findings suggested a diagnosis of promyelocytic leukaemia which was confirmed by bone marrow biopsy carried out on the right iliac crest under local anaesthesia. The normal marrow structure was largely replaced by promethic cells of the granulocyte series, many of which were abnormal, having large irregular nuclei with fine chromatin pattern suggesting immaturity while the cytoplasm contained large chunky neutrophilic granules. Occasional giant metamyelocytes and macropolycytes were present—however erythropoiesis was normoblastic. Few megakaryocytes were present.

Eight hours after the bone marrow biopsy considerable oozing from the site of puncture was noted. Investigation of her coagulation mechanism gave the following findings. The bleeding time (Duke) was greater than 25 minutes. The whole blood coagulation time in plain glass was 10 minutes. Capillary resistance (tourniquet test) was not decreased. The one-stage prothrombin time was prolonged, and the addition of Russell viper venom did not correct this abnormality. A thromboplastin generation screening test gave a normal result. Assay of her circulating coagulation factors gave the results shown in Table II, a. Evidence of fibrinolysis was not detected.

A transfusion of two pints of fresh blood was given, and treatment with prednisolone (120 mg per day), 6-mercaptopurine (100 mg per day) and epirub-aminocaproic acid (50 g orally per day) was commenced. The oozing from her puncture site was controlled by local measures and she remained free from external bleeding. During the following days her general condition improved little. However her leucocyte count rose progressively and on the ninth day after admission her condition worsened. A further study of her coagulation mechanism was carried out, the results of which are shown in Table II, b. She deteriorated rapidly and died later that day.

Table I

	30th June	3rd July	6th July	8th July
Haemoglobin, g/100 ml	7.9	5.5	6.6	6.4
Leucocytes per mm ³	8 850	15 900	41 600	35 000
Platelets per mm ³	47 000	50 000	71 000	58 000
Reticulocytes, %	3.6	3.2	2.3	3.6
Neutrophils, %	70	55	72	79
Metamyelocytes, %	1	2	1	1
Myelocytes, %	1	1	1	1
Promyelocytes, %	17	29	22	14
Blasts, %	3	2	1	1
Lymphocytes, %	8	11	3	3
Monocytes, %	—	—	—	—
Eosinophils, %	—	—	—	1

Table II

	U	
Prothrombin complex, %	39	28
Prothrombin and proconvertin, %	42	50
Prothrombin, %	25	40
Factor V, %	80	38
Factor VII and X, %	48	90
Factor X, %	100	100
Thromboplastin generation screening test	normal	normal
Fibrinogen, mg%	95	30
Fibrinolysis	absent	absent

Autopsy findings. At autopsy surprising absence of post-mortem clotting was noted. A small subendocardial extravasation of blood was present in the right atrium. Small subendothelial ecchymoses were present under the left parietal pleura. The bronchial walls were congested, and the larynx, trachea and bronchi contained some blood-streaked sputum and some altered blood. Submucosal ecchymoses were present in the lower third of the oesophagus. The stomach did not contain blood, but altered blood was present in the duodenum and the small and large intestines as far as the descending colon. The sites of bleeding could not be identified. Scattered ecchymoses were present under the peritoneum of the pelvis.

The lungs showed emphysema with basal congestion and slight oedema. Scarring was present at the right apex, which histological examination showed to have resulted from previous tuberculous infection.

The heart weighed 270 g, enlargement being due to concentric hypertrophy of the left ventricle which measured 17 mm. The right coronary artery had minute lumen just beyond its origin. Microscopic examination showed recanalisation of previous thrombus.

The liver weighed 1020 g. The cut surface showed congestion but was otherwise normal in appearance. Microscopically increased numbers of granulocytes were present in the portal tracts.

The spleen was of normal size, weighing 110 g, with smooth slate grey capsule. On section it was soft, congested, and with loss of its follicular pattern. Microscopically it showed congestion, with diffuse increase in granulocytes in the red pulp.

A few small lymph nodes were present at the hila of the lungs and in the mesentery. The hilar nodes contained anthracotic pigment but were otherwise normal. The mesenteric nodes contained small collections of granulocytes, most prominent in the subcapsular sinuses.

The kidneys were diminished in size, the right weighing 100 g, the left 110 g. An atheromatous plaque at the origin of the left renal artery caused narrowing of its lumen. Histological examination showed evidence of healed pyelonephritis and benign nephrosclerosis.

The total weight of the adrenal glands was 8 g and there was marked depletion of cortical lipid.

The pancreas was normal on gross and histological examination.

Bone marrow was hyperplastic and showed a marked increase in cells of the granulocyte series, with a predominance of early forms.

There was no histological evidence of microthrombi in any organ.

Discussion

Type of Cells

GROZAT AND FAVRE-GILLY (7) recorded that the bone marrow of their patient was replaced by myeloblasts and promyelocytes, and HILLESTAD (16) noted a marked increase in the proportion of promyelocytes in the bone marrow biopsy specimens from two patients, but none of these workers commented on the fine structure of these cells. In a more recent report, BERNARD *et al* (5) observed that the nuclear chromatin of the promyelocytes was denser than in myeloblasts but not so dense as in normal promyelocytes. Cytoplasmic granules were increased in number and usually in size also. ROSENTAL (27) pointed out that there was dyskinesia between the maturation of the nucleus and the cytoplasm, the nucleus being relatively immature whereas the cytoplasm showed signs of maturity in its loss of basophilia and content of granules. These granules varied in size, shape and staining characteristics, although within any one cell the granules had the same appearance. He suggested that the cells should be termed promyelocytoid. DIMISHEN *et al* (11) recorded large PAS-positive cytoplasmic granules in the promyelocytes of one of their patients. Abnormal promyelocytoid cells with prominent granules were present in increasing numbers in this patient's peripheral blood during her brief illness. The PAS-positive granules recorded by DIMISHEN *et al* could not be demonstrated.

Hypofibrinogenaemia

The hypofibrinogenaemia, a characteristic feature of this syndrome and present in this patient, is difficult to explain. Pos-

sible explanations are 1 decreased synthesis, 2. loss, 3 alteration 4. excessive utilisation, 5 fibrinolysis.

1 Decreased synthesis Tests of liver function did not reveal any abnormality in ROSENTHAL's patients. Findings in the patient reported here are Total serum proteins 6.1 g%, of which albumin formed 3.5 g and globulin 2.6 g Bilirubin—direct reacting—nil, indirect reacting 0.8 mg% Thymol turbidity 2 units. Zinc sulphate flocculation 3 units. Alkaline phosphatase 1.7 K.A. units. Serum glutamate-oxalacetate transaminase 27 units. Serum glutamate pyruvate transaminase 20 units. Although these tests are relatively insensitive they do not reveal any gross abnormality and the near normal albumin level suggests that protein synthesis is not gravely impaired and diminished production of fibrinogen an unlikely explanation.

2 Loss There was no evidence of protein loss either into the body cavities or externally. A loss of albumin, because of its smaller molecular size, would be expected to precede a loss of fibrinogen.

3. Alteration Estimation of fibrinogen by a technique in which fibrin is the product measured would give erroneously low results if there were interference with the conversion of fibrinogen to fibrin. BAKER AND JACOB (2) described a haemorrhagic disorder in pregnancy due to an 'anticoagulant' which prevented the conversion of fibrinogen to fibrin. FLETCHER *et al.* (14) reported that the presence of fibrinogen digestion products may interfere with fibrin polymerisation. High concentrations of urea may have an inhibitory effect on the polymerisation of fibrinogen (28). However ELLIS AND STRANSKY (13) found that artificially raising the plasma urea to 500 mg% did not influence the result in the estimation of fibrinogen, and concluded that interference by urea within circumstances likely to be encountered clinically was impossible.

The finding of a low circulating fibrinogen level by 6 techniques, associated with deficiencies of other circulating coagulation factors, suggests that a true fibrinogenopenia was present in this patient, whose blood urea was 70 mg%.

4 Excessive utilisation. Massive intravascular clotting of the type found in the fibrination-defibrination syndrome could explain the increased clearance of fibrinogen from the circulation found by DUBINSKY *et al.* (11). The defibrination syndrome is associated with thrombocytopenia, fibrinogenopenia, and a variable reduction of other circulating coagulation factors, all of which may be found in

promyelocytic leukaemia also. Deficiencies of factors II V VII VIII IX and X in varying combinations have been reported in promyelocytic leukaemia by NILSSON *et al.* (22) BERNARD *et al.* (5) and ROSENTHAL (27) of which factor V is the most constantly and the most severely affected. Yet ROSENTHAL administered heparin to one of his patients without improvement in the levels of fibrinogen or factor V, or diminution in the rate of clearance of fibrinogen from the circulation.

Intravascular coagulation and defibrination could explain the deficiencies of circulating coagulation factors found in this patient. The one discordant feature is the diminished levels of factors VII and X, with a normal level of factor X when this was estimated separately indicating a decreased level of factor VII. This would be unexpected in serum—which is what the plasma of a patient with defibrination syndrome resembles.

MERSKY *et al.* (21) reported a patient with hypofibrinogenaemia secondary to disseminated colonic cancer and concluded from their studies that systemic defibrination and locally induced fibrinolysis coexisted. Reduced levels of prothrombin factor V factor VIII and platelets were considered evidence of defibrination, while reduced levels of plasminogen, streptokinase and urokinase inhibitors, together with a prolonged thrombin clotting time, were considered to indicate fibrinolysis. Parenteral administration of heparin sequentially corrected defibrination and secondary fibrinolysis. Discontinuance of heparin resulted in recurrence of intravascular coagulation and reactivation of the fibrinolytic process.

5 Fibrinolysis An increase in fibrinolytic activity has been noted in the majority of reported cases of promyelocytic leukaemia. Its source is uncertain. HILLESTAD (16) states that promyelocytes contain trypsin, which activates plasminogen and also has a direct fibrinolytic effect, and considered that this may be responsible. ROSENTHAL (27) reported that a remission in one patient, with disappearance of the promyelocytes from the bone marrow was associated with a rise in the fibrinogen level. DIDURIEU *et al.* (11) reported similar findings, with a subsequent fall in the fibrinogen level accompanying a terminal rise in the promyelocyte count. ROSENTHAL could not demonstrate fibrinolytic material in an extract prepared from promyelocytes. In the largest series of reported cases, BERNARD *et al.* (4) demonstrated increased fibrinolysis in 11 of 15 patients in whom it was sought.

FLETCHER *et al.* (14) noted that plasmin, in addition to degrading fibrinogen and fibrin, also degrades other specific coagulation factors. They mention that there is agreement that factors V and VIII may be destroyed, but disagreement as to whether prothrombin, factor VII and factor IX are susceptible to enzymatic degradation. COON AND DUFF (6) using the method described by OWREN AND AAS (24) observed decreased factor V and factor VII activity after intravenous infusion of plasmin in dogs. HILLESTAD (16) who also used OWREN AND AAS's method, stated that plasmin may digest prothrombin, factor V and factor VII. McNICHOL *et al.* (20) reported decreased fibrinogen, prothrombin, factor V and factor VIII with a slight inconstant fall in factor IX, but without alteration in the levels of factors VII and X, in patients who had received intravenous infusions of streptokinase. DONALDSON (12) demonstrated reduction of factor V, factor VIII and factor IX following the incubation of normal plasma with plasmin, but failed to detect any diminution in factors VII, X, XI and XII. In a further experiment in which normal plasma was incubated with streptokinase, she found a constant decrease only in factor V and concluded that full activation of plasmin by streptokinase does not occur in undiluted plasma. FLETCHER *et al.* (14) report that, in patients treated with streptokinase, the factor V concentration fell, but that neither the prothrombin concentration nor the platelet count was reduced.

In the patient reported here, the levels of prothrombin, factor V and factor VII were decreased. The platelet count also was reduced, but few megakaryocytes were to be seen in the bone marrow and the thrombocytopenia may well have been due to a failure of production.

NILSSON (23) reported that the administration of epsilon-amino-caproic acid in a dose of 36 g orally per day to a patient in whom fibrinolytic activity was high brought about a disappearance of fibrinolytic activity. Increased fibrinolysis was not demonstrated in the patient reported in this paper in whom a rising promyelocyte count was associated with a falling fibrinogen level in spite of the administration of epsilon-amino-caproic acid.

However SHERRY *et al.* (29) state that increased fibrinolytic activity is not necessarily a prerequisite for the diagnosis of a fibrinolytic disorder since the factors responsible for this activity may be gone from the circulation by the time the study is made, while their

effects are demonstrable. Thus digestion by plasmin could explain the deficiencies found in this patient, while fibrinolytic activity remained undetected by the methods employed. If this is the explanation it is surprising that epsilon-amino-caproic acid did not block the activation of plasminogen and bring about an increase in the level of fibrinogen and other circulating coagulation factors. Perhaps the explanation is to be found in the statement of SHERRY *et al.* that in the late stages of some leukaemias, proteolytic enzymes other than plasmin may appear in the circulation and produce a 'hyper proteolytic state'.

BAKER *et al.* (3) reported a patient with acute myelogenous leukaemia who had severe bleeding associated with hypofibrinogenaemia. Reduced levels of factor V factor VIII and fibrinogen were consistent with either primary defibrination or primary fibrinolysis. Thrombocytopenia associated with a normal number of megakaryocytes in the bone marrow normal euglobulin lysis time normal antiplasmin levels and normal antithrombin activity were in favour of defibrination, but the normal prothrombin level and diminished plasminogen value were more in accord with primary fibrinolysis. Factor VII was reduced to 68% in this patient, but no comment made as to the significance of this. Administration of epsilon-amino-caproic acid and fibrinogen was without benefit. Heparin brought about a rise in the levels of fibrinogen, factor V and plasminogen, and accompanying transient clinical improvement. A second course of heparin was without benefit. Subsequent autopsy revealed evidence of widespread intravascular coagulation.

So it may be seen that in patients with promyelocytic leukaemia and accompanying hypofibrinogenaemia, the elucidation of the underlying mechanism(s) may be difficult. A further complicating feature is that patients with leukaemia who have an increased susceptibility to infection may have a disturbance of coagulation secondary to this. A report of coagulation studies in a patient with fatal *Pseudomonas* septicaemia by RAPAPORT *et al.* (25) is of interest. In their patient, diminished levels of fibrinogen, factor V and factor VIII in the absence of evidence of fibrinolysis, were considered evidence of extensive intravascular coagulation. Decreased levels of factors VII IX, X and XI were more difficult to explain, but these workers noted that a fall in the serum factors had been documented in rabbits given two injections of endotoxin, and suggested that endotoxin might have been responsible in their

patient for the decreased levels of circulating coagulation factors. Histological examination of the kidneys of their patient disclosed the widespread deposition of material staining like fibrin within the glomerular vessels. They believe that these findings show that bacterial endotoxin may induce a generalised Schwartzman reaction in man. However in the patient reported in the present paper there was no evidence either during life or at autopsy of generalised infection.

In summary this patient with promyelocytic leukaemia had decreased levels of prothrombin, factor V factor VII, fibrinogen and platelets. Few megakaryocytes were seen in her bone marrow and her thrombocytopenia can be attributed to a failure of platelet production. The decreased levels of fibrinogen and factor V could have been due to either defibrination or fibrinolysis. The decrease in prothrombin is more suggestive of defibrination. The lowered level of factor VII is surprising, as an increase or an unchanged level would be expected in defibrination, and opinion is divided as to whether factor VII is decreased or not in fibrinolysis.

Acknowledgement. I should like to thank Dr J. R. MASOV for permission to study this patient under his care and for helpful advice in the preparation of this paper.

Summary

A patient with acute promyelocytic leukaemia and accompanying hypofibrinogenæmia is described. Decreased levels of prothrombin, factor V factor VII and platelets were present. Evidence of fibrinolysis was not detected and administration of epsilon-amino-caproic acid failed to bring about any improvement. The underlying mechanisms which may have been responsible for the hypofibrinogenæmia are considered.

Résumé

Description du cas d'un malade atteint d'une leucémie promyélocytaire aiguë. Une diminution du taux de prothrombine, de facteur V et VII ainsi que du nombre des thrombocytes était présente. Une fibrinolyse ne put pas être mise en évidence et l'application d'acide epsilon-amino-caproïque n'apporta aucune amélioration. Les mécanismes pouvant avoir mené à l'hypofibrinémie sont discutés.

Zusammenfassung

Es wird über einen Patienten mit akuter Promyelosytenleukämie und Hypofibrinogenämie berichtet. Prothrombin, Faktor V, Faktor VII und Plättchenzahl waren vermindert. Eine Fibrinolyse war nicht nachzuweisen, und die Zufuhr von Epsilon-Aminocapronsäure war wirkungslos. Die pathogenetischen Mechanismen der Hypofibrinogenämie werden erörtert.

References

- 1 ALAGILLE, D.: Dosages différentiels de proconvertine de prothrombine et de proacclérine. *Rev. franç. Et. clin. biol.* 2: 517 (1957).
- 2 BAKER, S. J. AND JACOB, E.: A haemorrhagic disorder in pregnancy due to an anticoagulant preventing the conversion of fibrinogen to fibrin. *J. clin. Path.* 13: 214 (1960).
- 3 BAKER, W. G., BANG, N. I., NACHMAN, R. L., RAUFAT, F. AND HOWOWITZ, H. L.: Hypofibrinogenæmic haemorrhage in acute myelogenous leukaemia treated with heparin with autopsy findings of widespread intravascular clotting. *Ann. int. Med.* 67: 116 (1964).
- 4 BERNARD, J.; MATTHEI, G., BOCLAY, J.; CHOUARD, R. ET CHOUARD, B.: La leucémie aigue à promyélocytes. *Schweiz. med. Wochschr.* 89: 604 (1959).
- 5 BERNARD, J., LAVERET, J.; CHOUARD, J., LEVY, P. AND BORSOY, M.: A cytological and histological study of acute promyelocytic leukaemia. *J. lin. Path.* 16: 319 (1963).
- 6 COOK, W. W. AND DUFF, I. F.: Effects of intravenous human plasma on the blood clotting mechanism of the dog. *J. Lab. clin. Med.* 51: 381 (1958).
- 7 CHOUARD, P. ET FAVRE-GILLY, J.: Les aspects du syndrome hémorragiques des leucémies. *Sang.* 9: 417 (1949).
- 8 DACEY, J. V.: *Practical Haematology* 2nd ed. (Churchill, London 1956).
- 9 DELANEY, J. W.: *Handbook of Haematological and Blood Transfusion Technique* (Butterworth, London 1960).
- 10 DUBOW, R. W.: The specific assay of Prower Stuart factor and factor VII. *Acta haemat.* 25: 105 (1961).
- 11 DUBOW, R. W., THOMAS, J. S., VANDERVOORT, R. L. E. AND MEHRA, R. S.: Acute promyelocytic leukaemia with fibrinogen and factor V deficiencies. *Blood* 23: 717 (1964).
- 12 DONALDSON, V. J.: Effect of plasmin in vitro on clotting factors in plasma. *J. Lab. clin. Med.* 56: 644 (1960).
- 13 ELLIS, B. C. AND STRAUSS, A.: A quick and accurate method for the determination of fibrinogen in plasma. *J. Lab. clin. Med.* 53: 477 (1961).
- 14 FLETCHER, A. P., ALJASSEM, V. AND SMITH, S.: Pathogenesis of the coagulation defect developing during pathological plasma proteolysis ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. *J. clin. Invest.* 41: 806 (1962).
- 15 HICKS, V. D. AND FITZKY, W. R.: A rapid screening test for disorders of thromboplastin generation. *Brit. J. Haemat.* 3: 227 (1957).
- 16 HILLETAD, L. H.: Acute promyelocytic leukaemia. *Acta med. scand.* 159: 189 (1937).
- 17 INGRAM, G. I. C.: A suggested schedule for the rapid investigation of acute haemostatic failure. *J. clin. Path.* 14: 336 (1961).
- 18 KEND, E. J. AND WOOTTON, I. D. F.: *Micro-analysis in Medical Biochemistry* 3rd ed. (Churchill, London 1956).
- 19 MACFARLANE, R. G. AND BRON, R.: The diagnosis and treatment of haemophilia and in related conditions. *M. R. C. Memorandum* 32: 11 (1951).
- 20 MCNEVON, G. P., DOUGLAS, A. S. AND BYLE, C.: Experience with intrapleural infusions. *Lancet* ii: 1797 (1964).

21. MERRIS C. JOHNSON, A. L.; PERT J. H. AND WHEEL, H. Pathogenesis of fibrinolysis in defibrination syndrome: Effect of heparin administration. *Blood* 24: 701 (1964).
22. NILSSON, I. M.; SJÖSTRÖM, A. AND WALDENSTRÖM, J. Antifibrinolytic activity and metabolism of epsilon-aminocaproic acid in man. *Lancet* i: 1322 (1960).
23. NILSSON, I. Discussion in: *Thromb. Diath. haemorrh.* 6, suppl. 1: 323 (1961).
24. OWREN, P. A. AND AAS, K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. *Scand. J. clin. Lab. Invest.* 3: 201 (1951).
25. RAPAPORT S. L.; TATLER, D.; CORBIN-BARROW N. AND HJORT P. F. Pseudomonas septicemia with intravascular clotting leading to the generalised Schwartzman reaction. *New Engl. J. Med.* 271: 80 (1964).
26. REAK, E. Die Fibrinopenie. *Z. klin. Med.* 128: 605 (1935).
27. ROSENTHAL, R. L. Acute promyelocytic leukaemia associated with hypofibrinogenaemia. *Blood* 21: 495 (1963).
28. SCHULMAN, S.; ERLICH, P. AND FERRY J. D. An intermediate in the conversion of fibrinogen to fibrin. *J. Amer. chem. Soc.* 73: 1986 (1951).
29. SHERRY S. FLETCHER, A. P. AND ALQUIRRO, N. Fibrinolytic bleeding and its management. *Ann. N. Y. Acad. Sci.* 115: 481 (1964).

Author address: Dr. R. J. W. Ryder, Pathological Laboratories, St. Kevin's Hospital, Dublin (Eire).

Libri

D J Hochrath. The Thalassemia Syndromes. Blackwell Scientific Publ. Oxford 1965. 272 S. Preis 45 s.

Die Monographie vermittelt eine vollständige Übersicht über die Thalassemie-Varianten, über die mit einer Thalassemie kombinierten Hämoglobina-normalien und die differentialdiagnostisch wichtige hereditäre Hb F Persistenz. Neben klinischen Fragen werden Probleme der Pathogenese und der Genetik besprochen.

Nach einer kurzen historischen Orientierung wird zuerst die genetische Kontrolle der Hämoglobinsynthese und die Bedeutung der Thalassemie diskutiert. Dann folgen Kapitel über die verschiedenen Formen der β -Thalassemie mit speziellen Abschnitten über die δ -ketten-Thalassemie, über die Sichelzell-Thalassemie und die Kombination der β -Thalassemie mit den anomalen Hämoglobinen C, E, J, N, D, G und L. Ein besonderes Kapitel ist den Hb Lepore-Anomalien gewidmet, die Musterbeispiele einer thalassemieähnlichen Störung mit genauer bekanntem Defekt darstellen. Der β -Thalassemie wird sodann die andersgenetete Anomalie der hereditären Hb F Persistenz gegenübergestellt. Nachher werden die diagnostischen und pathogenetischen Probleme der α -Thalassemie abgehandelt. Ein abschließendes Kapitel betrifft klinische Gesichtspunkte der Diagnostik und Therapie. Es enthält u. a. stützliche diagnostische Hinweise für den Arzt, technische Angaben über die Bestimmung der normalen und anomalen Hämoglobine sowie Richtlinien über die Indikation zur Splenektomie und die Eisenentfernung aus dem Organismus. Den Schluss bilden eine kurze Übersicht über genetische und molekularbiologische Grundlagen der Thalassemie und ein Ausblick auf Zukunftsprobleme.

Das handliche Buch ist übersichtlich gegliedert, leicht lesbar und enthält für jedes Kapitel eine knappe Zusammenfassung. Zahlreiche Tabellen, Diagramme und gute Abbildungen sowie ein ausführliches Literaturverzeichnis erhöhen den Wert der Monographie, die jedem Hämatologen sehr empfohlen werden kann. H. R. Mair, Basel

Oscar B. Schabo. Veterinary Hematology. Lea & Febiger Philadelphia 1965. 2nd edition. 84 illustrations on 14 plates and 30 in color on 7 plates. Price: \$ 15.-

The second edition of this book (see review A.H. 28, 1962 p. 71) is greatly enlarged—good color plates are added. A great deal of additional useful and interesting information has been supplied e.g. autoimmune hemolytic anemia in dogs, indications for B12 therapy in dogs with megaloblastosis. The color plates, taken from other publications, are well reproduced. The inclusion of normal blood values for guinea-pig, hamster, monkey, rat and mouse will be helpful for everyone working in experimental haematology. On the whole the book can also be highly recommended to the human hematologist.

G. Rorrow New York

Arno J. Harris and Marya H. Zucker. The Physiology of Blood Platelets. Grune & Stratton, Inc., New York/London 1963, 162 pp. Price \$ 7.-

The authors present a comprehensive review on the more recent biochemical, morphologic and clinical research on platelets. Biochemistry, coagulation factors associated with platelets, thrombocytopathia, electron-microscopy haemostasis, thrombosis, thrombasthenia, thrombopoiesis and platelets transfusions are some of the discussed topics. 875 references are given.

G. Rorrow New York

University Clinic of Freiburg im Br. Dept. of Medicine
(Director: Prof. Dr. med. et h.c. L. HELLMEYER)

*On Standardization in Haematology**

CH. G. DE BOROVICZÉNY

In the past few years considerable effort has been directed toward standardizing haematological methods on an international level. The lively response to these activities proves how very necessary are such measures.

During the course of a round table discussion at the European Congress of Haematology in Vienna in 1961 the urgent demand for international regulations became particularly evident and haematologists in Germany (BOROVICZÉNY, HELLMEYER) joined forces with colleagues from the Netherlands (COSTER, HOLTZ, SPAANDER, VERLOOP) to start on the preparatory work. A symposium on standardization problems was held at the European Congress of Haematology in Lisbon at the end of which a European Standardizing Committee was founded. The enthusiasm with which the work of this Committee was met was by no means limited to Europe. In order to be able to continue this task on a world wide level, the Managing Board of the Committee was enlarged by members from other Continents on the occasion of yet another Standardizing Symposium which took place during the International Congress of Haematology in Stockholm. The committee was given the name of International Committee for Standardization in Haematology (ICSH). The statutes were drafted and subsequently endorsed at the European Congress of Haematology in Strasbourg in 1965. All the proceedings of the standardizing symposia held up to date are published in the transactions of the ICSH: *Erythrocytometric Methods and their Standardization* [Bibl. haemat. 18 (Karger, Basel/New York 1964)] *Standardization*

*Paper held at the 2nd Latino-American Symposium on Standardization in Mar del Plata on December 11th, 1965. My journey was supported by the Deutsche Forschungsgemeinschaft.

Documentation and Normal Values in Haematology [Bibl. haemat. 21 (Karger Basel/New York 1965)] Standardization in Haematology III [Bibl. haemat. 24 (Karger Basel/New York 1966)]

The lively interest with which the standardizing symposia and the above mentioned publications were followed shows that the initiative was indeed justified nevertheless, there are bound to be many who ask themselves why it is necessary to standardize haematology on an international level, who should undertake this task, how and where it should be done and what exactly should be standardized. The object of this paper is an endeavour to answer briefly these questions.

Standardization in haematology is a necessity to the well-being of our patients and to the scientific work in this field. This can best be illustrated by the following fictive example. When Miss SMITH boarded the plane in London, she was still in perfect health, her blood picture normal, with a haemoglobin level of about 80 %. On arriving in Stockholm two hours later her haemoglobin had sunk to a value of barely 60/1. It was fortunate that no over zealous colleague got hold of these values, as he would have sent her straight to hospital to have a transfusion, in spite of the fact that the young lady was just as fit as when boarding the plane. The bloodloss was not accounted for by an error of measurement, but by diverging opinions in the two countries on the millimolar extinction coefficient on the one hand and on the normal value of haemoglobin on the other. This incident naturally never really occurred and such a situation could no longer arise nowadays, as at least in Europe haemoglobinometry has been standardized. However serious misunderstandings could arise, for instance, in treatment with anticoagulants when patients travel abroad and many other examples could be cited. It is becoming more and more common for physicians to have to treat patients from some far away corner of the earth. These patients often bring medical reports with them, to which one adds one's own report, and it is evident that these are quite useless to the patient if they are not co-ordinated to have the same values.

Not only the patient's health but also research work can be impaired if misunderstandings arise between scientists. A particularly striking example thereof was the violent disagreement which took place more than 50 years ago between two leading haematologists, PAPPENHEIM AND TÖRK, with the result that the planned First International Congress of Haematology was delayed by a quarter of a




Fig 1 The foundation of expert panels.

century! Yet this quarrel, as the two opponents realized themselves later on, arose chiefly on account of discrepancies in the terminology and was nothing more than a misunderstanding. However even to-day situations frequently arise in which haematologists are at cross purposes, only because the haematological nomenclature is so divergent.

Who is to straighten out this state of affairs? Naturally those specialists who are most familiar with the problems in question. It goes without saying that it is necessary to call upon the services of many different scientists to solve such diverse problems. In order to be able to give a correct answer to the many questions which arise, the ICSH sets up an Expert Panel for each separate problem. Scientists from all five continents are invited to attend. A list of the participating specialists is published, and, if considered necessary further participants are included. The members of the Expert Panel first check the pertinent literature, discuss possible solutions, hold symposia and finally draft a proposal. This proposal is then submitted to the Managing Board of the ICSH, published and subsequently approved by the General Assembly of the ICSH. By this procedure access is gained to valuable criticism and suggestions from all parts of the world, so that eventually an international regulation can be worked out which is in every respect satisfactory (Fig 1 and 2).

These international regulations are not only intended for the limited circle of those haematologists who are interested in problems of standardization and who take part in the standardizing work, on the contrary they should reach every general practitioner through-




Fig. 2. The elaboration of standards.

out the world. Only then does standardization on an international level make sense. With this in mind, the international standardizing committee has encouraged from the very start the foundation of national and regional standardizing committees throughout the world, whose task it is to publish and promote locally the international resolutions and to see to it that they are put into practice. The best of resolutions would become meaningless if, for instance, it were not adopted by the South American industry for the simple reason that they were not informed thereof. We know from personal experience that it is almost impossible nowadays to keep up with all the literature, even in the narrowest of fields. It is, therefore, too much to expect every general practitioner and every manufacturer of haematological apparatus to be familiar with a regulation which was published in some foreign book. An Argentinian committee, however will certainly know in which Argentinian publications a revised translation of this resolution should appear and in addition which manufacturers should be notified personally. A national committee will also be in a position to give information on apparatus and preparations in its own country.

How should such a national or regional standardizing committee be established? It is of paramount interest to give this problem very careful thought, as the outcome of well intended work could be thwarted by an inadequate committee or by omitting to consult important authorities. In the first instance such competent autho-

rites as the Ministry of Health and Welfare and the national representative of the International Standard Organization (ISO) must be consulted, furthermore the societies of haematology medicine, pediatrics, clinical pathology etc. must be referred to. Finally personal advice is to be sought from prominent haematologists throughout the country. Once the competent authorities, societies and leading specialists have approved the formation of a national Standardizing Committee and promote its activities, a successful outcome can be expected, as was already the case in many countries. It is, of course, essential that those scientists of whom the committee is made up should not only possess personal initiative and a talent for organization, but also the necessary technical and professional knowledge. Members of the committee should therefore not be limited to specialists connected with such branches of haematology as morphology immunohaematology coagulation etc., but should include chemists, physicists and statisticians (Fig. 3).

Such national committees already exist in many countries throughout the world and are doing valuable work. South America will undoubtedly follow suit. There are haematological societies in many Latin American countries who have achieved a great deal over the past decades. Whether each country should found its own international standardizing committee or whether for instance, several Central American countries should join forces in forming a regional committee is a question which is impossible for a European haematologist to answer. It would be desirable, therefore, for the national committees within one continent to keep in touch with one another thus enabling mutual assistance. Experience has proved it to be advantageous for national or regional committees to exist as independent corporations. For this reason in the Germany 'Haemometer Test Board Institute for Standardization and Documentation in Haematology' (Haemometerprüfstelle, Institut für Standardisierung und Dokumentation in der Hämatologie) was founded as a legally registered association. I will be happy to supply any persons interested with the statutes (in German) of this society.

The national committees are members of the ICSH and naturally collaborate with the managing Board of the ICSH not only by promoting the Board's resolutions, but also by informing the Board of current trends, by indicating the degree or urgency of the various pending questions, by suggesting suitable persons to solve them and by expressing their views on preliminary proposals.




Fig. 2. The proposed composition of national standardizing committees.

Table 1
The expert panels of the ICSH.

Topic	Chairman
Blood Cell Counts	J. W. Stewart (London)
Coagulation Testing Procedures	R. J. Eilers (Kansas City)
Cytochemistry in Haematology	B. Thorell (Stockholm)
Determination of Packed Cell Volume	W. H. Crosby (Boston/Mass.)
Erythrocytic Sedimentation Test	G. A. Alexeff (Moscow)
Evaluation of Normal Values in Haematology	S. Watanabe (Hiroshima)
Haematinics	G. Lask (Jerusalem)
Haematological Documentation	G. Astaldi (Torino)
Haematological Serology	J. Crookston (Toronto/Ont.)
Haematological Terminology	L. Hellmeyer (Freiburg/Ber.)
Haemoglobinometry	J. Spaander (Utrecht)
Red-Cell Fragility	S. M. Lewis (London)

The final question is what should be standardized. The answer to this query is simple all haematological methods, haematological terminology and the documentation of haematological findings and literature. It is, of course, impossible to resolve all these problems at once. A host of scientific questions have to be gone into very thoroughly before a method can be standardized. Basic methods should obviously be given priority those of lesser importance can be attended to at a later date. For these reasons the ICSH started by standardizing haemoglobinometry and has achieved thereby excellent results. For the immediate future the ICSH is planning studies on roughly a dozen topics and has formed Expert Panels for this purpose (Table I)

Summary

The standardization of haematological methods, nomenclature and documentation is of primary importance. This work is carried out by the International Committee for Standardization in Haematology (ICSH). The work of the ICSH is prepared by Expert Panels and carried out by national or regional committees. The author expounds his personal opinion on how this task can best be performed.

Résumé

La standardisation de la nomenclature, de la documentation et des méthodes hématologiques est d'une importance primordiale. Ce travail est accompli par le Comité International pour la Standardisation en Hématologie (ICSH).

Le travail du CISH est préparé par des commissions d'experts et exécuté par des comités nationaux ou régionaux. L'auteur donne son opinion sur la façon dont cette tâche peut être le mieux accomplie.

Zusammenfassung

Die Standardisierung hämatologischer Methoden, der Terminologie und der Dokumentation sind dringend notwendig. Diese Arbeit wird vom «International Committee for Standardization in Haematology (ICSH)» durchgeführt. Die Arbeit des ICSH wird von «Expert Panels» vorbereitet und von nationalen, bzw. regionalen Standardisierungsausschüssen durchgeführt. Der Autor legt seine persönliche Auffassung dazu dar wie seiner Meinung nach diese Arbeit am vorteilhaftesten geleistet werden kann.

Author's address: Dr. Ch. G. de Boerckelley Med. Univ. Klinik, Hauptstrasse 33, D-38 Freiburg im Br. (Germany).

From the Cancer Research Unit, Veterans Admin. Hospital, Bronx, New York

The Rauscher Virus: A Mixture of the Friend Virus and of the Mouse Leukemia Virus (Gross)?

LUDWIK GROSS

A leukemogenic virus isolated a few years ago by RAUSCHER (12) has been employed extensively in studies dealing with experimental mouse leukemia. This virus has two principal pathogenic properties: it can induce in susceptible mice (a) the characteristic syndrome of FRIEND disease, or in mice of certain strains, and in rats, it can also induce (b) lymphoid leukemia, including thymic and generalized lymphosarcomas.

Development of Friend Syndrome in Mice Following Inoculation of the Rauscher Virus

When inoculated into either suckling or young adult (3 to 4 weeks old) mice of susceptible strains, such as C3H, BALB/c, or Swiss, the RAUSCHER virus induces, after a short latency of only a few weeks, a characteristic syndrome indistinguishable from that induced with the FRIEND virus (1-9). Considerable enlargement of spleen, and liver represent the most striking macroscopic feature of the induced disease. Characteristically and within a relatively short time, the spleen may become enormously enlarged, and filled with fragments of destroyed cells, and altered blood (Fig. 1). There are no thymic tumors, and the peripheral lymph nodes are not enlarged. This is in striking contrast to the great majority of the conventional forms of mouse leukemia (8). The white blood cell count is considerably increased, and the peripheral blood smears show evidence of pronounced anemia, presence of many nucleated red cells, and characteristically also very large numbers of smudge cells, among a variety of cells of the myeloid series in different

Aided, in part, by grants from the Damon Runyon Memorial Fund and the American Cancer Society



Fig. 1 Characteristic enlargement of spleen and liver induced with the RAUCHER virus. This CSH(1) female mouse was inoculated (0.5 ml i. p.) when less than 5 weeks old, with 5 RAUCHER virus filtrate, and was sacrificed 25 days after inoculation. Note the very large spleen and also enlarged liver. Significantly the thymus is not enlarged, and there is no enlargement of peripheral lymph nodes. WBC 158,200/mm³ with 347 smudge cells per 100 WBC, and presence of many nucleated red cells, among variety of white cells predominantly of the myeloid series in peripheral blood. Hb 7.2 gm/100 ml. This macroscopic and microscopic pathologic picture is indistinguishable from that induced with the FANT virus (19).

phases of maturation. On microscopic examination of liver and spleen, there is considerable infiltration with abnormal white cells, with areas of destruction and necrosis. Some of the other organs may also show infiltration with abnormal cells, but to a lesser extent. In most instances the disease is progressing rapidly and the animals



Fig. 1. Thymic lymphosarcoma induced in rat with the RAUSCHER virus. The RAUSCHER virus, after 10 consecutive passages through rats, was inoculated (0.4 ml of 10^6 blastic p.) into suckling less than 3 days old, Sprague Dawley female rat. After latency of 2 months, this rat developed large thymic lymphosarcoma, and multiple lymphosarcomas in the spleen, liver, cervical and mesenteric lymph nodes. WBC 58,500 mm^3 with 10^6 lymphoblasts among predominantly lymphocytes in peripheral blood. Hb 9 gm/100 ml. This pathologic picture of lymphoid leukemia was essentially identical with that usually resulting from inoculation of the mouse leukemia virus (GROSS).

die within 2 or 3 months after inoculation. This macroscopic, and microscopic picture of the disease induced in mice with the RAUSCHER virus, is identical with that resulting from inoculation of the FRIEND virus (19).

The current difficulties in clarification and classification of the mouse leukemia viruses (8, 9) have been increased by the introduction into the study of experimental mouse leukemia of a progressive disease of the hematopoietic system developing in mice following inoculation of the Friend virus (1). This curious syndrome seems to be a true 'laboratory disease' and appears to be exceedingly rare under natural life conditions, if it occurs spontaneously at all. This unusual disease of the hematopoietic system probably belongs to the broad group of leukemias, although it is very different from any of the usual forms of leukemia occurring in mice spontaneously or induced by radiation, chemicals, or hormones.

Development of Thymic Lymphosarcomas and Other Conventional Forms of Mouse Leukemia in Mice and Rats Following Inoculation of the Rauscher Virus

Under certain experimental conditions, inoculation of the RAUSCHER virus filtrate may induce lymphoid leukemia with the characteristic development of thymic and generalized lymphosarcomas. This may take place when suckling or weanling (3 to 4 weeks old) mice of certain strains, such as C57 Black or C57 Brown relatively resistant to the FRIEND virus, or when suckling rats, are inoculated with the RAUSCHER virus filtrate (12, 9)

The natural resistance of mice of certain strains, such as C57 Brown, to the induction of Friend disease, following inoculation of the RAUSCHER virus, is only relative, and is apparent when weanling mice are employed for bio-assay. On the other hand when newborn, or suckling, C57 Brown mice are inoculated with the RAUSCHER virus filtrate, some will develop after a short incubation period a well characterized enlargement of spleen and liver with the characteristic blood picture of Friend syndrome; other mice in each group will survive, but develop after a prolonged latency lymphoid leukemia with thymic and generalized lymphosarcomas; few develop 'mixed form, i. e. thymic and generalized lymphosarcomas with blood morphology similar to that observed in the Friend syndrome.

It should be pointed out that similar results could be obtained employing the Friend virus filtrate for inoculation of suckling, and 3 to 4 weeks old mice (9). Further more, the Friend virus can also induce thymic lymphosarcomas, as well as lymphatic, stem-cell, or myeloid leukemia, following inoculation into suckling rats (11, 9). This pathogenic action of the Friend virus may be due to the presence in the Friend virus filtrate of the Gross mouse leukemia virus component (9).

The interesting ability of the RAUSCHER virus to induce (a) the spleno-splenomegaly syndrome of Friend disease, with its characteristic pathologic features, and striking blood picture, or (b) conventional form of mouse leukemia, frequently associated with the development of a thymic lymphosarcoma, such as lymphatic, stem cell, or myeloid leukemia, could be explained by an assumption that a single virus, present in the RAUSCHER filtrate, has a wide range of pathogenic potential, and is capable of inducing both, the Friend syndrome and one of the conventional forms of mouse leukemia, such as thymic lymphosarcoma.

On the other hand, it would be also possible to assume that what is now considered to be the RAUSCHER virus may actually represent a mixture of two distinct viruses, the FRIEND virus, and in addition the GROSS mouse leukemia virus (8, 9)

A Mixture of Friend Virus and of Mouse Leukemia Virus (Gross) ?

Let us consider the possibility that the RAUSCHER virus strain, and actually though to a lesser extent, also the FRIEND virus filtrate (9) consists of a mixture of the FRIEND virus, in a relatively high titer and of the GROSS mouse leukemia virus (i.e. the passage A virus) (4) the latter in a relatively lower concentration. Following inoculation of such a filtrate into animals susceptible to both viruses, either form of disease could be induced. However the FRIEND virus induces disease after a relatively shorter latency and for that reason, when susceptible mice are inoculated they usually develop and die from, the FRIEND syndrome before they have an opportunity to develop lymphatic leukemia, or another form of leukemia caused by the mouse leukemia virus (9) the latter requires a considerably longer latency period for induction of disease (2, 4-6)

On the other hand, if the RAUSCHER filtrate, presumably consisting of a mixture of the two viruses, is inoculated into mice of certain inbred strains such as C57 Black or C57 Brown, or into suckling rats, which are relatively resistant to the induction of the FRIEND syndrome, one of the conventional forms of mouse leukemia such as lymphatic, or stem-cell leukemia, may develop as a result of the pathogenic action of the GROSS mouse leukemia virus present in the filtrate. Characteristically most of these animals develop thymic lymphosarcomas, as a rule absent in mice with FRIEND virus-induced syndrome.

In some instances, 'mixed' form representing mixture of both the FRIEND disease and one of the conventional forms of mouse leukemia, such as thymic lymphosarcomas, can also be induced in the same host. Pathologic manifestations which could be attributed to both viruses have been observed quite frequently in our laboratory in some of the mice, in certain instances also in rats, inoculated with the RAUSCHER virus strain, and occasionally also following inoculation of the FRIEND virus filtrate. The combined effect of both virus components may in some instances result in the induction, particularly in rats, of acute myelogenous leukemia with considerably enlarged spleen, erythroid anemia, presence of nucleated red cells, and characteristic smudge cells in peripheral blood, among variety of white cells of the myeloid series. Whether the possibility of synergistic action of both viruses should be considered remains an open question, since the mouse leukemia virus (Gross) alone may also induce in certain instances (5, 6) particularly in rats (7) acute myelogenous leukemia. Furthermore, the FRIEND virus is also

capable of inducing an acute syndrome with blood morphology which could be classified as disease belonging to the group of erythroid or myelogenous leukemias, even though there may exist some reservations as to the true nature of this curious disease.

Results of experiments carried out recently in our laboratory are consistent with the assumption that the RAUSCHER virus strain actually consists of a mixture of two viruses.

Attempt to Inhibit the Friend Virus Component of the Rauscher Virus Filtrate by Serum Neutralization

An attempt was made to neutralize *in vitro* the FRIEND virus component, presumably present in the RAUSCHER virus filtrate, by specific immune serum. The RAUSCHER virus was mixed with immune serum obtained from rabbits that had received several injections of FRIEND virus filtrates. The mixture was then inoculated into suckling, and also into 3 weeks old C57(f) mice. After neutralization with anti-Friend serum, the RAUSCHER virus strain filtrate was still able to induce lymphatic leukemia; however its potency to induce FRIEND disease was considerably diminished (9).

These experiments are now repeated with an effort to follow a more quantitative approach to the neutralization test; it is hoped that under more precise experimental conditions it will be possible to inhibit completely the FRIEND virus component of the RAUSCHER virus filtrate.

Attempt to Eliminate from the Rauscher Virus Filtrate the Friend Virus Component by Serial Passage Through Rats

Inoculation of either the FRIEND or the RAUSCHER virus, induces in rats, as a rule, lymphatic leukemia, in some instances stem-cell leukemia, and occasionally also the myelogenous form. Characteristically thymic lymphosarcomas develop in the great majority of such animals (Fig. 2)

Since rats do not develop typical FRIEND disease, as seen in mice but react, following inoculation of either FRIEND or RAUSCHER virus by the development of a conventional form of leukemia, it appeared of interest to pass the RAUSCHER virus serially through rats* in an attempt to determine whether such rat adapted RAUSCHER virus would still retain its ability to induce typical Friend disease when inoculated back into mice.

Accordingly the RAUSCHER virus, harvested from mice, was inoculated in form of 5/ filtrates, prepared in the usual manner

The virus employed in our studies was received from Dr. F. J. RAUSCHER, National Cancer Institute, in 1962, and has been maintained since that time in our laboratory in mouse-to-mouse passages. The method of preparation of filtrates was described previously (9).

employed in our laboratory (4-6) into suckling, less than 5 days old, Sprague Dawley rats. As soon as the inoculated rats developed leukemia, they were sacrificed; the virus was harvested from the leukemic rat donors, and inoculated again into newborn rats. This procedure was repeated serially, and the RAUSCHER virus was passed through 10 consecutive rat-to-rat passages, inducing in practically all inoculated animals thymic tumors and disseminated lymphosarcomas, occasionally stem-cell, or myelogenous leukemia, very similar to forms induced with the passage A virus (Gross). From each consecutive rat-to-rat passage, an attempt was made to inoculate the rat-adapted virus back into suckling, or 3 to 4 weeks old, C3H(f) mice, known to be uniformly susceptible to the induction of FRIEND disease.

After the initial 2 or 3 consecutive rat-to-rat passages, the RAUSCHER virus lost much of its ability to induce a typical FRIEND disease following inoculation into either suckling or 3 weeks old C3H(f) mice; the rat-adapted virus induced either typical lymphatic leukemia, or a mixed form, manifested by the development of thymic lymphosarcomas and also some of the features such as a very large spleen or the characteristic blood picture, of the FRIEND disease only exceptionally, however, did such a virus induce a typical FRIEND syndrome (Table I). After 7 to 8 consecutive rat

Table I

Results of inoculation of RAUSCHER virus strain into suckling and weanling C3H(f) mice, following 1 to 10 consecutive passages through rats.

No. of consecutive passages through rats	Average age at inoculation, days	No. of mice inoculated	Form of leukemia induced			Average age leukemias developed, months	No. of survivors, mice	Average age survivors died, months
			A	Type F*	mixed			
1 to 3	28	29	8		3	< 4	18	8
	5	16	7	2	7	< 3	—	—
4 to 6	32	47	5		1	< 8	41	12
	5	14	6	1	7	< 3	—	—
7 to 8	33	30	1			9	29	10
	5	2	2			< 3	—	—
9 to 10	26	30	1			< 4	29	5-8*
	5	7	7			< 3	—	—

Type A, usually lymphatic or stem-cell, with thymic tumors, enlargement of peripheral lymph nodes, etc., similar to that induced with passage A virus.

Type F (Friend) hepato-splenomegaly with no thymic tumors, and no peripheral lymph node enlargement. Characteristic blood morphology showing presence of variety of white cells of the myeloid series, large number of 'monocyte cells' and many nucleated red cells also severe anemia.

These mice are still alive, and under observation, ages varying from 5 to 9 months.

to-rat passages, however the RAUSCHER virus lost its characteristic potency to induce symptoms of FRIEND disease in susceptible mice, but retained nevertheless its ability to induce lymphatic leukemia in either mice or rats. Thus, when after 7 to 10 rat-to-rat passages, the RAUSCHER virus, harvested from leukemic rat donors, was inoculated into suckling or 4 to 5 weeks old C3H(f) mice none developed either the characteristic acute enlargement of spleen and liver or the distinctive blood picture typical for the FRIEND disease (Table I). It appeared therefore, that after several consecutive rat-to-rat passages, the RAUSCHER virus lost its FRIEND virus component. The same rat-adapted virus inoculated into 9 suckling mice induced in all of them thymic and generalized lymphosarcomas (Table I) presumably caused by the mouse leukemia virus (Gross) component remaining in the filtrate. Only 1 out of 30 mice in each of 2 consecutive experiments, inoculated at 4 to 5 weeks of age, developed lymphoid leukemia, during the observation time thus far elapsed (Table I) mice of that age are less susceptible than suckling animals to the mouse leukemia virus (Gross) (2, 4, 6).

The leukemogenic potency of the rat-adapted RAUSCHER virus for suckling rats, inducing predominantly thymic lymphosarcomas, became slightly increased for that species after consecutive rat to-rat passages as evidenced by increased incidence of induced lymphomas, and shorter latency*

Results of Serial Rat-to-Rat Passage of the Mouse Leukemia Virus (Gross)

As comparison, it is of interest to stress at this point that serial passage through rats of the passage A mouse leukemia virus did not alter its pathogenic potential determining the form of induced disease. Thus, the mouse leukemia virus (Gross) isolated originally from spontaneous mouse leukemia (4) was found to be pathogenic not only for mice, but also for rats (7) inducing in this species forms of leukemia and lymphomas essentially similar to those induced in mice. The virus has now been passed serially through 21 consecutive rat-to-rat passages, inducing predominantly thymic and disseminated lymphosarcomas, but also lymphatic, stem-cell, and myelogenous leukemia.

A several passage intervals, after 8, 10, 13, 17, 18, 20, rat consecutive rat-to-rat passages, the mouse leukemia virus, harvested from leukemic rats, was inoculated back into suckling C3H(f) mice, inducing the same forms of leukemia and lymphomas as did the original virus that had been harvested from leukemic mice (10). Thus serial passage through rats might have increased the titer of the virus for the rat species

Incidence of leukemia induced in rats practically 100% average latency approximately 3 months (Gross, L. Unpublished experiments). In this respect, therefore the rat-adapted RAUSCHER virus is indistinguishable from the passage A (Gross) leukemia virus passed in rats (7).

(7-10) but did not alter the intrinsic pathogenic property of the virus, expressed by the form of leukemia and lymphomas induced on inoculation tests in the host of origin, *i.* in mice.

Experiments are now in progress in our laboratory dealing with serial rat-to-rat passage of the Friend virus. Thus far only 3 consecutive rat-to-rat passages have been performed, and the inoculated rats developed large thymic lymphosarcomas. The rat-adapted Friend virus, harvested from leukemic rats, after 2 consecutive passages in that species, was inoculated back into 3 to 4 weeks old C3H(f) mice: out of 20 inoculated mice 4 developed typical lymphatic leukemia; the remaining 16 mice are thus far in good health, 6 months after inoculation: none developed the Friend disease. The original Friend virus, carried in our laboratory in mouse-to-mouse passage, induces 100% incidence of the characteristic Friend syndrome following inoculation into less than 4 weeks old C3H(f) mice.

Further rat-to-rat passages of Friend virus will be carried out; however, results of these preliminary experiments suggest that the Friend virus could be eliminated from Friend virus filtrate by serial passage through rats, leaving the mouse leukemia virus (Gross) component.

Neutralization in vitro of the Lymphatic Leukemia Virus Component of the Rauscher Virus Filtrate with Immune Mouse Leukemia (Passage 4—Gross) Virus Serum

Since the rat-adapted RAUSCHER virus strain retained its potency to induce in rats thymic and generalized lymphosarcomas, an attempt was made to determine whether this pathogenic potency of the RAUSCHER virus strain could be inhibited by an immune serum obtained from rabbits immunized with the passage A virus (Gross). The RAUSCHER virus strain, that had been passed through 8 consecutive rat-to-rat passages, was employed. The virus filtrate was prepared from thymic tumors and spleens of leukemic rat donors, employing our method used routinely (4, 6, 10) for the preparation of passage A filtrates. A 10^{-3} dilution of the rat-adapted RAUSCHER virus strain filtrate was then mixed *in vitro* with an equal amount of undiluted immune serum, obtained from rabbits that had received several consecutive injections of passage A virus harvested from leukemic C3H(f) mice with Freund adjuvant (10). In a simultaneous control experiment a 10^{-3} dilution of the virus filtrate was mixed with equal amount of undiluted serum obtained from rabbits that had received several injections of normal C3H(f) mouse organs, with Freund adjuvant (10). All sera were inactivated at 56°C for 1 h prior to neutralization tests. In a third group, as an additional control, the 10^{-3} virus filtrate dilution was mixed with an

Table II

Neutralization by filtrate of lymphatic leukemia component of the RAUCHER virus strain with immune passage A virus serum.

Antigen employed for preparation of rabbit serum	Serum dilution	Virus EL dilution **	No. of rats inoculated	No. dev leukemia	Average age leukemia dev. max.
Passage A virus harvested from mice (with Adj.)	undiluted	10 ⁻²	5	0	—
Normal mouse organs (with Adj.)	undiluted	10 ⁻²	6	6	< 5
Saline controls		10	6	6	< 4

Rat-adapted* following 8 rat-to-rat passages.

Virus filtrate incubated with serum at room temperature for 30 min, then at +4°C for 3½ h. Method of preparation of serum was previously described (10)

** Suckling < 7 days old Sprague Dawley rats inoculated 0.6–0.8 ml i. p.

Lymphatic leukemia with thymic tumors and generalized lymphosarcomas. (Rats in the first group, which remained in good health, free from leukemia, were observed for 10 months)

equal amount of physiological saline solution. The virus-serum mixtures, as well as the virus-saline control, were incubated at room temperature for 30 min, followed by incubation at +4°C for 3½ h, and were then inoculated into suckling Sprague Dawley rats. The results, summarized in Table II indicate clearly that the passage A immune rabbit serum inhibited completely the ability of the RAUCHER virus strain to induce lymphatic leukemia, following inoculation into suckling rats. There was no inhibiting effect whatever of the normal mouse organs serum. Virus filtrate mixed with normal mouse organs serum, as well as the virus filtrate diluted only as a control, with equal amount of physiological saline solution induced in all inoculated rats lymphatic leukemia with characteristic large thymic lymphosarcomas, and also generalized lymphosarcomas in spleens, livers, and other organs.

Mixture of Two Oncogenic Viruses in One Filtrate

A Common Difficulty in Experimental Mouse Leukemia Studies

It would not be the first time to observe that a filtrate prepared from leukemic mouse tissues may contain a mixture of two distinct oncogenic viruses. It may be of interest to recall at this point




Fig. 3. Electron micrographs of () RAUSCHER virus, (b) FRIEND virus, and () mouse leukemia virus (Gross). Electron microscopic studies of ultra-thin sections of leukemic organs, such as spleen, lymph nodes, etc. of mice and rats, that developed disease following inoculation of either RAUSCHER, FRIEND, or GROSS virus, revealed presence of spherical particles varying about 100 m μ in diameter essentially identical in their morphology and location, either of the doughnut-type or with electron-dense, centrally located, nucleoids. They were found either in intercellular spaces, within cytoplasmic vacuoles, or budding, usually from the edges of the cytoplasmic cell membranes of variety of cells. *Upper Section (A and A₁)* Fragments of spleen from C3H(f) mouse with

the early studies on mouse leukemia. In the initial experiments (2) when the mouse leukemia virus was first isolated from organs of AK mice with spontaneous leukemia, some of the extracts prepared from such organs inoculated into newborn C3H mice induced parotid gland tumors, instead of leukemia (3). A few animals developed both, leukemia and parotid tumors. The possibility had to be considered that a single virus was responsible for the induction of either leukemia, or parotid gland tumors. It was soon realized, however, that extracts prepared from leukemic mouse tissues contained two different viruses, one causing leukemia, and another causing parotid, and other salivary gland, tumors (3). The mouse leukemia virus, and the parotid tumor virus, even though initially present simultaneously in the same filtrates, could readily be separated by ultracentrifugation, or by differential heating since the mouse leukemia virus was found to be larger and more susceptible to heat. In general, however, the separation of two different viruses present in the same filtrate may be difficult, particularly if such viruses have similar physical, and biological properties.

Summary

The RAUSCHER virus can induce in susceptible mice considerable enlargement of spleen and liver and characteristic blood picture pathologic features identical with those resulting from inoculation of the FRIEND virus. In certain strains of mice however and also in rats, the RAUSCHER virus can induce thymic lymphosarcomas, and other conventional forms of leukemia commonly observed following inoculation of the mouse leukemia virus (GROSS). This dual pathogenic potency could be explained by an assumption that the RAUSCHER virus filtrate consists of a mixture of the FRIEND virus, and of the mouse leukemia virus (GROSS). Results of experiments here reported are consistent with such an assumption. Following several serial passages through rats, species relatively resistant to the FRIEND virus, the RAUSCHER virus lost its ability to induce FRIEND virus syndrome on mouse bio-assay. Furthermore, the ability of the rat-adapted RAUSCHER virus to induce thymic lymphosarcomas could be inhibited by neutralization in rats with the GROSS mouse leukemia virus immune serum.

The mouse leukemia virus (GROSS) as well as the FRIEND virus, and the RAUSCHER virus strain, have similar physical properties, and are indistinguishable in their morphology on electron microscopic examination (Fig. 3).

RAUSCHER virus-induced FRIEND syndrome (37,450 \times). *Middle Section* (B and B₁). Fragments of spleen of C3H(1) mouse with FRIEND virus-induced disease (33,600 \times). *Lower Section* (C). Fragment of spleen from Sprague Dawley rat with passage A (GROSS) virus-induced myeloid leukemia (37,450 \times). (C₁). Fragment of lymph node from C3H(1) female mouse with lymphoid leukemia induced with passage A virus (33,600 \times). (Electron micrographs prepared in our laboratory by Dr. D. G. FELLOMAN in cooperation with the author.)

Résumé

Le virus de RAUSCHER peut provoquer chez des souris susceptibles un agrandissement considérable de la rate et du foie, et une formule sanguine caractéristique trahit pathologiques identiques avec ceux résultant d'une inoculation du virus de FRIEND. Dans certaines souches de souris par contre, ainsi que chez le rat, le virus de RAUSCHER peut provoquer des lymphosarcomes thymiques et d'autres formes conventionnelles de leucémies communément observées après l'inoculation du virus de leucémie de la souris (Gross). Ce double pouvoir pathogène serait peut-être dû à ce que le filtrat du virus de RAUSCHER constituerait en un mélange du virus de FRIEND et du virus de la leucémie de la souris (Gross). Les résultats des expériences rapportées ici concordent bien avec cette hypothèse. Après plusieurs passages chez le rat, une espèce relativement résistante au virus de FRIEND, le virus de RAUSCHER perd sa faculté d'induire le syndrome de FRIEND. En plus, le pouvoir pathogène du virus de RAUSCHER adapté au rat, de produire un lymphosarcome du thymus, peut être neutralisé *in vivo* par un sérum spécifique préparé à l'aide d'un virus de Gross.

Zusammenfassung

Das RAUSCHER-Virus kann bei empfindlichen Mäusen eine beträchtliche Vergrößerung von Milz und Leber hervorrufen, pathologische Veränderungen, die mit denjenigen nach Inokulation des FRIEND-Virus identisch sind. Bei gewissen Mäuselinien und auch bei Ratten kann das RAUSCHER Virus Thymus-Lymphosarkome und andere gewöhnliche Leukämieformen erzeugen, wie sie nach Inokulation des Mäuseleukämie Virus (Gross) beobachtet werden. Diese zweifache pathogene Eigenschaft könnte mit der Annahme erklärt werden, daß das Filtrat des RAUSCHER Virus aus einem Gemisch des FRIEND-Virus und des Mäuseleukämie-Virus (Gross) besteht. Die Ergebnisse der hier mitgeteilten Versuche stehen mit dieser Annahme in Übereinstimmung. Nach mehreren Passagen bei Ratten, einer gegenüber dem FRIEND-Virus relativ resistenten Spezies, verliert das RAUSCHER-Virus seine Fähigkeit, das FRIEND-Virus-Syndrom im Mäuser auch zu erzeugen. Ferner kommt die Fähigkeit des an Ratten adaptierten RAUSCHER Virus zur Erzeugung von Thymus-Lymphosarkomen gebremst werden durch Neutralisation *in vivo* mit dem Immunsérum der Mäuseleukämie von Gross.

References

1. FRIEND, C. Cell-free transmission in adult Swiss mice of disease having the character of leukemia. *J. exp. Med.* **105**: 307-318 (1957).
2. GROSS, L. Pathogenic properties, and 'vertical' transmission of the mouse leukemia agent. *Proc. Soc. exp. Biol.*, N. Y. **78**: 342-348 (1951).
3. GROSS, L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. *Proc. Soc. exp. Biol.*, N. Y. **83**: 414-442 (1953).
4. GROSS, L. Development and serial cell-free passage of a highly potent strain of mouse leukemia virus. *Proc. Soc. exp. Biol.*, N. Y. **94**: 767-771 (1957).
5. GROSS, L. Development of myeloid (chloro-) leukemia in thymectomized C3H mice following inoculation of lymphatic leukemia virus. *Proc. Soc. exp. Biol.*, N. Y. **103**: 509-514 (1960).
6. GROSS, L. Pathogenic potency and host range of the mouse leukemia virus. *Acta haemat., Basel* **29**: 1-15 (1963).

7. GROSS, L. Serial cell-free passage in rats of the mouse leukemia virus. Effect of thymectomy. *Proc. Soc. exp. Biol., N. Y.* 112: 939-943 (1963).
8. GROSS, L. How many different viruses causing leukemia in mice? *Acta haemat., Basel* 32: 44-62 (1964).
9. GROSS, L. Attempt at classification of mouse leukemia viruses. *Acta haemat., Basel* 32: 81-98 (1964).
10. GROSS, L. Neutralization assays of mouse leukemia virus by specific immune serum. Importance of virus titration. *Proc. Soc. exp. Biol., N. Y.* 119: 420-427 (1965).
11. MIRANDA, E. A. AND GRACE, J. T. J. Induction of leukemia in rats with Friend virus. *Virology* 17: 364-366 (1962).
12. RACHGGER, F. J. A virus-induced disease of mice characterized by erythrocytopenia and lymphoid leukemia. *J. nat. Cancer Inst.* 29: 515-543 (1962).

Author's address: Dr. Luciwah Gross, Veterans Administration Hospital, 130 West Kensington Road, Boston 62, N. Y. (USA).

Clinica Pediatrica dell'Università di Firenze (Direttore: Prof. A. Cecchi)

Estimation of Foetal Haemoglobin in Leukaemia

G. BARTOLOZZI AND L. MARIANELLI

The concentration of foetal haemoglobin (Hb F) in children after the first year of life, and in adults is usually not greater than 1-2% of the total haemoglobin (1-4). Levels higher than this in patients older than one year suggests in the first place a rare congenital anomaly known as persistence of foetal haemoglobin (5-6). It is pathognomic of this condition that the foetal haemoglobin is distributed evenly in all the red cells, so that the percentage of foetal haemoglobin in each cell is similar to that in the total population of cells.

A raised foetal haemoglobin level is almost always found in certain other haemoglobinopathies (thalassaemia, sickle cell disease) in which there is a congenital abnormality affecting the synthesis of the β -chains. In such conditions the foetal haemoglobin is distributed irregularly in the red cells, so that one cell may have an abnormally high concentration while others are completely free from foetal haemoglobin (3). Investigations of the foetal haemoglobin levels in other haematological disorders have shown the levels to be significantly raised above normal in numerous pathological conditions: megaloblastic anaemia (1, 7-8), aplastic anaemia (1, 7-11) and leukemia (1, 7, 10, 12-20). From this point of view we have investigated the levels of foetal haemoglobin in children with leukaemia of various types, and at various stages of the disease.

Material and Method

We studied 22 cases of leukaemia in children aged 13 months to 12 years, of whom 16 had acute leukaemia, 3 had chronic myeloid leukaemia, and 3 had acute myeloid leukaemia; all were admitted to the paediatric clinic in Florence during the last years.

No.	Name	Age	Sex	FETAL HAEMOGLOBIN %			(Mean)	(S.D.)	Diagnosis
				10	20	30			
1	R.M.	47½	m.	C			12	2.3	A
							2.5	2.5	
2	R.M.	13	f.	C			13.5	2.2	L. A.
							14	2.0	
3	M.						10	2.3	A
4	E.	2½					4.5	4.2	A
5	W.	13 m.	m.				4.2	2.98	A
6	G.S.		m.				10	2.2	L. A.
7	G.						105.4	1.94	L. A.
8	E.						10.0	2.0	L. A.
9	L.B.						11	2.00	A
10	C.A.		m.				10.5	2.00	A
11	R.	10	m.				10	2.1	L. A.
12	G.B.	10 m.					10	2.5	A
13	L.A.	10					2.5	2.5	A
14	M.L.		m.				4.5	2.05	L. A.
15	L.B.	12					10.5	2.2	L. A.
16	R.	11					100	2.1	M. Cr
17	C.L.	10	m.				10.4	2.5	M. Cr
18	G.	10	m.				105	2.0	M. A.
19	47½	m.					5.5	2.50	M. A.
20	100	1.5					100	2.10	M. A.

L. A. = acute lymphocytic leukaemia

M. Cr = chronic granulocytic leukaemia

M. A. = acute granulocytic leukaemia.

The foetal haemoglobin levels of these patients was measured one or more times during the course of their illness, by means of Seious' method (14).

The results are set out according to the stage of the disease and the corresponding numbers of red and white cells are also given.

Results

Fig 1 shows the percentages of foetal haemoglobin in our 22 cases. Of the 16 children with acute leukaemia 5 had a foetal haemoglobin level of less than 1 /, and the rest varied from 3 to 20 / . In cases 1 and 2 in which the test was carried out a second time after an interval of 1 month the initial level was less than 1 / but at the end of the month, the levels of foetal haemoglobin had risen to 4 and 10 / respectively.

In all the 6 cases of myeloid leukaemia, acute and chronic, the foetal haemoglobin levels were much higher than normal, varying from 5 to 38.5 / . In two of the cases (19 and 21) the levels were the highest found in the whole study being 35 and 38.5 / respectively. In case 21 in which the test was repeated three times at intervals of 15 days and 2 months, the foetal haemoglobin level was permanently raised varying from 20 to 38.5 / . To exclude thalassaemia, we measured the level of haemoglobin A₂ in the parents of the child, and these were within normal limits.

In none of the patients did we find any positive correlation between the numbers of red cells and the percentage of foetal haemoglobin. It is possible, however that frequent blood transfusion masked a possible relation between these two factors. We found no correlation between percentage of foetal haemoglobin and the white cell count.

Discussion

The results we have obtained are more or less in agreement with those of other authors. VECCHIO (19) made the first study of foetal haemoglobin in two leukaemic patients in 1948 and found concentrations normal for the age of the subjects. SINGER *et al* (14-15) later found in two cases of acute leukaemia and one of chronic leukaemia, that the levels of foetal haemoglobin were significantly raised above normal (3.2-4.3 and 2.6 / respectively). POLCAA *et al*. (7-20) in 20 cases of various types of leukaemia, found increased levels of foetal haemoglobin in the haemocytoblastic and chronic myeloid leukaemias, which averaged 6.4 and 4.4 / respectively. In one case of haemocytoblastic leukaemia the foetal haemoglobin level was 25 / . BEAVEN *et al* (1-12-13) investigated 33 cases of leukaemia, of which 5 had raised foetal haemoglobin levels, but none were greater than 10 / . In contrast two other children show

ed very high levels, varying between 15 and 30 / over long periods of time. SHUTTER (16) reported a case of a girl of 12 with acute myeloid leukaemia in which the foetal haemoglobin concentration was 20 / right from the beginning. HARDESTY *et al.* (18) reported the cases of 4 children with myeloid leukaemia of the so-called juvenile type, in which the foetal haemoglobin levels varied between 40 and 50 /₁₀₀. RAPER (8) in 3 cases of a total of 11 of acute leukaemia in children, found an increase in the numbers of red cells containing foetal haemoglobin as compared with normal. KROSSOLON *et al.* (10) after investigating 11 cases of leukaemia in children, found increased foetal haemoglobin levels in the majority and concluded that the foetal haemoglobin was not distributed evenly in all the red cells.

The present results, together with those from the literature show that in the course of leukaemia in children a moderate increase in the foetal haemoglobin levels (<10 /) is very common, while the levels much more increased than this value are encountered only rarely.

We looked into those with very high foetal haemoglobin levels in an attempt to find some common factor. The two cases of BEAVEN (21) the 4 cases of HARDESTY (18) the single case of SHUTTER (16) and our two cases were all patients suffering from acute myeloid leukaemia. BEAVEN (21) and HARDESTY (18) considered that these patients were cases of myeloid leukaemia of the juvenile type, which is an atypical form of leukaemia characterised by thrombocytopenia, poor response to treatment, increased foetal haemoglobin levels, and an age-group of 1½-3½ years. This distinguishes it from the adult type, which affects older children. Such subdivisions however seem to us to be an oversimplification when one considers the foetal haemoglobin levels, since the case of SHUTTER and our two cases, although having raised foetal haemoglobin levels, do not satisfy all the criteria in the accepted definition of the juvenile type of myeloid leukaemia.

Various hypotheses have been put forward to explain the increased foetal haemoglobin levels in leukaemia. With the gradual decline in the synthesis of the γ -chains after birth, and after the substitution of β -chain synthesis (change over from Hb F to Hb A₁) during the first year of life, only few clones of erythroblasts maintain its capacity to synthesise the γ -chains, and these are responsible for the 1 / foetal haemoglobin found in adults.

The appearance of high levels of foetal haemoglobin in leukaemic patients, as well as in other haematological disorders, indicates a return to the synthesis of the γ -chain owing to stimulation of these clones by some sort of feedback mechanism (22-23). The irregular distribution of foetal haemoglobin through the red cell population supports this hypothesis. If this mechanism is admitted, then it can be seen that it is more efficient when it operates early in infancy rather than in adulthood (24). It is probable that this mechanism of the control of the synthesis of foetal haemoglobin is not, or is not only the effect of low oxygen tensions in the tissues, since it has been shown that in patients with congenital cyanotic and acyanotic heart diseases the change to haemoglobin A₁ is not retarded, nor are there increased foetal haemoglobin levels in older age groups (8, 25).

According to BAGLIOMI (3) in severely anaemic patients the stem cells differentiate to red cells after a limited number of cell divisions, whereas in normal erythropoiesis a considerable number of divisions is necessary for maturation from the erythroblast stage to mature red cells. After a small number of divisions the red cells contain considerably larger quantities of foetal haemoglobin than the cells resulting from a large number of divisions. This probably is the mechanism responsible for the high levels of foetal haemoglobin found in anaemic patients.

It has been shown however that in leukaemia, besides this hypothetical mechanism, there are other factors influencing the synthesis of foetal haemoglobin and the structure of the red cells. These factors presumably bring about a profound change in the bone marrow of leukaemic patients, and may produce ambient cellular conditions in which the synthesis of one chain is easier than the other. In fact, there are numerous reported cases of a change of blood group in leukaemia (26-27-28) and of the appearance of Hb H which is haemoglobin composed of four β -chains (17-27).

It therefore seems that in leukaemia there is an increase in the level of foetal haemoglobin to a moderate degree, as has been found in various other haemopoietic disorders. Only rarely there are high levels of foetal haemoglobin as in some acute myeloid leukaemia in infants, or on the other hand Hb H as in some leukaemias of the adults.

Summary

The levels of fetal haemoglobin were investigated in 22 children with leukaemia. Of 16 children with acute leukaemia, 5 had a level of fetal haemoglobin lower than 1% and the rest varied between 3 and 20%. In all 6 cases of myeloid leukaemia, acute and chronic, the fetal haemoglobin levels were much higher than normal, varying from 5 to 38.5%. In two of the cases the levels were the highest that we found in the whole study being 35 and 38.5% respectively.

Résumé

Le taux d'hémoglobine fœtale a été déterminé chez 22 enfants atteints de leucémie. Sur 16 enfants ayant une leucémie aiguë on a vu un taux d'hémoglobine fœtale de moins de 1% et les autres un taux variant de 3 à 20%. Les taux d'hémoglobine fœtale étaient beaucoup plus hauts que normalement, variant de 5 à 38,5% dans le cas de leucémie myéloïde aiguë et chronique. Deux de ces malades présentèrent les valeurs les plus élevées de toute l'étude, respectivement 35 et 38,5%.

Zusammenfassung

Bei 22 Kindern mit Leukämie wurde der Gehalt an fetalem Hämoglobin bestimmt. Von 16 Kindern mit akuter Leukämie hatten 5 Werte von unter 1%, die übrigen zwischen 3 und 20%. Bei allen 6 Fällen von akuter und chronischer myeloischer Leukämie waren die Werte wesentlich höher als normal und schwankten zwischen 5 und 38,5%. Zwei dieser Patienten zeigten die höchsten Werte der gesamten Untersuchung, nämlich 35 und 38,5%.

References

1. BEAVER, G. H.; ELLIS, M. J. AND WHITE, J. C. Studies on human fetal haemoglobin. II Fetal haemoglobin levels in healthy children and adults and in certain haematological disorders. *Brit. J. Haemat.* 6: 201 (1960).
2. CHERNOFF, A. I. Immunologic studies of hemoglobins. II Quantitative precipitation test using anti-fetal hemoglobin sera. *Blood* 4: 413 (1953).
3. BACIGLIONI, G. Correlation between genetics and chemistry of human hemoglobins. *Molecular Genetics*. Part I, p. 405 (J. Taylor Academic Press, New York-London 1963).
4. FRASER, I. D. AND RAPER, A. B. Observations on the change from fetal to adult erythropoiesis. *Arch. Dis. Childh.* 37: 289 (1962).
5. RAPER, A. B. Persistence of haemoglobin F. *Brit. med. J.* 2: 1758 (1962).
6. CONLEY, C. L.; WEATHERALL, F. J.; RICHARDSON, S. N. SEEFARD, M. K. AND CHARACHE, S. Hereditary persistence of fetal hemoglobin: study of 79 affected persons in 15 negro families in Baltimore. *Blood* 21: 261 (1963).
7. POLONA, P.; MOTTA, L. E. FALASPERA, A. Comportamento della Hb alkali-resistente in alcune emopatie anemiche. *Prog. med., Napoli* 13: 175 (1957).
8. RAPER, A. B. The occurrence of fetal erythropoiesis after infancy. *Arch. Dis. Childh.* 38: 533 (1963).
9. SMARIN, N. T.; GICKARD, P. S. AND DIAMOND, L. H. Alkali-resistant hemoglobin in aplastic anemia of both acquired and congenital types. *New Engl. J. Med.* 266: 117 (1962).
10. KROMGOLD, K. A.; WOLMAR, I. J. AND GARRICK, M. Fetal hemoglobin-containing erythrocytes. I. Counts of cells stained by the acid elution method compared with alkali denaturation measurements. *Blood* 21: 533 (1963).

- 11 ARON Y. L. AND SEGER, F. Fetal haemoglobin in acquired aplastic anaemia. *Acta haemat.*, Basel 32: 183 (1964).
- 12 WHITE, J. C. AND BEAVER, G. H. Fetal haemoglobin. *Brit. med. Bull.* 15: 33 (1959).
- 13 BEAVER, G. H. AND WHITE, J. C. Detection of fetal and sickle cell haemoglobins in human anaemias. *Nature* 172: 1006 (1953).
- 14 SINGER, K., CHERNIKOFF A. I. AND SINGER, I. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413 (1951).
- 15 SINGER, K. Clinical significance of abnormal hemoglobins. *Yb. Path. clin. Path.*, p. 382 (A. B. Weinstein, Chicago 1953-1954).
- 16 SUTHER, S., JONES, J. H. AND KILLPATRICK, G. S. Leukemia and fetal haemoglobin: a case study. *Brit. med. J.* 2: 1336 (1960).
- 17 WHITE, J. C., ELLIS, M., COLLIER, P. V., BEAVER, G. H., GRAYZER, W. B., SMOOTHER, E. M. AND SKINNER, E. R. An unstable haemoglobin associated with some cases of leukemia. *Brit. J. Haemat.* 6: 171 (1960).
- 18 HAKSTADT R. M., SVED, D. E. AND TELL, M. Granulocytic leukemia in children. *Proc. 9th Congr. europ. Soc. Haemat.*, Lisbon 1963 p. 932 (Karger Basel/New York 1963).
- 19 VECCHIO, F. Sulla resistenza dell'emoglobina alla denaturazione alcalina negli emmalati di anemia di Cooley e nei loro familiari. *Progr. med.*, Napoli 4: 201 (1948).
- 20 POLOSI, P., MOTTA, L. E FALSAPERLA, A. Il comportamento delle curve di solubilità della Hb negli emopatici. *Boll. Soc. ital. Biol. sper.* 35: 1 (1959).
- 21 BEAVER, G. H. AND WHITE, J. C. The occurrence of Hb F or Hb H in the leukemic state. *Proc. 9th Congr. europ. Soc. Haemat.*, Lisbon 1963, p. 342 (Karger Basel/New York 1963).
- 22 REED, L. J., BRADLEY T. B. AND RANBY H. H. The effect of association of anemia on the synthesis of fetal hemoglobin in sickle cell anemia. *Blood* 25: 37 (1965).
- 23 HELLER, P. The molecular basis on the pathogenecity of abnormal haemoglobin. Some recent developments. *Blood* 25: 110 (1963).
- 24 ZILLER, W. H. AND ROMSON, A. R. Hemoglobin F its significance in the genetics and evolution of haemoglobin. *Nature* 190: 237 (1961).
- 25 COOGLAN, M. E. AND JOSEPH, M. C. The disappearance of fetal haemoglobin in congenital heart disease. *Arch. Dis. Childh.* 35: 191 (1956).
- 26 BARTOVA, A.; NOVOTNY Z. AND SLAPICKA, J. Changes in the group A antigen in case of acute myeloblastic leukemia. *Blood* 19: 366 (1962).
- 27 REICHARDT, A. G. Loss of blood B antigen in chronic lymphocytic leukemia. *Lancet* 6: 178 (1962).
- 28 SCHMIDT, P. J., BAKER, M. F. AND MCGOWAN, M. H. The I blood group, PPLO and leukemia. *Blood* 24: 834 (1964).
- 29 BEAVER, G. H., STEVEN, B. L., DAWES, N. AND WHITE, J. C. Occurrence of haemoglobin H in leukemia. *Nature* 199: 1297 (1963).

Authors' address: Dr. G. Bartoloni and Dr. L. Marzavelli, Clinica Pediatrica dell'Università, Firenze (Italia).

Radiotherapy Research Unit, Institute of Cancer Research, Royal Cancer Hospital,
Royal Marsden Hospital Surrey Branch, Sutton

The Migration of Cells to the Thymus

E. O. FIELD AND ELIZABETH M. STANLEY

It has been shown that lymphoid cells of extra thymic origin can migrate to the thymus under a variety of experimental conditions. When marrow labelled with the T6 chromosome marker is administered to lethally irradiated mice, donor cells appear in the recipients bone marrow and thymus (6) and only later throughout the lymphoid system (17). By contrast, thymic and lymph node lymphocytes appear in lymph nodes and spleen (6, 18) as do thoracic duct lymphocytes (6). Similar results have been reported for unirradiated mice with thymocytes labelled with thymidine (21) and for rats with thoracic duct cells labelled with tritiated adenosine (8). Splenic cells can however migrate to the thymus in irradiated mice (7) possibly since this organ contains some haemopoietic tissue. These findings have led to the proposal that lymphoid cells leave the bone marrow enter and proliferate in the thymus and then distribute themselves in lymph nodes (6). The observation (1) that bone marrow contains two separate factors one responsible for marrow regeneration and the other for thymic regeneration in lethally irradiated recipients, supports this conclusion.

Further evidence that lymphocytes reside in the thymus during one stage of their maturation, but do not necessarily originate in this organ is derived from experiments involving thymic grafting into neonatally thymectomized (10, 19, 20) or lethally irradiated and thymectomized adult recipients (20). Such grafts have been shown, with the chromosome marker technique, eventually to be repopulated by host lymphocytes. Similar findings have been reported, using serological techniques for identification, when parental strain thymuses are grafted into F₁ hybrid hosts (9). Following grafting, cells of donor strain can be identified in the host's spleen (19, 20) and lymph nodes (10). Moreover when grafted thymuses are regrafted into second host strains, cells derived from the primary host again migrate to lymph nodes and spleen (11).

Irradiation experiments with partial body shielding, avoid the transfer of thoses from one animal to another. These have shown that if irradiation is carried out first with the lower half of the body shielded and then, one to three hours later with the

upper half shielded the L.D₅₀ is doubled (3). Hence, during the interval between irradiations, cells capable of repopulating the thymus must have migrated from, presumably haemopoietic sites in the lower half of the body. If only the spleen is shielded instead of the whole lower half the same effect is produced (14, 15), presumably due to haemopoietic tissue in the organ.

Recently an extensive turnover of thymic lymphocytes has been demonstrated by means of parabiosis; one partner of a pair carrying a chromosome marker (17). Kinetic studies in normal animals, involving only the administration of tritiated thymidine, have yielded more circumstantial evidence in support of the theory of 'thymic cellular traffic'. The life span of thymic duct, blood and lymph node small lymphocytes in variety of species is of the order of 8 to 14 weeks (2, 4, 18, 24-25) while that of bone marrow and thymic lymphocytes only 3 to 5 days (2, 34) suggesting that some relationship exists between the last named two cell types. However, MONTAGNI *et al.* (22) have commented on the remarkably high rate of proliferation of labelled thymocytes observed by them. Values for the rate of increase in the proportion of labelled cells in the thymus, reported both for rats (23) and for mice (21) following a single injection of tritiated thymidine also appear too rapid to be explained by cell division.

All the studies reviewed above have been carried out at the cellular level. We have approached the problem by measuring the changes in specific activity of the total DNA in the thymus following a single administration of tritiated thymidine. Since all injected thymidine is utilized within a period of approximately 30 min (13) any increase in specific activity of the DNA with time must result from a migration into the thymus of cells labelled elsewhere in the body. (The implications of the possible reutilization of labelled DNA breakdown products are discussed later.) In the experiments described here we have specifically depressed thymic incorporation during the period of thymidine availability in order to enhance any effect due to the immigration of labelled cells. We have used two methods to achieve this depression: irradiation and chilling.

Material and Methods

Animals. 17 weeks old male mice of an inbred Swiss Albino strain, weighing 30 to 35 g were used: three to five mice for each experimental point.

Tritiated thymidine was obtained from the Radiochemical Centre, Amersham, and had a specific activity of 13.5 Ci/mm. Each mouse received 5.0 µCi intraperitoneally. Except when otherwise stated, the mice were killed one hour after administration of thymidine.

Irradiation. 140 Kev X-rays, filtered through 0.1 mm Cu were delivered at a dose rate of 200 Ci/mm, to a total dose of 500 r. The mice were anaesthetized with Nembutal during irradiation. When the thymic region alone was irradiated, the remainder of the body was shielded by a 3 mm thick sheet of lead.

Thymic chilling was achieved by means of 'cold finger' (Fig. 1), which consisted of a thin-walled aluminium thimble, ½ in in diameter attached by a short length of rubber tubing to a thickwalled glass tube, 4 in in length. Alcohol, cooled by passing through a coil of copper tubing immersed in an alcohol-dry ice bath, circulated through the 'cold finger' at a rate that could be controlled by a screw clamp. The 'cold finger'




Fig 1 Apparatus for cooling the thymus, showing the position of the 'cold finger' over the thymus and the arrangement for varying the rate of flow of cold alcohol and for recording the temperature of the chest wall. The animal is fixed with rubber bands (not shown) to the inclined perspex holder (shaded black) 3 cm in width. Details of the assembly are given in the text.



Fig 2 Variations in the specific activity of DNA in the thymus over a period of 24 h following single i/p injection of tritiated thymidine.

was placed in contact with the chest wall, over the thymus, and the skin temperature recorded by means of a thermocouple. (Preliminary experiments with thermocouples introduced into the thymus itself had established that the thymic temperature could be adequately assessed by a thermocouple interposed between the 'cold finger' and the chest wall.) The required temperature was achieved by adjusting the rate of flow of alcohol. The body temperature was recorded by a rectal thermometer and was maintained by insulating the animal, anaesthetized with Nembutal, in a water-bath at 37° so that the 'cold finger' was just above the surface. A sheet of cellophane provided thermal insulation. Tritiated thymidine could be injected intraperitoneally through polythene capillary tubing attached to an indwelling needle.

Specific activity of DNA was determined by a method described previously (3). Tissue was homogenized in cold ethanol-amine and the precipitate successively extracted with ethanol, ether, 1% perchloric acid at 0° and 0.5% perchloric acid at 80°. The DNA hydrolysed by hot perchloric acid was estimated spectrophotometrically by absorption at 260 m μ and the radioactivity determined in a Packard Tricarb liquid scintillation counter. Specific activities, after correction for body weight, were expressed as percentages of the mean values obtained for the control group of mice in each separate experiment.

Results

When tritiated thymidine was administered to normal mice there was no appreciable change in the specific activity of DNA in the thymus for the first 24 h. Therefore, either cells of the thymus that became labelled remained in that organ for more than 24 h before they—or their progeny—were discharged, or the loss of tritium labelled cells from the thymus was exactly balanced by the gain of labelled cells from other parts of the body. The dip in the thymus curve of Fig. 2 at 16 h may reflect such a process.

Thymic irradiation. Two distinct aspects of the effects of irradiating the thymus were examined. One was concerned with the capacity of the thymus to continue to synthesize DNA following irradiation either of the whole body or of the thymus alone. The second was concerned with determining whether labelled DNA accumulates in the thymus after thymic DNA synthesis has been arrested by irradiation of the gland alone.

Fig. 3 shows the effect of 500 r of γ irradiation on the *total* DNA content of the thymus. Comparatively little change occurred during the first eight hours, but after 24 h there was a very profound drop. Moreover this sequence and the extent of the fall in DNA content was the same whether the whole body was irradiated or only the thymus.

The effect of irradiation on the capacity of the thymus to synthesize DNA is shown in Fig. 4. After whole-body irradiation this capacity fell roughly exponentially to about 1/10 of the normal




Fig. 2. Changes in the total DNA content of the thymus following single dose of 500 X-irradiation, either to the whole animal (shaded circles) or to the thymus alone (open circles). Vertical bars represent one standard error.

value at 7 h and was 4.5 / at 24 h. By contrast, when the thymus alone was irradiated the synthesizing capacity was only reduced to 50 / of the normal at 8 h and at 24 h it was still more than four times as high as after the whole body irradiation.

To examine the second aspect, tritiated thymidine was given three hours after irradiating the thymus alone, at which time the whole body irradiation experiment had shown that the capacity of the thymus to synthesize DNA had been reduced to about 30 %. The animals were killed 3, 5 and 21 h later. The specific activity of the DNA remained almost constant at about 30 / for the whole of this period (Fig. 5). There was, therefore, no evidence for a net accumulation of labelled DNA in the thymus. The profound fall in the *total* DNA of the thymus during this period (Fig. 3) appears to have resulted equally from a loss of labelled as of un-labelled cells.

Thymic chilling The foregoing experiments were concerned with the functions of a thymus damaged by irradiation. To depress thymic activity temporarily and reversibly local chilling of the gland was attempted. Fig. 6 shows that the thymic temperature recorded by a thermocouple buried within the gland drops rapidly on application of the cold finger and rises rapidly upon rewarming. The capacity to synthesize DNA is also restored immediately (Table I). Fig. 7 shows the effects of administering thymidine while the thymus was cooled and then of determining the specific activity of the DNA in the thymus at varying intervals thereafter.




Fig. 4. Rate of DNA synthesis in the thymus following 500 r λ -irradiation, either to the whole animal (shaded circles) or to the thymus alone (open circles). Tritiated thymidine injected i/p at the times shown and animals killed one hour later. Vertical bars represent one standard error.




Fig. 5. Variations in the specific activity of DNA in the thymus over a period of 24 h following single i/p injection of tritiated thymidine given 3 h after 500 r irradiation to the thymus (dotted line and open circles). The full line and shaded circles show how the capacity of the thymus to synthesize DNA falls after irradiation of the whole animal (Fig. 4).

It will be seen that the specific activity was reduced to 23.6% of the value in control animals during the period of cooling, but that the activity had risen to 63% 4 h after re-warming, and to 126%

Table

Effects of local cooling and of rewarming on the rate of DNA synthesis in the thymus

Thymic temperature °C	Thymidine administration	Rate of DNA synthesis % of control
23	During cooling	29.2
22	During cooling	35.4
21	During cooling	33.7
18	During cooling	17.5
12	During cooling	17.3
9	During cooling	16.8
4	Immediately on rewarming	187
4	5 h after rewarming	107




Fig. 6. Effect of applying a 'cold finger' to the chest wall over the thymus on the thymic temperature. Temperatures were recorded by means of a thermocouple buried within the gland.




Fig. 7. Specific activity of DNA in the thymus during cooling, and 4 and 11 h after rewarming. A single i/p injection of tritiated thymidine was given while the gland was cooled.

24 h later. In this study the control animals underwent the same experimental procedure, but cold alcohol was not circulated through the cold finger. Cooling the thymus had no effect on DNA synthesis in the spleen.

Discussion

Since the bulk of injected tritiated thymidine is utilised in the body in less than an hour any increase in the total radioactivity of an organ at longer intervals after injection must result from a transfer of labelled material from other parts of the body. In our studies, such accumulation of labelled DNA was demonstrated in the period following the specific depression of synthesizing activity in the thymus by local chilling. The extent of this accumulation precluded the possibility that reutilisation of labelled DNA breakdown products released at other sites could have made a significant contribution. Even if reutilisation occurred, the contribution by the hypothetical labelled products to the specific activity of the thymic DNA would have been relatively small since such labelled products would have been greatly diluted by corresponding unlabelled products released simultaneously. It is therefore concluded that the increase in specific activity of the thymic DNA observed in this experiment resulted from an influx of cells that had been labelled elsewhere in the body at the time that the thymic activity was depressed.

No net accumulation of labelled DNA was observed following the depression of synthesizing activity in the thymus by local irradiation. However there was appreciable restoration of synthesizing capacity as compared with that following whole-body irradiation, suggesting that after local irradiation cells capable of synthesizing DNA (and presumably therefore, of multiplying) migrated into the thymus from other sites. However an alternative explanation could be that a radio-sensitive humoral feed back mechanism, destroyed by whole body irradiation, stimulates cell proliferation in a depleted thymus.

The finding that labelled DNA accumulates in the thymus after local chilling but not after local irradiation requires some explanation. Chilling does not produce an appreciable change in the total cellular population of the thymus therefore, if the mean specific activity of the DNA of immigrating cells is higher than that of emigrating cells there will be a net increase in total labelled

DNA in the gland. Irradiation, however, produces involution of the gland: this, in turn, would reduce the numbers of cells able to immigrate into the gland as well as curtail their sojourn. Although these restrictions apply equally to pre-labelled as to potentially synthesizing cells, restoration of synthesizing capacity in the gland is, by virtue of the rapid and profound depression of this function (see Fig. 4) a much more sensitive test of cellular influx than is the net increase in specific activity of the total DNA.

An estimate may be made of the rate of cellular influx from the experimental data. In the chilled thymus the specific activity rose from 23.6% to 63% of the normal value in 4 h (Fig. 7) while in the irradiated thymus the rise was from 5% to 50% in 8 h (Fig. 4). Whether the subsequent release of labelled cells is sequential or random, both sets of data indicate an average period of sojourn within the thymus for these cells of roughly 14 h. The results further indicate that the cells that migrate into an irradiated thymus are capable of proliferating within it.

It follows from these conclusions that estimations of generation times for thymic lymphocytes, calculated from autoradiographic data, are invalid. If a substantial proportion of the thymocyte population is composed of cells in transit, estimates based on grain count analysis may reflect largely the generation times of precursor (bone marrow?) cells. Similarly estimates based on labelling indices (i. e., on changes in the proportion of cells labelled, with time) may reflect merely the turnover rate of migrant cells in the thymus. The similarity in generation times of thymic and of marrow lymphocytes reported by CAFFREY *et al.* (2) supports this contention.

Acknowledgments. This work was carried out as part of a study of 'secondary disease' initiated by Prof. D. W. SARRIS, Director of the Radiotherapy Department. We are very grateful to Miss E. M. HILLIER for clerical assistance.

Summary

The specific activity of thymic DNA has been determined in mice given a single intraperitoneal dose of tritiated thymidine following whole-body irradiation, thymic irradiation and thymic chilling. In normal mice the specific activity of the DNA remained unchanged for 18 h following injection. After 500 r whole-body irradiation the DNA synthesizing capacity of the thymus fell more steeply than after irradiation of the thymus alone. The specific activity of the DNA labelled while the thymus was chilled by means of a 'cold finger' was reduced to 23.6% of the normal but rose progressively on rewarming. These results were explained on the basis of an influx into the thymus of cells originating elsewhere in the body.

Institut de Clinique Médicale de l'Université de Pavie (Dir. Prof. P. LEROUX) et
Institut de Radiologie Médicale de l'Université de Bologne (Dir. Prof. V. BOLLINI)

Morphogénèse des micronoyaux supplémentaires (pseudo-corps de Jolly) dans les cellules érythro- polétiques irradiées

Recherches réalisées au laboratoire de morphologie en contraste de phase

E. G. RONDANELLI, A. TRENTA, E. MAOLIVULO, V. VAUGHN ET
G. GERMA

Assez souvent on observe dans les tissus hémostatiques, dans certaines conditions pathologiques, de cellules érythropoïétiques pourvues d'un ou plusieurs micronoyaux supplémentaires, en plus des noyaux principaux, ou de très petits corps de chromatine dispersés dans le cytoplasme (1). Il s'agit de véritables micronoyaux satellites, dont un cas particulier est celui des érythroblastes avec «pseudo-corps de Jolly» qui, comme le spécifie le préfixe «pseudo» ne doivent pas être confondus avec les vrais «corps de Jolly» (2). Tandis que ces derniers (3) sont des restes nucléaires correspondant à des phénomènes de dégénérescence du noyau à la fin de la maturation érythroblastique, les micronoyaux satellites des érythroblastes, ou «pseudo-corps de Jolly» possèdent une chromatine aux mêmes caractères de celle des noyaux principaux et peuvent se rencontrer à l'intérieur de cellules qui souvent sont encore très éloignées de ce stade de maturation érythroblastique où normalement on observe les vrais corps de Jolly. La morphogénèse des micronoyaux satellites n'ayant pas encore été complètement éclaircie, nous rapportons nos observations en contraste de phase sur la formation de «pseudo-corps de Jolly» dans des cellules érythropoïétiques irradiées. Ces résultats nous paraissent de la plus grande importance, vu le fait que les «pseudo-corps de Jolly» (micronoyaux satellites érythroblastiques) se rencontrent le plus souvent dans des érythropathies comme l'anémie Biermérenne (4) l'érythropathie benzénique et la maladie érythémique.




Fig. 1 Formation d'un micronoyau satellite à partir d'un chromosome (indiqué par la flèche) arrêlé au dehors d'une plaque métaphasique arrêtée par l'irradiation. 1-6 Plaque équestoriale avec quelques chromosomes aberrants. 7 = Conglutination de la plaque équestoriale. Le chromosome aberrant indiqué par la flèche subit le même processus de homogénéisation de la chromatine. 10-12 Etapes de la reconstruction d'un noyau géant en d'un micronoyau supplémentaire.




Fig. 2 Formation d'un micronoyau satellite à partir d'un groupement de chromosomes isolé au dehors d'une plaque métaphasique arrêtée par l'irradiation. 1-5 Plaque équatoriale. 6 Isolation d'un petit groupement de chromosomes. 7-9 Conglutination des chromosomes, pendant qu'une ébauche de sillon de division cytoplasmique se parvient pas à séparer les deux groupements de chromosomes en deux cellules-filles. 10-12 Réabsorption du sillon cytoplasmique et reconstruction d'un noyau géant et d'un micronoyau supplémentaire.




Fig. 3. Etapes de la formation d'une cellule géante à plusieurs micronoyaux supplémentaires (continue avec la fig. 4) 1-5 Prophase, 6-11 Métaphase, avec bicentrisme mé-
taphasique (pseudo-anaphase) à niveau des No. 9-11




Fig. 4. Mêmes mitoses de la fig. 3. 1 et 2 Bicentrique métaphasique avec chromosomes aberrants. 3 et 4 Dérangement complet de la figure métaphasique. 5 et 6 Reconstruction d'un noyau annulaire et de trois micronoyaux supplémentaires (indiqués par des flèches)

Matériel et Méthodes

On a observé en contraste de phase et on a effectué des prises cinématographiques de mitoses d'érythroblastes basophiles et polychromatophiles du *Tritus Melpis vulgaris* L., cultivés *in vitro* et irradiés avec 111^{25} . Pour l'obtention des cellules érythropoïétiques, la préparation des cultures, les données de l'irradiation et la technique de l'observation en contraste de phase et des prises cinématographiques, nous vous renvoyons au précédent travail de cytoradiobiologie (9).

Résultats

Nos observations montrent que les micronoyaux satellites et les «pseudo-corps de Jolly» peuvent se former par des troubles mitotiques qui conditionnent l'isolement dans le cytoplasme de chromosomes, ou petits groupements de chromosomes aberrants qui parallèlement à ce qui se vérifie dans le reste du matériel chromosomique, mais à une échelle de dimensions mineures, s'enveloppent d'une membrane nucléaire, se décondensent en chromatine aux caractères interphasiques, et reconstruisent des véritables noyaux en miniature. On peut observer deux principales modalités morphogénétiques de micronoyaux supplémentaires.

a) Une caryocinèse arrêtée en métaphase, soit avec isolement dans le cytoplasme au dehors de la plaque équatoriale d'un (fig. 1) ou plusieurs chromosomes réunis en petits groupements, avec leurs centromères rapprochés (fig. 2) soit avec dispersion presque complète des chromosomes dans les cytoplasmes (fig. 3 et 4). Ces chromosomes subissent ensuite des phénomènes de conglutination et de décondensation, semblables à ceux que l'on observe normalement en ana-télophase, mais se différenciant de ceux-ci pour le fait qu'ils se produisent dans des chromosomes aux caractères métaphasiques. Par conséquence des micronoyaux indépendants du ou des noyaux principaux vont se former à partir des chromosomes métaphasiques.

b) Une caryocinèse avec troubles de l'anaphase qui conduisent soit un retard (ou un manque complet) de la migration d'un chromosome ou de petits groupements de chromosomes, qui restent exclus du patrimoine génétique des noyaux se formant à partir des chromosomes ayant accompli normalement leur migration, soit des phénomènes de pluripolarité avec forte asymétrie de la migration chromosomique (fig. 5, 6 et 7). Ces chromosomes aberrants reconstruisent des micronoyaux satellites, indépendants du noyau principal (ou des noyaux principaux, si l'anaphase était pluripolaire). La catéchromasie chromosomique, différemment de ce qui arrivait dans la précédente modalité, se produit ici sur des chromosomes aux caractères anaphasiques.

c) Une modalité intermédiaire aux deux précédentes, pour le fait que les chromosomes aberrants ne sont ni tous métaphasiques, ni tous anaphasiques, les micronoyaux pouvant être formés par un




Fig. 5. Formation de micronoyaux par pluri-polarité anaphasique avec asymétrie de la distribution des chromosomes. 1-3 Anaphase tripolaire asymétrique. 4-6 Formation de sillons cytoplasmiques qui néanmoins ne parviennent pas à séparer les trois cellules-filles. Les trois noyaux asymétriques, dont celui en haut est un vrai micronoyau, restent dans la même cellule.




Fig. 6. Formation de micronoyaux par pluri-polarité anaphasique avec asymétrie de la distribution des chromosomes (continue avec la fig. 7). On observe la migration asymétrique des chromosomes-fils dans trois étoiles.

mélange de chromosomes des deux types (fig. 8). Ces chromosomes étaient restés isolés probablement dans différents moments de la mitose atypique ou leur migration (dans le cas des chromosomes métaphaniques) avait été empêchée par des phénomènes inhibant la séparation des centromères-fils.




Fig 7 Même mitose de la fig 6. 1-4 Fusion de deux étoiles anaphasiques, congutination réciproque des chromosomes. 5-6 Une ébauche de division cytoplasmique ne s'approfondit pas dans la cellule. Un noyau géant percé au centre par persistance d'un résidu des champs polaires centraux de l'étoile anaphasique, et un micronoyau se sont formés.

Discussion

La formation de micronoyaux, ou de «caryomères» en différents types cellulaires avait été décrite par TISCHLER (11) WILSON (18) et BEANS (1). Ce phénomène avait été rapporté après action de




Fig. 8. Formation de plusieurs micronoyaux par chromosomes fils et chromosomes non divisés dispersés dans le cytoplasme ou réunis en groupements. Les flèches et dans la photo 2 indiquent deux couples de chromosomes-fils aberrants. 3-6 La condensation qui tient sous les chromosomes réunis en groupements que les chromosomes dispersés porte à la formation de deux noyaux plus 3 micronoyaux, ces derniers et les chromosomes originaux étant indiqués par les mêmes flèches.

l'éther (13) des rayons γ (8) et de la podophyllotoxine (2) SCHWARZ (10) avait décrit dans les cellules érythropoïétiques deux types de micronoyaux. L'un par inhibition de l'activité du fuseau en méta

phase avec disposition des micronoyaux en couronne, et l'autre, par inhibition du fuseau avant la métaphase, avec la dispersion complète dans le cytoplasme des micronoyaux.

DISCOMBZ (4) et BESSIS (1) avaient soutenu l'origine des micronoyaux érythroblastiques («pseudo-corps de Jolly») par troubles de la mitose. DI GUGLIELMO (3) a magistralement décrit les «noyaux secondaires» dans les érythroblastes de la maladie érythrémique dont il a mis en évidence les différences vis-à-vis des vrais corps de Jolly: les premiers résultant, selon lui, de chromosomes aberrants et isolés, contenus le plus souvent dans des cellules immatures et donc encore capable de mitose. FLEJDER *et al* (5) ont soutenu les mêmes concepts, cependant sans les prouver pour l'origine des micronoyaux qu'ils avaient observé dans les cellules hémopoïétiques de sujets irradiés accidentellement. En outre ces micronoyaux étaient capables d'incorporer l' ^3H -thymidine: ce qui prouve la capacité de leur ADN de se redoubler. Nos observations en contraste de phase montrent définitivement que les petits noyaux supplémentaires que l'on observe dans les cellules érythropoïétiques immatures, et qui ont été définis par les noms de «pseudo-corps de Jolly», «faux corps de Jolly», caryomères, «noyaux secondaires» etc. résultent de chromosomes (ou fragments de chromosomes) isolés au dehors des groupements principaux en métaphase ou en anaphase dont ils ne suivent plus la dynamique mitotique. Cela s'accorde avec ce que DI GUGLIELMO (3) avait entrevu, bien que des phénomènes atypiques de fragmentation de noyaux immatures ne puissent pas être exclus, quoique nous ne les avons jamais observés dans notre matériel irradié.

Pour ce qui concerne la pathogénèse de la formation des micronoyaux satellites, il résulte de nos observations dans les cellules érythropoïétiques irradiées que: ou un procès de simple fragmentation du noyau interphasique puisse être exclus, des mécanismes mitotiques bien définis doivent être envisagés. Le premier est un pluricentrisme métaphasique ou une pluri polarité anaphasique avec forte asymétrie de la distribution chromosomique, probablement par une lésion des procès de redoublement des centres polaires. Mais cela ne paraît pas très acceptable si on considère que souvent le dérangement mitotique a été observé immédiatement après l'irradiation: ce qui semble indiquer mieux une lésion des fibres (soit continues que chromosomiques) du fuseau, ou de la jonction cen-

tromérique des chromosomes au fuseau même. La lésion du cynthochore peut-elle seule expliquer la séparation d'un chromosome isolé d'une plaque équatoriale d'autre part apparemment normale tandis qu'une destruction partielle des fibres du fuseau peut cependant signifier qu'un certain degré de polarisation est conservé, et expliquer l'isolement de petits groupements de chromosomes avec leur centromères accotés. Pour une destruction totale du fuseau, avec perte de la polarisation on a la dispersion complète des chromosomes dans le cytoplasme. Dans ce cas l'attraction mutuelle des cynthochores joue un rôle assez relevant en maintenant un certain nombre de chromosomes réuni en petits groupements formant des micronoyaux. Le dernier mécanisme est enfin la fragmentation chromosomique, avec impossibilité des fragments détachés de participer à la formation des noyaux principaux. Cela expliquerait la formation de ces très petits corps chromatiniens isolés dans le cytoplasme, pour lesquels le terme de micronoyaux pour le vrai ne paraît pas complètement applicable, bien qu'ils constituent les plus petits membres de la famille des «pseudo-corps de Jolly».

Il nous reste à discuter la destination des micronoyaux satellites dans les cellules irradiées. Deux possibilités peuvent être envisagées. 1. Pour des lésions graves provoquées par l'irradiation, elles sont destinées à ne pas se reproduire, ou à donner lieu à des mitoses abortives ou à dégénérer. Les micronoyaux satellites pourraient alors être soit expulsés, ou être lésés, ou simplement rester comme tels. 2. Ces cellules pourraient être encore capables de se diviser. Dans ce cas le problème se pose si les chromosomes des micronoyaux participent à la mitose. Il faut aussi tenir compte du fait que les cellules contenant les micronoyaux sont généralement polyploïdes, ce qui entraînerait des troubles particuliers de la distribution chromosomique dans les cellules filles, et éventuellement la perpétuation de souches cellulaires dysploïdes.

La vitesse de disparition des micronoyaux satellites dans les tissus irradiés a été employée par HORNSEY (6) pour calculer en admettant que les cellules avec micronoyaux satellites puissent entrer en mitose régulièrement, le temps de génération de ces tissus. Il résulte clairement de notre discussion sur la destination des micronoyaux supplémentaires que de telles déterminations chronologiques sont d'une valeur très limitée. Dans nos observations prolongées, nous n'avons jamais observé les cellules avec micronoyaux

dagegen höher wenn auch nicht annähernd so hoch wie zu Beginn der Kalt und Warmexposition. Die Mittelwerte der Kalt und Warmfrösche unterscheiden sich bei 1 / Irrtumswahrscheinlichkeit signifikant voneinander

$$t = 3.16 \quad t \frac{10}{p} = \frac{28}{15} = 2.76$$

Geschlechtsunterschiede waren auch hier nicht nachweisbar

Das Differentialblutbild entsprach in etwa den Angaben über die heimischen Anuren (18). Auffällig war das Auftreten von stabkernigen Neutrophilen bei denjenigen Tieren, die einer niedrigen Wassertemperatur ausgesetzt waren. Es fanden sich zwar im Mittel nur 0.5 / Stabkernige, jedoch bedeutet dies schon eine gewisse Linkerverschiebung, da bei den übrigen Tieren gar keine Stabkernigen gefunden wurden.

Diskussion

Die durchschnittliche Zahl der Leukozytenkernanhänge von *Xenopus laevis* die bei einer mittleren Temperatur von 20 °C gehalten wurden entspricht mit 3.0 ± 0.5 auf 200 neutrophile Leukozyten etwa dem Wert der heimischen Anuren (3.5 ± 0.2) mit Ausnahme derjenigen Werte, die im Frühjahr gewonnen wurden. Eine Unterscheidung der Geschlechter nach der Zahl der Kernanhänge bei neutrophilen Granulozyten ist nach unseren Befunden nicht möglich, da eine gleich große Häufigkeit bei den Geschlechtern vorhanden ist.

Demgegenüber glaubt SCHIFFNER (19) auf Grund der von ihm gefundenen unterschiedlichen Häufigkeit von Kernanhängen bei *Rana esculenta* (im Mittel 18.75 bei Weibchen 5.23 Kernanhänge bei Männchen auf 200 segmentierte Leukozyten) eine Geschlechtsdifferenzierung vornehmen zu können. Derartig hohe Werte wie sie von SCHIFFNER für Weibchen angegeben werden wurden von uns vereinzelt bei den heimischen Froscharten nur während des Frühlahrs, dann jedoch bei beiden Geschlechtern beobachtet.

Schon früher wies der eine von uns (3) darauf hin, daß nach WITKCHI (23-24) und GALGANO (7) bei *Rana temporaria* und *Rana esculenta* die Geschlechtschromosomen etwa gleich groß und morphologisch wenig voneinander unterscheidbar sind.

BARR (8) vertritt die Hypothese daß die Unterschiede hinsichtlich der Häufigkeit von Kernanhängen bei den Geschlechtern durch die unterschiedliche Größe der Geschlechtschromosomen bedingt sind. Ausnahmen – also etwa gleiche Häufigkeit – müssen

dementsprechend bei denjenigen Tieren auftreten, die durch die annähernd gleiche Größe der Geschlechtschromosomen ausgezeichnet sind. Dies ist nun tatsächlich für die heimischen Froscharten der Fall. Die Befunde von LÖERS UND LÖERS (12) an Mäusen Ratten und Meerschweinchen, die REYSECH *et al.* (18) an Mäusen und Meerschweinchen bestätigten, sprechen ebenfalls für die von BARR vertretene These. Diese Tierarten weisen ebenfalls keine Größenunterschiede der Geschlechtschromosomen auf. Die genannten Autoren stellten bei ihnen etwa die gleiche Häufigkeit von Kernanhängen sowohl beim weiblichen als auch beim männlichen Geschlecht fest.

Bei *Xenopus laevis* liegen die Verhältnisse gegenüber den heimischen Anuren etwas anders. Einmal sind nach CHANG UND WITTSCH (5) bei dieser Froschart die Weibchen heterozygot. Sie besitzen die Konstellation ZW wogegen die Männchen homozygot (ZZ) sind. Die gleichen Verhältnisse sind beispielsweise auch am Huhn gefunden worden. Andererseits stellten WEILER UND ORNO (22) neben den heterozygoten Verhältnissen beim weiblichen Krallenfrosch erhebliche Größenunterschiede zwischen den Geschlechtschromosomen fest. Nach neuen Ansichten (15 21) soll sich bei den Säugetieren nur das eine heteropyknotische Chromosom (hier ein X-Chromosom) in den Kernanhängen manifestieren und das Geschlechtschromatin bilden. Wenn dies auch bei den niederen Tierarten der Fall sein sollte, müßte beim männlichen Krallenfrosch das eine Z-Chromosom und beim Weibchen ebenfalls das entsprechende Z-Chromosom in den Kernanhängen festgelegt sein, um die gleiche Zahl von Kernanhängen bei beiden Geschlechtern erklären zu können. Das würde gleichzeitig bedeuten, daß die Ausbildung der Kernanhänge nicht grundsätzlich an die weiblichen Geschlechtschromosomen gebunden sein könnte. Damit stimmen die Befunde von ORNO *et al.* (14) überein, die nachweisen konnten, daß sowohl beim Hahn als auch beim Huhn ein Z (oder X)-Chromosom vom Vätertier stammt. Geschlechtsdifferenzen an den Leukozytenkernen sind bisher an Hühnern ebenfalls nicht gefunden worden (20 6, 1).

Die zunehmenden Temperaturen im Frühjahr lassen bekanntlich bei poikilothermen Organismen auch den Stoffwechsel ansteigen. So lag es nahe, die erhöhten Kernanhangszahlen beim Frosch im Frühjahr damit in Zusammenhang zu bringen, umso mehr als nach BURMEISTER (3) in verschiedenen Jahren der Beginn

dagegen höher wenn auch nicht annähernd so hoch wie zu Beginn der Kalt und Warmexposition. Die Mittelwerte der Kalt und Warmfrösche unterscheiden sich bei 1 / Irrtumswahrscheinlichkeit signifikant voneinander

$$t = 3.16 \quad t \frac{10}{p} = \frac{38}{11} = 2.76$$

Geschlechtsunterschiede waren auch hier nicht nachweisbar

Das Differentialblutbild entsprach in etwa den Angaben über die heimischen Anuren (18). Auffällig war das Auftreten von stabkernigen Neutrophilen bei denjenigen Tieren die einer niedrigen Wassertemperatur ausgesetzt waren. Es fanden sich zwar im Mittel nur 0,5 / Stabkernige, jedoch bedeutet dies schon eine gewisse Linksverschiebung da bei den übrigen Tieren gar keine Stabkernigen gefunden wurden.

Diskussion

Die durchschnittliche Zahl der Leukozytenkernanhänge von *Temnodactylus*, die bei einer mittleren Temperatur von 20 °C gehalten wurden, entspricht mit 3.0 ± 0.5 auf 200 neutrophile Leukozyten etwa dem Wert der heimischen Anuren (3.5 ± 0.2) mit Ausnahme derjenigen Werte, die im Frühjahr gewonnen wurden. Eine Unterscheidung der Geschlechter nach der Zahl der Kernanhänge bei neutrophilen Granulozyten ist nach unseren Befunden nicht möglich da eine gleich große Häufigkeit bei den Geschlechtern vorhanden ist.

Demgegenüber glaubt SCHIFFNER (19) auf Grund der von ihm gefundenen unterschiedlichen Häufigkeit von Kernanhangen bei *Rana esculenta* (im Mittel 18.75 bei Weibchen, 5.23 Kernanhänge bei Männchen auf 200 segmentierte Leukozyten) eine Geschlechtsdifferenzierung vornehmen zu können. Derartig hohe Werte wie sie von SCHIFFNER für Weibchen angegeben werden wurden von uns vereinzelt bei den heimischen Froscharten nur während des Frühjahrs, dann jedoch bei beiden Geschlechtern beobachtet.

Schon früher wies der eine von uns (3) darauf hin, daß nach WITSCHI (23-24) und GALGANO (7) bei *Rana temporaria* und *Rana esculenta* die Geschlechtschromosomen etwa gleich groß und morphologisch wenig voneinander unterscheidbar sind.

BARR (8) vertritt die Hypothese daß die Unterschiede hinsichtlich der Häufigkeit von Kernanhangen bei den Geschlechtern durch die unterschiedliche Größe der Geschlechtschromosomen bedingt und Ausnahmen – also etwa gleiche Häufigkeit – müssen

Zusammenfassung

Leukocytenkernanhänge konnten bei *Xenopus laevis* mit durchschnittlich $3,0 \pm 0,5$ auf 200 Zellen nachgewiesen werden. Ein Unterschied zwischen den Geschlechtern war nicht zu ermitteln. Langfristige Temperatursenkung (Sedw. Abkühlung) verringerte die Anzahl der Kernanhänge.

Summary

Nuclear appendages were found in an average of 3.0 ± 0.5 per 200 leukocytes in *Xenopus laevis*. No difference between the two sexes could be distinguished. Prolonged reduction of temperature diminished the number of these nuclear appendages.

Résumé

Des appendices nucléaires ont pu être trouvés en moyenne dans $3,0 \pm 0,5$ sur 200 leucocytes. Il y a pas de différence entre les deux sexes. Un abaissement prolongé de la température (diminution du métabolisme) diminue le nombre des appendices nucléaires.

Literatur

1. AMLEY, D. J. B. AND THOM, E. A. zitiert nach (13) Anat. Rec. 73, 115 (1959).
2. BRIDGES, D. K. AND KOPFERMANN, H. S. Sex differentiation by leukocyte morphology J. clin. Endocrin. 16, 1163-1179 (1956).
3. BORNHUTER, J. Über Leukocytenkernanhänge beim Frosch und ihre Beziehung zu Geschlecht und Jahreszeit. Proc. 8th Congress Europ. Soc. Haematology Wien 1961 Artikel Nr. 36 (Karger Basel / New York 1962).
4. CALLMEIER, R. Die gynologische Geschlechtsbestimmung. Diss. Rostock (1959).
5. CHANG, C. H. AND WITCHEL, E. Breeding of sex-reversed males of *Xenopus laevis* Daudin. Proc. Soc. exp. Biol., NY 49, 150-152 (1955).
6. DAVIDSON, W. M. AND SMITH, D. R. zitiert nach (15) Postgrad. med. J. 32, 578 (1959).
7. GALGANO, M. Evoluzione degli spermatozoi di I ordine: cromosomi pseudosessuali in alcuni specie di Anfibi. Arch. ital. Anat. Embriol. 32, 171-200 (1954).
8. GRAHAM, M. A. AND BARR, M. L. A sex difference in the morphology of metabolic nuclei in somatic cells of the cat. Anat. Rec. 112, 709 (1952).
9. HEINE, H. A. Zellkernmorphologische Geschlechtererkennung bei Säugetier und Mensch. Dtsch. med. Woch. 82, 1986-1991 (1957).
10. KORD, J. L. AND LICHENAU, H. Incidence of Sex Chromatin in *Gallus domesticus*. Science 130, 43-44 (1959).
11. KREYGE, W. UND DRELMANN, W. Über das Verhalten geschlechtsspezifischer Kernanhänge nach Kastration. Klin. Woch. 35, 1047-1048 (1957).
12. LÜTKE, T. UND LÜTKE, H. Vergleichende Untersuchungen zur Geschlechtsdiagnose aus Neutrophilen Leukocyten bei einigen Laboratorienmammern. Zool. Zbl. 160, 248-260 (1958).
13. MÜLLER, D. Zur Entwicklung der geschlechtsspezifischen sogenannten Drüsenstäcke an segmentkernigen Leukocyten. Anat. Woch. 14, 260-262 (1959).

14. ORDO, S. W., KAPLAN, W. D. AND KESNOTA, R.: zitiert nach (15) *Exp. Cell. Res.* 19: 180 (1960)
15. OVERZIER, C.: Über die Bedeutung und Beweiskraft der Kerngeschlechtsdiagnostik. *Klin. Wochschr.* 39: 557-563 (1961)
16. PRIETZ, G.: Untersuchungen zur Frage der Beeinflussung von sekundären Geschlechtsmerkmalen durch androgen wirksame Steroide. *Zbl. Gynäk.* 42: 220-226 (1960)
17. REYNOLDS, K. J.; BRUCHNER, G. UND SCHULZ, F. H.: Über morphologische Geschlechtsunterschiede an den Kernen von neutrophilen Granulozyten bei Tieren. *Dtsch. Gesundh. Wes.* 15: 240-243 (1960)
18. SCHÖNBERG, S.: Die Blutmorphologie der Laboratorienstiere (J. A. Barth-Verlag, Leipzig 1954)
19. SCHÖNBERG, J.: Die Zuverlässigkeit des Galls-Mainard-Testes. *Dtsch. Humboldt-Univ. Berlin* N. 2852 (1963).
20. SMITH, E. R. AND DAVIDSON, W. M.: zitiert nach (15) *Communication Path. Soc. Brit. and Irland* (1954).
21. SORVAL, A.: Chromosomes and sex chromatin in normal and anomalous sexual development. *Physiol. Rev.* 43: 306-356 (1963)
22. WEILER, C. AND ORDO, S.: Cytological confirmation of female heterogamety in the african waterfrog. *Oytogenetics* 1: 217-223 (1962)
23. WITTCHE, E.: Studien über die Geschlechtsbestimmung bei Fröschen. *Arch. mikr. Anat.* 86: 1-50 (1915)
24. WITTCHE, E.: Die Entwicklung der Keimzelle der *Rana temporaria*. *Z. Zellforsch.* 1: 523-561 (1924)

Address der Autoren: Prof. Dr. A. Beckmann und Dr. J. Bummelter: Physiologisches Institut der Universität, Garbenerstraße 9, Berlin (DDR).

Libri

Alexander S. Wiener with Section by Minoru Shaprio. *Advances in Blood Grouping*. II. Grune and Stratton, New York 1963. 434 p. Price: \$ 12.50.

With the preceding two volumes ('Rh-Hr Blood Types' 763 pages, 1954 and *Advances in Blood Grouping* 549 pages, 1961), Dr Wiener has selected for republication total of 189 of his over 500 published communications. The titles of the present and preceding volumes are, to this reviewer misleading because both fail to review advances in blood grouping or include, except for three reports by Serrano any serious contributions of others. These volumes, however are of value to anyone who enjoys reading Dr. Wiener's contributions or wishes to refer to them at frequent intervals.

The latest volume contains, in addition to reprints, 12 page 'Preface and Introduction' that attempts to convince the reader of the importance of Wiener's blood group terminology, one page 'Closing Remarks' repeating the same plea, and five pages of 1960-1965 publication references. There is also an 'Appendix' subtitled, LANDSTEINER and WINKLER 'Discovery of the Rh Factor' Written after testimonial dinner and scientific meeting in honor of Dr PHILIP LEVINE, this appendix claims the priority right of LANDSTEINER and WINKLER for the discovery of Rh, but gives credit to LEVINE for the discovery of the pathogenesis of erythroblastosis and the role of Rh in this process, and for first describing 'a', 'k' and 'TJ'. LIV the actual pectidicity of heterologous anti-rhesus agglutinins, was omitted, even though many persons consider this most perceptive LEVINE observation.

Dr Wiener's observations of facts have always been sound. In contrast, his opinions, even of himself, are sometimes unacceptable. For example, Dr Wiener states (p. 426) that he always consults sources and that his publications, therefore, 'are singularly free of misquotations and myths'. However ~~over human est.~~ On p. 443 of this volume WINKLER cites the first page of the 1941 report on erythroblastosis by LEVINE, BERNHARD, KATZ and VOGL as evidence of LEVINE's agreement to the priority for discovery of Rh by LANDSTEINER and WINKLER. On the second page, however is the evidence that the 1939 LEVINE and STERN case had anti-Rh in her serum. By not turning the page Dr WINKLER felt free, in this appendix, to suggest that anti-Au rather than anti-Rh, might have been involved in the LEVINE-STERN case. The truth of the matter is that this case was Rh-negative and had Rh antibodies. But the cases in 1936 of CULBERTSON and RATCLIFF died in this appendix, were also Rh-negative when they were tested later by LEVINE (personal communication) while agglutination of human cells by rabbit anti-rhesus serum was reported in 1933 by LEON BERNHARDSON (J. Immunol. 25: 33).

OSLER said, 'In science the credit goes to the man who convinces the world, not to the man to whom the idea first occurs'. Credit for human Rh (Rh₀, D or Rh1) polymorphism belongs to LANDSTEINER and WINKLER, who convinced the world with reliable agglutinating reagent, just as COSSON did for antiglobulin reactions that had been discovered many years previously by MOURMANN. R. E. ROSENFIELD New York

Paul Kallit and B. H. Winkmann: *Progress in Allergy*. Fortschritte der Allergielehre, Vol. 9. S. Karger AG Basel/New York 1963, VIII + 308 S., 45 Abb., 9 Tab. Preis sF ./DM 63.

Das erste Übersichtsarbeits von J. L. GOWANS und D. D. McGRILLOK über The

Dabei wird besonders eingehend das aktuelle Problem der Transplantationsreaktion erörtert. Unter kritischer Berücksichtigung der Literatur geben die Autoren eine klare Darstellung der doch recht komplizierten Materie, da sie eindeutig bewiesene Tatsachen von den noch mit Fragezeichen versehenen Erkenntnissen deutlich abgrenzen.

Der zweite Beitrag von M. KAMDAU über «The Analysis of the Antigenic Structure of Protein Molecules» ist deshalb wertvoll, weil besonders neuere Methoden, wie Gel-Diffusion und vor allem die von LARSEN eingeführte Methode des tiefen enzymatischen Abbaus eingehende Berücksichtigung finden.

K. E. HELLSTRÖM und G. MÖLLER behandeln im 3. Artikel über «Immunological and Immunogenetic Aspects of Tumor Transplantation» experimentelle Untersuchungen, welche hauptsächlich an Mäusen durchgeführt wurden. Das sehr vielschichtige Thema der immunologischen und immunogenetischen Probleme der Tumortransplantation wird aus der Sicht des Spezialisten zur Diskussion gestellt. Wie die Autoren selbst betonen, kann es sich nicht um eine Gesamtübersicht über die heute bestehende Literatur handeln.

Im letzten Kapitel über «Immunosuppressive Drugs» von R. S. SCHWARTZ wird die Anwendung von Antimetaboliten und Alkylierungsmittel besprochen, welche in die normale immunologische Reaktion wie auch in die nicht erwünschte Immunreaktion eingreifen können. Die Übersichtsarbeit enthält sehr viele Literaturangaben und ist durch die kritische Stellungnahme des Autors in bezug auf beobachtete experimentelle Wirkung und klinische Anwendungsmöglichkeit der betreffenden Medikamente gekennzeichnet.

Der vorliegende 9. Band der *Progress in Allergy* gibt einen Überblick über einige aktuelle Probleme der heutigen immunologischen Forschung und enthält eine Fülle von Literaturhinweisen, welche zur Einarbeitung in die verschiedenen Themen sehr nützlich sind.

Dr. M. SCHWARZ-SPECK, Zürich

Normierung in der Hämatologie

Mitteilungen der Hämmeterprüfstelle

Bekanntlich ist im Juli 1964 der Normenentwurf DIN 56931 Blatt 1 «Bestimmung des Gehaltes an Hämoglobin im Blut, Begriff, Maßeinheiten, Verfahren» erschienen. Es war im Rahmen des Deutschen Normenausschusses der erste Versuch, eine klinische Laboratoriumsmethode zu normen. Erfreulicherweise hat dieser Entwurf im In- und Ausland ein starkes und sehr positives Echo hervorgerufen, wobei in begrüßenswerter Weise auch kritische Verbesserungsvorschläge zu den einzelnen Punkten vorgebracht worden sind. Im März und Juni 1965 sind weitere Blätter dieser Norm als Entwurf erschienen.

Der Entwurf DIN 56931, Blatt 2, behandelt: Bestimmung des Hämoglobingehaltes im Blut, Anforderungen an die Reagenzien für die Hämoglobinstimmung nach der Hämoglobinzyanidmethode. Die einzelnen Punkte dieses Blattes führen den Titel: 1. Zweck; 2. Begriff; 3. Anforderungen: 3.1 Reaktionskinetische Eigenschaften; 3.2 Gehalt an Kaliumferrizyanid; 3.3 Toxizität; 3.4 Haltbarkeit; 3.5 Konzentrate; 3.6 Etikettierung und Verpackung; 4. Literatur. Anschließend folgen ausführliche Erläuterungen.

Der Entwurf DIN 56931, Blatt 3, behandelt: Bestimmung des Hämoglobingehaltes im Blut, Anforderungen an die Standardlösungen für die Hämoglobinstimmung nach der Hämoglobinzyanidmethode. Die einzelnen Punkte dieses Blattes sind betitelt: 1. Zweck; 2. Begriff; 3. Anforderungen: 3.1 Zusammensetzung; 3.2 Konzentration; 3.3 Typische Farbkurven; 3.4 Bakteriologische Anforderungen; 3.5 Haltbarkeit; 3.6 Abfüllen in Ampullen; 3.7 Etikettierung und Verpackung; 4. Literatur. Auch hier folgen Erläuterungen.

Der Entwurf DIN 56931, Blatt 4 behandelt: Bestimmung des Hämoglobingehaltes im Blut, Prüfung der Reaktionslösungen und Standardlösungen für die Hämoglobinstimmung nach der Hämoglobinzyanidmethode. Die einzelnen Abschnitte haben den Titel: 1. Zweck; 2. Begriff; 2.1 Hersteller; 2.2 Prüfer; 3. Anforderungen an die Prüfer und an die Prüflaboratorien; 4. Prüfverfahren für die Reaktionslösungen: 4.1 Prüfung der Hämolysebarkeit der Reaktionslösungen (diese und die folgenden Prüfungen sind jeweils aufgeteilt in «Prinzip» «benötigte Geräte» und «Durchführung»); 4.2 Prüfung der Reaktionszeit; 4.3 Prüfung der Umwandlung des Hämoglobins in Hämoglobinzyanid; 4.4 Prüfung der spektralen Eigenschaften der Reaktionslösung; 4.5 Prüfung des Ferrizyangehaltes der Reaktionslösung; 4.6 Prüfung des Zyanid-Ionen-Gehaltes der Reaktionslösung; 4.7 Prüfung des pH-Wertes der Reaktionslösung; 4.8 Prüfung der Toxizität der Reaktionslösung; 4.9 Prüfung der Haltbarkeit; 4.10 Prüfung von Konzentraten; 4.11 Prüfung der Verpackung und Etikettierung; 5. Prüfverfahren für Standardlösungen: 5.1 Prüfung der Standardlösung bei der Herstellung; 5.2 Prüfung der spektralen Eigenschaften der Standardlösung; 5.3 Auswertung der Meßergebnisse; 5.4 Prüfung der bakteriologischen Eigenschaften der Standardlösung; 5.5 Prüfung der Haltbarkeit; 5.6 Prüfung der Abfüllung in die Ampullen; 5.7 Prüfung der Etikettierung und Verpackung; 6. Literatur. Wie bei den vorhergehenden, folgt auch hier eine ausführliche Erläuterung (mit durchgerechneten Beispielen).

Vor wenigen Monaten ist vom Deutschen Normenausschuß ein Arbeitsausschuß «Laboratoriumsnormen» und im Rahmen dessen ein Unterausschuß Hämatologie gegründet worden. In diesem Unterausschuß sind Wissenschaftler (Mediziner, Che-

runder Physiker) wie auch Olegiers der herstellenden Industrie vertreten. Der Unterausschuß hat zur Zeit 16 Mitglieder. Im kommenden Herbst wird dieser Unterausschuß an einer Sitzung die bis zu diesem Zeitpunkt eingetroffenen Einsprüche zu den Normenentwürfen DIN 38931 Blatt 1-4 eingehend besprechen und die endgültige Norm verabschieden.

In der nächsten Zeit beabsichtigt der Unterausschuß «Hämatologie» die Normung der Blutkörperchenzählung und der Hämatokrit-Bestimmung in Angriff zu nehmen. Die Normung weiterer wichtiger hämatologischer Methoden ist geplant. Anregungen, Vorschläge, Einwände zur Normungsarbeit in der Hämatologie sind zu richten an die Häzometerprüfstelle (78 Freiburg/Br Hugstetterstraße 55) oder direkt an den Deutschen Normenausschuß (1 Berlin 15 Uhlandstraße 175).

K. G. v. Bonowacker Freiburg im Br

Ans der 2. Medizinischen Klinik der Medizinischen Akademie (Prof. Dr. K. Omanns)
und dem Zentrallaboratorium der Gesellschaft zur Bekämpfung der Krebskrankheiten
(Prof. Dr. C. G. Schmidt), Düsseldorf

Die Aminosäurezusammensetzung normaler und pathologischer γ G-Proteine

O. WETTER UND TH. HAKE

Die in quantitativer und qualitativer Hinsicht von den normalen menschlichen Serumproteinen fast immer deutlich abweichenden Paraproteine sind bald nach Einführung geeigneter vorwiegend elektrophoretischer Methoden und Fällungsreaktionen zu ihrer Isolierung auf die Aminosäurezusammensetzung untersucht und mit normalen γ -Globulinen verglichen worden (1, 2, 3, 4, 5, 6, 7). Die z.T. mit verschiedenen Methoden gewonnenen Ergebnisse stimmen im wesentlichen überein, werden aber unterschiedlich interpretiert. Einigkeit herrscht in der Feststellung des Fehlens ungewöhnlicher d. h. in Serumproteinen normalerweise nicht vorkommender Aminosäuren in den Paraproteinen mit einer Ausnahme (5). Mit der Anwendung der Säulenchromatographie an Cellulose Ionenaustauschermaterial (8, 9), der Immunelektrophorese (10) und der Stärkegelelektrophorese (1) haben die Methoden zur Charakterisierung und Strukturaufklärung einzelner Serumproteine eine bedeutende Bereicherung erfahren.

Die Immunelektrophoretische Analyse paraproteinämischer Seren z.B. führte bald zu der Entdeckung eines 3. Immunglobulins, des γ A-Proteins (12, 13, 14) und kürzlich eines 4. Immunglobulins, des γ D-Proteins (15, 16). Innerhalb der drei immunologisch unterscheidbaren Haupttypen von Immunglobulinen, der γ G-, γ A- und γ M-Proteine konnten mittels der oben genannten Methoden strukturelle Besonderheiten festgestellt werden. Säulenchromatographisch (17, 18) und elektrophoretisch im Stärkegel (17) konnte die Heterogenität von γ A-Paraproteinen gezeigt werden. Auch normales γ G-Protein erwies sich unter geeigneten Bedingungen uniheterisch. So konnte im Serum eines Falles von γ A-Paraproteinämie bei der Fraktionierung an DEAE-Ionenaustauscher immunologisch reines γ G-Protein in zwei Komponenten eluiert werden (18). Eine entsprechende Beobachtung wurde bei der Trennung von Kaninchen- γ -Globulin an dem gleichen Austauscher gemacht (19).

miker Physiker) wie auch Delegierte der herstellenden Industrie vertreten. Der Unterausschuß hat zur Zeit 16 Mitglieder. Im kommenden Herbst wird dieser Unterausschuß an einer Sitzung die bis zu diesem Zeitpunkt eingetroffenen Einsprüche zu den Normenentwürfen DIN 58931 Blatt 1-4 eingehend besprechen und die endgültige Norm verabschieden.

In der nächsten Zeit beabsichtigt der Unterausschuß Hämatologen die Normung der Blatkörperzählung und der Hämatokrit-Bestimmung in Angriff zu nehmen. Die Normung weiterer wichtiger hämatologischer Methoden ist geplant. Anregungen, Vorschläge, Einwände zur Normungsarbeit in der Hämatologie sind zu richten an die Hämoneterprüfstelle (78 Freiburg/Br., Hauptstrasse 55) oder direkt an den Deutschen Normenausschuß (1 Berlin 13, Uhlandstraße 175).

K. G. v. Bonowiczky Freiburg im Br.

Aus der 2. Medizinischen Klinik der Medizinischen Akademie (Prof. Dr. K. Oetters) und dem Zentrallaboratorium der Gesellschaft zur Bekämpfung der Krebserkrankheiten (Prof. Dr. G. O. Schmidt), Düsseldorf

Die Aminosäurezusammensetzung normaler und pathologischer γ G-Proteine

O. WETTER UND TH. HAKE

Die in quantitativer und qualitativer Hinsicht von den normalen menschlichen Serumproteinen fast immer deutlich abweichenden Paraproteine sind bald nach Einführung geeigneter vorwiegend elektrophoretischer Methoden und Fällungsreaktionen zu ihrer Isolierung auf die Aminosäurezusammensetzung untersucht und mit normalen γ -Globulinen verglichen worden (1-7). Die z.T. mit verschiedenen Methoden gewonnenen Ergebnisse stimmen im wesentlichen überein, werden aber unterschiedlich interpretiert. Einigkeit herrscht in der Feststellung des Fehlens ungewöhnlicher d. h. in Serumproteinen normalerweise nicht vorkommender Aminosäuren in den Paraproteinen mit einer Ausnahme (5). Mit der Anwendung der Säulenchromatographie an Cellulose-Ionenaustauschermaterial (8, 9), der Immunelektrophorese (10) und der Stärkegelelektrophorese (1) haben die Methoden zur Charakterisierung und Strukturaufklärung einzelner Serumproteine eine bedeutende Bereicherung erfahren.

Der immunchemischen Analyse paraproteinämischer Seren z.B. führte bald zu der Entdeckung eines 2. Immunglobulins, des γ A-Proteins (12, 13, 14) und kürzlich eines 4. Immunglobulins, des γ D-Proteins (15, 16). Innerhalb der drei immunologisch unterscheidbaren Haupttypen von Immunglobulinen, der γ G-, γ A- und γ M-Proteine konnten mittels der oben genannten Methoden strukturelle Besonderheiten festgestellt werden. Säulenchromatographisch (17, 18) und elektrophoretisch im Böttcher-Gelel (17) konnte die Heterogenität von γ A-Paraproteinen gezeigt werden. Auch normales γ G-Protein erwies sich unter geeigneten Bedingungen unschärflich. So konnte im Serum eines Falles von γ A-Paraproteinämie bei der Fraktionierung an DEAE-Sephadex (18) ein entsprechendes Beobachtung wurde bei der Trennung von Kadachin- γ -Globulin aus dem gleichen Austracker gemacht (19).

In der Stärkegel-Elektrophorese zeigten auch γ G-Paraproteine heterogene Zusammensetzung (17, 20). Abgesehen von der individuellen Spezifität jedes γ G-Proteins zeichneten sich die Paraproteine gegenüber den normalen γ G-Proteinen durch die diskontinuierliche Verteilung des Materials über einen Teil des γ -Globulinbereiches aus. Dem entspricht immunoelektrophoretisch eine charakteristische Deformierung der γ G-Präzipitate. Die Ursache dieses Phänomens der Diskontinuität der elektrophoretischen Verteilung von Paraproteinen (21) ist unbekannt. Versuche der Fraktionierung isolierter γ G-Paraproteine an DEAE-Cellulose Ionenaustauscher hatten bisher keinen Erfolg (22).

Kürzlich konnte gezeigt werden, daß elektrophoretisch isolierte γ G Proteine Gesunder und Plasmocytomkranker charakteristische Unterschiede in der optischen Drehfähigkeit aufweisen (23). Damit wurde zu den bekannten immunologischen und elektrophoretischen Eigenschaften in der Stärkegelelektrophorese ein weiteres Kriterium für die Paraproteinnatur von γ G-Proteinen gefunden. Durch die nachstehend mitgeteilten Untersuchungen sollte geklärt werden, ob die gruppenspezifischen Eigenschaften normaler und pathologischer γ G-Proteine einem charakteristischen physiko-chemischen Befund zugeordnet werden können und ob Unterschiede in der Aminosäurezusammensetzung zwischen beiden Gruppen bestehen.

Material und Methoden

Als Ausgangsmaterial für die Untersuchungen diente frisch gewonnenes Serum von 4 Gesunden und 8 Plasmocytomkranken sowie eines Patienten mit Makroglobulinämie (WALDENSTROM). Das Serum wurde entweder nach ein- bis zweitägiger Aufbewahrung bei 4°C oder nach Einfrieren und Auftauen sorgfältig gegen Veronalpuffer pH 8,6, Ionenstärke 0,1 bei 4°C dialysiert. Nach Verdünnung mit Veronalpuffer auf einen Proteingehalt von 2 bis 3 g% wurden die Proben in dem Spinco-H-Gerät bei 4°C elektrophoretisch getrennt. Nach etwa 60-minütiger Laufzeit bei 50 mA in der 60-ml-Zelle wurde das an dem hohen schmalen Gradienten kaudale Paraprotein mit der Präzipitanzelle aus dem absteigenden Schenkel der Thellus-Zelle entnommen. Bei den Normalseren wurde als γ G-Protein der vor dem Salzgradienten wandernde Gradient angesprochen.

Alle derartig isolierten Fraktionen wurden elektrophoretisch auf Membranfolien der Firma Schleicher und Schüll in dem Hochspannungsgerät der Firma Hormoth, Heidelberg, bei 1200 bis 1500 V und einer Laufzeit von 45 bis 60 min im Vergleich mit dem Vorserum untersucht.

Die Immunoelektrophorese wurde nach der von SCHLESINGER (24) angegebenen Methode in 2prozentigem Bacto- oder Noble-Agar der Firma Difco, Detroit, in Veronalpuffer pH 8,6, Ionenstärke 0,1 bei 40 V 50 bis 60 mA und 60 bis 70 min Laufzeit durchgeführt. Als Antiseren wurden Kanarienserum eigener Herstellung und solche der Behring-Werke Marburg benutzt.

Die Sedimentationsanalysen wurden in einer Spinco-Ultrazentrifuge Modell E bei 59780 RpM und 10°C in der 12-mm-Zelle bei einem schlierenoptischen Winkel von 60° vorgenommen.

Für die Bestimmung der optischen Drehung diente das Lichtelektrische Präzisionspolarimeter 0,005 der Firma Zeiss, Oberkochen. Die Messungen wurden bei Zimmertemperatur in der 2-cm-Zelle bei den Wellenlängen 365, 405, 436, 546 und 578 m μ vorgenommen. Lösungsmittel war in allen Fällen Veronalpuffer pH 8,6, Ionenstärke 0,1.

Die Auswertung der Meßergebnisse der optischen Drehfähigkeit wurde nach LOWRY (25) und MORTY (26, 27) in der an anderer Stelle (23) ausführlich dargestellten Weise vorgenommen.

Für die Eiweißbestimmung wurde die von BURET-SCHULZ (28) angegebene Modifikation der Biuret-Methode benutzt.

Zur Bestimmung der quantitativen Aminosäurezusammensetzung diente ein automatisches Gerät der Firma Technikon. Methodisch wurde nach der von SPACHMAN *et al.* (29) eingeführten Säulenchromatographie von Proteinhydrolysaten an Ionenaustauscherharzen in der Modifikation von FALK UND MORRIS (30) vorgegangen. Als Eichlösung wurde ein Aminosäuregemisch der Firma Beckman Instr. benutzt. Die Proben wurden in 6 n Salzsäure 20 h bei 110°C hydrolysiert (31). Die Laufzeit der einzelnen Chromatogramme betrug 90 h. Die Werte für Ops/2 und Met. wurden aus ihren Sulfonations- bzw. Sulfoxydwerten zurückgerechnet, da keine genauen Vergleichswerte vorlagen.

Ergebnisse

In Tab. I und II sind die Ergebnisse der elektrophoretischen Untersuchungen, der Immunelektrophorese, der Sedimentationsanalysen und der Bestimmungen der optischen Serumfraktionen zusammengefaßt. Die Proteinkonzentration betrug zwischen 1 und 8 mg/ml. Sowohl in der Trägerelektrophorese wie in der freien Elektrophorese handelte es sich in allen Fällen um einheitliches, in der γ -Region wanderndes Material. Wesentliche Unterschiede der Wanderungsgeschwindigkeit in den beiden Medien waren nicht festzustellen.

Immunelektrophoretisch war in einer Probe (Co) eine Spur γ G-Protein und in einer anderen Probe (We) eine Spur Transferrin als Beimengung zu dem Paraprotein nachzuweisen. In den Fällen Al und Mo handelt es sich um ein γ A bzw. γ M Paraprotein. Eine spezielle immunologische Analyse ergab, daß bei Al eine doppelte Proteinanomalie mit γ G- und γ A Paraproteinämie vorliegt.

Die Ergebnisse der Sedimentationsanalysen (Tab. I II und Abb. 1 2) zeigen, daß sämtliche γ G-Paraproteine als einheitliche, schmalbasige Gradienten sedimentieren. Lediglich bei Bl setzt sich an der Basis des absteigenden Gradienten etwas schneller sedimentierendes Material ab (Abb. 2). Da immunelektrophoretisch keine Beimengung anderer Serumproteine bestand, scheint es sich um eine Aggregation von 6 S-Molekülen zu handeln, wie sie noch deutlicher bei dem kommerziellen Präparat (Fr II der Firma Travenol, München) zum Vorschein kommt. Dieses immunologisch reine γ G-Präparat enthielt außer der mit 6 S wandernden Hauptkomponente noch eine geringe Menge 8,5 S-Materials (Abb. 1). Zu einer derartigen Aggregation kann es im Verlauf der Präparation durch

Probe	Lysozym- T-Aggl.-Z.	Bewegl. Fries-Z.	Immun- elektroph.	C in mg/ml	Sedimentations- koeffizienten bei 20°C	λ_{254} in mμ	$[\eta]$ 340 mμ	b_{90}	α -Häufig- %
Bo	+	+	γG-Protein	2,0	6,7	Spur schneller sedi- mentierendes Material	64,6	81,5	0
II	+	+	γG-Protein	1,5	5,7	Spur schneller sedi- mentierendes Material	49,7	—63,5	10,4
MI	+	+	γG-Protein γM Spur Transferrin	3,1			64,4	87,8	0
Me	+	+	γG-Protein	0,1	6,5		68,9	55,1	0
Pa	+	+	γG-Protein	0,7	6,5		61,2	63,4	0
Γ	+	+	γG-Protein	7,7	5,9	8,5	65,2	56,0	0

Tabelle II

Elektrophoretische Beweglichkeit, Immunelektrophoresen, Sedimentationskoeffizienten und optische Konstanten elektrophoretisch isolierter γG-Paraproteine.

Probe	Lysozym- T-Aggl.-Z.	Bewegl. Fries-Z.	Immun- elektroph.	C in mg/ml	Sedimentations- koeffizienten bei 20°C	λ_{254} in mμ	$[\eta]$ 340 mμ	b_{90}	α -Häufig- %
Bl	+	+	γG-Paraprotein	3,0	6,2	Spur schneller sedi- mentierendes Material	57,2	6,9	0
Co	+	+	γG-Paraprotein	3,2	7,0		50,0	11,8	0
Cz	+	+	γG-Paraprotein	8,0	6,8		63,8	—13,4	2,4
Ik	+	+	γG-Paraprotein	3,0	5,1		81,8	23,4	0
Ag	+	+	γG-Paraprotein	6,8	7,5		50,8	18,0	0
Ti	+	+	γG-Paraprotein	2,0	6,8		79,0	—7,7	1,2
V	+	+	γG-Paraprotein Transferrin	5,6	—		88,5	29,0	0
Mo	+	+	γA-Paraprotein	3,1	6,5	8,6	55,8	25,7	0
	+	+	γM Paraprotein	5,7	6,7	17,4	50,5	0	0
			γG-Paraprotein			24,8			



Abb. 1 Ultrazentrifugendiagramme normaler γ G-Proteine. Sedimentationsrichtung von links nach rechts. Aufnahmeverzeiten in Minuten nach Erreichen der Höchstgeschwindigkeit 59780 U/min, Schlierenoptischer Winkel 60°, Versuchstemperatur 20°C. Konzentrationen s. Tab. I. Sonstige Versuchsbedingungen siehe Text. a) Bo. Aufnahmezeit 3 min, Sed. Koeff. 6,7 s. b) Ha. Aufnahmezeit 3 min Sed. Koeff. 5,7 s. c) Me. Aufnahmezeit 5 min, Sed. Koeff. 6,5 s. d) Ra. Aufnahmezeit 3 min, Sed. Koeff. 6,3 s. e) F II Aufnahmezeit 10 min, Sed. Koeff. 5,1 und 8,5

Fällung kommen. Entsprechende Beobachtungen sind bei bovinem γ -Globulin gemacht worden (32, 33). Auch die Proben Bo und Ha der Normalgruppe, immunologisch ebenfalls reines γ G Protein, weisen Komponenten mit Sedimentationskoeffizienten größer als die 6,7 bzw. 5,7 s Hauptkomponente auf. Die genauen Werte der Sedimentationskoeffizienten ließen sich wegen zu geringer Konzentration nicht bestimmen.

Die Sedimentationskoeffizienten der normalen und pathologischen γ G Proteine liegen im übrigen zwischen 5,1 s und 7,5 s. Während hinsichtlich der Sedimentationskoeffizienten kein Unter-




Abb. 2. Ultrazentrifugendiagramme pathologischer γ -G-Proteine Versuchsbedingungen s. Abb. 1 Tab. II und Text. a) Bl. Aufnahmezeit 10 min, Sed. Koeff. 6,2 s. b) Co. Aufnahmezeit 15 min, Sed. Koeff. 7 s. c) Co. Aufnahmezeit 21 min, Sed. Koeff. 6,6 s. d) He Aufnahmezeit 8 min, Sed. Koeff. 5,1 s. e) h.l. Aufnahmezeit 6 min, Sed. Koeff. 7,5 s. f) TL Aufnahmezeit 7 min, Sed. Koeff. 6,8 s.

schied zwischen den beiden Gruppen festzustellen ist, besteht ein solcher augenfällig in der Form der Gradienten. Infolge größter molekulargewichtsmäßiger Einheitlichkeit zeichnen sich die Paraproteine durch schmalbange und hohe Gradienten im Gegensatz zu den breitbangen, gedrunghenen Gradienten der normalen γ -G-Moleküle aus. Die Proben Al und Mo sind sedimentationsanalytisch heterogen und weisen außer einer 6,3 bzw. 6,7 s Komponente schnellere Gradienten auf. Bei Al wurden die für Paraproteine charakteristischen mittelschweren Komponenten (8,6 s, 12,5 s) bei Mo die für Makroglobuline typischen Sedimentationskoeffizienten (17,4 s, 24,8 s) gemessen.

Die Ergebnisse der Messungen der optischen Drehfähigkeit sind ebenfalls in Tab. I und II aufgeführt. Die Auswertung der Drehwertbestimmungen nach LOWRY führt zu der Dispersionskonstanten k_d . Sie liegt für alle untersuchten Lösungen mit einer Ausnahme (Ha) in dem für globuläre Proteine des γ -Systems typischen Größenordnung von 170–217 $m\mu$. Dieses Verhalten ist neben den schon genannten Kriterien ein weiteres Reinheitsmaß. Weiterhin sind die spezifischen Drehwerte bei 546 $m\mu$ angegeben.

Die Berechnung der optischen Konstante b_0 nach MOTTITT UND YANG ergab überwiegend geringe positive Werte oder 0 d.h. ein wesentlicher Gehalt an α -Helixstruktur war in dem untersuchten Material nicht vorhanden. Lediglich das durch seine hohe Dispersionskonstante von 246 $m\mu$ auffällige Präparat Ha hatte einen nennenswerten α -Helixgehalt (10,4 %). Durch Einsetzen von 246 anstelle von k_d in die Mottitt-Gleichung ergab sich für b_0 ein positiver Wert (13,8) so daß in diesem Fall ein α -Helixgehalt durch sog. Pseudokomplexibilität vorgetäuscht sein dürfte.

Die sich nach dem Verfahren von MOTTITT UND YANG weiterhin ergebende optische Konstante a_0 normaler und pathologischer γ G-Proteine wird an anderer Stelle (23) mitgeteilt und wird deswegen hier nicht angeführt.

Die Ergebnisse der Aminosäureanalysen sind in Tab. III für die Normalgruppe (I) für die γ G-Paraproteine (II) für das γ_4 und das γ_M Paraprotein (III bzw. IV) zusammengefaßt. Zum Vergleich sind in Tab. IV mit gleichartiger Methode gewonnene Ergebnisse anderer Autoren (35, 36, 37, 38, 39, 40) wiedergegeben. Da das untersuchte Material bei unserem Vorgehen in Veronalpuffer vorlag aus dem bei der Hydrolyse NH_3 frei wurde, war eine Korrektur der Analyseergebnisse notwendig. Ausgehend von der an 2 entsalzten Proben gefundenen Bruttozusammensetzung an Aminosäuren wurde der «Veronalfehler» eliminiert und für alle Analysen ein NH_3 Wert von 3 % zugrunde gelegt. Er ergibt sich aus dem bei der Hydrolyse von Glu- NH_2 und Asp- NH_2 durch Zersetzung freierwerdenden NH_3 .

Die Proben Me₁ und Me₂ stammen von verschiedenen Präparationen desselben Serums, bei Al₁ und Al₂ dagegen handelt es sich um eine Doppelbestimmung.

Bei fehlenden Zahlenangaben war die Konzentration zu gering um auswertbare Ausschläge im Chromatogramm zu geben. Die Fehlerbreite der einzelnen Bestimmung beträgt etwa ± 5 .

Tabelle III

Aminosäurezusammensetzung elektrophoretisch isolierter γ G-Proteine Geander (I) γ G-Paraproteine (II) eines γ A-Paraproteins (III) und eines γ A₂ Paraproteins (IV) in g⁻¹ Aminosäuretotal

	I			II			III			IV	
	As	Val	Met	His	Ile	Leu	Ala	Thr	Val	As	Val
Asp.	8.5	7.8	9.5	8.2	7.5	8.8	7.9	8.0	7.7	7.4	7.5
Thr	9.9	9.7	10.7	10.7	9.4	7.1	7.4	8.7	8.6	8.9	9.6
Ser	10.9	11.5	10.0	11.7	10.1	10.7	11.3	12.4	11.6	12.5	11.8
Glu	10.1	9.9	10.3	8.2	11.0	11.8	10.5	11.0	11.0	8.5	11.5
Pro	7.0	7.4	6.0	6.9	7.1	10.0	7.9	7.5	7.6	10.2	6.7
Arg	6.8	6.9	7.2	7.3	7.0	4.9	6.5	6.7	6.4	7.1	7.0
Val	5.4	5.2	5.9	6.2	5.2	4.1	5.7	1.8	5.7	4.5	5.3
Leu	7.2	7.5	6.5	7.8	8.4	5.6	7.8	7.0	6.6	8.9	7.1
Ala	0.1	1.1	1.1	1.2	0.7	1.2	0.7	0.0	1.1	1.1	0.9
Arg 2	3.2	3.6	1.2		2.8	1.7	3.8	2.2	2.9	3.1	1.9
His	2.2	2.1	2.0	2.5	2.0	1.9	2.5	1.9	1.9	1.9	1.5
Leu	7.5	6.9	7.9	8.2	7.1	7.7	6.7	7.2	6.7	7.0	6.1
Thr	5.4	5.1	5.5	5.5	5.4	5.1	4.0	3.8	3.9	3.8	3.5
Pro	5.4	5.4	5.7	5.5	5.1	5.9	4.0	3.4	3.5	3.2	3.6
Val	5.0	5.0	0	5.0	5.0	2.2	5.0	5.0	5.0	5.0	5.0
Leu	5.7	5.9	5.4	6.2	5.8	6.7	5.1	6.1	6.0	5.8	5.2
His	1.9	2.0	2.0	2.1	1.9	2.4	1.5	1.8	1.8	1.5	1.5
Arg	3.1	2.9	1.9	1.9	3.0	3.1	3.1	3.5	3.6	3.6	3.5
Glu	1.1		0.8		0.6	1.0	0.7	0.6	0.7	0.5	1.1

NII

Tab. IV
 Messung des γ G-Proteins Grauer (I) beim γ G-Paraprotein (II) einem γ A-Paraprotein (III) und einem γ M-Paraprotein (IV) nach Literaturangaben.

Aminosäure	γ G (I)	γ G (II)	I γ G (III)	II (III)	G (IV)	III γ A (IV)	IV γ M (V)
Arg.	9.05	8.3	8.6	7.77	7.09	6.49	10.7
Thr.	8.90	8.2	6.5	7.01	7.18	8.19	8.7
Asp.	11.75	12.2	10.4	9.15	9.09	8.35	8.9
Glu.	12.47	10.2	11.7	11.16	11.26	11.49	11.2
Pro.	7.9	8.0	6.8	6.4	6.15	6.71	1.6
Gly.	4.47	7.0	3.9	3.37	3.35	3.44	4.2
Ala.	4.05	5.4	3.8	3.29	3.18	3.66	5.1
Val.	9.42	9.0	8.5	7.92	8.1	6.61	10.2
Met.	0.90	0.5	1.1	0.95	0.95	0.91	1.3
Cys ^{1/2}	2.96	2.2	2.2	2.07	2.2	2.66	4.5
Ile.	2.59	2.1	2.5	2.16	2.14	1.76	3.5
Leu.	8.37	7.7	8.5	7.40	7.21	8.93	9.2
Ty.	6.75	4.4	6.3	3.70	3.97	4.06	4.5
Phe.	4.79	3.5	1.8	4.07	4.5	3.96	6.4
NH ₂	1.75		4.02		1.46	0.31	
Lys.	8.01	6.5	7.4	7.00	6.98	4.81	7.1
His.	2.55	1.9	1.9	2.41	2.28	1.7	1.5
Ser.	4.45	5.0	4.5	4.02	1.02	4.76	7.0
Trp.	3.42			2.65	3.03		
Glu., NH ₂					2.9	2.35	
Hex.						3.7	

Try wurde nicht bestimmt. Bei den Angaben für Cys/2 und Met ist mit einem Fehler bis 10 % zu rechnen weil diese Werte aus ihren Sulfonsäuren bzw Sulfoxyden zurückgerechnet wurden und für diese keine genauen Vergleichswerte vorlagen

Aus Tab III geht hervor daß weder für eine Aminosäure noch für Glucosamin charakteristische Unterschiede zwischen den untersuchten Gruppen bestehen Innerhalb der methodischen Fehlerbreite ist die Aminosäurezusammensetzung der normalen und pathologischen γ G Proteine gleichartig Auch das γ A Paraprotein Al weicht im Aminosäuremuster nicht von dem des γ G-Proteins ab Bei dem untersuchten γ M Paraprotein Mo ist ein relativ hoher Threonin Gehalt festzustellen.

In Tab IV sind mit gleicher Methode zur Aminosäurebestimmung gewonnene Ergebnisse anderer Autoren aufgeführt Die Isolierung dieser Fraktionen erfolgte größtenteils mittels kombinierter Fällungsmethoden In der Gruppe I bietet sich ein ähnlich einheitliches Bild wie in Gruppe I der Tab III d.h. normales γ G-Protein zeigt unabhängig von der zu seiner Isolierung benutzten Methode gleiche Aminosäurezusammensetzung Ebenfalls keine wesentlichen Unterschiede ergaben sich für den Glukosamingehalt der normalen und pathologischen γ G-Proteine Glukosamin war in allen Proben nachweisbar konnte aber wegen zu geringer Konzentration in einigen Fällen nicht quantitativ bestimmt werden Das gleiche gilt für die fehlenden Methionin und Cysteinwerte bei Ti bzw Me.

Diskussion

Untersuchungen der Aminosäurezusammensetzung normaler und pathologischer γ -Globuline wurden zunächst an Serumfraktionen durchgeführt, die durch unterschiedliche elektrophoretische Beweglichkeit charakterisiert waren. Signifikante Unterschiede der Aminosäurezusammensetzung und der Endgruppen bei γ - und β -Plasmocytomproteinen wurden beschrieben (4) Die Hoffnung durch vergleichende Studien des Aminosäuregehaltes die Frage beantworten zu können, ob Paraproteine ihren Namen als normalerweise nicht vorkommende Serumproteine zu Recht tragen, erfüllten sich von einer Ausnahme abgesehen (5) nicht.

Nachdem durch immunologische Methoden mindestens 3 Komponenten des γ -Systems identifiziert werden konnten und Aminosäureanalysen mitgeteilt werden (39) Während Angaben

über den Aminosäuregehalt normaler γ G Proteine relativ häufig zu finden sind, wurden Untersuchungen an Paraproteinen offenbar seltener durchgeführt. Ausschlaggebend für unsere Untersuchungen war aber daß γ G Paraproteine sich durch ihr optisches Drehvermögen von normalem γ G unterscheiden (23). Es sollte geklärt werden, ob die Aminosäurezusammensetzung dieser Proteine Aufschluß über die Ursache der beobachteten optischen Eigenschaften gibt. Auch der Kohlenhydratgehalt war in diesem Zusammenhang zu berücksichtigen. Es zeigte sich, daß keine der am Aufbau des Globulins beteiligten Aminosäuren charakteristische gruppenspezifische Veränderungen aufweist. Auch der Glukosamengehalt war in den Gruppen der normalen und pathologischen γ G-Proteine nicht signifikant unterschiedlich. Offensichtlich hat auch die Tatsache, daß die Paraproteine im Gegensatz zu der Normalgruppe keine Antikörperwirksamkeit aufweisen, keinen entscheidenden Einfluß auf das Ergebnis der Aminosäureanalysen.

Durch einen von den normalen Verhältnissen auffällig und systematisch abweichenden Bruttogehalt an Aminosäuren sind demnach die zur Gruppenspezifität führenden Moleküleigenschaften der γ G-Paraproteine nicht zu erklären. Auch das ein charakteristisches immunoelektrophoretische und sedimentationsanalytische Verhalten aufweisende γ A- und γ M-Paraprotein (Al, Mo) unterscheidet sich im Aminosäuremuster nicht wesentlich von den γ G-Proteinen.

Durch Säulenchromatographie der Hydrolyseprodukte konnte bisher lediglich die Individualspezifität von Paraproteinen, die auch immunologisch nachzuweisen ist (41) bestätigt werden. Auch unterschiedlicher Kohlenhydratgehalt der Immunglobuline und der γ G- γ A- und γ M-Paraproteine wurde gefunden, ein Ergebnis, das schon früher mit chemischen Methoden erzielt worden war (42).

Versuche, durch physikalisch-chemische Untersuchungen und Fluoreszenzpolarimetrie Unterschiede zwischen spezifischen Kaninchen-Antikörpern gegen Kalbskryoglobulin und normalem γ -Globulin vom Kaninchen festzustellen, hatten ein negatives Ergebnis (43-44).

Erst neuerdings beanspruchen säulenchromatographische Aminosäureanalysen in diesem Zusammenhang wieder erhöhtes Interesse. Es konnte gezeigt werden, daß Antikörper verschiedener Spezifität unterschiedliche Aminosäurezusammensetzung aufweisen.

Derartige Untersuchungen sind zunächst an Kaninchen-Antikörpern, die gegen synthetische Haptene gerichtet sind vorgenommen worden (45-46). Es ergaben sich signifikante Unterschiede im Gehalt an Arg, Ileu, Leu, Asp und Tyr. Die Zugehörigkeit der Antikörper zu einer der γ -Globulin Allotypen prägte sich im Aminosäuremuster nicht aus (47). Für gereinigte spezifische menschliche Antikörper eines Individuums konnte kürzlich ein entsprechendes Verhalten für eine Reihe von Aminosäuren gezeigt werden (47). Unterschiede von 7 bis 32 Aminosäureresten zwischen Antikpermolekülen verschiedener Spezifität wurden festgestellt.

Mit der auf Buxer zurückgehenden Anschauung von der Zellstammauswahl (clonal selection) und der Information über die Aminosäuresequenz bei der Antikörpersynthese in Anwesenheit des Antigens sind diese Befunde zunächst besser zu vereinbaren als mit anderen Theorien nach denen die Antikörperspezifität durch Anpassung präformierter γ -Globulin Polypeptidketten an das Antigen hervorgerufen wird (template theory). Den neuen Gesichtspunkten, die sich durch den Befund der unterschiedlichen Aminosäurezusammensetzung von Antikörpern verschiedener Spezifität ergeben, versucht eine modifizierte template theory gerecht zu werden (48). Danach ist die Antikörperspezifität auf eine direkte Veränderung des genetischen Codes durch das Antigen zurückzuführen.

Zusammenfassung

Die Aminosäurezusammensetzung von 7 elektrophoretisch isolierten γ G-Paraproteinen, einem γ -L- und einem γ M-Paraprotein wird mit der von 5 normalen γ G- Proteinen verglichen. Ein Unterschied konnte nicht festgestellt werden. Auch der Glukosamingehalt ist innerhalb der methodischen Fehlerbreite gleich. Die Ergebnisse stimmen mit den Angaben anderer Autoren über γ G-Proteine, die durch Fällung isoliert wurden, gut überein. Die durch die Sedimentationsanalyse in der Ultrazentrifuge und durch die Immunelektrophorese in Agarose nachweisbaren Unterschiede zwischen beiden Gruppen lassen sich mit dieser Methode der Aminosäurebestimmung auch auf unterschiedlichen Aminosäuregehalt zurückführen. Es werden weiterhin die Ergebnisse der Messungen des optischen Drehvermögens der Proben mitgeteilt. Die Duperkonstante L_D und die optische Konstante b_D wurden ermittelt. Der aus b_D berechnete α -Helixgehalt war in fast allen Fällen 0.

Summary

The amino acid composition of seven electrophoretically isolated γ G-paraproteins, one γ -L- and one γ M-paraprotein is compared with that of five normal γ G-proteins. No distinction was observed. The glucosamine content is also identical within the margin of error of the method. This result agrees well with the findings of other workers on γ G-proteins isolated by precipitation. The differences shown between these

two groups of proteins by ultracentrifuge sedimentation analysis and immuno-electrophoresis in agar gel cannot be attributed by this method of determination to differences in amino acid composition. The results of measurement of optical rotation potential are also reported. The dispersion constant λ_D and the optical constant b_0 were determined. The ellipticity constant calculated from b_0 was 0 in almost every case.

Résumé

La composition en acides aminés de 7 γ G-paraprotéines isolées par électrophorèse, d'une γ A-paraprotéine et d'une γ M-paraprotéine est comparée à celle de 5 γ G-protéines normales. Une différence ne peut pas être constatée. Leur contenu en glucosamine est, dans le cadre de l'erreur-limita, semblable. Les résultats correspondent bien à ceux que d'autres auteurs ont obtenus par précipitation. Les différences constatées à l'aide de l'analyse de la sédimentation par ultracentrifuge et à l'aide de l'immunoélectrophorèse sur gel d'agar ne peuvent pas être attribuées (selon cette méthode d'analyse des acides aminés) à un contenu variable d'acides aminés. Les résultats de la détermination du pouvoir rotatoire des protéines sont rapportés. La constante de dispersion λ_D et la constante optique b_0 ont été déterminées. Le contenu en α -hélix, estimé à l'aide de b_0 , était presque dans tous les cas 0.

Literatur

1. HELLMANN, A.; HELLMANN, G. UND LÖNN, F. Myelom-Plasma-Proteine. I. Mitteilung. Über die chemische und physikalische Natur der Myelom- γ -Globuline. Z. Naturforsch. 18: 28 (1963)
2. GIBOLLA, F. T. AND CONLEY, P. P. Amino acid analysis of serum proteins in multiple myeloma. Cancer Res. 9: 851 (1953)
3. FEIGER, B.; WUTHERMANN, F. AND WOODWARD, C. Amino acid composition of macroglobulins in four cases of macroglobulinemia. Acta haemat. 11: 309 (1954)
4. SMITH, E. L.; BROWN, D. M.; McFARREN, M. L.; BERTHOLD-JANSEN, V. AND JACOB, B. V. Physical, chemical and immunological studies and globulins from multiple myeloma. J. biol. Chem. 216: 601 (1955)
5. MANDRICK, H.; SCHAAF, P. G. V. H. AND HENMAN, T. H. J. Investigations on the amino acid composition of macroglobulin and cryoglobulin. J. Lab. clin. Med. 45: 261 (1955).
6. MÜTZIG, D.: Der Aminosäuregehalt bei Plasmasystem. Klin. Wochr. 34: 231 (1956).
7. PUTNAM, F. W. The Plasma Proteins. L: 146 (Academic Press, New York 1960)
8. PETERSON, E. A. AND SOMER, H. A. Chromatography of proteins. I. Cellulose ion-exchange adsorbents. J. Amer. chem. Soc. 68: 751 (1956).
9. SOMER, H. A.; GUTTER, F. J.; WYCKOFF, M. M. AND PETERSON, E. A. Chromatography of proteins. II. Fractionation of serum proteins on anion-exchange cellulose. J. Amer. chem. Soc. 78: 756 (1956)
10. GRABAR, P. ET WILLIAMS, C. A. Méthode permettant l'étude conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines. Application au sérum sanguin. Biochim. biophys. Acta 10: 193 (1955)
11. SMITH, O. Zone electrophoresis in starch gels; Group variations in the serum proteins of normal human adults. Bioch. J. 61: 629 (1955).
12. GRABAR, P.; FAIVERT, R.; BURET, P. ET HARTMANN, L. Etude sur les protéines du myélome. II. L'analyse immuno-électrophorétique des sérums de 30 malades. Rev. franç. Et. clin. biol. 1: 175 (1956).
13. HEREMANS, J. F. AND HEREMANS, M. Th. Immuno-electrophoresis as diagnostic tool for myeloma and macroglobulinemia. Proc. 7th Int. Congr. Haemat. Rome 1958.

14. HERMANS, J. F., HERMANS, M. TH. AND SCHULTZ, H. E.: Isolation and description of a few properties of the β_2 A-Globulin of human serum. *Clin. chim. Acta* **4** 96 (1959).
15. ROWE, D. S. AND FARLEY, J. L.: A new class of human immunoglobulins. I. A unique myeloma protein. *J. exp. Med.* **121** 171 (1965).
16. ROWE, D. S. AND FARLEY, J. L.: A new class of human immunoglobulins. II. Normal serum IgD. *J. exp. Med.* **121** 185 (1965).
17. FARLEY, J. L.: Heterogeneity of myeloma proteins. *J. clin. Invest.* **41** 111 (1963).
18. WETTER, O. UND HERKENWITZ, Ch.: Untersuchungen zur Frage der Heterogenität von Paraproteinen. *Blut* (im Druck).
19. SELA, M., GIVOL, D. AND MOZER, E.: Resolution of rabbit γ -Globulin into two fractions by chromatography on diethylaminoethyl-Sephadex. 32nd Meeting of the Israel Chemical Soc., Jerusalem 1963.
20. SCHREIBER, P. G.: Immunologische Untersuchungen an heterogen zusammengesetzten Plasmacytom- γ -Globulinen. *Klin. Woch.* **41** 723 (1963).
21. WERNICKE, F. UND MÜLLER, H. H.: Dysproteïnämien und Paraproteinämien. (Schwabe, Basel 1963).
22. RISS, H. E.: Beitrag zur Frage der Heterogenität von Paraproteinen. *Des. Med. Akademie Düsseldorf* 1963.
23. WETTER, O. UND JÄGER, K.: Die optische Rotationsdispersion elektrophoretisch isolierter Paraproteine. I. Zur Gruppenspezifität normaler und pathologischer γ -Globuline. *Klin. Woch.* (zur Publikation vorgelegt).
24. SCHREIBER, L. L.: Une micro-méthode de l'immuno-électrophorèse. *Int. Arch. Allergy* **7** 103 (1953).
25. LOWRY, T. M.: Optical Rotatory Power (Longmans, Green, London 1933).
26. MORFITT, W. AND YAM, J. T.: The optical rotatory dispersion of simple polypeptides. I. *Proc. nat. Acad. Sci. (U.S.)* **42** 596 (1956).
27. MORFITT, W.: The optical rotatory dispersion of simple polypeptides, II. *Proc. nat. Acad. Sci. (U.S.)* **42** 736 (1956).
28. BERENSON, G., BOLTER, H. J.; SCHNEIDER, T., CZECH, R., GARRARD, A. H., MEYER-RODERT, E. UND FLEISCHER, G.: Diphosphofructose-Aldolase, Phosphoglycerat-Dehyd-Dehydrogenase usw. aus Kaninchenmuskel in einem Arbeitsgang. *Z. Naturforsch.* **8b** 555 (1953).
29. SPACHMAN, D. H., STEIN, W. H. AND MOORE, S.: Automatic recording apparatus for use in the chromatography of amino-acids. *Anal. Chem.* **30**: 1190 (1958).
30. PILL, A. AND MOORE, S.: A modified procedure for the automatic analysis of amino acids. *Anal. Biochem.* **1** 187 (1960).
31. CHRISTFIELD, A. M., STEIN, W. H. AND MOORE, S.: Alkylation and identification of the histidine residues of the active site of ribonuclease. *J. biol. Chem.* **237** 2413 (1962).
32. PHILLIPS, R. A. AND CARR, J. R.: On the modification of γ -globulin by acid. *Biochim. Biophys. Acta* (Amsterdam) **23** 149 (1957).
33. UHLEN, F. AND DOTY, P.: Optical rotation and the conformation of polypeptides and proteins. *Adv. Protein Chem.* **16** 301 (1961).
34. PHILLIPS, R. J. AND PUTNAM, F. W.: Chemical composition and molecular parameters of purified plasma proteins. *The Plasma Proteins I* 143 (Academic Press, New York 1962).
35. HILAO, S. H. AND PUTNAM, F. W.: The cleavage of human γ -globulin by papain. *J. biol. Chem.* **236** 122 (1961).
36. HINER, R., WOODS, K. R. AND ENGLE, R. L.: Amino acid analyses of rheumatoid factors and normal γ -globulins. *Proc. Soc. exp. Biol.*, **111** 110-115 (1962).

38. CHAMPTON, M. J. AND WILKINSON, J. M.: Amino acid compositions of human and rabbit γ -globulins and the fragments produced by reduction. *Biochem. J.* **88**, 228 (1963).
39. HENDRICKER, N.; HEINE, K.; HAUST, H. UND SCHULTZE, H. E.: Bestimmungsmethoden von Harnsäureumproteinen. *Clin. chim. Acta* **10**, 293 (1964).
40. DEUTSCH, H. F.: Molecular transformations of γ -globulins of human serum. *J. mol. Biol.* **7**, 662 (1963).
41. KUNKEL, H. G., MARX, M. AND WILLIAMS, R. C.: Individual antigenic specificity of isolated antibodies. *Science* **160**, 1218 (1963).
42. MÜLLER-ESCHERICH, H. J.; KUNKEL, H. G. AND FRANKLIN, E. C.: Two types of γ -globulin differing in carbohydrate content. *Proc. Soc. exp. Biol., N. Y.* **53**, 146 (1956).
43. EDELMAN, H.; LEFFELDT, R. E. AND STIERER, R. F.: Structural transitions in antibody and normal γ -globulins. I. Molecular properties. *J. Amer. chem. Soc.* **84**, 2133 (1962).
44. STIERER, R. F. AND EDELMAN, H.: Structural transitions in antibody and normal γ -globulins. II. Fluorescence polarization studies. *J. Amer. chem. Soc.* **84**, 2159 (1962).
45. KOSHLAND, M. E. AND EDELMAN, F. M.: Differences in the amino acid composition of two purified antibodies from the same rabbit. *Proc. nat. Acad. Sci. (U. S.)* **50**, 61 (1963).
46. KOSHLAND, M. E.; EDELMAN, F. M. AND SWAPANELA, R.: Differences in the amino acid compositions of third rabbit antibody. *Science* **163**, 1350 (1964).
47. BARNET, E. W., TANNENBAUM, S. W.; FREYMANER, K.; BROWN, S. M. AND KARAT, E. A.: Studies on human antibodies. III. Amino acid composition of four antibodies from one individual. *J. exp. Med.* **122**, 251 (1963).
48. HATKOWITZ, F.: Antibody formation and the cloning problem. *Nature* **205**, 847 (1963).

Abdruck der Autoren: Dr. O. Wotter, 2. Medizinische Klinik der Medizinischen Akademie, 4. Dezember, und Dr. Th. Rabe, Zentrallaboratorium der Gesellschaft zur Bekämpfung der Kreislauferkrankungen, 4. Dezember (Dresden).

14. HEREMANS, J. F. HEREMANS, M. TH. AND SCHULTZ, H. E.: Isolation and description of a few properties of the β_2 A-Globulin of human serum. *Clin. chim. Acta* 4 96 (1959).
15. ROWE, D. S. AND FAREY, J. L.: A new class of human immunoglobulins. I. A unique myeloma protein. *J. exp. Med.* 127 171 (1963).
16. ROWE, D. S. AND FAREY, J. L.: A new class of human immunoglobulins. II. Normal serum IgD. *J. exp. Med.* 121 183 (1963).
17. FAREY, J. L.: Heterogeneity of myeloma proteins. *J. clin. Invest.* 42 111 (1963).
18. WETTER, O. UND HARTMANN, CH.: Untersuchungen zur Frage der Heterogenität von Paraproteinen. *Blut* (im Druck).
19. SELA, M., GYOR, D. AND MOSES, E.: Resolution of rabbit γ -Globulin into two fractions by chromatography on diethylaminoethyl-Sephadex. 32nd Meeting of the Israel Chemical Soc., Jerusalem 1963.
20. SCHUTTLER, P. G.: Immunologische Untersuchungen an heterogen zusammengesetzten Plasmocytom- γ -Globulinen. *Klin. Woch.* 41 723 (1963).
21. WICHTLAGE, F. UND MARSH, H. H.: Dysproteinaemien und Paraproteinaemien. (Schwabe, Basel 1963).
22. REEM, H. E.: Beitrag zur Frage der Heterogenität von Paraproteinen. *Das. Med. Akademie Düsseldorf* 1963.
23. WETTER, O. UND JÄHNKE, K.: Die optische Rotationsdispersion elektrophoretisch isolierter Paraproteine. I. Zur Gruppenspezifität normaler und pathologischer γ_2 -Globuline. *Klin. Woch.* (zur Publikation vorgelegt).
24. SCHNEIDER, I. I.: Une micro-méthode de l'immuno-electrophorèse. *Int. Arch. Allergy* 7 103 (1953).
25. LOWRY, T. M.: Optical Rotatory Power (Longmans, Green, London 1933).
26. MORRIS, W. AND YANO, J. T.: The optical rotatory dispersion of simple polypeptides. I. *Proc. nat. Acad. Sci. (U. S.)* 42 596 (1956).
27. MORRIS, W.: The optical rotatory dispersion of simple polypeptides, II. *Proc. nat. Acad. Sci. (U. S.)* 42 736 (1956).
28. BERENDSE, G., BOLTER, H. J., BÖCHER, T., COOK, R., GARDNER, K. H., METZGER, E. UND FLEISHER, G.: Diphosphofructose-Aldolase, Phosphoglycerat-dehyd-Dehydrogenase usw. aus Kassinchenmarkel in chem. Arbeitsgang. *Z. Naturforsch.* 18 555 (1953).
29. SPACKMAN, D. H., STEIN, W. H. AND MOORE, S.: Automatic recording apparatus for use in the chromatography of amino-acids. *Anal. Chem.* 32 1190 (1958).
30. PILL, A. AND MORAN, L.: A modified procedure for the automatic analysis of amino acids. *Anal. Biochem.* 1 187 (1960).
31. CHRISTFIELD, A. M., STEIN, W. H. AND MOORE, S.: Alkylation and identification of the histidine residues of the active site of ribonuclease. *J. biol. Chem.* 238 2415 (1963).
32. PHELPS, R. A. AND CANN, J. R.: On the modification of γ -globulin by acid. *Kochin. Biophys. Acta* (Amsterdam) 23 149 (1957).
33. LEMKE, P. AND DOTY, P.: Optical rotation and the conformation of polypeptides and proteins. *Adv. Protein Chem.* 16 501 (1961).
34. PHELPS, R. Y. AND PUTNAM, F. W.: Chemical composition and molecular parameters of purified plasma proteins. *The Plasma Proteins I* 143 (Academic Press, New York 1960).
35. HIRAO, S. H. AND PUTNAM, F. W.: The cleavage of human γ -globulin by papain. *J. biol. Chem.* 236 121 (1961).
36. HEINER, R., WOODS, K. R. AND EXLER, R. L.: Amino acid analyses of rheumatoid factors and normal γ -globulins. *Proc. Soc. exp. Biol., N. Y.* 119 496 (1962).

Materials and Methods

Patients Investigated

Whole blood samples from 300 mothers without previous history of spontaneous abortion (the control group) were examined during pregnancy for the presence of cold-agglutinating antibodies to assess the normal incidence of this factor. From the same group 100 random samples were selected for the evaluation of serum complement. Similar investigations were also carried out on 222 pregnant mothers with a previous history of spontaneous abortion who also possessed the anti-Tj^a-like hemolysin.

In order that the full range of anti-Tj^a-like activity could be investigated, an additional six patients from the same abortion series, were selected at random for more detailed serological evaluation of the behaviour of the hemolysin in relation to other tests.

Routine serological tests for treponemal infection confirmed the absence of syphilitic conditions in the 522 mothers investigated during pregnancy.

Serological Procedures

(a) *The evaluation of cold-agglutinating antibodies.* This was determined by the ficin test using the slide method. To one drop of 1 percent concentration of commercial ficin in buffered saline was added one drop of serum which was previously inactivated at 56°C for 30 min. To this mixture was then added one drop of pooled group O red cells previously washed with normal saline (0.83% NaCl) to give final concentration of 10⁶ of red cells. At the completion of one hour incubation at 5°C the red cell agglutinates, if present, were examined at room temperature.

(b) *The evaluation of serum complement.* This test consisted of the preparation of optimally sensitised sheep red cells with commercial anti-sheep red cell hemolysin. To avoid possible variations in the value of serum complement due to prolonged storage it was necessary to test the serum samples within 24 h of collection.

Serial saline dilutions of serum to be examined were prepared in standard test tubes. To each of these dilutions was added an equal volume of 4% suspension of sensitised sheep red cells. After thorough mixing the contents of the tubes were placed for 1 h in 37°C water bath. The highest serum dilution showing definite hemolysis at the completion of this incubation period indicated the serum complement value of the blood sample under investigation.

(c) *The evaluation of the anti-Tj^a-like hemolysin.* The routine evaluation of the anti-Tj^a-like hemolysin, unless otherwise discussed in the results of this report, was carried out by the simple addition of 1 volume (0.5 ml) of red cells (2% saline suspension of group B Tj^a-positive red cells) to 1 volume (0.5 ml) of serum. In view of the observation that the anti-Tj^a-like hemolysin does not require sensitisation at 5°C prior to incubation, the test tubes were placed directly into 37°C water bath for one hour then centrifuged for two min at 1000 rpm. The degree of hemolysis was read by visual inspection of the supernatant and recorded as 0 to 4, 0 indicating the absence of hemolysis and 4 complete hemolysis.

Results and Discussion

The cold agglutinating antibody properties of heat inactivated PCH serum have been extensively studied by many investigators as cited by Dacie (1) and probably the most important observation has been the consistent agreement concerning the presence of cold

agglutinating antibodies in addition to hemolysins. LEVINE *et al.*, (4) confirmed that the agglutinating type of cold antibody found in PCH serum as well as the hemolysin do not differ in their specificity for Tj^a-positive red cells. It is however not unusual to find PCH bloods possessing more than one antibody and the presence of anti I in addition to anti Tj^a should be considered possible in some instances, as pointed out by WEINER *et al* (11)

With these observations in mind we investigated the frequency of cold agglutinating antibodies in normal pregnancies and compared these results with the occurrence of similar antibodies in threatened aborters producing anti Tj-like hemolysins. Table I

Table I

The incidence of cold-agglutinating antibodies among mothers possessing anti-Tj^a-like hemolysins and those lacking this hemolytic factor

Degree of cold-agglutinating antibody present in serum	300 control mothers lacking anti-Tj ^a -like hemolysin without history of previous abortion		222 mothers with anti-Tj ^a -like hemolysin, and history of previous abortion	
	No.	%	No.	%
No reaction	215	71.8	157	70.7
Weak to moderate reaction	50	16.6	40	18.0
Strong reaction	35	11.6	25	11.3
Total	300	100.0	222	100.0

shows the distribution of cold-agglutinating antibodies among 300 control mothers and 222 mothers with the anti-Tj-like hemolysin. The identical incidence of mothers lacking cold-agglutinating antibodies, or showing moderate to strong reactivity in both series of patients, suggests that the presence or absence of cold-agglutinating antibodies is in no way associated with the occurrence of the anti-Tj^a like hemolysin.

The 25 samples of serum among the aborters (Table I) which strongly agglutinated random group O red cells at 5 C were also examined for their ability to sensitize pp (Tj^a negative) red cells. The positive results obtained in each case confirmed that the cold-agglutinating antibodies differed in specificity from the anti-Tj^a like hemolysin which was also present in the serum. This preliminary investigation would indicate that in the case of anti Tj^a like hemolysin production the simultaneous occurrence of cold-agglutinating antibodies does not appear to be a characteristic feature

The importance of serum complement in the serology of classical anti-Tj^a hemolysins has been well established. Its complete absence in the serum by either heat inactivation or the introduction of anti-complementary factors is known to prevent hemolysins from taking place. Among PCH patients repeated *in vivo* episodes of red cell hemolysis have also been reported to lower the serum complement concentration (2-9).

In the serology of anti-Tj^a-like hemolysins the present study showed that the participation of serum complement does not appear to be a necessary mechanism for the activation of *in vitro* hemolysins. This observation was first established by examining blood samples in the presence of anticomplementary factors which was achieved by collecting the bloods into various anticoagulants. Table II shows the

Table II

The effect of various anticoagulants on the hemolytic potentiality of an anti-Tj^a-like and immune anti-A₁ serum.

Anti-complement used for the collection of blood samples	Hemolytic titre value of	
	Anti-Tj ^a -like	Immune anti-A ₁
Heparin	1/64	0
Mixed oxalates	1/64	0
Acid, citrate, dextrose	1/64	0
Sodium citrate	1/64	0
Control whole blood	1/64	1/16

effects of this test for an anti-Tj^a like hemolysin as well as for a sample of immune anti-A₁ hemolysin. The findings showed that the degree of Tj^a-like hemolytic reactivity was in no way impaired by this procedure, whilst the immune anti A₁ hemolytic action was completely inactivated by the presence of anticomplementary substances.

The consistent ability of the anti-Tj^a like hemolysins to auto-hemolyse the patients' own red cells under *in vitro* conditions (10) suggested the possibility that the amount of complement present in the serum may differ between aborters and nonaborters. Table III records the frequency of serum complement values by our methods in a series of control pregnancy cases and mothers possessing the anti Tj^a like hemolysins. The apparently normal distribution of these values observed in the two groups of cases rejects the possible

Table III

Serum complement value in patients with anti-Tj^a-like hemolysins and those lacking this factor

Serum complement activity expressed in dilutions	Control persons during pregnancy		Patients with anti-Tj ^a -like hemolysins	
	No.	%	No.	%
1 : 2	—	—	—	—
1 : 4	2	2.0	4	4.1
1 : 8	25	25.0	32	33.3
1 : 16	49	49.0	44	45.8
1 : 32	14	14.0	10	10.4
1 : 64	10	10.0	6	6.4
1 : 128	—	—	—	—
All dilutions	100	100.0	96	100.0

association of serum complement as a likely mechanism for *in vitro* enhancement of hemolysis among aborters.

The effect of heat on the stability of PCH hemolysins has been reported to fluctuate in some instances by STRENS (8). However SCHUBOTZ (7) and HINZ *et al.* (3) conclude that most PCH hemolysins are probably not affected by heating at 56 C for 30 min. The results of similar studies on the behaviour of the anti Tj^a like hemolysin show that heating the serum at 56 C for 30 min completely destroyed the hemolytic activity. The subsequent addition of fresh serum complement of human or animal origin failed to restore the hemolytic action, thus indicating that the anti Tj^a like hemolysin is probably not thermostable.

Prolonged 37 C incubation of serum samples containing these hemolysins also resulted in complete loss of hemolytic activity. This observation suggested the possibility that the rate of *in vitro* elimination of anti Tj^a like observed at 37 C may in some way be associated with the characteristic ability of this hemolysin to appear disappear and reappear at frequent intervals under *in vivo* conditions (10). To evaluate this probability it was necessary to measure the degree of hemolytic activity at different intervals in a patient's serum incubated at 37 C against the degree of hemolytic activity recorded when freshly collected samples of blood were tested from the same person at a corresponding interval of time. Fig. 1 shows the results of several experiments of this nature. The assumption that the *in vivo* and *in vitro* rate of disappearance of the hemolysins could be controlled by constant exposure to the same temperature was not confirmed.




Fig. 1 The behaviour pattern of anti- γ - γ -haemolysins incubated at 57°C (the *in vivo* hemolytic value) compared with the results obtained when fresh samples of blood were collected at corresponding intervals of time (the *in vitro* hemolytic value).

Under *in vitro* conditions the rate of hemolysin inactivation would appear to be directly related to the initial strength of the antibody whilst the *in vivo* behaviour shows typical curves of increased episodes of hemolysin production, followed in some instances by rapid

decrease in its intensity. The *in vivo* behaviour is in this sense referred to as the hemolytic value obtained immediately after the collection of blood. In case 3 the *in vivo* decrease in hemolytic activity appears even faster than the corresponding value recorded for the *in vitro* test. These observations are inclined to support the idea that the appearance of this hemolysin could be the result of active episodes of hemolysin production, induced by substances which perhaps originated from abnormal conceptions.

The ability of anti Tj^a like hemolysins to react directly against Tj^a positive red cells at 37°C without requiring the usual period of preincubation at the cold stage, not only differentiates them from the classical anti Tj^a found in Tj^a negative persons but also from the PCH patients possessing hemolysins of similar specificity. Although the optimum temperature for the direct hemolytic reaction of the anti Tj^a like hemolysin is 37°C, marked differences have frequently been noted. Table IV details the hemolytic action of six

Table IV
Degree of hemolytic reaction of anti-Tj^a-like in relation to temperature range and incubation time.

Case No.	37°C					25°C				5°C				Hemolytic titer value after 1 hour's incubation at 37°C
	15	30	45	60	75	30	45	60	75	15	30	45	60	
1	4	4	4	4	4	4	4	4	0	0	1	3	1	256
	4	4	4	4	1	3	4	4	0	0	0	0	2	128
3	0	3	4	4	0	0	0	3	0	0	0	0	0	32
4	0	0	3	4	0	0	0	2	0	0	0	0	0	16
5	0	0	1	3	0	0	0	0	0	0	0	0	0	8
6	0	0	0	3	0	0	0	0	0	0	0	0	0	4

4 = denotes complete hemolysis. 1, 2 and 3 = partial degree of hemolysis.
0 = no hemolysis.

samples of anti Tj^a like hemolysins with titration values ranging from 1/256 down to 1/4. By testing the reactivity of these samples at various temperatures it was noted that the ability of this hemolysin to react against red cells at temperatures below 37°C appeared to be directly related to the initial strength of the hemolysin, the maximum degree of hemolysis usually being recorded at 37°C. Variations of these results could not be enhanced by prior immersion of the cell-serum suspensions at 5°C.

The positive direct and indirect antiglobulin reactions frequently obtained by testing samples of blood from PCH patients has been reported by DACIE *et al.* (2) to be due to the fixation of serum complement on the erythrocytes together with the hemolytic antibody. Thus complement attachment into red cells is demonstrated by the positive agglutination reaction of the red cells when examined against an anti-complement antiglobulin reagent.

The capacity of anti Tj₁-like hemolysins to destroy red cells *in vitro* without the interaction of complement as mentioned in the earlier part of this report, would present evidence to suggest that hemolysins which do not require serum complement will probably also fail to be sensitized by antiglobulin reagents. This was particularly noticeable when red cells sensitized by anti Tj₁-like hemolysins, which lacked the presence of cold-agglutinating antibodies, were examined against specific anti-alpha, alpha plus beta and gamma globulin serum samples. The consistent failure of the various antiglobulin reagents to react against red cells sensitized by anti-Tj₁-like hemolysins lacking cold-agglutinating antibodies could however also indicate that the antiglobulin reagents do not appear to be specific for the composition of the protein complex to which the anti Tj₁-like factor is associated.

By physicochemical and immunochemical studies, high titered cold-agglutinating antibodies are generally classified as beta 2M (19S) macroglobulins, which characteristically occur between the beta and gamma globulin region of the protein complex. WENZEL *et al.* (11) recently confirmed that the agglutinating factor of PCH antibodies is definitely associated with the 7S gammaglobulin complex. This would suggest that the hemolytic factor should also be found within the same protein fraction.

Investigations so far completed in connection with the location of the anti Tj₁-like hemolysin has confirmed Dr. PHILIP Levine's original observation that the activity of this hemolysin is most intense between the alpha and beta globulin region (Fig. 2). Repeated tests carried out on individual samples of serum containing the anti-Tj₁-like hemolysin have consistently failed to show the presence of this hemolytic factor within the gamma globulin region of the fractionated protein.

Immuno-diffusion studies of the various electrophoretic fractions against specific anti-alpha, alpha plus beta and gamma globulin serum also confirmed that the fractions possessing anti-Tj₁-




Fig. 2. Serum electrophoresis of an anti-Tj^s-like hemolysin for the evaluation of its position within the various protein bands.

like hemolysins were definitely only associated with the alpha and beta protein complex and not the gamma globulins.

Conclusions

Since the main object of the present study was to compare the serological behaviour pattern of the anti-Tj^s-like hemolysin with the known pattern of PCH hemolysins, we have summarised in Table V the differences and similarities between the two hemolytic factors. The most significant deviations observed between the aborters in Western Australia and the PCH patients would appear to be the presence of cold-agglutinating antibodies, demand for serum complement, indirect antiglobulin reactivity thermolability and the established fact that PCH antibodies are associated with

Table V

Comparative reactivity of the hemolysin found in threatened aborters in Western Australia and PCH patients.

	Threatened aborters	PCH patients
1. <i>In vivo</i> autohemolytic reactivity	Always present	Always present
2. Specificity of hemolysin	Anti-T _{ja}	Anti-T _{ja}
3. Cold-agglutinating anti-T _{ja}	Always absent	Always present
4. Demand for serum complement	Not associated with lytic activity	Always necessary for lytic activity
5. Indirect antiglobulin reactivity at 5°C temperature of sensitization	Always absent	Always positive
6. Thermolability of hemolysin	Always thermolabile	Always thermostable
7. Location of lytic activity in protein complex	Only present within the alpha and beta globulin region	Always present within the gamma globulin region

As quoted by DACE (1) LEVINE *et al.* (4) and WATSON *et al.* (11).

gammaglobulins. From the point of view of specificity and *in vivo* autohemolytic reactivity these hemolysins do not appear to be different.

Since the topic concerning the serology of hemolysins is extremely large it would be impossible at this stage to review all the excellent work carried out in this field. But from the evidence presented in this report it is possible to conclude that the serological behaviour of the anti-T_{ja} like hemolysin appears to be significantly different from the classical varieties so far reported.

The observed variation could therefore facilitate the introduction of hypothesis which may or may not be significant with respect to the present interpretation of the mechanism of *in vivo* or *in vitro* hemolysis. It is for example possible to assume that the five dissimilar features recorded in this report between the anti T_{ja} like and the PCH hemolysins may represent the basic differentiating pattern which divides the active form of autohemolysins observed among PCH patients from the 'inactive' form of autohemolysins frequently found among the threatened aborters in Western Australia.

Although the absence of *in vivo* autohemolytic activity among the aborters has so far not been confirmed by current methods of

erythrocyte survival studies, it must be pointed out that the hundreds of abortion cases which have passed through this hospital have never seriously aroused clinicians' suspicion that they were more anaemic than other normally pregnant women.

The observation that the anti Tj^a-like hemolysin appears to be located within the alpha and beta regions of the protein complex would indicate that this lytic factor can probably not be regarded as a classical antibody which as a rule resides either in the 7S or 19S gamma-globulin fractions. Until further evidence is available the decision whether the anti Tj^a-like hemolysin can be regarded as a true antibody must therefore remain in doubt.

MUSCHELL (6) has proposed that the anti Tj^a like hemolysin may possess properties of an acute phase reactant like the C-reactive protein which has a structure complementary to the C-polysaccharide of the pneumococcus and is not regarded as an antibody (5). This hypothesis would regard the anti Tj^a like factor as part of a structure which is complementary to classical Tj.

Acknowledgements. I wish to thank Dr. R. A. BAXTER from the Department of Pathology, King Edward Memorial Hospital for Women, for his continued interest and support in this research. I am also indebted to Dr. P. LARSEN of the Ortho Research Foundation for his valuable suggestions during the course of this study.

Summary

The serological qualities of anti-Tj^a-like hemolysins have been investigated to determine the extent of their common similarities or differences to the classical behaviour of paroxysmal cold hemoglobinuria hemolysins, which in previous accounts has been reported to resemble in specificity and auto-hemolytic reactivity the hemolysins found in threatened aborters. Apart from the features already known to be alike this study also confirms that the hemolysins found in aborters do not require serum complement, are thermostable, fail to be sensitized by anti-human-globulin serum, and lack the characteristic presence of cold-agglutinating antibodies of similar specificity as the hemolysins. Further investigations also showed that these hemolysins are not located in the gamma-globulin region of the protein fraction. Their activity appears most intense between the alpha and beta regions only.

Zusammenfassung

Die serologischen Eigenschaften von anti-Tj^a-artigen Hämolytinen wurden mit denjenigen der klassischen Kälte-hämolytine der paroxysmalen Kälte-hämoglobinurie verglichen, die nach früheren Untersuchungen mit Bezug auf Spezifität und auto-hämolytischer Wirksamkeit den Hämolytinen bei Frauen mit drohendem Abort gleichen. Abgesehen von den bereits als ähnlich bekannten Eigenschaften bestätigte diese Untersuchung auch, daß die Hämolytine beim Abort kein Serumkomplement benötigen, thermostabil sind, mit anti-Mensch-Globulin-Serum nicht reagieren und das charakteristische Vorkommen von Kälteagglutininen gleicher Spezifität vermissen lassen. Weiter

bin ergab sich, daß diese Hämolytine nicht zur Gamma-Globulinfraction gehören. Ihre stärkste Aktivität scheint zwischen der Alpha- und Betazone zu liegen.

Résumé

Les propriétés sérologiques d'hémolytines ressemblant au type anti-Tj^a ont été étudiées et comparées à celles des hémolytines à froid de l'hémoglobinurie paroxysmique qui ressemblent selon des études antérieures quant à leur spécificité et leur activité auto-hémolytique aux hémolytines trouvées dans les cas d'avortement imminent. Cette étude a aussi confirmé à part les propriétés déjà connues pour étant semblables, que les hémolytines trouvées dans les cas d'avortement ne requièrent pas de complément sérique, qu'elles sont thermostables, ne réagissent pas avec de l'antiserum envers les globulines humaines et qu'il leur manque la présence caractéristique des agglutinines à froid de même spécificité. D'autres recherches démontrent que des hémolytines ne font pas partie de la fraction des gamma-globulines. Leur activité la plus forte semble se situer entre la zone alpha et beta.

References

1. DACEY, J. V. The haemolytic anaemias. Congenital and acquired. Part II. The autoimmune haemolytic anaemias, p. 343 (J. & A. Churchill Ltd., London 1962).
2. DACEY, J. V., GORDON, J. H. AND CHRISTOPHER, W. H. Incomplete cold antibodies. Role of complement in sensitization to anti-globulin serum by potentially haemolytic antibodies. *Brit. J. Haemat.* 3, 77 (1957).
3. HIRZ, C. F. J.; PETER, M. E. AND LEVOW, I. H. Studies on immune human hemolysis. I. The kinetics of the Donath-Landsteiner reaction and the Requirement for complement in the reaction. *J. exp. Med.* 113, 177 (1961).
4. LEVINE, P., CELANO, M. J. AND FALKOWSKI, F. The specificity of the antibody in paroxysmal cold hemoglobinuria (PCH). *Transfusion* 3, 278 (1963).
5. MISCHEL, L. H. AND WEATHERS, R. J. Complement fixation in the C-reactive protein system. *Proc. Soc. exp. Biol., N. Y.* 87, 191 (1954).
6. MISCHEL, L. H. Personal communication.
7. SCHUBOTZ, H. Serologie und Klinik der autoimmunhämolytischen Erkrankungen. *Ergeb. inn. Med. Kinderheilk.* 11, 466 (1958).
8. SODERF, A. A.; ZIGLER, W. H. AND WAGLEY, P. F. Observations on the mechanism of hemolysis in paroxysmal (cold) hemoglobinuria. *Blood* 3, 1967 (1948).
9. VAN LOGHEM, J. J., HART, M. A. V. DE AND DOWNES, H. Serologic studies in acquired hemolytic anaemia. *Proc. 6th Congr. Int. Soc. Haemat., Boston 1956*, p. 837 (Grune and Stratton, New York 1958).
10. VOE, G. H., CELANO, M. J., FALKOWSKI, F. AND LEVINE, P. Relationship of hemolysin resembling anti-Tj^a to threatened abortion in Western Australia. *Transfusion* 4, 87 (1964).
11. WEINER, W., GORDON, E. C. AND ROWE, D. A Donath-Landsteiner antibody (non-cyphallic type). *Voer Sang* 9, 684 (1964).

Author's address: Mr G. H. Voe, Department of Pathology, King Edward Memorial Hospital for Women, Subiaco, W. Australia (Australia).

Istituto di Chimica Biologica dell'Università di Genova di Patologia Speciale Medica
dell'Università di Modena

Metabolic Aspects of Erythrocytes and Leukocytes in a Case of Congenital Non-Spherocytic Haemolytic Anaemia

E. STORTI, G. LEONCINI, A. TRALDI AND G. FORNANI

During the course of the research that we have been conducting for many years (1-10) the case of a three-year-old boy is now added to our observations which clinical and hematological data have given a diagnosis of congenital non-spherocytic haemolytic anaemia.

We have examined some aspects of erythrocyte and leukocyte metabolism in this subject and in his family as we have already done in previous cases of a similar nature (4, 6, 8). In particular the content and stability of GSH, the utilization of glucose and the behaviour of the enzyme which conditions it or which are closely connected with it have been evaluated. This research has pointed out pathological behaviour of the activity level and of the electrophoretic properties of G-6-PD of the subject under examination and of the female antecedents.

Case report

A. B. Propositus. At 3 months of age the patient colouring became pallid and he demonstrated arthritis, and splenomegaly. At 5 months of age he was given blood transfusion which was initially well tolerated. Later the therapy had to be suspended due to violent febrile reactions and to rapid post transfusional haemolysis. At the time of admittance the pathological conditions were as follows: RBC 1670000, Hb 32%, globular value 0.96, anisopoikilocytosis, reticulocytes 15%, erythroblastic orthochromatic 8-9%, xantho-schistocytes, platelets 137000, WBC 7900, Serum bilirubin 1.63% with the Hymans van der Berg + direct ——— retarded ++ indirect +++ Coombs test negative, non-pathological haemoglobin, non enhanced haemolysis before and after

The following abbreviations have been used: GSH reduced glutathione; APH acetyl-phenyl-hydrazine; G-6-PD glucose-6-phosphate dehydrogenase; 6-P-GD 6-phosphogluconate dehydrogenase; GR glutathione reductase; AIR methaemoglobin reductase; PK pyruvate kinase; NADH reduced nicotinamide adenine dinucleotide; NADPH reduced nicotinamide adenine dinucleotide phosphate; NADPase NADP glycohydrolase.

The present work has been carried out under the Research Grant HE. 04506-06 of the National Institutes of Health.

incubation. Bone marrow with erythroblastic hyperplasia and features of maturing inhibition. Nothing of note for the granuloblastic series.

Splenectomy has not modified the haemolytic process determining rather the appearance of the erythroblasts. The patient's family (father mother paternal grandmother maternal grandmother maternal grandfather) do not demonstrate any haematologic diseases either from anamnesis or from up to date clinical examinations.

The examinations of the subjects used as controls were normal, for the referred experiments from pathological point of view or from biometric tests.

Research has always been carried out parallelly on the pathological subject and on one control.

Materials and Methods

Blood was drawn with siliconated syringe, and then added to EDTA (2 mg/ml of blood) or heparin (3 U/ml). To separate the leukocytes from the erythrocytes, blood has been added in equal quantities to solution containing 5% dextran, 5% glucose, NaCl 0.9%, and sedimented for an hour at 0°C. The supernatant fraction constituted by the leukocytes was collected by suction then centrifuged for 10 min at 800 rpm. The supernatant was discarded and the cells suspended in 0.15 M KCl. The collected erythrocytes after sedimentation were washed 3 times with 0.15 M KCl and suspended in the same solution. The lysis of the red and white cells was done by adding equal parts of water and freezing 3 times in mixture of dry ice/acetone. The removal of stroma was obtained by means of centrifugation for 30 min at 30 000 g. For the experiments of the utilization of glucose by erythrocytes, the incubation was performed in siliconated containers, whose internal dimensions were 18 x 36 mm (11) sealed by rubber stopper with vertical glass stick, at the end of which was fixed small piece of filter paper saturated with hydrochloride of Hyamine to fix the C^{14} . Incubation was performed at 37°C in thermostat bath, with shaking at 80 rpm. Before and at the end of incubation period, amounts of 2.0 ml of the reaction mixture were taken out, deproteinized with trichloroacetic acid (final concentration 10%) and centrifuged. The precipitate was then washed 3 times with 5% trichloroacetic acid, the supernatants were added again, neutralized with NaOH and brought to volume. Aliquots of these extracts were utilized for chemical determinations of glucose and lactic acid and for assays of the total radioactivity of lactic acid and of phosphorylated esters according to the method previously described (12).

For the experiments of the utilization of glucose in leukocytes the reaction mixture was placed in test tubes, and incubated according to methods described for erythrocytes. Before and after incubation 0.15 ml aliquots were taken out, deproteinized with trichloroacetic acid (final concentration 10%) and centrifuged. The neutralized supernatant was brought to volume and utilized for chemical determination of glucose and of lactic acid.

The GSH content, before and after incubation with APH (13) has been determined by the technique of GROWERY AND PHILLIPS (14) glucose with glucose oxidase (15) lactic acid according to BARKER AND SCHMIDSON (16).

The activities of G-6-PD and of 6-P-GD have been evaluated according to KORNBERG AND HORRICKER (17) and HORRICKER AND SMYTHOOTH (18). The PK activity according to BUCKER AND PYLENDERER (19) GR and MR according to BOROSOVSKY *et al.* (2) The NADPase has been prepared from rat spleen as previously described (20) one unit of NADPase is defined as that quantity of enzyme which splits 0.1 μ mol of NADP in an hour at 37°C.

The G-6-PD properties (sedimentation in sucrose gradient, electrophoresis on starch gel, thermostability affinity constants, pH optimum, and inactivation) have been evaluated according to methods previously described (21).

The content in GSH is expressed in mg/100 ml of erythrocytes. For all enzymatic activities, excluding NADPase, one unit has been described as that quantity of enzyme which determines 1.0/min variation of optical density at 340 nm: the erythrocyte specific activity is expressed in grams of hemoglobin, the leukocyte specific activity in grams of protein.

Spectrophotometric determinations were carried out with an Optics Spectrophotometer CF4: centrifugations have been done on Lourdes LRA and Spisco L2 Centrifuges; determinations of radioactivity on the Packard Tri-Carb Scintilator.

Results

Table I refers to the behaviour of the GSH content and of the erythrocyte enzyme activities of the studied subject and his family. We have taken for examination those enzymes which limit the oxidative shunt, i. e. G-6-PD and 6-P-GD which limits the balance between the oxidized and reduced forms of glutathione and of haemoglobin, i. e. GR and MR which in other cases of haemolytic anaemia showed pathological behaviour. We have studied also PK activity alteration of which (22-29) characterises non-spherocytic haemolytic anaemia of type II of SELWIN AND DACE (24). The only alteration observed has been that of G-6-PD of the propositus, of the mother and of the maternal grandmother: the enzyme of these subjects has an activity level of 50% lower in comparison with controls. The utilisation of glucose by erythrocytes (Table II) was evaluated by the consumption of the monosaccharide, by the synthesis of phosphorylated esters and of lactic acid and by the liberation of CO_2 : it did not present any variations in comparison with control subjects. The small number of reticulocytes present in the blood of the propositus excludes that the highest metabolic grade characteristic of the reticulocytes compensate a reduced activity of the old erythrocytes, both for the utilization process of glucose and for the enzymatic activity level, which are referred to in Table I. A recent research of ours (10) points out the presence of a direct relationship between the leukocytes and erythrocytes defect of G-6-PD in Italian subjects of different ethnical groups, sensitive to drugs and to fava beans. This has induced us to extend our investigations also to the leukocytes.

In all subjects examined the activity level of G-6-PD and 6-P-GD and the utilization of glucose have been evaluated. It has been possible to follow this process only on the basis of the uptake of hexose and of the production of lactate, despite the small quantity of cells obtained. The results referred to in Table III demonstrate

Table I
Glutathione content and enzymatic activities of erythrocytes.

No.	GSH		G-6-PD	6-P-OD	TK	OR		
	before	after APH				MADPH	NADH	MADPH
	72.3	59.4	15.5	12.8	13.8	7.4	1.6	1.7
	± 4.6	± 3.7	± 0.9	± 0.8	± 1.3	± 0.6	± 0.2	± 0.3
mother	70.7	55.2	7.2	13.5	12.2	6.6	1.9	2.0
	81.2	63.5	14.6	12.2	16.6	7.9	2.1	1.5
	75.5	64.1	5.4	12.5	16.5	7.1	1.4	1.7
grandmother	68.2	51.4	13.7	14.1	11.5	5.8	1.2	1.3
grandfather	65.9	53.5	16.5	11.5	12.4	8.3	2.2	2.1
grandmother	77.4	60.6	6.5	11.9	16.0	7.6	1.5	1.8

G content is expressed as mg/100 ml of erythrocytes and the enzymatic activities as specific activities are reported in the text. The relative results to normal subjects are the means of 12 experiments to pathological subjects of 3 experiments.

Table II
Glucose utilization of erythrocytes.

No.	Metabolized glucose		(c) Phosphorylated sugars cpm	Lactic acid		(f) CO ₂ cpm	% M glucose ($\frac{f}{b}$)
	(a) μmol	(b) cpm (a × 6)		(d) μmol	(e) cpm		
	5.2	154 930	16 940	8.4	136 790	1220	
	5.3	160 480	17 720	9.1	141 800	1160	
	4.9	142 250	15 700	7.9	125 240	1310	
	4.9	148 760	18 160	8.7	130 320	1280	
grandmother	5.5	165 010	17 580	9.2	146 500	1190	
grandfather	4.7	148 960	14 990	8.1	132 800	1170	
grandmother	5.9	156 850	17 930	8.5	139 650	1270	

a Incubation mixture contained per ml: 30 μmol of phosphate buffer pH 7.5; 10 μmol of glucose with specific activity of 52,000 counts/minute/μmol; 0.45 ml of erythrocytes. Incubation for 2 h at 37°C. For further indications see text. The relative results of normal subjects (5 experiments), the relative ones to pathological subjects are the means of 2 experiments. Radioisotopes of glucose is lacking because it is not possible to determine the pyruvate radioactivity considering 4-5% of transformed carbon as hexose is found again as pyruvate (cozymatic determinations) etc. Although the experiments have been carried out in uniformly labelled substrate, C¹⁴O₂ is good as a measure of metabolized hexose by oxidative shunt. The recyclicalization of pentosonic compounds by transketolase is in fact very small in erythrocytes (12).

Table III
Enzymatic activities and glucose utilization of the leukocytes.

Subjects	G-6-PD	6-P-GD	Minibolated glucose	Synthesized lactate
Controls	156.4 ± 14	108.5 ± 12	246.8 ± 52.6	393.6 ± 82.4
AB, Propositus	140.3	111.4	302.8	457.8
Father	129.5	102.4	235.0	421.3
Mother	143.4	116.0	352.6	461.0
Paternal grandmother	122.2	100.6	321.3	384.8
Maternal grandfather	130.6	119.3	237.0	314.6
Maternal grandmother	137.5	114.2	286.6	498.8

Enzymatic activities are expressed as specific activity. For the glucose utilization experiments each ml of reaction mixture contained: 30 μ mol of phosphate buffer pH 7.5, 10 μ mol of glucose, 10^6 leukocytes. Incubation for 2 h at 37°C. The results are expressed in μ mol 10^6 cells. For further indications see text. The results relative to normal subjects are the means of 8 experiments, the relative ones to pathological subjects of 3 experiments.

that the two enzymatic activities, and thus even the consumption of glucose and the synthesis of lactate do not present variations between subjects under examination and controls. Our studies show a single alteration that is a diminished activity level of the erythrocyte G-6-PD of the propositus and of the two female antecedents. In an attempt to clarify the nature of such modifications, the characteristics of the enzymatic protein of these subjects have been taken for examination. Beside the erythrocyte enzyme also the leukocyte enzyme has been taken for study because of the previously men-

Table IV
Properties of erythrocytes and leukocytes glucose-6-phosphate dehydrogenase

Subjects	Cells	Enacturation at 37°C per 60 min	Enacturation at 37°C per 2 weeks	10m G-6-PD	10m NADP	pH optimum	Electrophoretic mobility (in mm)
Controls	erythrocytes	9	36	6.2×10^{-3}	2×10^{-2}	8.7	64
	leukocytes	34	62	3.1×10^{-3}	2×10^{-2}	9.1	37
Propositus	erythrocytes	10	32	6.4×10^{-3}	2.2×10^{-2}	8.6	65
	leukocytes	32	68	3.3×10^{-3}	1.8×10^{-2}	9.2	45
Father	erythrocytes	8	40	6.0×10^{-3}	1.9×10^{-2}	8.7	62
	leukocytes	30	65	3.0×10^{-3}	2.0×10^{-2}	9.1	48
Mother	erythrocytes	8	35	6.3×10^{-3}	2.7×10^{-2}	8.8	68
	leukocytes	36	71	3.1×10^{-3}	2.5×10^{-2}	9.0	43

tioned relationship we have demonstrated between the two enzymes in the hemolytic anaemias with the defect of G-6-PD. No modification has been revealed of the two enzymes (Table IV) relative to stability, inactivation, affinity constants for substrate and co-enzyme, pH optimum, constant of sucrose sedimentation. Meanwhile for the erythrocyte enzyme, the electrophoretic migration in starch gel is also normal, the G-6-PD of leukocytes of all three subjects under examination reveal instead diminished migration.

DISCUSSION

On the basis of several cases of congenital non-spherocytic haemolytic anaemia which have been described by various authors (4, 6, 8, 22-37) it has been possible to conclude that these forms are amongst themselves heterogeneous for hereditary for clinical symptomatology and metabolic defects. A decisive contribution in classifying such forms was brought forward in 1952 by SELWIN AND DACIE (24) by auto-haemolysis tests and the consequent subdivision into two types. Type I is characterised by normal auto-haemolysis or by slightly increased auto-haemolysis, but in any case conducted to normal by the addition of glucose or inosine. It has not a serious symptomatology and generally with retarded appearance, and benefits the splenectomy. It is not classifiable on the basis of a precise metabolic defect although many cases have a low level of G-6-PD activity. Type II is instead characterised by greatly increased auto-hemolysis, by very precocious appearance, by seriousness of clinical symptomatology and does not benefit by the splenectomy. Recent research has then demonstrated a diminished level of PK activity (22, 23) of the content in the phosphorylated esters and a diminished turnover of phosphate (29, 22).

In the literature however numerous cases are reported which are unclassifiable into these two types because of a variety of clinical symptomatology and of metabolic defects and which can be classified as atypical forms (4, 6, 8, 30-33, 37). The case which has been observed by us, can apparently be classified as Type II of SELWIN AND DACIE, has instead demonstrated to be an atypical form. Despite the gravity of the clinical symptoms the characteristic features of the syndrome are in fact missing such as augmented auto-hemolysis, modifications of the PK activity and the content of

phosphorylated esters. In the propositus the only alteration observed is a diminished level of erythrocytes G-6-PD activity and a modification of electrophoretic behaviour of the same protein in the leukocytes. Similar modifications are observed in the mother and in the grandmother who never have presented a clinical symptomatology. However other properties of the erythrocyte enzyme are normal (pH optimum, constants of affinity and of sedimentation, thermostability and inactivation). Modified G-6-PD properties have been referred to by KIRKMAN (33) in cases of congenital non-spherocytic haemolytic anaemia with intermediate level of enzyme.

Other metabolic aspects of the erythrocytes and the leukocytes of the studied subject and his family are normal. In the range of the physiological limits are the content of glutathione and its lability, the activity of the systems regulating the balance between the oxidized and reduced forms of glutathione and haemoglobin, consumption of glucose, synthesis of phosphorylated esters, lactate and CO_2 production. In this subject, in the mother and in the grandmother the quantity of metabolised hexose by shunt is normal in spite of the diminished level of G-6-PD. Such behaviour can easily be explained because of the functional conditions of an enzymatic system are very different from whole cells and from ones which have been evaluated in reconstructed systems. In them are realised optimal conditions in concentrations of substrate, pH etc. In the case of G-6-PD when the activity is evaluated in the hemolysates, it has the capacity to oxidate 50 μmol of glucose per hour and per ml of erythrocytes. In the intact cell the rate of glucose metabolised per hour and per ml of erythrocytes by the oxidative shunt is 0.2 to 0.3 μmol . With this rate the erythrocytes needed in NADPH are assured. It is not therefore surprising that the diminished activity of G-6-PD as it is evaluated in the haemolyzate has no meaning for the quantity of glucose metabolised by shunt.

In this sense our recent research has demonstrated (38) that in the erythrocytes of various ages which possess a G-6-PD activity notably different (10 times higher in young cells than in old ones) the quantity of oxidised glucose phosphate by shunt does not vary even when the total uptake of hexose is varied. In the present case as in those already described by us and in other cases referred to in literature, it is impossible to connect the cause of augmented hemolysis to an metabolic defect. The small number of the family does not allow an evaluation of the mechanism of transmission of the defect.

The present observations give only a further evidence of the heterogeneity of forms and of the difficulty of clarifying pathogenesis of the syndrome.

Summary

Some aspects of erythrocytes and leukocytes metabolism have been studied in three year old boy affected by congenital non-spherocytic haemolytic anaemia, and in his family. The activities of glucose-6-phosphate-dehydrogenase, 6-phosphogluconate dehydrogenase, methaemoglobin-reductase, glutathione-reductase and pyruvate-kinase, glutathione content and stability and glucose uptake have been examined. The only metabolic alterations observed are those of G-6-PD of the propositus and his female antecedents. Erythrocyte enzymes have diminished activity and the leukocytes have modified electrophoretic properties.

Résumé

Le métabolisme des érythrocytes et des leucocytes a été étudié chez un garçon de 3 ans atteint d'une anémie hémolytique non-sphérocytaire et chez les membres de sa famille. L'activité de la glucose-6-phosphate-déshydrogénase, de la méthémoglobine réductase et de la pyruvate-kinase, la réorption du glucose, ainsi que le contenu en glutathion et sa stabilité ont été déterminés. Seule la glucose-6-phosphate-déshydrogénase du malade et de ses ancêtres féminins présente des altérations métaboliques. L'activité des enzymes érythrocytaires était diminuée et les leucocytes avaient des propriétés électrophorétiques modifiées.

Zusammenfassung

Bei einem 3 Jahre alten Knaben mit kongenitaler nicht sphärocytärer hämolytischer Anämie und bei seinen Familienangehörigen wurde der Stoffwechsel von Erythrocyten und Leukocyten untersucht. Es wurden die Aktivitäten der Glukose-6-phosphat-dehydrogenase, der 6-phosphogluconatdehydrogenase, der Methämoglobin-Reduktion, der Glutathionreduktase und der Pyruvatkinase, sowie Gehalt und Stabilität von Glutathion und die Aufnahme von Glukose bestimmt. Die einzige Abweichung zeigte die Glukose-6-phosphatdehydrogenase des Patienten und seiner weiblichen Vorfahren. Die Aktivität der Erythrocyten-Enzyme war vermindert, und die Leukocyten wiesen ein abweichendes elektrophoretisches Verhalten auf.

References

1. BOMBARDIERI, A.; FORMANI, G.; SERGI, G.; SETTELE, A. Comportamento di alcuni enzimi eritrocitari di un soggetto favico nel periodo post emolitico. Boll. Soc. ital. Biol. sper. 36: 1215 (1960).
2. BOMBARDIERI, A.; FORMANI, G.; SERGI, G.; FANTONI, A. Biometria di coenzima piridoxico in eritrociti con storia di favismo. Ital. J. Biochem. 10: 212 (1961).
3. BOMBARDIERI, A.; FORMANI, G.; SERGI, G. AND SETTELE, A. Transketolase and transaldolase reactions in the erythrocytes of human subjects with favism history. Biochem. Biophys. Res. Comm. 4: 147 (1961).
4. FORMANI, G.; BOMBARDIERI, E. Comportamento di alcune attività enzimatiche eritrocitarie in tre casi di anemia emolitica ereditaria non sferocitica. Boll. Soc. ital. Biol. sper. 37: 392 (1961).

5. FORMANO, G., LEONCINI, G., LUZZATTO, L. AND SEGGI, G. Glucose metabolism in human erythrocytes from normal and fava bean sensitive subjects. *J. clin. Invest.* 41: 1446 (1967).
6. SEGGI, P., BONOMOZZI, D., FORMANO, G. Utilizzazione del glucosio in eritrociti di soggetti umani affetti da anemia emolitica congenita non sferocitica. *Boll. Soc. Ital. Biol. sper.* 39: 434 (1963).
7. FORMANO, G., SEGGI, P., LEONCINI, G., BONOMOZZI, D. Proprietà della glucosio-6-fosfato deidrogenasi degli eritrociti di soggetti umani sensibili alle fave. *Enzym. biol. clin.* 3: 137 (1963).
8. FORMANO, G., BLANCHINI, E., LEONCINI, G. AND FANTONI, A. Metabolic aspects of red cells in congenital non spherocytic hemolytic anemia. *Brit. J. Haemat.* 10: 23 (1964).
9. BONOMOZZI, A.; FORMANO, G., FANTONI, A., LEONCINI, G. AND SEGGI, P. Relationship between age and enzymatic activities in human erythrocytes from normal and fava bean sensitive subjects. *J. clin. Invest.* 43: 834 (1964).
10. BONOMOZZI, A., FORMANO, G.; LEONCINI, G. AND FANTONI, A. Electrophoretic heterogeneity of erythrocyte and leukocyte glucosio-6-phosphate dehydrogenase in Italian subjects from different ethnic groups. *Nature*, submitted for publication (1965).
11. BONOMOZZI, A., FORMANO, G.; LEONCINI, G.; SEGGI, P., FANTONI, A.; Inibizione del glucosio sulla utilizzazione del fruttosio in eritrociti umani maturi. *Ital. J. Biochem.* 12: (1963).
12. BONOMOZZI, A., FORMANO, G., LEONCINI, G., SEGGI, P., CRIVELLI, O. Metabolismo del fruttosio negli eritrociti umani maturi. *Ital. J. Biochem.* 12: 171 (1963).
13. BEUTLER, E. The Glutathione instability of drug sensitive red cells: method for the *in vitro* detection of drug sensitivity. *J. lab. clin. Med.* 49: 87 (1957).
14. GRIFFITH, R. R. AND PHILLIPS, P. H. A modification of the nitroprusside method of analysis for glutathione. *Arch. Biochem.* 30: 217 (1951).
15. KAPLAN, N. O. Enzymatic determination of free sugars. *Methods in Enzymol.* ed. New York Academic Press, Vol. 3, p. 107 (1957).
16. BARBER, S. B. AND SUMNERSON, W. H. Colorimetric determination of lactic acid in biological material. *J. biol. Chem.* 130: 535 (1941).
17. KORNBERG, A. AND HORRIGER, B. L. Glucose-6-phosphate dehydrogenase. *Methods in Enzymol.* ed. New York Academic Press, Vol. 1, p. 323 (1955).
18. HORRIGER, B. I. AND SUMNERSON, P. Z. Phosphogluconic acid dehydrogenase from yeast. *J. biol. Chem.* 193: 571 (1951).
19. BOONER, T. AND FLEISHER, G. Pyruvate kinase from muscle. *Methods in Enzymol.* ed. New York Academic Press, Vol. 1, p. 435 (1955).
20. FANTONI, A., LEONCINI, G., CALZANO, P., CARLEVARO, C. AND FORMANO, G. Effect of NADP-glycophosphate on the glucosio-6-phosphate dehydrogenase. *Enzym. biol. clin.* 5: 161 (1963).
21. BONOMOZZI, A., FORMANO, G., FANTONI, A. AND LEONCINI, G. Purification and properties of glucosio-6-phosphate dehydrogenase of human leukocytes and erythrocytes. *Ital. J. Biochem.* 14: 218 (1965).
22. TAKAKA, K. R., VALENTINE, W. V. AND MIWA, S. Pyruvate kinase (PK) deficiency in hereditary non spherocytic hemolytic anemia. *Blood* 18: 794 (1961).
23. BRUNETTI, P., FUCEROU, A. AND VECI, G. Anemia emolitica congenita non sferocitica da carenza di piruvico cinasi (PK). *Acta haemat. Basel* 67: 505 (1962).
24. SELWYN, J. G. AND DACE, J. V. Autohemolysis and other changes resulting from the incubation *in vitro* of red cells from patients with congenital hemolytic anemia. *Blood* 9: 414 (1954).
25. DACE, J. B., MOLLISON, P. L., RICHARDSON, V., SELWYN, J. G. AND BRADON, L. Atypical congenital hemolytic anemia. *Quart. J. Med.* 22: 79 (1953).

26. MOTULSKY A. G., CROWY W. H. AND RAPAPORT H. Hereditary non spherocytic hemolytic disease. A Study of singular familial hemolytic syndrome. *Blood* 9: 749 (1954)
27. MOTULSKY A. G.; GARRO, B. V.; BERGLANDT J. AND FINCH, C. A. Erythrocyte carbohydrate metabolism in hereditary hemolytic anemias. *Amer J Med.* 19: 291 (1955).
28. FRANKED, T. A. J. Inborn errors of metabolism in red cells of congenital hemolytic anemia. *Amer J Med.* 22: 724 (1957)
29. NEWTON, W. A. AND BARR, J. C. Glutathione synth. chronic non spherocytic hemolytic anemia. *Amer J Dis. Child.* 95: 501 (1958)
30. LÖWEN, G. W. UND WALLER, H. D. Konstitutionselle Fermentanomalien der Erythrocyten. *Munch. med. Woch.* 100: 735 (1958)
31. ZUCKERMAN, W. H. AND LEVINE, R. E. Metabolic abnormalities of erythrocytes from patients with congenital non spherocytic anemia. *J. Pediat.* 55: 519 (1959).
32. SANDER, N. T. AND DIAMOND L. K. Enzyme deficiency in erythrocytes in congenital non spherocytic erythritic anemia. *Pediatrics* 24: 245 (1959).
33. KILGUS, H. V. RILEY H. D. AND CROWELL, B. D. Different enzymic expressions of mutants of human glucose-6-phosphate dehydrogenase. *Proc. natl. Acad. Sci. Wash.* 46: 138 (1960)
34. CONTRA, M. E., CROWY W. H. AND HOWE, D. L. Hereditary non spherocytic hemolytic disease. *Amer J Med.* 29: 811 (1960).
35. DE SANDRE, G., DIOTTO, G., BERTELLI, G. Il consumo eritrocitario di glucosio nelle anemie emolitiche costituzionali non sferocitiche. *Atti I Symp. Europ. Enzymol. Med. Milano*, p. 390 (1961)
36. ROBINSON, M. A., LONER, P. B. AND DE GUCHY, G. C. Red cell metabolism in non spherocytic congenital hemolytic anemia. *Brit. J Haemat.* 7: 327 (1961)
37. KILGUS, H. V. AND RILEY H. D. Congenital non spherocytic hemolytic anemia. Studies on family with qualitative defect in glucose-6-phosphate dehydrogenase. *Amer J Dis. Child* 102: 313 (1961)
38. FANTONI, A., LEONCHI, G.; SLOVI, P.; FORMAGGI, G. Rapporti tra Utilizzazione del glucosio l'età eritrocitaria. *Boll. Soc. Ital. Biol. sper.* 41: 568 (1965).

Authors' addresses: Drs. G. Formaggi and G. Leonchi, Istituto di Chimica Biologica dell'Università, Classe
 Drs. A. Fantoni and E. Sclavi, Dep. di Patologia Speciale Medica dell'Università,
 Padova (Italy).

From the University of Bergen, School of Medicine, the Gade Institute, Department of Pathology Bergen (Head: Prof. Dr. E. WAALER)

Separation of Lymphocytes from Human Blood

J O LARVIK

The circulating lymphocyte has recently become a cell of particular interest, because of its possible role as an immunologically competent cell. A number of publications from the last three years seem to indicate that lymphocytes from human blood are able to react to the stimulation of added antigens *in vitro* with morphological transformation and possibly specific antibody production (2 4 5 8, 9 14)

The study of the *in vitro* reactivity of human lymphocytes has been hampered by the difficulties in obtaining pure lymphocyte cultures. Most investigations have been performed on mixed leukocyte cultures.

Previous methods of separating lymphocytes from granulocytes have been based on centrifuging cells in an albumin density gradient (17) a gelatin sedimentation technique (1) a magnetic technique using the phagocytic ability of granulocytes and monocytes for iron (13) or the adhesion of granulocytes and monocytes to glass wool (10) or to glass beads (7 15). Most of the methods are rather complicated and there is always a risk that the cells are damaged by the procedure. A simple cotton wool filtration method for separating lymphocytes from heparinized blood was described by FICHTELIUS (6) and more recently used by WALKER *et al.* (18)

The purpose of the present investigation was to test the efficiency and reliability of the cotton wool separation of lymphocytes from leukocyte suspensions, using a modification of FICHTELIUS' technique. Leucocytes were suspended in platelet poor fresh autologous plasma and the differential counts and yields of separated cells estimated. The standard technique was compared with modifications, using different media for the leukocyte suspensions and different types of cotton wool columns.



Fig. 1. Microphotograph of type 1 cotton wool fibers. Polarized light.

Fig. 2. Microphotograph of type 2 cotton wool fibers. Polarized light.

Material and Methods

Cotton wool columns were prepared from Pyrex glass cylinders, 100 mm in length and with an internal diameter of 13 mm. The cylinders were filled with a weighed amount of borosilicate cotton wool. The standard columns contained 400 mg cotton wool

in a cylinder volume of 12 ml. Larger columns were prepared for the separation of lymphocytes from larger volumes of blood. The larger volumes contained 1400 mg absorbent cotton wool in cylinder volume of 45 ml (120 x 22 mm).

Two types of cotton wool were used in the experiments. Type 1 used in most of the experiments, showed irregularly dissected cotton wool fibers (Fig. 1) while type 2, used in one series of separations, had softer consistence with smooth and regular fibres (Fig. 2). In another experiment small columns containing standard type cotton wool with varying tightness, weighing 200 mg, 400 mg and 600 mg, were used.

All glassware used was cleaned as for tissue culturing and sterilized by dry heat at 160 °C for 1 h. Rubber stoppers for the ends of the cotton wool columns were sterilized by autoclaving.

Heparinized venous blood was mixed with dextran and the erythrocytes allowed to sediment to obtain leukocytes in platelet rich plasma. Platelet poor leukocyte suspension was prepared by low speed centrifugation, as previously described (11). The leukocytes were gently resuspended in different media: Ringer solution, stored pooled plasma, inactivated autologous plasma, fresh autologous plasma and fresh isologous plasma. Plasma was obtained from heparinized blood by high speed centrifugation and the volumes added to the leukocytes were equivalent to the volumes of leukocyte suspension before the separation of platelets.

The leukocyte suspensions were thoroughly mixed before being transferred to series of cotton wool columns. Six ml of leukocyte suspension were applied to the small columns, while the larger columns received 25 ml of cell suspension.

The columns were stoppered and incubated for 90 min at 37 °C. They were then washed through with volume of Ringer solution, equal to the volume of cells added to the columns. The washings were concentrated by centrifugation at 500 rpm (40 g) for 10 min. The cells were resuspended in AB serum.

Cell counts in the leukocyte suspensions and the concentrated effluents were estimated and means made for differential counts. The methods of Dacie (3) were followed. The cell counts in the effluents were corrected for the changes in volume.

Results

Table I gives the yields of granulocytes and lymphocytes and the differential counts in the effluents from small and large columns that had received leukocytes suspended in fresh, autologous plasma. The figures show that only about 1% of the granulocytes passed the small columns, while more than 50% of the lymphocytes were recovered. The proportions of lymphocytes found in the effluents varied within narrow limits. The total yield on the other hand varied from 60 to 100% of the lymphocytes added to the columns. In the large columns the granulocytes were completely retained. The lymphocyte yields were lower than in the small columns. Due to the large size of the columns, however $8-10 \times 10^6$ lymphocytes could be obtained from one separation.

In Table II the results of separating lymphocytes from platelet rich versus platelet poor leukocyte suspensions are shown. All columns retained the granulocytes almost completely and the

Table I
Lymphocyte separation in cotton wool columns.

	Cell No. per mm ²	Differential counts (%)			
		granulo- cytes	lympho- cytes	mono- cytes	damaged cells
<i>Small columns</i>					
Before separation	2800	70	25	1	4
After separation	750 (500-950)	5 (2-4)	86 (84-90)	0	11 (7-14)
<i>Large columns</i>					
Before separation	2200	54	31	1	14
After separation	500 (425-550)	0	78 (75-82)	0	22 (17-25)
		Yield			
		all cells	granulocytes	lymphocytes	
<i>Small columns</i>		26.8 (18-34)	1.0 (0.7-1.8)	91.4 (60-108)	
<i>Large columns</i>		22.7 (19.3-25)	0	56.6 (46.7-60.5)	

Mean and range from 5 columns.

Expressed as percentage of cells added to columns.

Table II
Lymphocyte separation from platelet-rich versus platelet-poor leukocyte suspension.

Suspension	Cell No. per mm ²	granulo- cytes	Differential counts (%)		
			lympho- cytes	mono- cytes	damaged cells
<i>Platelet-rich</i>					
Before separation	1600	70	20	4	6
After separation	165 (150-200)	2 (0-3)	90 (89-92)	0	8 (6-11)
<i>Platelet-poor</i>					
Before separation	1550	66	28	2	4
After separation	230 (180-365)	0	89 (88-90)	0	11 (10-12)
Suspension	all cells	Yield**			
		granulocytes		lymphocytes	
<i>Platelet-rich*</i>	10.3 (9.4-12.5)	0.3 (0-0.5)		46.5 (42-55.5)	
<i>Platelet-poor</i>	15.5 (11.6-23.5)	0		51.5 (37.4-74.2)	

Mean and range from 5 columns.

Expressed as percentage of cells added to columns.

Table III

Lymphocyte separation from leukocytes suspended in Ringer solution, stored plasma and fresh plasma.

Suspension	Cell No. per mm ³	Differential counts (%)			
		granulo- cytes	lympho- cytes	mono- cytes	damaged cells
<i>Ringer solution</i>					
Before separation	2200	72	16	4	8
After separation	710	48	31	0	21
	(670-750)	(46-51)	(30-32)		(17-24)
<i>Stored plasma</i>					
Before separation	2100	76	18	3	3
After separation	560	56	41	0	3
	(350-700)	(46-62)	(36-49)		(2-5)
<i>Fresh plasma</i>					
Before separation	2200	76	16	3	5
After separation	215	1	90	0	0
	(135-283)	(0-3)	(87-92)		(5-12)
Suspension	all cells	Yield ^{ab}			
		granulocytes			lymphocytes
<i>Ringer solution^a</i>	32.7	21.7			62.5
	(30.5-34)	(19.5-24)			(37-68)
<i>Stored plasma^a</i>	24	19			57.5
	(16.7-33.5)	(12-25.5)			(39-71)
<i>Fresh plasma^a</i>	9.8	0.15			54.4
	(6.1-15)	(0-0.7)			(34.5-74)

^aMean and range from 2 columns.

^bMean and range from 5 columns.

Expressed as percentage of cells added to columns.

effluents from all columns contained about 90 % lymphocytes, the rest being damaged cells. The yields of lymphocytes from the two leukocyte suspensions showed no significant difference.

The effluents from the columns having received leukocytes in Ringer solution and in stored plasma showed a high percentage of granulocytes (Table III). The yields of lymphocytes showed no clear difference. There was no difference in the degree of granulocyte contamination or lymphocyte yield between the Ringer and stored plasma suspensions.

The separation of lymphocytes from leukocytes suspended in heat inactivated plasma gave results closely similar to those obtained from leukocytes in fresh plasma. No difference was found between cells suspended in autologous or isologous plasma (Table IV).

Table IV

Lymphocyte separation from leukocytes suspended in inactivated autologous plasma, fresh autologous plasma and fresh allogeneic plasma.

Suspension	Cell No. per mm ³	Differential counts (%)			
		granulo- cytes	lympho- cytes	mono- cytes	damaged cells
<i>Inactivated autologous plasma</i>					
Before separation	1000	65	27	2	6
After separation	160	1	90	0	8
	(133-180)	(0-3)	(88-93)		(5-11)
<i>Fresh, autologous plasma</i>					
Before separation	1530	66	28	2	4
After separation	240	0	89	0	11
	(180-365)		(88-90)		(10-12)
<i>Fresh, allogeneic plasma</i>					
Before separation	1600	70	20	3	7
After separation	220	1	87	0	12
	(190-250)	(0-1)	(86-88)		(12-13)
Suspension	all cells	Yield* granulocytes	lymphocytes		
<i>Inactivated, autologous plasma*</i>	15.9	0.5	55		
	(13.5-18)	(0-0.6)	(45.5-62)		
<i>Fresh, autologous plasma*</i>	15.5	0	51.5		
	(11.6-23.5)		(37.4-74.2)		
<i>Fresh, allogeneic plasma*</i>	19.8	0.1	56.2		
	(11.9-15.6)	(0-0.2)	(46.4-62.5)		

*Mean and range from 5 columns.

*Mean and range from 2 columns.

Expressed as percentage of cells added to columns.

Lymphocyte separation in small columns containing cotton wool type 2 gave a high degree of granulocyte contamination (Table V)

Loose columns containing 200 mg of standard type cotton wool gave a significantly higher degree of granulocyte contamination than columns with 400 mg (standard columns) and 600 mg (Table VI) The lymphocyte yield was lower in the effluents from the tight columns.

Discussion

The main advantage of the cotton wool separation method is its simplicity. No complicated or expensive equipment is necessary. The results also show that a complete separation of lymphocytes from granulocytes is possible. Although most erythrocytes are

Table V

Lymphocyte separation in small cotton wool columns, containing different types of cotton wool.

Cotton wool	Cell No. per mm ²	Differential counts (%)			
		granulo- cytes	lympho- cytes	mono- cytes	damaged cells
<i>Type 1</i>					
Before separation	2200	76	16	9	5
After separation	215 (135-285)	1 (0-5)	90 (87-92)	0	9 (5-12)
<i>Type</i>					
Before separation	1500	80	16	2	2
After separation	370 (300-435)	26 (21-29)	61 (58-63)	1 (0-1)	13 (11-17)
Cotton wool	all cells	yield granulocytes		lymphocytes	
<i>Type 1</i>	9.8 (6.1-13)	0.15 (0-0.7)		54.4 (34.5-74)	
<i>Type 2</i>	24.7 (20-29)	8.0 (6.9-10.5)		91.7 (73-109)	

Mean and range from 5 columns.

Expressed as percentage of cells added to columns.

Table VI

Lymphocyte separation in small cotton wool columns of varying tightness.

	Cell No. per mm ²	Differential counts (%)			
		granulo- cytes	lympho- cytes	mono- cytes	damaged cells
Before separation	2200	76	16	9	5
After separation					
200 mg columns ^a	317 (270-363)	8 (8-8)	86 (83-87)	0	6 (5-7)
400 mg columns	215 (135-285)	1 (0-3)	90 (87-92)	0	9 (5-12)
600 mg columns	116 (100-132)	0	90 (89-90)	0	10 (10-11)
	all cells	yield ^a		lymphocytes	
		granulocytes			
200 mg columns ^a	14.4 (12.3-16.6)	1.5 (1.3-1.7)		77.5 (66.7-88.1)	
400 mg columns	9.8 (6.1-13)	0.15 (0-0.7)		54.4 (34.5-74)	
600 mg columns	5.3 (4.5-6)			23.6 (23.6-35.6)	

Mean and range from 2 columns.

Mean and range from 5 columns.

Expressed as percentage of cells added to columns

separated by dextran sedimentation, some erythrocytes are always applied to the columns. Non-aggregated erythrocytes are not retained by the columns. The effluents therefore always contained a similar or higher number of erythrocytes than lymphocytes. Being non-nucleated cells with only slight tendency to morphological change and degeneration and relative low metabolic activity the erythrocyte contamination seems to be of less importance than contamination with granulocytes and thrombocytes.

The volume of cell suspension applied to the columns was of importance for the efficiency of lymphocyte separation. The small columns did not retain the granulocytes in more than 8-9 ml leukocyte suspension. This was clearly dependent on the number of granulocytes and also somewhat dependent on the number of platelets in the leukocyte suspensions. It was also of importance not to increase the volume of the washing fluid over the volume of the cell suspension applied to the columns. A higher lymphocyte yield was obtained by increasing the washout, but the main purpose of the separation procedure was to obtain pure lymphocyte suspensions, the total number of lymphocytes obtained being of secondary importance.

The yield of lymphocytes was comparable to the values obtained by RABINOWITZ (15) with glass bead columns. The yields showed more variations than those obtained from glass bead columns. This is probably explained by the difficulties in obtaining standardized cotton wool columns. The volume and weight of the columns were constant, but there may probably have been variations in the tightness of cotton wool within each column with consequent variation in the retaining ability.

Fresh plasma is essential for the adhesion of granulocytes to the cotton wool and therefore also for the separation of lymphocytes from granulocytes. Leukocytes suspended in stored plasma gave no better results than cells suspended in Ringer solution. The higher viscosity of plasma suspensions is therefore of minor importance. In the glass bead columns fresh plasma was also found to be essential for the retaining of granulocytes, but in contrast to our findings inactivated serum gave poor separation (15). This discrepancy may be due to a different mechanism for the adhesion of granulocytes to cotton wool fibers as compared to glass beads.

A fresh serum adherence factor has been found to enhance the ability of granulocytes to stick to a glass surface (15, 16). This factor

appeared to be destroyed by heat-inactivation. Factors causing granulocyte adhesion to cotton wool fibers during incubation, however appear to be heat stable but storage labile.

The experiments with columns of different cotton wool types showed that there is a significant variation in granulocyte retaining ability. The cotton wool of type 2 microscopically showed a smooth and unbroken surface of the fibers compared to type 1 where the fibers were distorted and twisted. The latter type appeared to have a stronger attraction for the granulocytes.

The percentage of cells with damaged nuclear or cytoplasmic membranes was quite high in the smears made from deposits after centrifugation of leukocyte suspensions and effluents. Phase contrast microscopy and acridine orange vital staining of the effluents showed a low degree of cell damage (12). Most of the smudge cells found in the smears therefore probably were caused by the spreading of the cells. Cell vitality may on the other hand, be reduced without obvious morphological change. Cell culture studies on lymphocytes separated in cotton wool columns with evaluation of cell vitality are to be reported.

Summary

A simple modification of the cotton wool lymphocyte separation method of Fickertius is described. The separation gave almost pure lymphocyte effluents but the actual yield of lymphocytes was quite variable. Fresh plasma was essential for the adhesion of granulocytes to the cotton wool columns. The efficiency of the separation was dependent on the type of cotton wool used and the tightness of the column.

Zusammenfassung

Es wird eine einfache Modifikation der Baumwollmethode von Fickertius zur Isolierung von Lymphozyten beschrieben. Die Trennung ergab einen nahezu rein lymphozytären Abfluß, aber der wirkliche Ertrag an Lymphozyten war sehr wechselnd. Wesentlich für die Haftung der Granulozyten in der Baumwollstule war Frischplasma. Die Ausbeute der Trennung war abhängig von der Art der verwendeten Baumwolle und von der Dichte der Säulen.

Résumé

Une modification simple de la méthode de Fickertius servant à la séparation des lymphocytes, est décrite. La séparation donne un flux presque pur de lymphocytes, mais le rendement quantitatif en lymphocytes est très variable. L'emploi de plasma frais est essentiel pour l'adhésion des granulocytes aux colonnes de coton. L'efficacité du procédé dépend de l'espèce de coton employé et de la densité des colonnes.

References

1. COULSON, A. S. AND CHALMERS, D. G. Separation of viable lymphocytes from human blood. *Lancet* *1*: 468 (1964).
2. COWLESD, D. C. AND QUADRINO, H. Effects of some antigens on leukocyte cultures. *J. Path. Bact.* *89*: 63 (1963).
3. DACEY, J. V. *Practical Haematology* 2nd. ed. (J. & A. Churchill, London 1956).
4. ELVES, M. W.; ROATH, S.; TAYLOR, H. AND ISRAELS, M. C. G. The *in vitro* production of antibody lymphocytes. *Lancet* *1*: 1292 (1963).
5. FORBES, I. J. Specific and non-specific stimulation of antibody synthesis by human leucocytes *in vitro*. *Lancet* *1*: 196 (1963).
6. FICHTELER, K. E. A simple method to separate lymphocytes from the blood. *Acta Soc. Med. Upsal.* *35*: 27 (1931).
7. GARVY, J. E. Factors affecting the adhesiveness of human leukocytes and platelets *in vitro*. *J. exp. Med.* *114*: 51 (1961).
8. HENNINGSON, H., BACH, F., KOLONY, R. L., FUSCHER, J. L. AND HANSEN, V. Immune response and tolerance of human peripheral blood lymphocytes *in vitro*. *Science* *142*: 1185 (1963).
9. HOLLAND, P. AND MACHES, A. M. Drug-induced *in vitro* stimulation of peripheral lymphocytes. *Lancet* *1*: 1368 (1964).
10. JONHON, F. M. AND GARVY, J. E. Separation of lymphocytes in human blood by means of glass wool columns. *Proc. Soc. exp. Biol.*, *11*: 402, 333 (1959).
11. LARVIE, J. O. The transformation of human mononuclear leukocytes *in vitro*. I. Comparison of leukocytes in suspension and attached to coverslips. *Acta haemat.* (in press).
12. LARVIE, J. O. The transformation of human mononuclear leukocytes *in vitro*. II. Fixation of large mononuclear cells on coverslips. *Acta haemat.* (in press).
13. LEVINE, S. Magnetic techniques for *in vitro* isolation of leukocytes. *Science* *121*: 185 (1956).
14. PRAEMAN, G., LYCHETTE, R. R. AND FITZGERALD, P. H. Tuberculin-induced metastasis in peripheral blood leukocytes. *Lancet* *1*: 637 (1963).
15. RABINOWITZ, Y. Separation of lymphocytes, polymorphonuclear leukocytes and monocytes on glass columns, including tissue culture observations. *Blood* *21*: 811 (1964).
16. RABINOWITZ, Y. AND SCHERER, R. Monocytic cell of normal blood, Schilling and Vargh leukemia, and leukemic reticulo-endotheliosis in slide chambers. *Blood* *20*: 455 (1962).
17. SPANSON, A. L. AND ALEXANDER, R. F. Albumin gradient method for separating the different white cells of blood, applied to the concentration of circulating tumour cells. *Nature (Lond.)* *181*: 863 (1940).
18. WALKER, R. I., HENSON, J. C. AND PALMER, J. G. Leukocyte labeling with inorganic radiophosphorus. *Am. J. Physiol.* *201*: 1137 (1961).

Medical Department B, Copenhagen County Hospital, Hellerup
(Chief Dr P Riss)

A New Technique for the Histochemical Demonstration of Phosphorylase in Blood Films

H R. WULFF AND M. SØRENSEN

Considerable interest is attached to the phosphorylase activity of leucocytes, since this enzyme in association with various debranching factors is responsible for the degradation of stored glycogen. The enzyme catalyzes the following process by splitting 1-4 linkages between the glucose units of the polysaccharide molecule

$$\text{Phosphate} + (\text{glucose}) \rightleftharpoons (\text{glucose})_{n-1} + \text{glucose-1 phosphate}$$

Under *in vitro* conditions this reaction is readily reversed with the result that polysaccharide in the form of unbranched chains of glucose units is formed from glucose-1 phosphate, but *in vivo* glycogen synthesis possibly only takes place via a different pathway involving uridine diphosphate glucose (10)

A reliable technique for the histochemical demonstration of phosphorylase in tissue sections was first developed by TAKEUCHI AND KURIAKI (7). The sections were incubated in a medium containing glucose-1 phosphate, and an iodophilic polysaccharide was synthesized in cells possessing phosphorylase activity. Addition of muscle adenylic acid and a small amount of glycogen as a primer was found to stimulate the reaction.

The histochemical demonstration of phosphorylase activity in blood films has, however, presented difficulties, since direct application of TAKEUCHI's medium on air-dried films causes cell damage which prevents the reaction (9). To overcome this difficulty brief prefixation of the blood films either in methanol (6, 8) or in dilute acetone (3) has been advocated. In our hands, however, these methods give inconstant staining results due to enzyme destruction during fixation.

We therefore developed the following technique for the haematological application of the phosphorylase reaction, which permits the use of unfixed air-dried blood films, due to the protective effect of a high concentration of polyvinyl pyrrolidone in the incubating medium.

Method

Incubating Medium

The incubating medium, which was based on ELLIOT and PALEAM's medium (2), was composed as follows:

glucose-1-phosphate (dipotassium salt)	100 mg
adenosine-3-phosphoric acid	10 mg
sodium fluoride	20 mg
glycogen	4 mg
acetate buffer 0.1 M pH 6.0	10 ml
polyvinyl pyrrolidone (average MW = 12,000)	2 g
ethanol	1 ml

The various components were dissolved in the buffer solution before the addition of ethanol. When stored in the refrigerator the medium was found to be stable for at least one week. The medium was heated to room temperature before use. Glucose 1 phosphate and adenosine-3-phosphoric acid were obtained from Sigma, U.S.A., sodium fluoride and glycogen from Merck, Germany and polyvinyl pyrrolidone from Koch-Light, Great Britain.



Fig. 1 Incubation procedure. The inverted blood film is placed on top of thick slide with concavity which contains the incubating medium.

Histochemical Procedure

- (1) A film of capillary blood (or film of leucocyte concentrate) was dried in air and was left for not longer than 90 min.
- (2) The blood film was incubated in the incubating medium for one hour at 37°C under conditions suitable to prevent evaporation. For routine purposes thick slide with central shallow concavity (22 mm in diameter) was used. The concavity was filled with incubating medium, and the slide with the blood film was inverted and placed firmly on top of the thick slide (Fig. 1). Subsequently the preparation was placed in an incubator.
- (3) The blood film was removed from the thick slide, dipped in 40° ethanol and dried quickly in hot air.
- (4) Next, the blood film was fixed for one minute in methanol and dried in air.
- (5) Before examination under the microscope coverslip was mounted on the area of the blood film which had been in contact with the incubating medium, using drop of glycerine-saline (2 ml of Gram's saline solution to 3 ml of glycerine). The resulting staining reaction was stable for several hours.
- (6) When desirable the preparation was stored for later examinations after removal of the coverslip and rinsing in 40° ethanol.




Fig. 2 Phosphorylase reaction. a) Neutrophils, lymphocytes and thrombocytes in leucocyte concentrate film. b) Neutrophil and lymphocyte in a blood film. c) Basophil. d) Monocyte. e) Eosinophil.

Results

For the purpose of describing the method we confined our study to healthy subjects. The leucocytes in the blood films were well preserved morphologically after incubation, and when the films had been mounted in an iodine-containing medium the great majority of the different types of white cells presented a blue or violet staining reaction (Fig. 2).

The *neutrophilic granulocytes* gave the strongest staining reaction, since all cells belonging to this type showed a uniform coloration of moderate intensity. All *monocytes* also gave a uniform, but weaker staining of the cytoplasm. In the majority of the *lymphocytes* the narrow cytoplasmic rim gave a weak or moderate diffuse staining reaction or contained distinct iodophilic granules, but some were completely negative. In the *eosinophilic granulocytes* the granules were negative, but the intergranular substance was stained with a moderate intensity. *Basophilic granulocytes* contained coarse intensely stained granules, probably representing the basophilic granules. The identification of this cell type was facilitated by the examination of films of leucocyte concentrates prepared by a

modification of EFRATI and ROZENSAJN's method (1). The *thrombocytes* contained an intensely stained coarse granule probably at the site of the granulomere. The *erythrocytes* usually washed off during incubation.

Evaluation of the Method

A series of experiments were made to test the specificity of the method and the influence of some of the components of the incubating medium.

Specificity of the reaction. When glucose 1-phosphate was omitted from the incubating medium no staining was observed in any cell type, indicating that the iodophilic substances were synthesised during incubation and did not represent preformed polysaccharides. This finding is in agreement with the fact that preformed glycogen in normal blood leucocytes is not iodophilic (9). Substitution of glucose 1 phosphate by uridine diphosphate glucose also abolished the staining reaction, indicating that the polysaccharide synthesis takes place directly from glucose 1-phosphate and not via the glycogen synthetase system.

Effect of polyvinyl pyrrolidone. The effect of the addition of polyvinyl pyrrolidone was tested by preparing a series of incubating media containing different amounts of this substance. A rough estimate of the resulting staining intensity of lymphocytes, neutrophils and thrombocytes and the cellular damage incurred during incubation is recorded in Table I. It appears from this experiment that increasing amounts of polyvinyl pyrrolidone up to an optimum of 2 to 2.5 g increase the reaction by preventing damage to the leucocytes. Greater amounts inhibit the enzyme reaction.

Effect of ethanol. In similar experiments the effect of ethanol on the reaction was examined (Table II). When ethanol was omitted from the medium all lymphocytes were strongly positive containing coarse intensely stained granules however most neutrophils remained unstained and only a few presented an intense staining reaction. This result is explained by the observation that most neutrophils were very badly preserved after incubation in the ethanol free medium and presumably the enzyme or the synthesised polysaccharide had leaked from the cells. The lymphocytes on the other hand were shrunken but otherwise seemed intact. Increasing ethanol concentrations first enhanced the reaction in the neutrophils by diminishing cellular damage but at the same time the

Table I
Effect of polyvinyl pyrrolidone on phosphorylase reaction

	g PVP added to 11 ml incubating medium						
	0	1	1.5	2	2.5	3	4
Neutrophils	0	(+)	+++	+++	+++	++	0
Lymphocytes	0	(+)	+	+	+	+	0
Thrombocytes	++	+	+	+	+	+	0
Cellular damage	+++	++	+	0	0	0	0

Table II
Effect of ethanol on phosphorylase reaction

	ml ethanol added to 10 ml incubating medium					
	0	0.5	1	2	3	4
Neutrophils	0(to+++)	+++	+++	++	++	+
Lymphocytes	+++	++	+	(+)	0	0
Thrombocytes	+++	++	+	+	+	+
Cellular damage	+++	+	0	0	0	0

staining of lymphocytes and thrombocytes diminished due to enzyme inhibition. Addition of 1 ml ethanol to the medium constituted the optimum by giving a positive reaction in all neutrophils and in the majority of the lymphocytes.

Influence of sodium fluoride and insulin. Omission of sodium fluoride from the medium only weakened the reaction slightly. Addition of insulin to the medium, which according to TAKEUCHI AND KURIAKI (7) enhances the reaction, was in the present study found to have no effect.

Influence of pH. Reduction of the pH of the incubating medium to pH 5.6 weakened the staining result, whereas equally strong staining was observed at pH 6.0 and pH 7.0. The latter experiment was performed using a Tris buffer (0.1 M). These results show a higher pH optimum for the reaction than that found by TAKEUCHI AND KINOSHITA (6).

Conclusions

Previously the phosphorylase activity in blood films has been studied only after prefixation. TAKEUCHI AND KINOSHITA (6) used methanol-fixed films and demonstrated phosphorylase activity in some of the neutrophils. QUAGLINO AND HAYHOE (3) who employed acetone fixation observed phosphorylase activity in all granulocytes and also in some monocytes and lymphocytes. The

present method, which avoids enzyme destruction by prefixation, was more sensitive and in our experience more reliable. The results resembled those obtained by QUAGLINO AND HAYHOR, but phosphorylase activity was demonstrated in all white cells with the exception of some small lymphocytes. The fact that all lymphocytes possess some phosphorylase activity was however revealed by the experiments, where ethanol was excluded from the incubating medium.

The staining reaction with iodine was either blue or violet. Phosphorylase is only capable of synthesizing unbranched polysaccharide chains, which stain blue, and the observation of a violet coloration is therefore indicative of branching enzyme activity. The branching enzymes are however largely inhibited in these experiments due to the presence of ethanol (5).

The distribution of phosphorylase in the various cell types closely corresponds to the distribution of preformed glycogen, as previously recorded using the hexamine-silver technique (11). It was then shown that almost all lymphocytes also in normal subjects contain small amounts of glycogen. This correlation between the distribution of phosphorylase and glycogen is hardly surprising considering the physiological role of the enzyme, but nevertheless it is possible that preformed glycogen to some extent influences the outcome of the histochemical phosphorylase reaction by acting as a primer for polysaccharide synthesis (3).

The mode of action of polyvinyl pyrrolidone is not well established. The use of this inert substance in histochemistry was first recommended by SCARFELLI *et al.* (4) although in much smaller concentrations. It may simply protect the cells by increasing the viscosity of the medium and it is suggested that high concentrations of polyvinyl pyrrolidone may also be of use in the haematological application of other histochemical procedures.

Summary

A new method was described for the histochemical demonstration of phosphorylase in films of peripheral blood and leucocyte concentrates. The unfixed air-dried films were protected during incubation by using an incubating medium, which contained high concentration of polyvinyl pyrrolidone. The method proved more sensitive than previously reported methods, and phosphorylase activity was found in all granulocytes and monocytes, as well as in most lymphocytes. The influence of various constituents of the medium was evaluated.

Zusammenfassung

Es wird eine neue Methode zum histochemischen Nachweis von Phosphorylase in Ausstrichen von peripherem Blut und von Leukozytenkonzentraten beschrieben. Bei der Inkubation werden die unfixierten, luftgetrockneten Ausstriche durch eine Inkubationslösung mit hoher Konzentration an Polyvinylpyrrolidon geschützt. Die Methode erwies sich als empfindlicher als früher beschriebene Verfahren und ergab den Nachweis von Phosphorylase in allen Granulocyten und Monocyten sowie in den meisten Lymphocyten. Der Einfluss verschiedener Bestandteile des Mediums wurde untersucht.

Résumé

Une nouvelle méthode histochimique pour la mise en évidence de la phosphorylase dans les frottis de sang périphérique et de leucocytes concentrés est décrite. Les frottis non-fixés et séchés à l'air sont protégés durant l'incubation par une solution ayant une concentration de polyvinyl-pyrrolidone très forte. Cette méthode se révèle être plus sensible que les procédés antérieurs et mit en évidence de la phosphorylase dans tous les granulocytes et monocytes, ainsi que dans la plupart des lymphocytes. L'influence des différents constituants de la solution a été étudiée.

References

1. EPRATI, H. AND ROZENBLAT, L. The morphology of buffy coats in normal human adults. *Blood* 16, 1012 (1960).
2. ELLERÖ, O. AND FALKAMA, A. Improved localization of phosphorylase by the use of polyvinyl pyrrolidone and high substrate concentration. *J. Histochem. Cytochem.* 9, 585 (1961).
3. QUAGLIO, D. AND HAYES, F. G. J. Phosphorylase activity in haemic cells. *Nature* 194, 929 (1962).
4. SCARFELLI, D. G., HEN, R. AND FRANK, A. G. E. The cytochemical localizations of oxidative enzymes. 1. Diphosphopyridine nucleotide diaphorase and triphosphopyridine nucleotide diaphorase. *J. biophys. biochem. Cytol.* 4, 747 (1958).
5. TAKEUCHI, T. Histochemical demonstration of branching enzyme (amylase-1,4-1,6-transglucosidase) in animal tissues. *J. Histochem. Cytochem.* 6, 208 (1958).
6. TAKEUCHI, T. AND KAWAZITA, K. Histochemical demonstration of phosphorylase in blood and bone marrow cells. *Blood* 11, 373 (1956).
7. TAKEUCHI, T. AND KUBIKI, H. Histochemical detection of phosphorylase in animal tissues. *J. Histochem. Cytochem.* 2, 123 (1953).
8. TAKEUCHI, T.; TADOKORO, N. AND IMA, H. Histochemical study on glycogen synthesis from glucose 1-phosphate in blood cells under normal and pathological conditions. *J. Histochem. Cytochem.* 10, 372 (1962).
9. WULF, H. R. Histochemical studies of leukocytes from an inflammatory exudate. Glycogen and phosphorylase. *Acta haemat., Basel* 28, 86 (1962).
10. WULF, H. R. Histochemical studies of leukocytes from an inflammatory exudate IV. Uridine diphosphate glucose-glycogen transglycosylase. *Acta haemat., Basel* 30, 123 (1963).
11. WULF, H. R. AND WULF, H. R. Histochemical demonstration of polysaccharides in blood cells using the hexamine-silver technique. *Danish med. Bull.* 11, 70 (1964).

Laboratory of Radiobiology, San Francisco Medical Center, University of California

An Evaluation of Erythropoiesis in Canine Marrow*

P. K. LALA, H. M. PATT AND M. A. MALONEY

Although reference has been made to ineffective erythropoiesis in normal animals (4-13) this has not yet been substantiated by any direct experimental evidence. A recent analysis of cell fluxes during granulocyte formation in the dog has revealed a considerable ineffective granulopoiesis (7-11, 12). A similar analysis has now been made for erythropoiesis in canine marrow and the findings will be reported in this article.

Materials and Methods

Bone marrow preparations from two young adult beagles used in the analysis of granulopoiesis (7) and similar preparations from another beagle were used in this study. Proerythroblasts, basophilic normoblasts and early polychromatic normoblasts were included in the proliferative cell class (P); these cells are flash-labeled with tritiated thymidine (H^3 T). Late polychromatic normoblasts and orthochromatic normoblasts with distinct nuclear chromatin were grouped in the nonproliferative class (NP) since it was not known definitely whether transition from P after the last division occurred only to the late polychromatic cell or to the orthochromatic cell as well; the frequency of the latter is small in canine marrow. At least 1000 NP and all associated P intact red cells with pyknotic nuclei (CPN) and free pyknotic red cell nuclei (FPN) were scored at each interval for each dog. A minimum of 100 erythroid mitoses (metaphases and anaphases) were scored for the labeled mitosis study. Strong cytoplasmic basophilia was used as the criterion to distinguish erythroid from myeloid mitoses in the case of large cells, whereas small mitotic figures presented no difficulty in the Giemsa-stained preparations. Any cell with 2 or more silver grains over the nucleus was scored as labeled.

Results and Discussion

Figure 1 shows the percent labeled erythroid metaphases and anaphases in marrow (average for 3 dogs) with time after injection of H^3 thymidine. The pattern was the same whether mitoses were grouped for the whole erythroid series (Fig. 1) or classified in terms

*This work was performed under the auspices of U.S. Atomic Energy Commission. Part of this work was completed in the Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois.

Table I
Cell fluxes during erythroid development.

	Pre-erythroblast	Normoblast	Early polychromatic normoblast	NP	CFN + CFM
Relative Number (N)	25	108	339	465	71
0.5 hour labeling index (N_0/N)	0.63	0.56	0.59	0	0
Number in DNA synthesis (N_0)	16.3	59.4	140	0	0
Birth rate (K_p)	2.8	10.1	23.7	0	0
Influx (K_i)	+	2.8	12.9	37.2 ^a	—
Efflux (K_e)	2.8	12.9	36.6	—	—
Mean No. of mitoses ^b	—	2.3	1.4	—	—

$K_p = N/T$ where $T = 3.9$ h.

Indicates an unknown stem cell efflux into the proerythroblast pool; this is probably very small compared to the succeeding fluxes.

Determined from a turnover rate of 8%/h.

$K_e = K_i + K_p$

$K_0/2K_i$

Table II
Actual and theoretical recovery of labeled nonproliferative cells.

	Early polychromatic normoblast	Late polychromatic and orthochromatic normoblast (nonproliferative)
Relative Population Number	339	465
Percent labeled	28.5 (0.5 h 4+gr)	33.8 (7.5 h 2+gr)
Number labeled	102	157

which would swing the balance toward underproduction rather than overproduction or ineffective production.

A comparison of the actual recovery and the theoretical recovery into NP of early polychromatic cells after one division provides additional evidence for the absence of ineffective production. The cohort of 4+ cells in S in the last generation should be seen as 2+ cells in NP theoretically at a time given by $s + t$ or 7.5 h, where s is the interval occupied by 4+ cells in S (5.1 h) and t is the time from the end of s to recognition of these cells in NP (2.4 h). From the flux relationships in Table I the mean number of divisions occurring in the early polychromatic stage is 1.4. In that case after one division one labeled early polychromatic cell should give rise to 1.56 cells in the NP compartment. 102 of the former cells should give rise to 159 of the latter cells, and as shown in Table II the actual recovery was 157. Thus, ineffective erythro-

poiesis seems to be absent or insignificant in dog marrow up to the late polychromatic and orthochromatic stage. In regard to subsequent stages, an assessment of possible attrition before entry in blood can be made by comparing the daily production in marrow with the daily turnover in blood. If the approximate total nucleated erythroid population in dog marrow is $7 \times 10^8/\text{kg}$ (2) total production can be estimated as $6 \times 10^8/\text{kg}/\text{day}$ from the H^3T labeling index and the S period. This value when compared with a daily turnover of $4.8 \times 10^8/\text{kg}/\text{day}$ in the peripheral blood (10) reveals an imbalance, suggestive of an ineffective production of some 20% of total production. If this crude approximation is representative of the true picture we would infer that there is some loss after the orthochromatic stage, e. g. during the loss of nucleus and transition to a reticulocyte or in the reticulocyte stage itself.

Summary

Erythropoiesis in canine marrow was evaluated by an analysis of cell fluxes among the erythroid components after single injection of tritiated thymidine in 3 dogs. Erythroid precursors had an average cell cycle time of about 10 h which could be subdivided into the following time components on average: pre-DNA synthesis ~ 2 h; DNA synthesis ~ 6 h, post-DNA synthesis ~ 1 h; mitosis ~ 1 h. The average age of nondividing red cell at the beginning of nuclear pyknosis was ~ 12.5 h, there was a wide age distribution with minimum age of 6 h. No ineffective production was detected up to the orthochromatic stage before nuclear pyknosis. A crude comparison of the total daily production in marrow with the daily turnover in blood is suggestive of 20% cell loss between the process of enucleation and entry into circulation.

Zusammenfassung

Bei 3 Hunden wurde die Erythropoese untersucht durch Bestimmung der Zellverschiebungen unter den Komponenten der Erythropoese nach einer einmaligen Injektion von Tritium-Thymidin. Die roten Vorläufer wiesen eine mittlere Dauer ihres Zyklus von 10 Stunden auf. Diese ließ sich unterteilen in folgende mittlere Abschnitte vor der DNA-Synthese ~ 2 Std., DNA-Synthese ~ 6 Std., nach der DNA-Synthese ~ 1 Std., Mitose ~ 1 Std. Das mittlere Alter einer nicht in Teilung befindlichen roten Zelle zu Beginn der Kernpyknose betrug $\sim 12,5$ Std. Es fand sich eine breite Streuung des Alters mit einem Minimum von 6 Std. Bis zum orthochromatischen Stadium vor der Kernpyknose war keine ineffektive Produktion festzustellen. Ein grober Vergleich der gesamten täglichen Produktion im Knochenmark mit dem täglichen Umsatz im Blut spricht für einen Zellverlust von 20% zwischen dem Prozeß der Entkernung und dem Übertritt in die Zirkulation.

Résumé

L'érythropoïèse de la moelle osseuse du chien a été évaluée à l'aide de l'analyse du flux des cellules parmi les composantes érythroïdes après une injection unique de thymidine marquée à 3 chiens. Les précurseurs érythroïdes ont un cycle cellulaire d'environ

10 heures, temps qui peut être subdivisé dans les composantes moyennes suivantes: synthèse pré-ADN ~ 2 h; synthèse de l'ADN ~ 6 h; synthèse post-ADN ~ 1 h; mitose ~ 1 h. L'âge moyen des érythrocytes ne se divisant pas au début de la pyknose nucléaire était de ~ 12,5 h; les variations suivant l'âge sont très grandes, le minimum est de 6 h. Aucune production inefficace ne put être détectée jusqu'au stade orthochromatique avant la pyknose nucléaire. Une comparaison grossière de la production journalière dans la moelle osseuse avec le turnover journalier dans le sang semble indiquer une perte de 20% des cellules entre le processus d'énucléation et l'entrée en circulation.

References

1. ADAMS, L. R. A variant cytophotometric technique and its application to the study of erythropoiesis through measurement of total DNA and hemoglobin in single erythroid cells. Ph. D. Thesis, p. 128 (Lawrence Radiation Laboratory University of California, Berkeley 1964)
2. ALPERT, E. L., GRAMBS, D. AND JONESTON, M. E. Early observation on the effects blood loss; in Jacobson and Doyle, *Erythropoiesis*, pp. 184-188 (Grune and Stratton, New York 1962)
3. COTTER, H., ODARTCHENKO, N., FERNANDEZ, L. E., KEMER, G. AND BORD, V. P. Autoradiographic investigation on the extrusion of the nuclei of erythroblasts after labeling *in vivo* with Thymidine- H^3 (translated). *Schweiz. Med. Wochschr.* 93: 1061-1065 (1963)
4. LAJTHA, L. G. AND OLIVER, R. Studies on the kinetics of erythropoiesis: model of erythron in Wolfenbulte and O'Connor *Haemopoiesis*, pp. 289-314 (Little Brown and Company Boston 1960)
5. LALA, P. K., MALONEY, M. A. AND PATT, H. M. A comparison of two markers of cell proliferation in bone marrow. *Acta haemat.*, Basel 31: 1-8 (1964).
6. LALA, P. K., MALONEY, M. A. AND PATT, H. M. Measurement of DNA synthesis time in myeloid erythroid precursors. *Exp. Cell Res.* 38: 626-634 (1965)
7. MALONEY, M. A., WEBER, C. L. AND PATT, H. M. Myelocyte-Metamyelocyte transition in the bone marrow of the dog. *Nature* 197: 150-152 (1963)
8. ODARTCHENKO, N.; BORD, V. P.; FERNANDEZ, L. E. AND COTTER, H. Kinetics of erythrocytic precursor proliferation in dog; in Lamerton and Fry *Cell Proliferation*, pp. 172-187 (Blackwell Scientific Publishers, Oxford 1963).
9. ODARTCHENKO, N., COTTER, H., FERNANDEZ, L. E. AND BORD, V. P. Evaluation of mitotic time *in vivo*, using tritiated thymidine as a cell marker: Successive labeling with time of separate mitotic phases. *Exp. Cell Res.* 35: 402-411 (1964)
10. PATT, H. M. A consideration of myeloid erythroid balance in man. *Blood* 12: 777-787 (1957)
11. PATT, H. M. AND MALONEY, M. A. An Evaluation of granulocytopoiesis; in Lamerton and Fry *Cell Proliferation*, pp. 157-171 (Blackwell Scientific Publishers, Oxford 1963)
12. PATT, H. M. AND MALONEY, M. A. A Model of granulocyte kinetics. *Ann. N. Y. Acad. Sci.* 113: 515-522 (1964)
13. STOKELMAN, F. J. Observations on the kinetics of red cell proliferation. In Stokelman, J. *The kinetics of cellular proliferation*, pp. 318-324 (Grune and Stratton, New York 1959)

P.-L. Bräunert Symposium on Microvascular Methodology Bibl. anat., fasc. 5. Karger Basel/New York 1963. IV + 100 S., III Abb., 5 T b., Preis sF /DM 21
Symposium anlässlich der 3. Europäischen Konferenz über Mikrozirkulation.

WAYLAND (California Institute of Technology) gibt einen ausgezeichneten Überblick über Definition und Bedeutung rheologischer Parameter: Viskosität homo- und heterogener Flüssigkeiten, laminäre und turbulente Strömung, Bedeutung der Reynold'schen Zahl ein Überblick, den Jedermann lesen sollte, der das Wort «Hämodynamik» häufig braucht. Klar werden die Verfahren besprochen, mit denen sich diese Parameter erfassen lassen. Besonderes Interesse verdienen die Ausführungen über die Viskosimetrie.

BRÄUNERT UND HARDING befassen sich mit den Möglichkeiten der experimentellen und klinischen Bio-Mikroskopie. Während die Technik der üblichen biologischen Verarbeitungen für das Studium der Gefäßarchitektur durch WALLGÖW besprochen wird, fehlt leider ein Beitrag über die Leistungsfähigkeit der Elektronenmikroskope. I WOL berichtet über die Möglichkeiten intra- und extravasculärer Kapillar-Druckmessung. Methoden und Ergebnisse zur Prüfung der Kapillarpermeabilität (Kardiolidenblau und vitale Stäuben mit Farbstoffen und Fluorescein) werden von WITTE und SCHWARTZLOFF besprochen. MONRO bietet eine knappe Übersicht über Methoden zur Messung von korpuskulärer Deformation, Strömungsgeschwindigkeit und Gefäßdurchmesser.

Das sorgfältig redigierte Buch vermittelt eine gute Übersicht über den heutigen Stand und die zukünftigen Wege der Forschung in der Mikrozirkulation. Dank der Qualität der Referenzen und der zahlreichen Literaturzitate ist es auch für jeden wertvoll, der sich mit einem Teilproblem der Mikrozirkulation befassen will. Ähnlich mit hämodynamischen Neigungen seien besonders auf die grundlegenden Beiträge von W. LAND hingewiesen.

L. K. WIMMER, Basel

Donald G. McKay Disseminated Intravascular Coagulation. Hoeber Medical Division, Harper & Row New York/London 1963. 499 pp., 204 Illustr. Price \$ 16.

The author considers disseminated intravascular coagulation as fundamental mechanism in many diseases. After short review on blood coagulation the main part of the book discusses intravascular coagulation in wide variety of clinical syndromes, among these e.g. sickle cell anemia, Paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia. In reading the book one has the impression that the importance of intravascular coagulation for the pathogenesis of wide variety of diseases and syndromes is somewhat overstated.

G. Rosenow New York

Shirley A. Johnson and Tiber J. Grunewald. Coagulation and Transfusion in Clinical Medicine. Little, Brown and Co., Boston 1963. 203 pp. Price \$ 9.50.

This little book is intended as guide for the general practitioner and residents (assistants) in hospital for the management of bleeding conditions. The authors have coordinated their respective experience in management of blood bank and clinical hematology. A short introductory chapter on blood coagulation is followed by an outline of transfusion therapy. Chapters on hemophilia, thrombocytopenic antocoagulants, coagulation in liver disease, coagulation mechanism in the newborn are given. The book is kind of primer for the uninitiated or to fresh up on the subject. It contains fairly long list of references.

G. Rosenow New York

H. Kebab, P. Vesin, H. Diggelmann and S. Beraudon. *Physiology and Pathophysiology of Plasma Protein Metabolism*. Proceedings of the Third Symposium, held at Grindelwald, September 10-12 1964. Verlag H. H. Huber, Bern 1965. 240 S., 79 Abb., 28 T. b. Preis sF 10.50 DM 27.-

Im August 1961 diskutierte im Hôpital St. Antoine in Paris eine Gruppe jüngerer Kliniker die Problematik des gastrointestinalen Eiweißverlustes. Im Vordergrund des Interesses standen damals die mit dem Gordon-Test erhaltenen Befunde. Dieselbe Gruppe traf sich 1963 in Bruges 1964 tagte sie in Grindelwald. Dabei ist es interessant zu sehen, wie sich in Kurze ihr Interessenbereich weit über die ursprüngliche Fragestellung hinaus entwickelt hat. So standen anlässlich der Grindelwalder Tagung zahlreiche Aspekte der Physiologie und Pathologie des menschlichen Plasmaproteinstoffwechsels zur Diskussion, wobei zu Recht methodologische Fragen einen breiten Raum einnahmen. Die vorliegende Monographie vermittelt einen ausgezeichneten Überblick über ein aktuelles Gebiet biochemischer und klinischer Forschung.

A. HÄGG, Bern

Harmon Andrews. *Comparative Hematology*. Grune & Stratton Inc., New York/London 1965. 168 pp. Price \$ 22.75.

This well printed and illustrated large sized book is mainly a descriptive presentation of the morphology and particularly the histology of the blood forming organs of the invertebrates and vertebrates. Comparative aspects of the blood of invertebrates, discussed in separate chapters include remarks about the clotting mechanism unfortunately the information about the role of the blood in defense reactions is very scanty. The part on the vertebrates comprises the development of hematopoietic tissue in placental reptiles, birds and mammals. A number of electron microscope illustrations of blood cells are reproduced. Color plates, particularly of the peripheral blood cells contain also the excellent color plates from the *Atlas of Avian Hematology* by LUCAS AND JANKOVIC. A more comprehensive comparative presentation of the hematology of invertebrates and vertebrates would have been welcome. The role of the reticulo-endothelial system in mammals and its behavior in invertebrates is barely scratched. The section on diseases of the blood in man and animals is limited to a few comments.

The book, although falling short of comparative hematology in the proper sense, contains many facts and data which may be of importance for the human hematologist too.

O. ROSENOW, New York

Department of Paediatrics, University of Rome (Chief: Prof. A. COLARIZZI)

Contribution to the Knowledge of the Immunological Properties of Adult and Foetal Haemoglobin and of Their Polypeptide Chains

G. MAGGIONI, C. IOPPOLO AND G. GERLINI

It has long been known that the human haemoglobin possesses antigen properties, but only with the progress of the techniques of separating the haemoglobins it has been possible to demonstrate the antigen specificity of the normal haemoglobins HbA₁, HbA₂ (1, 2, 8, 19), HbF (1, 2, 5, 6, 7, 8, 22) and of the pathological ones HbS, HbC, Hb Bart's (2, 19), Hb Lepore (2) and to commence the study of the antigen properties of the polypeptide chains constituting the haemoglobins.

In 1963 MAGGIONI *et al.* (17) put forward the hypothesis that the antigenic specificity of HbF resides in the γ chain. In 1964 BOERMA AND HUISMAN (2) affirmed that the α , β , γ and δ chains all possess antigen capacities and demonstrated several antigenic sites, some of them in common. In the same year ROSE *et al.* (19) observed that the β , γ and δ chains are the most active antigen sites of haemoglobins A, A₂, F and Bart's and that in them reside the common antigenic groups of the haemoglobins themselves.

BOERMA AND HUISMAN and ROSE *et al.* deduced the antigen properties of the various polypeptide chains by using in their immunodiffusion and absorption studies human haemoglobins differing in one of the two pairs of polypeptide chains.

Recently YAKULIS AND HELLER (23) and KLEINHAUER AND MILENYI (12a) using immunological and physico-chemical techniques respectively on hybrids of HbF with dog haemoglobin, affirmed that the immunological, physico-chemical and functional characteristics of HbF can be basically referred to the γ chain.

In the present paper we report on the antigen properties of the polypeptide chains of adult and foetal haemoglobin separated by

means of hybridization with dog Hb. The dog haemoglobin, which furnished the globinic subunit of the hybrids, has never reacted with our antisera.

Material and Methods

Preparation of the Antigens

Fetal haemoglobin. The HbF was prepared from umbilical cord blood of group 0 Rh positive after washing and haemolysis of the erythrocytes according to current methods and by means of alkali denaturation according to the method of SERVAZ *et al.* (21). The alkali resistant fraction was then purified on a block of starch according to KLEIN (13), eluted and sterilized by passing through Seitz filters. The samples used for the immunization, each containing 20–40 mg of haemoglobin, were mixed with an equal volume of complete Freund adjuvant and kept in the refrigerator.

Adult haemoglobin was prepared from red corpuscles of normal adults of group 0 Rh positive, washed and haemolysed. The greater fraction of the normal adult haemoglobin was prepared on a block of starch according to Kunkel's method, eluted and sterilized through Seitz filters. The samples used for the immunization were prepared in the same way as for the HbF.

Both the adult and the fetal haemoglobin were used in the form of carboxy haemoglobin.

HbF and HbA hybrids. The hybrids of HbA and HbF with dog haemoglobin were prepared according to Itano's method (12) already experimented with in our laboratory by MAUCONI *et al.* (15) and by BOTTRO *et al.* (4). The hybrids obtained were prepared on a block of starch according to KLEIN (13) and eluted. In this system three bands appear: the first, nearest the anode, is formed of the hybrid $\alpha^{\text{dog}}\beta^{\text{A}}$ and respectively $\alpha^{\text{dog}}\beta^{\text{F}}$; the slow one, nearest the cathode, is represented by the hybrid $\alpha^{\text{A}}\beta^{\text{dog}}$ while the third, intermediate band consists of the haemoglobins set out with.

Immunization of the rabbits. Six rabbits were immunized, 3 with HbA and 3 with HbF with total of 8 injections at a distance of 10 days from each other: the first dose was 40 mg, the successive doses 20 mg each. At a distance of 8 days from the last inoculation, the blood was taken for preparing the anti-serum.

Immunoassay. The antigen-antibody reactions were carried out with the double diffusion method in agar gel according to OUCHTERLOFF (18) modified by BOSS *et al.* (1).

Absorption. The rabbit antisera were absorbed with the entire haemoglobin used for the immunization and with the respective hybrids until the disappearance of the reaction with the homologous antigen.

Results

The serum of the rabbits immunized with HbF reacted to the immunodiffusion both with HbF and the respective hybrids and with HbA and the respective hybrids. The reaction with HbF was performed at concentrations between 1 and 0.06 g / Put in contact with HbF at a concentration of 0.2 g / which has proved to be the optimal concentration for the antigen-antibody reaction, the serum gave an antibody titre of 1:4. The same antibody titre was obtained

with the HbF fast hybrid at a concentration of 0.2 g/100 ml. With regard to the HbF slow hybrid, the HbA and the respective slow and fast hybrids, the reaction disappeared with the dilution of the serum 1:2.

With the entire HbA as antigen, a reaction occurred at concentrations between 1 and 0.2 g/100 ml.

From the qualitative analysis of the reactions between the antiserum and the various antigens, taken at various concentrations, it will be seen that the reaction with HbF is of an intensity equal to that with the HbF fast hybrid, while this reaction becomes progressively weaker when the antiserum is put in contact with the HbF slow hybrid, with HbA and the slow and fast hybrids of this (Table I, Fig. 1).

Still examined at the point of equivalence with respect to the antiserum being studied, the HbF gives an identity reaction with the respective fast hybrid (Fig. 1) while the reaction with the HbF slow hybrid, the HbA and the hybrids of this, is of partial identity with pictures of greater antigenic complexity on the part of the HbF (Fig. 1, 2, 3).

The HbF fast hybrid further presents a behaviour identical with HbF when it is compared with HbA and the hybrid of this (Fig. 2, 3, 4). Because of the weak reaction of the HbA and its hybrids with the antiserum being studied, it is difficult to interpret the morphology of the respective lines of precipitation: the HbA forms two short thin lines which give an identity reaction with the HbA fast hybrid for one of the two lines (Fig. 1).

Table I
Reactions of antiserum anti-HbF during the immunodiffusion test.

Antigen	Non absorbed serum	HbA	HbF	Serum absorbed with			
				$\alpha^S \beta^{HbA}$	$\alpha^F \beta^{HbA}$	$\alpha^{HbA} \beta^A$	$\alpha^{HbF} \beta^F$
HbA	+	—	—	±	±	±	—
HbF	+++	+++	—	++	++	++	—
SA	+	—	—	—	—	—	—
SF	++	±	—	—	—	+	—
FA	+	—	—	±	±	—	—
FF	+++	++	—	++	++	++	—

SA slow HbA hybrid (β^{HbA})

SF slow HbF hybrid ($\alpha^F \beta^{HbA}$)

FA fast HbA hybrid ($\alpha^{HbA} \beta$)

FF fast HbF hybrid ($\alpha^{HbF} \beta^F$)




Fig 1 1 = HbF 2 = $\alpha^{\text{HbA}}\gamma^{\text{F}}$ 3 = $\alpha^{\text{F}}\beta^{\text{HbA}}$ 4 = HbF 5 = HbA, 6 = $\alpha^{\text{A}}\beta^{\text{HbA}}$
7 = $\alpha^{\text{HbA}}\beta^{\text{A}}$ 8 = HbA, in the middle anti-HbF

Fig 2 1 = HbA, 2 = $\alpha^{\text{HbA}}\gamma^{\text{F}}$ 3 = $\alpha^{\text{F}}\beta^{\text{HbA}}$ 4 = HbA, 5 = HbF 6 = HbA, 7 =
 $\alpha^{\text{HbA}}\beta^{\text{A}}$ 8 = $\alpha^{\text{A}}\beta^{\text{HbA}}$ in the middle anti-HbF

Fig 3 1 = $\alpha^{\text{A}}\beta^{\text{HbA}}$ 2 = $\alpha^{\text{HbA}}\gamma^{\text{F}}$ 3 = $\alpha^{\text{HbA}}\beta^{\text{A}}$ 4 = $\alpha^{\text{F}}\beta^{\text{HbA}}$ 5 = HbF 6 = $\alpha^{\text{A}}\beta^{\text{HbA}}$
7 = $\alpha^{\text{HbA}}\beta^{\text{A}}$ 8 = HbF in the middle anti-HbF




Fig 4 1 = $\alpha^{\text{HbA}}\beta^{\text{A}}$ 2 = $\alpha^{\text{HbA}}\gamma^{\text{F}}$ 3 = $\alpha^{\text{F}}\beta^{\text{HbA}}$ 4 = $\alpha^{\text{A}}\beta^{\text{HbA}}$ in the middle anti-HbF

The HbF slow hybrid gives an identity reaction with that of the HbA (Fig 4) while both furnish a picture of partial identity with the HbA fast hybrid with a picture of greater antigenic complexity in favour of the slow hybrids (Fig 3)

Absorption When the antiserum being studied is absorbed indifferently with the HbF and its fast hybrid, all the reactions disappear both towards the entire haemoglobins and towards their hybrids. When it is absorbed with the slow hybrid of both the HbF and the HbA, the reaction with them disappears that with the HbA and its fast hybrid appears scarcely perceptible, while the reaction with the HbF and its fast hybrid remains quite clear (Fig 5) When it is absorbed with HbA, the reaction with this and its hybrids disappears and a serum remains which reacts clearly with the HbF less intensely with the HbF fast hybrid and very weakly with the HbF slow hybrid (Fig 13)

The absorption with the HbA fast hybrid caused the persistence of the reaction with HbF and its hybrids, while the reaction with the HbA is not only very slight but sometimes, if the reaction conditions are varied, is not perceptible (Fig 5) the reaction with the HbA slow hybrid, on the contrary disappears in every case.

The serum of the rabbits immunized with HbA reacted to the immunodiffusion both with HbA and its respective hybrids and with HbF and its respective hybrids (Table II Fig 7 8) The reaction with the HbA occurred at concentrations between 1 and 0.2 g/%. Put in contact with HbA at a concentration of 0.2 g/% which in this case also proved optimal for the antigen antibody reaction, the serum gave an antibody titre of 1:4. With the HbF as antigen a reaction was obtained with the haemoglobin at concentrations between 1 and 0.06 g/%. The antibody titre both towards the HbA and the HbF hybrids resulted 1:2.

At the immunodiffusion the HbA and HbF give a cross reaction picture (Fig 6) which is repeated when the HbA is compared with the HbF fast hybrid (Fig 7) and the HbA and HbF fast hybrids are compared with each other (Fig 8)



Fig 5.1 HbF 2 = $\alpha^{\text{HbF}}\gamma^{\text{HbF}}$ 3 = $\alpha^{\text{HbF}}\gamma^{\text{HbF}}$ 4 = HbA, in the middle anti-HbF absorbed with $\alpha^{\text{HbF}}\beta$ 5 = HbF 6 = $\alpha^{\text{HbF}}\gamma^{\text{HbF}}$ 7 = $\alpha^{\text{HbF}}\gamma^{\text{HbF}}$ 8 = HbA, in the middle anti-HbF absorbed with $\alpha^{\text{HbF}}\beta$

Table II
Reactions of antiserum anti HbA during the immunodiffusion test.

Antigen	Non absorbed serum	HbA	HbF	Serum absorbed with			
				$\alpha^A \beta^{con}$	$\alpha^F \beta^{con}$	$\alpha^{con} \beta^A$	$\alpha^{con} \beta^F$
HbA	+++	—	++	++	++	—	—
HbF	+++	++	—	++	++	++	—
SA	++	—	—	—	—	—	—
SF	++	—	—	—	—	—	—
FA	++	—	±	±	±	—	±
FF	++	++	—	±	±	±	—

SA slow HbA hybrid ($\alpha^A \beta^{con}$)

SF slow HbF hybrid ($\alpha^F \beta^{con}$)

FA fast HbA hybrid ($\alpha^{con} \beta^A$)

FF fast HbF hybrid ($\alpha^{con} \beta^F$)




Fig. 6. 1 = HbF 2 = HbA, 3 = HbF 4 = HbA, in the middle anti HbA.



Fig. 7. 1 = $\alpha^F \beta^{con}$ 2 = HbA, 3 = HbF 4 = $\alpha^F \beta^{con}$ 5 = $\alpha^{con} \beta^F$ 6 = HbA, 7 = HbF 8 = $\alpha^{con} \beta^F$ in the middle anti-HbA.



Fig. 8. 1 = $\alpha^A \beta^{con}$ 2 = $\alpha^{con} \beta^F$ 3 = $\alpha^{con} \beta^F$ 4 = $\alpha^{con} \beta^A$ in the middle anti-HbA.

The HbA compared with the HbA slow hybrid and with the HbF itself shows a partial identity reaction with a picture of greater antigenic complexity in favour of the Hb (Fig 7 9) with regard to the fast HbA hybrid, on the contrary an identity reaction is observed (Fig 9)

In the comparative reactions between HbF and the HbA and HbF slow hybrids respectively, a picture will be seen of partial identity between the haemoglobin and the slow hybrids with an appearance of greater antigenic complexity in favour of the entire haemoglobin (Fig 7 9) The HbF on the contrary gives an identity reaction with its own fast hybrid (Fig 7)

Absorption. When the antiserum being studied was absorbed with HbF the disappearance was obtained of the reaction with this, with the HbF fast hybrid and the HbA and HbF slow hybrid respectively while the reaction is still observed with the HbA and its respective fast hybrid (Fig 14) Absorption with the HbF fast hybrid gave rise to an antiserum which behaved in exactly the same way as the antiserum absorbed with HbF (Fig 16) When absorbing with HbA, the disappearance was observed of the reaction with this, with the HbA fast hybrid and both the HbA and HbF slow hybrids, while the reaction with the HbF and its fast hybrid persisted (Fig 15) In this case too absorption with the HbA fast hybrid gave rise to an antiserum which reacted in the same way as the antiserum absorbed with HbA (Fig 16)

When absorbing both with the HbA slow hybrid and the HbF slow hybrid, the disappearance of the reaction with these hybrids was obtained the reaction with the entire HbA and HbF persisted very clearly although slightly weaker than that of the non-absorbed serum still weaker but clear was the reaction with the HbA and HbF fast hybrids.

The lines of precipitation obtained in the various immunodiffusion tests always gave a distinct colouring with benzidine, demonstrating the haemoglobinic nature of the immunoprecipitates. The dog haemoglobins, cemented at various concentrations with our antisera, never showed precipitation reactions.

Discussion

The anti HbF serum reacted both with the HbF and its hybrids and with the HbA and its respective hybrids (Fig 1) This behaviour could be attributed to the presence in the antiserum being studied




Fig 9 1 = $\alpha^A_1\beta^{cm}$ 2 = HbA, 3 = HbF 4 = $\alpha^A\beta^{cm}$ 5 = $\alpha^{cm}\beta^A$ 6 = HbA
7 = HbF 8 = $\alpha^{cm}\beta^A$ in the middle anti-HbA.

Fig 10 1 = anti-HbA absorbed with $\alpha^A_1\beta^{cm}$ 2 = anti-HbA absorbed with $\alpha^F\beta^{cm}$
3 = anti-HbA absorbed with $\alpha^{cm}\beta^A$ 4 = anti-HbA absorbed with $\alpha^{cm}\gamma^F$ in the
middle HbF 5 = anti-HbA absorbed with $\alpha^A_1\beta^{cm}$ 6 = anti-HbA absorbed with
 $\alpha^F\beta^{cm}$ 7 = anti-HbA absorbed with $\alpha^{cm}\beta^A$ 8 = anti-HbA absorbed with $\alpha^{cm}\gamma^F$
in the middle HbA.

Fig 11 1 = anti-HbF absorbed with $\alpha^A_1\beta^{cm}$ 2 = anti-HbF absorbed with $\alpha^F\beta^{cm}$
3 = anti-HbF absorbed with $\alpha^{cm}\beta^A$ 4 = anti-HbF absorbed with $\alpha^{cm}\gamma^F$ in the
middle HbF 5 = anti-HbF absorbed with $\alpha^A_1\beta^{cm}$ 6 = anti-HbF absorbed with
 $\alpha^F\beta^{cm}$ 7 = anti-HbF absorbed with $\alpha^{cm}\beta^A$ 8 = anti-HbF absorbed with $\alpha^{cm}\gamma^F$
in the middle HbA.

of several specific antibodies or to the antigenic resemblance between the haemoglobins and their respective polypeptidic chains. The latter hypothesis seems more probable.

In fact, the antibody titre of the serum being studied towards the HbF is higher than that towards the HbA at the immunodiffusion the HbF presents a picture of greater antigenic complexity



Fig 12. 1 = $\alpha^F \beta^{Hb}$ 2 = $\alpha^{Hb} \gamma^F$ 3 = $\alpha^{Hb} \beta^A$ 4 = $\alpha^A \beta^{Hb}$ in the middle anti-HbF

Fig 13. 1 = $\alpha^F \beta^{Hb}$ 2 = $\alpha^{Hb} \gamma^F$ 3 = $\alpha^{Hb} \beta^A$ 4 = $\alpha^A \beta^{Hb}$ in the middle anti-HbF absorbed with HbA.

Fig 14. 1 = HbF 2 = HbA, 3 = $\alpha^{Hb} \beta$ 4 = $\alpha^{Hb} \gamma^F$ in the middle anti-HbA absorbed with HbF

than the HbA when the antiserum is absorbed with HbF every reaction disappears, while when it is absorbed with HbA the reaction of the antiserum with the HbF remains (Fig 13)

Furthermore, it seems possible that the anti HbF antibodies can be identified with the anti γ antibodies. In fact the HbF and its fast hybrid show an identity reaction at the immunodiffusion (Fig 1) the antibody titre of the antiserum is the same for both, and lastly when absorbing with the HbF fast hybrid the reaction with the HbF itself disappears (Fig 11) The γ and β chains react with the antiserum since they possess antigenic determinants in common with the γ chain, as is shown by the partial identity pictures at the immunodiffusion and by the absorption tests (Fig 1 3 4 12) The α chains possess antigenic determinants in common with the γ chain and in a larger number than the β chain with which they give a partial identity reaction with a picture of greater antigenic complexity in favour of the α chains (Fig 2 3)

Also in the case of immunization with HbA an antiserum was obtained which reacted both with the HbA and its hybrids and with the HbF and its respective hybrids (Fig 7 8) However the behaviour of the antiserum is such as to suggest the presence in it of distinct anti HbA and anti HbF antibodies. In fact, the reaction of the antiserum with the two haemoglobins was of equal intensity at the immunodiffusion the two antigens gave a picture of partial identity with double crossing (Fig 6) Finally when the antiserum being studied was absorbed with the HbA a specific anti HbF and anti- γ antiserum was obtained (HbF fast

hybrid, Fig 15) while when it was absorbed with HbF a specific anti HbA and anti- β serum was obtained (HbA fast hybrid, Fig 14)

Moreover the serum absorbed with the HbA fast hybrid behaves in the same way as the serum absorbed with the HbA, which suggests that the antigenic specificity of the HbA is due to its β chain (Fig 10 15 16) The absorption with the HbF fast hybrid further confirms that the antigenic specificity of the HbF is due to the γ chain (Fig 16)

As regards the behaviour of the α chains we observe that anti- α antibodies are present both in the anti HbF antiserum and in the anti HbA antiserum, as is shown by the absorption tests with the α chains (Table I) These antibodies, however are not specific, but in our opinion are produced by antigenic determinants in common both with the γ chain and the β chain. In fact, we have never been able to obtain a specific anti- α antiserum.

We consider that the presence of anti HbF antibodies in the serum of the rabbits immunized with HbA should be attributed to the presence of traces of HbF in the haemolysate of the adult haemoglobin used for the immunization




Fig 15. 1 - HbF 2 - α^{HbA} 3 - α^{HbA} 4 - α^{HbA} 5 - HbA, 6 - β^{HbA}
7 - HbF 8 - α^{HbA} in the middle anti-HbA absorbed with HbA

Fig 16. 1 - HbF 2 - HbA, 3 - α^{HbA} 4 - α^{HbA} in the middle anti-HbA absorbed with α^{HbA} 5 - HbF 6 - HbA, 7 - α^{HbA} 8 - α^{HbA} in the middle anti-HbA absorbed with α^{HbA}

Summary

Both HbA and HbF possess antigenic individuality in the rabbit. The antigenic specificity of the HbA resides in the β chain, that of the HbF in the γ chain. The α chains are immunologically active for the antigenic determinants in common with the β and γ chains. The β and γ chains possess at least one antigenic determinant in common and at least one specific determinant of their own.

Zusammenfassung

Beim Kaninchen besitzen HbA als auch HbF eine Antigenpezifität. Diese befindet sich beim HbA in der β -Kette, beim HbF in der γ -Kette. Die α -Ketten sind immunologisch aktiv gegenüber den mit den β - und γ -Ketten gemeinsamen Antigenlokalisierungen. Die β - und γ -Ketten weisen mindestens eine gemeinsame Antigenlokalisierung und eine ihnen eigene spezifische Antigenlokalisierung auf.

Résumé

Ainsi bien l'HbA que l'HbF possèdent chez le lapin une individualité antigénique. La spécificité antigénique de l'HbA est située dans la chaîne beta, celle de l'HbF dans la chaîne gamma. Les chaînes alpha sont immunologiquement actives en ce qui concerne les déterminants antigéniques qu'elles ont en commun avec les chaînes gamma. Les chaînes beta et gamma possèdent au moins une localisation commune d'antigènes et une localisation d'antigènes propres à elles-mêmes.

References

1. BORRMA, W. F. & HUGHES, T. H. J. AND MAANDER, E. Serologic investigations of some human and animal hemoglobins by the agar gel diffusion method. *Clin. chim. Acta* 5: 564 (1960).
2. BORRMA, W. F. AND HUGHES, T. H. J. Serologic investigations of human hemoglobins. II Antibodies produced by mixed human hemoglobin types with known structural differences. *J. lab. clin. Med.* 63: 264 (1964).
3. BOUTY, P., HARTMAN, L. ET FAUVERT, R. Identification des protéines hydrosolubles des lysats d'hématies humaines par l'électrophorèse travers gel d'amidon et l'immunoélectrophorèse. *Rev. franç. Et. clin. biol.* 4: 799 (1959).
4. BOTTINI, E., IORFALO, C., DELLA PORTA, G. Esperimenti di fridazione dell'emoglobina A₂ con l'emoglobina carnos. *Ped. Inter.* 12: 303 (1962).
5. CHESKOFF, A. I. Immunologic studies of hemoglobins. I. The production of anti-hemoglobin sera and their immunologic characteristics. *Blood* 8: 399 (1953).
6. DARROW, R. R., NOWAKOWSKY, S. AND ACETIS, M. H. Specificity of fetal and of adult hemoglobin precipitation. *Arch. Path.* 37: 873 (1940).
7. GOODMAN, N. AND CAMPBELL, H. H. Differences in antigenic specificity of human normal adult, fetal and sickle-cell anemia hemoglobins. *Blood* 8: 422 (1953).
8. HELLER, P., YAKELIN, V. J. AND JOHANNSEN, A. M. Immunologic studies of human hemoglobins. *J. lab. clin. Med.* 59: 401 (1962).
9. HUGHES, T. H. J. AND DORV, A. M. Studies on the heterogeneity of hemoglobin. IV Chromatographic behaviour of different human hemoglobins on anion exchange cellulose DEAE cellulose. *J. Chromatogr.* 7: 180 (1962).
10. HUGHES, T. H. J. AND MEYERING, C. A. Studies on the heterogeneity of hemoglobin. II The heterogeneity of different human hemoglobin types in CMG and in Amberlite IRC50 chromatography. Qualitative aspects. *Clin. chim. Acta* 5: 103 (1960).

11. HUBMAN T. H., J. MARTIN, E. A. AND DORY A. M.: Chromatography of hemoglobin on carboxymethylcellulose. *J. lab. clin. Med.* 52: 912 (1958).
12. ITANO, H. A. AND ROSSIGNOL, E.: Properties and inheritance of hemoglobin by asymmetric recombination. *Nature* 184: 1468 (1959).
- 12a. KLIMAUER, E. UND MÜLLER, N.: Die Bedeutung der γ -ketten für die Eigenschaften des fetalen Hämoglobins. *Acta haemat., Basel* 31: 280 (1964).
13. KUNKEL, H. G.: Methods of biochemical analysis. Ed. Gluck Interscience N. Y. 141 (1954).
14. KUNKEL, H. G. AND WALLENTIN, G.: New hemoglobins in normal adult blood. *Science* 122: 188 (1955).
15. MAGGIORI, G. BOTTINI, E. ANTONOVIC, G.: La tecnica dell'ibridazione nello studio genetico delle emoglobinopatie. *Haemat. lat. Milano* 48: 75 (1963).
16. MAGGIORI, G. BOTTINI, E.; IOPPOLO, C. & BENVENISTELLI, L.: Comportamento elettroforetico su gel di amido dell'Hb umana, dell'Hb canina dei loro prodotti di ricombinazione in differenti sistemi tampone a differenti pH. *Haemat. lat., Milano* 48: 133 (1963).
17. MAGGIORI, G. IOPPOLO, C. GERLINO, G.: Sulle proprietà immunologiche delle catene polipeptidiche dell'emoglobina fetale. *Boll. Soc. Ital. Biol. sper.* 39: 1536 (1963).
18. OUCHTERLOFFY O.: Diffusion-in-gel methods for immunological analysis. *Progr. Allergy* vol. 5, p. 1 (Karger Basel/New York 1956).
19. ROSE, G. SCHNEIDER AND LAMARCA: Immunological relationships of various types of hemoglobin. I. Reaction of antisera A, F Bart's with hemoglobins with various polypeptide chains. *Brit. J. Haemat.* 10: 15 (1964).
20. ROSE, N. PIERCE, F. RUDY & MICHELL, A. ET GRABAR, P.: Etude immuno-chimique des hémolysates des globules rouges humains. I. Principaux constituants antigéniques. *Ann. Inst. Pasteur* 98: 70 (1960).
21. SCHERER, K., CHENOWETH A. I. AND SWISS, L.: Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkalidenaturation. *Blood* 6: 413 (1951).
22. VECCHIO, F. & BARRAGALLO, E.: Ricerche sierologiche sul potere antigenico di alcuni tipi di emoglobina umana patologica. I. L'emoglobina dell'anemia di Cooley dell'anemia drepanocitica. *Pediatrics, Napoli* 58: 481 (1950).
23. YASULIS, V. J. AND HELLER, P.: Immunologic characteristics of human hemoglobin fractions and their subunits. *Ann. N. Y. Acad. Sci.* 123: 607 (1964).

Authors' address: Drs. G. Maggiori, C. Ioppolo and G. Gerlino, Clinica Pediatrica, Università di Roma, Roma (Italia).

Department of Haematology Postgraduate Medical School of London and Weizmann
Institute of Science, Rehovoth

Red Cell Osmotic Fragility as an Indication of Marrow Depression after Irradiation and Effectiveness of Marrow Graft

S. M. LEWIS,* I. BLIKBERG AND D. DAGON

A rapid micromethod for the determination and automatic recording of the red-cell osmotic fragility has recently been described (2). For this a continuous reduction in salt concentration is achieved by dialysis. The 'Fragiligraph' is an instrument based on this method and devised for the simultaneous recording of cumulative and derivative fragiligrams (osmotic fragility curves). Each test requires 0.05 ml of a 1:30 dilution of whole blood, and the resulting fragiligrams are determined by about 100 to 150 recorded points for the derivative curve and 200 to 300 recorded points for the cumulative curve. This high resolution is of special significance in detecting, within a heterogeneous cell population, a minor group of cells which are osmotically more fragile or more resistant (3, 4). The present paper reports on the use of this method for the demonstration of variations in the red-cell population induced by irradiation and the effectiveness of marrow transplant in restoring erythropoiesis. Failure of erythropoiesis after irradiation should result in an increasing proportion of cells of more uniform age distribution. Conversely reactivation of erythropoiesis by marrow transplant should be demonstrated by the introduction into circulation of a new population of osmotically more resistant cells. This has been borne out by the experimental results of this study.

Material and Methods

Nine male mice F (C3H/NC57BL) about 3 months old and weighing about 27 g, were used in each of four similar experiments. Three of the mice were maintained untreated as controls; the remainder in leucine containers were exposed to doses of

850 total body X-irradiation using General Electric Maxlinear III X-Ray machine (250 kv 15 ma) with 0.5 mm Cu and 1 mm Al filters, t - target distance t 50 cm (dose rate, 83 /min). Immediately after irradiation 3 of the mice were injected intravenously with 3×10^6 cells from isologous bone marrow. In one of the experiments 4th group was added, in which the marrow was transplanted 24 h after irradiation.

At 2 or 3 day intervals during a period of 12 to 20 days 0.1 ml of blood obtained from a section in the tail-tip of each mouse was collected into heparinized capillaries, of the type used in microhaematocrit determinations. Bleeding was controlled by tourniquet and in no instance did haemorrhage occur.

Immediately after collection, the blood samples were diluted 1:30 in isotonic NaCl buffered to pH 7.3 with veronal acetate buffer. About 0.05 ml of the blood suspension was introduced into a container cell having two walls made of dialysing membrane mounted on a specially constructed stainless steel frame, 0.5 mm thick. Distilled water was used as the external medium. The test was repeated several times in succession on each blood suspension. The cumulative and derivative fragiligrams were simultaneously recorded by means of the Fragiligraph Model D 2 (Elron Electronic Industries, Haifa, Israel).

Results

In the control series a normal fragiligram was obtained and this did not vary throughout the period of study (Figure A). The sigmoidal curve depicts the cumulative fragiligram. The angle and slope of the curve before reaching the plateau is governed by the time taken for completion of haemolysis, and thus by the proportion of more resistant cells which are present. The normal distribution of cells as a single population in terms of osmotic fragility is well illustrated in the unimodal derivative curve.

The irradiated animals showed the same normal fragiligram before and one day after irradiation, but an altered pattern began to appear thereafter and was clearly recognisable on the 6th day following total body irradiation (Figure B6). On subsequent days, until the mice died about 12 days after irradiation, the cumulative curve showed a progressive disappearance of the slope towards the plateau with a less rounded angle to the top shoulder of the curve and there was a narrower peak in the derivative curve. These features indicate a more uniform population with disappearance of the most resistant cells. It will be noted that on days 6 and 8 (Figure B) the base line of the cumulative curve was elevated. As the dilution of blood is constant (1:30) and the zero of the Fragiligraph recorder is aligned with no light transmission, the base line is determined by the number of cells per unit volume. Thus, elevation of the base line in the cumulative curve indicates a progressively decreasing haematocrit.




Figure. Automatically-recorded cumulative and derivative curves in representative experiment. Salt concentration on abscissa and degree of lysis on ordinate. *CH* complete haemolysis. *A* control mouse. *B* irradiated mouse. *C* mouse irradiated and subsequently infected with isologous marrow. The numbers refer to the day after the beginning of the experiment.

In the mice which were transplanted with marrow the pattern was similar to that in the irradiated mice for the first few days with slight individual variations. On the 6th day however the presence of a small number of cells of greater osmotic resistance was detected (Figure, C 6). This component increased progressively and gradually joined the main population of mature cells, until by the 12th day the curve had become similar to the original curve, showing practically a single population.

Discussion

Reticulocytes are in general more resistant to drastic osmotic haemolysis than the main population of red cells whereas the oldest red cells are most fragile (5-8). It has been demonstrated by phase microcinematography that in gradual haemolysis old cells are the first to haemolyse and young cells are the most resistant (1). The Fragiligraph which functions on the basis of gradual osmotic haemolysis thus provides curves, particularly the derivative curve which represents an age population distribution of the red cells.

In the experiment described in this paper it can be seen that while the control blood maintained a normal pattern of osmotic fragility, irradiation resulted in disappearance of the more resistant cells as apparent from the alteration in the fragiligram. This appears to be due to maturation of the younger cells without replacement of this age group because of erythropoietic failure, and hence there was a gradual narrowing of the age distribution in the cell population, well illustrated in the narrowing of the peak of the derivative fragiligram. In the marrow-grafted mice the evidence of production of a new population of red cells is well illustrated. Serial determinations have made it possible to detect renewed erythropoietic activity at an early stage. Because only a minute amount of blood is required for the test, the picture is not confused by the production of blood-loss anaemia.

Summary

By means of the Fragiligraph it is possible to determine osmotic fragility by rapid micro-method and with high resolution as each curve is based on about 250 recordings of the degree of lysis in progressively decreasing salt concentrations. The method has been applied to blood samples obtained from untreated mice, mice subjected to lethal total body irradiation and, in some of the batch, to subsequent bone-marrow transplant. The blood samples have shown changes in age population distribution as evidenced by changes in the fragiligram, especially apparent in the derivative curves. Use of the Fragiligraph provides convenient technique for demonstrating the extent of erythropoietic inhibition caused by irradiation, and for detecting erythropoietic reactivation after marrow transplant.

Zusammenfassung

Mit Hilfe des Fragiligraphen ist es möglich, die osmotische Resistenz durch eine rasche Mikromethode und mit hoher Auflösung zu bestimmen, da jede Kurve auf ca. 250 Bestimmungen des Hamolysegrades in fallenden Salzkonzentrationen beruht. Die Methode wurde angewendet aus Blutproben von unbehandelten Mäusen, von Mäusen nach letaler Ganzkörperbestrahlung und bei einigen denselben nach nachfolgender Knochenmarkstransplantation. Die Blutproben zeigten Veränderungen der Altersverteilung der Population, was sich in den Abweichungen im Fragiligramm und besonders deutlich aus den Kurvenabweichungen hervorgehen. Die Verwendung des Fragiligraphen ermöglicht eine Beurteilung des Ausmaßes der erythropoetischen Hemmung durch Bestrahlung und den Nachweis einer Reaktivierung der Erythropoese nach Knochenmarkstransplantation.

Résumé

A l'aide du fragiligraphie il est possible de déterminer la fragilité osmotique par une micro-méthode rapide et d'un grand pouvoir de discrimination, chaque courbe reposant sur à peu près 250 déterminations du degré de lyse dans une concentration de sel allant diminuant. La méthode est appliquée à des échantillons de sang prélevés

sur des souris non traitées, sur des souris ayant été soumises à une irradiation à dose létale du corps entier et sur quelques unes de celles-ci après la transplantation consécutive de moelle osseuse. Les échantillons de sang montrèrent des changements dans la distribution de l'âge de la population, changements qui furent mis en évidence par des modifications du filigrane spécialement apparentes dans les dérivées. L'emploi du filigrane rend possible une appréciation de l'importance de l'inhibition érythropoïétique causée par l'irradiation et la détection d'une réactivation de l'érythropoïèse après la transplantation de moelle osseuse.

References

1. DAWOY, D. Osmotic hemolysis by gradual decrease in the ionic strength of the surrounding medium. *J. cell. comp. Physiol.* 57: 111 (1961).
2. DAWOY, D. A rapid micromethod for recording red cell osmotic fragility by continuous decrease of salt concentration. *J. clin. Path.* 16: 377 (1963).
3. DAWOY, D., FAIR, Y. F., RADCO, A. and BEEB, E. van, A. Simple rapid osmotic fragility test proposed as routine in blood banks. *Transfusion, Philad.* 4: 339 (1964).
4. FAIR, Y. F.; PERK, K. and DAWOY, D. Correlation between osmotic resistance and fetal hemoglobin in bovine erythrocytes. *Exp. Cell Res.* 30: 561 (1963).
5. MARKE, P. A. and JOWNSON, A. R. Relationship between the age of human erythrocytes and their osmotic resistance—basis for separating young and old erythrocytes. *J. clin. Invest.* 37: 1542 (1958).
6. SOROK, E. R. and TOWERS, Y. J. Fractionation of human erythrocytes on the basis of their age. *Nature, Lond.* 180: 1211 (1957).
7. SJÖLUND, S. The resistance of red cells *in vitro*. *Acta paediat., Uppsala* 98 (1954).
8. STEVENSON, J. G. Surface and fragility differences between mature and immature red cells. *J. Physiol., Lond.* 99: 30 (1941).

Authors' address: Dr S. M. LEVIN, Department of Hematology, Postgraduate Medical School, London W 12 (England); Drs I. Binkov and D. Dawoy, The Weizmann Institute of Science, Rehovot (Israel).

Department of Surgery Roswell Park Memorial Institute
(New York State Department of Health) Buffalo, N. Y.

Separation of Viable Leukocytes from Normal Human Blood*

K. ULRICH AND G. E. MOORE

To obtain normal human leukocytes for certain studies involving cell culture, our laboratory needed a method that would meet the following criteria: high viability of the leukocytes, freedom from erythrocytes, and as large a yield as possible. Best results were provided by a combination of several methods developed in other laboratories. To enhance the sedimentation of erythrocytes, we use polyvinylpyrrolidone (PVP) employed for this purpose first by ROBINEAUX *et al.* (9) in 1949 and subsequently by many investigators (13). For further purification of leukocyte suspensions, we lyse the remaining erythrocytes with streptolysin-O according to a modified version of the technique described by MALMGREN *et al.* (5).

Materials and Methods

Blood from a normal person is treated with 25 units of heparin (e.g. Sodium Heparin, Upjohn) per ml of blood. A leukocyte count is done on the sample and the rest of the blood is transferred to one or two tall, slender separatory funnels. (All glassware including syringes, funnels, and centrifuge tubes, was silicized.) To each 10 ml aliquot of blood is added 40 ml of cold Earle's buffered salt solution (EBSS) with pH of 7.4 and to this is added 50 ml of 3.5% solution of PVP (Polyvinylpyrrolidone #30, Oxford Laboratories, approx. mol. weight 40000) in EBSS. The blood-EBSS-PVP mixture in each funnel is mixed well by pipetting it up and down a few times, and the funnel is left standing upright at 4°C for 1 h.

The sedimented erythrocytes, approximately 5% of the total column of fluid, are drawn off through the bottom of the separatory funnel. The supernatant, containing leukocytes and usually somewhat contaminated with erythrocytes, is transferred to centrifuge tubes and is diluted 1:1 with cold EBSS. The cells are spun for 10 min at 250 G in refrigerated centrifuge and the resulting cell pellets are combined and resuspended in 10 ml of cold EBSS. To this suspension is added 140 mg of streptolysin-O (Difco) dissolved in 10 ml of EBSS. The tubes are shaken gently in water bath at 37°C.

Supported by Grant CA-08204-01 and Contract PH43-63-616 from the U. S. Public Health Service.

for 1 to not more than 2 min. An increase in the transparency of the cell suspension indicates that the red cells are lysed. After 20 ml of cold EBSS is added to the tube, the cells are spun down in refrigerated centrifuge at $160 \times G$ for 5 min. The leukocyte pellet is resuspended in the desired medium. We usually prefer culture medium RPMI #906 (7) supplemented with 5% fetal calf serum (FCS). A viability count, using exclusion of trypan blue, is performed.

The principal test to determine the viability of the leukocytes was measurement of their oxygen uptake (11) by means of standard Warburg manometry. Varying amounts of cells, depending on the amounts available from individual samples, were suspended in 6 to 8 ml of the phosphate-buffered medium RPMI #906 supplemented with 5% FCS. After 20 min of equilibration with atmospheric air oxygen uptake was measured for 2 h. Q_{O_2} was expressed as μl of oxygen taken up per 10×10^6 cells per hour.

Short-term cultures (3 to 5 days) were initiated from a third of the samples of separated leukocytes. Cells were inoculated in Eagle T-flasks containing culture medium RPMI #906 supplemented with 5% FCS and including 0.01 ml of phytohemagglutinin P (Difco) per ml. The cultures were observed for attachment of cells, for amoeboid movements, and for change in the pH of the medium. In some instances, chromosome slides were prepared in order to demonstrate mitoses. After 72 h of incubation, 10 μg of Colcemide (Diacetylmethylcolchicine, Ciba) per ml of medium was added to the culture, and the cells were harvested 14 h later by scraping them off the glass, subjecting them to brief treatment with hypotonic medium and fixing them with 1:3 mixture of glacial acetic acid and absolute methanol. Air-dried slides were prepared and Giemsa stained.

Results

The percentage of viable cells recovered ranged from 25 up to 84% of the number of leukocytes initially present in the blood sample; the mean recovery rate was 57%. In most instances, the viability of the cells recovered was more than 89% on the basis of trypan blue exclusion. From examination of Giemsa-stained smear slides or from observation of the cells in the counting chambers, it was always quite obvious that the ratio of erythrocytes to leukocytes was far below 1:1, more likely 1:50 or less.

In short term cultures, attachment of cells to the glass was observed after a few hours of incubation at 37°C. Amoeboid movements were obvious, as was intracellular streaming of the cytoplasm. During the next few days, a falling pH in all cultures provided evidence of active cell metabolism. In the instances where chromosome slides were prepared, numerous mitoses were observed. Oxygen uptake was measured for 9 of the 15 samples of leukocyte suspension prepared. The Q_{O_2} values ranged from 1.17 to 13.3 (Table 1) which is in good accord with similar measurements done by FALLOV *et al* (3) and RABINOWITZ (8) on leukocyte suspensions prepared from normal human blood by other methods.

Table I
Separation of leukocytes from normal blood.

Sex of donor	Vol. of sample (ml)	Total leucocytes (x 10 ⁶)	Recovered leukocytes			O ₂ O ₂	Culture	Attachment	Attachment
			Total leucocytes (x 10 ⁶)	% recovered	viable (trypan blue)				
m	20	2790	55.8	22.2	41	96			
f	20	3550	111.0	66.9	60	92			
m	10	7320	75.2	19.3	5	99	13.3		
m	20	2070	41.4	16.4	40	91			
f	20	6610	132.2	98.8	75	94			
f	20	6390	127.8	70.6	55	94			
f	20	5750	115.0	36.1	31		2.0		
f	20	4520	68.4	37.3	54		2.0		
m	20	5800	116.0	122.0	100				
f	20	7140	142.8	105.2	74		1.2		
f	10	4480	44.8	24.7	55	84	8.4		
m	10	2710	27.1	15.9	58	84	7.4		
m	10	6620	66.2	47.2	71	89	3.3		
f	10	5370	53.7	20.0	37	91	8.7		
m	10	6050	60.5	50.0	84	89	1.9		

Discussion

Our method for separating leukocytes from normal whole blood utilized PVP for rapid sedimentation of most of the erythrocytes, followed by a short exposure to streptolysin-O for lysis of the remaining erythrocytes. The method meets our criteria since the leukocytes retain a high viability and a reasonable percentage of the cells are recovered with very little erythrocyte contamination. Streptolysin-O is known to be injurious to polymorphonuclear leukocytes when it is used according to the method described by MALMÖREN *et al* (5) in a concentration of 16 mg/ml at 39°C for 10 min, it lyses large amounts of polymorphonuclear leukocytes. In a concentration of 7 mg/ml at 37°C for 1 to not more than 2 min, as in our method, streptolysin-O has caused no observed decrease in the number of polymorphonuclear leukocytes. No specific measurements were performed to determine the degree of erythrocyte contamination in the preparations, as it was obvious from microscopical observation of the leukocyte suspensions that only a very small number of erythrocytes remained after the separation procedure.

The yields obtained seem reasonable in comparison with those of other methods recorded in the literature (1-4, 6, 8, 10, 11, 14)

A mean of 57% of the leukocytes initially present in the samples could be recovered. This rather good percentage of recovery was aided to some extent by diluting the initial 10 ml of blood with 90 ml of fluid (essentially EBSS) before sedimentation.

A slight tendency toward aggregation of the leukocytes could sometimes be observed, but brief and gentle pipetting of the cell suspensions would easily break up any clumps of cells. In a few instances where leukocyte pellets had been stored at 4°C for 24 or 48 h, an appreciable amount of clumping was seen. In these instances, it was difficult to break up the clumps mechanically. In such instances it may be of advantage to add small amounts of streptokinase-streptodornase, as has been done by FALLON *et al* (3).

The viability studies were based primarily on measurements of the leukocytes' uptake of oxygen after separation was completed. The Q_{O_2} values obtained compare favorably with those obtained by other investigators after separation of leukocytes from normal blood (2, 3, 8, 11). Such results do not necessarily imply that alterations in the cells do not occur during the separation procedure. It seems reasonable to conclude, however, that the active respiration measured, as well as the demonstrated ability of the cells to multiply during short-term culture, indicates that the separation procedure induced no gross alterations in the cells, and certainly no serious loss of viability. Attachment of the cells in culture and the occurrence of amoeboid movements also support the conclusion that leukocytes not only tolerate our method of separation quite well, but may be generally quite resistant to the unphysiological conditions involved.

Acknowledgments: We wish to thank Miss B. COPELAND for skilled technical assistance.

Summary

A method for the separation of viable leukocytes from normal human blood is described. It is based on sedimentation of the erythrocytes with polyniethylpyrrolidone and subsequent lysis of the remaining erythrocytes with streptolysin-O. A mean of 57% of the leukocytes initially present in the samples could be recovered. The ratio of erythrocytes to leukocytes was far below 1:1, more likely 1:50 or less after completion of the separation. The rather good percentage of recovery was aided to some extent by diluting the initial blood sample 1:10 before the sedimentation. Viability studies after the separation was completed included measurements of the leukocytes' uptake of oxygen, dyestachion tests, observation of division in short-term cultures, as well as attachment of the cells and amoeboid movements. All parameters thus observed indicated that the separation procedure induced no gross alterations in the cells, and certainly no serious loss of viability.

Zusammenfassung

Es wird eine Methode zur Abtrennung lebender Leukozyten aus normalem menschlichem Blut beschrieben. Sie beruht auf einer Sedimentation der Erythrozyten mit Polyvinylpyrrolidon und nachfolgender Lyse der verbleibenden roten Blkörperchen mit Streptolysin O. Im Mittel konnten 57% der ursprünglich in den Proben vorhandenen Leukozyten gewonnen werden. Das Verhältnis von Erythrozyten zu Leukozyten lag weit unter 1:1; es betrug eher 1:50 oder weniger nach beendeter Abtrennung. Die gute Ausbeute wurde bis zu einem gewissen Grade unterstützt durch Verdünnung der ursprünglichen Blutprobe im Verhältnis 1:10 vor der Sedimentierung. Untersuchungen der Lebensfähigkeit nach vollzogener Abtrennung betrafen Messungen der Sauerstoffaufnahme durch die Leukozyten, Farbstoffausschlüsse, Feststellung von Teilungen in kurzfristigen Kulturen, sowie Haftung und amoeboides Bewegen der Zellen. Aus diesen Kriterien ging hervor, daß das Verfahren keine großen Zellveränderungen und daher keine wesentliche Beeinträchtigung der Lebensfähigkeit zur Folge hat.

Résumé

Une méthode servant à la séparation de leucocytes vivants du sang humain normal est décrite. Elle repose sur la sédimentation des érythrocytes en présence de polyvinylpyrrolidone et sur la lyse consécutive des érythrocytes restants par le streptolysine O. En moyenne 57% des leucocytes initialement présents dans les échantillons de sang prélevés ont pu être récupérés. Le nombre relatif des érythrocytes et des leucocytes était très en dessous de 1:1 plutôt de 1:50 ou même encore la séparation terminée. Le pourcentage assez élevé de récupération a été en partie amélioré par la dilution de 1:10 avant la sédimentation des prélevements de sang. La séparation une fois terminée les examens de viabilité comprenaient des déterminations de l'absorption de l'oxygène par les leucocytes, des tests d'exclusion de colorants, l'observation de la division dans des cultures de courte durée, ainsi que de l'adhésion des cellules et de leurs mouvements amoéboides. Ces critères mirent en évidence que la méthode décrite ne provoque pas d'altérations graves des cellules ni de diminution importante de leur viabilité.

References

1. AGRAWAL, B. W., VALLER, B. L. and WATSON, D. F. Centrifugal subfraction of polymorphonuclear leukocytes, lymphocytes and erythrocytes. *Blood* 9: 804 (1954).
2. CHAMBLER, A. R.; SARRA, A. J. and BARDAGILL, W. A. Isolation of highly purified, viable leukocytes from blood. *Amer. J. clin. Path.* 37: 237 (1963).
3. FALLON, H. J., FAXI, E., III, D., MOON, J. D., TIER, J. B. and DEER, D. Leukocyte preparations from human blood. Evaluation of their morphologic and metabolic state. *J. lab. clin. Med.* 59: 779 (1962).
4. LI, J. G. and OROGOO, E. E. A method for the rapid separation of leukocytes and nucleated erythrocytes from blood or marrow with phytohemagglutinin from red beans. *Blood* 4: 670 (1949).
5. MALMÖREN, R., PERITT, J., DELVROCH, F. and POTTER, J. Method for the cytologic detection of tumor cells in whole blood. *J. nat. Cancer Inst.* 30: 1203 (1958).
6. MINOR, A. H. and BRYANT, L. A method for obtaining living leukocytes from human peripheral blood by acceleration of erythrocyte sedimentation. *Blood* 1: 799 (1948).
7. MOORE, G. E., MOUNT, D., TARA, G. and SCHWARTZ, N. Growth of human tumor cells in suspension cultures. *Cancer Res.* 23: 1735 (1963).

8. RABINOWITZ, Y. Separation of lymphocytes, polymorphonuclear leukocytes and monocytes on glass columns, including tissue culture observations. *Blood* 29, 811 (1964).
9. ROSENBLAU, R., LEBRY, J., KOCHELKY, R. and DELACROIX, A. Sur un nouveau procédé d'obtention des leucocytes à partir du sang circulant. *Ann. Inst. Pasteur* 77, 710 (1949).
10. SEWELL, T. P., SELSBERG, I. and SCHWARTZ, S. The preparation of morphologically intact leukocytes from peripheral blood by means of gramicidin and lysocleithin. *Blood* 1, 88 (1947).
11. TULL, J. L. Preservation of leukocytes. *Blood* 8, 563 (1963).
12. VALLER, B. L., HIGGINS, W. L. and GROSS, J. G. A method for the separation of leukocytes from whole blood by flotation on serum albumin. *Blood* 1, 82 (1947).
13. WALFORD, R. L. *Leukocyte Antigens and Antibodies* (Grune & Stratton, New York/London 1960).
14. WASSERMAN, C. Separation of leukocytes. *Scand. J. clin. lab. Invest.* 8, 14 (1956).

Authors' address: Dr K. Ulrich, The Fibiger Laboratory K-1, Lyngby (Denmark); Dr G. L. Moore, Dept. of Surgery, Randall Park Memorial Institute, Raleigh, N. C. (USA).

Department of Pathology Kyoto Prefectural University of Medicine

Electron Microscopic Observations on the Finer Structure of Basophilic Granulocytes of Newt (*Triturus pyrrhogaster*)

O TAKEOKA, S MATSUI AND T ASHIHARA

Recently it has been reported that cytoplasmic membranes are deformed by osmium fixation (1). We have had a similar experience in examining the granules of basophilic granulocytes of newt blood.

The presence or absence of these structures in the granules of the tissue mast cells and the basophilic blood leucocytes of mammals is important therefore we report our results on the blood granulocytes of newt, even though the results obtained in amphibians cannot directly be applied to the mammals.

Material and Method

One drop of newt blood was fixed in the fixation fluid in which the blood made thin layer less than 0.5 mm in thickness. In one series, the blood was fixed in Carnifield's osmic acid fixative for one hour. In another series, the blood was fixed in 5% glutaraldehyde solution buffered at pH 7.4 and added with sucrose at the room temperature for one hour and post-fixed in Carnifield's fixative for one hour. The specimens were then dehydrated in ethanol, embedded in Epon 812, cut with Porter Blum microtome and examined with Hitachi HU-11 electron-microscope.

Results and Discussion

In the specimens fixed with osmic acid and stained with uranyl acetate there was a distinct structure in the granules which consisted of bundles of needle-like crystals (Fig. 1). The remaining areas in the granules contained a small amount of minute particles. In some granules polygonal structures were visible, suggesting a cross section of the bundle of crystals. A few of granules showed homogeneously fine granular content. Corresponding to these inner structures found electron microscopically, rod-like metachromatic ma-

terial was seen in the granules on the section cut from the same epon block and stained with toluidine blue (Fig. 2). Except for the rod like metachromatic structure, the content of the granules remained unstained. When the sections for the electron microscopic examination were stained with lead hydroxide, the needle-like crystals were not stained, being seen as empty narrow spaces, and the remaining parts of the granules appeared more dense with fine granular material. Moreover these fine granular material seemed to be reduced in density proportionally to the distance from the Golgi area. The granules nearest to the Golgi area had no crystals.

In the specimens fixed with glutaraldehyde followed by post fixation with osmium, we could not find any crystal structure in the granules. The content of granules was either homogenous and amorphous (Gh. in Fig. 3) or fine reticular (Gr. in Fig. 3) and filled each granule entirely. In some granules both elements were present together. Corresponding to these inner structures seen electron microscopically a section from the same epon block, when stained with toluidine blue showed a homogenous metachromatic material filling the granules.

It should be mentioned here that with routine staining methods on smear specimens or when observed in a native preparation with a phase contrast microscope the content of the granules appeared as a homogenous material without any significant inner structures. Therefore the pattern of staining of the granules from the electron-microscopic material fixed with glutaraldehyde was almost identical with those of the routine smear specimens corresponding more with the granules of the living granulocytes. The conclusion was warranted that the crystal structure in the granules of the specimens fixed with osmium tetroxide is an artefact owing to the osmium fixation.

According to SMITH (2) the preservation of the cytoplasmic organelles of tissue mast cells of rat or mouse was very difficult in the electron-microscopic material. We had similar experiences on the mast cells of rat or mouse, and also on the granulocytes of newt blood, when osmic acid was used as a fixative. However in the glutaraldehyde-fixed material of newt blood, the preservation of the Golgi bodies, endoplasmic reticulum and mitochondria was far better than in those of osmium fixed material.

In the light microscopic studies, many authors have described differences between basophilic leucocytes and tissue mast cells of mammals. Although in general differences in the cell size and the numbers of granules between basophilic leucocytes and the tissue mast cell do exist, these differences are quantitative and not qualitative they do not appear fundamental. MAXIMOW (3) who described the differences between both cell types, stated that in some instances it was difficult to differentiate them. On the other hand one of us (4) observed the mast cells with a scanty cytoplasm and very few granules in the lymph nodes of rat both in normal and pathological states. This feature has been described as specific to the blood basophilic leucocytes. In the pathological state, where a marked increase of mast cells was observed in the mediastinal lymph nodes, distinct mast cells appeared in the peripheral blood. As to the form of the nucleus, one of us (5) already reported that the nucleus of mast cells in the peritoneal fluid of mouse can show a simple or complicated indentation which has been described also as specific to the blood basophilic leucocytes. Recently COWDEN *et al* (6) have reported the differences between both types of basophilic cells in newt. Here again the differences seem to be quantitative rather than qualitative.

From the beginning of the electron microscopic examinations on the mast cells and basophilic leucocytes, the existence or absence of inner structure within the granules of both types of basophilic granulocytes has been an interesting and important problem.

POLICARD *et al* (7) who described the presence of an inner structure in the granules of rat tissue mast cells, believed that this is a fundamental difference which allows to differentiate tissue mast cells from basophilic leucocytes. The latter has, according to him, no such inner structure. On the other hand, PEASE (8) and WENQVIST (9) described the presence of lamellar structure in the granules of rat basophilic myelocytes. SETOGUTI *et al* (10-11) described the presence of lamellar structure in the granules of newt tissue mast cells using the osmic acid fixative they believed that

Fig. 3. Basophilic granulocyte of newt blood, glutaraldehyde-fixed. Note the homogeneous and amorphous or fine reticular contents of the granules ($\times 40,000$).

Fig. 4. Basophilic granulocyte of the section from the same epon block as Fig. 3, stained with toluidine blue. Note the homogeneous metachromatic staining of the contents of granules ($\times 2,000$).



Fig. 1 Basophilic granulocyte of newt blood, osmium-fixed. Note the crystal structures in the granules ($\times 20\,000$)

Fig. 2 Basophilic granulocyte of the section from the same epon block as Fig. 1 stained with toluidine blue. Note the rod-like metachromatic structures in the granules ($\times 20\,000$)

this is an essential structure in these cells. Many authors reported that there are inner structures in the granules of tissue mast cell STOECKENIUS (12) in man, HATAI *et al.* (13) in *Clemmys japonica*, HIRAS *et al.* (14) in man (round cell). Others found an almost homogeneous (granular or fine reticular) structure of the granules of tissue mast cell SMITH on hamster and rat, HATAI *et al.* on *Geoclemmys reevesii* and HIRAS *et al.* on man (long cell). There can be, therefore, not definitely concluded whether or not the granules of the basophilic granulocytes have an inner structure.

According to our observation the crystal structure in the granules of basophilic granulocytes of newt blood is an artefact due to osmic acid fixation. Moreover the facts that there are differences in the density of content of granules in one and the same cell, which is fixed osmic acid and stained with lead hydroxide, and that the granules near to the Golgi area are free of crystal structures, suggest different stages of the development of granules.

Of course, these observations on the newt blood granulocytes can not be applied directly to those of the mammals nevertheless they indicate that the presence or absence of some crystal or lamellar structure in the granules of tissue mast cells or blood basophilic leucocytes of mammals cannot be used as criterion to differentiate both types of cells.

Summary

The basophilic granulocytes of newt blood were examined electron-microscopically with two kinds of fixation method. With osmic acid fixation there was crystal structure in the granules of the cell, but none with glutaraldehyde fixation. The granules had homogeneous or fine reticular content. In comparing the toluidine blue stained epon sections with the routine smear specimens and the living granulocytes, the conclusion appears verified that the crystal structure in the granules of the basophilic granulocytes of newt blood, observed in the electron-microscopic material is an artefact owing to the osmium fixation.

Zusammenfassung

Die basophilen Granulocyten aus dem Blut des Wassermolches wurden elektronenmikroskopisch mit zwei Fixationsverfahren untersucht. Eine kristalline Struktur der Granula wurde mit Osmiumtetroxidfixation gefunden, jedoch nicht bei Fixation mit Glutaraldehyd. Die Granula waren einem homogenen oder fein-retikulären Inhalt auf. Beim Vergleich der mit Toluidinblau gefärbten Epon-Schnitte und der Routineausstriche oder der lebenden Granulocyten ergab sich, daß die Kristallstruktur der basophilen Granulocyten des Wassermolches, wie sie im Elektronenmikroskop beobachtet wird, ein durch die Osmiumfixation bedingtes Artefakt darstellt.

Résumé

Les granulocytes basophiles du sang de la salamandre aquatique ont été étudiés au microscope électronique à l'aide de deux modes de fixation. Une structure cristalline se trouva dans les granulations des cellules fixées à l'aide d'acide osmique, mais pas dans celles fixées à l'aide de glutaraldéhyde. Les granulations montrèrent un contenu homogène ou une fine structure réticulaire. En comparant les coupes (épon colorées au bleu de toluidine aux frochis de routine ou aux granulocytes vivants, nous avons tiré la conclusion que la structure cristalline des granulations des granulocytes basophiles de la salamandre aquatique comme elle apparaît au microscope électronique est un artefact dû à la fixation à l'osmium.

References

1. TORNEY J. M. Difference in membrane configuration between osmium tetroxide-fixed and glutaraldehyde-fixed ciliary epithelium. *J. Cell. Biology* 23: 636 (1964)
2. SMITH, D. E. Electron-microscopy of normal mast cells under various experimental conditions. *Ann. N. Y. Acad. Sci.* 103: 40 (1963)
3. MAXIMOW A. Untersuchungen über Blut und Bindegewebe. VI. Über Blutmasszellen. *Arch. mikroskop. Anat.* 63: 247 (1913)
4. TAKEOKA, O., ANGIYOKI, D. M. AND LALICH, J. J. Stimulation of mast cells in rats fed various chemicals. *Amer. J. Path.* 40: 545 (1962)
5. TAKEOKA, O. The mast cell in the peritoneal fluid. *J. Kyoto Pref. Med. Univ.* 62: 66 (1957)
6. COWDER, R. R., VARADY, A. AND BEVENSON, G. C. Basophil leucocytes and tissue mast cells in newt, *Desmognathus viridescens*. *Acta haemat., Basel* 32: 250 (1964)
7. POLICARD, A.; COLLET A. ET PRIGERMAN, S. Étude au microscope électronique des mastocytes des tissus chez les mammifères. *Rev. Hémat.* 17: 374 (1960)
8. FRANK, D. C. Marrow cells seen with the electron-microscope after ultrathin sectioning. *Rev. Hémat.* 10: 300 (1955)
9. WENQVIST G. Electron-microscopy of the basophilic granulocyte. *Ann. N. Y. Acad. Sci.* 103: 352 (1963)
10. SETOGUTI, T. AND YASAMURA, H. The fine structure of tissue mast cells in *Triturus pyrrhogaster* (Bole). *Arch. Histol. J.* p. 23: 311 (1963).
11. SETOGUTI, T. AND YASAMURA, H. Further observations on the mast cell granules in *Triturus* by electron-microscope. *Okajimas Folia anat. Jap.* 40: 327 (1963)
12. STOLCKENHUS, W. Zur Feinstruktur der Granula menschlicher Gewebemaszellen. *Exp. Cell Res.* 11: 566 (1956)
13. HATAI, T.; HAMMOTO, A., UCHIDA, A. AND SHIMIZAWA, M. Studies on mast cells in tortoise by electron-microscope. *J. med. Soc. Toho Univ.* 5: 101 (1958)
14. HORNE, R. G., BURCH, G. E. AND PHILLIPS, J. H. Electron-microscopic observations on the human mast cell. *Amer. Heart J.* 60: 121 (1960)

Index rerum ad Vol. 31-35

Confecti G. ROZEM, Basel

(B) = Book reviews - Buchbesprechungen - Livres non caux

(C) = Communications - Vorträge - Communications

- Abkühlung des Thymus, v Thymus
 Abnormal cell (V-cell) occurrence of
 an abnormal cell in murine virus-in-
 duced leukaemia, II, 159
 Abnormal hemoglobins, nomenclature,
 II, 368
 - Haemoglobin
 Aborters, threatened the serology of
 anti-Tj^a-like haemolysis observed in
 the serum of threatened aborters in
 Western Australia, II, 272
 Absorption, Radio-iron
 Absorption (Vitamin K), Hypopro-
 thrombinæmia
 Art LITTREsche Sowsche Krankheit,
 Intoxicopathie
 ACD-Blutkonserven Entstehung von
 Aggregaten in ACD-Blutkonserven,
 II, 89
 Acid phosphatase, Phosphatase
 Acides aminés, Gamma G-Proteine
 Acquired idiopathic hypoprote-thrombin-
 æmia, Hypoprote-thrombinæmia
 Adaptor Protein synthesis
 Adenosintriphosphat, v Thrombocyten-
 stoffwechsel
 Adsorption, Desorption, Plasma-pro-
 teinfilm
 Advances in blood grouping, Vol. II
 II, 253 (B)
 Advances, Progress
 Äthylen Ethylen
 Afibrinogenæmia, v Fibrinopenia, Hy-
 pofibrinogenæmia
 Agar-gel electrophoresis, Electropho-
 resis
 Age of erythrocytes an attempt to se-
 parate erythrocytes according to age
 by new type of centrifuge, II, 163
 Agglomerated erythrocytes, Wider-
 stand, elektrischer
 Agglutinin, v Phytohaemagglutinin
 Agglutinins (Phytohaemagglutinins)
 Lymphocyte
 Aggregate Entstehung von Aggregaten
 in ACD-Blutkonserven, II, 89
 Akropoikilämie und V-Chromo-
 somenanomalie bei Hämophilie A, II,
 49
 AHG (= Antihäemophilie globulin)
 v Haemophilie
 Albumin, v Copper turnover
 Alimentation (sans protéine) Ery-
 thropoiesis
 Allergy progress (Vol. 8) II, 127 (B)
 (Vol. 9) II, 253 (B)
 Alpha-thalassaemia, homozygous,
 Thalaemic syndromes
 Alter der Erythrocyten, Age of ery-
 throcytes
 AMARO SINGHART † II, 248
 AMAROsche Krankheit (= kongenitale
 maligne Histiocytopathie Histo-
 ciopathie
 Amidon, gel d'amidon, Electrophoresis,
 v Starch-block electrophoresis
 β-(4-Amino-1-methylbutyl)amino-6-
 methoxyrhodamine, Primaquine
 Amnionleukämia/Leukämie normaler
 und pathologischer γ-G-Proteine, II,
 257
 Anaemia, platic fetal haemoglobin in
 acquired platic anaemia, I, 183
 Anaemia, aregenerative von absorp-
 tion and excretion in aregenerative
 anaemia (A collaborative radiobio-
 american whole body counter red)
 II, 80
 Anaemia, Cooley anaemia the tha-
 lassaemia syndromes V Cooley
 anaemia with low level of fetal haemo-
 globin. A genetic study in four fami-
 lies) II, 291

- Hb-binding serum proteins, Thalassemia (major and minor) Thalassemic syndromes
- Anaemia, haemolytic, autoimmune case of autoimmune haemolytic anaemia, thrombocytopenia and LAMARCA-GILLIAN-BAKER syndrome, 31 361
- - ; idiopathic, in MALAYA, 31 282
- Anaemia, haemolytic, non-spherocytic, case, metabolic aspects of erythrocytes and leukocytes, 33, 284
- Anaemia, hypochromic, microcytic, v Haemoglobin A₂, Haemoglobin H
- Anaemia, iron deficiency gastric lesion, 31 313
- Anaemia, macrocytic, Macrocytosis
- Anaemia, mediterranean, v Haemoglobin A₂, Hb-binding serum proteins, Thalassemia, β -Thalassemia, Thalassemia syndromes, Thalassemia
- Anaemia, pernicious (An erythrokinetic and autoradiographic study using TP-thymidine, H³-uridine and TP-cytidine) 32, 65
- Pernicious-Krankheit
- Anaemia, pyridoxine-responsive, ferrokinetics, 32, 1
- Anaemia, sideroblastic, non-hereditary idiopathic, refractory electron microscopic observations on bone marrow and liver tissue in non-hereditary refractory sideroblastic anaemia, 31 9
- Anaemias, haemolytic, non-spherocytic, congenital, with specific enzyme defects, studies, 31 63
- Anaemias, haemolytic, non-spherocytic, hereditary 31 177 (C)
- Anaemias, sideropenic, Gastrotoxy
- Anaemias, Anisocytosis, Haemoglobin II
- Anaemie, hämolytische, angeborene, mit Monoklonfärsung und Immunkörperbildung nach Splenektomie, 32, 314
- Anämie, hämolytische, erworbene, Heparinbehandlung, 32 37
- Anämie, Scheinanämie, v Anämie, Verdünnungsanämie
- Anämie, Verdünnungsanämie (Tierexperimentelle Untersuchungen über den Einfluss des Blutstroms auf die Erythrocytenregulation) 33, 1
- Angiology Microangiological problems
- Anisocytosis mechanisms for the induction of anisocytosis, 31 129 (C)
- Antibiotics, neue Nebenwirkungen der modernen Chemotherapeutica (2. Internationales Symposium für Chemotherapie Part I) (= Antibiotica et Chemotherapie, Vol. 11), 31 364 (B)
- Chloramphenicol
- Antibodies, v Anämie, hämolytische, Blood group antibodies Rh-incompatibility; Thrombocytopenia
- Anticoagulant antiplatelet passager et cellules de HANCOCK au cours d'une ostomyelose, 32, 206
- Anticoagulant therapy Prothrombin times
- Anticoagulants, v Heparinbehandlung, Phenindione
- Anticorps, Antibodies
- Antigen, v Immunological properties
- Antihämophile globulin (= Factor VIII = AHG A) Haemophila
- Antihämophile globulin C, Factor X
- Antikörper Antibodies
- Antithrombotische Faktoren und Lepra erythematodes-Phänomen, 31 361 (B)
- Antiplatelet; anticoagulant antiplatelet passager et cellules de HANCOCK au cours d'une ostomyelose, 32, 206
- Anti-T_H-like haemolysis the serology of anti-T_H-like haemolysis observed in the serum of threatened abortion in Western Australia, 33, 172
- Aplastic anaemia, acquired; fetal haemoglobin in acquired aplastic anaemia, 32 168
- Aregenerative anaemia from absorption and excretion in aregenerative anaemia (A) collaborative swedish-american whole body counter study) 33, 80
- Argyrophil fibres, v Reticular cell tissue
- Arteriosclerosis, microangiological problems, Memorial Foundation Dr HARRY KANZER
- Arthritis, rheumatoid destructive effect of lymphoid cells from patients with rheumatoid arthritis in tissue culture, 31 225 (C)
- Arzneimittelkennung und Pharmakodynamik (Kolloquium Basel, 23. bis 27. Oktober 1962) (Antibiotica et Chemotherapie, Vol. 12) 33, 331 (B)

- Aspiration of sternal marrow v Mitotic index
- Atmagastransportfunktion des Blutes und die Erythropoese junger Kanarienvögel, 37 129
- Atlas of bone tumors (including tumor like lesions) 37 361 (B)
- Atlas, v Leucemias
- ATP v Thrombocytenstoffwechsel
- Attachement des globules blancs à des perles de verre, v Glass beads
- Aufspaltung, hämatologische, der durch das Virus der myeloischen Leukämie der Maus induzierten Leukosen, 33, 139
v Virus leukaemia
- Anstriche, Blutstriche, Phosphorylase
- Anstrich, Western Australia, v Anti-TJA-like haemolysis
- Antibodies, v Thrombocytopenia
- Autohaemolysis, Anti-TJA-like haemolysis
- Auto-immune haemolysis, v Anti-TJA-like haemolysis
- Auto-immune haemolytic anaemia, idiopathic, in *Alseya* 31 282
- Auto-immune haemolytic anaemia, thrombocytopenia and Lander-Gutlad-Barré syndrome a case, 34 361
- Auto-immune hämolytische Krankheit, Stoffwechselveränderungen in Erythrocyten, 34 68
- Autoimmunity recent studies, 37 187 (C)
- Automatic red cell counting v Thalassemias
- Autoradiographic and immunoelectrophoretic patterns of Hb-binding serum proteins, 33, 210
- Autoradiography (= microautoradiography) v Erythroblasts H^3 -Thymidine-Incorporation; H^3 -thymidine-Lymphocytes; Lymphocytes, ultrastructure Pernicious anaemia; Protein synthesis
- Avortement imminent, v Abortions, threatened
- Bank blood, Blutkonserven
- Barré, Lander
- Bart; haemoglobin Bart, and H in Swedish boy 37 239
- Bart haemoglobin Bart, v Fetal haemoglobin
- Basophil leukocytes and tissue mast cells in newt, *Dipsosaurus dorsalis*, 32, 250
- Basophilic granulocytes electron microscopic observations on the finer structure of basophilic granulocytes of newt (*Triturus pyrrhogaster*) 33, 344
- Basophils; studies of basophils (The effects of exogenous heparin upon the number and morphology of basophils) 37 24
- Basophils, studies (Basophilic leukocytes and gonadal activity in the rabbit), 37 356
- Baumwollfaser-Methode (Fickler) Separation of lymphocytes
- Beans, v Favlum
- Bestrahlung v Strahlenschaden
- Beta-thalassemia cytochemical observations on β -thalassaemia (L. The PAS positive substance of erythroblasts) 34 1
- Bleeding capacity of iron, v Iron absorption
- Bisected erythropoietic cells, Rayon A
- Bilirubin; binding of bilirubin from red cell with glucose-6-phosphate dehydrogenase deficiency 37 33
- Biological fluids, proteins (VIIIth colloquium, Bruges, april/may 1963), 33, 63
- Biopsies (medic course), Mitotic index
- Bifurcation; hämolytische Krise bei Mangel an Glukose-6-phosphatdehydrogenase und Bifurkation, 34 338
- Heavy metals
- Ble, radioaktive, v Heavy metals
- Bleues cutanées, v Skin wounds
- Bloc d'amidon, électrophorèse, Starch-block electrophoresis
- Blood cells; quantitative cell counts of the bone marrow and blood and their secular variations in the normal adult rat, 37 50
- regulatory mechanisms for protein synthesis in normal blood cells, 37 129
- Blood, circulation, Circulation

- Blood coagulation, hemorrhage and thrombosis (Methods of study) 33, 191 (B)
- Blood coagulation, laboratory methods, 34 127 (B)
- Blood coagulation, v Anticoagulant
Coagulation Coagulation, intravascular Factor X; Fibrin-fibrinolytic-häufig: Fibrinolysis Fibrinogenase
Haemophilia Haemophilia A,
Haemophilus Haemophilus A,
Haemostatic function Heparin; Hypofibrinogenemia Hypoprothrombinemia; Parahaemophilia; Phenothiazine; Prothrombin times Purpura; Streptokinase therapy Thrombocytopenia; Thrombolysis
- Blood diseases, 32, 63 (B)
- Blood films; new technique for the histochemical demonstration of phosphorylase in blood films, 35, 304
- Blood group serological and genetical observations on the blood group A₂B, 31 106
; the X-linked blood group system Xg (Work in progress) 31 205 (C)
Anti-Tj^a-like haemolysis, Group sanguinis, Rh-isocorpuscularity
- Blood group antibodies, characterization by serological and immunochemical methods (IXth congress of the European Society of Haematology 1963) (Vox sanguinis Vol. 9, Nr. 1) 33, 64 (B)
- Blood grouping advances, Vol. 11, 35 235 (B)
- Blood, human separation of lymphocytes from human blood, 35, 294
separation of viable leukocytes from normal human blood, 35, 338
- Blood plasma, Copper turnover
- Blood platelets, physiology 35, 192 (B)
- Blood transfusion; XIth congress of the International Society of Blood Transfusion (Sydney 1966), 34 64, 128
- Blood transfusion, International Society
JEAN JULLIARD prize, 34 370
- Blood transfusion, ACD-Bloodconser-
von, Blood group antibodies, Blut-
transfusionsforschung Transfusion
- Blood volume, Erythrocytes
- Blut, peripheres, v. Peripheres Blut
- Blutuntersuche, v. Phosphorylase
- Blutgerinnung, v. Blood coagulation
- Blutgruppen, v. Anti-Tj^a-like haemo-
lysis, Blood group, Blood group anti-
bodies, Blood grouping, Groupes
sanguinis
- Blutnerven Entzündung von Aggre-
gaten in ACD-Blutnerven, 32 83
- Blutplättchen, Antiplateletäre
Blood platelets, Platelets, Thrombo-
cytic, Thrombocytopenia, Throm-
bocytopenic, Thrombopenia, Throm-
bocytostoffwechsel
- Blutplättchen, Aktivität des Faktors I
v. Parahaemophilia
- Blutserum der Wert der Vitamin-B₁₂-
Bestimmung im Serum für die
klinische und hämatologische Dia-
gnostik, 35 144
- Bluttransfusionsforschung, Ergebnisse
(Bd. VIII) (Bibliotheca haematologi-
ca, fasc. 20) 35 64 (B)
- Blood transfusion
- Blutvolumen die Indikation zur Be-
stimmung von Blutvolumen und zur
Indikation Erythrocytenmenge bei
Polycythæmia vera und Polyglobu-
lia, 34 116
; Verdünnungsanalyse (Therapen-
monitore Untersuchungen über den
Einfluß des Blutvolumens auf die
Erythrocytenregulation) 35, 1
- Body irradiation (partial), Typhoid
verries
- Body irradiation (whole body irradi-
ation) Thymus
- Bohnen, v. Fava
- Bone marrow comparison of two
markers of cell proliferation in bone
marrow 31 1
electron microscopic observations on
bone marrow and liver tissue in non-
hereditary refractory sideroblastic
anemia, 31 9
; an evaluation of erythropoiesis in
canine marrow 35, 311
human, during the last three months
of intramural life (A histological
study) 34 226
an investigation of lymphocyte pro-
duction in granulocyte bone marrow
33, 331
lymphocytes of the rat as studied by
autoradiography 33, 19

- ; quantitative cell counts of the bone marrow and blood and their secular variations in the normal adult rat, 31 30
- transplantation after whole-body irradiation. An experimental study in the rat, 31 128 (B)
- ; the use of regenerating bone marrow to protect guinea pigs against lethal irradiation, 32 146
- v Chloramphenicol, Erythrémie, Erythropoiesis, Granuloblasts, Knochenmark, Leukocyte production, Marrow graft, Megakaryocyte, Myeloproliferative disorders, Osteomyelofibrosis, Osteomyelofibrose, Proliferation
- Bone tumors, atlas (including tumorlike lesions) 31 361 (B)
- Book reviews, v Libri
- Boru v Leukaemic cells
- Brain, Central nervous system
- Burrows, methemoglobin reduction test, simplified procedure, 33, 176
- Bruges XIIIth colloquium, Bruges, april/may 1965 (Protides of the biological fluids) 33, 63
- Buchbesprechungen, Libri
- Buulfentum, v Myleria
- C¹⁴ v Erythrémie
- Caillot, Luc, v Streptokinase therapy
- Call embryo, Leukaemic cells
- Cancer hémoglobines anormales chez les malades marocains cancéreux, 35 33
- Cancer marrow evaluation of erythropoiesis in cancer marrow 35 311
- Casu/analytic Cancer marrow Erythropoietin, Mitotic index
- Capacity in oxygen, v Atmospätransportfunktion
- Carcinoma, v Hémoglobines anormales
- Casu parcellar Hypoxia, Irradiation, Lymphocyte production
- Cell counts, quantitative, v Quantitative cell counts
- Cell proliferation comparison of two markers of cell proliferation in bone marrow 31 1
- 'Cellscope' v Elektronische Erythrocytenzählung

- Cells, blood cells regulatory mechanisms for protein synthesis in normal blood cells, 35, 129
- Cellular influx, v Thymus
- Cellules bimodèles érythropoétiques, v Rayons X
- Cellules endothéliales, Endothelzellen
- Cellules de HARGRAVES, v HARGRAVES
- Central nervous system in regulation of erythropoiesis, 35, 65
- Centrifuge, new type: an attempt to separate erythrocytes according to age by a new type of centrifuge, 35, 163
- Cerebrum, v Central nervous system, Intrakranielle Anordnung der Leukämien
- CERRELL HARGREY-STEFANOWSKI syndrome, four cases, histochemical and genetic studies, 31 20
- CERRELL leukocytic anomaly cytological and cytochemical study 32, 114
- Chelating agent, v Desferrioxamine, Versenats
- Chemotherapeutics, moderne, Nebenwirkungen, Neue Antibiotika (2. internationales Symposium für Chemotherapie. Part I) (= Antibiotika et Chemotherapie, Vol. 11) 31 364 (B)
- Chemotherapy v Leukemia
- Chien, v Canine marrow Erythropoietin, Mitotic index
- Children with leukemia, v Haemoglobin, foetal
- Children, v Idiopathic
- Chinese residents of Taiwan, haemoglobin H disease, 32, 178
- Chirurgie, v Mages
- Chloramphenicol and erythropoiesis, 31 321
- Chloroleukemia of rats, Leukocyte production
- CHRISTMAS, Hemo-
- Christmas disease: a modification of the Hines and Primary test for the distinction between haemophilia A and christmas disease, 32 353
- Christmas factor v FPG
- Chromatographic (Carboxymethylcellulose-Säurechromatographic), v Hb I Isolektion
- Chromatographic, Papier-Chromatographie, v Porphyrinsynthese

- Chromium, radioactive, v. Enzyme de-
fects, Erythrocytopenia, Hb-binding
serum proteins, Osteomyelitis,
Potassium anaemia, Verdun-
magnetite
- Chromosome complement in some my-
eloproliferative disorders, investiga-
tions, 34 36
- Chromosome (X chromosome) X-
linked blood group
- Chromosomes, v. Erythropoiesis,
Microcytosis, supplementaria, X-
Chromosomenanalyse
- Clinicographia, v. Microcytosis sup-
plementaria
- Circulation, Handbook of physiology
- Cirrhosis of the liver macrocytosis (A
clinical and experimental study) 35,
30
- Citrated blood; in vitro and local co-
agulation of heparinized and citrated
blood from skin wounds, 33 57
- Classification, Leucocytes
- Clinical assessment of granulopoiesis, 31
150 (C)
- Clinical laboratory methods and diag-
nosis (Grazziosi) (6th ed.) (Vol. I
and 2) 31 363 (B)
; v. Dysproteinemia
- Clinical medicine coagulation and
transfusion in clinical medicine, 33
319 (B)
- Clot dissolution, Streptokinase the-
rapy
- Clotting, intravascular and spontaneous
fibrinolysis, 31 239 (C)
- Co⁶⁰ Irradiation, Strahlenschaden
- CO₂ Aemgstransportfunktion
- Coagulation in vitro and local co-
agulation of heparinized and citrated
blood from skin wounds, 33 57
- Coagulation of blood, Anticoagulants,
Blood coagulation, Coagulation, Fac-
tor X, Fibrinfilamentbildung, Fibrino-
lyse, Fibrinopenia, Haemophilia,
Haemophilus A, Haemophilus, Ha-
mophilic A, Haemostatic function,
Heparin, Hypofibrinogenemia, Hy-
poprothrombinaemia, Laboratory
methods, Parahaemophilia, Phenin-
dione, Prothrombin time, Purpura,
Streptokinase therapy Thrombocyto-
penia, Thrombolysis
- Coagulation, intravascular disseminat-
ed, 33 319 (B)
- Coagulation and transfusion in clinical
medicine, 33 319 (B)
- Cobalt, v. Erythropoietin
- Cobalt, radioactive, Irradiation,
Strahlenschaden
- Cobaya, v. Hypoxia, Irradiation
- Cocryme-linked dehydrogenases, v. In-
flammatory reactions
- Coculoplasmin, v. Copper turnover
- Cold haemaglobinuria, paroxysmal, v.
Anti-TJA-RBC haemolysis
- Cold-labile proteins, v. Serum compo-
sition
- Colloquium, Braga
- Colonization, v. Oxylogenschnelle
- Colours of cotton wool fibres (method
of FICHTLER) Separation of lym-
phocytes
- Committee, International, for Standar-
dization in Haematology Docu-
mentation, Hemometer Standardi-
zation
- Comparative hematology 35, 320 (B)
- Competition, v. Memorial Foundation
- Compte automatique des érythrocytes,
Thalassemie
- Comptes rendus du 9e congrès de la
Société Européenne d'Hématologie,
Lisbonne 1963 1re partie I-III
(après 31 p. 128), 31 129-239; 2e
partie, Index V XX (avant 31 p.
129)
- Comptes rendus, Blood group anti-
bodies, Bluttransfusionsforschung,
Haemophilus, Iron metabolism, Pro-
ceedings, Society Standardization,
Symposium
- Concours, Memorial Foundation
- Conductibility Erythrocytes,
gaps
- Conferências do IX congresso da Socie-
dade Europeia de Hematologia, Lis-
boa 1963, parte I I-III (depois da
pág 31 128) 31 129-239 parte II
Index V XX (antes da pág 31 129)
- Congenital familial methemoglobin-
emia, Kongenitale Methämoglo-
binämie
- Congenital fibrinopenia fatal pul-
monary embolus in congenital fibrino-
penia (Report of two cases), 35, 36

Elektroechterkrankheiten, v. Desferal
not, Desferrioxamine

Eiweiß, v. Proteins

Electron microscope, v. Erythrinic
Leukaemia virus; Lymphocytes, ultra-
structure; Platelets; Reticular cell
tissue

Electron microscopic observations on
the finer structure of basophilic gra-
nulocytes of newt (*Triturus pyrrhoges-
ter*) 33, 344

Electron microscopic observations on
bone marrow and liver tissue in non-
hereditary refractory sideroblastic
anemia, 31 9

Electrophoresis investigations on the
electrophoretic mobility of factor X
on starch-block, 32 200

Electrophoresis, Bart, Haemoglobin
A₂, Haemoglobin E, Haemoglobin,
foetal, Haemoglobin H, Hb 1, Isoantib-
Hämoglobins anormales, Myelom-
proteine, Phosphatase, Sicking phe-
nomenon, Spherocytosis, Thalam-
aemia, Thalassemic syndromes,
Thrombocytosis

Electrophoresis (immunoelectrophoresis)
v. Hb-binding serum proteins

Electrophoretic studies of erythrocyte
glucose-6-phosphate dehydrogenase in
normal and enzyme-deficient Sardin-
ian subjects, 33, 46
v. Elektrophorese (auf Membran-
folien)

Elektrischer Widerstand die Ursache
des elektrischen Widerstandes gepack-
ter Erythrocyten im niederfrequenten
Bereich, 34 51

Elektronische Erythrocytenzählung bei
Thalassemie, 33, 308

Elektrophorese (auf Membranfolien)
Gauts G-Proteine
v. Elektrophorese

Embolism fatal pulmonary embolism in
congenital fibrinogenemia (Report of
two cases) 35 56

Embryo, v. Foetal, Foetales

Embryo (cult), v. Leukaemic cells

Embryo (human) v. Bone marrow

Endothelzellen im peripheren Blut, v. or
kommen und Bedeutung 32, 39

Energy metabolism of leukocytes, regu-
lating factors, studies, 33, 321

Enfants, v. Idiopathic

Enfants atteint de leucémie, v. Haemo-
globin, foetal

Enfants mort-nés, v. Human bone mar-
row Rh-incompatibility

Entründung, v. Inflammatory exudate

Enzyme defect; electrophoretic studies
of erythrocyte glucose-6-phosphate
dehydrogenase in normal and en-
zyme-deficient Sardinian subjects, 33,
46

Enzyme defects, specific; studies in con-
genital non-spherocytic haemolytic
anemias with specific enzyme defects,
studies, 31 65

Enzyme deficient subjects, v. Phospho-
tase

Enzyme systems studies on the tetra-
hydrofolate acid dependent enzyme
system in human leukocytes, 34 72

Enzymes; erythrocyte enzymes in tha-
lassemia and thalassaerythrocytosis,
34 379
v. Ferment

Eosinophil leukocytes, 31 248 (B)

Epidemiology v. Leukemia

Ergänzung der Bluttransfusionsor-
gung (Bd. VIII) (Bibliotheca hae-
matologica, fasc. 20) 33, 64 (B)

Ernährung (proteinfrei), v. Erythro-
poiesis

Erratum (ad. Vol. 30 (1963), 133-143),
31 64

Erythremia; altérations érythroblasti-
ques et érythrocytaires dans la myé-
lose érythémique aiguë 34 277

Erythroblastic hyperplasia, v. Sidero-
blastic anemia

Erythroblasts altérations érythroblasti-
ques et érythrocytaires dans la myé-
lose érythémique aiguë, 34 277
the PAS positive substance of erythro-
blasts (Cytochemical observations on
β-thalassemia I) 34 1
RNA and protein metabolism in nor-
mal human erythroblasts and granulo-
blasts, 32 271
v. Anisocytosis, Microcytosis, nephe-
matosis

Erythroblastosis foetalis, Rh-incom-
patibility

- Erythrocyte bleeding of bilirubin from red cell with glucose-6-phosphate-dehydrogenase deficiency 37 35
- Erythrocyte enzymes in thalassemia and thalassaerythrocytosis 34 329
- Erythrocyte glucose-6-phosphate dehydrogenase in normal and enzyme-deficient Sardinian subjects, electrophoretic studies 35 46
- Erythrocyte, membrane; molecular and rheological considerations of the red cell membrane in view of the internal fluidity of the red cell 32 259
- ~ Erythrocyten, gepackte
- Erythrocyten Bedeutung der unversierten Fettsäuren für das Verhalten von Erythrocyten 32 348
- Plasma-proteinfilm an der Oberfläche menschlicher Erythrocyten 34 239
- Stoffwechselveränderungen in Erythrocyten bei der autoimmunen hämolytischen Krankheit 34 88
- ; Untersuchungen über die Hämerythese in roten Blutkörperchen (I. Die Bildung von Fe^{2+} Hämoglobin in Hämolyse und Suspensionen aus Kaninchenerythrocyten, Anwendung einer Fritschpneumomethode zur Isolierung des Hämochroms) 34 193
- Erythrocyten, gepackte; die Ursache des elektrischen Widerstandes gepackter Erythrocyten im niederfrequenten Bereich 34 51
- Erythrocyte, membrane
- Erythrocytenklinik, Osteocytofibrose
- Erythrocytose, zirkulierende; die Indikation zur Bestimmung von Erythrozyten und zirkulierende Erythrocytose bei Polycythaemia vera und Polyglobulien 34 116
- Erythrocytoregulation; Verdauungsanomalie (Nierexperimentelle Untersuchungen über den Einfluß des Blasenstatus auf die Erythrocytoregulation) 35 1
- Erythrocytose, elektronische, bei Thalassemie 35 308
- Erythrocytes; an attempt to separate erythrocytes according to age by new type of centrifuge 35 163
- ~ abérations érythroblastiques et érythrocytaires dans la myélome érythromélique aiguë 34 277
- ; factors in normal human serum affecting proliferation and maturation of erythrocytes and granulocytes 35 279
- ; fragility osmotic, as an indication of marrow depression after irradiation and effectiveness of marrow graft 35 333
- ~ human; description of some local heavy coats from human erythrocytes *in vivo* 34 101
- Life span and sites of sequestration of normal erythrocytes in normal and splenectomized mice and rats 35 118
- ~ (mean corpuscular diameter) Macrocytosis
- ; metabolic aspects of erythrocytes and leukocytes in case of congenital non-spherocytic haemolytic anaemia 35 284
- ; red cell acid phosphatase in normal and glucose-6-phosphate dehydrogenase deficient Sardinian subjects 35 250
- Anisocytosis, Eukaryotism, Drepanocytosis, Erythroplasia, Favian, Leukozytenbildung, Macrocytosis, Stöckung phenomenon
- Erythrocytic defects three inherited intra-erythrocytic defects Hereditary spherocytosis, Hb S and Hb C, 32 253
- Erythrocytic disease, non-spherocytic, constitutional, subimmune-haemolytic therapy 31 303
- Erythrocytometric methods and their standardization (Transactions of the standardizing committee and proceedings of symposium XVIII of the ninth congress of the European Society of Haematology (Lisbon, 1963) (Bibliotheca haematologica fasc. 18) 32 64 (8)
- Erythroid marrow Erythroplasia
- Erythroid populations, Mitotic index
- Erythroidosis, Pernicious anaemia
- Erythroidleukemia, Erythraemia
- Erythroplasia über die Atemgastrumperturbation des Blutes und die Erythroplasia junger Kaninchen 32 129
- in cancer marrow evaluation 35 311

- ; central nervous system in regulation of erythropoiesis, 35, 63
- ; and chloramphenicol, 31 321
- effect of hypoxic guinea pig plasma upon erythropoiesis in the polycythemic mouse and polycythemic guinea pig, 31 329
- and protein metabolism (III.: The erythroid marrow in protein-starved rats and its response to erythropoietin) 32, 257
- v Erythrocytoregulation, Erythrocytic disease, Iron absorption, Marrow graft, Osteomyelofibrosis, Strahlenschaden
- Erythropoietic porphyrias, 31 137 (C)
- Erythropoietic stimulus, produced by hypoxia in plethoric mouse, quantitation, 31, 246
- Erythropoietin influence of X-irradiation of the dog kidney on erythropoietin production, 31 90
- ; protective effects of erythropoietin against M₁ leukaemia induced haemato-depression, 33 167
- v Erythropoiesis
- Erythropoietiques, cellules érythropoietiques morphogénèse des cellules érythropoietiques à deux noyaux par l'action des rayons X, 33, 97
- cellules érythropoietiques irradiées, v Microcytaux supplémentaires
- Ectomax, Gastrectomy Gastric lesion, Alages
- Ectogema, Basophils
- Ethylenediaminetetraacetate (= EDTA) sodium, 1 cresate
- European Society of Haematology 10th congress, proceedings, Lisbon 1963, part I I-III (after 31 128) 31 129-239; part II Index 1-XX (before 31 129)
- proceedings of the ninth congress (Lisbon, 1963), 32 128 (B)
- 2nd session of the board of the standardizing committee (1964) 31 310
- (IXth congress, 1963) Blood group antibodies
- (v Européenne Hémoglobino-metric, Standardization

- Européenne Société Européenne d'Hématologie, 10e congrès (Strasbourg, 1963), 32 63
- Evaluation of erythropoiesis in canine marrow 35, 311
- Evolution en traitement des purpuras thrombopéniques idiopathiques, 31 163 (C)
- Evolution, v Hémoglobins
- Examen hématologique, Savoir lacrer préter
- Excretion of iron, Iron absorption
- Excretion, urinary of iron, v Desferrioxamine
- Expansur plasmatique, Bêta-albumen
- Experimental tumor research, progress (Vol. 4), 31 362 (B) (Vol. 5; Vol. 6) 31 255 (B)
- Expert panel on documentation in haematology of ICSH (= International Committee for Standardization in Haematology) 35, 350
- Exsudatmakrophagen, v Makrophagen
- Extraits de tissus, v Tissue extracts
- Exudate, v Inflammatory exudate
- Factor I (= Fibrinogen) Hypofibrinogenaemia
- Factor I of platelets, activity : Parahæmophilia
- Factor 1 (= Proaccelerin) Parahæmophilia
- Factor VIII (= antihæmophilic Globulin = AHG A), Hæmophilie A
- Factor IX (= PTC = Plasma thromboplastin component = Christmas factor = AHG B), Christmas disease PTC
- Factor X (= Antihæmophilic globulin C = STUART PROWERS factor) Investigations on the electrophoretic mobility of factor X on starch-block, 32 400
- Factor XI v PTA
- Factors influencing leukocyte release from isolated perfused femora of rats with chloroleukæmia (Mechanisms of leukocyte production and release IV.) 33 287
- Factors in normal human serum affecting proliferation and maturation of erythrocytes and granulocytes, 32 29
- Factors regulating the energy metabolism of leukocytes, studies, 32 321

- Factors; thrombocytic and thrombopenic factors in normal human serum, 37 341
- Färbung, v. Glykogennachweis
- Falkiformes, erythrocytes falkiformes, Drepanocyten, Sickling phenomenon
- Familial chronic thrombocytopenia with platelet auto-antibodies, 39 30
- Familie mit kongenitaler Methämoglobinämie infolge Desphorase-mangel, 34 215
- Families with CMEIAS-syndrom, CMEIAS
- Familie, Thalassemia
- Family from Japan parahaemophilia the report on one family from Japan, 35, 102
- Family; Negro families, Foetal hemoglobin
- Family Congenital non-spherocytic haemolytic anaemia
- Fatal pulmonary embolus in congenital fibrinopenia (Report of two cases) 35, 56
- Favism the mechanism of haemolysis in favism (Some analogy in the activity of Favaquinase and Fava juice) 33, 129
- i Phosphatase
- Fe²⁺ uptake of Fe²⁺ by acid insoluble elements of normal and thalassaemic haemolysates. In vitro studies, 37 79
- i Erythropoietin, Fer Ferrokinetik, Haemaythase, Hb-binding serum proteins, Hypoxia, Iron absorption, Osteomyelofibrosis, Pernicious anaemia, Radio-iron
- Federation world federation of haemophilia, third congress, 7-9 september 1965, Paris, 35, 63
- Feldstruktur v. Basophilic granulocytes Erythroid; Leukaemia virus Lymphocytes, ultrastructure Plasmota Reddular cell tissue Sideroblastic anaemia
- Femora of rat with chloroleukaemia, isolated and perfused, v. Leukocyte production
- Fer dépôts, mobilisation, Desferal test
- Fer; Exploration isotopique du métabolisme du fer (Anciens et nouveaux modèles) 33, 63
- manques de fer v. Desferrioxamine théorèmes du fer v. Desferrioxamine
- Per v. Erythropoietin, Fe²⁺ Ferrokinetik, Hb-binding serum proteins, Haemaythase, Hypoxia, Iron absorption, Iron deficiency Iron metabolism, Osteomyelofibrosis, Osteoma, Pernicious anaemia, Radio-iron, Sideroblastic anaemia
- Ferment defect electrophoretic studies of erythrocyte glucose-6-phosphate dehydrogenase in normal and enzyme deficient Sardinian subjects, 35, 46
- Fermentes erythrocyte enzymes in thalassaemia and thal i parahaem, 34 229
- studies in congenital non-spherocytic haemolytic anaemia, with specific enzyme defects, 37 63
- i studies on the tetrahydrofolic acid dependent enzyme system in human leukocytes, 34 72
- Ferments, v. Congenital non-spherocytic anaemia, Desphorase-mangel, Energy metabolism, Glucose-6-phosphate dehydrogenase, Glucose-6-phosphate dehydrogenase, Haemolytische Krankheit, Haemaythase, Inflammatory exudate, Leukaemic cells, Leukaemic leukocytes, Lipase, Memorial Foundation, Myelodysplasia, Phosphatase(), Phosphorylase, Porphyrysynthese, Streptokinase
- Ferritin, Sideroblastic anaemia
- Ferrokinetik in pythia. congenital anaemia, 32, 1
- Ferrokinetik, Osteomyelofibrosis
- Fetal, Foetal
- Fettsäuren, unversäuert; Bedeutung der unversäerten Fettsäuren für die Reifung der Erythrocyten, 37 348
- Fetus, Foetus
- Fever, F vom
- Fibrinfibrillenbildung und Fibrinolyse-erregung, 31 262
- Fibrinogenase, Auflösung, Streptokinase therapy
- Fibrin, v. Reticular cell tissue
- Fibrinogen (= Factor I) Hypofibrinogenaemia
- Fibrinolysis, activation with 3-pyridyl-acetic acid, 35, 91

- spontaneous and intravascular clotting *J* 239 (C)
- Thrombolysis
- Fibrinopenia, congenital fatal pulmonary embolus in congenital fibrinopenia (Report of two cases) *J* 56
- Film, v. Plasmaproteinfilm
- Films, blood films a new technique for the histochemical demonstration of phosphorylase in blood films, *J* 304
- Fine structure, v. Basophilic granulocytes; Erythrinic Leukaemia virus; Lymphocytes, ultrastructure; Platelets; Reticular cell tissue; Sideroblastic anaemia
- Fluidity, internal, of the red cell, c. Red cell membrane
- Foetal haemoglobin in acquired aplastic anaemia, *J* 188
- ; Bedeutung der γ -Ketten für die Eigenschaften des fetalen Hämoglobins, *J* 280
 - contribution to the knowledge of the immunological properties of adult and foetal haemoglobin and of their polypeptide chains, *J* 321
 - in leukaemia, estimation, *J* 214
 - slight increase of foetal haemoglobin in apparently healthy negroes, *J* 312
 - v. Thalassemia
- Foetus (calf) Leukaemic cells
- Foetus (human) v. Bone marrow
- Foie, v. Hepatic uptake Liver tissue
- Foie, cirrhose, v. Cirrhosis of the liver
- Fortschritt, v. Advances, Progress
- Foundation, v. Memorial Foundation
- Fragilgraph Fragility
- Fragility osmotic, of red cells, as an indication of marrow depression after irradiation and effectiveness of marrow graft, *J* 333
- FÄRMO virus, Mouse leukaemia, RAC-SCHER virus
- Frog *Xenopus laevis*
- Froed hémoglobémique paroxystique à froed, v. Anti-T₂-like haemolysis
- Froch, v. *Xenopus laevis*
- Frois de sang, Phosphorylase
- Gamma-globulin therapy substitutive-inhibitory as prevention of stillbirth in Rh-incompatibility *J* 209
- Gamma G-Globulin, metabolism of γ G-globulin in chronic leukaemia, *J* 44
- Gamma G-Proteine, normale und pathologische, Aminoazidzusammensetzung *J* 257
- Gamma-Ketten (= γ -Ketten) Bedeutung für die Eigenschaften des fetalen Hämoglobins, *J* 280
- Gesamtkörperbestrahlung v. Irradiation, Thyms
- Gastrocnemius; increased absorption of radio-iron in gastrocnemius patients by the addition of hydrochloric acid, *J* 200
- Gastric lesion in iron deficiency anaemia, *J* 313
- GALLERIA-Zellen über andauernde Anschwellung von GALLERIA-Zellen ins Blut (Zytophysik und Zytochemie) *J* 113
- Gefäße, v. Microangiological problems, Microvascular methodology
- Gehirn, v. Central nervous system
- Gel d'amidon, Electrophoresis, v. Electrophoresis
- Genetic and histochemical studies in four cases of CARDINAL-HIGGINS-SYNDROME syndrome, *J* 20
- Genetical and serological observations on the blood group A₂B, *J* 106
- Genetics progress in medical genetics (Vol. 3) *J* 128 (B)
- Genetics, Glucose-6-phosphate dehydrogenase, Haemoglobin A₀, Haemoglobin E, Haemoglobin H, Haemoglobin, Mimosilfluoride, Parahaemoglobin, Phosphatase, Porphyrin synthesis, Sickle cell phenomenon, Spherocytosis, Thalassemia, β -Thalassemia, Thalassemic syndromes, X-Chromosomaltranslocation, X-linked blood group
- Geschlechtschromatin, X-Chromosomenanomalie
- Gesellschaften (Gesellschaftsförderung) Blood group antibodies, Blutgruppenforschung Deutsche Hämatologische Gesellschaft, European Society of Haematology Haemophilus, 1

- ternational Society of Haematology, Société, Society Standardization, Symposium
- Gewebekulturen, v Leukaemic cells, Lymphnode cells, Lymphocyte, Plasma factors
- Gewebsextrakte, v Tissue extracts
- Gewebeszellen, v Mast cells
- Gewervelde dieren (= Vertebrata)
- Granulocytes
- Glasperlen, v Glass beads
- Glass beads; the trapping of white blood corpuscles on glass beads, 37 183
- Globules rouges, v Erythrocytes, Erythrocytes
- Globulin metabolism of γ G-globulin in chronic leukaemia 34 44
- Globulins, v AHG, Factor IX, Factor X, Gamma-globulin-Therapie, Gamma-globulin therapy Gamma G-Globulin, Gamma G-Proteine, Hämoglobine, Hämophilie A, Makroglobuline, Starch-block electrophoresis
- γ -Globulin, v Gamma-globulin therapy
- γ G-globulin, Gamma-G-globulin
- Glucose-6-phosphate-dehydrogenase binding of bilirubin from red cell with glucose-6-phosphate-dehydrogenase deficiency 31 35
- ; electrophoretic studies of erythrocyte glucose-6-phosphate dehydrogenase in normal and enzyme deficient Sardinian subjects, 35 46
- red cell acid phosphatase in normal and glucose-6-phosphate dehydrogenase deficient Sardinian subjects, 37 230
- Glucose-6-phosphatidehydrogenase; hämolytische Krise bei Mangel an Glucose-6-phosphatidehydrogenase und Methämoglobinbildung, 34 338
- v Congenital non-spherocytic haemolytic anaemia, Methaemoglobin reduction
- Glykogennachweis zur Methodik und Spezifität des Glykogennachweises in den Leukocyten mittels der PAS-Reaktion, 32 108
- Glycolysis, v Energy metabolism
- Glykoproteide, v Myeloproteins
- Conadal activity in the rabbit and basophilic leukocytes (Studies in basophils) 32 358
- G6P-DH, v Glucose-6-phosphate-dehydrogenase
- γ G-Proteine, normale und pathologische, Antikörperreaktion, 35 357
- Gradwohl, clinical laboratory methods and diagnosis (6th ed.) (Vol. 1 and 2), 31 363 (B)
- Granulations, giant, anomalous, v CARDIAK's leukocytic anomaly
- Granuloblasts RNA and protein metabolism in normal human erythroblasts and granuloblasts, 37 271
- Granulocytes basophilic; electron microscopic observations on the finer structure of basophilic granulocytes of neut (*Triloma grynigaster*) 35 344
- bijdrage tot de kennis van de morfologie van de granulocyten bij de mens en de gewervelde dieren (Beitrag zur Kenntnis der Morphologie der Granulocyten beim Menschen und bei den Wirbeltieren), 34 250 (B)
- factors in normal human serum affecting proliferation and maturation of erythrocytes and granulocytes, 33 279
- über den Nachweis einer sauren Lipase in weißen Blutzellen, 33 335
- White blood corpuscles
- Granulocytes, neutrophil (anomalous granulocytes), CARDIAK
- Granulopoiesis clinical assessment of granulopoiesis, 31 150 (C)
- Antagistransportfunktion
- Granulomatosaes ischiopodae per diaphanische granulomatosaes dell'infanzia, 32 127 (B)
- Gravidity Abortus, threatened Basophils; Human bone marrow
- Grenville, James Lewis
- GRIFFIN, v RUTTI
- Gross virus (= mouse leukaemia virus) v RABCOER virus
- Grosser, Aborts, threatened, Basophils Human bone marrow
- Groupes sanguins et immunisation groupale en Gage, 31 128 (B)
- Groupes sanguins, Anti-T₂-bke Sac molysins, Blood group, Blood group antibodies, Blood grouping
- Günther'sche Porphyria congenita, Beitrag der Porphyrydiagnose, 34 65
- GULLAUF, LAUREY

Guinea-pig: an investigation of lymphocyte production in guinea-pig bone marrow 33, 351

v Hypoxia, Irradiation

Gewässerische Schollen zytochemische Untersuchung von Zytoplasmfragmenten und Gewässerischen Schollen bei akuten Leukosen, 31 294

H² v Granuloblasts, Fertilisom anemia

Haemagglutinine, v Lymphocyte, Phytohaemagglutinin

Haematocrit, v Erythrocytes, gepackte; Fluidity Internal

Haematodepression; protective effects of erythropoietin against Mykera induced haematodepression, 33 167

Hämatologie; Normierung in der Hämatologie (Affiliation der Hämatologie repräsentiert) 35 235

Standardisierung in der Hämatologie

(1 Internationales Symposium, 14-18. Juni 1963 in Südamerika) 35, 64

- Hämatologie

Hämatologie (Diagnostik) v Vitamin B₁₂-Bestimmung

Hämatologische Aufspaltung der durch das Virus der myeloblastischen Leukämie der Mäus induzierten Leukosen, 33, 139

- v Virus leukaemia

Hämatologische Gesellschaft, Deutsche, Jahrestagung (Tübingen, 9-10. Oktober 1964) 31 127

- 11 Tagung (Oktober 1965), 33 127

Haematology comparative, 35 320 (B) documentation expert panel on documentation in haematology of ICSH (= International Committee for Standardisation in Haematology), 35, 350

European Society of Haematology proceedings of the ninth congress (Lisbon, 1963) 31 128 (B)

; - tenth congress (Strasbourg, 1965) 31 63

European Society of Haematology (11th congress 1963) v Blood group antibodies

-; European Society of Haematology 2nd session of the board of the standardizing committee (1964) 31 310

-; proceedings of the ninth congress of European Society of Haematology, Lisbon 1963, part I: I-III (after 31 p. 128) 31 129-239; part II: Index V-JCK (before 31 p. 129)

- 11th Congress of the International Society of Haematology (Stockholm, 30. 8.-4. 9. 1964) 31 64

; 11th congress of the International Society of Haematology (Sydney 1966), 31 64 128

- program (Vol. IV) 35, 192 (B)

- of some South African Republics, 31 250 (B)

- standardization in haematology 35, 191; 35, 193, 350

- v Haemometer Hämatometerprüfstelle, Normierung

- veterinary (2nd ed.), 35, 192 (B)

Haematopolesis, Erythropoietiques Haematodepression, Proliferation

Haematuria, v Haematuria

Haemochromatosis, v Desferrioxamine

Haemoglobin; immunoelectrophoretic and autoradiographic pattern of Hb-binding serum proteins, 35, 210

-; Acetaminophen transport function Fluidity Internal; Haemometer Hämatometerprüfstelle; Hämoglobins anormales; Methaemoglobin Methaemoglobinemia

Haemoglobin (Fetal-Haemoglobin) Haemoglobin

Haemoglobin A₂; thalassemia with complete absence of haemoglobin A₂ in an adult, 35, 186

-; elevated, homozygous, Thalassemic syndromes

Haemoglobin, adult; contribution to the knowledge of the immunological properties of adult and foetal haemoglobin and of their polypeptide chains, 35, 321

Haemoglobin Bart's, and H in Swedish boy 31 239

Haemoglobin, foetal

Haemoglobin-binding serum proteins immunoelectrophoretic and autoradiographic pattern of Hb-binding serum proteins, 31 210

Haemoglobin C, v Spherocytosis

- Haemoglobin E; further example of *thalassaemia-haemoglobin E disease* in Turkey 34 334
- Haemoglobin, foetal (—Haemoglobin F) in acquired aplastic anaemia, 32, 188
- Bedeutung der γ -Ketten für die Eigenschaften des fetalen Hämoglobins, 32 280
- contribution to the knowledge of the immunological properties of adult and foetal haemoglobin and of their polypeptide chains, 35, 321
- in leukaemia, estimation, 33, 214
- slight increase of foetal haemoglobin in apparently healthy negroes, 33, 312
- Age of erythrocytes, *Thalassaemia*
- Haemoglobin H, disease among Chinese residents of Taiwan, 33 178
- Haemoglobin Bari
- Hämoglobin I, Variante, neue Hb I isoliert, 32, 9
- Haemoglobin S the sickling phenomenon in white male without Hb-S, 34 347
- Drepanocytose, Spherocytose
- Haemoglobin, synthesis, Fer
- Hämoglobine, menschliche, normale und pathologische (Pathologie und Klinik in Einzelherstellungen, Bd. VIII) 31 362 (B)
- Hämoglobinoelectrie, Normierung (Mittelung der Hämoelektrophoretische) 32 236 35, 235
- Haemoglobinopathy v β -Thalassaemia
- Haemoglobins, abnormal, nomenclature, 32, 368
- Hämoglobins anormale
- Haemoglobins in genetics and evolution, 31 312 (B)
- Hämogloburie, paroxysmale, nicht Nichte: In-vitro- und In-vivo-Untersuchungen über die Beeinflussbarkeit der Hämolyse mit einer Mercaptenverbindung (Penicillamin) 32, 168
- Hämolyse; paroxysmale nächtliche Hämogloburie In-vitro- und In-vivo-Untersuchungen über die Beeinflussbarkeit der Hämolyse mit einer Mercaptenverbindung (Penicillamin) 32, 168
- Haemolysis in favism, mechanism (Sotoc analogy in the activity of Primaquine and Fava Judo) 33 129
- v Haematur
- Haemolysis the serology of anti-Tj-like haemolysis observed in the serum of threatened aborters in Western Australia, 33 272
- Haemolytic anaemia metabolic aspects of erythrocytes and leukocytes in case of congenital non-spherocytic haemolytic anaemia, 35 284
- Haemolytic anaemia, autoimmune case of autoimmune haemolytic anaemia, thrombocytopenia and Landry-Goulet-Barnet syndrome, 34 361
- Haemolytic anaemia, auto-immune, idiopathic, in *Malaga*, 31 282
- Haemolytic anaemias, non-spherocytic, hereditary 31 177 (C)
- Haemolytic disease, Erythrocytic disease
- Hämolytische Anämie, angeborene, mit Mesoblastenurie und Leukocytenbildung nach Splenektomie, 32 314
- Hämolytische Anämie, erworbene, Heilbehandlung, 32 27
- Hämolytische Krankheit, autoimmune, Stoffwechselveränderungen in Erythrocyten, 34 88
- Hämolytische Krise bei Mangel an Glucose-6-phosphatdehydrogenase und Blomulation, 34 338
- Hämometer; Normierung in der Hämologie (Mittelung der Hämometerprüfstelle) 32, 236 35 235
- Hämometerprüfstelle Normierung der Hämoglobinoelectrie (Mittelung der Hämometerprüfstelle) 32 236
- Haemophagocytic reticulosis, diagnosed during life, 31 349
- Haemophelia A modification of the Hottel and Perry test for the distinction between haemophelia A and chistoma disease, 32 335
- X-Chromosomenanomalie und Achromatophilie bei Hämophelia A, 33, 49
- due to combined deficiency of AHO, FIC and FTA factors, 31 36

- parahæmophilias: the report of one family from Japan, 35, 102
world federation of hæmophilias, third congress, 7-9 september 1963, Paris, 35, 63
- Hæmophilias (International symposium) 34 127 (B)
- Hæmorrhagic diathesis, v Hypoprothrombinaemia, Parahæmophilias
- Hæmorrhagic syndrome, v Ostéomyélocécrose
- Hæmorrhagy v Blood coagulation, Thrombocytopenia
- Hæmorrhagic function of blood platelets, mechanism, 31 250 (C)
- Hæmopoiesis in roten Blutstetten, Untersuchungen (L.: Die Bildung von Fe²⁺-Hämoglobin in Hämolyraten und Suspensionen aus hämischen-retikulären. Anwendung einer Präcipitationsmethode zur Isolierung des Hämoeisens) 34 193
- - v Porphyrinsynthese
- Haftung von weißen Blutstetten an Glasperlen, v Glass beads
- Hälymphknoten, Pathologie, 39 127 (B)
- HÄND-SCHILLER-CHRISTIAN'sche Krankheit, v Iridocyclitis
- Handbook of physiology (Section 2: Circulation, Vol. II) 31 361 (B)
- Haptoglobin, v Aaptoglobinsäure
- HÄRGAVER, cellules de HÄRGAVER (= cellules LE); anticoagulant antiplaquettaire passager et cellules de HÄRGAVER au cours d'une ostéomyélocécrose, 52, 206
- Häutschwellungen, v Porphyrins
- Hautwunden, Skin wounds
- Hb A, Hæmoglobin, adult
- Hb A (Hb A₂, Hb C, Hb F) Hémoglobines anormales
- Hb A₂, Hæmoglobin A₂
- Hb A₂, elevated, homozygous, Thalassemic syndromes
- Hb Bart's, Hæmoglobin Bart's
- Hb-binding serum proteins; immunoelectrophoretic and autoradiographic pattern of Hb-binding serum proteins, 31 210
- Hb C, v Spherocytosis
- Hb E a further example of thalassemia-hæmoglobin E disease in Turkey 34 354
- Hb F Erythrocytes, age Hæmoglobin, foetal
- Hb H, Hæmoglobin Bart's, Hæmoglobin H
- Hb I Isonæm; also neue Hæmoglobine I Varianten: Hæmoglobin I Isonæm 31 9
- Hb S the sickling phenomenon in a white male without Hb S, 34 347
-; v Spherocytosis
- HCl, v Hydrochloric acid
- H²-cytidine, v Granuloblasts, Pernicious anaemia
- H²-cytidine (H²-leucine, H²-uridine) Protein synthesis
- Heavy metals, toxic, description from human erythrocytes in vitro, 34 101
- Hématies, v Erythrocytes, Erythrocytes
- Hématologie; savoir interpréter (12) Un examen hématologique, 31 64 (B)
- ; Société Européenne d'Hématologie 10e congrès (Strasbourg, 1965) 31 65
- Hematology comparative, 35, 320 (B)
European Society of Hematology proceedings of the ninth congress (Lisbon, 1963) 31 128 (B)
; for medical technologists (3rd ed.), 31 361 (B)
- ; program (Vol. IV) 31 19* (B)
; veterinary (2nd ed.) 35, 192 (B)
; Hematology
- Hématosarcomes = leucémies; aspects histologiques et cytologiques des leucémies et hématosarcomes. Nomenclature, classification, diagnostic, atlas, 31 128 (B)
- Hemoglobin (hæmoglobin) Hæmoglobin ()
- Hémoglobines anormales chez les malades marocains cancéreux, 35 53
- Hemoglobin in genetics and evolution, 31 312 (B)
- Hémoglobinepathie, v Hémoglobines anormales
- Hemoglobin, abnormal, nomenclature 31, 368
- Hémoglobineuric paroxysmique nocturne, Hämoglobinsurie

- Hemolysis per autoimmunisation, v
Hämolytische Krankheiten
- Hemolytic disease, v Erythrocytic disease
- Hemophiles (International symposium)
31 177 (B)
v Haemophiles
- Hemorrhage, v Blood coagulation
- Hémorragie, syndrome hémorragique,
v Ostomyelocidrose
- Hemostatic function of blood platelets,
mechanism, 31 230 (C)
- Hem. (hém) v Haem
- Hepar Cirrhosis of the liver Liver
tissue, Hepatic uptake
- Heparin; studies of hemophils (The ef-
fects of exogenous heparin upon the
number and morphology of hemophils)
31 34
in vitro and local coagulation of he-
parinized and clotted blood from
skin wounds, 33, 57
; and thromboplastin, with survey on
von WILLEBRAND disease, 31 127 (B)
- Heparinbehandlung bei erworbenem hä-
molytischer Anämie, 32, 27
- Hepatic uptake of radio-iron, increased,
in acute leukaemia, 33 193
- Hereditary non-spherocytic haemolytic
anaemia, 31 177 (C)
- — — studies in congenital non-spherocytic
haemolytic anaemia with specific
enzyme defects, 31 63
- Hereditary spherocytosis three inherited
heme-erythrocytic defects Hereditary
spherocytosis, Hb S and Hb C, 32, 233
- Heredity v Blood group, Phosphatase,
X-linked blood group
- Heredopathy CHILDREN Conge-
nital non-spherocytic haemolytic ane-
mia Desferrioxamine Erythrocytic
disease; GALTHER-Zellen Glucose-6-
phosphatase dehydrogenase Haemo-
philia Haemoglobin E Haemoglo-
bin, foetal; Haemoglobin H Hae-
detary Microblastocytosis Mac-
rocytoblastosis; Parahemophelia
Porphyria congenita Purpura
Pyridoxine-responsive anaemia Sick
cell phenomenon; Thalassemia β -
Thalassemia; Thalassemic syn-
drome Thrombocytopenia X-Chro-
mosomal anaemia
- Hg²⁺ v Heavy metals
- Hicks and Ferry test for the distinc-
tion between haemophilia A and
Christmas disease, modification, 32,
333
- HIGGINS- CHILDREN
Histocytopathic, Inocitopena
- Histochemical studies of leukocytes from
an inflammatory exudate. (VI. De-
monstration of non-diaphorase-cou-
pled dehydrogenase activity using
phenanthro methosulphate) 32, 17
- Histochemical demonstration of phos-
phorylase in blood films, new tech-
nique, 33, 304
- Histochemistry CHILDREN Ery-
throcyte enzymes, GALTHER-Zellen,
Glykogenaktivität, GALTHER'sche
Schollen, Hämolytische Krankheiten,
Hämolytische Krise, Leukämische Zellen,
Lipase, Mast cells, Phosphatase ()
Tetrahydrofolic acid, β -Thalassemia
- Histology, Leukocytes
- H³leucine, Granuloblasts
- Homme, Granulocytes
- Homolog Transplantation, v Bone
marrow transplantation, Marrow
graft
- Homozygous alpha-thalassemia,
Thalassemic syndromes
- Homozygous elevated Hb A₂ without
microcytosis (COOPER-like disease
due to homozygous elevated Hb A₂
without microcytosis) Thalas-
semic syndromes
- Hormones, Erythropoiesis
- H³-Thymidin-Inkorporation im frak-
tioniert-strahlengeschädigten Knochen-
mark, 33 220
- H³-thymidine bone marrow lympho-
cytes of the rat as studied by auto-
radiography 33, 19
an investigation of lymphocyte pro-
duction in guinea pig bone marrow
33 351
Erythropoiesis, Granuloblasts,
Follicular anaemia, Plasma factors,
Thymus
- Human blood separation of lympho-
cytes from human blood, 33, 294
; separation of viable leukocytes from
human blood, 33, 338

- Human bone marrow during the last three months of intrauterine life (A histological study) 34 228
- Human erythroblasts and granuloblasts, normal, RNA and protein metabolism, 32 271
- Human erythrocytes, Erythrocytes, human
- Human haemoglobin, v Haemoglobin, foetal
- Human leukaemic leucocytes, v Leucocytes, leukaemic
- Human leucocytes, v *Cellulae Granulocyticae*; Leucocytes, human
- Lymphocytes, ultrastructure
- Human plasma a megakaryocyte stimulating substance in normal human plasma, 33 86
- Human serum, v Proliferation Serum, human
- Hund, Canine marrow Erythropoietin, Mitotic index
- Härridene, Granuloblasts, Pernicious anaemia
- Hybridisierung (Hämoglobin) Haemoglobin, foetal
- Hydrochloric acid, increased absorption of radio-iron in gastrectomized patients by the addition of hydrochloric acid, 33 200
- Hydrolysates, protéines hydrolisables, v Serumkomponenten
- Hydroxymädiureverbindung v Desferal test
- 5-Hydroxytryptamin : Freisetzung von 5-Hydroxytryptamin und Thrombozytenstoffwechsel, 33 110
- Hyperplasia of megakaryocytes megakaryocyte stimulating substance in normal human plasma, 33 86
- Hypernatraemia, Iron absorption
- Hypobinaerogenanaemia and promyelocytic leukaemia, 33 181
- Hypoprothrombenaemia, acquired, idiopathic (Acquired hypoprothrombenaemia secondary to selective deficient absorption of vitamin K.) 34 187
- Hypothalamus : central nervous system in regulation of erythropoiesis, 33 63
- Hypoxia effect of hypoxic guinea pig plasma upon erythropoiesis in the polycythaemic mouse and polycythaemic guinea pig 31 329
- quantitation of the erythropoietic stimulus produced by hypoxia in the plethoric mouse, 33 246
- ICSH, (=International Committee for Standardization in Haematology) v Documentation, Normierung Standardization
- Idiogram, v X-Chromosomenanalyse
- Idiopathic acquired hypoprothrombenaemia, v Hypoprothrombenaemia
- Idiopathic auto-immune haemolytic anaemia in *Muscle*, 31 282
- Immunoelectrophoretic and autoradiographic pattern of Hb-binding serum proteins, 33 210
- Immunoelektrophorese, v Gamma G-Proteine
- Immune tolerance, disorders, v Auto-immune haemolytic anaemia
- Immunhämatologische Erkrankung v Anämie, hämolytische
- Immunisation groupale et groupale sanguine au Cagne 31 128 (B)
- Immunity Autoimmunity
- Immunkörper v Autoimmune hämolytische Krankheit
- Immunochemical methods, v Blood group antibodies
- Immunodiffusion, v Immunological properties
- Immunological properties of adult and foetal haemoglobin and of their polypeptide chains, contribution to their knowledge, 33 321
- Immunology v Auto-immune haemolytic anaemia, Cerebroglobulin-Therapie Plasma factors, Reticulo-endothelial system
- Implantation, v Bone marrow transplantation, Marrow graft
- Inclusion bodies, v Leukocytobildung
- Index mitotique v Mitotic index
- Indon, v Phenindione
- Induction of anisocytosis, mechanical, 31 129 (C)
- Infantia, v Idiopathic
- Infarction, pulmonary v Fibrinopenia
- Infections monoclonales, v Lymphocytes, ultrastructure
- Inflammatory exudate; histochemical studies of leucocytes from an inflammatory exudate (VII) Demonstration of non-diaphorase-coupled dehydro-

- gonase activity using phenazine methosulphate) 32 17
- Inherited three intra-erythrocytic defects Hereditary spherocytosis, Hb S and Hb C, 32, 233
- Injections of regenerating bone marrow
Regenerating bone marrow
- Innaskörperbildung: angeborene hämolytische Anämie mit Mesoblastenchauris und Innenkörperbildung nach Splenektomie, 32 314
- Interleukin, v Hämo-globin-I Variants
- International Committee for Standardization in Haematology (= ICSH)
Documentation, Normierung, Standardization
- International Society of Blood Transfusion, XIth congress (Sydney 1966) 34 64, 128
- JEAN JULIARD prize, 34 370
- International Society of Haematology
XIth Congress (Stockholm, 30. 8. 4. 9 1964) 31 64
- International Society of Haematology
XIth congress (Sydney 1966) 34 64, 128
- International symposium, Reticulo-endothelial system
- Interpréter savoir interpréter (N 12)
Un examen hématologique, 32, 64 (B)
- Intoxication, Biotinisation, Heavy metals
- Intra-erythrocytic defects, Erythrocytic defects
- Intrakranielle Ausbreitung der Leukämien, unter besonderer Berücksichtigung der leukämischen Meninge-papile, 31 538
- Intrauterine life; human bone marrow during the last three months of intra-uterine life (A histological study), 34 228
- Intravascular clotting and spontaneous fibrinolysis, 31 239 (C)
- Intravascular coagulation, disseminated, 33, 319 (B)
- Iron; absorption and excretion in regenerative anaemia (A collaborative swedish-american whole body counter study) 33 80
- deficiency anaemia, gastric lesion, 31 313
- deficiency anaemia, spantiation of iron deficiency 34 137 (B)
- excretion, v Iron absorption
- ; ferrokinetics in pyridoxine-responsive anaemia, 32, 1
- increased absorption of radio-iron in gastrectomized patients by the addition of hydrochloric acid, 33, 200
- increased hepatic uptake of radio-iron in acute leukaemia, 33, 193
- metabolism (International symposium) 33 64 (B)
- storage disease, diagnosis with desferrioxamine (Desferal ion) 32 321
- storage disease, studies in the development of screening test, 33, 297
- uptake of Fe^{59} by acid insoluble elements of normal and thalassaemic haemolysates. In vitro studies, 31 79
- Erythropoietin, Fer Haem-synthese, Hb-binding serum proteins, Hypoxia, Osteomyelofibrosis, Pernicious anaemia, Sideroblastic anaemia
- Irradiation bone marrow transplan-tation after whole-body irradiation. An experimental study in the rat, 31 128 (B)
- the effect of typhoid vaccine injection of partial body irradiated rats, 34 301
- lethal; the use of regenerating bone marrow to protect guinea pigs against lethal irradiation, 32 146
- Marrow graft, Rayons X, Strahl-enschaden, Thymus, X-irradiation
- Isolated perfused femora of rats with chlorokalaemia, Leukocyte pro-duction
- Isologous transplantation, Marrow graft
- Isoenzyme, v Porphyrin-synthese
- Isotope, radioaktive l'exploration iso-topique du métabolisme du fer (An-ciens et nouveaux modèles) 33 63
- major pitfall in the use of the same radio isotope for the repetition of erythrocyte and other survival studies, 33, 257
- Isotope, radioaktive, Copper turn-over Enzyme defects, Erythremic, Erythrocytomegaly, Erythropoiesis, Erythropoietin, Fe^{59} Granuloblasts, Haemoglobin A₂, Haem-synthese, Hb-binding serum proteins, Heavy metals, H^3 Thymidine- H^3 -thymidine Hypoxia, Iron absorption, Irradia-

- tion, Life span Lymphocyte()
 Osteomyelofibrose, Plasma factors,
 Pernicious anaemia, Protein synthesis,
 Radio-iron, Thymus, Verdauungs-
 anämie
- Istiocitopatie iperdiploplastiche granulocytomatosi dell'infanzia, 32 127 (B)
- Japan; present status of leukaemia in Japan, with special reference to epidemiology and studies on the effect of chemotherapy, 31 214 (C)
- ; v Parahaemophilia
- JOLLY pseudo-corpus de JOLLY Microcytaux supplémentaires
- JULLIARD, JEAN, prize 34 370
- Kältehämoglobinurie, paroxysmale v Anti-TJA-like haemolysis
- Micelabiles Serumkomponenten, v Serumkomponenten
- Haß (Embryo) Leukaemic cells
- Kaninchen, Basiophils
- Kaninchen, neugeborene und wachsende, Atmungs-transportfunktion
- KARZIS, Dr HARTZ, Memorial Foundation competition 1964 Enzymology of leukaemic cells (Winners of the prize) 32 320
- competition 1965 Microangiological problems in arteriosclerosis, before 32 321
- competition 1965 Microangiological problems in arteriosclerosis (Winner of the prize) 33, before 65
- competition 1966 Early diagnosis of liver metastases (Laparotomy in parascopy and biopsy excluded) 33, before 63
- competition 1967 Morphological investigations on virus synthesis, 33, before 63
- Kerne Antinukleäre Faktoren, Erythropoëtiques, kernabhängige Microcytaux supplémentaires, X-Chromosomenanomalie, X (chromosome)
- Kernabhängige der Leukocyten bei *Xenopus laevis* und ihre Beeinflussung durch den Stoffwechsel, 35 246
- Ketten (γ -Ketten) Bedeutung für die Eigenschaften des fetalen Hämoglobins, 32 260
- Kidney influence of X-irradiation of the dog kidney on erythropoietin production, 31 90
- Renal failure
- Kinder v Istiocitopatie
- Kinder mit Leukämie, Hämoglobin, foetal
- Kinematographie (Mikrokinematographie) v Microcytaux supplémentaires
- Klassifikation, v Leucämies
- Klinisch, v Clinical Dysproliferation, Vitamin-B₁₂-Bereitstellung
- Knochen, v Bone tumors
- Knochenmark; Verhalten der IP Thyridin-Inkorporation bei fraktioniert strahlengeschädigten Knochenmark, 33, 270
- Knochenmark, Bone marrow Chlorambucil, Erythraemie, Erythropoiesis, Granuloblasts, Leukocyte production, Lymphocyte production, Lymphocytes, Marrow graft, Megakaryocyte, Myeloproliferative disorders, Osteomyelofibrose, Osteomyeloiderose, Proliferation
- Kobalt, Erythropoietin
- Kobalt, radioaktiv, Irradiation, Strahlenschaden
- Koenzym, v Coenzyme
- Konduktoria, Haemophilia
- Kongenital, v Congenital
- Kongenitale Fibrinolyse, v Fibrinolysis
- Kongenitale maligne Istiocitopatie (Am. 10) Istiocitopatie
- Kongenitale Methämoglobinämie (uniläre, infolge Diaphorase-mangel), 34 215
- Kongenitale Porphyrie (GUTHRIE) Porphyrinsynthese
- Kongo Congo
- Kongress, v Blood group antibodies, Bluttransfusionsforschung, Congress, Deutsche Hämatologische Gesellschaft, Hämoglobinometrie, Society Standardization
- Konservenbitter, Blutkonserven
- Korrektorenrechnung, Atmungs-transportfunktion
- Krallenfrosch, *Xenopus laevis*
- Krebs, Hémoglobines anormales
- Kühlung v Thymus
- Kupfer Copper turnover

- Labilitätsphänomene, v. Serumkomponenten
 Laboratory methods in blood coagulation, 3/ 127 (B)
 Landry-Goullain-Barrel syndrome
 case of autoimmune haemolytic anaemia, thrombocytopenia and Landry-Goullain-Barrel syndrome, 3/ 361
 Læpin, v. Basophile
 Lætos, nouveau-nés et en période de croissance, v. Asomagastransportfunktion
 Lead poisoning, Bieinfordistion
 Lead, radioactive, poisoning, Heavy metals
 Lebede Leukocyten, Abtrennung, v. Viable leukocytes
 Lebensdauer v. Life span Survival of erythrocytes
 Leber Hepatic uptake Liver metastases, Liver tissue
 Lebercirrhose, v. Cirrhosis of the liver
 LE cells, v. HARRIS, cells of HARRIS
 Leitfähigkeit gepackter Erythrocyten, Widerstand, elektrischer
 Lethal irradiation, the use of regenerating bone marrow to protect guinea-pigs against lethal irradiation, 32, 146
 LÉTIENNE, v. Art
 Leucémies et hématosarcomes aspects histologiques et cytologiques des leucémies et hématosarcomes. Nomenclature, classification, diagnostic, atlas, 32 128 (B)
 Leucos (H⁺-leucos) v. Graueleukos, Protein synthesis
 Leukaemia (2. ed.) 33 192 (B)
 Leukaemia, acute; increased hepatic uptake of radio-iron in acute leukaemia, 33, 193
 -; chronic, metabolism of γ G-globulin, 3/ 44
 ; foetal haemoglobin in leukaemia, estimation, 33, 214
 ; plasma factors (Immunological and *in vitro* cultural studies) 3/ 249
 present status of leukaemia in Japan, with special reference to epidemiology and studies on the effect of chemotherapy 3/ 214 (C)
 promyelocytic, and hypofibrinogenemia, 33, 181
 - Chloroleukaemia of rats Leucemias; Leukaemia, virus-induced; Myeloproliferative disorders; Virus Leukaemia virus; attempt at classification of mouse leukaemia viruses (Mouse leukaemia virus type A and the Friend virus), 32, 181
 - how many different viruses causing leukaemia in mice? 32, 44
 virus-induced, murine occurrence of an abnormal cell (V-cell) in murine virus-induced leukaemia, 33, 159
 - Leukämie, myelische, der Maus Leukaemic cells formation of tryptophan-pyruvase in leukaemic cells incubated with RNA, obtained from the spleen of calf embryo, 32 263
 Memorial Foundation
 Leukaemic leukocytes metabolic responsiveness of human leukaemic leukocytes to phagocytic stimulation, 33 28
 Leukaemic and normal leukocytes, Leukocytes, human, normal and leukaemic
 Leukämie, myelische, der Maus Untersuchungen zur hämatologischen Aufspaltung der durch das Virus der myelischen Leukämie der Maus induzierten Leukosen, 33, 159
 Leukaemia virus
 Leukämie, chronische, lymphatische, Lipase
 chronische, myelische, Lipase
 Leukämien über die intrakranelle Ausbreitung der Leukämien unter besonderer Berücksichtigung der leukämischen Meningeopathie, 3/ 338
 Leukosen
 Leukomogene virus the RACHINE virus mixture of the Friend virus and of the mouse leukaemia virus (Oncos)? 33 200
 Leukemia (2. ed.) 33, 192 (B)
 Leukocyte production and release, mechanisms (IV. Factors influencing leukocyte release from isolated perfused femora of rats with chloroleukaemia) 33, 287
 Leukocyten; zur Methodik und Spezifität des Glykogenschwanzes in den

- Leukocyten mittels der PAS-Reaktion, 32 108
- ; Nachweis einer sauren Lipase in weißen Blutzellen, 33, 335
- v Granulozyten
- Leukocytenkernabhängige bei *Yersinia* *letalis* und ihre Beeinflussung durch den Stoffwechsel, 35, 246
- Leukocytes the action *in vitro* and *in vitro* of sodium versenate on the phagocytic activity of neutrophilic leukocytes, 31 289
- basophil, and tissue mast cells in nerve, *Dasyatis iridex*, 32, 250
- ; studies of basophils (Basophilic leukocytes and gonadal activity in the rabbit) 32 358
- eosinophil, 31 248 (B)
- ; histochemical studies of leukocytes from an inflammatory exudate. (VI Demonstration of non-diaphorase coupled dehydrogenase activity using phenazine methosulphate) 32 17
- ; human, normal and leukaemic; studies on the tetrahydrofolic acid dependent enzyme system in human leukocytes, 34 72
- ; leukaemic; metabolic responsiveness of human leukaemic leukocytes to phagocyte stimulation, 33 28
- ; metabolic aspects of erythrocytes and leukocytes in case of congenital nonspherocytic haemolytic anaemia, 35, 284
- ; les phosphatases leucocytaires alcalines et acides V relations pathologiques, régulation humorale et rapports avec les phosphatases plasmatiques, 34 129
- ; studies on some factors regulating the energy metabolism of leukocytes, 31 371
- ; ultrastructure the relation of ultrastructure to DNA synthesis in human leukocytes (I Atypical lymphocytes in phytohemagglutinin cultures and infectious mononucleosis) 33 257
- ; viable from human blood, separation, 35, 338
- ; v Basophils, Granulozyten, Granulopoeia, Phosphorylase White blood corpuscles
- Leukocytic anomaly CREAMER 2, cytological and cytochemical study 32 114
- ; cytochemical and genetic studies in four cases of CREAMER-HUGHES-STERNBERG syndrome, 34 20
- Leukocytosis; prednisolone-induced leukocytosis in man, mechanism, 33 40
- Leukopenia (after partial body irradiation) v Typhoid vaccine
- Leukosen; Untersuchungen zur histologischen Aufspaltung der durch das Virus der myelischen Leukämie der Maus induzierten Leukosen, 31, 139
- v Leukemia virus
- ; cytochemische Untersuchung von Zytoplasmafragmenten und Gewissensschollen bei akuten Leukosen, 31 294
- ; Leukem Leukäm
- Libri, 31 127 128 (B) 247-248 (B) 312 (B) 361 364 (B); 32 63-64 (B) 127 128 (B) 33, 63-64 (B) 127 178 (B) 191 192 (B) 34 127 (B) 250-255 (B); 35, 192 (B) 233 (B) 319-320 (B) 351 (B)
- Lien, v GARCIA-Zellen, Leukaemic cells, Splenectomy
- Life span and sites of sequestration of normal erythrocytes in normal and splenectomized mice and rats, 33, 118
- Life span, v Survival of erythrocytes
- Lipase, saure, Nachweis in weißen Blutzellen, 33 335
- Lipoidose v GARCIA-Zellen
- Liver metastases, early diagnosis, Memorial Foundation
- Liver tissue electron microscopic observations on bone marrow and liver tissue in non-hereditary refractory sideroblastic anaemia, 31 9
- Liver Cirrhosis of the liver Hepatic uptake
- Livres nouveaux, v Libri
- Local coagulation, Coagulation
- Lungenembolie Fibrinopenia
- Lupus erythematosus Phänotypen und die antinukleäre Faktoren, 31 361 (B)
- Lymphknoten Pathologie der Lymphknoten, 33, 127 (B)

- Lymphnode cells destructive effect of lymphnode cells from patients with rheumatoid arthritis in tissue culture, 31 225 (C)
- Lymphocyte the place of the lymphocyte in the reticulo-endothelial system. A study of the *in vitro* effect of prednisolone on lymphocytes, 31 100
- Lymphocyte production in guinea-pig bone marrow an investigation, 31 331
- Lymphocytes, from human blood, separation, 31, 294
- (adult), of bone marrow of the rat as studied by autoradiography 31, 19
- ultrastructure the relation of ultrastructure to DNA synthesis in human leukocytes (L. Atypical lymphocytes in phytohaemagglutinin cultures and infectious mononucleosis) 31 257
- Carotax White blood corpuscles
- Lymphoid cells, migration. Thymus
- Lymphosarcomas; thymic lymphosarcoma, v. Rauscher virus
- Macrocytosis in cirrhosis of the liver (A clinical and experimental study) 31, 90
- Magen der operierte Magen (Bibliotheca gastroenterologica, Sec. 6), 31 191 (B)
- Gastroscopy Gastric lesion
- Makroglobuline und Myelomproteine, Charakterisierung, 31 144
- Paraproteinämien
- Makroglobulin (Properdin) Hämoglobinerie
- Makrophagen; unterschiedliche saure Phosphataseaktivität von Monocyten und Eosinophilmakrophagen, 31 325
- Malaria, Anaemia, haemolytic
- Maligne kongenitale Histocytopathie (AKATO) Histocytose
- Mam, v. Human Mens, Menschliche
- Manque de fer Desferrioxamine
- Marcanis cancéreux, Hémoglobines anormales
- Marrow depression after irradiation, Marrow graft
- Marrow graft; red-cell osmotic fragility as an indication of marrow depression after irradiation and effectiveness of marrow graft, 31, 333
- Mast cells basophil leukocytes and tissue mast cells in newt, *Dipsosaurus dorsalis*, 31 250
- Maturation and proliferation of erythrocytes and granulocytes, affecting factors in normal human serum, 31 279
- Maus, v. Hypoxia, Leukaemia virus, Lipo span Plithoric mouse, Rauscher virus, Thymus, Virus, Virus leukaemia
- Mechanische Resistenz von Erythrocyten v. Rotisten
- Mechanism of haemolysis in favism (Some analogy in the activity of Primaquine and Fava bean), 31, 129
- Mechanism of the hemostatic function of blood platelets, 31 230 (C)
- Mechanism of prednisolone-induced leukocytosis in man, 31 40
- Mechanism for the induction of anisocytosis, 31 129 (C)
- Mechanism of leukocyte production and release (IV. Factors influencing leukocyte release from isolated perfused femora of rats with chloroleukemia), 31, 267
- Medical genetics, progress (Vol. 5) 31, 128 (B)
- Medical technologists, Hematology
- Mediterranean anaemia, Hb-binding serum proteins, Thalassemia β -Thalassaemia, Thalassemia syndromes, Thalassemia
- Medulla ossea, Bone marrow Chlorambucol, Erythraemia, Knochenmark, Leukocyte production, Lymphocyte production, Lymphocytes, Marrow graft, Megakaryocyte
- Modèle osseux, Myeloproliferative disorders, Osteomyelofibrosis, Osteomyelofibrose, Proliferation
- Motorschwächen, Hypoxia, Irradiation
- Megakaryocyte stimulating substance in normal human plasma, 31 86
- Megakaryocyte ultrastructural aspects of platelets and megakaryocytes in

- case of 'primary' thrombocythæmia, 33, 113
- Megakaryocytes, stimulation, v Thrombocytic
- Megakaryocytopoiesis, v Thrombocytopoiesis
- Megaloblastic Anæmie, v Pernicious Krankh., Pernicious anæmia
- Membran der Erythrocyten, v Erythrocyten, gepackte Heavy metals
- Membrane of the red cell molecular and rheological considerations of the red cell membrane in view of the internal fluidity of the red cell, 32, 299
- Memorial Foundation Dr Herz Kaszka, competition 1964 Enzymology of leukæmic cells (Winners of the prize) 32, 320
- - - competition 1963: Microangiological problems in arteriosclerosis before 32, 321
- - - competition 1963 Microangiological problems in arteriosclerosis (Winner of the prize) 33, before 63
- - - competition 1966 Early diagnosis of liver metastases (Laparotomy laparoscopy and biopsy excluded) 33, before 63
- - - competition 1967: Morphological investigations on virus synthesis, 33 before 63
- Meningopathie über die intrakranielle Ausbreitung der Leukämien, unter Berücksichtigung der leukämischen Meningopathie, 31 333
- Mens (= Mensch) Granulocytes
- Menschliche Hämoglobine, Hämoglobine
- Mercaptanverbindung paroxysmale nächtliche Hämoglobinurie In-vitro- und in-vivo-L. versuchungen über die Bräunfärbbarkeit der Hämolyse mit einer Mercaptanverbindung (Penicillamin) 32 168
- Mercury radioactive, v Heavy metals
- Micobilfuscinurie angeborene hämolytische Anämie mit Micobilfuscinurie und Isonukleärbildung nach Splenektomie 32 314
- Messenger-ribonucleic acid, . Protein synthesis
- Metabolic aspects of erythrocytes and leukocytes in case of congenital non-spherocytic hæmolytic Anæmia, 33, 284
- Metabolic responsiveness of human leukemic leukocytes to phagocytic stimulation, 33, 28
- Metabolism, iron metabolism (International symposium), 33, 64 (B)
- of γ G-globulin in chronic leukæmia, 34 44
- of plasma proteins, physiology and pathophysiology (Proceedings of the third symposium, september 1964) 33, 320 (B)
- ; studies on some factors regulating the energy metabolism of leukocytes, 33, 321
- ; v Copper turnover Ferrokinetics, Iron absorption, Iron storage Protein metabolism, Stoffwechsel, Stoffwechselveränderungen, Thrombocytenstoffwechsel
- Métabolisme du fer exploration isotopique (Anciens et nouveaux modèles) 33, 65
- Metals, heavy toxic, v Heavy metals
- Methæmoglobin reduction test after Barwer, a simplified procedure, 33 176
- Methämoglobinämie kongenitale familiäre, infolge Dysphoræmies, 34 215
- Methode, v Blood coagulation Centrifuge new type Clinical laboratory methods Desferal test Desferrioxamine Elektronische Erythrocytenzählung Glykogenasehem; Hæmosynthese Hämoglobinometrie Hæm and Petver test Medical technology Métabolisme du fer Methæmoglobin reduction test; Methodology Mitotic index Phosphorylase Flaminogen Prothrombin times Radioisotopes Separation of lymphocytes Standardization Viable leukocytes
- Methodology symposium on microvascular methodology (Bibliotheca anatomica, fasc. 31 33, 319 (B)
- Methoda laboratory methods in blood coagulation, 34 137 (B)
- Mice, . Maus
- Mice leukæmia concepts in classification of mouse leukæmia viruses

- (Mouse leukaemia virus type A and the Fausov virus) 32, 81
how many different viruses causing leukaemia in mice? 32, 44
- Virus
- McNELL, RUTH-
Microangiological problems in arteriosclerosis, v Memorial Foundation
- Microautoradiographie, Autoradiography
- Microdiagraphie, v Microcytaux supplémentaires
- Microcythemia, v Thalassemic syndromes
- Microcytaux supplémentaires morphogénèse des microcytaux supplémentaires (pseudo-corps de JOLLY) dans les cellules érythropoïétiques irradiées (Recherches cinématographiques en contraste de phase) 35, 232
- Microscope à contrast de phase, v Erythropoïétiques Microcytaux supplémentaires
- Microscope électronique, v Basophilic granulocytes Erythremic Lymphocytes, ultrastructure; Leukemia virus; Platelets Reticular cell tissue Sideroblastic anemia
- Microvascular methodology symposium (Bibliotheca anatomica, fasc. 5) 35, 319 (B)
- Migration of cells to the thymus, 35, 221
- Mikroteme, Microcytaux supplémentaires
- Mix, v GAUCHEZ Zellen. Leukemic cells
- Mix (Extirpation) / Life span
- Mischungen, v Merges
- Mitose, Chloramphenicol, Erythremic, Erythropoïétiques Microcytaux supplémentaires
- Mitotic index; comparison of two markers of cell proliferation in bone marrow 31, 1
- Mollic osseus, v Medulla osseus
- Molch, Basophil leukocytes, Erythropoïétiques Microcytaux supplémentaires, Newt
- Molecular and rheological considerations of the red cell membrane in view of the internal fluidity of the red cell, 32, 299
- Molge vulgaris Molch
- Mongoliens étude clinique de 134 mongoliens, 34, 127 (B)
- Mononuclear blood cells, v White blood corpuscles
- Mononucleous infections, Lymphocytes, ultrastructure
- Monocytes unterschiedliche saure Phosphatstraktion von Monocyten und Eosinophilen, 31, 375
White blood corpuscles
- Morbus GAUCHEZ, v GAUCHEZ-Zellen
- Morphogénèse des microcytaux supplémentaires (pseudo-corps de JOLLY) dans les cellules érythropoïétiques irradiées (Recherches cinématographiques en contraste de phase) 35, 232
- Morphology Reticulo-endothelial system
- Mort fétale, Human bone marrow Rh-incompatibility
- Mouse, Hypoxia, Life span Plethoric mouse, RABBIT virus, Thymus, Virus, Virus leukaemia
- Mouse leukaemia attempt 1 classification of mouse leukaemia viruses (Mouse leukaemia virus type A and the Fausov virus) 32, 81
how many different viruses causing leukaemia in mice? 32, 44
- Mouse leukaemia virus (Gross) RABBIT virus
- Murine leukaemia, RABBIT virus, Virus, Virus leukaemia
- Mus musculus Mouse, Mouse leukaemia
- Myeloid populations, Myeloid index
- Myelische Leukämie der Maus, Leukämie, myelische, der Maus
- Myelische Reaktion, v Lippe
- Myelomproteine und Makroglobuline, Charakterisierung, 34, 144
Paraproteinämien
- Myelopoiesis, Aemgustransportfunktion, Strahlenschaden
- Myeloproliferative disorders investigations on the chromosome complement in some myeloproliferative disorders, 34, 36
- Myelose erythropoïétique altérations érythroblastiques et érythrocytaires dans

- La myélose érythrémique aiguë 34 277
- Myleran; protective effect of erythropoietin against Myleran induced haematodepression, 33 167
- Nebenwirkungen, v Antibiotica
- Necrologia, 34 371
- Negroes; slight increase of fetal haemoglobin in apparently healthy negroes, 33 312
- Nerves; central nervous system in regulation of erythropoiesis, 33 63
- Nervens (Nervensystem, Zentralnervensystem) v Intrakranielle Ausbreitung der Leukämie
- Neonatal thrombocytopenia in association with rubella, 33 136
- Neoplasma v Haemoglobin Bart's, Human bone marrow
- Neutrophil granulocytes, v Granulozyten
- Neutrophile leukocytes; the action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophile leukocytes, 31 289
- ; v Leukocytes
- New-born, v Haemoglobin Bart's, Human bone marrow
- Newt; electron microscopic observations on the finer structure of basophilic granulocytes of newt (*Triturus pyrrhogaster*) 33, 344
- v Basophil leukocytes, Erythropoietiques
- Nicotinic acid, v 3-Pyridyl-acetic acid
- Niederfrequenter Bereich, Erythrocyten, gepackte
- Niere, kidney Renal failure
- Nikotin, 3-Hydroxytryptamin
- Nodi lymphatici, v Lymphnode cells
- Nodi lymphatici regionis colli, v Halslymphknoten
- Nomenclature of abnormal hemoglobins, 32 308
- Nomenclature, v Leucæmies, Standardization
- Non-disphorase-coupled dehydrogenase, v Inflammatory exudate
- Non-spherocytic erythrocytic disease constitutional, substitutive-inhibitory therapy 31 303
- Non-spherocytic haemolytic anaemia, congenital, case, metabolic aspects of erythrocytes and leukocytes, 31 281
- Non-spherocytic haemolytic anaemias, congenital, with specific enzyme defects, studies, 31 63
- Non-spherocytic haemolytic anaemias, hereditary 31 177 (C)
- Normierung der Hämoglobinelektrophorese (Ablistung der Hämometerprüfstelle) 32 256
- v Standardization
- Normierung in der Hämatologie (Mitteilungen der Hämometerprüfstelle) 33, 233
- Normoblasts, v Erythroblasts
- Noonan's, v Haemoglobin Bart's, Human bone marrow
- Noyaux, v Nuclei
- Nuclei, Antikörper Faktor, Erythropoietiques, Kernabhängige Microtoxus supplementaires, V-Chromosomenuomere V-(chromosome)
- Nutrition (sensu protein) v Erythropoiesis
- O₂, v Hypoxia
- Oberfläche menschlicher Erythrocyten, Plasmaproteinfilm, 34 239
- v Erythrocytes, gepackte Heavy metals
- Obituary notice 31 248
- Oestrogenwirkung v Basophile
- O₂-heparinase, v Acetogastransportfunktion
- Oncogenic virus, Virus
- Ontogenese, Human bone marrow
- Operierter Magen (Bibliotheca gastroenterologica, fasc. 6) 33, 191 (B)
- 'Operon model' Protein synthesis
- Opische Aktivität, Gamma O-Proteine
- Oryctolagus cuniculus Acetogastransportfunktion, Basophile
- Ox, v Bone tumors
- Oxler Varrez, Morbus Polycythæmia vera
- Osmotic fragility of red cells as an indication of marrow depression after irradiation and effectiveness of marrow graft, 33, 333
- Osmotische Resistenz von Erythrocyten, Resistenz

- Osteomyelofibrose (Untersuchung der Ferro- und Erythrocytenkinetik mit radioaktivem Eisen und Chrom) 34 257
- Osteomyelofibrose polyglobulique anticoagulant antiplaquettaire passager et cellules de HAEMAPHYSALIS cornu d'une osteomyelofibrose, 32, 206
- Ovarien, v. Oöphilie
- Oxigen, v. Hypoxia
- Oxygen, capacity v. Atmungs-transport funktion
- Oxemia, manifestation of iron deficiency 34 127 (B)
- Pädiatrie, Ictiodiätetik
- Pancytopenia, v. Apathic anaemia
- Paper electrophoresis, Electrophoresis
- Parahämophilie the report of one family from Japan, 33, 102
- Paraproteinkämien und Dysproteinkämien (Grundlagen, Klinik und Therapie) 31 127 (B)
- Paraproteinkämien Ureurosemen über kälte-labile und wasser-labile Serumelemente bei Paraproteinkämien und Dysproteinkämien, 34 160 v. Mikroglobulinose
- Paroxysmal cold haemoglobinuria, Anti-Tj-like haemolysis
- Paroxysmale nächtliche Hämoglobinurie In-vitro- und in-vivo-Untersuchungen über die Beeinflussbarkeit der Hämolyse mit einer Mercaptanverbindung (Penicillamin) 32, 168
- PAS (= Periodic acid SCHARR)-Reaction zur Methodik und Spezifität des Glykogennachweises in den Leukocyten mittels der PAS-Reaktion, 32 108
- PAS (= Periodic acid SCHARR) positive substances in erythroblasts (Cytochemical observations on β -thalassaemia I.), 34 1
- PATRICK effect, v. Energy metabolism
- Pathologie der Hämophylienosen, 33, 127 (B)
- Pathology synopsis (6. ed.) 33, 128 (B)
- Pathophysiology and physiology of plasma protein metabolism (Proceedings of the third symposium, september 1964) 33, 320 (B)
- Pb, v. Defixionisation
- Pb²⁰⁰ v. Heavy metals
- Pean, affections, Porphyries
- Penicillamin paroxysmale nächtliche Hämoglobinurie In-vitro- und in-vivo-Untersuchungen über die Beeinflussbarkeit der Hämolyse mit einer Mercaptanverbindung (Penicillamin) 32 168
- Periodic acid SCHARR reaction, PAS
- Periphere Blut, Vorkommen und Bedeutung von Endothelzellen im peripheren Blut, 32 39
- Petres de verre, v. Glass beads
- Pernicious anaemia (An erythrokinetic and autoradiographic study using H³-thymidine, H³-uridine and H³-cytidine) 32 63
- Pernicious-Krankheit, Untersuchung der Thrombocytopoese, 34 173
- PHA, v. Phytohaemagglutinin
- Phagocytic activity the action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophilic leucocytes, 31 289
- Phagocytosis metabolic responsiveness of human leukemic leucocytes to phagocyte stimulation, 33, 28
- Pharmakotherapie und Arzneimitteltoxisierung (Kolloquium Bernol, 25. bis 27 Oktober 1962) (Ambliotica et Chemotherapie, Vol. 12) 33, 331 (B)
- Phase contrast microscope, v. Erythropoietiques Micronoyaux supplémentaires
- Phenazine methosulphate, Inflammatory exudates
- Phenindione tolerance to phenindione of patients with thromboembolic disorders, 32 338
- Phenotype, v. Phosphatase
- 2 Phenyl-1,3-indandione, v. Factor X, Phenindione
- Phosphatase red cell acid phosphatase in normal and glucose-6-phosphate dehydrogenase deficient Sardinian subjects, 32 230
- unterschiedliche saure Phosphatase-reaktion von Monozyten und Extradarmakrophagen, 31 323
- Phosphatase leucocytes alkaline et acides Variations pathologiques, régulation humorale et rapports avec les phosphatases plasmatiques, 34 123

Phosphate, inorganic, Energy metabolism

Phosphorylase: a new technique for the histochemical demonstration of phosphorylase in blood films, 35, 304

Physiology of blood platelets, 35, 192 (B)

Physiology handbook (Section 2 Circulation, Vol. 11) 3/ 361 (B)

Physiology and pathophysiology of plasma protein metabolism (Proceedings of the third symposium, september 1964) 35, 320 (B)

Physohaemagglutinin, Lymphocyte Physohaemagglutinin cultures, v Lymphocytes, ultrastructure

Pirry, ALFRED (1896-1963) 3/ 371

Pittall, major in the use of the same radioisotope for the repetition of erythrocyte and other survival studies 35 237

Pivry and Hacks test for the distinction between haemophilia A and Christmas disease, a modification, 32, 355

Plaquettes sanguines, Platelets

Plaquettes sanguines, activité du facteur I Parahaemophilia

Plasma les phosphatases leucocytaires alcalines et acides Variations pathologiques, régulation humorale et rapports avec les phosphatases plasmatiques, 3/ 129

Plasma expander Blutvolumen

Plasma factors in leukemias Immunological and in vivo cultural studies 11 49

Plasma from guinea pigs exposed to 1 potus, Hypoxia

Plasma, normal, human megakaryocyte stimulating substance in normal human plasma, 35 86

Plasmaproteinfilm an der Oberfläche menschlicher Erythrocyten, 3/ 239

Plasma protein metabolism, physiology and pathophysiology (Proceedings of the third symposium, september 1964) 35, 320 (B)

Plasma thromboplastin antecedent PTA Haemophilia

Plasma thromboplastin component

-PTC Christmas factor Factor IX

Factor IX Haemophilia

Plasma, Copper turnover Phosphatases

Plasminogen technique for routine evaluation of plasminogen in humans during streptokinase therapy 3/ 303

Plasmocytoma, v Myeloproliferative disorders

Platelets the mechanism of the hemostatic function of blood platelets, 3/ 230 (C)

- physiology of blood platelets, 35, 192 (B)

ultrastructural aspects of platelets and megakaryocytes in case of primary thrombocythemia, 35 115

v Antiplaquettaire Thrombocytenstoffwechsel, Thrombocyte Thrombocytopenia, Thrombocytopenie, Thrombopense

Factor I activity Parahaemophilia Pletoric mouse; quantitation of the erythropoietic stimulus produced by hypoxia in the pletoric mouse 35 246

Pomb intoxication, v Bleifortsetzung Pomb, radioactive intoxication, Heavy metals

PALS (=phenazine methosulphate) Inflammatory exudate

Polycythemia effect of hypoxic guinea pig plasma upon erythropoiesis in the polycythemic mouse and polycythemic guinea pig, 3/ 329

Polycythemia vera; die Indikation zur Bestimmung von Blutvolumen und zirkulierender Erythrocytenmenge bei Polycythemia vera und Polyglobulien, 3/ 116

Polycythemic osteomyelocytosis, Osteomyelocytose

Polyglobulie v. ordnungsgemäßer Polyglobulien; die Indikation zur Bestimmung von Blutvolumen und zirkulierender Erythrocytenmenge bei Polycythemia vera und Polyglobulien, 3/ 116

Polypeptide chains contribution to the knowledge of the immunological properties of adult and fetal haemoglobin and of their polypeptide chains, 35 321

Porphyria congenita (G6PD) Steuerung der Porphyrinbiosynthese bei der G6PD-mangel Porphyria congenita, 3/ 63

- Porphyria erythropoietic porphyrias, 31 137 (C)
- Porphyria cutanea tarda/intermittens apparues à la suite d'affections hématologiques, 31 200 (C)
- Porphyryrhythmus, Störung bei der GUERKHA schen Porphyria congenita, 31 63
- Präcipitationsmethode (Münster)
Hämnerythrose
- Predalolone; the place of the lymphocyte in the reticulo-endothelial system
A study of the in vitro effect of predalolone on lymphocytes, 32 100
- Predalolone-induced leukocytosis in man, mechanism, 32 40
- Pregnancy Basophils, Human bone marrow
- Preisachschreiben, v Memorial Foundation
- Primaquine; the mechanism of haemolysis in fava (Korse analogy in the activity of Primaquine and Fava Juice) 33, 129
- Prinz JEAN JULLIARD prize, 34 370
- Procoagulin (=Factor V), Parahæmophilus
- Proceedings of the ninth congress of the European Society of Haematology Lisbon 1963 part I I-III (after 31 128) 32 129-139; part II Index V XX (before 31 p. 129)
- Proceedings of the ninth congress of the European Society of Haematology (Lisbon, 1963), 32 128 (B)
- Standardization
- Proceedings of the IVth international symposium on RES (29 Mai bis 1 Juni 1964) The reticulo-endothelial system, Morphology immunology and regulation, 33, 351 (B)
- Proceedings, Blood group antibodies, Bluttransfusionsforschung, Iron metabolism, Plasma protein metabolism
- Production and release of leukocytes, Leucocyte production
- Progress in allergy (Vol. 8) 32, 127 (B) (Vol. 9) 33, 253 (B)
- Progress in haematology (Vol. IV), 33, 192 (B)
- Progress in medical genetics (Vol. 3) 33, 128 (B)
- Progress in experimental tumor research (Vol. 4) 31 362 (B) (Vol. 5 Vol. 6), 34 255 (B)
- Progress, Advances
- Proliferation and maturation of erythrocytes and granulocytes, affecting factors in normal human serum, 33 279
- Proliferation, cell proliferation, Cell proliferation
- Promyelocytic leukemia and hypofibrinogenæmia, 33 181
- Propenilin, Hämoglobulinurie
- Proteinfilm Plasmaproteinfilm an der Oberfläche menschlicher Erythrocyten, 34 239
- Protein metabolism and erythropoiesis (III. The erythroid marrow in protein-starved rats and its response to erythropoietin) 32 257
- Protein metabolism and RNA in normal human erythroblasts and granuloblasts, 32, 271
- Protein-starved rats, Protein metabolism
- Protein synthesis in normal blood cells, regulatory mechanisms, 33, 129
- Proteins, Dysproteïnämie, Fe²⁺ Gemmaglobulin-Therapie, Globulin, Human plasma, Myelomproteine, Plasma protein metabolism, Serumkomponenten, Serum proteins
- Protides of the biological fluids (XIIIth colloquium, Brugis, pril/may 1965) 33, 63
- Prothrombin, Hypoprothrombinæmia
- Prothrombin time; the effect of the use of different tissues extracts on one-stage prothrombin times, 32, 292
- Phenylendione
- Powers-STUART factor v Factor X
- Pseudo-anæmia, v Verdünnungsanæmie
- Pseudopregnancy v Basophils
- PTA (= Plasma thromboplastin antecedent; Factor XI) Hæmophilus
- PTU (= Plasma thromboplastin component Christmas factor; Factor IX) Factor IX, Hæmophilus
- Pulmonary embolus, fatal, in congenital fibrinopenia (Report of two cases), 33, 56

Function (bone marrow) v. Mitotic index

Purpura thrombocytopenic, v. Thrombocytopenia

Purpura, thrombocytopenic, idiopathic, (familial) v. Thrombocytopenia

Purpura: évolution et traitement des purpuras thrombopéniques idiopathiques, 31 163 (C)

3-Pyridyl-acetic acid; the activation of fibrinolysis with 3-pyridyl-acetic acid, 33, 91

Pyridoxine-responsive anaemia, ferrokinetics, 32, 1

Pyrolysac, v. Tryptophan-pyrolysac

Quantitation of the erythropoietic stimulus produced by hypoxia in the plethoric mouse, 33, 246

Quantitative cell counts of the bone marrow and blood and their secular variations in the normal adult rat, 31 50

Quersäuber radioaktives, v. Heavy metals

Quersäuberung, v. Fibrinfibrillenbildung

Rabbit, Basophil

Rabbits, newborn and growing,

Atemgastrisporifunktion

Radiation, Irradiation, Marrow graft,

Rayons X, Strahlenschaden, Thymus, Typhoid vaccine, X-irradiation

Radioautography v. Radiography

Radio-Bis (Radio-Quersäuber Radio-Thallium) Heavy metals

Radiocarbon, Erythrokin

Radiochrome, Enzyme defects, Erythrocytenmenge Hb-binding serum proteins, Life span, Osteomyelofibrosis, Pernicious anaemia, Verdauungsanalyse

Radio-cobalt, Regeneration bone marrow Strahlenschaden

Radio-copper Copper turnover

Radiography (microautoradiography)

Erythroblasts Hb-binding serum proteins H³-Thymidine-Inkorporation H³-thymidine Lymphocytes, ultrastructure Pernicious anaemia

Radio-iron increased absorption of radio-iron in gastrectomized patients by the addition of hydrochloric acid, 32 200

-; increased hepatic uptake of radio-iron in acute leukaemia, 32 193

- v. Fe⁵⁹ For Ferrokinetics, Haemopoiesis, Hb-binding Hypoxia, Iron absorption, Osteomyelofibrosis, Pernicious anaemia

Radioisotopes; a major pitfall in the use of the same radioisotope for the repetition of erythrocyte and other survival studies, 33, 237

Radio-Quersäuber Heavy metals

Radio-Thallium, v. Heavy metals

Ratocentrifuge-Zentrifuge, v. Centrifuge new type

Rat; quantitative cell counts of the bone marrow and blood and their secular variations in the normal adult rat, 31 50

v. Erythropoiesis, Irradiation, Leukocyte production, Life span Lymphocytes, Rickettsia virus, Typhoid vaccine

Rat, v. Gartner-Zellen, Leukämie cells, Splenectomy

Rat (splenectomized) v. Life span

Rickettsia virus a mixture of the Fasto virus and the mouse leukaemia virus (Gao) ? 35 200

Rayons X; morphogénèse des cellules erythropoïétiques à deux doses par fraction des rayons X, 33, 97

; v. Marrow graft, Thymus, Typhoid vaccine X-irradiation

Red cell acid phosphatase in normal and glucose-6-phosphate dehydrogenase deficient Sardinian subjects, 32, 230

Red cell membrane molecular and biological considerations of the red cell membrane in view of the lateral fluidity of the red cell, 32 77

Red-cell osmotic fragility as an indication of marrow depression after irradiation and effectiveness of marrow graft, 35, 333

Red cells, Erythrocytes, Erythrocytes Régénération du thymus, v. Thymus

Regenerating bone marrow the use of regenerating bone marrow to protect guinea pigs against lethal irradiation, 32, 146

Regulation, Reticulo-endothelial system

- Regulatory mechanisms for protein synthesis in normal blood cells, 35, 129
- Rein, v Kidney Renal failure
- Release and production of leukocytes, Leukocyte production
- Ren, Kidney Renal failure
- Renal failure, therapeutic and diagnostic problems in severe renal failure, 34 255 (B)
- Reptiles hematology of some South African reptiles, 34 230 (B)
- Résistance électrique, v Widerstand, elektrischer
- Resistenz, mechanische und osmotische von Erythrocyten Bedeutung der unverstärkten Fettsäuren für die Resistenz von Erythrocyten, 37 348
- Resorption (Vitamin K) Hypoproteithinemia
- Respiration, Energy metabolism, Hypoxia
- Reticular cell tissue, submicroscopical structure, 37 193
- Reticulo-endothelial system the place of the lymphocyte in the reticulo-endothelial system. A study of the in vitro effect of prednisolone on lymphocytes, 32, 100
- ; proceedings of the IVth international symposium on RES The reticuloendothelial system. Morphology immunology and regulation, 35 351 (B)
- Retikuloendotheliosen, v Intoxicopathie
- Retikulo-, hämophagocyten, diagnosed during life, 31 349
- Retikuloeyten, Erythrocytoregulation
- Retikuloeyton (Knochenmarkretikuloeyton), Hämozythosen
- Rheological and molecular considerations of the red cell membrane in view of the internal fluidity of the red cell, 32, 209
- Rheumatoid arthritis destructive effect of lymphocyte cells from patients with rheumatoid arthritis in tissue culture, 31 215 (C)
- Rh-incompatibility; substitutive-inhibitory gamma-globulin therapy as prevention of stillbirth in Rh-incompatibility 34 209
- Ribonucleic acid (= RNA) v Leukæmic cells, Protein synthesis, RNA
- Ribonucleic acid, synthesis, v Pernicious anaemia
- Riesengranulationen, orblich-konditionelle, Cancer
- Ricetti-Graves-Monelli, Thalassaemia
- RNA (= Ribonucleic acid) and protein metabolism in normal human erythroblasts and granuloblasts, 32 271
- , v Leukæmic cells, Protein synthesis
- Röntgenstrahlen, Marrow graft, Rayons X, Thymus, Typhoid vaccine, X-irradiation
- Roteln, Rubella
- Rosolen, Rubella
- Rubella neonatal thrombocytopenia in association with rubella, 35, 158
- Robelen, Rubella
- Serien aus Baumwoll-Fasern (Methode von FICHTENBERG) Separation of lymphocytes
- Salamandra, Nowt
- Sang conservé, v Blutkonserven
- Sarcomes thymic lymphosarcomes, RAUSCHER VIRUS
- Sarcomes, Hématosarcomes
- Sardinen subjects electrophoretic studies of erythrocyte glucose-5-phosphate dehydrogenase in normal and enzyme-deficient Sardinian subjects, 35, 46
- Phosphatase
- Sauerstoff, Hypoxia
- Sauerstoff, Bindungsvermögen, Atmungstransportfunktion
- Säure Phosphataseaktivität, Phosphatase
- Savole Interpréter (Nr 12) U examen hématologique, 32 64 (B)
- Schädel, Intrakranielle Ausbreitung der Leukämien
- Schothanamide, Verflüssigungsmittel
- Schütteln, Hämolyse
- Schwangerschaft, Abortion, threatened Haemophil leukocytes; Human bone marrow
- Schwermetalle, toxische, Heavy metals

- Screening test of iron storage disease, studies in its development, 33, 297
- Secular variations, v Quantitative cell counts
- Sedimentation, different sedimentation rate, v Centrifuge, new type
- Sedimentationsanalyse mit der Ultrazentrifuge, v Gamma G-Proteine
- Serumketten (Hämoglobin) Haemoglobin, foetal
- Separation of lymphocytes from human blood, 33, 294
- Separation of viable leucocytes from normal human blood, 33, 338
- Sequestration of erythrocytes, v Life span
- Serological and genetical observations on the blood group A₂B, 31 106
- Serological methods, v Blood group antibodies
- Serology of anti-Tj^a-E₁ haemolysis observed in the serum of threatened abortions in Western Australia, 33 272
- Serotonin, 5-Hydroxytryptamin
- Serum der Wert der Vitamin-B₁₂-Bestimmung für die klinische und hämatologische Diagnostik, 33 144
- Serum iron, Desferal test, Iron absorption
- Serum, human, normal; proliferation and maturation of erythrocytes and granulocytes, affecting factors in normal human serum, 33 279
- thrombocytic and thrombopenic factors in normal human serum, 33, 341
- Serumkomponenten; Untersuchungen über kälte-labile und wasser-labile Serumkomponenten bei Paraproteidämien und Dysproteidämien, 34 160
- v Makroglobuline
- Serum proteins immunoelectrophoretic and autoradiographic pattern of Hb-binding serum proteins, 33, 210
- Gamma G-Proteine
- Sex chromatin, v Hämophilie A
- Sway-chloroakæmia of rats, Leucocyte production
- Sickling phenomenon in a white male without Hb-S, 34 347
- v Drepasocytosis
- Sideræmia (hypersideræmia) v Iron absorption
- Sideroachrestic anæmia, v Sideroblastic anæmia
- Sideroblastic anæmia electron microscopic observations on bone marrow and liver tissue in non-hereditary sideroblastic anæmia, 31 9
- Sitzungsberichte, v Blood group antibodies, Bluttransfusionsforschung, Hämophilie, Iron metabolism, Proceedings, Society Standardization, Symposium
- Snow, v Art
- Skin, affections, v Porphyria
- Skin wounds in vitro and local coagulation of heparinized and citrated blood from skin wounds, 33, 37
- Skull, v Intrakranielle Ausbreitung der Leukämien
- Smears of blood, v Phosphorylase
- Société Européenne d'Hématologie 10e congrès (Strasbourg, 1965) 32, 63
- Society proceedings of the ninth congress of the European Society of Haematology Lisbon 1963, part I: 1-III (after 31 p. 128) 31 129-239 part II Index V-VI (before 31 p. 129)
- proceedings of the ninth congress of the European Society of Hematology (Lisbon, 1963), 32, 128 (B)
- European Society of Haematology 2nd session of the board of the standardizing committee (1964) 31 310
- v Standardisierung, Standardisation
- XIth congress of the International Society of Blood Transfusion (Sydney 1966) 34 64 128
- International, of Blood Transfusion, JEAN JULLIARD prize
- International Society of Haematology Xth congress (Stockholm, 30.8.4.9. 1964) 31 64
- XIth congress of the International Society of Haematology (Sydney, 1966), 34 64 128
- Society v Blood group antibodies, Bluttransfusionsforschung, Deutsche Hämatologische Gesellschaft, Hämophilie(s), Symposium
- Sodium versenate, v Versenate
- Sourin, v Mouton
- South Africa; haematology of some South African reptiles, 34 250 (B)

- Spherocytosis, hereditary: three inherited intra-erythrocytic defects. Hereditary spherocytosis, Hb S and Hb C, 32, 233
- Spherocytosis, v Non-spherocytic haemolytic anaemia
- Splen, v Gaucher-Zellen, Leukemic cells
- Splenoctomie angeborene hämolytische Anämie mit Mesoblastenurie und Innenkörperbildung nach Splenoctomie, 32, 314
- ; v Life span
- Sponaneous fibrinolysis, v Fibrinolysis
- Stafaktor v ACD-Blutkonserven
- Staining, v Glykogennachweis
- Standardisierung in der Hämatologie (1. Internationales Symposium 14. 18. Juni 1963 in Bodensee) 35, 64
- Standardization; erythrocytometric methods and their standardization (Transactions of the standardizing committee and proceedings of symposium XVIII of the sixth congress of the European Society of Haematology (Lisbon, 1963) (Bibliotheca haematologica, fasc. 18) 32 64 (B)
- Standardization in haematology 33, 191; 35, 193, 350
- Hämoglobinnorm, Normierung (Einstellung der Hämmometerprüfreihe) 32 256
- Standardizing committee 2nd session of the board of the standardizing committee (1964) (European Society of Haematology) 31 310
- Starch-block electrophoresis Investigations on the electrophoretic mobility of factor X on starch-block, 32 200
- Electrophoresis
- Starvation (protein), Erythropoiesis
- Statistische Auswertung, Ag of erythrocytes, Atemgastransportfunktion, Basophile, Bilirubin, Chloramphenicol, Desferal test, Energy metabolism, Enzyme defects, Erythrocyte enzymes, Erythrocytoma, Erythropoiesis, Erythropoietin, Fibrinolysis, Hämolytische Krankheit, Human bone marrow Hypoxia, Iron absorption, Leukemic leukocytes, Lethal irradiation, Leukocytenkernanhang Life span
- Methaemoglobin reduction, Phosphatase(s) Thymus, Quantitative cell counts
- Steroide v Cerebrale
- Steroide, v Prothrombin (-)
- Stillbirth; substitutive-inhibitory gamma-globulin therapy as prevention of stillbirth in Rh-incompatibility 34 209
- Stillborn children, Human bone marrow
- Stimulation of megakaryocytes; megakaryocyte stimulating substance in normal human plasma, 33, 86
- Stimulation, Proliferation
- Stoffwechsel; Leukocytenkernanhang bei Kasper Lewis und ihre Beeinflussung durch den Stoffwechsel, 35 246
- v Copper turnover Energy metabolism, Fer Iron absorption, Metabolic aspects, Metabolic responsiveness, Metabolism, Plasma protein, Thrombocytenstoffwechsel
- Stoffwechselveränderungen in Erythrocyten bei der erworbenen hämolytischen Krankheit, 34 88
- Stomach, Gastrostomy Gastric lesion, Malign
- Storage of blood, Blutkonserven
- Storage of iron, disease, v Desferrioxamine
- Strahlenschaden Verhalten der H³ Thyridin-Laborporation im fraktionierten strahlungsgefährdeten Knochenmark, 33, 220
- Strahlungswirkungen, Irradiation, Radiation
- Streptokinase therapy; technique for routine evaluation of plasminogen in humans during streptokinase therapy 34 505
- replication in thrombolytic agent, further experience, 31 103
- Stuart Power factor Factor X
- Submicroscopical structure of the reticular cell tissue, 32 193
- Submicroscopical structure, Basophile granulocytes; Erythrin-Lukaemia virus Lymphocytes, ultrastructure Platelets Sideroblastic anaemia
- Succinate Energy metabolism

- Surface of erythrocytes, v Erythrocytes, repack: Heavy metals; Plasmaproducts
- Surgery v Asepsis
- Survival of erythrocytes; major pitfall in the use of the same radioisotope for the repetition of erythrocyte and other survival studies, 33, 237
- ; v Life span
- Swedish boy v Haemoglobin Bart
- Symposium on microvascular methodology (Bibliotheca anatomica, fasc. 5), 33, 319 (B)
- Symposium, 2. Internationaler für Chemotherapie, v Antibiotika
- Symposiums, v Blood group antibodies, Haemophilias, Iron metabolism, Reticulo-endothelial system, Standardisierung, Standardisation
- Synopsis of pathology (6. ed.), 33 128 (B)
- Synthese des Porphyrins, v Porphyrinsynthese
- Système nerveux central, v Central nervous system
- Tagungsberichte, v Blood group antibodies, Blutzustandsforschung, Iron metabolism, Proceedings, Standardisierung, Standardisation
- Taiwan haemoglobin H disease among Chinese residents of Taiwan, 33, 178
- Tay system, v Anti-TJA-like haemolysis
- Technik, v Methode
- Technique for routine evaluation of plasminogen in humans during streptokinase therapy 34 305
- Technique, new v Phosphorylase
- Technologie, medical, v Hematology
- Temperatur v Leukocytenkernanähänge
- Temps de survie (erythrocytes) v Life span Survival of erythrocytes
- Temps variations au cours du temps, Quantitative cell counts
- Teratologie, v Monoglosses
- Test, v Desferal test, Desferrioxamine, Histo and Privacy test
- Tetrahydrofolic acid studies on the tetrahydrofolic acid dependent co-synase system in human leukocytes, 34 72
- Thalassemia with complete absence of haemoglobin A₂ in a adult, 33, 186
- Thalassemia erythrocyte enzymes in thalassemia and thalassaerythrocytosis, 34 329
- β -Thalassemia cytochemical observations on β -thalassaemia (I: The PAS positive substance of erythroblasts) 34 1
- Thalassemia-haemoglobin E disease in Turkey a further example, 34 334
- Thalassemia-like disease, Haemoglobin Bart's
- Thalassemia (major and minor); uptake of Fe⁵⁹ by acid insoluble elements of normal and thalassaemic haemolysis. In vitro studies, 31 79
- (v Cooley's anaemia with low level of fetal haemoglobin. A genetic study in four families) 34 291
- Thalassemia major v Hb-binding serum proteins
- Thalassemia syndromes, 33, 192 (B)
- - two new thalassaemic syndromes
-) Haemolytic alpha-thalassaemia.
- b) Cooley-like disease due to homozygous elevated Hb A₂ without microcytosis, 32, 221
- ; v Erythrocytic disease
- Thalassemie elektronische Erythrocytenanähänge bei Thalassaemie, 33 308
- Thalassaerythrocytosis, v Thalassemia
- Thallium, radioactive, v Heavy metals
- Therapeutic and diagnostic problems in severe renal failure, 34 253 (B)
- Therapy streptokinase therapy: technique for routine evaluation of plasminogen during streptokinase therapy 34 305
- ; substitutive-inhibitory gamma-globulin therapy as prevention of stillbirth in Rh-incompatibility 34 269
- v Antibiotika, Arzneimittelbehandlung, Dysprotektosen, Erythrocytic disease, Erythropoietin, Gamaglobulintherapie, Hepatinfarktbehandlung, Leukemia, Purpura, Regenerating bone marrow
- Thrombocytopenia des fer v Desferrioxamine
- Thrombocytostoffwechsel und Freisetzung von 5-Hydroxytryptamin, 33, 110

- Thrombocytes, Antiplaquettaire
Platelets, Thrombo
- Thrombocytes, factor I activity v Parahæmophilias
- Thrombocythæmia ultrastructural aspects of platelets and megakaryocytes in case of 'primary' thrombocythæmia, 35 113
- Thrombocytic and thrombopenic factors in normal human serum, 33 341
- Thrombocytopenia; case of autoimmune hæmolytic anaemia, thrombocytopenia and LUXURY-GILLMAN-BARRÉ syndrome, 34 361
- Thrombocytopenia, familial, chronic, with platelet autoantibodies, 34 30
- Thrombocytopenia, neonatal, in association with rubella, 35 158
- Thrombocytopoies bei Perniciöse-Krankheit, Untersuchung, 34 175
- Thromboembolic disorders; tolerance to phenedolone of patients with different thromboembolic disorders, 32 338
- Thrombolysis; further experience with streptokinase as thrombolytic agent, 31 103
- Thrombopenic and thrombocytic factors in normal human serum, 33 341
- Thrombopénie évolution et traitement des purpures thrombopéniques idiopathiques, 31 163 (C)
- Thromboplastin and heparin, with survey on VAN VELLEBRAND's disease, 31 127 (B)
- Thromboplastin, Haemophilias
- Thromboplastin reagents, Prothrombin times
- Thrombopoiesis, Thrombocytic
- Thrombosis, Blood coagulation
- Thrombus, Auflösung, Streptokinase therapy
- Thyroid lymphomarcosis, RAUSCHER virus
- Thymidin (H^3 Thymidin) Verhalten der H^3 Thymidin-Inkorporation im fraktioniert-strahlengeschädigten Knochenmark, 33 220
an investigation of lymphocyte production in guinea pig bone marrow 33 351
bone marrow lymphocytes of the rat as studied by autoradiography 33 111
- Erythropoiesis, Granuloblasts, Pernicious anaemia
- Thymus die Biologie des Thymus nach dem heutigen Stande der Forschung, 31 247 (B)
- the migration of cells to the thymus, 35 221
- Thou réticulaire, v Reticular cell tissue
- Thrombocytes, Erythropoietiques
Leukæmic cells Lymphnode cells; Lymphocyte Lymphocytes, ultrastructure; Microcytaires supplémentaires Plasma factors
- Thrombocyte extracts the effect of the use of different thrombocyte extracts on one-stage prothrombin times, 32 292
- Thrombocyte cells, v Mast cells
- Tp¹⁰⁰ Anti-Tp¹⁰⁰-like hæmolytic
- Tl¹⁰⁰ Heavy metals
- Tolerance to phenedolone of patients with different thromboembolic disorders, 32 338
- Totgeburten, Human bone marrow Rh-incompatibility
- Toxic heavy metals, Heavy metals
- Traitement et évolution des purpures thrombopéniques idiopathiques, 31 163 (C)
- Transfusions, Blood group antibodies, Bluttransfusionsforschung, Haemophilias, Iron metabolism, Proceedings, Society Standardization, Symposium
- Transfer-ribonucleic acid, Protein synthesis
- Transfusion and coagulation in clinical medicine, 33 319 (B)
- Transfusion of regenerating bone marrow Regenerating bone marrow
- Transfusion, Blood group antibodies, Blood transfusion, Blutkonserven, Bluttransfusionsforschung
- Transplantation, Bone marrow transplantation, Marrow graft
- Trapping of white blood corpuscles on glass beads, 32 183
- Trichloroacetic acid precipitable fraction, Fe⁵⁹
- Trisium, Bone marrow Erythropoiesis, Granuloblasts, Pernicious anaemia, Plasma factors, Protein synthesis, Thymus, Thymus
- Trisium, Molch
- Trisium pyridoxin 'New'

- Tryptophan-pyrolase formation of tryptophan-pyrolase in leukaemic cells incubated with RNA obtained from the spleen of calf embryo, 37 265
- Tumor research, experimental, progress (Vol. 4) 31 362 (B) (Vol. 5 Vol. 6) 34 255 (B)
- Tumors; atlas of bone tumors (including tumorlike lesions) 31 361 (B)
- ; v Hématosarcomes, Hémoglobines anormales, Memorial Foundation, Virus
- Turkey further example of thalassaemia-haemoglobin E disease in Turkey 34 354
- Turnover of copper in blood plasma, 33, 1
- Typhoid vaccine injection, effect of partial body irradiated rats, 34 301
- Überlebenszeit, v Life span Survival of erythrocytes
- Ultrastructural aspects of platelets and megakaryocytes in a case of 'primary' thrombocythaemia, 35, 113
- Ultrastructure; the relation of ultrastructure to DNA synthesis in human leukocytes (I Atypical lymphocytes in phytohaemagglutinin cultures and infectious mononucleosis) 33 237
v Basophilic granulocytes; Erythremic Leukaemia virus; Lymphocytes, ultrastructure Reticular cell thase Sideroblastic anaemia
- Ultracentrifuge, v Gamma G-Proteoloe
- Unesterified free fatty acids, Unveresterte Fettsäuren
- Unveresterte Fettsäuren, Bedeutung für die Resistenz von Erythrozyten, 32 348
- Urethane (H¹-uridine) v Granuloblasts, Pernicious anaemia, Protein synthesis
- Urinary excretion of iron, Desferrioxamine
- Vaccine effect of typhoid vaccine injection of partial body irradiated rats, 34 301
- Vasculum, v Microangiological problems, Microvascular methodology
- VAGTEL, v OELER
- Varia, 31 64 127 310 32 63, 256, 320 368 33, 63, 127 191 34 64, 127 370 35, 64, 253, 350
- Variations, secular v Quantitative cell counts
- Virus (embryon) v Leukaemic cells
- V-cells (abnormal cells) v Virus leukaemia
- Ventriculus, v Gastric lesion, Gastroenteric Magen
- Verdünnungsmanömanie (Tierexperimentelle Untersuchungen über den Einfluß des Blutvolumens auf die Erythrocytenregulation), 35, 1
- Vererbungsang, v Hämophilie A
- Vergleichende Hämatologie, v Comparative hematology
- Verhandlungsbericht des 9. Kongresses der Europäischen Gesellschaft für Hämatologie, Lissabon 1963, 1 Teil I III (nach 31 S. 128) 31 129-239; 2 Teil Index v CX (vor 31 S. 129)
- Verhandlungsberichte, v Blood group antibodies, Bluttransfusionsforschung, Iron metabolism, Proceedings, Society Standardization, Symposium
- Versenate the action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophilic leukocytes, 31 289
- Fortsetzung v Granulocytes
- Vesich, v Microangiological problems, Microvascular methodology
- Veterinary hematology (2nd ed.), 35, 192 (B)
- Viable leukocytes from human blood, separation, 35 338
- Vitro-falsch, v Favism, Phosphatase
- Virus attempt at classification of mouse leukaemia viruses (Mouse leukaemia virus type A and the Friend virus) 32, 61
; how many different viruses causing leukaemia in mice? 32 44
- Untersuchungen zur hämatologischen Aufspaltung der durch das Virus der myelischen Leukämie der Maus induzierten Leukosen, 31, 139
- Virus leukaemia; occurrence of an abnormal cell (V-cell) in murine virus-induced leukaemia, 31, 139
- Virus, leukaemogenic the RABBIT virus a mixture of the Friend virus and the mouse leukaemia virus (Gross)? 35, 200

- Virus synthesis, morphological investigations, Memorial Foundation
- Viscosity of blood & high values of haematocrit (packed cells) v Red cell membrane
- Vitamin B₁₂; pyridoxine-responsive anaemia, Ferrokinetics, 31 1
- Vitamin-B₁₂-Bestimmung im Blutserum, Wert für die klinische und hämatologische Diagnostik, 33, 144
- v Perniciosa-Kranke
- Vitamin K; acquired idiopathic hypoprothrombinemia (Acquired hypoprothrombinemia secondary to selective deficient absorption of vitamin K) 34 187
- Volume sanguis, v Blutvolumen
- VON WILLEBRAND disease, heparin and thromboplastin, with survey on VON WILLEBRAND's disease, 31 127 (B)
- WALDENSTRÖM, Morbus Makroglobulin, Paraproteinkrisen
- Wasserlösliche Serumkomponenten, Serumkomponenten
- Wassermolch, v Moich
- Water-labile proteins, Serumkomponenten
- Weisse Blutzellen Nachweis einer sauren Lipase in weißen Blutzellen, 33, 335
- White blood corpuscles, trapping on glass beads, 32, 183
- White male without Hb-S, sickling phenomenon, 34 347
- Whole body irradiation, Irradiation, Thymus
- Widerstand, elektrischer; die Ursache des elektrischen Widerstandes gepackter Erythrocyten im niederfrequenten Bereich, 34 51
- WILLEBRAND, VON WILLEBRAND disease
- Wirbeltiere, Granulocytes
- Womans, Aborters, threatened
- World federation of haemophilia, third congress, 7-9. september 1963, Paris, 33, 63
- X-Chromosomenanomalie und Ahaptoglobulinämie bei Hämophilie A, 33, 49
- X(chromosome)-linked blood group system Xg (Work in progress) 31 205 (C)
- Nadel
- Xampus laevis Leukocytenkernanhänge bei Xampus laevis und ihre Beeinflussung durch den Stoffwechsel, 33, 246
- X-ray-irradiation Influence of the dog kidney on erythropoietin production, 31 90
- ; v Irradiation, Marrow graft, Thymus, Typhoid vaccine, Rayons X
- Zählung, automatische, von Erythrocyten, v Thalassemie
- Zeitliche Veränderungen, Quantitative cell counts
- Zellkern, Nuclei
- Zellkulturen, v Erythropoietiques; Leukaemic cells Lymphatic cells Lymphocyte; Lymphocytes, ultrastructure Micronyxus supplementum Plasma factors
- Zell Ocell
- Zentralnervensystem, v Central nervous system
- Zentrifuge, Centrifuge, new type; Erythrocyten, gepackte
- Zitrat, Citrated blood
- Zytochemie, GARCIA-Zellen
- Zytochemische Untersuchung, Genetische Schoßen
- Zytologie, GARCIA-Zellen
- Zytoplasmfragmente, v Genetische Schoßen

Index autorum ad Vol. 31-35

(B) = Book reviews - Buchbesprechungen - Livres nouveaux

(C) = Communications - Vorträge - Communications

- Abbott, D. Varadi, S.
 Adachi, A., v. Wakabayashi, G.
 Adar, H., v. Sadan, N.
 Aksoy M., and Erdem, S., 34 291
 Aksoy M., and Sefer, F. 32 188
 Aki, F. A., and Shearman, D. J. C., 34 361
 Alwall, N. 34 233 (B)
 Amato, M., Catalano, D., 32 127 (B)
 Amery A., Vermeyen, J. Maes, H., and Verstraete, M., 31 103
 Andersen, St. B., 34 44
 Anderson, W. A. D. 32 128 (B)
 Andrew W. 32 330 (B)
 Angelopoulos, B., Lourepi, M., Vicatos, M., and Mourdjini, Ath., 31 36
 Antonelli, J. A., Baer A., et Vannotti, A., 34 129
 Arpaia, G. v. Gardikas, G.
 Arcaşoy A., v. Okçuoğlu, A.
 Archer R. K., 31 248 (B)
 Artusi, T. v. Torelli, U.
 Ashihara, T., v. Takeoka, O.
 Atamer M. A., 32 63 (B)
 Attiya, I. R. v. Torelli, U.
 Avery G., v. Vossough, P.
 Bachmann F. v. Frick, F. G.
 Baer A., v. Antonelli, J. A.
 Bahner H., 31 128 (B)
 Barandun, S., 33, 34 (B)
 Barandun, S., Koblet, H.
 Barbier F. 34 230 (B)
 Bartolucci, G. and Marianelli, L., 35, 314
 Bearn, A., Steinberg, A. G.
 Beck, E., v. Wright, I. S.
 Becker H.J., and Spengler D., 35 1
 Beckmann, A., Barmelster J.
 Begemann, H., Rastetter J. Waubke, R., und Ketterer H., 35, 144
 Beckert, A., 31 361 (B)
 Belfiore, F., Meldolesi, J., and Calcare, G., 34 329
 Bell, W. N. v. Thompson, R. B.
 Benegmos, J. v. Groszka, L.
 Bernard, J. 31 163 (C)
 Bernat, I. 34 127 (B)
 Beveridge, G. C., v. Cowden, R. R.
 Bicanová, J., v. Brabec, V.
 Boeckmann, P. Fitzgerald, J. D., and Kerber, H., 33, 297
 Blackwell, R. Q. Lin, Kuo-Sin
 Bielberg, L., v. Lewis, S. M.
 Bornstein, J. v. Dietrich, G. P.
 Borovická Ch. G. de, 32 64 (B) 35, 193
 Borovický R. G. v. 35, 235
 Borovický R. G. und Klein, N., 32, 236
 Bourne, M. S., v. Routh, St.
 Bowdler A. J. and Frankard, T. A. J. 31 63
 Bowie, E. J. W. T. ms, W. N., Seckney J. M., and Kleit J. M., 33, 193
 Brabec, V. Bicanová, J. Friedman, B., Kout, M., Mitravová, L., Palek, J. Vopatová, M., und Volk, V. 34 68
 Bräckenmark, P. L., 35 319 (B)
 Brann, L., v. Schiffer L. M.
 Braunstein H., und Dörsel, F. 31 325
 Braunstein H., Dörsel, F. and Eibl, M., 31 225 (C)
 Braunstein H., Dörsel, F. Saller, S., und Sandhofer F. 32 314 33, 333
 Brattell, Iris, v. Gurney C. W.
 Briefmann, A. 31 338
 Brinkhous, K. M. (Editor), 34 127 (B)
 Brown, E. B., Moore, C. V.
 Bruner H. E., 34 237
 Bundecluh, G., v. Wlkowski, R.
 Burgan, W. Klein, N.
 Burnscher J. und Beckmann, A., 35, 246

- Buscarini, L., v. Introzzi, P.
 Buss, L., Jean, G. and Le Goutre, L.,
 35, 113
 Calcare, G. v. Belfiore, F.
 Carrara, P. M., v. Ponti, G. B.
 Catalano, D., Amato, M.
 Cataldo, F. de, v. de Cataldo, F.
 Cheng, F. H. F. Steinberg, B.
 Choné, B., 33, 270
 Clément, F. Delaloy, B., et Vannotti,
 A., 33 63
 Clotten, R., v. Helmeyer, L.
 Clotten, R., v. Hempel, H.
 Cohen, L., Levene, C.
 Colonna, A., v. Grignani, F.
 Cooper, E. H., Insman, D. R.
 Cowden, R. R., Merwin, A., and Beve-
 ridge, G. C., 32, 250
 Cowling, D. C., Quaglini, D. and
 Hayhoe, F. G. J. 31 249
 Craddock, Ch. G. 33, 19
 Croizat, P. Revol, L., and Morel, P.
 32, 64 (B)
 Cronkite, E. P. Schiffer, L. M.
 Cruz, W. O. v. Dietrich, C. P.
 Cséfalvi, L. Rák, K.
 Dacie, J. V. 31 177 (C)
 Dancosbek, W. 31 187 (U)
 Dancosbek, W. and Goss, F. 33, 192 (B)
 Danson, D. Lewis, S. M.
 de Borovitskij Ch. G., Borovitskij
 Ch. G. de
 de Cataldo, F. 34 187
 Delaloy, B., Clément, F.
 Decker, F. and Müller, G., 33, 191 (B)
 de Vilhens Pemaar U. 34 250 (B)
 De Vreker R. A., 34 305
 De Vreker R. A., Vermylen, J.
 de Wolff, E., Wolff, E. de
 Dionet, F. Braunssteiner H.
 Dietrich, C. P. Cruz, W. O. Magal-
 hães, J. R., and Borenstajn, J. 33 57
 Dietz, A. A., Sozioborg, B.
 Di Francesco, L., Vecchio, F.
 Diggelmann, H., Koblet, H.
 Dini, E., Quattrin, N.
 Densenfuss, L., 32, 299
 Dornfest, B. S., Varma, Evelyn E.
 Duibe, B., v. Kumar, S.
 Dekor, P. Müller, J. F. A. P.
 Efrati, P. Sackin, N.
 Ehrly, A. M., Gernsch, F. and Müller
 H. E., 32 348
 Eibl, M., v. Braunssteiner H.
 Eicheberger J. W. Jr. 34 127 (B)
 Elvot, M. W. Gough, J. and Lersch, M.
 C. G., 32, 100
 Emery, J. L., Kalpaktsoglou, Pita K.
 Emilia, G., Torrici, U.
 Erdem, S., Aksoy, M.
 Erickson, U. v. Lockner, D.
 Erikani, S., Ponti, G. B.
 Esposito, S., 32 265
 Fanchelli, G., v. Schettini, F.
 Felten, A. von, 32 168
 Fesus, Ph., and Papsyannopoulos,
 Thalia, 34 1
 Fey, F. und Graff, A., 33 139
 Fichtelma, K. E., and Johansson, Maj-
 Lie, 32, 163
 Field, E. O. and Stanley Elizabeth M.,
 33 221
 Firenze, F. v. Vermylen, J.
 Fischl, A., and Sacchetti, C., 31 150 (C)
 Fisher, J. W. Rob, B. L., and Shetop,
 K., 31 90
 Fitzgerald, J. D., v. Biedermann, P.
 Fonio, A., 31 262
 Fornalini, G. Storti, E.
 Forman, O. and Nordqvist, P. 31 289
 Francesco, L. Di, v. Di Francesco, L.
 Fombei, S. and Reisman, S., 31 363 (B)
 Freuchen, E. (Editor), 33, 351 (B)
 Fresen, O., 32, 193
 Frick, P. 31 362 (B) 32, 128 (B); 33, 64
 (B) 34 127 (B)
 Frick, P. G., Bachmann, F. und Schmid,
 J. R., 34 215
 Friedmann, B., Brabec, V.
 Gajdos, A., 31 200 (U)
 Gannoul, A., and Rheinberg, F. 34 338
 Gardikas, C., Arapakis, G., Jordanoglou,
 J. and Thomopoulos, D. 32, 200
 Gardikas, C., Arapakis, G., Thomopo-
 los, D., and Katsaghinis, T. 32, 333
 Garber, U. Schrod, J. R.
 Garfini, G. Maggioni, G.
 Gerna, G., Rondanelli, E. G.
 Gilmer, W. S. jr. Hagley G. B., and
 Kilgore, W. E., 31 361 (B)
 Gluffré, L., Priolli, A.
 Gloor, F. 33, 127 (B) 34 255 (B) 35,
 351 (B)
 Götz, E., 32, 39
 Götz, E., and Papp, H., 31 113
 Götz, H., Schellfarth, F.

- Gordon, A. S., v Varza, Evelyn E.
 Gordon, R. R., v Varadi, S.
 Gordon, Clara S., v Ullmann, J. E.
 Gorini, P., v Roudanelli, E. G.
 Gough, J. v Elvov, M. W.
 Graffi, A., v Fey, F.
 Gramlich, F., v Ehrly, A. M.
 Gramlich, F., v Müller, H. E.
 Greenwalt, T. J. v Johnson, Sh. A.
 Grignani, F., Colonna, A., Martelli, M.,
 Maerodicaea, Maria, and Tonato,
 M., 33, 321
 Grignani, F., Martelli, M., Tonato, M.,
 and Colonna, A., 34 72
 Gross, L., 32 44 81 35 200
 Grossi, G. Torchi, U.
 Grouta, L., Benegna, J. et Leveque,
 M., 35 53
 Gsell, O. (Editor) 31 364 (B)
 Guns, F. v Dornshick, W.
 Gurney C. W. Munt, Pamela Braetfi,
 Iris; and Hofstra, Diana, 33, 246
 Gysfaki, E., v Mahamos, B.
 Haegi, V. Schmid, J. R.
 Häsig, A., 31 127 128 (B) 33 64 (B)
 35 320 (B)
 Hahn, Dorothy A., v Horton, B. H.
 Hake, Th., Wetter, O.
 Halvorsen, S., 35, 65
 Hamilton, W. F. (Editor) 31 361 (B)
 Handler, E. S., Varza, Evelyn E.
 Harris, D., and Sachs, V. 34 30
 Harris, P. F. and Kogler, J. H., 32 146
 33 351
 Hayhoe, F. G. J. v Cowling, D. G.
 Heilmeyer, L., 31 137 (C)
 Heilmeyer, L., and Clotien, R., 34 63
 Heilmeyer, L., v Hempel, H.
 Hempel, H., Clotien, R., and Heil-
 meyer, L., 34 193
 Heine, K. M., Hermann, H., and
 Stobbe, H., 32 27
 Heilmann, A., and Owen, P. A., 31 230
 (C)
 Hermann, H., Heine, K. M.
 Herdt, M., 31 294
 Hertz, G. v. Lockner, D.
 Higley, G. B., v Gilmer, W. S. Jr.
 Hirsch, H., v Künzel, H. P.
 Hitzig, W. 33, 63 (B)
 Hochman, A., Robinson, E.
 Hofstra, Diana, Gurney C. W.
 Holmér, R., 31 361 (B)
 Hornburger, F. (Editor), 31 362 (B)
 34 235 (B)
 Hopkins, Jeanne C., and Siegel, R. V.
 33, 159
 Horton, B. F. Hahn, Dorothy A., and
 Hufman, T. H. J. 33 312
 Huang, Jeanette Tung-Huang, Lin,
 Kuo-Sin
 Huber, H., Lewis, S. M., and Saur, L.,
 31 116
 Hufman, T. H. J. v Horton, B. F.
 Hulse, E. V. 31 50
 Hurst, J. M., v Medici, P. T.
 Ikala, E., and Siirala, M., 31 313
 Ingram, G. L. C., McBrien, D. J. and
 Spencer, H., 35, 56
 Ingram, V. M., 31 312 (B)
 Intman, D. R., and Cooper, E. H., 33,
 257
 I trossi, P. Baccariol, L., et Nocchi,
 Anthony, 34 277
 Ioppolo, C., Maggioni, G.
 Israels, M. C. G., v Elvov, M. W.
 Israels, M. C. G., v Roeth, St.
 Ito, K., Schmaus, J. W. and Rein-
 mann, A. R., 32, 257
 Jean, G., v Band, L.
 Jepson, Joanne H., and Lowenstein, L.,
 31 329
 Johanson, Maj-Lis, v Fichtel, K. E.
 Johnson, Sh. A., and Greenwalt, T. J.
 35, 319 (B)
 Jordanoglou, J. v Gardine, C.
 Kaplan, M., and Moritz, H., 35, 102
 Kallós, P. and Wakeman, B. H. (Edi-
 tors) 32 127 (B); 35, 253 (B)
 Kalpakoglou, Pina K., and Emery,
 J. L., 34 228
 Kanaghink, T. v Gardine, C.
 Karel, L. A., v Tocantins, L. M.
 Kcherle, H., Biedermann, P.
 Kikos, E., Strass, I.
 Kettner, H., Bergmann, H.
 Kiecy, J. M., v Bowie, E. J. W.
 Kilgore, W. E., v Gilmer, W. S. Jr.
 Kleihauer, E., und Mikényi, A. 32 280
 Kleins, N. und Bergman, W. 34 51
 Kleins, N. v Borovicksky, K. G.
 Klemm, D. Schuboth, H.
 Koblet, H., Vols, F. Degelmann, H.,
 and Branden, S., 35, 320 (B)
 Koller, F. 31 239 (C)
 Koller, F. Wright, I. S.

- Kourtel, M., Angelopoulos, B.
 Kout, M., Brabet, V
 Kriss, F v Rik, K.
 Kuennerle, P Preziosi, P und
 Rentschick, P (Editores) 31 364 (B)
 Kharzi, H. P und Hirsch, H., 32, 89
 Kugler J H., Harris, P F
 Kumar S., Dube, B., and Mehrotra,
 P N 33, 30
 Kutter D 33, 308
 Lala, P K., Maloney M. A., and Patt,
 H. M., 31 1
 Lala, P K., Patt, H. M., and Maloney
 M. A., 35 311
 Lamvik, J O 35 294
 Larizza, P and Orlandi, F 31 9
 Le Coultre, L., Bond, L.
 Lee, Ting-Chien, v Lin, Kuo-Sin
 Leikin, S., Vonnag, P
 Lemert, K., 33 127 (B)
 Leoncini, G v Scotti, E.
 Levene, C., and Cohen, I., 31 106
 Lovéque, M., Grosdea, I.
 Lewis, F J W Noor Eldin, F
 Lewis, S. M., Bleiberg, I., and Dawson,
 D 35, 333
 Lewis, S. M., v Huber H.
 Lie-Injo, Loan Eng, and Pillay R. P
 31 282
 Lin, Kuo-Sin; Lee, Ting-Chien Lin,
 Tsung-Cho Huang, Jeanette Tung-
 Hsiang and Blackwell, R. Q. 33 178
 LoBos, J v Varas, Evelyn E.
 Lochner D., Ericson, U and Hevery
 G 33 1
 Lorber M 33 237
 Lowenstein, L., Japane, Jomoro H.
 Lu, Tsung-Cho, Lin, Kuo-Sin
 Lutz, H., Scheffarth, F
 Mahr G., 32, 106
 Märki, H. H., v Wukmann, F
 Maca, H., Amery A.
 Magalhães, J R., Dietrich, G. P
 Maggioni, G., Ioppolo, C., and Garlini,
 G., 33, 321
 Maghale, E., Rondanelli, E. G.
 Malamos, B., Gyftaki, E., and Prouka-
 kis, Ch 31 79
 Maloney M. A., Lala, P K.
 Marcus, A. J and Zucker Marjorie B.,
 35, 192 (B)
 Mariasoli, L., Bertoloni, G.
 Martelli, M., Grignani, F
 Marti, H. R., 31 127 (B) 247 (B) 362
 (B) 32 64 (B) 35, 192 (B)
 Marti, H. R., Pk, C., und Moskmann,
 P 32 9
 Martin, Ruth A., Steinberg, B.
 Mastrodice, Maria, v Grignani, F
 Mathé, G et Seman, G 32 128 (B)
 Matsui, S., Takroka, O
 Mauri, C., and Silingardi, V 32 114
 Mauri, C., Torrelli, U
 Mayer G., Mayer S., et Waltz, R., 32
 306
 Mayer S., v Mayer G.
 McBrick, D J v Ingram, G. I G.
 McKay D G 35 319 (B)
 Medici, P T Herst, J M., and Pátero,
 S. J 33, 167
 Mehrotra, P N., Kumar S
 Meier Rago, W 31 362 (B)
 Meia, Clara, v Schettini, F
 Mecklen, J Belfiore, F
 Meloni, T v Schettini, F
 Meloni, T Vecchio, F
 Müller G., Dencher F
 Müller J F A. P und Dukor P 31
 247 (B)
 Mihényi, N Klehner E.
 Minnich, Virginia, Okuongha, A.
 Mitravová, L., Brabet, V
 Miyamoto, K., v Wakimza, G.
 Moeschlin, S., 32 64 (B)
 Moeschlin, S., Schmid, J R., and Schmi-
 der Th., 33 200
 Moeschlin, S., Schmid, J R.
 Monette, Francis C., v Varas, Evelyn E.
 Monif, G., Vonnag, P
 Moore, C. V and Brown, E. B., 33, 192
 (B)
 Moore, G. E., Ulrich, A.
 Morel, P Crozat, P
 Moritz, H., Kagami, M.
 Moskmann, P Marti, H. R.
 Motulsky A. G., 31 312 (B)
 Mourdjian, Ath., Angelopoulos, B.
 Müller H. E., und Grumbach, F 34 239
 Müller H. E., Ehrly A. M.
 Munt, Pamela, Gurney C. W
 Nakamura, T Wakaka, G.
 Narsin, A., Cowden, R. R.
 Neumark, E., 34 371; 35, 63
 Nordqvist, P Forsman, O.
 Notario, Anzola, Introvi, P

- Nour Eldin, F. and Lewis, F. J. W., 32, 338
- Odum, J. v. Thompson, R. B.
- Ohta, H., 33, 28
- Okuyoglu, A., Misenich, Virginia, and Arcasoy A., 34 334
- Orlandi, F., v. Larrosa, P.
- Orth, G. W. v. Willenegger H.
- Ottensmeyer, R., 33 191 (B)
- Owren, P. A., v. Hellem, A.
- Palek, J. v. Brabec, V.
- Panikou, F. and Zaccarello, F. 33, 129
- Pannacchini, I. v. Thirionello, A.
- Papayannopoulou, Thalia, v. Fossa, Ph.
- Part, H. M., v. Lala, P. h.
- Pera, H., v. Gott, E.
- Pienaar U. de Villiers, v. de Villiers Pienaar U.
- Pik, G., v. Marti, H. R.
- Fibero, S. J. v. Medici, P. T.
- Pillay R. P. Lie-I jo, Luan Eng
- Pöller L., 32 292
- Ponti, G. B., Valentini, R., Carrara, P. M., and Erikani, S., 34 36
- Prankerd, T. A. J. v. Bowdler A. J.
- Presion, P., v. Kuemmerle, P.
- Prionel, A., and Cluffel, L., 33 210
- Proukakis, Ch., Mahmos, B.
- Quaglini, D. v. Cowling, D. G.
- Quaglini, D. v. Torelli, U.
- Quattrin, N., Dini, E., and Ventruto, V. 32 221
- Raco, R. R., and Sanger Ruth, 31 205 (C)
- Rathle-Person, Carla, v. Walton, A.
- Raja, S., v. Schuboth, H.
- Rák, K., Krizsa, F. Varga, L., and Gerbáti, I. 34 173
- Rascher J. Begemann, H.
- Rau, P. J. Thompson, R. B.
- Reber H., 31 364 (B) 33, 351 (B)
- Reichmann, K. R., v. Iso, h.
- Reitman, S., Frankel, S.
- Reinmann, P. v. Schiffer L. M.
- Reinmann, P. Kuemmerle, P.
- Reuter J. C., 31 128 (B)
- Revol, L., Croiset, P.
- Rewald, E., 31 303
- Rewald, E., and Springar F. 34 209
- Rhomberg, F. v. Ganzoni, A.
- Riegl, K., und Rührmann, G., 32 129
- Roth, St., Bourne, M. S., and Isabella, M. G. G., 32, 1
- Robertson, M. G., Thompson, R. B.
- Robinson, E., and Hochman, A., 34 301
- Rob, B. L., v. Fibber J. W.
- Rondanelli, E. G., Gorini, P. and Magliolo, E., 34 321
- Rondanelli, E. G., Trento, A., Magliolo, E., Vannini, V., et Geros, G., 33, 97 33, 232
- Rosenfeld, R. E., 35 253 (B)
- Rosenow O., 31 361, 363 (B); 32, 63 (B) 128 (B); 33, 128 (B) 191 192 (B); 34 127 (B) 35 182 (B) 319 320 (B)
- Rossi, E., 32 127 (B)
- Rosenstein, L., v. Sadan, N.
- Ruhrmann, G., v. Riegl, K.
- Rusino, G. v. Vocchio, F.
- Ryder R. J. W. 35, 181
- Sacchetti, C., v. Fieschi, A.
- Sachs, V. Harms, D.
- Sadan, N. Yaffe, D. Rosenstein, L., Adar H., Soroker B., and Efrati, P. 34 20
- Saller S., v. Braunsteiner H.
- Sakurai, M., v. Wakasaka, G.
- Salvidio, E., v. Thirionello, A.
- Sandhofer P. v. Braunsteiner H.
- Sanger Ruth, v. Raco, R. R.
- Schalm, O. W. 192 (B)
- Scheiffarth, F. Gock, H., und Lutz, H., 34 144
- Scherini, F. and Micconi, T. 32, 33
- Scherini, F., Micconi, T. Mela, Clara, and Fancinelli, G. 33, 230
- Scherini, F. v. Vocchio, F.
- Schleisslein, H., 33, 110
- Schiffer L. M., Brann, L., Cronke, Z. P. and Reichenstein, P. 35 80
- Schmama, J. W. v. Ito, K.
- Schmid, J. R., Moerschlin, S., and Haegi, V. (and Gerber U.), 32, 65
- Schmid, J. R., v. Frick, F. G.
- Schmid, J. R., v. Moerschlin, S.
- Schneider Th., Moerschlin, S.
- Schwyder U. W. 32 127 (B)
- Schuboth, H., Raja, S., und Klein, D., 34 160
- Schwarz-Sperk, M., 35 253 (B)
- Schweizer W. 31 361 (B)
- Seger P. Akoy M.
- Schverd, Ch. E., 31 361 (B)
- Seman, G., Mathé, G.

- Sono, S., *31* 129 (C)
 Sever J v Vossough, P
 Shapiro, M., Wiener A. S.
 Shearman, D. J. C., v. Ala, F. A.
 Shenep, K., Fisher J W
 Shirakawa, S., v. Wakasaka, G.
 Siegel, B. V v Hopkins, Jeanne C.
 Slingardi, V v Mauri, G.
 Storala, M., Ikkala, E.
 Stölin, St., Wallentin, G., and Wrasme, L., *32* 239
 Snapper L., *31* 361 (B)
 Soroker B v Sadan, N
 Sorenson, M., v. Wulff, H. R.
 Speira, R. S., *31* 248 (B)
 Spencer H., Ingram, G. I. C.
 Spengler D., v. Becker HJ.
 Spielmann, W v Willensegger H.
 Stadler G., *31* 127 (B)
 Stanley Elizabeth M., Field, E. O.
 Steinberg, A. G. and Bearn, A., *33*, 128 (B)
 Steinberg, B., and Cheng F. H. F. *33*, 86
 Steinberg, B., Cheng, F. H. F. and Martin, Ruth A., *33* 279
 Steinberg, B., Cheng, F. H. F. Martin, Ruth A., and Dietz, A. A., *33* 341
 Stern, C., *33* 128 (B)
 Stickney J M., Bowe, E. J W
 Stobbs, H., Holme, K. M.
 Storti, E., Leoncini, G., Traldi A., and Fornalini, G., *33*, 294
 Strauss, L., Kohn, E., and Seibeni, Agnes, *33*, 40
 Sturmer F. Rowald, E.
 Szecsei, Agnes, Strauss, I.
 Surr L. Huber H.
 Takroka, O., Matsui, S., and Ashihara, T. *33* 344
 Tancot, W N. Bowie, E. J W
 Thölen, H., *34* 255 (B)
 Thonopoulos, D., Gavrilakis, C.
 Thompson, R. B., Odum, J. Warrington, R., and Bell, W. N., *33*, 186
 Thompson, R. B., Ran, P. J. Odum, J. and Bell, W. N., *34* 347
 Thompson, R. B., and Robertson, M. G. *32* 233
 Thonard-Newmann, E., *31* 24 *32*, 358
 Tiziollo, A., Pannacchilli, I. and Salvadori, E., *35*, 176
 Tocantins, L. M., and Kasal, L. A., *33*, 191 (B)
 Tomato, M., Grignani, F.
 Torelli, U. Grossi, G. Artusi, T. Emil-
 Ba, G. Attiya, I. R., and Mauri, C., *32* 271
 Torelli, U. Quaglini, D., and Mauri, G., *35* 129
 Traldi, A., Storti, E.
 Trenta, A., v. Rondanelli, E. G.
 Uchino, H., Wakasaka, G.
 Ulrich, K., and Moore, G. E., *35*, 338
 Ulmann, J. E., and Gordon, Clara S., *33*, 118
 Usdritz, E., *34* 250 (B)
 Valentini, R., Ponti, G. B.
 Vannini, V v Rondanelli, E. G.
 Vannotti, A. Antonelli, J. A.
 Vannotti, A., Clément, F.
 Varadi, S., Gordon, R. R., and Abbott, D. *31* 349
 Varga, L., Rák, K.
 Varga, Evelyn E., LoBos, J. Handler E. S., Dorfner, B. S., Gordon, A. S., and Monens, Francis C., *33* 287
 Vecchio, F. Schettini, F. De Francesco, L., Meloni, T. and Rosino, G., *35*, 46
 Ventrone, V. Quattrio, N.
 Vermylen, J. Fierens, F. De Vreker R. A., and Verstraete, M., *35*, 91
 Vermylen, J. v. Amery A.
 Verstraete, M., Amery A.
 Verstraete, M., Vermylen, J.
 Vesin, P. Koblet, H.
 Vlachou, M. Angelopoulos, B.
 Villiers Picotier U de, de Villiers Picotier U.
 Volck, V. Brabec, V.
 von Borovickásky K. G., Borovickásky K. G.
 von Felten, A., Felten, A. von
 von Heesay G. Heesay G.
 Vopatová, M., Brabec, V.
 Vos, G. H., *33*, 272
 Vossough, P. Leikin, S., Avery G., Mosolf, G. and Sever J. *35*, 156
 Vreker R. A. De, De Vreker R. A.
 Walter, R., Mayer G.
 Wakasaka, G. Uchino, H., Nakamura, T. Shirakawa, S., Adachi, A., Sakurai, M., and Miyamoto, K., *31* 214 (C)

- Wakeman, B. H., v Kalkó, P.
 Wallenius, G v Spölin, Se.
 Warrington, R., v Thompson, R. B.
 Waubler, R., v Begemann, H.
 Weatherall, D. J 33, 192 (B)
 Weiser O und Hake, Th., 31 237
 Widmer L. K., 33, 319 (B)
 Wiener A. S. (and Shapiro, M.) 33
 253 (B)
 Willenegger H., Orth, G. W. und
 Spielmann, W 33, 64 (B)
 Wilson, A. (and Ralike Person, Carin),
 33 163
 Wikowski, R., Zabel, H., und Bond-
 schuh, G., 33, 49
 Witschi, H., 31 101
 Wise, S., 31 128 (B)
 Wöhler F 32 321
 Wolff, Emmanuelle de, 34 127 (B)
 Wrascoe, L., v Spölin, Se.
 Wright, L. S., Kolier F., und Beck, E.
 (Editores) 31 127 (B)
 Wahrenmann, F und Märki, H. H.,
 31 127 (B)
 Wulff, H. R., 32 17
 Wulff, H. R., and Sorensen, M., 33 304
 Yaffe, D v Saden, N.
 Zabel, H., v Wikowski, R.
 Zaccardo, F., v Pantron, F
 Zucker Maryole B., v Marcus, A. J

